Clustering O 0 0.0002628205402288586
of O 0 6.657639914919855e-06
missense O 0 0.0016872492851689458
mutations O 0 5.305721424520016e-05
in O 0 4.168401574133895e-06
the O 0 0.00012254143075551838
ataxia B-Disease 1 0.9999974966049194
- I-Disease 1 0.999729573726654
telangiectasia I-Disease 1 0.9998917579650879
gene O 0 2.2028532384865684e-06
in O 0 2.042653335365685e-07
a O 0 1.235270474353456e-06
sporadic B-Disease 0 0.0010710235219448805
T I-Disease 1 0.9926860332489014
- I-Disease 0 0.2860319912433624
cell I-Disease 0 0.10362835228443146
leukaemia I-Disease 1 0.8569145202636719
. O 0 2.305883026565425e-05

Ataxia B-Disease 1 0.9999860525131226
- I-Disease 1 0.999826967716217
telangiectasia I-Disease 1 0.9999665021896362
( O 0 0.0002007995790336281
A B-Disease 1 0.7279288172721863
- I-Disease 1 0.9998717308044434
T I-Disease 1 0.9999862909317017
) O 0 4.0785229771245213e-07
is O 0 1.2416822414706985e-07
a O 0 7.543718538727262e-07
recessive B-Disease 0 0.0001334014377789572
multi I-Disease 0 0.16029459238052368
- I-Disease 1 0.9931921362876892
system I-Disease 0 0.07257608324289322
disorder I-Disease 0 0.1280747354030609
caused O 0 3.7740642255812418e-06
by O 0 1.4826646577148495e-07
mutations O 0 4.304222045448114e-07
in O 0 3.787509328390115e-08
the O 0 4.838037881427226e-08
ATM O 0 5.9858862186956685e-06
gene O 0 2.749757754827442e-07
at O 0 4.2390956878080033e-07
11q22 O 0 4.0517610614188015e-05
- O 0 8.649304072605446e-05
q23 O 0 3.4033640986308455e-05
( O 0 2.7830836302200623e-07
ref O 0 7.197527884272859e-05
. O 0 1.4186366570356768e-07
3 O 0 7.568398814328248e-07
) O 0 2.845983999577584e-07
. O 0 1.9441006315901177e-06

The O 0 9.459375178266782e-06
risk O 0 3.5187396861147135e-05
of O 0 4.054631972394418e-06
cancer B-Disease 0 0.25740694999694824
, O 0 8.785098088992527e-07
especially O 0 6.916235975040763e-07
lymphoid B-Disease 0 0.0002101061400026083
neoplasias I-Disease 0 0.00509980320930481
, O 0 3.885719763729867e-07
is O 0 1.6082972820186114e-07
substantially O 0 3.833263235719642e-06
elevated O 0 1.5049097783048637e-05
in O 0 4.6716004931113275e-07
A B-Disease 0 0.06710416823625565
- I-Disease 1 0.9999102354049683
T I-Disease 1 0.9999990463256836
patients O 0 5.328711267793551e-05
and O 0 7.982043825904839e-07
has O 0 7.860384698687994e-07
long O 0 5.9092526498716325e-06
been O 0 6.459325163632457e-07
associated O 0 6.982749255257659e-06
with O 0 3.046554047614336e-05
chromosomal O 1 0.9999470710754395
instability O 1 0.9928386807441711
. O 0 0.00010272546933265403

By O 0 2.0348545149317943e-05
analysing O 0 0.0004580879758577794
tumour B-Disease 1 0.9998965263366699
DNA O 0 0.0006601120112463832
from O 0 3.9532992559543345e-06
patients O 0 1.0807360922626685e-05
with O 0 4.270156068741926e-07
sporadic B-Disease 0 0.0002728358085732907
T I-Disease 1 0.9755403399467468
- I-Disease 0 0.13843943178653717
cell I-Disease 0 0.02520189806818962
prolymphocytic I-Disease 1 0.936625063419342
leukaemia I-Disease 1 0.9941692352294922
( O 0 4.271062607585918e-06
T B-Disease 0 0.16291353106498718
- I-Disease 0 0.00023812810832168907
PLL I-Disease 0 0.00010701514838729054
) O 0 6.62658763417312e-08
, O 0 5.3572524194578364e-08
a O 0 1.9695085029525217e-07
rare O 0 1.2008800695184618e-05
clonal B-Disease 0 0.007815364748239517
malignancy I-Disease 0 0.18896108865737915
with O 0 2.652174657669093e-07
similarities O 0 6.166230264170736e-07
to O 0 5.8545730041714705e-08
a O 0 6.447293685596378e-07
mature B-Disease 0 0.0001933480816660449
T I-Disease 1 0.7556846737861633
- I-Disease 0 0.011403288692235947
cell I-Disease 0 0.009802130982279778
leukaemia I-Disease 0 0.21063318848609924
seen O 0 7.059967629174935e-06
in O 0 5.537740435102023e-07
A B-Disease 0 0.023662123829126358
- I-Disease 1 0.9977421760559082
T I-Disease 1 0.9999526739120483
, O 0 2.068143345468343e-07
we O 0 2.4408192800251527e-08
demonstrate O 0 7.440120697310704e-08
a O 0 2.5728708052952243e-08
high O 0 1.8090123887759546e-07
frequency O 0 1.2726391673822945e-07
of O 0 4.321207924817827e-08
ATM O 0 2.3010041331872344e-05
mutations O 0 7.138483510971128e-07
in O 0 4.4602876414501225e-07
T B-Disease 0 0.17523056268692017
- I-Disease 0 0.0007449270924553275
PLL I-Disease 0 0.0013095906469970942
. O 0 1.1008897672581952e-05

In O 0 9.629995474824682e-06
marked O 0 2.6470037482795306e-05
contrast O 0 3.448255483817775e-06
to O 0 1.55310516447571e-07
the O 0 1.5416082987940172e-07
ATM O 0 6.064243643777445e-05
mutation O 0 6.040532412043831e-07
pattern O 0 2.758472191999317e-06
in O 0 7.963787993503502e-07
A B-Disease 0 0.15728434920310974
- I-Disease 1 0.9997143149375916
T I-Disease 1 0.9999865293502808
, O 0 3.592342920910596e-07
the O 0 3.2539460903535655e-08
most O 0 2.3779374913601714e-08
frequent O 0 1.0614047596391174e-07
nucleotide O 0 2.54280934086637e-07
changes O 0 5.2190973320875855e-08
in O 0 3.730147923874938e-08
this O 0 1.97932052969918e-07
leukaemia B-Disease 0 0.14568856358528137
were O 0 4.41779911852791e-06
missense O 0 0.0003238440549466759
mutations O 0 1.3117472008161712e-05
. O 0 1.1192822967132088e-05

These O 0 3.823248334811069e-06
clustered O 0 4.519579670159146e-05
in O 0 2.3910823188089125e-07
the O 0 4.726397406784599e-08
region O 0 1.671903646638384e-07
corresponding O 0 4.429744748790654e-08
to O 0 1.6554894344267268e-08
the O 0 1.8640026411276267e-08
kinase O 0 8.01638805114635e-07
domain O 0 9.268921274951936e-08
, O 0 2.1425996976631723e-08
which O 0 1.3396824094513704e-08
is O 0 1.552313833030894e-08
highly O 0 2.689719202919605e-08
conserved O 0 4.156663990784182e-08
in O 0 2.5277408610691054e-08
ATM O 0 2.124919046764262e-05
- O 0 8.286636330012698e-06
related O 0 1.7707777999476093e-07
proteins O 0 2.4463794545681594e-08
in O 0 5.3921688447644556e-08
mouse O 0 1.5350856301665772e-06
, O 0 6.904427607423713e-08
yeast O 0 1.782296521923854e-06
and O 0 4.112816895940341e-07
Drosophila O 0 4.751172127726022e-06
. O 0 2.1950331756670494e-06

The O 0 6.518779173347866e-06
resulting O 0 5.115884960105177e-06
amino O 0 9.524155188955774e-07
- O 0 5.822927960252855e-06
acid O 0 1.775966609329771e-07
substitutions O 0 1.6878632891348389e-07
are O 0 3.2774661207213285e-08
predicted O 0 4.838245217797521e-07
to O 0 1.5187424651230685e-08
interfere O 0 1.9020765762434166e-07
with O 0 7.213743202783007e-08
ATP O 0 5.8706758863991126e-05
binding O 0 1.8754163875200902e-06
or O 0 5.372242526391346e-07
substrate O 0 2.7803889679489657e-05
recognition O 0 1.8960181478178129e-06
. O 0 3.7250047171255574e-06

Two O 0 3.008512749147485e-06
of O 0 6.040198172740929e-07
seventeen O 0 7.659280527150258e-06
mutated O 0 9.270454756915569e-05
T B-Disease 0 0.10261925309896469
- I-Disease 0 8.086910384008661e-05
PLL I-Disease 0 6.564961950061843e-05
samples O 0 8.240284614657867e-07
had O 0 1.1795405185921481e-07
a O 0 2.4593768443992303e-07
previously O 0 2.7250300718151266e-06
reported O 0 3.672566526802257e-05
A B-Disease 0 0.0060995216481387615
- I-Disease 1 0.973691999912262
T I-Disease 1 0.9985061287879944
allele O 0 1.9838153093587607e-05
. O 0 5.818121280753985e-06

In O 0 2.435243732179515e-05
contrast O 0 4.417242234922014e-05
, O 0 2.485626055204193e-06
no O 0 6.969444257265422e-07
mutations O 0 1.4721314300913946e-06
were O 0 3.748521066881949e-07
detected O 0 1.8202835008196416e-06
in O 0 1.4739625520121535e-08
the O 0 1.904617441539358e-08
p53 O 0 1.6969630678431713e-07
gene O 0 7.576466742875709e-08
, O 0 4.0603904238878386e-08
suggesting O 0 1.9198654399588122e-07
that O 0 3.31650475970946e-08
this O 0 4.683064389610081e-07
tumour B-Disease 1 0.9989489912986755
suppressor O 0 8.793352753855288e-05
is O 0 1.9911590243282262e-07
not O 0 7.211995978195773e-08
frequently O 0 1.6432149152478814e-07
altered O 0 5.640799827233423e-07
in O 0 2.2446334924097755e-07
this O 0 1.3267462009025621e-06
leukaemia B-Disease 1 0.6895043849945068
. O 0 2.3336595404543914e-05

Occasional O 0 0.00033593151601962745
missense O 0 0.001744382898323238
mutations O 0 3.071314495173283e-05
in O 0 8.553794828003447e-07
ATM O 0 5.2745603170478716e-05
were O 0 4.884378768110764e-07
also O 0 2.0593475369423686e-07
found O 0 6.183036020956933e-07
in O 0 7.651306077605113e-07
tumour B-Disease 1 0.9998278617858887
DNA O 0 7.216951053123921e-05
from O 0 8.36950732718833e-07
patients O 0 3.1212471185426693e-06
with O 0 3.4112255775653466e-07
B B-Disease 0 0.0015839255647733808
- I-Disease 0 0.0008949562325142324
cell I-Disease 0 0.00037650897866114974
non I-Disease 0 6.801808922318742e-05
- I-Disease 1 0.9856282472610474
Hodgkins I-Disease 1 0.9999765157699585
lymphomas I-Disease 1 0.9557199478149414
( O 0 3.5137415466124367e-07
B B-Disease 0 1.9796574633801356e-05
- I-Disease 0 7.645757250429597e-06
NHL I-Disease 0 2.445535756123718e-07
) O 0 1.9577177212681818e-08
and O 0 2.2941360811046252e-08
a O 0 1.5285600341030658e-07
B B-Disease 0 8.275283471448347e-05
- I-Disease 0 0.0001156694779638201
NHL I-Disease 0 9.839416634349618e-06
cell O 0 3.402426591492258e-05
line O 0 2.1846912204637192e-05
. O 0 5.1493557293724734e-06

The O 0 4.013432771898806e-06
evidence O 0 2.232205815744237e-06
of O 0 1.2532409243704024e-07
a O 0 2.0919131316077255e-07
significant O 0 4.800621695721929e-07
proportion O 0 2.988801099945704e-07
of O 0 8.552557773100489e-08
loss O 0 7.030198321444914e-05
- O 0 0.0001042719668475911
of O 0 3.840497129203868e-07
- O 0 0.0013155883643776178
function O 0 5.92252263231785e-07
mutations O 0 3.487015760583745e-07
and O 0 6.14638508977805e-08
a O 0 9.948293211436976e-08
complete O 0 1.6879323538887547e-06
absence O 0 3.9820537267587497e-07
of O 0 3.2370280678151175e-08
the O 0 2.2820559664182838e-08
normal O 0 7.221342457341962e-08
copy O 0 2.2512321606882324e-07
of O 0 3.0862203459491866e-08
ATM O 0 8.874967534211464e-06
in O 0 2.5434244932398542e-08
the O 0 2.6871349589896454e-08
majority O 0 3.233825793813594e-07
of O 0 1.3712354984818376e-07
mutated O 0 0.00011438319779699668
tumours B-Disease 1 0.9981561303138733
establishes O 0 3.5771681723417714e-06
somatic O 0 9.287143257097341e-06
inactivation O 0 0.0012588630197569728
of O 0 1.2042258390465577e-07
this O 0 3.0936107009438274e-08
gene O 0 1.076945963518483e-07
in O 0 1.9509185378296934e-08
the O 0 5.765983246419637e-08
pathogenesis O 0 7.49914124753559e-06
of O 0 2.2729298621015914e-07
sporadic B-Disease 0 0.0006879694992676377
T I-Disease 1 0.9061395525932312
- I-Disease 0 0.000526238523889333
PLL I-Disease 0 8.865297422744334e-05
and O 0 2.881556326883583e-07
suggests O 0 2.9571353366009134e-07
that O 0 4.217614701929051e-08
ATM O 0 5.7751462918531615e-06
acts O 0 1.954142447857521e-07
as O 0 1.3044586921751034e-07
a O 0 3.957569333579158e-06
tumour B-Disease 1 0.9993497729301453
suppressor O 0 0.0008978532277978957
. O 0 1.3349171240406577e-05

As O 0 6.1737837313557975e-06
constitutional O 0 7.590129371237708e-06
DNA O 0 1.5209073353616986e-05
was O 0 7.76469846641703e-07
not O 0 5.998922603112078e-08
available O 0 4.977437839670529e-08
, O 0 7.718004724210914e-08
a O 0 4.5014562033429684e-07
putative O 0 0.00021024519810453057
hereditary O 0 0.07880758494138718
predisposition O 0 0.0014703009510412812
to O 0 1.7917936929734424e-05
T B-Disease 1 0.9860379099845886
- I-Disease 0 0.0014512290945276618
PLL I-Disease 0 9.990001126425341e-05
will O 0 9.635781594852233e-08
require O 0 7.886442432436525e-08
further O 0 8.403213058727488e-08
investigation O 0 2.7016069452656666e-06
. O 0 7.471248864021618e-07
. O 0 4.6023692448216025e-06

Myotonic B-Disease 1 0.9999665021896362
dystrophy I-Disease 1 0.9998888969421387
protein O 0 0.00012178703036624938
kinase O 0 0.00010648430179571733
is O 0 4.861023512603424e-07
involved O 0 2.230315487850021e-07
in O 0 3.36821130986209e-08
the O 0 1.436784202724084e-08
modulation O 0 1.0457308263767118e-07
of O 0 3.674321291669003e-08
the O 0 1.941727418852679e-07
Ca2 O 0 6.611958087887615e-05
+ O 0 0.0001109301665564999
homeostasis O 0 0.00046070539974607527
in O 0 3.0113114917185158e-06
skeletal O 0 0.02033575251698494
muscle O 0 0.00039797567296773195
cells O 0 5.4815252951812e-05
. O 0 1.0696518984332215e-05

Myotonic B-Disease 1 0.9999830722808838
dystrophy I-Disease 1 0.999990701675415
( O 0 0.011207002215087414
DM B-Disease 1 0.9999909400939941
) O 0 7.394872227450833e-06
, O 0 6.544203188241227e-07
the O 0 1.1374946495834592e-07
most O 0 5.581168238677492e-07
prevalent O 0 0.0003749430179595947
muscular B-Disease 1 0.9968036413192749
disorder I-Disease 1 0.8122748732566833
in O 0 2.250769284728449e-06
adults O 0 7.474693848052993e-05
, O 0 1.5340758636739338e-06
is O 0 6.430026928683219e-07
caused O 0 4.516257831710391e-06
by O 0 1.7285211129092204e-07
( O 0 9.453879812326704e-08
CTG O 0 4.7254874516511336e-05
) O 0 9.31398744796752e-08
n O 0 7.041288426989922e-06
- O 0 1.8675954152058694e-06
repeat O 0 2.404684096291021e-07
expansion O 0 8.918273408653477e-08
in O 0 7.396100620837842e-09
a O 0 1.0566313157767127e-08
gene O 0 2.1551125328755916e-08
encoding O 0 3.025447981030993e-08
a O 0 5.5717134017641e-08
protein O 0 3.325461648273631e-07
kinase O 0 1.7523934729979374e-06
( O 0 1.1130069310638646e-07
DM B-Disease 1 0.9511480331420898
protein O 0 2.3038229812755162e-07
kinase O 0 8.065935048762185e-07
; O 0 9.106806686531854e-08
DMPK O 0 4.246407843311317e-05
) O 0 1.1978981362403829e-08
and O 0 1.3713186142183531e-08
involves O 0 7.30831928308362e-08
changes O 0 4.698041067285885e-08
in O 0 1.0322612098434547e-07
cytoarchitecture O 0 0.00017780819325707853
and O 0 1.535529236207367e-06
ion O 0 0.0012399370316416025
homeostasis O 0 0.0014402279630303383
. O 0 1.1585732863750309e-05

To O 0 7.581678801216185e-06
obtain O 0 4.280110715626506e-06
clues O 0 4.544717739918269e-06
to O 0 1.233267710176733e-07
the O 0 7.28125755244946e-08
normal O 0 3.544290052559518e-07
biological O 0 3.5075709092780016e-07
role O 0 4.519371543665329e-08
of O 0 5.074041098396265e-08
DMPK O 0 0.00021781983377877623
in O 0 2.1426981788863486e-07
cellular O 0 1.558740586915519e-05
ion O 0 0.00019858636369463056
homeostasis O 0 0.00024987972574308515
, O 0 3.089518827437132e-07
we O 0 5.813058123749215e-08
have O 0 3.086026012510956e-08
compared O 0 2.671406207355176e-07
the O 0 2.2553788170398548e-08
resting O 0 6.3820962168392725e-06
[ O 0 1.045502926899644e-06
Ca2 O 0 3.267107558713178e-06
+ O 0 5.211972620600136e-06
] O 0 1.8881994492403464e-06
i O 0 1.3137083954006812e-07
, O 0 9.28000876143642e-09
the O 0 4.761302907496656e-09
amplitude O 0 1.3053933400897222e-07
and O 0 2.6910946360203525e-08
shape O 0 1.6482121623084822e-07
of O 0 3.6169005568353896e-08
depolarization O 0 2.7547956051421352e-05
- O 0 0.000988724990747869
induced O 0 0.00018801618716679513
Ca2 O 0 2.8912705602124333e-05
+ O 0 1.8158110833610408e-05
transients O 0 2.940008562291041e-05
, O 0 8.931959882829688e-08
and O 0 1.3732449843928407e-08
the O 0 6.403257923892625e-09
content O 0 9.650308108177796e-09
of O 0 8.109775961884225e-09
ATP O 0 5.082525149191497e-06
- O 0 7.339193416555645e-06
driven O 0 1.2240058140378096e-06
ion O 0 5.141254405316431e-06
pumps O 0 9.563464118400589e-07
in O 0 7.364206311422095e-08
cultured O 0 2.4175191356334835e-05
skeletal O 0 0.00018605732475407422
muscle O 0 4.849474862567149e-06
cells O 0 4.433980222984246e-07
of O 0 5.9319066991747604e-08
wild O 0 2.519289864721941e-06
- O 0 7.620828546350822e-05
type O 0 4.867201823799405e-06
and O 0 4.757964404689119e-07
DMPK O 0 0.0003392153885215521
[ O 0 4.021218046545982e-06
- O 0 0.00013336607662495226
/ O 0 0.00010001286864280701
- O 0 0.0003071407263632864
] O 0 2.0510780814220197e-05
knockout O 0 0.0005894607165828347
mice O 0 7.107679266482592e-05
. O 0 9.075765774468891e-06

In O 0 1.2753130249620881e-05
vitro O 0 0.00021501623268704861
- O 0 0.00040523140341974795
differentiated O 0 3.3580388844711706e-05
DMPK O 0 0.0011912175687029958
[ O 0 1.3898577890358865e-05
- O 0 0.00019871741824317724
/ O 0 3.319962343084626e-05
- O 0 2.962546750495676e-05
] O 0 1.8893216520154965e-06
myotubes O 0 9.446447620575782e-06
exhibit O 0 5.212571068113903e-07
a O 0 1.4080141852446104e-07
higher O 0 4.686254158059455e-07
resting O 0 9.010342182591558e-06
[ O 0 7.69441214742983e-07
Ca2 O 0 2.358520305278944e-06
+ O 0 3.7717325085395714e-06
] O 0 4.2749397266561573e-07
i O 0 6.209059222328506e-08
than O 0 1.6274068315169643e-08
do O 0 2.3293656781220307e-08
wild O 0 2.8445433031265566e-07
- O 0 1.5175113730947487e-05
type O 0 6.629129984503379e-06
myotubes O 0 6.682183447992429e-05
because O 0 3.4803303350372516e-08
of O 0 8.067933876532152e-09
an O 0 1.0952056150870249e-08
altered O 0 2.1066259137114685e-07
open O 0 1.4234896639209182e-07
probability O 0 5.291648363936474e-08
of O 0 2.2534480947911106e-08
voltage O 0 2.2915614863450173e-06
- O 0 8.34528236737242e-06
dependent O 0 1.9833405531244352e-06
l O 0 6.458819552790374e-05
- O 0 1.831361441873014e-05
type O 0 2.7124447115056682e-06
Ca2 O 0 5.09508981849649e-06
+ O 0 1.3632857189804781e-06
and O 0 1.505757580844147e-07
Na O 0 1.8117219951818697e-05
+ O 0 5.453354788187426e-06
channels O 0 3.810039743257221e-06
. O 0 2.478453779986012e-06

The O 0 1.261743364011636e-05
mutant O 0 8.615455590188503e-05
myotubes O 0 0.0002715062000788748
exhibit O 0 1.0140806807612535e-05
smaller O 0 1.4861317367831361e-06
and O 0 2.1194300359184126e-07
slower O 0 7.278379598574247e-06
Ca2 O 0 3.309972817078233e-05
+ O 0 6.95282733431668e-06
responses O 0 2.2708390190473438e-07
upon O 0 9.806583278759717e-08
triggering O 0 1.8747404055829975e-06
by O 0 1.6836207805681624e-07
acetylcholine O 0 1.0137953722733073e-05
or O 0 2.559006588853663e-07
high O 0 3.0393869110412197e-06
external O 0 1.3717399269808084e-05
K O 0 7.96412568888627e-05
+ O 0 1.7493011910119094e-05
. O 0 4.116220679861726e-06

In O 0 8.083622560661752e-06
addition O 0 2.8858789846708532e-06
, O 0 4.650406424389075e-07
we O 0 6.128428253759921e-08
observed O 0 8.48428527433498e-08
that O 0 8.130467854527978e-09
these O 0 1.63016853349518e-08
Ca2 O 0 1.0811463653226383e-05
+ O 0 2.5722245482029393e-05
transients O 0 3.7122717913007364e-05
partially O 0 1.5103641999303363e-06
result O 0 1.0827933749624208e-07
from O 0 1.1359222895634957e-08
an O 0 2.1694679386285998e-09
influx O 0 2.2743385841295094e-08
of O 0 6.4863048265806356e-09
extracellular O 0 3.478180872207304e-07
Ca2 O 0 2.7113792384625413e-06
+ O 0 6.951813134037366e-07
through O 0 2.1930919302803886e-08
the O 0 4.6566992040197874e-08
l O 0 7.520623330492526e-05
- O 0 2.7471378416521475e-05
type O 0 9.66433890425833e-06
Ca2 O 0 2.446237158437725e-05
+ O 0 1.2657494153245352e-05
channel O 0 2.336189390916843e-05
. O 0 6.087030669732485e-06

Neither O 0 6.27247936790809e-05
the O 0 1.0101956604557927e-06
content O 0 1.0756788242360926e-06
nor O 0 5.668301810146659e-07
the O 0 2.506281226999363e-08
activity O 0 9.322821625801225e-08
of O 0 5.259128244006206e-08
Na O 0 3.6807425203733146e-05
+ O 0 6.141941867099376e-06
/ O 0 2.952470140371588e-06
K O 0 2.251117166451877e-06
+ O 0 1.0395068557045306e-06
ATPase O 0 3.866799943352817e-06
and O 0 1.9098052916888264e-07
sarcoplasmic O 0 1.7574715457158163e-05
reticulum O 0 2.8085945814382285e-05
Ca2 O 0 2.710831176955253e-05
+ O 0 1.5578831153106876e-05
- O 0 7.476960945496103e-06
ATPase O 0 1.2325674106250517e-05
are O 0 6.179875811085367e-08
affected O 0 3.5177245649720135e-07
by O 0 4.0411836721432337e-07
DMPK O 0 0.0013991092564538121
absence O 0 1.210245318361558e-05
. O 0 6.442133326345356e-06

In O 0 5.6356611821684055e-06
conclusion O 0 2.7831338229589164e-06
, O 0 4.267770634669432e-07
our O 0 1.0389058502369153e-07
data O 0 2.1675710115687252e-07
suggest O 0 3.346088988109841e-07
that O 0 4.666782160711591e-08
DMPK O 0 0.00031934905564412475
is O 0 1.2222125178595888e-07
involved O 0 2.2755716599931475e-07
in O 0 5.3114476372684294e-08
modulating O 0 1.7015473758874577e-06
the O 0 2.3079257616132054e-08
initial O 0 1.9518496685577702e-07
events O 0 2.9264867862366373e-08
of O 0 5.7801436526006e-08
excitation O 0 3.904135155607946e-06
- O 0 0.00013988983118906617
contraction O 0 9.675479304860346e-06
coupling O 0 7.464279406121932e-06
in O 0 1.569154505887127e-06
skeletal O 0 0.0006570381228812039
muscle O 0 2.059366670437157e-05
. O 0 1.7299865930908709e-06
. O 0 7.037991963443346e-06

Constitutional O 0 0.0011021129321306944
RB1 O 1 0.7164885401725769
- O 0 0.0016571111045777798
gene O 0 2.227205732197035e-05
mutations O 0 1.1306284250167664e-05
in O 0 2.105225348714157e-06
patients O 0 2.9865590477129444e-05
with O 0 2.6748682557808934e-06
isolated O 0 0.0005775891477242112
unilateral B-Disease 0 0.0008899663225747645
retinoblastoma I-Disease 0 0.44065725803375244
. O 0 3.3899381378432736e-05

In O 0 1.313685152126709e-05
most O 0 4.688981789513491e-06
patients O 0 4.730455839307979e-05
with O 0 1.2791090284736129e-06
isolated O 0 0.0001497904013376683
unilateral B-Disease 0 0.0003497999277897179
retinoblastoma I-Disease 1 0.7186707258224487
, O 0 1.646920463826973e-05
tumor B-Disease 0 0.004078310448676348
development O 0 4.233653783103364e-07
is O 0 6.458432011413606e-08
initiated O 0 4.0263500977744116e-07
by O 0 4.386411944778956e-08
somatic O 0 2.046874669758836e-06
inactivation O 0 0.00014942519192118198
of O 0 7.287634673502907e-08
both O 0 8.19896044390589e-08
alleles O 0 2.5568255068719736e-07
of O 0 1.182961781864833e-07
the O 0 1.534732859909127e-06
RB1 O 0 0.012730100192129612
gene O 0 1.3002886589674745e-05
. O 0 5.565559149545152e-06

However O 0 1.6292990039801225e-05
, O 0 6.449267857533414e-07
some O 0 2.349893080122456e-08
of O 0 7.897747167362468e-08
these O 0 3.84407371711859e-07
patients O 0 2.2133137463242747e-05
can O 0 6.599267408091691e-07
transmit O 0 0.0003520734317135066
retinoblastoma B-Disease 1 0.6459195613861084
predisposition O 0 0.0007420371402986348
to O 0 5.108851155455341e-07
their O 0 7.457381911990524e-07
offspring O 0 5.281183257466182e-05
. O 0 1.1225363778066821e-05

To O 0 3.585597823985154e-06
determine O 0 1.3287785805005115e-06
the O 0 1.442520982664064e-07
frequency O 0 7.283520631062856e-07
and O 0 2.0323606975125585e-07
nature O 0 1.7880870473163668e-07
of O 0 1.0437899078397095e-07
constitutional O 0 1.0943871529889293e-05
RB1 O 0 0.2633311450481415
- O 0 0.0005548735498450696
gene O 0 3.789695256273262e-06
mutations O 0 2.0799229787371587e-06
in O 0 6.571921744580322e-07
patients O 0 6.6737356974044815e-06
with O 0 3.9641389548705774e-07
isolated O 0 4.508950951276347e-05
unilateral B-Disease 0 9.567941015120596e-05
retinoblastoma I-Disease 0 0.004854108206927776
, O 0 1.9546362750588742e-07
we O 0 6.40323563061429e-08
analyzed O 0 3.395056751287484e-07
DNA O 0 8.972040177468443e-07
from O 0 9.309511739274967e-08
peripheral O 0 4.479396011447534e-05
blood O 0 4.280588200344937e-06
and O 0 7.547907330263115e-07
from O 0 6.296119863691274e-06
tumor B-Disease 0 0.10105056315660477
tissue O 0 0.0004829970421269536
. O 0 1.2137315025029238e-05

The O 0 2.3028551368042827e-06
analysis O 0 2.61334366769006e-06
of O 0 2.2333899778459454e-06
tumors B-Disease 1 0.9994088411331177
from O 0 9.667036238170112e-07
54 O 0 5.042179509473499e-06
( O 0 1.2681128680469556e-07
71 O 0 2.2018114123056876e-06
% O 0 3.362511336035823e-08
) O 0 5.819799753226107e-09
of O 0 1.5081340620781702e-08
76 O 0 3.7233212424325757e-06
informative O 0 1.9491577404551208e-05
patients O 0 8.772456931183115e-05
showed O 0 2.2330992578645237e-05
loss O 0 7.862988240958657e-06
of O 0 3.4628172329576046e-07
constitutional O 0 6.972999108256772e-05
heterozygosity O 0 0.3282237946987152
( O 0 2.318621591257397e-05
LOH O 1 0.9975895881652832
) O 0 7.491654514524271e-07
at O 0 3.013014747921261e-06
intragenic O 0 0.00037452325341291726
loci O 0 3.001102595590055e-05
. O 0 9.034297363541555e-06

Three O 0 4.476264166441979e-06
of O 0 1.5146222267503617e-06
13 O 0 1.3975507499708328e-05
uninformative O 1 0.6980623006820679
patients O 0 0.002603118307888508
had O 0 5.12262204210856e-06
constitutional O 0 1.7409334759577177e-05
deletions O 0 0.0003403297159820795
. O 0 3.841571742668748e-05

For O 0 4.36020081906463e-06
39 O 0 7.647630809515249e-06
randomly O 0 2.0857587514910847e-06
selected O 0 3.416582103454857e-06
tumors B-Disease 1 0.9967337846755981
, O 0 2.281091155964532e-06
SSCP O 0 0.0030458171386271715
, O 0 1.4955408005334903e-06
hetero O 0 0.00017210518126375973
- O 0 2.3684066036366858e-05
duplex O 0 0.00011306119995424524
analysis O 0 3.4761350775625033e-07
, O 0 4.9742396868168726e-08
sequencing O 0 2.73826685770473e-07
, O 0 5.795278568143658e-08
and O 0 2.8292619802527952e-08
Southern O 0 9.573057724310274e-08
blot O 0 8.910763426683843e-06
analysis O 0 9.738715789353591e-08
were O 0 4.8416563203090845e-08
used O 0 6.593907642127306e-08
to O 0 2.2429600221585133e-07
identify O 0 6.302451311057666e-06
mutations O 0 1.1873400580952875e-05
. O 0 6.242073595785769e-06

Mutations O 0 0.00020322611089795828
were O 0 2.695790271900478e-06
detected O 0 6.234149168449221e-06
in O 0 7.836824522655661e-08
21 O 0 2.1117914172918972e-07
( O 0 4.772852335577227e-08
91 O 0 5.44202123364812e-07
% O 0 4.294168931551212e-08
) O 0 1.7783385430902854e-08
of O 0 2.0203484041303454e-07
23 O 0 0.00041661818977445364
tumors B-Disease 1 0.999724805355072
with O 0 7.433139398926869e-05
LOH O 1 0.9993923902511597
. O 0 2.931299059127923e-05

In O 0 4.134109076403547e-06
6 O 0 3.16145042233984e-06
( O 0 2.2498498708500847e-07
38 O 0 5.362512638384942e-07
% O 0 5.7504976780364814e-08
) O 0 1.1546470446432977e-08
of O 0 5.12757019066612e-08
16 O 0 5.6966771808220074e-05
tumors B-Disease 1 0.9997240900993347
without O 0 9.347245395474602e-06
LOH O 1 0.9994688630104065
, O 0 3.285449565737508e-07
one O 0 8.26872081916008e-08
mutation O 0 2.5576500206625497e-07
was O 0 5.04862327943556e-07
detected O 0 1.6847205870362814e-06
, O 0 4.025904232207722e-08
and O 0 4.023977240308341e-08
in O 0 3.8358628273726936e-08
9 O 0 1.1909040722457576e-06
( O 0 2.9778327359508694e-08
56 O 0 3.967595603171503e-07
% O 0 2.11309423292505e-08
) O 0 5.377417622298708e-09
of O 0 1.698242968473096e-08
the O 0 2.3258332930709003e-06
tumors B-Disease 1 0.9998695850372314
without O 0 9.807649803406093e-06
LOH O 1 0.9989173412322998
, O 0 5.877296302969626e-07
both O 0 1.1040800274031426e-07
mutations O 0 1.2120852943553473e-06
were O 0 3.2882803679967765e-07
found O 0 1.3557787497120444e-06
. O 0 4.302221441321308e-06

Thus O 0 1.9752504158532247e-05
, O 0 6.472046152339317e-07
a O 0 1.716404796070492e-07
total O 0 1.074139603929325e-07
of O 0 9.394561573117244e-08
45 O 0 7.355109232776158e-07
mutations O 0 1.0189723980147392e-06
were O 0 2.9553984859376214e-07
identified O 0 1.1759617336792871e-05
in O 0 1.911109393404331e-06
tumors B-Disease 1 0.9961129426956177
of O 0 1.671960831117758e-06
36 O 0 0.00016783620230853558
patients O 0 9.169453551294282e-05
. O 0 7.242637366289273e-06

Thirty O 0 0.00014926798758096993
- O 0 8.055292710196227e-05
nine O 0 6.038643505235086e-07
of O 0 6.906864058464635e-08
the O 0 8.328186140715843e-08
mutations O 0 7.687964966862637e-07
- O 0 5.635967681882903e-06
including O 0 1.0853656107201459e-07
34 O 0 4.2143341261180467e-07
small O 0 3.040866261017072e-07
mutations O 0 2.761557595931663e-07
, O 0 5.2103246162005235e-08
2 O 0 2.646090990765515e-07
large O 0 3.8160803228493023e-07
structural O 0 6.4488208408874925e-06
alterations O 0 8.652315045765135e-06
, O 0 3.1215967055686633e-07
and O 0 4.3836433860633406e-07
hypermethylation O 0 0.0016645397990942001
in O 0 4.590208959598385e-07
3 O 0 0.00015894098032731563
tumors O 1 0.9998756647109985
- O 0 0.0013574872864410281
were O 0 4.7682533477200195e-07
not O 0 4.473745107702598e-08
detected O 0 4.722162429970922e-07
in O 0 1.493426537990672e-08
the O 0 3.775946666451091e-08
corresponding O 0 1.2526879800134338e-06
peripheral O 0 0.00012389328912831843
blood O 0 4.0823393646860495e-05
DNA O 0 6.815521192038432e-05
. O 0 1.582065669936128e-05

In O 0 7.2956695476023015e-06
6 O 0 8.577569133194629e-06
( O 0 2.9845372750969545e-07
17 O 0 4.5569379381049657e-07
% O 0 3.9116677896799956e-08
) O 0 5.689139381814812e-09
of O 0 6.271340780017454e-09
the O 0 4.953958665510072e-08
36 O 0 1.1543315849849023e-05
patients O 0 7.425769126712112e-06
, O 0 8.559052844248072e-08
a O 0 8.237049797799045e-08
mutation O 0 4.5169628037911025e-07
was O 0 1.3344641729418072e-06
detected O 0 2.5384676973772002e-06
in O 0 2.6917156503714068e-08
constitutional O 0 2.0779789622338285e-07
DNA O 0 3.5261891753179953e-06
, O 0 9.332196526656844e-08
and O 0 3.048165098107347e-08
1 O 0 4.8680377062737534e-08
of O 0 1.0798930638600268e-08
these O 0 1.2974521013120466e-08
mutations O 0 1.6223603438447753e-07
is O 0 1.985863740117111e-08
known O 0 3.889957156388846e-08
to O 0 2.6492518401255438e-08
be O 0 4.457884728026329e-08
associated O 0 5.111682526148797e-07
with O 0 3.5318763025316e-07
reduced O 0 2.4416900487267412e-05
expressivity O 0 0.004212202504277229
. O 0 1.631136728974525e-05

The O 0 6.1953764998179395e-06
presence O 0 1.6413086996180937e-06
of O 0 8.84262831846172e-08
a O 0 4.398434327868017e-07
constitutional O 0 5.027347924624337e-06
mutation O 0 4.292786798032466e-06
was O 0 3.5050638871325646e-06
not O 0 1.1133254673723059e-07
associated O 0 2.4974991674753255e-07
with O 0 1.48675614042304e-08
an O 0 1.5207309189690932e-08
early O 0 1.0018076181950164e-06
age O 0 4.09431277148542e-06
at O 0 4.145752427575644e-06
treatment O 0 3.815677700913511e-05
. O 0 1.023654385789996e-05

In O 0 7.0763344410806894e-06
1 O 0 7.689989615755621e-06
patient O 0 2.0430952645256184e-05
, O 0 5.093293680147326e-07
somatic O 0 4.3386840843595564e-05
mosaicism O 0 0.3211710751056671
was O 0 5.444011549116112e-06
demonstrated O 0 1.327118297922425e-06
by O 0 7.235239252167958e-08
molecular O 0 7.06957621332549e-07
analysis O 0 1.566639298289374e-07
of O 0 8.38596818653059e-08
DNA O 0 7.87739918450825e-06
and O 0 4.827215889235958e-07
RNA O 0 1.2462476206565043e-06
from O 0 7.271208346537605e-07
peripheral O 0 0.00027663673972710967
blood O 0 5.839663936058059e-05
. O 0 8.403208084928337e-06

In O 0 1.172679549199529e-05
2 O 0 3.321032636449672e-05
patients O 0 1.8989436284755357e-05
without O 0 2.3785914038398914e-07
a O 0 4.550679761905485e-07
detectable O 0 1.2805694495909847e-05
mutation O 0 4.576047274440498e-07
in O 0 1.4210115750756813e-07
peripheral O 0 0.00022747369075659662
blood O 0 4.682610961026512e-05
, O 0 1.5542683513558586e-06
mosaicism O 0 0.006762306671589613
was O 0 2.931825292762369e-06
suggested O 0 5.089083856546495e-07
because O 0 3.8217681463947883e-08
1 O 0 4.3971503771444986e-08
of O 0 2.352736494515284e-08
the O 0 6.933789791219169e-07
patients O 0 0.0001184325956273824
showed O 0 0.020276522263884544
multifocal O 1 0.999985933303833
tumors B-Disease 1 0.9999918937683105
and O 0 1.5503128452110104e-06
the O 0 8.532175144182474e-08
other O 0 2.2082446093918406e-08
later O 0 2.7168306360181305e-07
developed O 0 1.5412275615744875e-06
bilateral B-Disease 0 3.36386619892437e-05
retinoblastoma I-Disease 0 0.0669875293970108
. O 0 2.7981839593849145e-05

In O 0 8.298790817207191e-06
conclusion O 0 5.895715275983093e-06
, O 0 4.884583972852852e-07
our O 0 1.2732047593999596e-07
results O 0 1.5021375077139965e-07
emphasize O 0 4.018478705347661e-07
that O 0 3.197613551719769e-08
the O 0 4.762422278759004e-08
manifestation O 0 1.3170091506253812e-06
and O 0 1.6466599106479407e-07
transmissibility O 0 1.2119420716771856e-05
of O 0 6.756872750202092e-08
retinoblastoma B-Disease 0 8.428240107605234e-05
depend O 0 3.518449318562489e-07
on O 0 2.1071603839573072e-07
the O 0 5.8762097410181013e-08
nature O 0 1.7372765626078035e-07
of O 0 2.5751537791052215e-08
the O 0 3.68182782040094e-08
first O 0 1.0646144232850929e-07
mutation O 0 2.217793024783532e-07
, O 0 2.0459065552813627e-08
its O 0 4.818429211184139e-09
time O 0 7.59446194820157e-09
in O 0 7.23163573468355e-09
development O 0 8.889097813380431e-08
, O 0 3.7702612587509066e-08
and O 0 2.5910626533232062e-08
the O 0 8.802742534896879e-09
number O 0 1.4740638043519994e-08
and O 0 2.1574939168544915e-08
types O 0 5.8267669800216026e-08
of O 0 3.0697176356397904e-08
cells O 0 6.647233590229007e-07
that O 0 2.539260890443984e-08
are O 0 4.334514613901774e-08
affected O 0 3.363281848578481e-07
. O 0 2.325428880567415e-07
. O 0 2.5341187210869975e-06

Hereditary B-Disease 1 0.9999749660491943
deficiency I-Disease 1 0.9994140863418579
of I-Disease 0 2.1579564872808987e-06
the I-Disease 0 4.828307282878086e-07
fifth I-Disease 0 2.631776396810892e-06
component I-Disease 0 1.3573712749348488e-06
of I-Disease 0 8.36489775224436e-08
complement I-Disease 0 8.576544132665731e-07
in O 0 5.90811509937339e-07
man O 0 1.5537585568381473e-05
. O 0 5.480047548189759e-06

I O 0 0.0012265659170225263
. O 0 0.00018554036796558648

Clinical O 0 0.0034886684734374285
, O 0 1.171114945464069e-05
immunochemical O 0 0.003015988739207387
, O 0 2.53472535405308e-06
and O 0 1.0875618272621068e-06
family O 0 4.017710580228595e-06
studies O 0 4.373031060822541e-06
. O 0 1.3175769709050655e-05

The O 0 3.0727455850865226e-06
first O 0 1.5436104376931326e-06
recognized O 0 1.9639692254713736e-06
human O 0 3.3825022001110483e-06
kindred O 0 0.0016449826071038842
with O 0 0.00578055065125227
hereditary B-Disease 1 0.9999943971633911
deficiency I-Disease 1 0.998114824295044
of I-Disease 0 3.2531582405681547e-07
the I-Disease 0 2.925081616922398e-07
fifth I-Disease 0 4.8517322284169495e-06
component I-Disease 0 9.858022167463787e-07
of I-Disease 0 8.4825053647819e-08
complement I-Disease 0 1.0059858368549612e-06
( O 0 2.648863528520451e-07
C5 O 0 0.00019335471733938903
) O 0 2.467482147494593e-07
is O 0 3.4471105436750804e-07
described O 0 6.3631109696871135e-06
. O 0 4.955587883159751e-06

The O 0 1.2549536222650204e-05
proband O 0 0.0008168104104697704
, O 0 9.660345767770195e-07
a O 0 1.8122828748801112e-07
20 O 0 2.6556776333563903e-07
- O 0 1.0061728062282782e-05
year O 0 4.8385356876679e-07
- O 0 7.548717985628173e-05
old O 0 1.693345620878972e-05
black O 0 3.730252865352668e-05
female O 0 8.211672138713766e-06
with O 0 0.010990804061293602
systemic B-Disease 1 0.9999995231628418
lupus I-Disease 1 0.9999991655349731
erythematosus I-Disease 1 0.9999951124191284
since O 0 6.61543890601024e-05
age O 0 1.7968159227166325e-05
11 O 0 3.5023906548303785e-06
, O 0 8.21757339508622e-07
lacked O 0 0.00011052872287109494
serum O 0 0.002105085179209709
hemolytic O 0 0.12897120416164398
complement O 0 3.8988861206235015e-07
activity O 0 3.583282648378372e-07
, O 0 8.696176223565999e-08
even O 0 1.3726968006722018e-07
during O 0 2.085691221509478e-06
remission O 0 0.00012977120059076697
. O 0 6.3779225456528366e-06

C5 O 0 0.009483249858021736
was O 0 8.82306121638976e-05
undetectable O 0 0.00028465496143326163
in O 0 1.0414348707854515e-06
her O 0 1.9060857994190883e-06
serum O 0 1.667951983108651e-05
by O 0 2.5809274006860505e-07
both O 0 4.78816161830764e-07
immunodiffusion O 0 0.0034645888954401016
and O 0 6.804143777117133e-05
hemolytic O 1 0.9986528158187866
assays O 0 0.0003881265874952078
. O 0 1.7352382201352157e-05

Other O 0 4.05400214731344e-06
complement O 0 2.434682983221137e-06
components O 0 1.4570553048542934e-06
were O 0 8.486956204478702e-08
normal O 0 1.6574236383348762e-07
during O 0 4.99759607919259e-07
remission O 0 8.278905443148687e-05
of O 0 1.1819151950476225e-05
lupus O 1 0.9983541965484619
, O 0 1.8141676036975696e-06
but O 0 5.031646423958591e-07
C1 O 0 0.0002226295619038865
, O 0 3.542637614373234e-07
C4 O 0 0.0001328370999544859
, O 0 4.217349385271518e-07
C2 O 0 9.774419595487416e-05
, O 0 1.447432396162185e-07
and O 0 8.513454190506309e-07
C3 O 0 0.003077463945373893
levels O 0 4.5192869038146455e-06
fell O 0 0.00013303483137860894
during O 0 9.033728019858245e-06
exacerbations O 0 0.04225610941648483
. O 0 2.0924864656990394e-05

A O 0 3.8534006307600066e-05
younger O 0 2.6116664230357856e-05
half O 0 5.159142347110901e-06
- O 0 0.0018252094741910696
sister O 0 0.000346648768754676
, O 0 2.411901050436427e-06
who O 0 2.437670673316461e-06
had O 0 4.159990112384548e-06
no O 0 1.1039954188163392e-05
underlying O 0 0.21040672063827515
disease O 0 0.004248268436640501
, O 0 1.8848548961614142e-06
was O 0 4.512568466452649e-06
also O 0 1.2735897314541944e-07
found O 0 2.239172971485459e-07
to O 0 2.191823256225689e-07
lack O 0 6.749930435034912e-06
immunochemically O 0 0.08944209665060043
detectable O 0 0.0005162789602763951
C5 O 0 0.0012404202716425061
. O 0 1.9243861970608123e-05

By O 0 0.00025907994131557643
hemolytic O 1 0.9993101358413696
assay O 0 0.00014867138816043735
, O 0 2.793299472614308e-06
she O 0 4.5341792542785697e-07
exhibited O 0 6.2504449260814e-07
1 O 0 5.125668280925311e-07
- O 0 4.932198135065846e-05
2 O 0 4.485656006636418e-07
% O 0 1.0476189693520155e-08
of O 0 7.84375941975668e-09
the O 0 3.4833256279398483e-08
normal O 0 7.376913799816975e-07
serum O 0 7.0542605499213096e-06
C5 O 0 1.2535338100860827e-05
level O 0 1.6434751159977168e-07
and O 0 3.855182484358011e-08
normal O 0 1.0949929674097802e-07
concentrations O 0 2.0620321095066174e-07
of O 0 1.6184051432333035e-08
other O 0 7.611519237116227e-08
complement O 0 1.9344797692610882e-06
components O 0 1.062259434547741e-05
. O 0 4.8632396101311315e-06

C5 O 0 0.002977498574182391
levels O 0 9.914705515257083e-06
of O 0 3.629347133937699e-07
other O 0 1.0600209776612246e-07
family O 0 4.545635476915777e-07
members O 0 3.2823265883052954e-08
were O 0 4.1300317832337896e-08
either O 0 2.7343283193204115e-08
normal O 0 6.858802947817821e-08
or O 0 3.66748764690783e-08
approximately O 0 3.856837693660964e-08
half O 0 1.5862511304476357e-07
- O 0 1.0270004167978186e-05
normal O 0 3.6809996117881383e-07
, O 0 8.023312858540521e-08
consistent O 0 4.397452642024291e-07
with O 0 5.085285579298215e-07
autosomal O 0 7.158537482609972e-05
codominant O 0 0.004014173056930304
inheritance O 0 5.237288860371336e-06
of O 0 1.6206762154524768e-07
the O 0 5.69346184420283e-07
gene O 0 1.7522466805530712e-05
determining O 0 0.004628109745681286
C5 B-Disease 1 0.999992847442627
deficiency I-Disease 1 0.99996018409729
. O 0 7.53850326873362e-05

Normal O 0 0.007587312720716
hemolytic O 1 0.9998854398727417
titers O 0 0.25932109355926514
were O 0 7.166469004005194e-06
restored O 0 6.296937044680817e-06
to O 0 3.968511634866445e-07
both O 0 9.916396948028705e-07
homozygous O 0 0.0002838046057149768
C5 B-Disease 1 0.999906063079834
- I-Disease 1 0.9998908042907715
deficient I-Disease 1 0.9999159574508667
( O 0 1.1795122190960683e-05
C5D B-Disease 1 0.999886155128479
) O 0 7.703737310293945e-07
sera O 0 1.8986645955010317e-05
by O 0 3.866205844360593e-08
addition O 0 3.724055730458531e-08
of O 0 5.662532132078013e-08
highly O 0 1.5479402009077603e-06
purified O 0 9.911387678585015e-06
human O 0 2.368982222833438e-06
C5 O 0 0.0006794232176616788
. O 0 1.0661862688721158e-05

In O 0 1.1257395271968562e-05
specific O 0 5.624799086945131e-06
C5 O 0 0.000609084905590862
titrations O 0 0.003724761540070176
, O 0 2.197314188379096e-06
however O 0 4.371286479454284e-07
, O 0 1.5050282797801628e-07
it O 0 4.734869918365803e-08
was O 0 3.8620092368546466e-07
noted O 0 1.0485589285735841e-07
that O 0 1.6315558681867515e-08
when O 0 3.492339573085701e-08
limited O 0 4.09575058313294e-08
amounts O 0 4.821870192017741e-08
of O 0 2.274772370469691e-08
C5 O 0 2.9202725272625685e-05
were O 0 1.5578105205804604e-07
assayed O 0 1.1166104059157078e-06
in O 0 1.3780702801113875e-08
the O 0 8.915310267809673e-09
presence O 0 2.9213616414835997e-08
of O 0 2.639441731844272e-08
low O 0 6.918822691659443e-06
dilutions O 0 1.2864717064076103e-05
of O 0 9.690965185882305e-08
either O 0 1.688581164671632e-06
C5D B-Disease 1 0.9991108775138855
serum O 0 1.9861037799273618e-05
, O 0 5.2760270818907884e-08
curving O 0 7.166866566876706e-07
rather O 0 4.6690082911027275e-08
than O 0 1.9331906742081628e-08
linear O 0 5.32685362486518e-07
dose O 0 1.0805832744154031e-06
- O 0 2.7038338430429576e-06
response O 0 9.81489165496896e-08
plots O 0 4.7321972829195147e-07
were O 0 8.102589532654747e-08
consistently O 0 4.201428396299889e-07
obtained O 0 1.1452544868006953e-07
, O 0 5.367071054251937e-08
suggesting O 0 2.8702922350021254e-07
some O 0 9.391963828875305e-08
inhibitory O 0 6.478433988377219e-06
effect O 0 4.340332907304401e-06
. O 0 4.7332987378467806e-06

Further O 0 1.0111265510204248e-05
studies O 0 2.9096063371980563e-06
suggested O 0 3.0517073810187867e-06
that O 0 1.9446554233581992e-07
low O 0 7.3139499363605864e-06
dilutions O 0 5.4857926443219185e-05
of O 0 6.267498520173831e-07
C5D B-Disease 1 0.9998980760574341
serum O 0 0.00024149238015525043
contain O 0 4.7148816406661354e-07
a O 0 8.110521321214037e-08
factor O 0 1.8467090967533295e-07
( O 0 2.5783041479598978e-08
or O 0 3.399189907327127e-08
factors O 0 3.5108467244526764e-08
) O 0 1.3434105383680617e-08
interfering O 0 2.0390118038449145e-07
at O 0 8.220883529475032e-08
some O 0 8.03491673195822e-09
step O 0 3.835358484138851e-07
in O 0 6.361821647260513e-08
the O 0 5.326147629602929e-07
hemolytic O 1 0.9572717547416687
assay O 0 3.1799379485164536e-06
of O 0 1.491592485081128e-07
C5 O 0 0.0004316236882004887
, O 0 2.0095643549211673e-07
rather O 0 6.088001214266114e-08
than O 0 4.616514104327507e-08
a O 0 3.2426208917968324e-07
true O 0 5.335778496373678e-06
C5 O 0 0.0057033053599298
inhibitor O 0 6.754437345080078e-05
or O 0 3.570637545635691e-06
inactivator O 0 0.0002908651949837804
. O 0 9.792247510631569e-06

Of O 0 6.5937215367739554e-06
clinical O 0 7.146125426515937e-05
interest O 0 3.12417159875622e-06
are O 0 2.608219347166596e-07
( O 0 9.85947252729602e-08
a O 0 1.084411707097388e-07
) O 0 6.070596469953671e-08
the O 0 2.1090919233301975e-08
documentation O 0 1.5408352282975102e-06
of O 0 3.7301238080544863e-06
membranous O 1 0.9996740818023682
glomerulonephritis B-Disease 1 0.9999991655349731
, O 0 0.005501885432749987
vasculitis B-Disease 1 0.9999837875366211
, O 0 0.0015149593818932772
and O 0 0.18197928369045258
arthritis B-Disease 1 0.9999996423721313
in O 0 2.5062581698875874e-06
an O 0 3.868368025905511e-07
individual O 0 7.17120201443322e-07
lacking O 0 1.3023114661336876e-05
C5 O 0 0.0014949908945709467
( O 0 1.0983920617491094e-07
and O 0 2.86340995359069e-08
its O 0 2.2191210646838044e-08
biologic O 0 6.98803887644317e-06
functions O 0 2.9133323309338266e-08
) O 0 2.2075454353398527e-08
, O 0 1.5079557158514945e-08
and O 0 3.6312510331981684e-08
( O 0 3.9890011294119176e-08
b O 0 4.0571771933173295e-06
) O 0 2.017910105678311e-08
a O 0 4.8875381963853215e-08
remarkable O 0 1.273926613976073e-06
propensity O 0 8.045419963309541e-05
to O 0 1.9089882698608562e-05
bacterial B-Disease 1 0.9996034502983093
infections I-Disease 1 0.9868304133415222
in O 0 5.113305974191462e-07
the O 0 5.372390887714573e-07
proband O 0 0.010404739528894424
, O 0 2.3127120130084222e-07
even O 0 3.556468186616257e-08
during O 0 4.2010594114572086e-08
periods O 0 1.290945732534965e-07
of O 0 2.738618753994615e-08
low O 0 8.088466529443394e-06
- O 0 1.621734190848656e-05
dose O 0 5.195384460421337e-07
or O 0 3.561491723758081e-08
alternate O 0 1.1191740156846208e-07
- O 0 6.464226771640824e-06
day O 0 4.170914507994894e-06
corticosteroid O 0 0.0004464730154722929
therapy O 0 2.6784140572999604e-05
. O 0 4.463169716473203e-06

Other O 0 3.1223967198457103e-06
observations O 0 5.4359079513233155e-06
indicate O 0 1.9718061139428755e-06
that O 0 8.815179342036572e-08
the O 0 2.230177358342189e-07
C5D B-Disease 1 0.9968273043632507
state O 0 2.2586425529880216e-07
is O 0 3.209889598565496e-08
compatible O 0 3.5690135291588376e-07
with O 0 5.352584864226628e-08
normal O 0 5.626390588986396e-07
coagulation O 0 4.911012001684867e-05
function O 0 1.52585684531914e-07
and O 0 3.30609601917331e-08
the O 0 1.4775373813336046e-08
capacity O 0 1.1558803691968933e-07
to O 0 6.83042102878062e-08
mount O 0 3.052027022931725e-05
a O 0 4.930270279146498e-06
neutrophilic O 1 0.8831217885017395
leukocytosis O 1 0.6942961812019348
during O 0 0.000256829836871475
pyogenic B-Disease 1 0.9881256818771362
infection I-Disease 0 0.0006971386028453708
. O 0 2.627047024361673e-06
. O 0 6.3539669099554885e-06

Susceptibility O 1 0.6238316297531128
to O 0 0.02390315756201744
ankylosing B-Disease 1 0.9999996423721313
spondylitis I-Disease 1 1.0
in O 0 0.0024444099981337786
twins O 0 0.057059623301029205
: O 0 6.381144430633867e-07
the O 0 4.171484491166666e-08
role O 0 7.321713013652698e-08
of O 0 4.0726376937527675e-08
genes O 0 3.149943381686171e-07
, O 0 6.398950631592015e-07
HLA O 0 0.008025799877941608
, O 0 2.254914903687677e-07
and O 0 2.2170654290221137e-07
the O 0 3.717445622442028e-07
environment O 0 1.6938398402999155e-05
. O 0 5.054836947238073e-06

OBJECTIVE O 0 2.2917232854524627e-05
To O 0 7.448298333656567e-07
determine O 0 6.763576720913989e-07
the O 0 1.3607434823370568e-07
relative O 0 3.587225592127652e-06
effects O 0 1.3742820783591014e-06
of O 0 1.4585093310870434e-07
genetic O 0 6.8833819568681065e-06
and O 0 1.0386893336544745e-06
environmental O 0 9.833789590629749e-06
factors O 0 6.799925245104532e-07
in O 0 1.934092324518133e-06
susceptibility O 0 0.0385672003030777
to O 0 0.0928591936826706
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00037548941327258945
AS B-Disease 0 0.0006543092895299196
) O 0 2.619276756377076e-06
. O 0 6.9265470301616006e-06

METHODS O 0 0.0001467872061766684
Twins O 0 0.00039162757457233965
with O 0 3.85676776204491e-06
AS B-Disease 0 2.6931673346552998e-05
were O 0 4.448694710390555e-07
identified O 0 6.411913204829034e-07
from O 0 2.9692969860661833e-08
the O 0 4.672936881888745e-08
Royal O 0 8.569491001253482e-06
National O 0 7.005802217463497e-06
Hospital O 0 0.004993353970348835
for O 0 0.0009132569539360702
Rheumatic B-Disease 1 0.9999942779541016
Diseases I-Disease 1 0.5605008602142334
database O 0 5.271502595860511e-05
. O 0 1.7336207747575827e-05

Clinical O 0 0.0031084942165762186
and O 0 9.86830400506733e-06
radiographic O 0 0.006274627987295389
examinations O 0 3.807847679127008e-05
were O 0 7.692431154282531e-07
performed O 0 9.155464795185253e-07
to O 0 8.789223926441991e-08
establish O 0 2.4114549432852073e-06
diagnoses O 0 0.01824996992945671
, O 0 1.9016255464521237e-05
and O 0 0.0071186041459441185
disease O 0 0.2970918118953705
severity O 0 0.007911939173936844
was O 0 6.892887540743686e-06
assessed O 0 7.940028808661737e-06
using O 0 1.7247700156985957e-07
a O 0 2.718037990234734e-07
combination O 0 7.108612294359773e-07
of O 0 1.6980979467007273e-07
validated O 0 5.984465133224148e-06
scoring O 0 2.8163781280454714e-06
systems O 0 4.9298134399577975e-05
. O 0 4.739012638310669e-06

HLA O 0 0.007642762735486031
typing O 0 6.294002378126606e-05
for O 0 3.0298888304969296e-06
HLA O 0 0.002088087610900402
- O 0 0.000159122355398722
B27 O 0 4.848387106903829e-05
, O 0 5.860589453732246e-07
HLA O 0 0.00014374851889442652
- O 0 3.552835914888419e-05
B60 O 0 2.014597885136027e-05
, O 0 1.2085735079381266e-07
and O 0 2.7140802671965503e-07
HLA O 0 0.0024849618785083294
- O 0 0.0018723916728049517
DR1 O 0 0.006618131883442402
was O 0 1.7303135564361583e-06
performed O 0 4.881259201283683e-07
by O 0 1.230678208230529e-07
polymerase O 0 1.0654127436282579e-05
chain O 0 4.930026079819072e-06
reaction O 0 7.384432620938242e-08
with O 0 1.626066392645953e-08
sequence O 0 4.768639527696905e-08
- O 0 5.746763349634421e-07
specific O 0 2.246016173046428e-08
primers O 0 6.275016630752361e-07
, O 0 3.598281139716164e-08
and O 0 1.2477146071887546e-07
zygosity O 0 0.00022866357176098973
was O 0 1.3690028026758227e-06
assessed O 0 4.371780505607603e-06
using O 0 1.5958513586156187e-06
microsatellite O 0 0.000745372730307281
markers O 0 0.00011012452887371182
. O 0 1.698186133580748e-05

Genetic O 0 0.0012134434655308723
and O 0 5.837940989295021e-06
environmental O 0 4.032077868032502e-06
variance O 0 4.325143436290091e-06
components O 0 9.50991852732841e-06
were O 0 8.15093358141894e-07
assessed O 0 6.919377028680174e-06
with O 0 7.216674902110753e-08
the O 0 4.8572974975513716e-08
program O 0 4.906714252683742e-07
Mx O 0 3.026007289008703e-05
, O 0 1.5914432438535187e-08
using O 0 1.5495094984885327e-08
data O 0 6.152495757305587e-08
from O 0 8.213168811721516e-09
this O 0 4.4936085963342975e-09
and O 0 1.7520841666396336e-08
previous O 0 6.131561747224623e-08
studies O 0 2.7787864453898692e-08
of O 0 6.365462468238547e-08
twins O 0 7.500241190427914e-05
with O 0 1.302606847275456e-06
AS B-Disease 0 0.0002358727651881054
. O 0 8.304697075800505e-06

RESULTS O 0 5.164428148418665e-05
Six O 0 2.5023082343977876e-06
of O 0 5.529144004867703e-07
8 O 0 1.2522996257757768e-05
monozygotic O 0 0.0023698501754552126
( O 0 2.4366388515772996e-06
MZ O 1 0.7189249992370605
) O 0 9.703169325803174e-07
twin O 0 0.0002860342210624367
pairs O 0 3.398546368771349e-06
were O 0 1.4508208550978452e-05
disease O 0 6.694212061120197e-05
concordant O 0 0.00023595194215886295
, O 0 8.322849112119002e-07
compared O 0 1.5890127542661503e-06
with O 0 4.035467782159685e-08
4 O 0 1.1688275947108195e-07
of O 0 2.1449631404379943e-08
15 O 0 3.165705777519179e-07
B27 O 0 1.6029278413043357e-05
- O 0 2.9105915018590167e-05
positive O 0 4.741335999369767e-07
dizygotic O 0 5.984493691357784e-05
( O 0 2.2471779459465324e-07
DZ O 0 0.0011009757872670889
) O 0 1.3090560457840184e-07
twin O 0 9.516359568806365e-06
pairs O 0 1.3393622566582053e-07
( O 0 2.0456839777693858e-08
27 O 0 1.3142020804934873e-07
% O 0 1.847444863756209e-08
) O 0 9.587782123787747e-09
and O 0 1.3499449558196375e-08
4 O 0 9.8690115635236e-08
of O 0 6.909301930591027e-08
32 O 0 8.918543244362809e-06
DZ O 0 0.09427954256534576
twin O 0 7.067956175887957e-05
pairs O 0 1.9043217491798714e-07
overall O 0 3.7900463212281466e-07
( O 0 3.094737976994111e-08
12 O 0 4.861504976361175e-08
. O 0 1.3804195120314944e-08
5 O 0 1.4819012505995488e-07
% O 0 1.6148044323927024e-07
) O 0 2.3221312517307524e-07
. O 0 1.4957220173528185e-06

Nonsignificant O 0 0.03541817143559456
increases O 0 0.00019278623221907765
in O 0 1.996695573325269e-06
similarity O 0 2.2291681034403155e-06
with O 0 1.3657188446813961e-07
regard O 0 2.4850521640473744e-07
to O 0 1.0949595719011995e-07
age O 0 8.660240382596385e-06
at O 0 0.00026298544253222644
disease O 0 0.009683568961918354
onset O 0 0.0017895628698170185
and O 0 3.157360026762035e-07
all O 0 2.0456294436144162e-08
of O 0 1.3003028698221897e-07
the O 0 1.1157398148498032e-05
disease O 0 0.016240233555436134
severity O 0 0.0002922386338468641
scores O 0 4.980362518836046e-06
assessed O 0 4.187039394309977e-06
were O 0 4.799463226845546e-07
noted O 0 9.279850132770662e-07
in O 0 3.0356732168002054e-06
disease O 0 0.0019844488706439734
- O 0 0.05974321812391281
concordant O 1 0.806346595287323
MZ O 1 0.9989431500434875
twins O 0 0.0011359627824276686
compared O 0 2.4626520826132037e-05
with O 0 7.0358246375690214e-06
concordant O 0 0.09738905727863312
DZ O 1 0.9278945922851562
twins O 0 0.0011609219945967197
. O 0 1.721176886348985e-05

HLA O 0 0.14598380029201508
- O 0 0.0011485442519187927
B27 O 0 0.00010227039456367493
and O 0 1.0860734391826554e-06
B60 O 0 4.5563421736005694e-05
were O 0 4.719708783795795e-07
associated O 0 6.442438120757288e-07
with O 0 2.868428623514774e-07
the O 0 2.508740408302401e-06
disease O 0 6.621044303756207e-05
in O 0 2.490382939868141e-07
probands O 0 0.009903195314109325
, O 0 2.95854562182285e-07
and O 0 8.340442292364969e-08
the O 0 5.567208916090749e-08
rate O 0 2.4210546598624205e-06
of O 0 9.781268772712792e-07
disease O 0 3.663569441414438e-05
concordance O 0 8.782838449405972e-06
was O 0 2.4638118247821694e-06
significantly O 0 1.949804754985962e-06
increased O 0 6.659429345745593e-07
among O 0 1.6604723214186379e-06
DZ O 1 0.5057286024093628
twin O 0 0.0008514369837939739
pairs O 0 4.410775602536887e-07
in O 0 4.836450884226906e-08
which O 0 4.281141130491051e-08
the O 0 1.0561501539996243e-07
co O 0 0.00013113954628352076
- O 0 0.0021080358419567347
twin O 0 0.00016688971663825214
was O 0 2.964386283110798e-07
positive O 0 3.196034015218174e-08
for O 0 2.0963701885534647e-08
both O 0 1.0082681001222227e-07
B27 O 0 3.041201489395462e-05
and O 0 3.817073320533382e-06
DR1 O 0 0.013198497705161572
. O 0 8.106761015369557e-06

Additive O 0 0.00015828308823984116
genetic O 0 0.00012858916306868196
effects O 0 1.1937539056816604e-05
were O 0 5.465988692776591e-07
estimated O 0 5.486660370479512e-07
to O 0 3.515932789355247e-08
contribute O 0 7.095581366911574e-08
97 O 0 5.298273890730343e-07
% O 0 4.796296693143631e-08
of O 0 2.5777190160169994e-08
the O 0 1.0559688945477319e-07
population O 0 2.840683066551719e-07
variance O 0 6.173912879603449e-06
. O 0 5.997211246722145e-06

CONCLUSION O 0 0.00022672623163089156
Susceptibility O 0 0.000983741250820458
to O 0 1.7741293731887708e-06
AS B-Disease 0 3.843700324068777e-05
is O 0 1.4816879456702736e-07
largely O 0 1.231077391139479e-07
genetically O 0 4.7079259957172326e-07
determined O 0 1.3632078434966388e-06
, O 0 1.6488236553868774e-07
and O 0 1.297779306241864e-07
the O 0 1.0728291499617626e-07
environmental O 0 8.476475159113761e-06
trigger O 0 8.29690725367982e-06
for O 0 3.215816093415924e-07
the O 0 5.557656550081447e-06
disease O 0 0.0005091155180707574
is O 0 6.127178266979172e-07
probably O 0 7.605322934978176e-06
ubiquitous O 0 3.336002555442974e-05
. O 0 6.24007361693657e-06

HLA O 0 0.16559840738773346
- O 0 0.0005820950027555227
B27 O 0 0.00010711866343626752
accounts O 0 1.7281499822274782e-06
for O 0 1.193704122215422e-07
a O 0 3.244476829422638e-07
minority O 0 6.71366365168069e-07
of O 0 5.216330123403168e-08
the O 0 1.1036021163590704e-07
overall O 0 1.2301130482228473e-05
genetic O 0 6.516249413834885e-05
susceptibility O 0 9.007177141029388e-05
to O 0 1.3342018974071834e-06
AS B-Disease 0 0.00019777195120695978
. O 0 1.0862310773518402e-05

Cell O 0 0.0005173474783077836
cycle O 0 5.039362076786347e-05
- O 0 6.350595504045486e-05
dependent O 0 3.6684361930383602e-06
colocalization O 0 3.6862089473288506e-05
of O 0 3.5803654441224353e-07
BARD1 O 0 0.0019822462927550077
and O 0 7.934919494800852e-07
BRCA1 O 0 7.327354069275316e-06
proteins O 0 8.233624981812682e-08
in O 0 6.946883246428115e-08
discrete O 0 5.587864507106133e-06
nuclear O 0 0.00028148177079856396
domains O 0 9.247320122085512e-06
. O 0 4.972019269189332e-06

Germ O 0 0.26634469628334045
- O 0 0.003179621184244752
line O 0 2.7187350497115403e-05
mutations O 0 2.225599473604234e-06
of O 0 1.4640501433405007e-07
the O 0 2.4249126795439224e-07
BRCA1 O 0 0.00012454096577130258
gene O 0 2.8395663775881985e-06
predispose O 0 1.0298525921825785e-05
women O 0 1.434566740954324e-07
to O 0 3.396636216734805e-08
early O 0 2.4774235498625785e-06
- O 0 0.2588536739349365
onset O 1 0.9760874509811401
breast B-Disease 1 0.9999170303344727
and I-Disease 1 0.9971931576728821
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999916553497314
by O 0 2.6269970021530753e-06
compromising O 0 0.00016362094902433455
the O 0 5.54053485757322e-07
genes O 0 3.0300216167233884e-06
presumptive O 0 0.015879781916737556
function O 0 2.144953299421104e-07
as O 0 1.0218163026820548e-07
a O 0 2.972677293655579e-06
tumor B-Disease 0 0.004597942810505629
suppressor O 0 0.00021076867415104061
. O 0 8.415147931373212e-06

Although O 0 1.3093961570120882e-05
the O 0 1.016312239698891e-06
biochemical O 0 1.1183455171703827e-05
properties O 0 4.236224413034506e-06
of O 0 3.526645855345123e-07
BRCA1 O 0 6.657942867605016e-05
polypeptides O 0 7.61203500587726e-06
are O 0 2.5577890028216643e-07
not O 0 1.936013944714432e-07
understood O 0 1.123082370213524e-06
, O 0 7.564293724726667e-08
their O 0 2.524599373998626e-08
expression O 0 9.662468158921911e-08
pattern O 0 5.276500587569899e-07
and O 0 9.097882269770707e-08
subcellular O 0 2.995491968249553e-06
localization O 0 1.1294420119156712e-06
suggest O 0 2.3768249945987918e-07
a O 0 8.934379280844951e-08
role O 0 1.873144839237284e-07
in O 0 3.250472673244076e-07
cell O 0 6.992935232119635e-05
- O 0 7.387195364572108e-05
cycle O 0 8.177629752026405e-06
regulation O 0 4.346819878264796e-06
. O 0 4.660263130062958e-06

When O 0 3.820349229499698e-05
resting O 0 0.0005619159201160073
cells O 0 1.1989517588517629e-05
are O 0 2.590919905287592e-07
induced O 0 1.383219932904467e-05
to O 0 1.1482127604267589e-07
proliferate O 0 1.5620844351360574e-05
, O 0 5.535855862603967e-08
the O 0 1.808259852964511e-08
steady O 0 2.1851310521014966e-06
- O 0 6.379315436788602e-06
state O 0 4.448320822802998e-08
levels O 0 2.5371306833221752e-08
of O 0 9.896943709009065e-09
BRCA1 O 0 1.8253020925840246e-06
increase O 0 5.1890218344397e-08
in O 0 3.015935590156005e-08
late O 0 1.8674459170142654e-06
G1 O 0 0.00013655384827870876
and O 0 1.000717517740668e-07
reach O 0 1.462025664977773e-07
a O 0 7.623578568427547e-08
maximum O 0 4.328401530528936e-07
during O 0 1.3674682577402564e-06
S O 0 0.0003643507952801883
phase O 0 3.59763580490835e-05
. O 0 5.867568688699976e-06

Moreover O 0 8.169122884282842e-05
, O 0 1.4435712500926456e-06
in O 0 4.245079310294386e-07
S O 0 0.00024011961068026721
phase O 0 2.5705741791171022e-05
cells O 0 3.4658673939702567e-06
, O 0 1.7218216896708327e-07
BRCA1 O 0 2.8160827696410706e-06
polypeptides O 0 1.0155168865821906e-06
are O 0 5.378661427357656e-08
hyperphosphorylated O 0 1.848460487963166e-05
and O 0 2.36286012977871e-07
accumulate O 0 3.805442474913434e-06
into O 0 1.403113571996073e-07
discrete O 0 4.9644618229649495e-06
subnuclear O 0 0.00023490950115956366
foci O 0 0.00010562156967353076
termed O 0 3.88479238608852e-05
" O 0 7.33780052541988e-06
BRCA1 O 0 0.0002471253974363208
nuclear O 0 0.0003385209711268544
dots O 0 0.00019507837714627385
. O 0 2.0087541997781955e-05

" O 0 0.00019516434986144304
BRCA1 O 0 0.017433423548936844
associates O 0 0.00738899689167738
in O 0 1.8990328953805147e-06
vivo O 0 0.0002887294685933739
with O 0 8.458366664854111e-07
a O 0 3.478543476376217e-06
structurally O 0 0.00274389935657382
related O 0 5.109050471219234e-05
protein O 0 1.2254085049789865e-05
termed O 0 0.00017746552475728095
BARD1 O 0 0.006953103933483362
. O 0 2.2771942894905806e-05

Here O 0 1.011133281281218e-05
we O 0 4.1676835849102645e-07
show O 0 1.4319151375730144e-07
that O 0 1.0812822637262798e-08
the O 0 1.7548666519928702e-08
steady O 0 5.089266778668389e-06
- O 0 4.0586448449175805e-05
state O 0 1.3294526013396535e-07
levels O 0 6.134555974313116e-08
of O 0 1.2063173571164043e-08
BARD1 O 0 0.00011759714834624901
, O 0 7.598985973800154e-08
unlike O 0 9.189600547188093e-08
those O 0 1.766391832802583e-08
of O 0 5.410744208234064e-08
BRCA1 O 0 4.819594687432982e-05
, O 0 3.635603604834614e-07
remain O 0 5.903963824493985e-07
relatively O 0 4.5738136122963624e-07
constant O 0 8.299055593852245e-07
during O 0 1.804066073418653e-06
cell O 0 6.98403237038292e-05
cycle O 0 2.135299473593477e-05
progression O 0 7.161283429013565e-05
. O 0 4.865828486799728e-06

However O 0 1.7785878299036995e-05
, O 0 2.9509699288610136e-06
immunostaining O 0 0.0005068170721642673
revealed O 0 1.599267852725461e-05
that O 0 3.835629343029723e-07
BARD1 O 0 0.012019801884889603
resides O 0 1.06366451291251e-05
within O 0 3.8365143950613856e-07
BRCA1 O 0 6.564010254805908e-05
nuclear O 0 0.00018474069656804204
dots O 0 1.3357296666072216e-05
during O 0 1.1031618214474292e-06
S O 0 0.0002512629725970328
phase O 0 1.6901697108551161e-06
of O 0 3.916557389516129e-08
the O 0 5.3568133040471366e-08
cell O 0 6.792964541091351e-06
cycle O 0 1.3771185649602558e-06
, O 0 1.1653293796598518e-07
but O 0 2.9352522190606578e-08
not O 0 9.128402034264127e-09
during O 0 8.095313575040564e-08
the O 0 2.2519556353017833e-07
G1 O 0 0.0005266233929432929
phase O 0 5.715155566576868e-05
. O 0 1.0436229786137119e-05

Nevertheless O 0 0.00018983305199071765
, O 0 7.661939889658242e-06
BARD1 O 0 0.0009566921507939696
polypeptides O 0 1.8254593669553287e-05
are O 0 2.197723745211988e-07
found O 0 9.041039561452635e-08
exclusively O 0 3.4243345936602054e-08
in O 0 1.6397045499161322e-08
the O 0 2.0484446139334977e-08
nuclear O 0 1.0919724218183546e-06
fractions O 0 6.680548381154949e-08
of O 0 1.5379702844597887e-08
both O 0 3.4257585213026687e-08
G1 O 0 3.7611043808283284e-05
- O 0 1.1791320503107272e-05
and O 0 7.055136279632279e-07
S O 0 0.0007337745628319681
- O 0 5.4004900448489934e-05
phase O 0 6.563284114236012e-05
cells O 0 9.803712600842118e-06
. O 0 4.135260496695992e-06

Therefore O 0 2.795021100610029e-05
, O 0 1.6441694015156827e-06
progression O 0 1.0017016393248923e-05
to O 0 3.00983629131224e-07
S O 0 0.0002714572474360466
phase O 0 1.4792577530897688e-05
is O 0 1.6329917684743123e-07
accompanied O 0 5.634772719531611e-07
by O 0 2.7981887029682184e-08
the O 0 1.9331020340018767e-08
aggregation O 0 3.75418096609792e-07
of O 0 8.165998366393978e-08
nuclear O 0 6.7884087911807e-05
BARD1 O 0 0.00010002527415053919
polypeptides O 0 3.508331246848684e-06
into O 0 7.572810432066035e-07
BRCA1 O 0 7.464351074304432e-05
nuclear O 0 0.00014465325511991978
dots O 0 0.0001364403433399275
. O 0 1.0730726899055298e-05

This O 0 8.730618901608977e-06
cell O 0 3.670245496323332e-05
cycle O 0 9.371809028380085e-06
- O 0 8.723655628273264e-05
dependent O 0 3.0626815714640543e-06
colocalization O 0 3.25408109347336e-05
of O 0 1.9091388026026834e-07
BARD1 O 0 0.007006040308624506
and O 0 1.7096657529691583e-06
BRCA1 O 0 5.270145265967585e-05
indicates O 0 8.00125746991398e-07
a O 0 1.3019196387631382e-07
role O 0 1.3922010566602694e-07
for O 0 1.773668003579587e-07
BARD1 O 0 0.000492806255351752
in O 0 5.944750114394992e-07
BRCA1 O 0 0.0004199316317681223
- O 0 0.020324252545833588
mediated O 0 0.10169662535190582
tumor B-Disease 0 0.3081355392932892
suppression O 0 0.0001606395235285163
. O 0 1.5255616744980216e-05

Ethnic O 0 0.00011081049160566181
differences O 0 3.2787454983917996e-05
in O 0 1.5700270523666404e-06
the O 0 1.5357679785665823e-06
HFE O 0 0.0009814832592383027
codon O 0 2.2699763576383702e-05
282 O 0 3.32583804265596e-05
( O 0 4.856598025071435e-06
Cys O 0 0.019591953605413437
/ O 0 0.0004926373949274421
Tyr O 0 0.001291736145503819
) O 0 3.2560963063588133e-06
polymorphism O 0 0.00012524754856713116
. O 0 1.5974845155142248e-05

Recent O 0 3.4000393497990444e-05
studies O 0 3.7593001707136864e-06
have O 0 8.601108447692241e-07
shown O 0 4.98219606015482e-06
that O 0 0.00017318873142357916
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
( O 0 0.0023683467879891396
HH B-Disease 1 0.9999561309814453
) O 0 1.0439775905979332e-06
is O 0 3.3187578196702816e-07
likely O 0 7.570571369797108e-07
to O 0 5.616944775965749e-08
be O 0 1.1646794462194521e-07
caused O 0 1.26449504023185e-06
by O 0 1.6624926502117887e-07
homozygosity O 0 7.034276495687664e-05
for O 0 1.184012532462475e-07
a O 0 6.958207450225018e-07
Cys282Tyr O 0 0.0002026931761065498
mutation O 0 3.8387875633816293e-07
in O 0 5.1407507584144696e-08
the O 0 1.8365051346336259e-07
HFE O 0 0.00024485093308612704
gene O 0 1.7691080529402825e-06
located O 0 2.0825191313633695e-06
4 O 0 3.042249090867699e-06
. O 0 3.914328317478066e-06

5 O 0 0.0001962997775990516
Mb O 0 0.0009376232046633959
telomeric O 0 0.0013610938331112266
to O 0 1.0159043085877784e-05
HLA O 0 0.00734818447381258
- O 0 0.00018116863793693483
A O 0 7.827919944247697e-06
. O 0 7.748958523734473e-06

Population O 0 7.600298431498231e-06
studies O 0 7.991504276105843e-07
of O 0 6.409199215795525e-08
this O 0 4.4990056125016054e-08
polymorphism O 0 3.730785465450026e-06
are O 0 6.109882377813847e-08
facilitated O 0 1.0796911737998016e-06
by O 0 9.699028424847711e-08
the O 0 6.418007103548007e-08
fact O 0 1.270773850592377e-07
that O 0 2.380951258373898e-08
the O 0 1.5421566956774768e-07
Cys282Tyr O 0 0.0008411582093685865
mutation O 0 1.34202457502397e-06
creates O 0 7.811095201759599e-07
a O 0 6.20657260697044e-07
Rsal O 0 0.0002482097188476473
restriction O 0 7.3634150794532616e-06
site O 0 1.2941822205903009e-05
. O 0 6.456187293224502e-06

We O 0 9.305069397669286e-06
have O 0 3.116346647402679e-07
studied O 0 2.4193226977331506e-07
the O 0 6.665681695494641e-08
codon O 0 8.525551606908266e-07
282 O 0 4.605406957125524e-06
( O 0 5.386904717852303e-07
Cys O 0 0.004864655900746584
/ O 0 9.070641681319103e-05
Tyr O 0 0.00012935239647049457
) O 0 1.1049417025787989e-07
polymorphism O 0 1.0602793736325111e-06
in O 0 4.4926601105999e-08
different O 0 6.0198637186204e-08
ethnic O 0 5.208953552937601e-07
groups O 0 1.0622255786074675e-06
. O 0 3.5729915452975547e-06

In O 0 7.737910891592037e-06
agreement O 0 8.132702532748226e-06
with O 0 2.973270625261648e-07
previous O 0 3.833339974335104e-07
observations O 0 8.153273824973439e-07
the O 0 1.008808681035589e-07
Tyr O 0 9.393211075803265e-05
allele O 0 1.0311301821275265e-06
appeared O 0 5.473594342220167e-07
to O 0 4.507990070123924e-08
be O 0 9.431600744846946e-08
rare O 0 2.261242570966715e-06
or O 0 5.526771928998642e-07
absent O 0 1.2006037195533281e-06
in O 0 9.319603577750968e-08
Asiatic O 0 1.0340626431570854e-05
( O 0 1.9142544260830618e-07
Indian O 0 3.411993532154156e-07
, O 0 6.669777263823562e-08
Chinese O 0 3.1980707859702306e-08
) O 0 1.5098356698217685e-07
populations O 0 1.3708919368582428e-06
. O 0 2.200715471190051e-06

The O 0 5.0019916670862585e-06
highest O 0 5.432642865343951e-06
allele O 0 2.3352215521299513e-06
frequency O 0 6.29303087862354e-07
( O 0 6.704853205974359e-08
7 O 0 1.6806593805540615e-07
. O 0 2.118607156376129e-08
5 O 0 1.0448734855117436e-07
% O 0 5.0566704601351375e-08
) O 0 2.7661059220918105e-08
was O 0 2.7531214641385304e-07
found O 0 2.2347612116391247e-07
in O 0 3.29841896018479e-07
Swedes O 0 9.282794781029224e-05
. O 0 7.540261776739499e-06

Saamis O 0 0.01148965023458004
( O 0 4.5628448788193054e-06
2 O 0 1.4497824167847284e-06
% O 0 1.2962962614437856e-07
) O 0 2.6106624417820967e-08
and O 0 6.40888160319264e-08
Mordvinians O 0 2.725437661865726e-05
( O 0 2.4165458967218e-08
1 O 0 2.53875711564433e-08
. O 0 5.469637187616172e-09
8 O 0 1.140655854214856e-07
% O 0 2.8030285648128483e-08
) O 0 1.0984314791073757e-08
had O 0 2.4749335025830987e-08
significantly O 0 1.419081741005357e-07
lower O 0 8.843117882406659e-08
frequencies O 0 7.9189547363967e-08
of O 0 4.233807260334288e-08
the O 0 4.042660179948143e-07
Tyr O 0 0.0007095608743838966
allele O 0 2.425571801722981e-05
. O 0 6.142603524494916e-06

Comparisons O 0 6.071360985515639e-05
with O 0 1.8618283093019272e-06
allele O 0 2.875025529647246e-06
frequencies O 0 8.947354217525572e-07
based O 0 3.459773836311797e-07
on O 0 4.930901127409015e-07
prevalence O 0 2.7685407985700294e-05
estimates O 0 9.403593708157132e-07
of O 0 5.063561161477992e-07
HH B-Disease 1 0.9996901750564575
showed O 0 3.9228434616234154e-05
some O 0 8.452062871810995e-08
disagreements O 0 8.81509458849905e-06
with O 0 1.2280987959911727e-07
the O 0 7.928763778863868e-08
RFLP O 0 1.856859671534039e-05
data O 0 8.44955422962812e-07
, O 0 1.9894773117812292e-07
particularly O 0 7.527190177825105e-07
in O 0 5.392013804339513e-07
Finns O 0 9.088556544156745e-05
. O 0 7.018239557510242e-06

The O 0 2.3866083211032674e-05
newly O 0 6.47242195555009e-05
described O 0 0.0001456859172321856
HFE O 0 0.13542145490646362
marker O 0 6.607268733205274e-05
provides O 0 3.9337101043201983e-07
a O 0 1.029966085752676e-07
new O 0 6.382957451478433e-08
approach O 0 1.2791903714060027e-07
to O 0 1.3704975820871823e-08
the O 0 2.0653574850371115e-08
screening O 0 5.299122562973935e-07
of O 0 2.007438268947226e-07
HH B-Disease 1 0.9159621000289917
as O 0 7.414493552460044e-08
well O 0 4.4235644480750125e-08
as O 0 7.76076625186306e-09
studies O 0 5.038971462312247e-09
of O 0 9.377013832079228e-09
the O 0 6.844766886615616e-08
relationship O 0 6.707871875732963e-07
between O 0 2.3295019957458862e-07
the O 0 1.0517853752389783e-06
HFE O 0 0.3454428017139435
Tyr O 0 0.004302504006773233
allele O 0 9.024721293826587e-06
and O 0 1.848051283559471e-06
different O 0 5.8070568229595665e-06
disorders O 1 0.9204149842262268
including O 0 0.00209883414208889
cancer B-Disease 1 0.9968485236167908

Autosomal B-Disease 1 0.9926438927650452
dominant I-Disease 1 0.8146015405654907
neurohypophyseal I-Disease 1 0.999890923500061
diabetes I-Disease 1 0.9999967813491821
insipidus I-Disease 1 0.9999675750732422
associated O 0 0.00082339474465698
with O 0 1.8733303477347363e-06
a O 0 3.782690782827558e-06
missense O 0 7.411708065774292e-05
mutation O 0 2.4974472125904867e-06
encoding O 0 2.2655985958408564e-06
Gly23 O 0 0.00027705798856914043
- O 0 0.0002922831627074629
- O 0 0.00035910564474761486
> O 0 5.589270222117193e-05
Val O 0 0.0002626138739287853
in O 0 8.497936505591497e-07
neurophysin O 0 0.001406739465892315
II O 0 0.018293799832463264
. O 0 1.3610847418021876e-05

Autosomal B-Disease 1 0.9732740521430969
dominant I-Disease 1 0.5213853120803833
neurohypophyseal I-Disease 1 0.9998424053192139
diabetes I-Disease 1 0.9999929666519165
insipidus I-Disease 1 0.9999251365661621
( O 0 7.621700933668762e-05
ADNDI B-Disease 1 0.623572587966919
) O 0 2.1460286916408222e-06
is O 0 3.3178096146002645e-06
an O 0 0.0003714068152476102
inherited B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999905824661255
caused O 0 0.0002686392981559038
by O 0 9.44405110203661e-06
progressive O 0 0.09892210364341736
degeneration O 1 0.8036770224571228
of O 0 5.671162739417923e-07
the O 0 9.444630677535315e-07
magnocellular O 0 0.0005054404027760029
neurons O 0 1.7266344229938113e-06
of O 0 6.492916782008251e-08
the O 0 1.07429528384273e-07
hypothalamus O 0 3.563653763194452e-06
leading O 0 3.8774464883317705e-07
to O 0 7.453913042354543e-08
decreased O 0 2.0620727809728123e-06
ability O 0 3.758909272733035e-08
to O 0 1.1176163106085824e-08
produce O 0 1.1881400752145055e-07
the O 0 6.734896373927768e-08
hormone O 0 7.642022978870955e-07
arginine O 0 1.5955272374412743e-06
vasopressin O 0 5.3456037676369306e-06
( O 0 4.073656043601659e-07
AVP O 0 4.1666411561891437e-05
) O 0 5.230497777120036e-07
. O 0 2.50211701313674e-06

Affected O 0 0.0002960553392767906
individuals O 0 5.527844223252032e-06
are O 0 4.05246879608967e-07
not O 0 3.4052061437250813e-07
symptomatic O 0 0.0002062837447738275
at O 0 1.3157889952708501e-05
birth O 0 1.2454144780349452e-05
, O 0 2.1390128779330553e-07
but O 0 2.6956544729728193e-07
usually O 0 8.049329380810377e-07
develop O 0 0.00014011970779392868
diabetes B-Disease 1 0.9675859212875366
insipidus I-Disease 1 0.8900749087333679
at O 0 3.5559708067012252e-06
1 O 0 2.9148245630494785e-06
- O 0 0.000221800321014598
6 O 0 1.1774218364735134e-05
yr O 0 0.0011077135568484664
of O 0 4.247978893090476e-07
age O 0 7.559774076071335e-06
. O 0 7.588942025904544e-06

The O 0 1.1062634257541504e-05
genetic O 0 3.1091472919797525e-05
locus O 0 1.1069029824284371e-05
of O 0 1.1281717888778076e-06
the O 0 1.408796561008785e-05
disease O 0 0.00039406100404448807
is O 0 9.536936573795174e-08
the O 0 1.3637236406793818e-07
AVP O 0 0.011385010555386543
- O 0 0.0985822081565857
neurophysin O 0 0.4343072175979614
II O 0 0.32380780577659607
( O 0 4.686629893058125e-07
NPII O 0 0.00022383169562090188
) O 0 5.272606884432207e-08
gene O 0 5.923223511672404e-08
, O 0 3.894426114925409e-08
and O 0 1.1136949495949011e-07
mutations O 0 4.289277626412513e-07
that O 0 8.527895545284991e-08
cause O 0 6.211621439433657e-06
ADNDI B-Disease 0 0.032907843589782715
have O 0 2.9202928431004693e-07
been O 0 1.4319518015781796e-07
found O 0 9.87635502269768e-08
in O 0 1.599690513387486e-08
both O 0 1.3807697207823821e-08
the O 0 1.0720003551512036e-08
signal O 0 2.7854574113916897e-07
peptide O 0 6.543915986867432e-08
of O 0 8.18617529318999e-09
the O 0 3.9770888804468996e-08
prepro O 0 9.238896745955572e-05
- O 0 6.326194852590561e-05
AVP O 0 0.0002249991230200976
- O 0 5.1566468755481765e-05
NPII O 0 5.382248491514474e-05
precursor O 0 1.1463891951279948e-06
and O 0 2.8443318456083944e-07
within O 0 8.865044378580933e-07
NPII O 0 0.00029400395578704774
itself O 0 9.678553396952339e-06
. O 0 6.618416591663845e-06

An O 0 1.315841745963553e-05
affected O 0 4.3248703150311485e-05
girl O 0 0.0002609792281873524
who O 0 1.2249330438862671e-06
presented O 0 1.0944579571514623e-06
at O 0 6.678948807348206e-07
9 O 0 1.0329716815249412e-06
months O 0 2.1546364337154955e-07
of O 0 5.988565021652903e-08
age O 0 1.1908085753020714e-06
and O 0 3.5809048881674244e-07
her O 0 7.566147246507171e-07
similarly O 0 5.05239358972176e-06
affected O 0 1.0776985845950549e-06
younger O 0 2.731941322053899e-06
brother O 0 1.4638570974057075e-05
and O 0 7.301679261217942e-07
father O 0 8.032933692447841e-06
were O 0 1.2712828834082757e-07
all O 0 1.636932722703932e-08
found O 0 2.537431669225043e-07
to O 0 5.533607705388022e-08
have O 0 8.145014618321511e-08
a O 0 3.8047713246669446e-07
novel O 0 2.8025583560520317e-06
missense O 0 4.319277286413126e-05
mutation O 0 8.087009177870641e-07
( O 0 1.0998260080441469e-07
G1758 O 0 9.295987183577381e-06
- O 0 0.00027451931964606047
- O 0 0.00751384487375617
> O 0 7.570171146653593e-05
T O 0 6.044821202522144e-05
) O 0 8.55655102327546e-09
encoding O 0 3.192415221064948e-08
the O 0 7.2851848997856905e-09
amino O 0 2.9320403882593382e-08
acid O 0 3.455367902915896e-08
substitution O 0 1.1242188691085175e-07
Gly23 O 0 5.762877208326245e-06
- O 0 1.6513051377842203e-05
- O 0 6.176723400130868e-05
> O 0 2.491728082532063e-05
Val O 0 0.00011489546159282327
within O 0 1.322109483226086e-06
NPII O 0 0.0004021216300316155
. O 0 7.99591089162277e-06

The O 0 3.0370276363100857e-05
mutation O 0 4.8826481361174956e-05
was O 0 6.630445568589494e-06
confirmed O 0 2.6501318188820733e-06
by O 0 7.731972004876297e-07
restriction O 0 5.630960004054941e-06
endonuclease O 0 0.0001929392310557887
analysis O 0 9.864465027931146e-06
. O 0 1.6732206859160215e-05

A O 0 0.00011584574531298131
T1 O 0 0.20151592791080475
- O 0 7.559754885733128e-05
weighted O 0 4.494803761190269e-06
magnetic O 0 2.1027772163506597e-06
resonance O 0 1.2171751677669818e-06
imaging O 0 9.648003469919786e-06
of O 0 1.1033411340122257e-07
the O 0 3.849169161185273e-07
fathers O 0 2.5519862902001478e-05
pituitary O 0 0.0007800778839737177
gland O 0 0.0002169381477870047
demonstrates O 0 4.8907968448475e-06
an O 0 3.37879669132235e-07
attenuated O 0 0.00027965797926299274
posterior O 0 0.001695873448625207
pituitary O 0 0.005733812227845192
bright O 0 0.000262191315414384
spot O 0 5.777928527095355e-05
. O 0 1.4620015463151503e-05

This O 0 1.0080014362756629e-05
mutation O 0 2.236756517959293e-05
may O 0 1.1404484894228517e-06
be O 0 2.5179053508850302e-08
valuable O 0 6.108588479492028e-08
for O 0 2.1959884577427147e-08
developing O 0 2.8712366884064977e-07
models O 0 7.736456382190227e-07
of O 0 8.736939776099462e-07
dominantly B-Disease 1 0.9213434457778931
inherited I-Disease 1 0.9879688024520874
neurodegeneration I-Disease 1 0.9999973773956299
, O 0 5.971711743768537e-06
as O 0 4.695228028595011e-08
the O 0 2.0299038894222576e-08
early O 0 2.574348911821289e-07
age O 0 2.8600263135558635e-07
of O 0 1.6573905270433897e-07
onset O 0 0.0027555024717003107
of O 0 8.539925147488248e-06
symptoms O 0 0.0002463864511810243
suggests O 0 2.2466194877779344e-06
that O 0 9.176324766713151e-08
this O 0 9.441770032481145e-08
mutation O 0 1.2478662938519847e-06
may O 0 5.402380338637158e-07
be O 0 6.24759621814519e-08
particularly O 0 2.876657845263253e-07
deleterious O 0 1.1878074701598962e-06
to O 0 1.5415994880640937e-07
the O 0 5.2126210903225e-07
magnocellular O 0 0.000696272065397352
neuron O 0 7.19870877219364e-05
. O 0 1.5683151559642283e-06
. O 0 6.1516143432527315e-06

Frequent O 0 0.00021747576829511672
inactivation O 0 0.002217494184151292
of O 0 1.0765372280729935e-05
PTEN O 0 0.11070603877305984
/ O 0 0.0012900352012366056
MMAC1 O 0 0.04160859063267708
in O 0 2.7734715331462212e-05
primary O 1 0.9382941722869873
prostate B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999803304672241
. O 0 0.00027035409584641457

Sporadic B-Disease 1 0.9982682466506958
prostate I-Disease 1 0.9999982118606567
carcinoma I-Disease 1 0.9999997615814209
is O 0 0.00010579029185464606
the O 0 1.6091578345367452e-06
most O 0 2.0171555661363527e-06
common O 0 1.3740575013798662e-05
male B-Disease 0 4.464371522772126e-05
cancer I-Disease 0 0.01133963093161583
in O 0 1.3094606288177602e-07
the O 0 7.433298065961935e-08
Western O 0 3.022345538283844e-07
world O 0 1.9504558679273032e-07
, O 0 6.036086119820538e-08
yet O 0 5.9202189817142425e-08
many O 0 4.521490293285524e-09
of O 0 7.004651081388147e-09
the O 0 2.8731149015470692e-08
major O 0 6.640150331804762e-07
genetic O 0 4.07546679070947e-07
events O 0 4.382146912007556e-08
involved O 0 3.8042486494305194e-07
in O 0 8.388015970695051e-08
the O 0 7.930503187481008e-08
progression O 0 2.3349498405877966e-06
of O 0 3.1019716573155165e-08
this O 0 5.455625000649889e-07
often O 0 3.995822771685198e-05
fatal O 1 0.991142988204956
cancer B-Disease 0 0.20263437926769257
remain O 0 2.6600068849802483e-06
to O 0 2.621646046918613e-07
be O 0 1.2557763966469793e-06
elucidated O 0 9.507423237664625e-05
. O 0 7.778307917760685e-06

Numerous O 0 5.190997399040498e-05
cytogenetic O 0 0.0031376322731375694
and O 0 9.550345566822216e-06
allelotype O 0 0.001434324774891138
studies O 0 2.0215907170495484e-06
have O 0 5.165421157471428e-07
reported O 0 1.3938877600594424e-05
frequent O 0 1.3065435268799774e-05
loss O 0 9.404135926160961e-05
of O 0 1.1410663773858687e-06
heterozygosity O 0 0.006605153437703848
on O 0 1.5419700503116474e-05
chromosomal O 0 0.15240539610385895
arm O 0 0.005287685431540012
10q O 0 0.0004326789057813585
in O 0 8.830104889057111e-06
sporadic B-Disease 1 0.9618442058563232
prostate I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999772310256958
. O 0 0.0001560213277116418

Deletion O 0 0.00023231464729178697
mapping O 0 0.00018496063421480358
studies O 0 9.499203770246822e-06
have O 0 1.0343695748815662e-06
unambiguously O 0 7.247440953506157e-05
identified O 0 9.834446245804429e-06
a O 0 6.175080784487363e-07
region O 0 2.049138174697873e-06
of O 0 1.717400408551839e-07
chromosome O 0 1.5114971574803349e-05
10q23 O 0 2.4823124476824887e-05
to O 0 6.816339492843326e-08
be O 0 1.7678411623478496e-08
the O 0 2.977679436355629e-08
minimal O 0 1.1431336588429986e-06
area O 0 4.30850150223705e-07
of O 0 2.669562206847331e-07
loss O 0 0.0002782940282486379
. O 0 1.5031655493658036e-05

A O 0 3.0156827051541768e-05
new O 0 8.432652975898236e-06
tumor B-Disease 0 0.00043621647637337446
suppressor O 0 4.3223135435255244e-05
gene O 0 2.7767871415562695e-06
, O 0 7.718444976489991e-07
PTEN O 0 0.0012002534931525588
/ O 0 0.00017946396837942302
MMAC1 O 0 0.04431312531232834
, O 0 1.2640429076782311e-06
was O 0 6.427466814784566e-06
isolated O 0 2.1351466784835793e-05
recently O 0 2.3651693936699303e-06
at O 0 1.6046357131926925e-07
this O 0 2.2081435346876788e-08
region O 0 1.2153293482697336e-07
of O 0 3.0432271813651823e-08
chromosome O 0 4.854416602029232e-06
10q23 O 0 5.937539754086174e-05
and O 0 5.41677934506879e-07
found O 0 1.7067434043838148e-07
to O 0 1.778040115141266e-08
be O 0 1.6382132983494557e-08
inactivated O 0 8.514955425198423e-07
by O 0 5.594854002310967e-08
mutation O 0 3.096568832461344e-07
in O 0 2.077624259300137e-07
three O 0 0.000425790436565876
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999923706054688
cell O 0 0.014060275629162788
lines O 0 9.06363784451969e-05
. O 0 1.5910198271740228e-05

We O 0 2.7020169000024907e-05
screened O 0 0.00014884103438816965
80 O 0 0.0010017099557444453
prostate B-Disease 1 0.999927282333374
tumors I-Disease 1 0.9999665021896362
by O 0 3.4967904412042117e-06
microsatellite O 0 0.00045501519343815744
analysis O 0 2.4343532913917443e-06
and O 0 7.79743061229965e-07
found O 0 9.267645282307058e-07
chromosome O 0 7.198430012067547e-06
10q23 O 0 2.823862450895831e-05
to O 0 9.012665458385527e-08
be O 0 8.606362200680451e-08
deleted O 0 1.2131862376918434e-06
in O 0 3.1520170296062133e-07
23 O 0 3.368833404238103e-06
cases O 0 2.0764191503985785e-06
. O 0 3.8943849176575895e-06

We O 0 1.72062536876183e-05
then O 0 2.6621739834808977e-06
proceeded O 0 2.488633754182956e-06
with O 0 7.13159096221716e-08
sequence O 0 7.460783280066607e-08
analysis O 0 5.57465789086109e-08
of O 0 3.428216643897031e-08
the O 0 5.521641099903718e-08
entire O 0 4.8721153689257335e-06
PTEN O 0 0.0032995480578392744
/ O 0 0.0001594762725289911
MMAC1 O 0 0.0014686804497614503
coding O 0 3.2094671041704714e-05
region O 0 5.3478470363188535e-06
and O 0 6.886473897793621e-07
tested O 0 1.5383213849418098e-06
for O 0 1.1153615275816264e-07
homozygous O 0 1.116139856094378e-06
deletion O 0 7.368349770331406e-07
with O 0 1.1370510577535242e-07
new O 0 6.096379365772009e-07
intragenic O 0 0.0016383498441427946
markers O 0 7.779301995469723e-06
in O 0 4.957522392601277e-08
these O 0 3.763773293030681e-08
23 O 0 2.2943629574001534e-06
cases O 0 5.057711973677215e-07
with O 0 6.233907470232225e-07
10q23 O 0 0.0003545035724528134
loss O 0 5.923423668718897e-05
of O 0 4.589212039718404e-06
heterozygosity O 0 0.005694953259080648
. O 0 3.438955536694266e-05

The O 0 4.49615845354856e-06
identification O 0 2.4685771222721087e-06
of O 0 2.717835911880684e-07
the O 0 1.3625485451029817e-07
second O 0 8.462166647404956e-07
mutational O 0 5.5558342864969745e-05
event O 0 1.2130288951084367e-06
in O 0 1.1827282975218623e-07
10 O 0 1.4477525667189184e-07
( O 0 6.452054179817424e-08
43 O 0 1.2569290674946387e-06
% O 0 6.001474162076192e-07
) O 0 1.6207549151658895e-06
tumors B-Disease 1 0.9823050498962402
establishes O 0 2.4168322852347046e-05
PTEN O 0 0.02271243743598461
/ O 0 0.00041678856359794736
MMAC1 O 0 0.005363553296774626
as O 0 1.3293282563608955e-07
a O 0 9.92394078025427e-08
main O 0 5.173753265808045e-07
inactivation O 0 0.00016013788990676403
target O 0 8.496218129039335e-07
of O 0 1.1280378231504073e-07
10q O 0 3.2790521800052375e-05
loss O 0 1.052484458341496e-05
in O 0 2.3350744413619395e-06
sporadic B-Disease 1 0.9714097380638123
prostate I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999761581420898
. O 0 8.877642358129378e-06
. O 0 2.789006248349324e-05

Risk O 0 0.0012092666001990438
reversals O 0 0.0002760857460089028
in O 0 3.9910896703077015e-06
predictive O 0 4.8245514335576445e-05
testing O 0 0.00017006687994580716
for O 0 0.0010789107764139771
Huntington B-Disease 1 0.9999953508377075
disease I-Disease 1 0.9997370839118958
. O 0 7.768115756334737e-05

The O 0 2.40451049648982e-06
first O 0 9.394952371621912e-07
predictive O 0 1.2062792848155368e-05
testing O 0 4.982882455806248e-05
for O 0 0.0026273394469171762
Huntington B-Disease 1 0.9999992847442627
disease I-Disease 1 0.9993000030517578
( O 0 9.890698038361734e-07
HD B-Disease 0 0.0035730935633182526
) O 0 8.382129834672014e-08
was O 0 2.420850648832129e-07
based O 0 5.2423832386239155e-08
on O 0 8.818610552907558e-08
analysis O 0 1.613112914355952e-07
of O 0 1.28205314808838e-07
linked O 0 1.2819891708204523e-05
polymorphic O 0 7.902032848505769e-06
DNA O 0 6.685214430035558e-06
markers O 0 3.387622200534679e-06
to O 0 4.338973269568669e-08
estimate O 0 3.4743752053145727e-07
the O 0 3.685811833520347e-08
likelihood O 0 3.4204970233986387e-07
of O 0 9.587347449269146e-08
inheriting O 0 1.3467886674334295e-05
the O 0 1.751376572656227e-07
mutation O 0 1.4373099475051276e-06
for O 0 8.12453151866066e-07
HD B-Disease 0 0.001666138763539493
. O 0 1.1532169082784094e-05

Limits O 0 1.70096245710738e-05
to O 0 4.1572437226022885e-07
accuracy O 0 2.29276588470384e-06
included O 0 4.223181520046637e-07
recombination O 0 2.3976638203748735e-06
between O 0 4.0626221675665874e-07
the O 0 1.7086863124404772e-07
DNA O 0 2.0572113498928957e-05
markers O 0 1.2626342140720226e-05
and O 0 3.0148061114232405e-07
the O 0 1.5913316531168675e-07
mutation O 0 7.596745490445755e-07
, O 0 2.1622896895223676e-07
pedigree O 0 5.777415935881436e-06
structure O 0 8.843418868309527e-07
, O 0 9.68900693010255e-08
and O 0 4.55697239942765e-08
whether O 0 1.5474766712486598e-07
DNA O 0 1.549227931718633e-06
samples O 0 2.0393736122059636e-07
were O 0 5.0293238018639386e-08
available O 0 9.510597465123283e-08
from O 0 1.0857341692371847e-07
family O 0 1.0207717195953592e-06
members O 0 1.4020556591276545e-06
. O 0 6.008305717841722e-06

With O 0 4.378272478788858e-06
direct O 0 1.0074988949781982e-06
tests O 0 7.909843020570406e-07
for O 0 8.627975489616801e-08
the O 0 1.3254722830424726e-07
HD B-Disease 0 0.0002400571247562766
mutation O 0 7.153456067499064e-07
, O 0 8.760002856433857e-08
we O 0 2.7111873635021766e-08
have O 0 1.2651770298077736e-08
assessed O 0 1.9955255936565663e-07
the O 0 2.1213001133446596e-08
accuracy O 0 8.079207987066184e-07
of O 0 4.0457024397255736e-08
results O 0 2.856455694200122e-07
obtained O 0 1.8034296545010875e-07
by O 0 7.26168707387842e-08
linkage O 0 1.809859440982109e-06
approaches O 0 1.1041618108720286e-06
when O 0 9.73672840132167e-08
requested O 0 1.2059393839081167e-07
to O 0 2.1388023796475863e-08
do O 0 4.2803328881291236e-08
so O 0 1.722047393570847e-08
by O 0 1.6929163848544704e-08
the O 0 6.25149425559357e-08
test O 0 3.5921725611842703e-06
individuals O 0 6.7370802980804e-07
. O 0 2.3872778456279775e-06

For O 0 5.733309080824256e-06
six O 0 2.3315408270718763e-06
such O 0 2.893104920076439e-07
individuals O 0 2.93931492478805e-07
, O 0 2.3559253747862385e-07
there O 0 7.912251476227539e-08
was O 0 1.2675557172769913e-06
significant O 0 7.317622134905832e-07
disparity O 0 1.605086072231643e-05
between O 0 2.467729132149543e-07
the O 0 3.8804725477348256e-07
tests O 0 5.1400629672571085e-06
. O 0 4.181787517154589e-06

Three O 0 7.927243132144213e-06
went O 0 3.8834145925648045e-06
from O 0 2.475951532687759e-07
a O 0 4.1216279100808606e-07
decreased O 0 3.8697176933055744e-05
risk O 0 1.179949435936578e-06
to O 0 1.833396723327496e-08
an O 0 1.331213006494636e-08
increased O 0 8.428074238508998e-07
risk O 0 1.6782901184342336e-06
, O 0 4.799573005698221e-08
while O 0 3.727473796288905e-08
in O 0 2.0691269142503188e-08
another O 0 5.5381160990464195e-08
three O 0 5.1630177466677196e-08
the O 0 1.4931494263237255e-07
risk O 0 1.1270843970123678e-05
was O 0 3.913887667295057e-06
decreased O 0 3.5907742130802944e-05
. O 0 6.082712843635818e-06

Knowledge O 0 1.5370458640973084e-05
of O 0 1.2107105931136175e-06
the O 0 3.5627493844003766e-07
potential O 0 1.1681249816319905e-06
reasons O 0 1.5462772751106968e-07
for O 0 2.5728217778464568e-08
these O 0 1.4794944824814138e-08
changes O 0 4.321884006230903e-08
in O 0 2.036457580345541e-08
results O 0 2.3112811220471485e-07
and O 0 1.0281878104478892e-07
impact O 0 1.9481136348531436e-07
of O 0 3.709862284040355e-08
these O 0 7.225020937084992e-08
risk O 0 1.5623886611138005e-06
reversals O 0 5.366218829294667e-06
on O 0 2.244531515316339e-06
both O 0 3.3263859222643077e-06
patients O 0 3.376258609932847e-05
and O 0 2.2273015076734737e-07
the O 0 8.512083837786122e-08
counseling O 0 8.441282943749684e-07
team O 0 6.212150793771798e-08
can O 0 9.87900783400164e-09
assist O 0 4.936010000733404e-08
in O 0 1.747518396655323e-08
the O 0 9.846839787996942e-09
development O 0 3.494185207841838e-08
of O 0 1.5562656940915076e-08
strategies O 0 4.209429391721642e-07
for O 0 3.616224830693682e-08
the O 0 1.1703713198585319e-07
prevention O 0 3.2466421089338837e-06
and O 0 1.2440527541457413e-07
, O 0 7.951753389079386e-08
where O 0 6.19993514305861e-08
necessary O 0 2.0751252804984688e-07
, O 0 1.8572993099041923e-07
management O 0 2.5650976454016927e-07
of O 0 4.4024794476626994e-08
a O 0 2.8521105832624016e-06
risk O 0 1.799062010832131e-05
reversal O 0 6.234244665392907e-06
in O 0 8.771623072334478e-08
any O 0 9.433490077981332e-08
predictive O 0 3.900588581018383e-06
testing O 0 5.51402308701654e-06
program O 0 1.2100895219191443e-06
. O 0 5.609695676866977e-07
. O 0 2.425512775516836e-06

A O 0 0.00011012179311364889
novel O 0 4.949254071107134e-05
common O 0 1.571845314174425e-05
missense O 0 0.0002633231633808464
mutation O 0 8.613900718046352e-06
G301C O 0 2.8666190701187588e-05
in O 0 2.0721924443023454e-07
the O 0 1.56433870301953e-07
N O 0 6.1030848883092403e-05
- O 0 4.76715067634359e-05
acetylgalactosamine O 0 0.00019515168969519436
- O 0 8.173664537025616e-05
6 O 0 5.714214694307884e-06
- O 0 0.0008226277423091233
sulfate O 0 0.0002272053388878703
sulfatase O 0 0.00018194540461990982
gene O 0 1.5615872825947008e-06
in O 0 1.2984345403310726e-06
mucopolysaccharidosis B-Disease 0 0.005863611586391926
IVA I-Disease 0 0.4111175239086151
. O 0 4.3183918023714796e-05

Mucopolysaccharidosis B-Disease 1 0.980076253414154
IVA I-Disease 1 0.9988196492195129
( O 0 0.0009535425924696028
MPS B-Disease 1 0.9991801381111145
IVA I-Disease 1 0.9999885559082031
) O 0 1.4238458788895514e-05
is O 0 6.105366992414929e-06
an O 0 2.696323281270452e-05
autosomal B-Disease 1 0.9811576008796692
recessive I-Disease 1 0.9997947812080383
lysosomal I-Disease 1 0.9999954700469971
storage I-Disease 1 0.9999955892562866
disorder I-Disease 1 0.9995656609535217
caused O 0 0.0003687293501570821
by O 0 6.453761670854874e-06
a O 0 0.0002659263845998794
genetic B-Disease 1 0.9987132549285889
defect I-Disease 1 0.9973856806755066
in O 0 1.4940810615371447e-06
N O 0 0.011290925554931164
- O 0 0.0007458021864295006
acetylgalactosamine O 0 0.0028285484295338392
- O 0 0.00039851179462857544
6 O 0 1.5172392522799782e-05
- O 0 0.03046976402401924
sulfate O 0 0.01840069890022278
sulfatase O 0 0.0015226041432470083
( O 0 6.30005104085285e-07
GALNS O 0 0.0001302819000557065
) O 0 1.019359160636668e-06
. O 0 2.9414195523713715e-06

In O 0 4.965418156643864e-06
previous O 0 2.1667951841664035e-06
studies O 0 6.460674057962024e-07
, O 0 2.5452450813645555e-07
we O 0 1.1353715478890081e-07
have O 0 4.074378168184012e-08
found O 0 1.3125800535362941e-07
two O 0 2.9191168593456496e-08
common O 0 1.7359418791329517e-07
mutations O 0 2.8966221066184517e-07
in O 0 1.2227954471200064e-07
Caucasians O 0 3.524834255586029e-06
and O 0 3.343001537814416e-07
Japanese O 0 1.2546033758553676e-06
, O 0 4.41602821865672e-07
respectively O 0 2.7520004550751764e-06
. O 0 3.233716370232287e-06

To O 0 9.791079719434492e-06
characterize O 0 5.1934184739366174e-05
the O 0 1.4488466604234418e-06
mutational O 0 0.0001224622392328456
spectrum O 0 1.4031248610990588e-05
in O 0 1.8892662012603978e-07
various O 0 7.748507613314359e-08
ethnic O 0 2.848889835149748e-07
groups O 0 1.0258489169245877e-07
, O 0 9.631518338437672e-08
mutations O 0 2.221378849753819e-07
in O 0 1.8792457368022042e-08
the O 0 5.514715795129632e-08
GALNS O 0 7.643397839274257e-05
gene O 0 3.356501565576764e-07
in O 0 2.1356720480980584e-07
Colombian O 0 0.00011879634257638827
MPS B-Disease 1 0.997418999671936
IVA I-Disease 1 0.9999978542327881
patients O 0 0.0031935563310980797
were O 0 4.866617473453516e-06
investigated O 0 0.00010538172500673681
, O 0 1.1692540056174039e-06
and O 0 8.227422085838043e-07
genetic O 0 3.6756505323864985e-06
backgrounds O 0 5.272808039080701e-07
were O 0 1.4273163628786278e-07
extensively O 0 2.5460414576627954e-07
analyzed O 0 3.1930520094647363e-07
to O 0 5.1524320809903656e-08
identify O 0 3.8126898971313494e-07
racial O 0 2.621125929636037e-07
origin O 0 6.198185076300433e-08
, O 0 4.709084322485069e-08
based O 0 1.2723513975743117e-07
on O 0 5.086818077870703e-07
mitochondrial O 0 2.475654946465511e-05
DNA O 0 2.8675320209003985e-05
( O 0 3.931512253529945e-07
mtDNA O 0 1.6747551399021177e-06
) O 0 4.1692501895340683e-07
lineages O 0 2.9937784802314127e-06
. O 0 2.3672071165492525e-06

Three O 0 9.06737295736093e-06
novel O 0 2.796041917463299e-05
missense O 0 0.001246209954842925
mutations O 0 7.839773024898022e-05
never O 0 1.904364034999162e-05
identified O 0 6.8265862864791416e-06
previously O 0 6.764248041690735e-07
in O 0 5.1535725020812606e-08
other O 0 2.7835076465976272e-08
populations O 0 2.241595780105854e-07
and O 0 1.1996134219316446e-07
found O 0 2.4556695166211284e-07
in O 0 2.1890047108286126e-08
16 O 0 5.6497803768706945e-08
out O 0 2.0833278213672202e-08
of O 0 4.55051036851728e-08
19 O 0 1.8314118506168597e-06
Colombian O 0 3.230742004234344e-05
MPS B-Disease 1 0.5346786975860596
IVA I-Disease 1 0.9996412992477417
unrelated O 0 5.052498454460874e-05
alleles O 0 2.455103185639018e-06
account O 0 7.501591881009517e-07
for O 0 1.524177037026675e-06
84 O 0 4.453214569366537e-05
. O 0 7.054226898617344e-06

2 O 0 2.327614311070647e-05
% O 0 1.124971163335431e-06
of O 0 8.500175852077518e-08
the O 0 7.0547734765114e-08
alleles O 0 3.880235510678176e-07
in O 0 5.787954648894811e-08
this O 0 1.307033841158045e-07
study O 0 2.091582928187563e-06
. O 0 6.476704584201798e-06

The O 0 5.213025815464789e-06
G301C O 0 9.867527114693075e-05
and O 0 1.7423119516024599e-06
S162F O 0 3.550532346707769e-05
mutations O 0 1.4644427892562817e-06
account O 0 2.966592091979692e-07
for O 0 5.99521058575192e-07
68 O 0 1.9618426449596882e-05
. O 0 6.1450414250430185e-06

4 O 0 0.00014288646343629807
% O 0 7.420622296194779e-06
and O 0 1.8373756347500603e-06
10 O 0 4.982101017958485e-06
. O 0 7.097596153471386e-06

5 O 0 2.0468904040171765e-05
% O 0 1.1152493470945046e-06
of O 0 1.3906392837270687e-07
mutations O 0 1.0288445082551334e-06
, O 0 1.1366640251253557e-07
respectively O 0 3.8302485450003587e-07
, O 0 9.464777406265057e-08
whereas O 0 1.595578993374147e-07
the O 0 2.0454500315736368e-08
remaining O 0 6.118687565503933e-07
F69V O 0 0.00048437074292451143
is O 0 9.604057282786016e-08
limited O 0 1.0511661230339087e-07
to O 0 3.3693808632051514e-08
a O 0 1.7469226065713883e-07
single O 0 1.956025243998738e-06
allele O 0 9.604469596524723e-06
. O 0 5.593067726294976e-06

The O 0 9.32984403334558e-06
skewed O 0 6.233363092178479e-05
prevalence O 0 7.270809874171391e-05
of O 0 4.3271549543533183e-07
G301C O 0 0.0001709653588477522
in O 0 3.106133874553052e-07
only O 0 1.520751879979798e-07
Colombian O 0 2.4833301722537726e-05
patients O 0 1.1263527085247915e-05
and O 0 1.6414763592820236e-07
haplotype O 0 3.6510830341285327e-06
analysis O 0 2.3070286658821715e-07
by O 0 1.1454937265398257e-07
restriction O 0 4.902167916043254e-07
fragment O 0 3.972392278228654e-06
length O 0 2.5764957172214054e-06
polymorphisms O 0 2.5526985609758412e-06
in O 0 3.914720281272821e-08
the O 0 4.146409438021692e-08
GALNS O 0 5.2808511100010946e-05
gene O 0 1.0435351072146659e-07
suggest O 0 8.371425508357788e-08
that O 0 2.9834154702257365e-08
G301C O 0 7.4540289460856e-06
originated O 0 2.563192822435667e-07
from O 0 4.159011268711765e-08
a O 0 2.8995572165513295e-07
common O 0 1.4009757478561369e-06
ancestor O 0 1.0180565368500538e-05
. O 0 6.811374987591989e-06

Investigation O 0 8.548921323381364e-05
of O 0 2.8428069072106155e-06
the O 0 1.2483995988077368e-06
genetic O 0 1.162531043519266e-05
background O 0 1.9007035234608338e-06
by O 0 3.010097202604811e-07
means O 0 1.2178749386748677e-07
of O 0 3.483033239604083e-08
mtDNA O 0 5.686554231942864e-07
lineages O 0 2.501358267181786e-07
indicate O 0 2.349418650737789e-07
that O 0 1.8076150354318088e-08
all O 0 3.153754235540873e-08
our O 0 5.505161766450328e-07
patients O 0 3.397758973733289e-06
are O 0 2.7761695164940647e-08
probably O 0 2.8310279276411165e-07
of O 0 9.578884174743507e-08
native O 0 2.0477004909480456e-06
American O 0 3.957003173127305e-06
descent O 0 0.0005940004484727979

Low O 0 7.764087786199525e-05
frequency O 0 9.128958481596783e-06
of O 0 1.6597361991443904e-06
BRCA1 O 0 0.00019339010759722441
germline O 0 0.000586837821174413
mutations O 0 6.421083071472822e-06
in O 0 4.7659938218203024e-07
45 O 0 2.498023422958795e-05
German O 1 0.6004114747047424
breast B-Disease 1 0.9999825954437256
/ I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999955892562866
families O 0 0.0004316946433391422
. O 0 5.106839307700284e-05

In O 0 6.056041002011625e-06
this O 0 3.1752060181133857e-07
study O 0 4.194394307432958e-07
we O 0 2.458368726365734e-07
investigated O 0 3.584835212677717e-06
45 O 0 5.16023465024773e-06
German O 0 0.29753249883651733
breast B-Disease 1 0.9999830722808838
/ I-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999963045120239
families O 0 9.32809962250758e-06
for O 0 1.6149474504345562e-06
germline O 0 0.005200678948312998
mutations O 0 7.073203960317187e-06
in O 0 2.7152660209139867e-07
the O 0 1.2569099681059015e-06
BRCA1 O 0 0.00035724416375160217
gene O 0 1.6225169019890018e-05
. O 0 8.577929293096531e-06

We O 0 2.8166519769001752e-05
identified O 0 1.739450090099126e-05
four O 0 1.0677354111976456e-06
germline O 0 0.00021231368009466678
mutations O 0 4.578218067763373e-06
in O 0 7.308228191504895e-07
three O 0 1.6568577848374844e-05
breast B-Disease 1 0.9996166229248047
cancer I-Disease 1 0.7604237794876099
families O 0 1.753941774040868e-06
and O 0 4.2736843397506163e-07
in O 0 6.192324804032978e-07
one O 0 3.987539457739331e-05
breast B-Disease 1 0.9999630451202393
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
family O 0 0.00015790863835718483
. O 0 2.9731288009315904e-07
among O 0 1.0939533723330896e-07
these O 0 1.749799771744165e-08
were O 0 1.566874061609269e-07
one O 0 1.918556620239542e-07
frameshift O 0 0.00017874072364065796
mutation O 0 9.137548886428704e-07
, O 0 1.3400840259691904e-07
one O 0 6.630380511296607e-08
nonsense O 0 1.2371010598144494e-05
mutation O 0 6.778998340450926e-07
, O 0 8.303743470605696e-08
one O 0 2.3028075446518415e-08
novel O 0 5.274955583445262e-07
splice O 0 2.016458529396914e-05
site O 0 6.238104106159881e-06
mutation O 0 5.432909802038921e-07
, O 0 9.041954029953558e-08
and O 0 2.527794435991382e-07
one O 0 9.346195497528242e-07
missense O 0 0.00030102013261057436
mutation O 0 3.0204375434550457e-05
. O 0 1.1092891327280086e-05

The O 0 2.357430275878869e-05
missense O 0 0.0008623842732049525
mutation O 0 3.861869117827155e-05
was O 0 6.458422376454109e-06
also O 0 3.894434144058323e-07
found O 0 4.1863020783239335e-07
in O 0 2.5173008566525823e-07
2 O 0 3.0395028716156958e-06
. O 0 4.1477373997622635e-06

8 O 0 3.1238952942658216e-05
% O 0 1.106214995161281e-06
of O 0 1.3262967968330486e-07
the O 0 7.529531842465076e-08
general O 0 4.1363708191966e-07
population O 0 1.1022537194094184e-07
, O 0 1.414196617588459e-07
suggesting O 0 6.44973511043645e-07
that O 0 3.724517227965407e-08
it O 0 9.288795865813881e-08
is O 0 8.711297709851351e-07
not O 0 5.3028711590741295e-06
disease O 0 0.0005302241770550609
associated O 0 1.8091010133503005e-05
. O 0 1.5870313291088678e-05

The O 0 3.3348542274325155e-06
average O 0 8.398167665291112e-06
age O 0 2.583241894171806e-06
of O 0 4.622356300387764e-06
disease O 0 0.03472089394927025
onset O 0 0.031975336372852325
in O 0 1.3830781426804606e-06
those O 0 1.2045329640386626e-06
families O 0 1.1895013813045807e-05
harbouring O 1 0.5159435272216797
causative O 0 0.0003928500518668443
mutations O 0 7.99600275058765e-06
was O 0 1.6487025504829944e-06
between O 0 1.375707483930455e-06
32 O 0 1.3884748113923706e-05
. O 0 7.004098733887076e-06

3 O 0 9.899352880893275e-05
and O 0 1.1278671991021838e-05
37 O 0 3.151765849906951e-05
. O 0 1.7569504052517004e-05

4 O 0 6.0989365010755137e-05
years O 0 4.93291327074985e-06
, O 0 6.221815169737965e-07
whereas O 0 6.66706739593792e-07
the O 0 1.0709155873200871e-07
family O 0 3.2049917990661925e-06
harbouring O 0 0.001191549003124237
the O 0 1.9935073680699134e-07
missense O 0 3.90132081520278e-05
mutation O 0 1.5405764770548558e-06
had O 0 1.7019955578234658e-07
an O 0 3.077221322200785e-08
average O 0 9.690222668723436e-07
age O 0 2.5813113779804553e-07
of O 0 1.0819345419577076e-07
onset O 0 0.00012567585508804768
of O 0 7.847457368370669e-07
51 O 0 4.3453586840769276e-05
. O 0 6.9310931394284125e-06

2 O 0 0.00019873373094014823
years O 0 3.518934317980893e-05
. O 0 2.415601738903206e-05

These O 0 8.420463018410373e-06
findings O 0 4.425658971740631e-06
show O 0 2.8000820293527795e-06
that O 0 4.592354230226192e-07
BRCA1 O 0 8.307470852741972e-05
is O 0 8.375001243621227e-07
implicated O 0 2.0735833459184505e-05
in O 0 7.638438859203234e-08
a O 0 1.1383519193941538e-07
small O 0 3.7798960761392664e-07
fraction O 0 7.62399906761857e-07
of O 0 7.4649342423072085e-06
breast B-Disease 1 0.9999755620956421
/ I-Disease 1 0.9999984502792358
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999960660934448
families O 0 9.128401870839298e-06
suggesting O 0 4.827345492230961e-06
the O 0 9.577423298878784e-08
involvement O 0 2.1575326627498725e-06
of O 0 1.3493894357452518e-07
another O 0 3.3229555356228957e-06
susceptibility O 0 0.0003946286451537162
gene O 0 8.868951226759236e-06
( O 0 3.158461368002463e-06
s O 0 0.0008572645601816475
) O 0 2.249387944175396e-05

Paternal O 0 0.018227459862828255
transmission O 0 0.016978511586785316
of O 0 0.24054571986198425
congenital B-Disease 1 0.9999994039535522
myotonic I-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999936819076538
. O 0 0.014085621573030949

We O 0 1.6283669538097456e-05
report O 0 3.864584414259298e-06
a O 0 1.3311897646417492e-06
rare O 0 1.2569851605803706e-05
case O 0 7.1746890171198174e-06
of O 0 2.7933212550124153e-05
paternally O 1 0.9997894167900085
transmitted O 1 0.999806821346283
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999996423721313
( O 0 0.39432185888290405
DM B-Disease 1 0.999996542930603
) O 0 9.560590115142986e-05
. O 0 4.688724220613949e-05

The O 0 9.563415005686693e-06
proband O 0 0.0006944179767742753
is O 0 9.561430260873749e-07
a O 0 5.060341550233716e-07
23 O 0 1.1430443009885494e-06
year O 0 1.096244318432582e-06
old O 0 0.00036501052090898156
, O 0 0.00029971887124702334
mentally B-Disease 1 0.9999953508377075
retarded I-Disease 1 0.9999090433120728
male O 0 0.0011680572060868144
who O 0 0.036935508251190186
suffers O 1 0.9998407363891602
severe O 1 0.9856157302856445
muscular B-Disease 1 0.9984973669052124
weakness I-Disease 1 0.948137104511261
. O 0 0.00020165665773674846

He O 0 4.629268732969649e-05
presented O 0 6.315441714832559e-05
with O 0 7.383181218756363e-05
respiratory O 0 0.2288604974746704
and O 0 1.0543187272560317e-05
feeding O 0 0.0001284960308112204
difficulties O 0 0.00036385274142958224
at O 0 3.119851680821739e-05
birth O 0 0.00016674639482516795
. O 0 2.097347351082135e-05

His O 0 7.041255594231188e-05
two O 0 2.7163507184013724e-05
sibs O 1 0.9171222448348999
suffer O 0 0.004428056534379721
from O 0 1.0388844202680048e-05
childhood O 0 0.1397131085395813
onset O 1 0.999090313911438
DM B-Disease 1 0.9999918937683105
. O 0 0.0004335465491749346

Their O 0 7.899667252786458e-06
late O 0 4.1792318370426074e-05
father O 0 2.5061935957637616e-05
had O 0 3.5811510201710917e-07
the O 0 3.422950456410945e-08
adult O 0 6.327664436867053e-07
type O 0 2.8246197416592622e-06
of O 0 1.297011181122798e-06
DM B-Disease 1 0.9999955892562866
, O 0 1.4959516647650162e-06
with O 0 4.5008982851868495e-07
onset O 0 0.00017560823471285403
around O 0 6.105968850533827e-07
30 O 0 9.887642136163777e-07
years O 0 1.1276016493866337e-06
. O 0 2.80885706160916e-06

Only O 0 4.8385545596829616e-06
six O 0 1.0426293783893925e-06
other O 0 8.533346829153743e-08
cases O 0 2.142228225920917e-07
of O 0 1.2263151916158677e-07
paternal O 0 8.983065345091745e-05
transmission O 0 0.0010779517469927669
of O 0 0.00633409945294261
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 0.9999997615814209
have O 0 2.7065763788414188e-05
been O 0 6.17280011283583e-06
reported O 0 5.570051507675089e-05
recently O 0 3.7741538108093664e-05
. O 0 6.873875918245176e-06

We O 0 4.463599907467142e-06
review O 0 2.3934464934427524e-06
the O 0 3.54463821850004e-07
sex O 0 3.4846395919885254e-06
related O 0 1.1670955245790537e-05
effects O 0 7.888133950473275e-06
on O 0 7.40624909667531e-06
transmission O 0 0.0009794567013159394
of O 0 0.001800391124561429
congenital B-Disease 1 0.9999970197677612
DM I-Disease 1 0.9999947547912598
. O 0 0.0006824160227552056

Decreased O 0 0.001586843398399651
fertility O 0 7.008665124885738e-05
of O 0 4.953080292580125e-07
males O 0 9.643354133004323e-07
with O 0 4.570970588702039e-07
adult O 0 2.8494669095380232e-05
onset O 1 0.9768415093421936
DM B-Disease 1 0.9999992847442627
and O 0 1.4868737707729451e-05
contraction O 0 1.8599399481900036e-05
of O 0 1.0037110342864253e-07
the O 0 2.3413105054714833e-07
repeat O 0 8.298157808894757e-06
upon O 0 2.645714971549751e-07
male O 0 4.009459644294111e-07
transmission O 0 1.2042090702379937e-06
contribute O 0 5.6039429097154425e-08
to O 0 2.0401159872562857e-08
the O 0 3.049549235356608e-08
almost O 0 6.709868216603354e-08
absent O 0 3.660143761408108e-07
occurrence O 0 4.4152113787276903e-07
of O 0 2.2625533802056452e-07
paternal O 0 7.627648301422596e-05
transmission O 0 0.00033390751923434436
of O 0 0.0023061102256178856
congenital B-Disease 1 0.9999982118606567
DM I-Disease 1 0.9999970197677612
. O 0 0.0009712980245240033

Also O 0 8.68049119162606e-06
the O 0 7.445578376064077e-07
fathers O 0 1.7909590042108903e-06
of O 0 1.2030355378556123e-07
the O 0 2.75630299029217e-07
reported O 0 2.2230193280847743e-05
congenitally O 0 0.002448857529088855
affected O 0 6.531909548357362e-06
children O 0 9.70730752669624e-07
showed O 0 5.945174962107558e-06
, O 0 7.952390745913362e-08
on O 0 2.1173472930513526e-07
average O 0 1.057118993230688e-06
, O 0 7.016032554929552e-08
shorter O 0 1.2129664810345275e-06
CTG O 0 5.302924182615243e-05
repeat O 0 1.3190177696742467e-06
lengths O 0 1.7986812963499688e-05
and O 0 2.8952356956324365e-07
hence O 0 6.365219746840012e-07
less O 0 2.5463334623054834e-06
severe O 0 0.02535385452210903
clinical O 0 0.01932513900101185
symptoms O 0 0.00019674256327562034
than O 0 3.878430163695157e-07
the O 0 3.2624853929519304e-07
mothers O 0 3.0955109195929253e-06
of O 0 4.1085283442043874e-07
children O 0 3.671964077511802e-05
with O 0 0.00672989571467042
congenital B-Disease 1 0.9999972581863403
DM I-Disease 1 0.999997615814209
. O 0 0.0013692262582480907

We O 0 1.3672981367562898e-05
conclude O 0 2.3993607101147063e-05
that O 0 7.803500920999795e-07
paternal O 0 6.109007517807186e-05
transmission O 0 0.0003033916582353413
of O 0 0.0064526768401265144
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 0.9999998807907104
is O 0 0.0008829226135276258
rare O 0 0.00012679904466494918
and O 0 2.3128054635890294e-06
preferentially O 0 1.4410993571800645e-05
occurs O 0 5.323653908817505e-07
with O 0 1.6272926472993277e-07
onset O 0 0.00014457548968493938
of O 0 1.4839082496109768e-06
DM B-Disease 1 0.9999780654907227
past O 0 1.944701580214314e-06
30 O 0 3.610078067595168e-07
years O 0 1.255791630683234e-07
in O 0 2.9007676261016968e-08
the O 0 9.849698301422904e-08
father O 0 2.5094871034525568e-06
. O 0 4.277117398032715e-07
. O 0 4.294870905141579e-06

The O 0 4.173628622083925e-05
RB1 O 0 0.014363942667841911
gene O 0 2.733345354499761e-05
mutation O 0 6.9451998570002615e-06
in O 0 4.1006600781656743e-07
a O 0 1.6848667883095914e-06
child O 0 0.00010296770051354542
with O 0 9.29996749619022e-05
ectopic B-Disease 1 0.9997243285179138
intracranial I-Disease 1 0.9999386072158813
retinoblastoma I-Disease 1 0.9919187426567078
. O 0 0.0001547644060337916

The O 0 3.526600630721077e-05
RB1 O 0 0.007642412558197975
gene O 0 2.5933648430509493e-05
mutation O 0 1.1706704754033126e-05
was O 0 3.383963985470473e-06
investigated O 0 2.704589678614866e-05
in O 0 3.630725018410885e-07
a O 0 2.0328077425801894e-06
child O 0 5.894707646802999e-05
with O 0 2.4889612177503295e-05
ectopic B-Disease 1 0.9983097314834595
intracranial I-Disease 1 0.999974250793457
retinoblastoma I-Disease 0 0.17029275000095367
using O 0 1.0702086683522793e-06
DNA O 0 7.733719940006267e-06
obtained O 0 2.982084765790205e-07
from O 0 3.826640693205263e-08
both O 0 1.6471240371629392e-08
the O 0 7.408188906765645e-08
pineal B-Disease 0 0.00025116378674283624
and I-Disease 0 2.2331929358188063e-05
retinal I-Disease 1 0.9689339995384216
tumours I-Disease 1 0.9998505115509033
of O 0 1.8887396890931996e-06
the O 0 1.0771389497676864e-05
patient O 0 0.0005466833245009184
. O 0 2.5172552341246046e-05

A O 0 3.771448245970532e-05
nonsense O 0 6.713653419865295e-05
mutation O 0 7.329248091991758e-06
in O 0 6.31363775482896e-07
exon O 0 1.633752071938943e-05
17 O 0 8.216343303502072e-07
( O 0 6.556285114811544e-08
codon O 0 1.8649953403837571e-07
556 O 0 3.97780240746215e-07
) O 0 9.248115162563408e-09
of O 0 7.816116642800353e-09
the O 0 5.796505320176948e-08
RB1 O 0 0.0003255062911193818
gene O 0 2.998382058194693e-07
was O 0 2.4194844172598096e-07
found O 0 5.9010535125025854e-08
to O 0 2.873657400925822e-08
be O 0 2.210672001012881e-08
present O 0 1.1461187909844739e-07
homozygously O 0 7.2991824708879e-05
in O 0 5.55955850245482e-08
both O 0 2.3887567479619065e-08
the O 0 1.057940508530919e-07
retinal B-Disease 0 0.00012074677943019196
and I-Disease 0 1.8650252968654968e-06
the I-Disease 0 7.3256769610452466e-06
pineal I-Disease 1 0.8608660101890564
tumours I-Disease 1 0.9997958540916443
. O 0 3.452401142567396e-05

The O 0 3.1773581667948747e-06
same O 0 1.0827205869645695e-06
mutation O 0 1.498137407907052e-06
was O 0 7.684893148507399e-07
present O 0 2.3394468939841317e-07
heterozygously O 0 0.0001990686432691291
in O 0 9.190284089299894e-08
the O 0 3.998202302568643e-08
DNA O 0 2.065881517410162e-06
from O 0 2.9888205688166636e-08
the O 0 2.6699995103740548e-08
constitutional O 0 3.739245073575148e-07
cells O 0 1.103414817293924e-07
of O 0 1.5322957125363246e-08
the O 0 7.213646426862397e-07
patient O 0 9.956544818123803e-05
, O 0 4.834228093386628e-07
proving O 0 1.9156372218276374e-05
it O 0 3.006247339953916e-08
to O 0 2.5305194384372953e-08
be O 0 2.799341736192673e-08
of O 0 1.7259645801459556e-07
germline O 0 0.00016800461162347347
origin O 0 2.030966925303801e-06
. O 0 4.027935119665926e-06

The O 0 3.919785740436055e-06
initial O 0 1.1283330422884319e-05
mutation O 0 3.6192170682625147e-06
was O 0 3.126372405404254e-07
shown O 0 1.8532459478137753e-07
to O 0 6.418667908292264e-08
have O 0 5.656638180084883e-08
occurred O 0 2.5229968514395296e-07
in O 0 4.358764371659163e-08
the O 0 4.597424663188576e-07
paternally O 0 0.00017291844415012747
derived O 0 1.1033681403205264e-05
RB1 O 0 0.0011229118099436164
allele O 0 2.1667890905519016e-05
. O 0 1.2167840395704843e-05

The O 0 5.8189202718494926e-06
mutation O 0 8.415580850851256e-06
is O 0 3.1043038006828283e-07
in O 0 1.315926567713177e-07
an O 0 1.6945962855174912e-08
area O 0 2.39307837546221e-07
of O 0 1.8668703916091545e-08
the O 0 4.509710294087199e-08
gene O 0 1.485807104018022e-07
that O 0 6.0830074311013504e-09
encodes O 0 4.21128021343975e-08
the O 0 1.8529501488728783e-08
protein O 0 9.642106135743234e-08
- O 0 6.950474016775843e-06
binding O 0 1.8381433619651943e-07
region O 0 3.0961552965891315e-07
known O 0 7.548023006620497e-08
as O 0 1.271333438523925e-08
the O 0 3.665662262619662e-08
pocket O 0 0.0008004072587937117
region O 0 1.0267957577525522e-06
and O 0 1.48189570836621e-07
has O 0 7.949736868795299e-08
been O 0 6.142997932556682e-08
detected O 0 8.405101539210591e-07
in O 0 1.928557580299639e-08
other O 0 1.3418739897019805e-08
cases O 0 1.0101757652591914e-07
of O 0 2.2947232025671838e-07
retinoblastoma B-Disease 0 0.01886851154267788
. O 0 1.6846595372044249e-06
. O 0 9.474822945776395e-06

Low O 0 0.0001855518639786169
levels O 0 1.6642708260405925e-06
of O 0 9.699805048057897e-08
beta O 0 8.066596706157725e-07
hexosaminidase O 0 1.5526296920143068e-05
A O 0 2.716752760534291e-07
in O 0 1.198010579628317e-07
healthy O 0 1.4838262814009795e-06
individuals O 0 1.8171391502619372e-07
with O 0 8.1815769590321e-06
apparent O 1 0.963331401348114
deficiency O 0 0.4321843981742859
of O 0 1.9161686282131996e-07
this O 0 5.200168402552663e-07
enzyme O 0 4.818753041035961e-06
. O 0 3.200379751433502e-06

Appreciable O 0 0.0010551427258178592
beta O 0 0.0002444578567519784
hexosaminidase O 0 0.001849635038524866
A O 0 8.041434739425313e-06
( O 0 3.735121367753891e-07
hex O 0 6.395488071575528e-06
A O 0 1.8109525967702211e-07
) O 0 2.168608403962935e-08
activity O 0 7.195837525841853e-08
has O 0 1.2788557768317332e-08
been O 0 2.0397541433681e-08
detected O 0 3.54862606855022e-07
in O 0 2.130972021063826e-08
cultured O 0 7.244356766022975e-06
skin O 0 8.709574467502534e-05
fibroblasts O 0 6.568663229700178e-05
and O 0 0.0006128164823167026
melanoma B-Disease 1 0.9998937845230103
tissue O 0 0.003584819845855236
from O 0 1.5001634210420889e-06
healthy O 0 5.076208253740333e-06
individuals O 0 2.3853334596424247e-07
previously O 0 2.7584512736211764e-06
reported O 0 4.2530697101028636e-05
as O 0 2.9846560209989548e-06
having O 0 0.0002995241084136069
deficiency B-Disease 0 0.04730212688446045
of I-Disease 0 1.1022999757415164e-07
hex I-Disease 0 4.7638241085223854e-05
A I-Disease 0 1.9873610312970413e-07
activity O 0 2.0575160419866734e-07
indistinguishable O 0 2.26803194891545e-07
from O 0 1.3568734580360342e-08
that O 0 8.108244742288662e-09
of O 0 1.6529155288935726e-07
patients O 0 3.5275221307529137e-05
with O 0 0.001843941048718989
Tay B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999977350234985
Sachs I-Disease 1 0.9999982118606567
disease I-Disease 0 0.17387861013412476
( O 0 4.6073182602413e-06
TSD B-Disease 0 0.17068888247013092
) O 0 2.0994768874516012e-06
. O 0 5.772800705017289e-06

Identification O 0 5.9969821450067684e-05
and O 0 6.255369044083636e-06
quantitation O 0 0.0002176709967898205
of O 0 1.2328437151154503e-06
hex O 0 0.00010016825399361551
A O 0 1.1687945971061708e-06
, O 0 3.9689129494036024e-07
amounting O 0 2.402085556241218e-06
to O 0 4.3294127749504696e-07
3 O 0 5.489557224791497e-06
. O 0 5.837351181980921e-06

5 O 0 5.745078669860959e-05
% O 0 1.4934934370103292e-05
- O 0 0.000281642860500142
6 O 0 2.5775729227461852e-05
. O 0 1.3223340829426888e-05

9 O 0 5.319583215168677e-05
% O 0 1.0226190170214977e-06
of O 0 6.972023669504779e-08
total O 0 2.205917297715132e-07
beta O 0 7.877329721850401e-07
hexosaminidase O 0 1.251681078429101e-05
activity O 0 5.950138302068808e-07
, O 0 8.721774236164492e-08
has O 0 4.277468335089907e-08
been O 0 4.2371436137500496e-08
obtained O 0 8.083818414661437e-08
by O 0 1.4246332113998506e-07
cellulose O 0 0.0003069674130529165
acetate O 0 0.0001337315479759127
gel O 0 0.00039200924220494926
electrophoresis O 0 7.774030382279307e-05
, O 0 6.601634368053055e-07
DEAE O 0 0.00020829933055210859
- O 0 3.2925006962614134e-05
cellulose O 0 4.7361976612592116e-05
ion O 0 4.443241414264776e-05
- O 0 1.609457831364125e-05
exchange O 0 1.2745426829496864e-06
chromatography O 0 5.192348544369452e-05
, O 0 1.9898111247584893e-07
radial O 0 5.346041689335834e-06
immunodiffusion O 0 6.46294211037457e-05
, O 0 3.268187072080764e-07
and O 0 1.2836230780521873e-06
radioimmunoassay O 0 0.0007860639598220587
. O 0 8.605550647189375e-06

Previous O 0 3.644105527200736e-05
family O 0 1.5564010027446784e-05
studies O 0 1.3952956123830518e-06
suggested O 0 1.762985789355298e-06
that O 0 9.914045762116075e-08
these O 0 7.374411126193081e-08
individuals O 0 1.9288340524781233e-07
may O 0 8.080101565610676e-07
be O 0 1.1011022138518456e-07
compound O 0 7.213286608021008e-06
heterozygotes O 0 4.6888121687516104e-06
for O 0 4.824537924719152e-08
the O 0 8.465728029705133e-08
common O 0 5.276958745525917e-07
mutant O 0 8.099512342596427e-06
TSD B-Disease 0 0.000633183924946934
gene O 0 7.709778628850472e-07
and O 0 3.018292602519068e-07
a O 0 8.77247373409773e-07
rare O 0 8.05739273346262e-06
( O 0 4.0169919657273567e-07
allelic O 0 2.4610370019217953e-05
) O 0 4.7218739496202033e-07
mutant O 0 4.60064438811969e-06
gene O 0 5.845573468832299e-06
. O 0 4.886964234174229e-06

Thus O 0 3.448841016506776e-05
, O 0 1.392724357174302e-06
the O 0 1.6379219403006573e-07
postulated O 0 2.702977781154914e-06
rate O 0 6.824716365372296e-07
mutant O 0 1.536954869152396e-06
gene O 0 2.670876142474299e-07
appears O 0 2.1352852286327106e-07
to O 0 1.2465581455955999e-08
code O 0 1.5395286823149945e-08
for O 0 5.430146998719465e-09
the O 0 9.083695573508521e-09
expression O 0 2.495043993633317e-08
of O 0 3.777315527031533e-08
low O 0 5.679964488081168e-06
amounts O 0 4.869240797233942e-07
of O 0 2.1171291564314743e-07
hex O 0 4.728809290099889e-05
A O 0 2.487983238097513e-06
. O 0 2.6491866265132558e-06

Heterozygotes O 0 0.0019248134922236204
for O 0 5.607798811979592e-06
the O 0 1.1267513855273137e-06
rare O 0 1.929330755956471e-05
mutant O 0 7.68107856856659e-05
may O 0 4.889761385129532e-06
be O 0 1.2355927481166873e-07
indistinguishable O 0 2.7972394036623882e-06
from O 0 3.0022133046259114e-07
heterozygotes O 0 1.0112500604009256e-05
for O 0 1.337110973054223e-07
the O 0 2.9818485813848383e-07
common O 0 5.788192083855392e-06
TSD B-Disease 0 0.016081970185041428
mutant O 0 0.00011083986464655027
. O 0 1.125154631154146e-05

However O 0 9.427493750990834e-06
, O 0 4.388156753520889e-07
direct O 0 2.969728427615337e-07
visualization O 0 1.0209644642600324e-05
and O 0 5.354147560865385e-07
quantitation O 0 0.00017799461784306914
of O 0 4.880281494479277e-07
hex O 0 7.740653381915763e-05
A O 0 2.4695418687770143e-07
by O 0 4.914572571124154e-08
the O 0 2.4012230426251335e-08
methods O 0 3.9137989915616345e-07
described O 0 6.012186531734187e-06
may O 0 7.259450285346247e-07
prevent O 0 1.1521257192725898e-06
false O 0 1.9675046587508405e-06
- O 0 9.563927596900612e-05
positive O 0 1.2991825997232809e-06
prenatal O 0 0.0006129318499006331
diagnosis O 0 0.0006509945378638804
of O 0 1.0504782039788552e-06
TSD B-Disease 1 0.9080378413200378
in O 0 7.595067472720984e-06
fetuses O 0 0.0001637301902519539
having O 0 5.15323847594118e-07
the O 0 1.3777567176020966e-07
incomplete O 0 3.125164585071616e-05
hex B-Disease 0 0.01771860383450985
A I-Disease 0 0.00010496731556486338
deficiency I-Disease 0 0.0020646005868911743
of O 0 5.581701145729312e-08
the O 0 1.9268300377461856e-07
type O 0 1.708137642708607e-05
described O 0 2.3777481601428008e-06
in O 0 7.467559726137551e-08
the O 0 1.7403576180186064e-07
four O 0 1.318590079790738e-06
healthy O 0 2.3648610294912942e-05
individuals O 0 1.1591866496019065e-05

The O 0 4.837829328607768e-05
tumor B-Disease 0 0.0015955923590809107
suppressor O 0 0.00028546107932925224
gene O 0 2.6029962100437842e-05
Smad4 O 0 0.0007486448157578707
/ O 0 0.00013217121886555105
Dpc4 O 0 0.0003552616108208895
is O 0 1.8861014439153223e-07
required O 0 7.741358132307141e-08
for O 0 6.244724914949984e-08
gastrulation O 0 0.00043672305764630437
and O 0 4.0817445778884576e-07
later O 0 1.4903568512636411e-07
for O 0 1.0109178560924192e-07
anterior O 0 1.970360790437553e-05
development O 0 1.5930336871861073e-07
of O 0 6.636694394046572e-08
the O 0 2.890520818255027e-07
mouse O 0 4.086335320607759e-05
embryo O 0 5.359185888664797e-05
. O 0 1.0537096386542544e-05

Mutations O 0 0.0002578888670541346
in O 0 2.382446837145835e-06
the O 0 1.7042318631865783e-06
SMAD4 O 0 0.04197053983807564
/ O 0 0.0014058119850233197
DPC4 O 0 0.19096311926841736
tumor B-Disease 0 0.002876314800232649
suppressor O 0 3.641805596998893e-05
gene O 0 7.754597390885465e-07
, O 0 6.270673225117207e-08
a O 0 4.812635623352435e-08
key O 0 3.6564210859069135e-07
signal O 0 5.469816528602678e-07
transducer O 0 3.2008831567509333e-06
in O 0 4.1279527351889556e-08
most O 0 4.381620399840358e-08
TGFbeta O 0 9.666010737419128e-05
- O 0 8.795876783551648e-05
related O 0 1.9997103208879707e-06
pathways O 0 2.126333811247605e-07
, O 0 2.386525288500252e-08
are O 0 4.7598951447014315e-09
involved O 0 3.171937024148974e-08
in O 0 2.2873113181276494e-08
50 O 0 2.057053052340052e-07
% O 0 2.62589452404427e-07
of O 0 1.0645261681929696e-05
pancreatic B-Disease 1 0.9999861717224121
cancers I-Disease 1 0.9867860674858093
. O 0 2.453007073199842e-05

Homozygous O 0 0.002414750400930643
Smad4 O 0 0.017669450491666794
mutant O 0 0.002117304829880595
mice O 0 0.0019980245269834995
die O 0 0.00035680067958310246
before O 0 1.8937158756671124e-06
day O 0 2.9852765237592394e-06
7 O 0 1.168691596831195e-05
. O 0 6.333493729471229e-06

5 O 0 6.389247573679313e-05
of O 0 1.1944131074415054e-05
embryogenesis O 0 0.0017344590742141008
. O 0 0.00011807018745457754

Mutant O 0 0.00010141307575395331
embryos O 0 2.9092288968968205e-05
have O 0 6.263907152970205e-07
reduced O 0 6.017636451360886e-07
size O 0 2.956575599455391e-06
, O 0 1.5847798806589708e-07
fail O 0 1.3017921673963428e-06
to O 0 6.624919279829555e-08
gastrulate O 0 0.00016370211960747838
or O 0 1.7491899484411988e-07
express O 0 4.959915145263949e-07
a O 0 1.5650400086997251e-07
mesodermal O 0 5.43594105693046e-05
marker O 0 2.0579884221660905e-05
, O 0 1.3963909850644995e-07
and O 0 1.0600230382351583e-07
show O 0 1.5799795392013039e-06
abnormal O 0 2.3607623006682843e-05
visceral O 0 4.586294380715117e-05
endoderm O 0 0.0004335905541665852
development O 0 1.3058956938039046e-05
. O 0 1.2934726328239776e-05

Growth B-Disease 1 0.9995169639587402
retardation I-Disease 1 0.9999321699142456
of O 0 1.7987608771363739e-06
the O 0 1.673852921157959e-06
Smad4 O 0 0.2389218956232071
- O 0 0.13030751049518585
deficient O 0 0.0003828309418167919
embryos O 0 8.320087090396555e-07
results O 0 3.48478806699859e-07
from O 0 1.1045877101878432e-07
reduced O 0 1.9703359157574596e-06
cell O 0 2.9636996259796433e-05
proliferation O 0 2.309760748175904e-05
rather O 0 1.617725331470865e-07
than O 0 1.4921999991202028e-07
increased O 0 1.5026948858576361e-06
apoptosis O 0 2.306991518707946e-05
. O 0 5.006023911846569e-06

Aggregation O 0 0.0001094993858714588
of O 0 6.031981683918275e-06
mutant O 0 0.00015364587306976318
Smad4 O 0 0.0042565385811030865
ES O 0 0.00019300197891425341
cells O 0 3.1984634460968664e-06
with O 0 2.3502208534864621e-07
wild O 0 3.2542927783651976e-06
- O 0 9.531388059258461e-05
type O 0 1.242544749402441e-05
tetraploid O 0 0.00010888589167734608
morulae O 0 0.00035400153137743473
rescues O 0 9.491119271842763e-05
the O 0 2.921584609794081e-06
gastrulation B-Disease 0 0.04082239046692848
defect I-Disease 0 0.002407858846709132
. O 0 1.979899207071867e-05

These O 0 6.378871148626786e-06
results O 0 5.518752459465759e-06
indicate O 0 2.464810904712067e-06
that O 0 2.1974973662963748e-07
Smad4 O 0 0.0004731055232696235
is O 0 1.7499273496923706e-07
initially O 0 2.635956093399727e-07
required O 0 3.928865410784965e-08
for O 0 1.3330043735493291e-08
the O 0 1.2311895503103187e-08
differentiation O 0 1.1957675383200694e-07
of O 0 1.3206721050096348e-08
the O 0 5.212372045093616e-08
visceral O 0 1.3682946701010223e-05
endoderm O 0 7.573962648166344e-05
and O 0 4.1361067815159913e-07
that O 0 4.9314181183035544e-08
the O 0 1.4916649604401755e-07
gastrulation B-Disease 0 0.028168367221951485
defect I-Disease 0 0.0008687732042744756
in O 0 1.7662425477737997e-07
the O 0 1.7849045264028973e-07
epiblast O 0 0.007352634333074093
is O 0 2.3829122142160486e-07
secondary O 0 3.400143668841338e-07
and O 0 2.982096134473977e-07
non O 0 3.660314860098879e-06
- O 0 0.0009237375925295055
cell O 0 0.00013360702723730356
autonomous O 0 5.601742486760486e-06
. O 0 7.940013347251806e-06

Rescued O 0 0.0022650074679404497
embryos O 0 0.00026333495043218136
show O 0 0.00014970773190725595
severe O 0 0.016531184315681458
anterior O 0 0.010179512202739716
truncations O 0 0.259753555059433
, O 0 2.7441528800409287e-05
indicating O 0 1.6323861927958205e-05
a O 0 2.6832816502064816e-07
second O 0 4.463236393803527e-07
important O 0 9.530771905019719e-08
role O 0 1.2190439235837403e-07
for O 0 2.3453443986909406e-07
Smad4 O 0 0.0006763776182197034
in O 0 5.443407076199946e-07
anterior O 0 7.152206671889871e-05
patterning O 0 0.00014212660607881844
during O 0 8.739124496059958e-06
embryogenesis O 0 0.0005911316839046776
. O 0 1.6079940905910917e-05

Prevalence O 0 0.0021129006054252386
of O 0 5.274077921058051e-06
p16 O 0 0.0001311230444116518
and O 0 4.70423765364103e-06
CDK4 O 0 0.002491325605660677
germline O 0 0.00032879828359000385
mutations O 0 7.19378385838354e-06
in O 0 1.0680429340936826e-06
48 O 0 0.00048633257392793894
melanoma B-Disease 1 0.9999356269836426
- O 1 0.9611731767654419
prone O 0 0.24755702912807465
families O 0 3.600434638428851e-06
in O 0 8.760517857808736e-07
France O 0 2.5209114028257318e-05
. O 0 1.6742917068768293e-05

The O 0 5.203635373618454e-05
French O 0 0.0016069953562691808
Familial B-Disease 1 0.9987679123878479
Melanoma I-Disease 1 0.999940037727356
Study O 0 6.29743590252474e-05
Group O 0 8.820437506074086e-05
. O 0 2.302424400113523e-05

Germline O 0 0.08352097868919373
mutations O 0 0.00016214055358432233
in O 0 1.2561071116579114e-06
the O 0 2.988689971061831e-07
p16 O 0 9.941207281372044e-06
and O 0 1.1615928769970196e-06
CDK4 O 0 0.0011650825617834926
genes O 0 8.747277320253488e-07
have O 0 1.7001039509523252e-07
been O 0 1.9320964383950923e-07
reported O 0 7.610631769239262e-07
in O 0 3.763773293030681e-08
a O 0 1.547472123775151e-07
subset O 0 2.2960198293731082e-06
of O 0 3.5446621495793806e-06
melanoma B-Disease 1 0.994631290435791
pedigrees O 0 0.0002264579088659957
, O 0 7.591958137709298e-07
but O 0 1.5411571041568095e-07
their O 0 6.335472590990321e-08
prevalence O 0 4.453078145161271e-05
is O 0 1.2285370587505895e-07
not O 0 1.3616573824037914e-07
well O 0 4.116839136258932e-07
known O 0 3.143112735415343e-06
. O 0 7.351880412898026e-06

We O 0 6.880749879201176e-06
searched O 0 1.842747224145569e-05
for O 0 1.2358201217921305e-07
such O 0 1.5835682631859527e-07
germline O 0 7.736572297289968e-05
mutations O 0 9.797728353078128e-07
in O 0 1.4217978616670734e-07
48 O 0 8.966326277004555e-06
French O 0 0.0006613037548959255
melanoma B-Disease 1 0.9998352527618408
- O 1 0.9720057845115662
prone O 0 0.324327677488327
families O 0 4.3646630842886225e-07
selected O 0 1.1409321132305195e-07
according O 0 5.2638242209468444e-08
to O 0 2.5876991216478018e-08
two O 0 2.3770578394533004e-08
major O 0 5.834206717736379e-07
criteria O 0 2.559943652613583e-07
families O 0 7.422530501344227e-08
with O 0 6.400134822115433e-08
at O 0 4.157005832894356e-07
least O 0 2.0253017041227395e-08
three O 0 2.0257576949234135e-08
affected O 0 8.055820899244281e-08
members O 0 9.30343801996969e-09
( O 0 3.68307802034451e-08
n O 0 2.564927672210615e-05
= O 0 8.981961627796409e-07
20 O 0 3.78742974760371e-08
) O 0 6.419522691203383e-09
or O 0 1.7501301741162933e-08
families O 0 2.7367336841166434e-08
with O 0 2.121186781778306e-08
two O 0 3.227398437388729e-08
affected O 0 1.840063958979954e-07
members O 0 1.7452332912171187e-08
, O 0 3.20691597721634e-08
one O 0 4.83302686760112e-09
of O 0 5.730676377879718e-09
them O 0 1.5437098710435748e-08
affected O 0 5.193952645754507e-08
before O 0 4.2220413831728365e-08
the O 0 9.679692603015155e-09
age O 0 6.209970848658486e-08
of O 0 1.0581016063326842e-08
50 O 0 1.1380360831481084e-07
( O 0 2.521403885680229e-08
n O 0 6.61497188048088e-06
= O 0 6.595441846002359e-07
28 O 0 9.112627452623201e-08
) O 0 6.107864436444288e-09
, O 0 1.0099594938139944e-08
and O 0 1.9149441143895274e-08
one O 0 2.2222044648856354e-08
additional O 0 1.207603474995267e-07
minor O 0 9.755996870808303e-06
criterion O 0 3.7855807022424415e-05
. O 0 4.231153980072122e-06

Sixteen O 0 6.585686060134321e-05
different O 0 2.9553748390753753e-06
p16 O 0 5.994717503199354e-05
germline O 0 0.000579007959458977
mutations O 0 2.109275919792708e-05
were O 0 6.686998403893085e-07
found O 0 1.7422077291939786e-07
in O 0 6.606572355849494e-08
21 O 0 9.519504828858771e-07
families O 0 2.0992595750612963e-07
, O 0 9.830741731775561e-08
while O 0 1.325337137814131e-07
one O 0 7.974126248200264e-08
germline O 0 1.6029631296987645e-05
mutation O 0 2.2294436519132432e-07
, O 0 1.354774070705389e-07
Arg24His O 0 4.3400250433478504e-05
, O 0 2.362832987046204e-07
was O 0 5.198085659685603e-07
detected O 0 1.0493847639736487e-06
in O 0 5.848702144817253e-08
the O 0 3.5177851032131e-07
CDK4 O 0 0.0009491149103268981
gene O 0 1.3024207873968408e-05
. O 0 8.433642506133765e-06

The O 0 1.978994987439364e-06
frequency O 0 1.333227714894747e-06
of O 0 2.2035371216588828e-07
p16 O 0 6.761385520803742e-06
gene O 0 7.975286848704854e-07
mutation O 0 2.97518511160888e-07
in O 0 2.6525382779141182e-08
our O 0 4.382615159670422e-08
sample O 0 1.5029743849481747e-07
( O 0 2.16439364209009e-08
44 O 0 1.6653457635129598e-07
% O 0 5.5193350334548086e-08
) O 0 1.9151485730617424e-08
is O 0 2.637634999302918e-08
among O 0 1.7534883767211795e-08
the O 0 2.6893243187942062e-08
highest O 0 3.061110646740417e-06
rates O 0 4.241138071847672e-07
yet O 0 2.464232125021226e-07
reported O 0 6.24406993665616e-07
and O 0 5.960531268556224e-08
the O 0 1.0139399364561541e-07
CDK4 O 0 0.0017201743321493268
mutation O 0 3.1320516313826374e-07
is O 0 3.074528365232254e-08
the O 0 1.9120315997156467e-08
second O 0 5.888567216061347e-07
mutation O 0 7.157495360843313e-07
detected O 0 1.4316734677777276e-06
in O 0 4.211505100215618e-08
this O 0 6.757233705911858e-08
gene O 0 8.880130621946591e-07
worldwide O 0 1.1789394420702592e-06
. O 0 3.2537714105274063e-06

In O 0 5.664320724463323e-06
summary O 0 1.0563215255388059e-05
, O 0 5.823883384437067e-07
our O 0 2.5176731810461206e-07
results O 0 4.379469089599297e-07
show O 0 5.624577283924737e-07
frequent O 0 6.335961302283977e-07
involvement O 0 6.593592729586817e-07
of O 0 3.3359622619855145e-08
the O 0 1.3853656355422572e-07
p16 O 0 8.02830072643701e-06
gene O 0 8.900835837266641e-07
in O 0 1.385605060022499e-06
familial B-Disease 1 0.6792749166488647
melanoma I-Disease 1 0.9997847676277161
and O 0 7.868074135330971e-06
confirm O 0 5.390556452766759e-06
the O 0 4.323945290707343e-08
role O 0 3.505586931851212e-08
of O 0 1.0581984177804316e-08
the O 0 4.6356259275626144e-08
CDK4 O 0 0.00012199380580568686
gene O 0 2.396412810412585e-07
as O 0 1.1748007722189868e-07
a O 0 8.440271813014988e-06
melanoma B-Disease 1 0.9942441582679749
- O 0 0.0019336628029122949
predisposing O 0 9.708003926789388e-05
gene O 0 2.719378244364634e-06
. O 0 1.0884416496992344e-06
. O 0 9.222361768479459e-06

Progression O 0 0.00022118068591225892
of O 0 3.2530390399188036e-06
somatic O 0 0.00011962548887822777
CTG O 0 0.005224837921559811
repeat O 0 3.561349876690656e-05
length O 0 1.2418813639669679e-05
heterogeneity O 0 0.00011293191346339881
in O 0 4.732775380489329e-07
the O 0 6.754856372026552e-07
blood O 0 8.333480218425393e-05
cells O 0 7.198461389634758e-05
of O 0 0.00041885016253218055
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999978542327881
patients O 0 0.1724931001663208
. O 0 0.00010079316416522488

The O 0 1.0553750144026708e-05
genetic O 0 3.047821155632846e-05
basis O 0 5.02953480463475e-06
of O 0 0.0002256092120660469
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999996423721313
( O 0 0.10984628647565842
DM B-Disease 1 0.9999995231628418
) O 0 7.178891337389359e-06
is O 0 1.4262046477142576e-07
the O 0 1.774841429380558e-08
expansion O 0 3.0940418582758866e-07
of O 0 4.997415103957792e-08
an O 0 1.370072197914851e-07
unstable O 0 0.0061432491056621075
CTG O 0 0.0014565434539690614
repeat O 0 2.4534597287129145e-06
in O 0 3.750136912117341e-08
the O 0 2.416338418242958e-08
34 O 0 3.1291585855797166e-07
UTR O 0 2.449901330692228e-06
of O 0 3.841053697328789e-08
the O 0 2.805824124152423e-07
DM B-Disease 1 0.9990339279174805
protein O 0 7.71472912219906e-07
kinase O 0 1.881446223706007e-06
gene O 0 3.5920757568419504e-07
on O 0 3.703747495364951e-07
chromosome O 0 2.230315476481337e-05
19 O 0 8.021650501177646e-06
. O 0 3.636689143604599e-06

One O 0 3.239510078856256e-06
of O 0 3.952760891934304e-07
the O 0 1.1477923322900097e-07
principal O 0 3.922718576632178e-07
features O 0 1.3322269865057024e-07
of O 0 9.36636439519134e-08
the O 0 3.598937610149733e-06
DM B-Disease 1 0.9999990463256836
mutation O 0 6.0791639953095e-06
is O 0 1.1324776494348043e-07
an O 0 4.23465493781805e-08
extraordinarily O 0 4.609225652529858e-05
high O 0 2.75185607279127e-06
level O 0 1.1441705538572933e-07
of O 0 6.697708698766291e-08
somatic O 0 3.001749428221956e-05
mosaicism O 0 0.07512317597866058
, O 0 7.826441219549451e-07
due O 0 3.456476065366587e-07
to O 0 4.7400387614970896e-08
an O 0 6.487494630391666e-08
extremely O 0 2.215218592027668e-05
high O 0 5.779637376690516e-06
degree O 0 3.3162962154165143e-07
of O 0 4.217614701929051e-08
somatic O 0 1.2067073839716613e-05
instability O 0 8.210168743971735e-06
both O 0 4.140458642609701e-08
within O 0 3.696844430578494e-08
and O 0 6.109777217488954e-08
between O 0 3.0470960155071225e-07
different O 0 5.168367920305172e-07
tissues O 0 2.7005122319678776e-05
. O 0 5.941592462477274e-06

This O 0 1.6620486348983832e-05
instability O 0 0.00021589630341622978
appears O 0 6.882666184537811e-06
to O 0 1.569974727999579e-07
be O 0 4.213096005400985e-08
biased O 0 5.964546403447457e-07
towards O 0 7.188155137782815e-08
further O 0 3.079593113852752e-08
expansion O 0 3.099848413512518e-07
and O 0 5.6008865101375704e-08
continuous O 0 4.206913217785768e-07
throughout O 0 5.079318654566123e-08
the O 0 2.775481178218797e-08
life O 0 8.576178345265362e-08
of O 0 2.2969643964643183e-08
an O 0 1.4573851458976605e-08
individual O 0 4.650184592946971e-08
, O 0 8.569392662138853e-08
features O 0 4.070820978085976e-07
that O 0 7.437736826432229e-08
could O 0 4.243630371547624e-07
be O 0 6.958619280794665e-08
associated O 0 2.8932595341757406e-07
with O 0 4.836441647171341e-08
the O 0 1.2057000731147127e-07
progressive O 0 1.557364703330677e-05
nature O 0 5.498854420693533e-07
of O 0 4.6481807203235803e-07
the O 0 1.8835697119357064e-05
disease O 0 0.003940041642636061
. O 0 1.3551759366237093e-05

Although O 0 2.3180093194241636e-05
increasing O 0 7.877654752519447e-06
measured O 0 7.981177077454049e-06
allele O 0 4.710809662356041e-06
size O 0 9.186476745526306e-06
between O 0 6.3436855270992965e-06
patients O 0 2.497627974662464e-05
clearly O 0 7.82220297423919e-07
correlates O 0 3.08013909489091e-06
with O 0 1.3424863709587953e-07
an O 0 1.0375315184774081e-07
increased O 0 9.703256182547193e-06
severity O 0 0.0002785395772662014
of O 0 3.6732672015205026e-06
symptoms O 0 0.0001403183996444568
and O 0 1.7312397915247857e-07
an O 0 3.643697610300478e-08
earlier O 0 2.014957999563194e-06
age O 0 2.9463984674293897e-07
of O 0 1.0266846572903887e-07
onset O 0 0.0016149206785485148
, O 0 1.757792063017405e-07
this O 0 1.7115102224352086e-08
correlation O 0 2.892056727432646e-07
is O 0 4.19895265224568e-08
not O 0 1.0087120472235256e-08
precise O 0 1.0491470447959728e-07
and O 0 8.983557364672379e-08
measured O 0 1.0851643992282334e-06
allele O 0 4.13203366633752e-07
length O 0 9.421852382729412e-07
cannot O 0 4.414255556639546e-07
be O 0 1.5337137782012178e-08
used O 0 1.7879157709899118e-08
as O 0 3.881269527994391e-09
an O 0 4.544454146326871e-09
accurate O 0 7.595072020194493e-07
predictor O 0 9.623513506085146e-06
of O 0 1.680842132145699e-07
age O 0 1.0034178785645054e-06
of O 0 8.935331266002322e-07
onset O 0 0.03508540987968445
. O 0 1.4711697076563723e-05

In O 0 5.355058419809211e-06
order O 0 7.179905878729187e-07
to O 0 7.829294190742075e-08
further O 0 8.506825110998761e-08
characterize O 0 1.7879212919069687e-06
the O 0 7.564769788359627e-08
dynamics O 0 1.237202468473697e-05
of O 0 1.2006496490357677e-06
DM B-Disease 1 0.9999877214431763
CTG O 0 0.03163013979792595
repeat O 0 2.4821087208692916e-05
somatic O 0 2.079813930322416e-05
instability O 0 1.6765603504609317e-05
, O 0 2.0284028323658276e-07
we O 0 6.491728044011325e-08
have O 0 2.087922368332329e-08
studied O 0 1.0460061616868188e-07
repeat O 0 5.343251814338146e-07
length O 0 2.1944040895505168e-07
changes O 0 5.54164536481494e-08
over O 0 5.7998231994815796e-08
time O 0 6.763087867511786e-08
in O 0 6.974610187171493e-07
111 O 1 0.6166234612464905
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999990463256836
patients O 0 0.0069029973819851875
with O 0 2.6942075237457175e-06
varying O 0 3.900324009009637e-05
clinical O 0 0.0011950248153880239
severity O 0 0.003917524591088295
and O 0 7.112544153642375e-06
CTG O 0 0.007549187634140253
repeat O 0 2.018203304032795e-05
size O 0 4.767739483213518e-06
over O 0 1.714284678655531e-07
time O 0 5.1959442970428427e-08
intervals O 0 1.307947883333327e-07
of O 0 2.2662757004354717e-08
1 O 0 4.7366989974761964e-07
- O 0 2.020980537054129e-05
7 O 0 1.336621721748088e-06
years O 0 8.221414304898644e-07
. O 0 2.069705487883766e-06

We O 0 1.5098260519152973e-05
have O 0 1.2199573120597051e-06
found O 0 2.2747296668512718e-07
a O 0 4.905366779439646e-08
direct O 0 1.0514568771213817e-07
progression O 0 2.2205390450835694e-06
of O 0 3.881930155102964e-08
the O 0 6.673772645626741e-08
size O 0 2.636740646266844e-06
heterogeneity O 0 1.331714156549424e-05
over O 0 4.448397703527007e-07
time O 0 9.747170537366401e-08
related O 0 4.789130230165028e-07
to O 0 3.828670358529962e-08
initial O 0 1.3461262824421283e-06
CTG O 0 0.00014748520334251225
repeat O 0 1.65750577707513e-06
size O 0 6.377694603543205e-07
and O 0 4.7954461734889264e-08
the O 0 9.846538695512663e-09
time O 0 2.0154443447495396e-08
interval O 0 2.9096625553393096e-07
and O 0 4.817549381641584e-08
always O 0 5.4262365267732093e-08
biased O 0 3.6741604958479e-07
towards O 0 1.909051405846185e-07
further O 0 1.4106055346019275e-07
expansion O 0 4.339778115536319e-06
. O 0 4.049195013067219e-06

Attempts O 0 3.962196205975488e-05
to O 0 1.8402271280137938e-06
mathematically O 0 8.856991371430922e-06
model O 0 2.5178342184517533e-06
the O 0 3.1043038006828283e-07
dynamics O 0 0.00010742984159151092
have O 0 2.9686185598620796e-07
proved O 0 2.1721994016843382e-06
only O 0 3.689884309210356e-08
partially O 0 1.120946535593248e-06
successful O 0 3.556536967153079e-07
suggesting O 0 9.076976539290627e-07
that O 0 3.008139870530613e-08
individual O 0 1.943979910379312e-08
specific O 0 1.1216914685974189e-07
genetic O 0 4.335476205596933e-06
and O 0 1.8302594071428757e-06
/ O 0 0.0016723856097087264
or O 0 1.8357396811552462e-06
environmental O 0 6.568353001057403e-06
factors O 0 2.6383250428807514e-07
also O 0 4.7935714064806234e-08
play O 0 3.3394893961258276e-08
a O 0 8.563036857367479e-08
role O 0 2.160010126317502e-07
in O 0 3.513721082981647e-07
somatic O 0 7.279266719706357e-05
mosaicism O 0 0.016219694167375565
. O 0 2.7181260975339683e-06
. O 0 7.675718734390102e-06

Aspartylglucosaminuria B-Disease 1 0.9774683713912964
among O 0 0.00010565480624791235
Palestinian O 0 0.00014446773275267333
Arabs O 0 0.00012859948037657887
. O 0 2.567386945884209e-05

Aspartylglucosaminuria B-Disease 1 0.9996521472930908
( O 0 0.0007799678714945912
AGU B-Disease 1 0.9995290040969849
) O 0 4.196473128104117e-06
is O 0 8.89065518094867e-07
a O 0 6.738308456988307e-06
rare O 0 0.001728155999444425
disorder B-Disease 0 0.014612413942813873
of I-Disease 0 8.495618999404542e-07
glycoprotein I-Disease 0 0.028619322925806046
metabolism I-Disease 0 0.00017995608504861593
caused O 0 1.1392416126909666e-05
by O 0 9.176487765216734e-07
the O 0 6.072882570151705e-06
deficiency B-Disease 0 0.008471149951219559
of I-Disease 0 5.318705831314219e-08
the I-Disease 0 7.953678391459107e-07
lysosomal I-Disease 0 0.15809205174446106
enzyme I-Disease 0 1.7617874618736096e-05
aspartylglucosaminidase I-Disease 0 0.0012158551253378391
( O 0 1.563032469675818e-06
AGA O 0 0.00013550941366702318
) O 0 1.879663614090532e-06
. O 0 4.285498107492458e-06

AGU B-Disease 1 0.9997726082801819
is O 0 0.0013609202578663826
inherited O 1 0.7335395812988281
as O 0 9.042106285050977e-06
an O 0 7.62313584345975e-06
autosomal O 1 0.5850948095321655
recessive O 1 0.7520919442176819
trait O 0 0.0009545451612211764
and O 0 1.1345362509018742e-05
occurs O 0 1.2789041647920385e-06
with O 0 1.5505004569149605e-07
a O 0 3.0401298545257305e-07
high O 0 2.0475638393691042e-06
frequency O 0 3.136316593099764e-07
in O 0 8.836423859293063e-08
Finland O 0 1.8479755681255483e-06
because O 0 5.624674415116715e-08
of O 0 6.990372725113048e-08
a O 0 6.413357027668098e-07
founder O 0 3.268100772402249e-05
effect O 0 4.488887952902587e-06
. O 0 3.707914174810867e-06

While O 0 7.904587255325168e-05
very O 0 1.4405112779058982e-05
few O 0 7.355421075772028e-06
patients O 0 7.114738400559872e-05
with O 0 9.445600881008431e-06
AGU B-Disease 1 0.9999477863311768
have O 0 1.2791786048182985e-06
been O 0 4.753696316583955e-07
reported O 0 8.861806577442621e-07
from O 0 4.470640391218694e-08
non O 0 1.3396526128417463e-06
- O 0 0.00024004913575481623
Finnish O 0 1.6201991456910037e-05
origin O 0 1.622456267114103e-07
, O 0 4.51658820566081e-07
we O 0 6.702476639475208e-06
diagnosed O 0 0.049088411033153534
the O 0 3.3326032280456275e-06
disorder O 0 0.010298210196197033
in O 0 6.243117240956053e-07
8 O 0 0.00011422396346461028
patients O 0 4.300974069337826e-06
originating O 0 9.285802349268124e-08
from O 0 6.62356782754614e-08
3 O 0 7.391350322905055e-07
unrelated O 0 1.5573083373965346e-06
families O 0 1.3642231522226211e-07
, O 0 3.482003663179967e-08
all O 0 9.257150601627018e-09
Palestinian O 0 2.8166095944470726e-07
Arabs O 0 2.2947078548440913e-07
from O 0 1.6553757475890052e-08
the O 0 3.3235018292998575e-08
region O 0 3.3663110343695735e-07
of O 0 1.383738919003008e-07
Jerusalem O 0 0.00015473799430765212
. O 0 1.067556604539277e-05

The O 0 3.095231295446865e-05
clinical O 0 0.011495213955640793
diagnosis O 0 0.4585358202457428
of O 0 0.00012495827104430646
AGU B-Disease 1 0.999983549118042
is O 0 1.6232970665441826e-05
often O 0 1.7955421753867995e-06
difficult O 0 1.5753361367387697e-05
, O 0 2.8127925588705693e-07
in O 0 5.529324198505492e-08
particular O 0 6.895281501329009e-08
early O 0 1.5423141519477213e-07
in O 0 3.519072677704571e-08
the O 0 2.1801794147791043e-08
course O 0 1.741923142617452e-06
of O 0 7.12446706074843e-08
the O 0 1.4967365586926462e-06
disease O 0 0.0004905224777758121
, O 0 2.2192656956576684e-07
and O 0 2.1083684487166465e-07
most O 0 1.4070552722955654e-08
of O 0 2.627351847195314e-08
the O 0 5.760695671597205e-07
patients O 0 2.220048918388784e-05
are O 0 1.4172981082083425e-06
diagnosed O 0 0.008424310013651848
after O 0 7.362154974543955e-07
the O 0 8.117795857742749e-08
age O 0 2.456465608702274e-07
of O 0 8.78357653277817e-08
5 O 0 2.1720584300055634e-06
years O 0 1.6538236877750023e-06
. O 0 5.589377906289883e-06

However O 0 1.7568816474522464e-05
, O 0 1.8934811123472173e-06
since O 0 1.4735600188942044e-06
these O 0 1.935943743092139e-07
patients O 0 3.194579903720296e-06
excrete O 0 1.6260994470940204e-06
early O 0 2.113034440753836e-07
large O 0 1.5412334164466301e-07
amounts O 0 1.0213857137841842e-07
of O 0 2.230616935605667e-08
aspartylglucosamine O 0 8.820160292088985e-05
in O 0 2.370900347159477e-07
urine O 0 1.293860918849532e-06
, O 0 1.352700707002441e-07
biochemical O 0 1.5276054909918457e-06
screening O 0 2.0218067220412195e-06
is O 0 1.5820255327980703e-07
easy O 0 2.0652335024351487e-06
by O 0 5.014492217014777e-07
urine O 0 9.845612112258095e-06
chromatography O 0 0.0003675392654258758
. O 0 6.191851866788056e-07
. O 0 3.527295575622702e-06

Detection O 0 9.206680988427252e-05
of O 0 1.2428092759364517e-06
heterozygous O 0 5.690319540008204e-06
carriers O 0 3.3972312394325854e-06
of O 0 4.419424044499465e-07
the O 0 8.14930463093333e-05
ataxia B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999730587005615
telangiectasia I-Disease 1 0.9999772310256958
( O 0 1.1799179446825292e-06
ATM O 0 2.110020250256639e-05
) O 0 4.0593217676132554e-08
gene O 0 1.0246520787404734e-07
by O 0 1.204232802365368e-07
G2 O 0 0.00014824133540969342
phase O 0 1.562871148053091e-05
chromosomal O 0 0.0009669666760601103
radiosensitivity O 0 0.0004484698874875903
of O 0 1.2131515632063383e-06
peripheral O 0 0.01122121512889862
blood O 0 0.002098296768963337
lymphocytes O 0 0.004109568428248167
. O 0 2.287650750076864e-05

In O 0 0.001992361154407263
ataxia B-Disease 1 0.999993085861206
- I-Disease 1 0.999913215637207
telangiectasia I-Disease 1 0.9999862909317017
( O 0 5.1443043048493564e-05
A B-Disease 1 0.5477047562599182
- I-Disease 1 0.9999397993087769
T I-Disease 1 0.9999979734420776
) O 0 9.11581446416676e-06
patients O 0 4.223089854349382e-05
, O 0 2.745397580383724e-07
mutations O 0 6.250564297261008e-07
in O 0 5.132589464551529e-08
a O 0 9.27622565427555e-08
single O 0 1.7501676552456047e-07
gene O 0 1.7676900654350902e-07
, O 0 1.4611293863708852e-07
ATM O 0 2.988918095070403e-05
, O 0 2.522544662042492e-07
result O 0 5.685848805114802e-07
in O 0 3.8903317545191385e-06
an O 0 0.008561454713344574
autosomal B-Disease 1 0.9999990463256836
recessive I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999997615814209
that O 0 5.156225597602315e-06
embraces O 0 2.4992696125991642e-05
a O 0 3.6773926126443257e-07
variety O 0 2.344320222391616e-07
of O 0 1.7473209368290554e-07
clinical O 0 3.728016235982068e-05
features O 0 6.985779691603966e-06
and O 0 5.895310550840804e-06
manifests O 0 3.841190482489765e-05
extreme O 0 0.00014281005132943392
radiosensitivity O 0 0.002326440531760454
and O 0 2.8897792958559876e-07
a O 0 2.5047430085578526e-07
strong O 0 6.500389417851693e-07
pre O 0 0.0001974437036551535
- O 0 0.0027247765101492405
disposition O 0 0.00036716926842927933
to O 0 7.6119772529636975e-06
malignancy B-Disease 0 0.4851453900337219
. O 0 1.632132443774026e-05

Heterozygotes O 0 0.000792400969658047
for O 0 3.2137422749656253e-06
the O 0 5.90310833104013e-07
ATM O 0 3.233183088013902e-05
gene O 0 8.640142823423957e-07
have O 0 2.0067415107405395e-07
no O 0 2.4757557071097835e-07
clinical O 0 2.1429118532978464e-06
expression O 0 1.9940075901558885e-07
of O 0 4.926341148348001e-07
A B-Disease 0 0.41642051935195923
- I-Disease 1 0.9993071556091309
T I-Disease 1 0.9999942779541016
but O 0 5.950257218501065e-06
may O 0 8.330891432706267e-06
be O 0 6.323656180029502e-06
cancer B-Disease 0 0.12201894819736481
prone O 0 0.0014877135399729013
with O 0 1.4084386634749535e-07
a O 0 7.610639158883714e-07
moderate O 0 0.00010660875705070794
increase O 0 3.4919875702144054e-07
in O 0 8.958200226061308e-08
in O 0 3.536625570177421e-07
vitro O 0 0.00023361224157270044
radiosensitivity O 0 0.0032165134325623512
. O 0 8.848819561535493e-06

We O 0 2.519472036510706e-05
performed O 0 7.399421974696452e-06
a O 0 1.9120791421300964e-06
blind O 0 5.130733552505262e-05
chromosomal O 0 0.000210769081604667
analysis O 0 1.4885288237564964e-06
on O 0 2.624632998049492e-06
G2 O 0 0.029038749635219574
- O 0 0.00010294964158674702
phase O 0 5.368541678762995e-05
lymphocytes O 0 0.00011553464719327167
from O 0 5.620459475608186e-08
7 O 0 1.0104664625032456e-06
unrelated O 0 1.0431483133288566e-05
A B-Disease 0 0.17279134690761566
- I-Disease 1 0.9999738931655884
T I-Disease 1 0.9999991655349731
patients O 0 5.994271850795485e-05
, O 0 2.766969373624306e-07
13 O 0 6.293847150118381e-07
obligate O 0 1.5077823718456784e-06
A B-Disease 0 0.05452682077884674
- I-Disease 1 0.9998300075531006
T I-Disease 1 0.9999902248382568
heterozygotes O 0 9.684859833214432e-05
( O 0 1.0948092210583127e-07
parents O 0 5.575934025614515e-08
of O 0 1.9935184170094544e-08
the O 0 4.784583325090352e-07
patients O 0 5.754804533353308e-06
) O 0 3.9246561556183224e-08
, O 0 3.668005277290831e-08
and O 0 4.953344756586375e-08
14 O 0 7.912779409480208e-08
normal O 0 6.362015625427375e-08
controls O 0 1.3120131825417047e-07
following O 0 5.9239688710022165e-08
X O 0 6.385385495377705e-05
- O 0 5.608707851934014e-06
irradiation O 0 1.4672791621705983e-06
with O 0 4.4273463117860956e-08
1 O 0 2.922025714724441e-07
Gy O 0 1.4057969565328676e-05
in O 0 8.400949269571356e-09
order O 0 1.1785573406086769e-08
to O 0 1.06871755889415e-08
evaluate O 0 1.5254086349614226e-07
this O 0 1.4439683226896705e-08
cytogenetic O 0 1.0607218428049237e-05
method O 0 6.661843343636065e-08
as O 0 1.7531606388843102e-08
a O 0 3.8951466052594697e-08
tool O 0 4.826268309443549e-07
for O 0 6.715399791801246e-08
detection O 0 3.5273831144877477e-06
of O 0 4.864900233769731e-07
ATM O 0 0.00021270716388244182
carriers O 0 1.3473025319399312e-05
. O 0 5.494700417330023e-06

Both O 0 5.4464842833112925e-05
A B-Disease 0 0.018875539302825928
- I-Disease 1 0.995692789554596
T I-Disease 1 0.9998917579650879
homozygotes O 0 0.0004832210543099791
and O 0 1.3021025324633229e-06
heterozygotes O 0 3.081160321016796e-05
showed O 0 2.962028247566195e-06
significantly O 0 8.560045330341381e-07
increased O 0 1.746885942566223e-07
levels O 0 6.752736680937232e-08
of O 0 5.937475933137648e-08
radiation O 0 0.0004164410347584635
- O 0 0.008431821130216122
induced O 0 0.02034112997353077
chromatid O 1 0.5560283064842224
damage O 0 0.0020994434598833323
relative O 0 2.2742444798495853e-06
to O 0 4.3009389827375344e-08
that O 0 2.6469285430152922e-08
of O 0 1.1830002222268376e-07
normal O 0 2.1161008589842822e-06
controls O 0 1.4510588698612992e-05
. O 0 7.077103873598389e-06

These O 0 3.452856162766693e-06
results O 0 2.668047955012298e-06
show O 0 8.061367680056719e-07
that O 0 6.292862764212259e-08
the O 0 1.460438312506085e-07
G2 O 0 0.0223348718136549
- O 0 8.391221490455791e-05
phase O 0 4.4680346036329865e-05
chromosomal O 0 0.0017020596424117684
radiosensitivity O 0 0.00044029176933690906
assay O 0 5.183198936720146e-06
can O 0 3.562171002613468e-08
be O 0 5.28221733020473e-09
used O 0 6.303239263871774e-09
for O 0 6.4223146800657105e-09
the O 0 1.5656647534001422e-08
detection O 0 1.747460373735521e-06
of O 0 4.122225618630182e-07
A B-Disease 0 0.050929732620716095
- I-Disease 1 0.998953104019165
T I-Disease 1 0.9998983144760132
heterozygotes O 0 0.0014677305007353425
. O 0 1.3813717487209942e-05

In O 0 1.6915801097638905e-05
combination O 0 2.369988214923069e-05
with O 0 1.184676079901692e-06
molecular O 0 2.710782064241357e-05
genetic O 0 8.592486665293109e-06
analyses O 0 7.74160071159713e-06
, O 0 3.0219854352253606e-07
this O 0 6.452115997035435e-08
test O 0 3.1920187666401034e-06
may O 0 2.463715134126687e-07
be O 0 5.516332279853486e-09
of O 0 4.949762821837567e-09
value O 0 2.1378152581519316e-08
in O 0 9.594148586700157e-09
studies O 0 2.1572304831352085e-08
of O 0 6.431191934552771e-08
familial B-Disease 0 0.00013021954509895295
and I-Disease 0 2.5777737846510718e-06
sporadic I-Disease 0 0.0006839584675617516
cancers I-Disease 0 0.005768212489783764
aimed O 0 2.1472549178724876e-06
at O 0 7.567966235910717e-07
determination O 0 6.316450367194193e-07
of O 0 2.3483966771209452e-08
the O 0 6.355442394578859e-08
potential O 0 2.92045996275192e-07
involvement O 0 2.0298618608194374e-07
of O 0 9.267383660471751e-08
ATM O 0 0.0002693528076633811
mutations O 0 2.180010596930515e-06
in O 0 1.1793329122156138e-06
tumor B-Disease 0 0.15614357590675354
risk O 0 7.063214070512913e-06
or O 0 1.2242679758855957e-07
development O 0 4.542345948266302e-07
. O 0 5.11109760736872e-07
. O 0 3.732301365744206e-06

Ataxia B-Disease 1 0.9999898672103882
- I-Disease 1 0.9997557997703552
telangiectasia I-Disease 1 0.9999109506607056
: O 0 5.2768605200981256e-06
identification O 0 1.729595737742784e-06
and O 0 2.1149455164959363e-07
detection O 0 1.9909305137844058e-06
of O 0 7.95698795741373e-08
founder O 0 7.540687511209399e-05
- O 0 0.0007081901421770453
effect O 0 1.3001617844565772e-06
mutations O 0 3.4582694752316456e-07
in O 0 2.4601035875093658e-08
the O 0 7.007513147527789e-08
ATM O 0 1.4655305676569697e-05
gene O 0 5.228582722338615e-07
in O 0 1.4684715665680415e-07
ethnic O 0 1.3979367849970004e-06
populations O 0 4.280996563466033e-06
. O 0 4.665951109927846e-06

To O 0 3.247602080591605e-06
facilitate O 0 2.6920038180833217e-06
the O 0 3.7700462485190656e-07
evaluation O 0 9.461002150601416e-07
of O 0 2.249219193117824e-07
ATM O 0 9.128910460276529e-05
heterozygotes O 0 1.3258381841296796e-05
for O 0 1.6703467053957866e-07
susceptibility O 0 1.9069466361543164e-05
to O 0 2.906051577156177e-07
other O 0 6.443955840040871e-07
diseases O 0 0.002171853557229042
, O 0 3.3917169162123173e-07
such O 0 3.7938434616080485e-07
as O 0 2.814895924529992e-05
breast B-Disease 1 0.998049259185791
cancer I-Disease 1 0.8149033784866333
, O 0 1.4069419194129296e-06
we O 0 1.7021075393586216e-07
have O 0 1.917136849272083e-08
attempted O 0 3.3868815307869227e-07
to O 0 5.0504628035241694e-08
define O 0 9.998052519222256e-07
the O 0 9.62821218308818e-08
most O 0 9.96479627701774e-08
common O 0 3.3781944352995197e-07
mutations O 0 1.9968410924775526e-07
and O 0 4.918464213687912e-08
their O 0 1.8755430986061583e-08
frequencies O 0 8.2381473021087e-07
in O 0 8.663461812830064e-06
ataxia B-Disease 1 0.9999945163726807
- I-Disease 1 0.9998973608016968
telangiectasia I-Disease 1 0.999984622001648
( O 0 1.520895693829516e-05
A B-Disease 0 0.4516112506389618
- I-Disease 1 0.9998865127563477
T I-Disease 1 0.9999796152114868
) O 0 8.331998060384649e-07
homozygotes O 0 1.2337585758359637e-05
from O 0 2.146178843531743e-07
10 O 0 3.539135775554314e-07
ethnic O 0 8.827358897178783e-07
populations O 0 3.8432931432907935e-06
. O 0 3.7179138416831847e-06

Both O 0 9.254041287931614e-06
genomic O 0 3.8363323255907744e-05
mutations O 0 1.2548292033898178e-05
and O 0 4.5566423523268895e-07
their O 0 9.353402674605604e-08
effects O 0 9.717939519759966e-07
on O 0 4.5024435735285806e-07
cDNA O 0 8.718564458831679e-06
were O 0 2.1954142539470922e-06
characterized O 0 4.768410144606605e-05
. O 0 1.3758001841779333e-05

Protein O 0 4.87532488477882e-05
- O 0 3.827529144473374e-05
truncation O 0 1.4149497474136297e-05
testing O 0 1.2454266880013165e-06
of O 0 4.570011569171584e-08
the O 0 5.8125149138277266e-08
entire O 0 5.203725095270784e-07
ATM O 0 2.0510933609330095e-06
cDNA O 0 5.389998136706708e-07
detected O 0 7.556462833235855e-07
92 O 0 2.8984680966459564e-07
( O 0 3.16695540902856e-08
66 O 0 6.379610795193003e-07
% O 0 9.064591921514875e-08
) O 0 5.045571427331197e-08
truncating O 0 3.7482816424017074e-06
mutations O 0 4.957797159477195e-07
in O 0 5.793587476432549e-08
140 O 0 1.0355480526413885e-06
mutant O 0 8.131623872031923e-06
alleles O 0 8.300833542307373e-06
screened O 0 2.2028358216630295e-05
. O 0 8.837256245897152e-06

The O 0 8.268109922937583e-06
haplotyping O 0 0.0008474041824229062
of O 0 7.185905360529432e-06
patients O 0 0.0003604224475566298
with O 0 2.230884319942561e-06
identical O 0 0.00019553033052943647
mutations O 0 1.2716003766399808e-05
indicates O 0 3.3375331440765876e-06
that O 0 2.7305290473123023e-08
almost O 0 1.8371631327340765e-08
all O 0 4.00436706016194e-09
of O 0 1.1772048225111575e-08
these O 0 2.0367140862731503e-08
represent O 0 1.4114843338575156e-07
common O 0 9.120736876866431e-07
ancestry O 0 1.5317104953282978e-06
and O 0 1.4891421074025857e-07
that O 0 4.972826417315446e-08
very O 0 2.188489816035144e-07
few O 0 4.6473650172629277e-07
spontaneously O 0 6.046991984476335e-06
recurring O 0 1.3813242730975617e-05
ATM O 0 0.00027572247199714184
mutations O 0 7.435718544002157e-06
exist O 0 2.7158509965374833e-06
. O 0 3.067127408939996e-06

Assays O 0 0.00011176406405866146
requiring O 0 1.2517479262896813e-05
minimal O 0 9.18394471227657e-06
amounts O 0 5.31572936779412e-07
of O 0 7.022485704055725e-08
genomic O 0 2.249975295853801e-06
DNA O 0 3.450802068982739e-06
were O 0 1.1134230248899257e-07
designed O 0 7.432418556163611e-07
to O 0 2.6266604891134193e-08
allow O 0 1.2907659652228176e-07
rapid O 0 1.4834145076747518e-06
screening O 0 1.297216613238561e-06
for O 0 1.9570089193621243e-07
common O 0 1.3302151273819618e-06
ethnic O 0 3.0104413326625945e-06
mutations O 0 1.5575116776744835e-05
. O 0 7.162710971897468e-06

These O 0 7.849606845411472e-06
rapid O 0 2.2334825189318508e-05
assays O 0 5.2217299526091665e-05
detected O 0 1.3077938092465047e-05
mutations O 0 6.627396373914962e-07
in O 0 4.473762160728256e-08
76 O 0 1.7274546735279728e-06
% O 0 6.961366949553849e-08
of O 0 6.852134504242713e-08
Costa O 0 9.549164678901434e-05
Rican O 0 7.23399716662243e-05
patients O 0 9.968262929760385e-06
( O 0 3.319611963092939e-08
3 O 0 1.1313193937212418e-07
) O 0 2.0232631570138437e-08
, O 0 1.0932187599621557e-08
50 O 0 3.091728828508167e-08
% O 0 1.0700760277870813e-08
of O 0 4.355232618991067e-08
Norwegian O 0 0.003692972008138895
patients O 0 1.5768902812851593e-05
( O 0 3.916236579470933e-08
1 O 0 1.791029120568055e-07
) O 0 1.6177231998426578e-08
, O 0 1.4746881937810485e-08
25 O 0 2.7586770201537547e-08
% O 0 1.6034784167118232e-08
of O 0 3.9465906098712367e-08
Polish O 0 0.01135017815977335
patients O 0 2.1088797439006157e-05
( O 0 5.778236911169188e-08
4 O 0 4.459007527657377e-07
) O 0 2.7063100205282353e-08
, O 0 1.8588758976534336e-08
and O 0 3.742448129173681e-08
14 O 0 1.3403486320839875e-07
% O 0 3.288505467935465e-08
of O 0 6.563266197190387e-08
Italian O 0 0.0007031745044514537
patients O 0 9.081358257390093e-06
( O 0 5.2530928940086596e-08
1 O 0 1.9588985367136047e-07
) O 0 1.952679440364591e-08
, O 0 1.4390550973075733e-08
as O 0 6.907045602133621e-09
well O 0 2.3223167389119226e-08
as O 0 2.1029780583603497e-08
in O 0 6.787978179545462e-08
patients O 0 3.9232460835592065e-07
of O 0 7.088357989459837e-08
Amish O 0 9.26837747101672e-05
/ O 0 0.0004100255318917334
Mennonite O 0 6.049111470929347e-05
and O 0 1.7598058548173867e-06
Irish O 0 6.925239631527802e-06
English O 0 1.678046942288347e-06
backgrounds O 0 1.3834970559400972e-05
. O 0 8.789541425358038e-06

Additional O 0 3.096577347605489e-05
mutations O 0 3.64946827176027e-05
were O 0 1.2050546729369671e-06
observed O 0 1.0339218761146185e-06
in O 0 7.739040341903092e-08
Japanese O 0 4.820274739358865e-07
, O 0 8.995183264914886e-08
Utah O 0 7.367029297711269e-07
Mormon O 0 2.1779482040074072e-07
, O 0 4.0090768038680835e-08
and O 0 7.485113684424505e-08
African O 0 3.173253446675517e-07
American O 0 1.3419913784673554e-06
patients O 0 2.469632454449311e-05
. O 0 3.7289287320163567e-06

These O 0 3.945811386074638e-06
assays O 0 7.6128703767608386e-06
should O 0 2.4346243776562915e-07
facilitate O 0 4.520638867688831e-07
screening O 0 2.187378640883253e-06
for O 0 9.413141128788993e-07
A B-Disease 0 0.10593161731958389
- I-Disease 1 0.9994944334030151
T I-Disease 1 0.9999644756317139
heterozygotes O 0 4.0984647057484835e-05
in O 0 1.455302509612011e-07
the O 0 1.3413882982149516e-07
populations O 0 1.0456285508553265e-06
studied O 0 7.272428774740547e-07
. O 0 5.657246902046609e-07
. O 0 3.0162807433953276e-06

The O 0 0.00013623051927424967
von B-Disease 1 0.9402210712432861
Hippel I-Disease 1 0.9751493334770203
- I-Disease 1 0.5365434288978577
Lindau I-Disease 1 0.9479262828826904
tumor I-Disease 0 0.0919361487030983
suppressor O 0 0.00015469358186237514
gene O 0 2.888982407966978e-06
is O 0 8.779539939496317e-08
required O 0 6.741116465036612e-08
for O 0 9.400279310511905e-08
cell O 0 1.855004666140303e-05
cycle O 0 3.36649532073352e-06
exit O 0 1.0882053175009787e-05
upon O 0 1.5332597058659303e-06
serum O 0 9.738247899804264e-05
withdrawal O 0 4.4546839490067214e-05
. O 0 9.518375009065494e-06

The O 0 6.210306764842244e-06
inactivation O 0 0.0004183976270724088
of O 0 6.963411465221725e-07
the O 0 2.521255737519823e-06
von B-Disease 1 0.9928154945373535
Hippel I-Disease 1 0.9954568147659302
- I-Disease 1 0.9574073553085327
Lindau I-Disease 1 0.9630724787712097
( I-Disease 0 3.2538582672714256e-06
VHL I-Disease 0 0.00026328227249905467
) I-Disease 0 4.13683636679707e-07
tumor I-Disease 0 2.8235206627869047e-05
suppressor O 0 1.2310401871218346e-05
gene O 0 1.1921630402866867e-06
predisposes O 0 1.0695050150388852e-05
affected O 0 6.933539111741993e-07
individuals O 0 4.5262211756380566e-08
to O 0 6.611740843709413e-08
the O 0 8.365805115317926e-07
human O 0 0.010716259479522705
VHL B-Disease 1 0.9999974966049194
cancer I-Disease 1 0.9999990463256836
syndrome I-Disease 1 0.9999309778213501
and O 0 6.1013392951281276e-06
is O 0 1.2837381291319616e-06
associated O 0 3.006241286129807e-06
with O 0 1.0034696060756687e-05
sporadic B-Disease 1 0.987972617149353
renal I-Disease 1 0.9999996423721313
cell I-Disease 1 0.9999825954437256
carcinomas I-Disease 1 0.9999996423721313
( O 0 0.0002657398290466517
RCC B-Disease 1 0.8919448852539062
) O 0 3.132877964162617e-06
and O 0 7.117374934750842e-06
brain B-Disease 0 0.0009720061789266765
hemangioblastomas I-Disease 0 0.0100674694404006
. O 0 2.3706437787041068e-05

VHL O 0 0.01325096096843481
- O 0 0.0006645789835602045
negative O 0 1.3035902156843804e-05
786 O 0 7.72419516579248e-05
- O 0 0.00032959418604150414
0 O 0 8.101234925561585e-06
RCC B-Disease 0 0.000892403710167855
cells O 0 1.2335164001342491e-06
are O 0 3.309888185754062e-08
tumorigenic O 0 7.8529046732001e-05
in O 0 4.387340766243142e-07
nude O 0 0.0004350176313892007
mice O 0 3.635296525317244e-05
which O 0 2.632373821143119e-07
is O 0 2.093018593996021e-07
suppressed O 0 5.765416517533595e-07
by O 0 6.101695504412419e-08
the O 0 1.0712015807712305e-07
reintroduction O 0 8.693597010278609e-06
of O 0 2.894210865633795e-06
VHL B-Disease 0 0.0014463724801316857
. O 0 1.3262125321489293e-05

Remarkably O 0 0.00145332224201411
, O 0 4.6536410991393495e-06
this O 0 2.2719373760082817e-07
occurs O 0 2.8056180667590525e-07
without O 0 3.4854721775445796e-08
affecting O 0 1.039748340758706e-07
the O 0 2.9590523809019942e-08
growth O 0 1.028746282827342e-06
rate O 0 4.525971064595069e-07
and O 0 1.300777938695319e-07
cell O 0 5.1929496294178534e-06
cycle O 0 1.3367440487854765e-06
profile O 0 5.243198302196106e-07
of O 0 3.309452623057041e-08
these O 0 4.55485249517551e-08
cells O 0 7.948551683512051e-07
in O 0 1.9181067045792588e-07
culture O 0 4.0386048567597754e-06
. O 0 6.224572643986903e-06

The O 0 6.508852038678015e-06
786 O 0 9.692796447779983e-05
- O 0 0.0001999440573854372
0 O 0 4.501933744904818e-06
cell O 0 9.330315151601098e-06
line O 0 2.590816166048171e-06
, O 0 8.23891923573683e-08
like O 0 2.3890763145573146e-07
many O 0 1.1070681438241081e-07
cancer B-Disease 0 0.001220392994582653
cells O 0 1.1049708064092556e-06
, O 0 1.0339459777242155e-07
fails O 0 9.331873798146262e-07
to O 0 1.8984842142799607e-08
exit O 0 7.020262842161173e-07
the O 0 7.17191355192881e-08
cell O 0 5.067187430540798e-06
cycle O 0 1.9616145436884835e-06
upon O 0 9.437634957976115e-07
serum O 0 5.0649447075556964e-05
withdrawal O 0 3.424059468670748e-05
. O 0 8.93718060979154e-06

Here O 0 1.9474447981338017e-05
, O 0 1.0920589375018608e-06
it O 0 6.223037019026378e-08
is O 0 3.1160968916310594e-08
shown O 0 4.151497989823838e-08
that O 0 6.580913591847093e-09
reintroduction O 0 1.8532794854309032e-07
of O 0 1.6235436106626366e-08
the O 0 3.2634059010661076e-08
wild O 0 3.570569788280409e-06
- O 0 0.00041275148396380246
type O 0 3.702174581121653e-05
VHL B-Disease 0 4.852513302466832e-05
gene O 0 4.2506698605393467e-07
restores O 0 6.745174232491991e-07
the O 0 4.319724666856928e-08
ability O 0 1.1726012871804414e-07
of O 0 1.373601890009013e-07
VHL O 0 0.00030682989745400846
- O 0 0.0005231008981354535
negative O 0 4.602084663929418e-05
RCC B-Disease 1 0.9930692911148071
cancer I-Disease 0 0.061028171330690384
cells O 0 5.075648346064554e-07
to O 0 2.292019019023428e-08
exit O 0 4.888311764261744e-07
the O 0 4.902532779738067e-08
cell O 0 1.7857263401310774e-06
cycle O 0 6.845660323051561e-07
and O 0 2.1119383575296524e-07
enter O 0 1.0653634490154218e-06
G0 O 0 0.0016321734292432666
/ O 0 2.970629429910332e-05
quiescence O 0 0.0001483527448726818
in O 0 1.3543120758185978e-06
low O 0 0.0001807078515412286
serum O 0 0.0002523889997974038
. O 0 9.112780389841646e-06

Both O 0 3.388845652807504e-05
VHL O 0 0.0051134745590388775
- O 0 0.000235765750403516
positive O 0 1.3561769947045832e-06
and O 0 5.843739927513525e-07
VHL O 0 0.0003083474875893444
- O 0 7.460067718056962e-05
negative O 0 2.7213163775741123e-06
RCC B-Disease 0 0.0013588692527264357
cells O 0 1.1165444675498293e-06
exit O 0 8.257040917669656e-07
the O 0 7.665629198072565e-08
cell O 0 9.003882951219566e-06
cycle O 0 1.2727037983495393e-06
by O 0 2.7970583005298977e-07
contact O 0 3.7528457141888794e-06
inhibition O 0 8.738599717617035e-06
. O 0 6.783203389204573e-06

The O 0 1.5550422176602297e-05
cyclin O 0 0.0031716995872557163
- O 0 7.184012065408751e-05
dependent O 0 4.856676696363138e-06
kinase O 0 7.63056959840469e-06
inhibitor O 0 4.717909177998081e-06
, O 0 2.3904391355245025e-07
p27 O 0 7.317270501516759e-06
, O 0 9.100451592303216e-08
accumulates O 0 5.581593995884759e-07
upon O 0 9.22530318803183e-08
serum O 0 4.665999767894391e-06
withdrawal O 0 4.556056865112623e-06
, O 0 5.651612511314852e-08
only O 0 1.0477748446646729e-08
in O 0 1.3344060079134579e-08
the O 0 1.2920536640592672e-08
presence O 0 9.063243311402402e-08
of O 0 1.0671332972833625e-07
VHL B-Disease 0 0.000318917038384825
, O 0 1.0292963992242221e-07
as O 0 1.4819232951879258e-08
a O 0 4.714323864618564e-08
result O 0 5.4869538246293814e-08
of O 0 1.0431705277369474e-08
the O 0 3.0724002897386526e-08
stabilization O 0 2.303986548213288e-06
of O 0 5.53661614333123e-08
the O 0 2.694192176022625e-07
protein O 0 4.980371613783063e-06
. O 0 2.859763981177821e-06

We O 0 8.669545422890224e-06
propose O 0 6.787240636185743e-06
that O 0 2.1501411140434357e-07
the O 0 1.1717639836206217e-07
loss O 0 4.235254891682416e-06
of O 0 8.316487765114289e-08
wild O 0 1.9489720216370188e-05
- O 0 0.011100923642516136
type O 0 5.523525396711193e-05
VHL B-Disease 0 4.683486622525379e-05
gene O 0 2.532258349674521e-07
results O 0 1.7706631183500576e-07
in O 0 3.0471070999738004e-08
a O 0 6.972769028834591e-08
specific O 0 4.360677507975197e-07
cellular O 0 0.0006561814225278795
defect O 0 0.00030288731795735657
in O 0 3.367239003182476e-07
serum O 0 4.180938412901014e-05
- O 0 4.630240437109023e-05
dependent O 0 1.403227543050889e-06
growth O 0 3.609344787491864e-07
control O 0 1.9476901513826306e-07
, O 0 4.922584295741217e-08
which O 0 5.492796617545537e-08
may O 0 6.222609840733639e-07
initiate O 0 2.982167643494904e-05
tumor B-Disease 0 0.020770275965332985
formation O 0 2.9766697480226867e-05
. O 0 6.357991424010834e-06

This O 0 5.872522706340533e-06
is O 0 1.026233917400532e-06
corrected O 0 2.9870536764065037e-06
by O 0 7.694590209439411e-08
the O 0 2.8309461441722306e-08
reintroduction O 0 7.141921969378018e-07
of O 0 1.1497117213821184e-07
wild O 0 8.367947884835303e-06
- O 0 0.004049891140311956
type O 0 0.0002052557101706043
VHL B-Disease 0 0.0005237694131210446
, O 0 7.164837256823375e-07
implicating O 0 8.97271529538557e-05
VHL B-Disease 0 0.00010628454037941992
as O 0 3.22015516474039e-08
the O 0 2.6071891312540174e-08
first O 0 2.4931514985837566e-07
tumor B-Disease 0 0.00011007035936927423
suppressor O 0 5.975722160656005e-06
involved O 0 1.1932624488508736e-07
in O 0 1.7853123424060868e-08
the O 0 1.0091854463212258e-08
regulation O 0 4.603518277690455e-08
of O 0 2.8036060584213374e-08
cell O 0 1.2021187103528064e-05
cycle O 0 9.903025102175889e-07
exit O 0 6.211704658198869e-06
, O 0 1.6154636739429407e-07
which O 0 4.973177425426911e-08
is O 0 4.263897324108257e-08
consistent O 0 2.0528102595562814e-07
with O 0 5.3471257643877834e-08
its O 0 1.2082647060651652e-07
gatekeeper O 0 4.158812953392044e-05
function O 0 1.4614596466344665e-07
in O 0 1.1054940074473052e-07
the O 0 8.815311502985423e-07
kidney O 0 0.008315385319292545
. O 0 8.534125299775042e-07
. O 0 7.341553100559395e-06

Piebaldism B-Disease 1 0.9996548891067505
with O 0 0.04062578082084656
deafness B-Disease 1 0.999994158744812
: O 0 2.0350176782812923e-05
molecular O 0 4.990533852833323e-05
evidence O 0 4.081404767930508e-06
for O 0 1.2157458968431456e-06
an O 0 3.134976168439607e-06
expanded O 0 0.002100210404023528
syndrome O 1 0.9733762145042419
. O 0 1.3981893971504178e-05

In O 0 1.1150759746669792e-05
a O 0 2.4142923393810634e-06
South O 0 2.9675954920094227e-06
African O 0 7.461208610948233e-07
girl O 0 9.753819540492259e-06
of O 0 3.3391589226994256e-07
Xhosa O 0 0.010471086949110031
stock O 0 5.47958115930669e-05
with O 0 1.7803597529564286e-06
severe O 0 0.0057478840462863445
piebaldism B-Disease 1 0.73757404088974
and O 0 0.002250166144222021
profound O 1 0.9858148097991943
congenital O 1 0.9999998807907104
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 0.9999998807907104
we O 0 0.009243561886250973
identified O 0 0.00018084746261592954
a O 0 2.132892859663116e-06
novel O 0 3.5965222195954993e-06
missense O 0 6.989425401116023e-06
substitution O 0 2.7387395107325574e-07
at O 0 1.5973162703630805e-07
a O 0 6.382531125836977e-08
highly O 0 1.0296380281715756e-07
conserved O 0 1.1162617852278345e-07
residue O 0 2.571387369698641e-07
in O 0 1.0479827672327247e-08
the O 0 1.5251549356776195e-08
intracellular O 0 4.2836688862735173e-07
kinase O 0 4.78482945709402e-07
domain O 0 5.6348433474795456e-08
of O 0 2.0950910339934126e-08
the O 0 1.0360404445464155e-07
KIT O 0 0.00021664811356458813
proto O 0 0.00029633232043124735
- O 0 0.00018406656454317272
oncogene O 0 5.4245534556685016e-05
, O 0 1.1840639899673988e-06
R796G O 0 6.545645737787709e-05
. O 0 4.206562607578235e-06

Though O 0 0.00012998594320379198
auditory B-Disease 0 0.001070900005288422
anomalies I-Disease 0 0.07664207369089127
have O 0 1.607804961167858e-06
been O 0 2.5573228867870057e-07
observed O 0 1.1210107686565607e-06
in O 0 3.050605528187589e-07
mice O 0 1.4696706784889102e-05
with O 0 1.7945220633919234e-06
dominant O 0 0.00011016192001989111
white O 0 0.0007631514454260468
spotting O 0 0.032946400344371796
( O 0 2.76758942163724e-06
W O 0 0.04778774455189705
) O 0 5.873441821790948e-08
due O 0 1.7921533412845747e-07
to O 0 2.3562219553241448e-07
KIT O 0 0.15232589840888977
mutations O 0 3.059419759665616e-05
, O 0 1.6052330465754494e-05
deafness B-Disease 1 0.9999682903289795
is O 0 1.0634530553943478e-06
not O 0 1.7158534149075422e-07
typical O 0 3.682084752654191e-06
in O 0 6.275315627135569e-07
human O 0 6.039534127921797e-06
piebaldism B-Disease 0 0.00948856770992279
. O 0 1.8022012227447703e-05

Thus O 0 3.210107024642639e-05
, O 0 1.9483882169879507e-06
the O 0 2.605758027129923e-07
occurrence O 0 9.448862329008989e-06
of O 0 2.1850684788660146e-05
sensorineural B-Disease 1 0.9999973773956299
deafness I-Disease 1 0.9999996423721313
in O 0 1.9922958017559722e-05
this O 0 3.2715690849727252e-06
patient O 0 6.571338599314913e-05
extends O 0 6.693712293781573e-06
considerably O 0 2.3098561996448552e-06
the O 0 4.0797281997129176e-08
phenotypic O 0 6.572711868102488e-07
range O 0 7.260460961333592e-07
of O 0 5.8267229263719855e-08
piebaldism B-Disease 0 0.00010880711488425732
due O 0 7.39898098345293e-07
to O 0 2.3547528371636872e-07
KIT O 0 0.0017278337618336082
gene O 0 5.39148402367573e-07
mutation O 0 1.2873753973963176e-07
in O 0 1.911251423791782e-08
humans O 0 6.04078493893212e-08
and O 0 9.809314605035979e-08
tightens O 0 2.4129038138198666e-05
the O 0 2.2784857378610468e-07
clinical O 0 9.562275408825371e-06
similarity O 0 1.5708359342170297e-06
between O 0 1.416903387507773e-06
piebaldism B-Disease 0 0.0033135779667645693
and O 0 1.0885521817272092e-07
the O 0 1.9594100564290784e-08
various O 0 2.3824865635901915e-08
forms O 0 2.2254698706092313e-06
of O 0 0.002120289718732238
Waardenburg B-Disease 1 0.9999964237213135
syndrome I-Disease 1 0.9987319111824036
. O 0 3.361913741173339e-06
. O 0 1.5691164662712254e-05

Cycloheximide O 0 0.00341227138414979
facilitates O 0 6.795274384785444e-05
the O 0 1.4478314369625878e-06
identification O 0 1.135296201937308e-06
of O 0 2.691659801712376e-07
aberrant O 0 0.00011522372369654477
transcripts O 0 6.373358337441459e-05
resulting O 0 3.041045147256227e-06
from O 0 8.93434588533637e-08
a O 0 1.2032890595037316e-07
novel O 0 1.0956506457659998e-06
splice O 0 6.884895992698148e-05
- O 0 0.00011197209096280858
site O 0 3.0152511953929206e-06
mutation O 0 2.625388901833503e-07
in O 0 1.1086042661645479e-07
COL17A1 O 0 0.00015067656931933016
in O 0 3.27214166873091e-07
a O 0 1.9272320059826598e-06
patient O 0 5.055872679804452e-05
with O 0 7.939104762044735e-06
generalized O 0 0.14606836438179016
atrophic B-Disease 1 0.9999451637268066
benign I-Disease 1 0.9988391995429993
epidermolysis I-Disease 1 0.9991063475608826
bullosa I-Disease 1 0.9957013726234436
. O 0 0.0003987450909335166

Patients O 0 0.05721632018685341
with O 0 6.738585216226056e-05
generalized O 0 0.19554919004440308
atrophic B-Disease 1 0.9999558925628662
benign I-Disease 1 0.9997631907463074
epidermolysis I-Disease 1 0.9997612833976746
bullosa I-Disease 1 0.9983832836151123
often O 0 3.9844988350523636e-05
show O 0 6.67549966237857e-06
decreased O 0 5.971620339551009e-06
expression O 0 1.1667772525925102e-07
of O 0 1.5103655925940984e-07
type O 0 8.623881149105728e-05
XVII O 1 0.6680746078491211
collagen O 0 0.0004930783179588616
, O 0 4.584057933243457e-07
a O 0 4.7113397272369184e-07
transmembrane O 0 2.552407568146009e-05
hemidesmosomal O 0 4.9812530050985515e-05
protein O 0 4.6836984779474733e-07
encoded O 0 3.698530406381906e-07
by O 0 6.980965281400131e-07
COL17A1 O 0 0.00019116316980216652
. O 0 5.676894033967983e-06

This O 0 4.388807155919494e-06
report O 0 2.5348970211780397e-06
documents O 0 2.1198557078605518e-06
a O 0 2.296338692531208e-07
novel O 0 1.1827006574094412e-06
splice O 0 0.0001098903885576874
- O 0 0.00020912599575240165
site O 0 4.969274414179381e-06
mutation O 0 3.763364588849072e-07
in O 0 1.164622815963412e-07
COL17A1 O 0 0.0003566933737602085
in O 0 2.6055715807160595e-07
a O 0 2.2446579350798856e-06
patient O 0 4.7500478103756905e-05
with O 0 2.8542656309582526e-06
generalized O 0 0.021856307983398438
atrophic B-Disease 1 0.9999723434448242
benign I-Disease 1 0.9924059510231018
epidermolysis I-Disease 1 0.9993078708648682
bullosa I-Disease 1 0.9980973601341248
, O 0 1.3056740499450825e-05
and O 0 4.145263687860279e-07
applies O 0 1.3286577882354322e-07
a O 0 5.159138893873205e-08
new O 0 5.77650709487898e-08
methodology O 0 3.1443880743609043e-07
to O 0 6.268616203897182e-08
define O 0 7.753532713650202e-07
and O 0 1.8845641136522318e-07
characterize O 0 6.5833032749651466e-06
the O 0 2.513800723136228e-07
resulting O 0 1.7821333813117235e-06
mRNA O 0 2.387981339779799e-06
splice O 0 3.719450978678651e-05
variants O 0 1.0093577657244168e-05
. O 0 7.344060122704832e-06

Mutational O 0 0.0018167969537898898
analysis O 0 2.191794919781387e-05
of O 0 6.666484296147246e-06
COL17A1 O 0 0.05819002538919449
identified O 0 2.604664405225776e-05
a O 0 1.6123989325933508e-06
maternally O 0 0.0005050416220910847
inherited O 0 0.008333666250109673
G O 0 0.006987507920712233
- O 0 0.00011944084690185264
to O 0 8.70412293352274e-07
- O 0 0.009847396984696388
T O 0 0.015331989154219627
transversion O 0 3.805154483416118e-05
at O 0 1.4092259448261757e-07
the O 0 2.523877107307726e-08
- O 0 3.812969453065307e-06
1 O 0 1.1679395583996666e-07
position O 0 5.899523358721126e-08
of O 0 7.66823262665639e-08
exon O 0 1.301422616961645e-05
32 O 0 7.356768037425354e-06
. O 0 3.932010258722585e-06

This O 0 8.910398719308432e-06
acceptor O 0 4.374162745079957e-05
splice O 0 0.00014346970419865102
- O 0 0.000270705932052806
site O 0 6.107370609242935e-06
mutation O 0 5.538099685509223e-07
led O 0 2.007332824405239e-07
to O 0 1.7975892774302338e-08
the O 0 2.8742988433805294e-08
formation O 0 2.462331565311615e-07
of O 0 2.2389587073234907e-08
aberrant O 0 7.917481525510084e-06
transcripts O 0 1.6045453321567038e-06
present O 0 2.864300938654196e-07
at O 0 9.435943866265006e-07
extremely O 0 9.368663086206652e-06
low O 0 1.7743624994182028e-05
levels O 0 2.05663650376664e-06
. O 0 1.3545535466619185e-06

Based O 0 1.5621440979884937e-05
on O 0 2.3633904220332624e-06
our O 0 5.792471711174585e-07
recent O 0 4.3698196350305807e-07
finding O 0 8.826415864859882e-07
that O 0 1.1885968831393257e-07
cycloheximide O 0 0.0002652106049936265
stabilized O 0 0.00023509658058173954
mutant O 0 8.832244020595681e-06
COL17A1 O 0 9.97108145384118e-05
transcripts O 0 1.9332071587996325e-06
in O 0 1.9362005332368426e-07
keratinocytes O 0 1.9806679119938053e-05
homozygous O 0 2.823014483510633e-06
for O 0 1.266703577584849e-07
a O 0 1.1717812640199554e-06
frameshift O 0 0.0015017170226201415
mutation O 0 2.4220385057560634e-06
, O 0 1.7351274550492235e-07
the O 0 3.999926434516965e-08
effects O 0 2.43240549480106e-07
of O 0 2.2655539666516233e-08
the O 0 1.0812908612933825e-07
splice O 0 6.0841124650323763e-05
- O 0 0.00019943169900216162
site O 0 3.520742211549077e-06
mutation O 0 9.290727120969677e-08
on O 0 3.277622084851828e-08
splicing O 0 1.327918113247506e-07
of O 0 1.112900775979142e-07
COL17A1 O 0 0.0001443044311599806
transcripts O 0 1.587558585924853e-06
were O 0 8.544454033199145e-08
determined O 0 1.3221293215792684e-07
using O 0 9.846448989492274e-08
reverse O 0 3.3474659630883252e-06
transcriptase O 0 1.4729482245456893e-05
polymerase O 0 9.575333933753427e-06
chain O 0 1.935424506882555e-06
reaction O 0 8.005152807299964e-08
of O 0 9.941574674598996e-09
total O 0 7.120744527355782e-08
RNA O 0 2.2030201307643438e-07
from O 0 5.4592277365372865e-08
keratinocytes O 0 2.5252793420804664e-06
incubated O 0 1.6290920257233665e-06
for O 0 1.5783395213020412e-07
2 O 0 2.287312781845685e-06
. O 0 2.900817662521149e-06

5 O 0 6.323264096863568e-05
h O 0 0.0002751437423285097
in O 0 2.781125658657402e-07
the O 0 5.99345568730314e-08
presence O 0 1.4168641371270496e-07
or O 0 5.6306529216954004e-08
absence O 0 1.0264771077572732e-07
of O 0 4.984278234587691e-08
10 O 0 4.6251690832832537e-07
microg O 0 0.00018291603191755712
cycloheximide O 0 7.639499381184578e-05
per O 0 3.400614787096856e-06
ml O 0 0.00014530244516208768
. O 0 5.014705948269693e-06

Using O 0 9.041054909175728e-06
this O 0 4.384095291243284e-07
approach O 0 1.6306588577208458e-06
, O 0 3.424952694786043e-07
an O 0 7.894222875393098e-08
abnormally O 0 6.220821524038911e-05
spliced O 0 2.062955900328234e-05
transcript O 0 9.162425703834742e-05
was O 0 2.3626404072274454e-05
identified O 0 1.8949931472889148e-06
that O 0 9.898038833000555e-09
contains O 0 1.3894641881506686e-08
an O 0 5.4975419772063105e-09
extra O 0 3.427641104281065e-08
264 O 0 2.4637901674395835e-07
bases O 0 4.929330188474523e-08
upstream O 0 7.900158038864902e-08
from O 0 1.0261302030301067e-08
exon O 0 3.085746982378623e-07
32 O 0 1.5428774702286319e-07
, O 0 3.6762351385277725e-08
resulting O 0 6.761075610484113e-08
in O 0 1.3772110563081696e-08
a O 0 1.659137893739171e-07
premature O 0 9.672360647527967e-06
termination O 0 3.2537714105274063e-06
codon O 0 8.021511916922464e-07
27 O 0 7.288398364835302e-07
bp O 0 4.795684162672842e-06
downstream O 0 7.947218136905576e-07
from O 0 7.097828103042048e-08
the O 0 2.2254373277519335e-07
cryptic O 0 1.2675131074502133e-05
splice O 0 6.219255010364577e-05
site O 0 1.9149467334500514e-05
. O 0 6.395860054908553e-06

Three O 0 4.035567144455854e-06
other O 0 9.030696332956722e-07
splice O 0 3.375914093339816e-05
variants O 0 4.362775598565349e-06
, O 0 2.956616356186714e-07
including O 0 7.226370968282936e-08
one O 0 4.2431118174590665e-08
derived O 0 3.962082217867646e-08
from O 0 1.7399685248165042e-08
the O 0 1.293286544523653e-08
skipping O 0 1.9938630657634349e-07
of O 0 3.249635227575709e-08
exon O 0 2.5927961360139307e-06
32 O 0 7.584591230624937e-07
, O 0 9.890625563002686e-08
were O 0 1.412344659001974e-07
also O 0 2.732645043579396e-07
identified O 0 4.8378901738033164e-06
. O 0 4.519390586210648e-06

These O 0 3.204062522854656e-06
results O 0 4.530809292191407e-06
indicate O 0 1.0196566790909856e-06
the O 0 6.728618018314592e-08
usefulness O 0 1.0353209063396207e-06
of O 0 1.9107271498342016e-07
cycloheximide O 0 0.11001512408256531
treatment O 0 2.8150570869911462e-05
in O 0 1.2289986273117393e-07
evaluating O 0 3.083036972384434e-06
the O 0 1.0954232720905566e-07
abnormal O 0 2.54289216172765e-06
processing O 0 2.406099497420655e-07
of O 0 1.0812306605600952e-08
mRNA O 0 6.095041982234761e-08
due O 0 6.328781410047668e-08
to O 0 3.446153229447191e-08
splice O 0 7.928073500806931e-06
- O 0 4.481036739889532e-05
site O 0 5.616517228190787e-06
mutations O 0 6.812036303927016e-07
, O 0 1.1977991221101547e-07
because O 0 6.925715467787086e-08
( O 0 3.928116498741474e-08
i O 0 3.352598696437781e-07
) O 0 1.380151015695219e-08
aberrant O 0 3.2040060204963083e-07
splicing O 0 3.455704700172646e-07
often O 0 6.435486454847705e-08
generates O 0 1.146300263599187e-07
a O 0 1.1116448916936861e-07
premature O 0 6.270365247473819e-06
termination O 0 4.669588179240236e-06
codon O 0 5.424714686341758e-07
, O 0 1.5561505506411777e-07
( O 0 9.441554027489474e-08
ii O 0 2.492543171683792e-05
) O 0 4.0046899130175007e-08
transcripts O 0 1.1621879139056546e-06
with O 0 5.110220513415697e-07
premature O 0 0.00018044610624201596
termination O 0 1.2949970368936192e-05
codons O 0 6.190700787556125e-07
can O 0 4.549130494524434e-08
occur O 0 4.975691680897398e-08
at O 0 1.3922263519816624e-07
low O 0 4.280114353605313e-06
or O 0 3.577689540179563e-07
undetectable O 0 4.780451035912847e-06
levels O 0 4.264060038394746e-08
due O 0 3.997302755465171e-08
to O 0 1.5668778274857686e-08
nonsense O 0 1.609759465281968e-06
- O 0 1.477316914133553e-06
mediated O 0 3.262861980601883e-07
mRNA O 0 2.326621739712209e-08
decay O 0 1.4757256394659635e-07
, O 0 1.691486595234437e-08
and O 0 3.3881732974805345e-08
( O 0 1.9966195807796794e-08
iii O 0 1.3480171219271142e-05
) O 0 1.1343201933300406e-08
the O 0 5.157365201569064e-09
levels O 0 2.3043805086331304e-08
of O 0 4.5867407649780034e-09
these O 0 1.0009959083845388e-08
transcripts O 0 5.185074201108364e-07
can O 0 2.1108869319164114e-08
be O 0 1.948887984326575e-08
increased O 0 2.665700264969928e-07
by O 0 6.186510290717706e-07
cycloheximide O 0 0.0007495585596188903
. O 0 5.5288032854150515e-06

A O 0 6.47654669592157e-05
deletion O 0 0.00010015164298238233
mutation O 0 1.1464776434877422e-05
in O 0 6.432578629755881e-07
COL17A1 O 0 0.0012011375511065125
in O 0 3.119710072496673e-07
five O 0 7.653064244550478e-07
Austrian O 0 0.00018879979324992746
families O 0 2.4300900349771837e-06
with O 0 3.855164322885685e-06
generalized O 0 0.12272326648235321
atrophic B-Disease 1 0.9999710321426392
benign I-Disease 1 0.999235987663269
epidermolysis I-Disease 1 0.9995877146720886
bullosa I-Disease 1 0.992594301700592
represents O 0 1.7095440853154287e-05
propagation O 0 3.772826403292129e-06
of O 0 3.846420781883353e-07
an O 0 1.185731775876775e-06
ancestral O 0 0.00010115230543306097
allele O 0 3.9079375710571185e-05
. O 0 1.0221812772215344e-05

Patients O 0 0.030804293230175972
with O 0 7.919639756437391e-05
generalized O 0 0.4842689633369446
atrophic B-Disease 1 0.9999629259109497
benign I-Disease 1 0.9997734427452087
epidermolysis I-Disease 1 0.9996960163116455
bullosa I-Disease 1 0.9994229078292847
, O 0 4.340488158049993e-05
a O 0 1.6200842765101697e-06
usually O 0 5.806625154036738e-07
nonlethal O 0 1.5242005247273482e-05
form O 0 4.067476027103112e-07
of O 0 1.742601057230786e-06
junctional B-Disease 1 0.9911077618598938
epidermolysis I-Disease 1 0.9984476566314697
bullosa I-Disease 1 0.9925550818443298
, O 0 7.2355464908469e-06
have O 0 7.503066399294767e-07
generalized O 0 2.2507849280373193e-05
blistering B-Disease 0 0.009438875131309032
, O 0 9.450117067899555e-05
nail B-Disease 1 0.9999234676361084
dystrophy I-Disease 1 0.9994555115699768
, O 0 0.0004868174437433481
patchy B-Disease 1 0.9998947381973267
alopecia I-Disease 1 0.9999934434890747
, O 0 9.913316171150655e-05
and O 0 0.0009045028127729893
dental B-Disease 1 0.9967561364173889
abnormalities I-Disease 1 0.9900992512702942
. O 0 5.856489951838739e-05

Skin B-Disease 1 0.9735732674598694
fragility I-Disease 0 0.29906004667282104
in O 0 7.956280569487717e-06
most O 0 1.098765665119572e-06
cases O 0 1.6922114127737586e-06
is O 0 2.64200110677848e-07
due O 0 2.46991930907825e-06
to O 0 3.338308545153268e-07
mutations O 0 7.431214044117951e-07
in O 0 3.4584601849019236e-08
the O 0 3.053559538557238e-08
gene O 0 2.2436297797412408e-07
encoding O 0 7.373608355010219e-07
type O 0 2.698818570934236e-05
XVII O 0 0.18216125667095184
collagen O 0 0.0011396723566576838
( O 0 2.3068137124937493e-06
COL17A1 O 0 0.0010663381544873118
) O 0 1.3191926200306625e-06
. O 0 3.680989493659581e-06

Recently O 0 0.0002583347668405622
, O 0 3.485839215500164e-06
we O 0 5.097924713481916e-07
reported O 0 1.602013298906968e-06
five O 0 3.3420960221519636e-07
Austrian O 0 0.00012027919001411647
families O 0 3.3198703022208065e-06
with O 0 5.611334927380085e-06
generalized O 0 0.0926041379570961
atrophic B-Disease 1 0.9999759197235107
benign I-Disease 1 0.9986237287521362
epidermolysis I-Disease 1 0.9990445971488953
bullosa I-Disease 1 0.9987284541130066
who O 0 3.971706610172987e-05
share O 0 2.591577413113555e-06
the O 0 4.729860449970147e-07
same O 0 1.7937143184099114e-06
COL17A1 O 0 0.0032432707957923412
mutation O 0 1.990985037991777e-05
. O 0 7.588999778818106e-06

Affected O 0 0.00024757799110375345
individuals O 0 4.334578989073634e-06
in O 0 2.7182713324691576e-07
three O 0 2.0565175873343833e-07
families O 0 5.578480681833753e-07
are O 0 6.832375731846696e-08
homozygous O 0 7.593536679451063e-07
for O 0 2.291691885147884e-07
4003delTC O 0 0.0002707619278226048
, O 0 4.0853277027963486e-07
whereas O 0 3.1081873430593987e-07
those O 0 3.558829675398556e-08
in O 0 3.489436650738753e-08
two O 0 6.272635033610641e-08
others O 0 4.608838253261638e-07
are O 0 1.6103570033010328e-07
compound O 0 1.2231480468472e-05
heterozygotes O 0 6.170199776533991e-05
. O 0 4.3760765038314275e-06

To O 0 8.977989637060091e-06
determine O 0 5.973300631012535e-06
if O 0 3.344270567140484e-07
the O 0 5.147422754703257e-08
occurrence O 0 4.90195304791996e-07
of O 0 8.714058452596873e-08
4003delTC O 0 0.00019785945187322795
in O 0 2.0407159695423616e-07
these O 0 8.724186528752398e-08
unrelated O 0 1.0714140444179066e-05
families O 0 7.038543117232621e-07
signifies O 0 1.7239443650396424e-06
propagation O 0 5.926862058913684e-07
of O 0 6.797812091008382e-08
an O 0 1.0666082772559093e-07
ancestral O 0 4.227305907988921e-06
allele O 0 4.829398676520213e-07
or O 0 8.770602732965926e-08
a O 0 1.516271197488095e-07
mutational O 0 0.0001092256570700556
hot O 0 9.910680091707036e-05
spot O 0 1.0175372153753415e-05
, O 0 2.1585420029168745e-07
haplotypes O 0 1.8978814750880701e-06
were O 0 1.175610009340744e-07
determined O 0 4.70019642762054e-07
for O 0 1.497838866271195e-07
polymorphisms O 0 9.900202712742612e-06
both O 0 8.432996878582344e-08
within O 0 1.7195735324548878e-07
and O 0 7.882176760176662e-07
flanking O 0 0.002007771283388138
COL17A1 O 0 0.05038617551326752
. O 0 1.7708818631945178e-05

Five O 0 2.4490032956236973e-05
intragenic O 0 0.0011561595601961017
polymorphisms O 0 0.00010131699673365802
were O 0 9.615822591513279e-07
chosen O 0 4.0533768697059713e-07
based O 0 1.9520730631938932e-07
on O 0 4.154738917350187e-07
their O 0 6.020977707521524e-07
informativeness O 0 0.0005611909436993301
. O 0 7.709802048339043e-06

One O 0 4.063012511323905e-06
of O 0 2.364126743259476e-07
these O 0 1.0134063188615983e-07
, O 0 1.0399446637165966e-07
not O 0 4.2949466205755016e-08
previously O 0 7.032310236354533e-07
reported O 0 2.37005542658153e-06
, O 0 1.1416134526598398e-07
was O 0 4.883009410150407e-07
2988 O 0 1.2025877367705107e-05
A O 0 2.7191453000341426e-07
or O 0 1.8961145542562008e-07
C O 0 1.2133517884649336e-05
that O 0 1.1724723414374694e-08
introduces O 0 1.0606883904529241e-07
a O 0 4.7253244872536015e-08
new O 0 5.301660266354702e-08
restriction O 0 4.441953933564946e-07
site O 0 1.0454550647409633e-06
for O 0 2.591122552075831e-07
Eco0109 O 0 7.970879232743755e-05
I O 0 1.3296315955813043e-05
. O 0 4.212496151012601e-06

All O 0 3.6076455671718577e-06
the O 0 8.824875976642943e-07
4003delTC O 0 3.9743739762343466e-05
alleles O 0 2.4436292278551264e-06
showed O 0 2.3676384444115683e-06
the O 0 7.950191616146185e-08
same O 0 1.6706111694020365e-07
haplotype O 0 3.495610144454986e-06
for O 0 6.702322252749582e-08
these O 0 5.4207745847634214e-08
five O 0 5.295510732139519e-07
polymorphic O 0 0.00013581679377239197
markers O 0 9.084674093173817e-05
. O 0 1.3729820238950197e-05

Fourteen O 0 0.00022646870638709515
microsatellite O 0 0.0020370001439005136
polymorphisms O 0 0.00025384375476278365
were O 0 1.9961644284194335e-06
selected O 0 2.354159960304969e-07
based O 0 2.3345792499185336e-07
on O 0 2.3717643671261612e-07
their O 0 8.395378614522997e-08
high O 0 9.228468115907162e-06
heterozygosity O 0 6.427852349588647e-05
and O 0 6.213027603507726e-08
their O 0 1.4625618938168827e-08
location O 0 2.4552946342737414e-07
within O 0 1.2131475557453086e-07
10q23 O 0 8.159176104527432e-06
- O 0 3.116896186838858e-05
q25 O 0 7.367173384409398e-05
near O 0 1.885075653262902e-05
COL17A1 O 0 0.00056634028442204
. O 0 5.08701532453415e-06

Three O 0 1.784860978659708e-05
families O 0 1.7091284462367184e-05
shared O 0 7.069023013173137e-06
microsatellite O 0 0.0010951969306915998
polymorphisms O 0 8.618964784545824e-05
covering O 0 1.719754254736472e-05
at O 0 1.6592153997407877e-06
most O 0 9.261128042226119e-08
19 O 0 1.119193711929256e-06
cM O 0 3.38337522407528e-05
, O 0 1.0007098438791218e-07
whereas O 0 1.606180433100235e-07
the O 0 3.103249923697149e-08
others O 0 1.5426745392232988e-07
shared O 0 1.0673042538655864e-07
smaller O 0 6.080313710299379e-07
regions O 0 5.125438633513113e-07
consistent O 0 4.2046110593219055e-07
with O 0 1.2702008689302602e-07
cross O 0 2.7234350454818923e-06
- O 0 2.4446677343803458e-05
over O 0 1.741785666808937e-07
events O 0 7.005348834354663e-08
during O 0 1.3440529755825992e-07
passage O 0 2.1793029247874074e-07
of O 0 2.4188425484794607e-08
this O 0 4.654159724282181e-08
mutation O 0 2.7799643476100755e-07
through O 0 6.166229837845094e-08
several O 0 1.7496103055236745e-07
generations O 0 4.808809990208829e-06
. O 0 3.1686402053310303e-06

These O 0 5.437048457679339e-06
results O 0 5.7487213780405e-06
indicate O 0 2.6054376576212235e-06
that O 0 3.336541851695074e-07
4003delTC O 0 0.00023078998492565006
occurs O 0 9.13044061690016e-07
on O 0 2.686538778107206e-07
a O 0 1.7073635660835862e-07
single O 0 9.542774250803632e-07
ancestral O 0 7.593763712065993e-06
allele O 0 2.131815108441515e-06
. O 0 4.0964152958622435e-07
. O 0 2.6924428766506026e-06

The O 0 3.857040428556502e-05
haptoglobin O 0 0.004149816930294037
- O 0 0.00045654087443836033
gene O 0 7.307479791052174e-06
deletion O 0 9.950626008503605e-06
responsible O 0 4.505241122387815e-06
for O 0 2.8505767204478616e-06
anhaptoglobinemia B-Disease 0 0.007069077808409929
. O 0 2.6441879526828416e-05

We O 0 1.3482639587891754e-05
have O 0 1.3347543017516728e-06
found O 0 4.61431795883982e-07
an O 0 5.7150703725028507e-08
allelic O 0 7.702812581555918e-06
deletion O 0 2.104763552779332e-06
of O 0 1.6820351333990402e-07
the O 0 5.700817951037607e-07
haptoglobin O 0 0.0017611762741580606
( O 0 3.3238319474548916e-07
Hp O 0 2.3019131276669214e-06
) O 0 3.8032325733183825e-08
gene O 0 7.637623156142581e-08
from O 0 2.1224819235499126e-08
an O 0 1.822254525052358e-08
individual O 0 8.430648534840657e-08
with O 0 8.868552754393022e-07
anhaptoglobinemia B-Disease 0 0.002671952359378338
. O 0 7.95731284597423e-06

The O 0 1.7756354282028042e-05
Hp O 0 6.393331568688154e-05
gene O 0 1.4715612451254856e-05
cluster O 0 2.0484565538936295e-05
consists O 0 4.408479412632005e-07
of O 0 1.0128710670187502e-07
coding O 0 5.724649327021325e-06
regions O 0 1.775703992734634e-07
of O 0 1.80912227421004e-08
the O 0 3.1719245896510984e-08
alpha O 0 5.604914576906594e-07
chain O 0 1.3936531786384876e-06
and O 0 4.342259884992927e-08
beta O 0 1.6135790303906106e-07
chain O 0 1.4964923877869296e-07
of O 0 6.809202979241036e-09
the O 0 3.3109170516354425e-08
haptoglobin O 0 1.9007373339263722e-05
gene O 0 3.6178016671328805e-07
( O 0 2.1545412565160404e-08
Hp O 0 1.40869531151111e-07
) O 0 5.736997543692723e-09
and O 0 6.835657817561014e-09
of O 0 3.602413256587056e-09
the O 0 1.2672515481426672e-08
alpha O 0 3.555797718490794e-07
chain O 0 1.3572432635555742e-06
and O 0 3.913428514579209e-08
beta O 0 2.646984569310007e-07
chain O 0 2.253435980037466e-07
of O 0 9.931567568344235e-09
the O 0 5.8544724623743605e-08
haptoglobin O 0 5.699377288692631e-05
- O 0 3.91194989788346e-05
related O 0 2.5958022433769656e-06
gene O 0 5.130974614075967e-07
( O 0 1.481307947415189e-07
Hpr O 0 2.7255311579210684e-05
) O 0 3.0109756465890314e-08
, O 0 3.754745847572849e-08
in O 0 3.458427144664711e-08
tandem O 0 7.235187695187051e-06
from O 0 7.572970162073034e-08
the O 0 1.2353665113096213e-07
5 O 0 1.0699820904847002e-06
side O 0 3.017779818037525e-06
. O 0 3.371870889168349e-06

Southern O 0 0.00011695123976096511
blot O 0 0.0003697039792314172
and O 0 2.714670017667231e-06
PCR O 0 1.4068376003706362e-05
analyses O 0 4.136905317864148e-06
have O 0 2.1366459179716912e-07
indicated O 0 1.3397306020124233e-06
that O 0 3.495991762747508e-08
the O 0 3.2130134997032656e-08
individual O 0 3.826830408115711e-08
with O 0 2.425715308618237e-07
anhaptoglobinemia B-Disease 0 0.002952917478978634
was O 0 2.36082678384264e-06
homozygous O 0 3.852654231195629e-07
for O 0 2.1652482473655255e-08
the O 0 4.139321774232485e-08
gene O 0 1.663238009541601e-07
deletion O 0 5.138114147484885e-07
and O 0 2.0515381038421765e-07
that O 0 1.546940353591708e-08
the O 0 4.912866558015594e-08
gene O 0 2.4841989443302737e-07
deletion O 0 6.140152208899963e-07
was O 0 3.100259391430882e-07
included O 0 1.4667404002466355e-07
at O 0 2.4005277055039187e-07
least O 0 1.8261655299056656e-08
from O 0 1.0882589940308662e-08
the O 0 1.923223891253656e-08
promoter O 0 6.55121220916044e-06
region O 0 1.335789221457162e-07
of O 0 2.436437540609404e-08
Hp O 0 8.067535759437305e-07
to O 0 8.065937606716034e-08
Hpr O 0 1.2051536032231525e-05
alpha O 0 4.7348518705803144e-07
but O 0 2.7286805703852224e-08
not O 0 1.1544444511457641e-08
to O 0 4.9127731216458415e-08
Hpr O 0 2.9987739253556356e-05
beta O 0 1.5519340195169207e-06
( O 0 3.447909477927169e-07
Hpdel O 0 2.741239222814329e-05
) O 0 5.813944881083444e-07
. O 0 1.5936931276883115e-06

In O 0 5.4142669796419796e-06
addition O 0 1.121370019063761e-06
, O 0 3.3373854080309684e-07
we O 0 6.93369841542335e-08
found O 0 4.9394380141620786e-08
seven O 0 5.398446134563528e-08
individuals O 0 2.6011045761720197e-08
with O 0 4.72968864073664e-08
hypohaptoglobinemia B-Disease 0 0.00024982827017083764
in O 0 1.3722532798965403e-07
three O 0 2.822342253239185e-07
families O 0 8.379027462979138e-07
, O 0 2.42837472796964e-07
and O 0 1.310047537117498e-07
the O 0 3.6169421235854315e-08
genotypes O 0 1.8167905864174827e-06
of O 0 1.587150855186792e-08
six O 0 5.814466064180124e-08
of O 0 1.4701217132540023e-08
the O 0 4.273961451417563e-08
seven O 0 1.5487728433072334e-07
individuals O 0 2.95774338354704e-08
were O 0 3.70006105754328e-08
found O 0 4.025827138320892e-08
to O 0 2.6285196241815356e-08
be O 0 4.3082712863906636e-07
Hp2 O 0 0.002708104671910405
/ O 0 0.00044528674334287643
Hpdel O 0 0.0003975497093051672
. O 0 6.671674327662913e-06

The O 0 1.700268330750987e-05
phenotypes O 0 0.00017695152200758457
and O 0 3.0168332614266546e-06
genotypes O 0 3.540402394719422e-05
in O 0 1.907409910018032e-07
one O 0 4.860977043108505e-08
of O 0 2.148640021459869e-08
these O 0 1.8625810227490547e-08
three O 0 5.8332833674512585e-08
families O 0 4.0992523508975864e-07
showed O 0 2.948477458630805e-06
the O 0 7.831833670479682e-08
father O 0 1.0410198001409299e-06
to O 0 2.374538432547979e-08
be O 0 1.676724252774875e-07
hypohaptoglobinemic B-Disease 0 0.0006935899145901203
( O 0 1.1395206911402056e-07
Hp2 O 0 1.033876196743222e-05
) O 0 2.172259883082006e-08
and O 0 8.553145391942962e-08
Hp2 O 0 6.52052040095441e-05
/ O 0 7.460749657184351e-06
Hpdel O 0 5.808933201478794e-05
, O 0 7.004974378332918e-08
the O 0 3.091953004741299e-08
mother O 0 7.438928264491551e-07
to O 0 7.684979763666888e-09
be O 0 4.644883588866833e-08
Hp2 O 0 1.723929563013371e-05
- O 0 1.0563497198745608e-05
1 O 0 1.1745923700345884e-07
and O 0 1.1004407696191265e-07
Hp1 O 0 6.342733831843361e-05
/ O 0 1.1213101061002817e-05
Hp2 O 0 4.520277798292227e-05
, O 0 5.223040488999686e-08
one O 0 7.902942300574978e-09
of O 0 5.211335363242142e-09
the O 0 9.100586950694378e-09
two O 0 1.9844701881766014e-08
children O 0 5.128958591171795e-08
to O 0 1.9760324931894502e-08
be O 0 5.576337969159795e-08
hypohaptoglobinemic B-Disease 0 0.0004982444224879146
( O 0 9.417183832738374e-08
Hp2 O 0 8.731477464607451e-06
) O 0 1.4670740178246433e-08
and O 0 5.737591379784135e-08
Hp2 O 0 3.388626282685436e-05
/ O 0 2.6013882234110497e-05
Hpdel O 0 7.770768570480868e-05
, O 0 9.820583812825134e-08
and O 0 4.268568076781776e-08
the O 0 3.242837109951324e-08
other O 0 4.478261317331089e-08
child O 0 9.308781727668247e-07
to O 0 3.785631363939501e-08
be O 0 8.506289361775998e-08
Hp1 O 0 3.0002554922248237e-05
and O 0 3.2820267392708047e-07
Hp1 O 0 0.00031385483453050256
/ O 0 7.169879245338961e-05
Hpdel O 0 0.00015269304276444018
, O 0 2.6601665581438283e-07
showing O 0 1.0719553529270343e-06
an O 0 5.4765607160334184e-08
anomalous O 0 2.1748692233813927e-05
inheritance O 0 4.4448120206652675e-06
of O 0 4.028869682315417e-07
Hp O 0 5.835822958033532e-05
phenotypes O 0 3.7522055208683014e-05
in O 0 3.5785970453616756e-07
the O 0 4.151696941789851e-07
child O 0 2.8630673114093952e-05
with O 0 3.3286773941654246e-06
Hp1 O 0 0.001888035680167377
. O 0 6.851128546259133e-06

The O 0 2.9033335522399284e-05
Hp2 O 0 0.0027362105902284384
/ O 0 0.0013993263710290194
Hpdel O 0 0.006754996720701456
individuals O 0 1.5291680028894916e-06
had O 0 2.896547641739744e-07
an O 0 3.2125722526643585e-08
extremely O 0 3.4181141472799936e-06
low O 0 2.400922085143975e-06
level O 0 7.316827321801611e-08
of O 0 1.9218305169488303e-08
Hp O 0 1.5152868400036823e-06
( O 0 4.181043067319479e-08
mean O 0 3.372696255610208e-07
+ O 0 3.87494264941779e-06
/ O 0 3.377315806574188e-06
- O 0 5.2240543482184876e-06
SD O 0 3.4492783015593886e-05
= O 0 9.025598615153285e-07
0 O 0 7.229377274597937e-08
. O 0 2.0409878231930634e-08
049 O 0 2.5032770736288512e-06
+ O 0 7.692005965509452e-07
/ O 0 6.514632104881457e-07
- O 0 9.928897952704574e-07
0 O 0 1.1217471040936289e-07
. O 0 2.818161881634751e-08
043 O 0 2.189248561990098e-06
mg O 0 4.1408366087125614e-06
/ O 0 2.9990051189088263e-06
ml O 0 8.912540579331107e-06
; O 0 1.0108599468594548e-07
n O 0 4.876429557043593e-06
= O 0 3.868131841500144e-07
6 O 0 4.96808638672519e-08
) O 0 6.729141244221637e-09
, O 0 7.012096681080493e-09
compared O 0 5.925460655475945e-08
with O 0 8.473139523346163e-09
the O 0 9.32390342711642e-09
level O 0 7.706795912554298e-08
( O 0 9.863700078938109e-09
1 O 0 1.8876592733363395e-08
. O 0 9.638186249105729e-09
64 O 0 2.0056241112342832e-07
+ O 0 1.1934301937799319e-06
/ O 0 1.8532595049691736e-06
- O 0 1.3277222024044022e-06
1 O 0 6.559987042464854e-08
. O 0 1.8322046102525746e-08
07 O 0 2.9288275982253253e-07
mg O 0 3.9961964830581564e-06
/ O 0 3.7701790915889433e-06
ml O 0 2.8767151434294647e-06
) O 0 7.1362284970177825e-09
obtained O 0 8.461737088794052e-09
from O 0 1.3310404334276882e-08
52 O 0 2.459968300172477e-07
healthy O 0 1.9634603631857317e-07
volunteers O 0 1.6555785009586543e-07
having O 0 7.972757032348454e-08
phenotype O 0 2.019451812884654e-06
Hp2 O 0 4.216325032757595e-05
, O 0 8.750633639920125e-08
whereas O 0 1.4526887071042438e-07
the O 0 5.225072996495328e-08
serum O 0 5.109828634886071e-06
Hp O 0 1.0438909612275893e-06
level O 0 7.400407753266336e-08
of O 0 1.3211658433931461e-08
an O 0 1.3771085605185363e-08
individual O 0 3.468064591061193e-08
with O 0 1.2821264760987106e-07
Hp1 O 0 0.0011800481006503105
/ O 0 8.854694169713184e-05
Hpdel O 0 0.00013930040586274117
was O 0 3.9374021980620455e-06
0 O 0 7.91222100815503e-06
. O 0 3.2593056857876945e-06

50 O 0 6.271773600019515e-05
mg O 0 0.00037750255432911217
/ O 0 0.0001609615283086896
ml O 0 7.724165334366262e-05
, O 0 1.2268111504454282e-07
which O 0 2.853955116677298e-08
was O 0 5.1658936683907086e-08
approximately O 0 1.4319745389457239e-08
half O 0 1.7459392154250963e-08
the O 0 1.2143903660444266e-08
level O 0 4.413434240291281e-08
of O 0 1.3413826494002024e-08
Hp O 0 1.2840614544984419e-06
in O 0 6.889811743349128e-08
control O 0 2.179690454795491e-06
sera O 0 2.4483728338964283e-05
from O 0 8.202182755212561e-08
the O 0 1.1468163307881696e-07
Hp1 O 0 0.0003277954529039562
phenotype O 0 3.3466233162471326e-06
( O 0 3.2849950315494425e-08
1 O 0 5.8536130609354586e-08
. O 0 1.025273377308622e-08
26 O 0 1.217593847968601e-07
+ O 0 6.922538204889861e-07
/ O 0 6.405349495253176e-07
- O 0 1.1451697901065927e-06
0 O 0 5.771309119495527e-08
. O 0 5.946448666804827e-09
33 O 0 1.18097673862394e-07
mg O 0 9.639877589506796e-07
/ O 0 2.094597221002914e-06
ml O 0 7.328681931539904e-06
; O 0 9.890607088891556e-08
n O 0 3.557680429366883e-06
= O 0 3.966029566981888e-07
9 O 0 7.830623616200683e-08
) O 0 1.0301719477467941e-08
, O 0 1.4861296193657836e-08
showing O 0 1.6883446107840427e-07
a O 0 8.485159241899964e-08
gene O 0 1.0436360753374174e-06
- O 0 0.00014782451034989208
dosage O 0 8.276901644421741e-05
effect O 0 4.1247913031838834e-06
. O 0 4.531336344371084e-06

The O 0 5.851341029483592e-06
other O 0 8.409335237047344e-07
allele O 0 5.230460374150425e-06
( O 0 3.7558567100859364e-07
Hp2 O 0 4.4470056309364736e-05
) O 0 3.0290568275859187e-08
of O 0 1.4368445100387817e-08
individuals O 0 4.772816097897703e-08
with O 0 1.533085622895669e-07
Hp2 O 0 0.0009829449700191617
/ O 0 9.912058885674924e-05
Hpdel O 0 0.0008307781536132097
was O 0 2.0274951566534583e-06
found O 0 1.4974590101246577e-07
to O 0 1.6582957229616113e-08
have O 0 1.7568023480407646e-08
, O 0 2.6763881777469578e-08
in O 0 1.192847953745968e-08
all O 0 1.4163177297632501e-08
exons O 0 1.5198181699815905e-06
, O 0 1.7829547971359716e-07
no O 0 7.999017270776676e-08
mutation O 0 2.08879129104389e-07
, O 0 6.928647877657568e-08
by O 0 1.357339982632766e-07
DNA O 0 4.882688244833844e-06
sequencing O 0 9.226179827237502e-06
. O 0 5.169204086996615e-06

On O 0 4.3706295400625095e-06
the O 0 1.974078003286195e-07
basis O 0 8.243210913860821e-08
of O 0 3.7231536964554834e-08
the O 0 3.869961417990453e-08
present O 0 1.4961956651404762e-07
study O 0 2.806254997267388e-07
, O 0 1.0805445782580136e-07
the O 0 1.1400876687162054e-08
mechanism O 0 3.2920322468044105e-08
of O 0 3.7055130519547674e-08
anhaptoglobinemia B-Disease 0 0.0007781898020766675
and O 0 1.3138161136794224e-07
the O 0 3.585722652132972e-08
mechanism O 0 1.1315093217945105e-07
of O 0 4.2815738510171286e-08
anomalous O 0 2.87725397356553e-05
inheritance O 0 4.2382694118714426e-06
of O 0 2.71617750513542e-07
Hp O 0 7.421962800435722e-05
phenotypes O 0 1.455500751035288e-05
were O 0 5.725456162508635e-07
well O 0 8.809042242319265e-07
explained O 0 8.470187822240405e-06
. O 0 5.976987267786171e-06

However O 0 2.24771756620612e-05
, O 0 1.231346686836332e-06
the O 0 2.236761105223195e-07
mechanism O 0 8.897542898012034e-07
of O 0 7.344273171838722e-07
hypohaptoglobinemia B-Disease 0 0.03655350208282471
remains O 0 0.00026156409876421094
unknown O 0 0.00011222992179682478

ATM O 0 0.004379437305033207
mutations O 0 0.00018456988618709147
and O 0 1.2949154552188702e-05
phenotypes O 0 0.0006192864966578782
in O 0 0.00012585440708789974
ataxia B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999758005142212
telangiectasia I-Disease 1 0.9999909400939941
families O 0 1.4230585293262266e-05
in O 0 1.5193370472843526e-07
the O 0 1.9990800126379327e-07
British O 0 5.119081379234558e-06
Isles O 0 4.3913656554650515e-05
: O 0 1.1670866939539337e-07
expression O 0 4.0505664600232194e-08
of O 0 2.5321803320821346e-08
mutant O 0 1.8103843331118696e-06
ATM O 0 8.363990673387889e-06
and O 0 5.4113531433586104e-08
the O 0 9.156514835240159e-08
risk O 0 4.586997874866938e-06
of O 0 5.937265086686239e-06
leukemia B-Disease 1 0.9999747276306152
, O 0 0.13355806469917297
lymphoma B-Disease 1 1.0
, O 0 4.41629090346396e-05
and O 0 0.007985826581716537
breast B-Disease 1 0.9999094009399414
cancer I-Disease 1 0.9608939290046692
. O 0 3.920445669791661e-05

We O 0 1.8310000086785294e-05
report O 0 1.7358503328068764e-06
the O 0 1.6411038927799382e-07
spectrum O 0 1.3752207905781688e-06
of O 0 1.0703907804554547e-07
59 O 0 5.962173872831045e-06
ATM O 0 4.14975693274755e-05
mutations O 0 1.0793513638418517e-06
observed O 0 2.4480796128045768e-06
in O 0 2.3599248379468918e-05
ataxia B-Disease 1 0.9999973773956299
- I-Disease 1 0.999980092048645
telangiectasia I-Disease 1 0.9999922513961792
( O 0 1.4987796021159738e-05
A B-Disease 1 0.6202353835105896
- I-Disease 1 0.9999502897262573
T I-Disease 1 0.9999959468841553
) O 0 3.3928276934602764e-06
patients O 0 3.404778226467897e-06
in O 0 6.789272788410017e-08
the O 0 2.0673445533248014e-07
British O 0 9.191244316753e-06
Isles O 0 0.0001906885881908238
. O 0 1.4701893633173313e-05

Of O 0 1.1370188076398335e-05
51 O 0 8.889490709407255e-05
ATM O 0 0.0006121218320913613
mutations O 0 3.4644195693545043e-05
identified O 0 3.3908513614733238e-06
in O 0 1.2095570411929657e-07
families O 0 5.3521159770753e-07
native O 0 2.389258781931858e-07
to O 0 4.9657273848424666e-08
the O 0 8.711747767620182e-08
British O 0 1.3465191841532942e-06
Isles O 0 2.189824590459466e-05
, O 0 3.4352731859144114e-07
11 O 0 6.227644462342141e-07
were O 0 3.8211641140151187e-07
founder O 0 6.451497029047459e-06
mutations O 0 3.2533816352042777e-07
, O 0 4.814720000467787e-08
and O 0 3.770822587512157e-08
2 O 0 6.627181647900215e-08
of O 0 1.020937290263646e-08
these O 0 1.8763339326710593e-08
11 O 0 5.150457695890509e-07
conferred O 0 1.7562180119057302e-06
a O 0 7.516429718634754e-07
milder O 0 0.0008311847341246903
clinical O 0 0.00045262055937200785
phenotype O 0 5.868504013051279e-05
with O 0 1.9253036498412257e-07
respect O 0 3.2947090744528396e-07
to O 0 4.3519861492313794e-07
both O 0 5.781483650935115e-06
cerebellar B-Disease 1 0.9786721467971802
degeneration I-Disease 1 0.8643753528594971
and O 0 1.566341961733997e-05
cellular O 0 0.0005722257192246616
features O 0 6.534121348522604e-05
. O 0 2.9754917704849504e-05

We O 0 1.055902521329699e-05
report O 0 2.0436930299183587e-06
, O 0 2.798739160425612e-07
in O 0 4.418522081550691e-08
two O 0 8.010742647002189e-08
A B-Disease 0 0.01536356657743454
- I-Disease 1 0.9993886947631836
T I-Disease 1 0.9999918937683105
families O 0 1.355109134237864e-06
, O 0 1.1616943140779767e-07
an O 0 3.4565676543252266e-08
ATM O 0 6.285987910814583e-05
mutation O 0 6.219198667167802e-07
( O 0 6.284298592618143e-08
7271T O 0 5.2389373195183e-06
- O 0 6.0720674809999764e-05
- O 0 0.000660919991787523
> O 0 2.919554026448168e-05
G O 0 4.862964487983845e-05
) O 0 1.0689948481967804e-08
that O 0 1.0309798348373533e-08
may O 0 4.8357772897134055e-08
be O 0 9.664638866979658e-09
associated O 0 7.267950508094145e-08
with O 0 2.4457309066860944e-08
an O 0 2.3677815264022684e-08
increased O 0 1.4930483303032815e-06
risk O 0 4.959550096828025e-06
of O 0 2.6624227302818326e-06
breast B-Disease 1 0.9965943694114685
cancer I-Disease 0 0.4438425898551941
in O 0 5.605642172668013e-07
both O 0 4.3354327772249235e-07
homozygotes O 0 9.779250103747472e-05
and O 0 2.332659505555057e-06
heterozygotes O 0 4.1661573050078005e-05
( O 0 2.1474852474057116e-07
relative O 0 5.6414410209981725e-06
risk O 0 1.145235387411958e-06
12 O 0 1.2968673956947896e-07
. O 0 5.218201337697792e-08
7 O 0 1.1964274335696246e-06
; O 0 9.335309982816398e-07
P O 0 0.0312555767595768
= O 0 2.4959256279544206e-06
. O 0 4.288562038823329e-08
0025 O 0 4.564167738863034e-06
) O 0 1.5746763892821036e-08
, O 0 1.3813887811409131e-08
although O 0 1.712646735541057e-08
there O 0 1.4744575338454524e-08
is O 0 1.5818137910628138e-08
a O 0 1.3118754793595144e-07
less O 0 2.3251279799296753e-06
severe O 0 0.0022022014018148184
A B-Disease 0 0.4824911952018738
- I-Disease 1 0.999900221824646
T I-Disease 1 0.9999940395355225
phenotype O 0 1.8424660083837807e-05
in O 0 4.5678675064664276e-08
terms O 0 7.790207945390648e-08
of O 0 4.6019380306461244e-08
the O 0 2.0285342827719433e-07
degree O 0 1.2118115591874812e-05
of O 0 4.217519744997844e-05
cerebellar B-Disease 1 0.9989732503890991
degeneration I-Disease 1 0.9969894289970398
. O 0 0.00018387289310339838

This O 0 7.575896688649664e-06
mutation O 0 1.930783037096262e-05
( O 0 8.705849268153543e-07
7271T O 0 6.073330223443918e-05
- O 0 0.0009116138098761439
- O 0 0.006143222562968731
> O 0 3.4240791137563065e-05
G O 0 4.027510658488609e-05
) O 0 3.1673543787746894e-08
also O 0 9.406015522017697e-09
allows O 0 1.0917893256134903e-08
expression O 0 9.105622034155658e-09
of O 0 3.8350487230331964e-09
full O 0 1.352605210058755e-07
- O 0 1.1670298590615857e-05
length O 0 7.882063641773129e-07
ATM O 0 3.185036803188268e-06
protein O 0 4.036946066321434e-08
at O 0 3.013216343106251e-08
a O 0 2.619665728786913e-08
level O 0 9.243586873708409e-08
comparable O 0 6.524847435684933e-07
with O 0 4.7071090136796556e-08
that O 0 3.73441935153096e-08
in O 0 3.9025542264425894e-07
unaffected O 0 6.125865911599249e-05
individuals O 0 1.7125050817412557e-06
. O 0 6.122754712123424e-06

In O 0 6.0580741774174385e-06
addition O 0 1.3240792213764507e-06
, O 0 3.886887327553268e-07
we O 0 1.0089972590776597e-07
have O 0 4.13610159455402e-08
studied O 0 2.6211208137283393e-07
18 O 0 2.0322534055594588e-06
A B-Disease 0 0.04058214649558067
- I-Disease 1 0.9999223947525024
T I-Disease 1 0.9999991655349731
patients O 0 8.613664977019653e-05
, O 0 7.781787303429155e-08
in O 0 1.6619116749438945e-08
15 O 0 2.065421256247646e-07
families O 0 2.231170839195329e-07
, O 0 2.496817899100279e-07
who O 0 1.977976125999703e-06
developed O 0 0.0020498984958976507
leukemia B-Disease 1 0.9998937845230103
, O 0 0.011360385455191135
lymphoma B-Disease 1 0.9999997615814209
, O 0 2.9269302103784867e-05
preleukemic O 1 0.5315210223197937
T O 1 0.763989269733429
- O 0 0.0002427183062536642
cell O 0 7.684426236664876e-05
proliferation O 0 0.0012510461965575814
, O 0 7.314787126233568e-06
or O 0 0.013898555189371109
Hodgkin B-Disease 1 0.9999992847442627
lymphoma I-Disease 1 0.9999998807907104
, O 0 5.269980647426564e-06
mostly O 0 6.889554811095877e-07
in O 0 1.2232355857122457e-06
childhood O 0 9.930886881193146e-05
. O 0 1.297884045925457e-05

A O 0 3.3644886570982635e-05
wide O 0 2.550358658481855e-05
variety O 0 1.4392054481504601e-06
of O 0 3.7917888562333246e-07
ATM O 0 0.0002141515869880095
mutation O 0 1.685154416009027e-06
types O 0 4.780027325068659e-07
, O 0 1.4516956525767455e-07
including O 0 4.3781457748082175e-07
missense O 0 9.68172971624881e-05
mutations O 0 1.207129685099062e-06
and O 0 2.487221308911103e-07
in O 0 1.5543497511316673e-07
- O 0 0.000299220671877265
frame O 0 3.722424662555568e-05
deletions O 0 7.970132173795719e-06
, O 0 2.671691561317857e-07
were O 0 1.3609172810902237e-07
seen O 0 5.90270815337135e-07
in O 0 1.1999910043414275e-07
these O 0 4.1438173070673656e-07
patients O 0 1.4297319467004854e-05
. O 0 3.851731889881194e-06

We O 0 4.6632599151053e-06
also O 0 3.6585382190423843e-07
show O 0 1.5183375978722324e-07
that O 0 1.7470318525170114e-08
25 O 0 6.684027908931967e-08
% O 0 1.833977236742612e-08
of O 0 1.155105255890021e-08
all O 0 1.3994186076615733e-07
A B-Disease 1 0.5011423826217651
- I-Disease 1 0.9999823570251465
T I-Disease 1 0.9999994039535522
patients O 0 2.0713241610792466e-05
carried O 0 1.6815569097161642e-06
in O 0 1.4600512088236428e-07
- O 0 0.00012270407751202583
frame O 0 4.611846088664606e-05
deletions O 0 8.451870598946698e-06
or O 0 2.134140004272922e-06
missense O 0 3.386842581676319e-05
mutations O 0 1.6944434264587471e-06
, O 0 1.164989313906517e-07
many O 0 7.098989840415015e-09
of O 0 1.4614993659733955e-08
which O 0 7.121844447510739e-08
were O 0 2.171899780023523e-07
also O 0 1.4674441217721323e-07
associated O 0 2.771593869965727e-07
with O 0 4.925288976664888e-08
expression O 0 1.2330818321970582e-07
of O 0 1.436683305655606e-07
mutant O 0 1.4580237802874763e-05
ATM O 0 5.595430047833361e-05
protein O 0 5.178381343284855e-06
. O 0 3.098461547779152e-06

The O 0 3.225323962396942e-05
DMPK O 0 0.0010769054060801864
gene O 0 2.2397300199372694e-05
of O 0 8.388482456211932e-06
severely O 1 0.7555921077728271
affected O 1 0.5725694894790649
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999996423721313
patients O 1 0.5843856930732727
is O 0 1.413664358551614e-05
hypermethylated O 0 0.1670752316713333
proximal O 0 0.0033957308623939753
to O 0 5.938970275565225e-07
the O 0 3.525388478919922e-07
largely O 0 1.2311002137721516e-06
expanded O 0 2.8312945232755737e-06
CTG O 0 0.0005330525455065072
repeat O 0 5.7303870562464e-05
. O 0 6.388904694176745e-06

Using O 0 9.822485480981413e-06
methylation O 0 6.614164885831997e-05
- O 0 0.0001450940762879327
sensitive O 0 1.732843702484388e-05
restriction O 0 1.7919908259500517e-06
enzymes O 0 9.912265568345902e-07
, O 0 1.589612992347611e-07
we O 0 5.735512331739301e-08
characterized O 0 7.570571369797108e-07
the O 0 2.8023764642171045e-08
methylation O 0 3.336540203235927e-06
pattern O 0 1.4165102584229317e-06
on O 0 2.0418217161477514e-07
the O 0 3.897606859482039e-08
5 O 0 2.1541062267260713e-07
side O 0 6.817652575819011e-08
of O 0 1.2358410295121303e-08
the O 0 7.245265720712268e-08
CTG O 0 0.00024966636556200683
repeat O 0 3.4857164337154245e-06
in O 0 4.9236078325520793e-08
the O 0 4.155458910304333e-08
DMPK O 0 2.2522664949065074e-05
gene O 0 7.991392436679234e-08
of O 0 2.6473626846268417e-08
normal O 0 3.757429567485815e-07
individuals O 0 8.506273729835812e-08
and O 0 9.375121834409583e-08
of O 0 6.622657906518725e-07
patients O 0 7.192450721049681e-05
affected O 0 1.86810993909603e-05
with O 0 0.006460461765527725
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999854564666748
, O 0 3.3261196676903637e-06
showing O 0 6.7928294811281376e-06
expansions O 0 8.906940820452292e-06
of O 0 1.558812101620788e-07
the O 0 5.575922159550828e-07
repetitive O 0 8.634397090645507e-05
sequence O 0 8.182591955119278e-06
. O 0 5.7017050494323485e-06

The O 0 3.993336122221081e-06
gene O 0 3.7871807307965355e-06
segment O 0 4.855593033425976e-06
analyzed O 0 1.4215567034625565e-06
corresponds O 0 3.7404933550533315e-07
to O 0 3.47998536653904e-08
the O 0 6.310170164169904e-08
genomic O 0 2.4468843093927717e-06
SacI O 0 2.911141018557828e-05
- O 0 1.5742547475383617e-05
HindIII O 0 1.5822466593817808e-05
fragment O 0 1.0289503507010522e-06
carrying O 0 8.104682365228655e-07
exons O 0 1.9257843177911127e-06
11 O 0 5.306273465066624e-07
- O 0 1.063443414750509e-05
15 O 0 1.7097178215408348e-06
. O 0 1.989990778383799e-06

There O 0 7.470959644706454e-06
is O 0 6.425049150493578e-07
constitutive O 0 3.292690735179349e-06
methylation O 0 4.363557764008874e-06
in O 0 2.136666381602481e-07
intron O 0 0.00018051185179501772
12 O 0 7.021092756076541e-07
at O 0 2.258461648807497e-07
restriction O 0 1.4556897554030002e-07
sites O 0 5.912455591783328e-08
of O 0 2.3885290190150954e-08
SacII O 0 1.4027288671059068e-05
and O 0 1.2726160036891088e-07
HhaI O 0 1.7557342289364897e-05
, O 0 4.299569411614357e-08
localized O 0 3.1366937491839053e-07
1 O 0 5.507735423293525e-08
, O 0 2.4004583210057717e-08
159 O 0 4.970693225914147e-07
- O 0 5.0245580496266484e-06
1 O 0 5.4727394172005006e-08
, O 0 1.619899947513659e-08
232 O 0 1.2496151668983657e-07
bp O 0 8.095003067865036e-07
upstream O 0 9.302537051780746e-08
of O 0 7.587482642179566e-09
the O 0 2.5358149358112314e-08
CTG O 0 5.077740934211761e-05
repeat O 0 2.460996256559156e-06
, O 0 9.887683205533904e-08
whereas O 0 1.6989272921819065e-07
most O 0 2.5647374002346623e-08
, O 0 5.2075822765118573e-08
if O 0 1.4380536761393614e-08
not O 0 5.5740168036777504e-09
all O 0 3.790391112090674e-09
, O 0 9.96268223474317e-09
of O 0 3.747839816270471e-09
the O 0 7.887838826547977e-09
other O 0 4.670929865113749e-09
sites O 0 2.9969839943078114e-08
of O 0 2.034555457441911e-08
SacII O 0 4.5351916924118996e-05
, O 0 1.2357281775621232e-07
HhaI O 0 3.039026887563523e-05
, O 0 5.358172572300646e-08
and O 0 1.3070152249383682e-07
HpaII O 0 3.159777043038048e-05
in O 0 2.8156742715168548e-08
this O 0 2.5211441823103087e-08
region O 0 3.1846587944528437e-07
are O 0 1.9713720433855997e-08
unmethylated O 0 2.622893407533411e-05
, O 0 3.952353111458251e-08
in O 0 2.2696326595905703e-08
normal O 0 1.8752861308257707e-07
individuals O 0 3.3957878287083076e-08
and O 0 3.7766238136782704e-08
most O 0 1.4004954529411862e-08
of O 0 8.566369302798194e-08
the O 0 4.151437678956427e-06
patients O 0 9.986649092752486e-05
. O 0 5.916881946177455e-06

In O 0 6.000523626426002e-06
a O 0 1.2281790304768947e-06
number O 0 1.1668418409271908e-07
of O 0 1.3764014283879078e-07
young O 0 2.8373358418321004e-06
and O 0 4.6890445446479134e-06
severely O 0 0.06909666955471039
affected O 0 3.071103856200352e-05
patients O 0 1.860443808254786e-05
, O 0 1.637301920709433e-07
however O 0 7.101972698819736e-08
, O 0 5.065338370968675e-08
complete O 0 1.895091230608159e-07
methylation O 0 6.76160368584533e-07
of O 0 2.0555365409791193e-08
these O 0 1.536055904693967e-08
restriction O 0 9.485886209859018e-08
sites O 0 3.897941667219129e-07
was O 0 3.7282848097675014e-07
found O 0 1.044379374093296e-07
in O 0 5.606284148029772e-08
the O 0 1.4633354794568731e-07
mutated O 0 9.684609722171444e-06
allele O 0 1.008367780741537e-05
. O 0 3.833197297353763e-06

In O 0 2.22012386075221e-06
most O 0 2.2484256589905272e-07
of O 0 1.321928806419237e-07
these O 0 3.5338641168891627e-07
patients O 0 5.9558660723268986e-06
, O 0 9.528390876312187e-08
the O 0 8.67457430331342e-08
onset O 0 0.000189999642316252
of O 0 1.546865860291291e-06
the O 0 0.00012066183990100399
disease O 1 0.8109801411628723
was O 0 0.18291588127613068
congenital O 1 0.9999569654464722
. O 0 0.0001473593874834478

Preliminary O 0 5.8663328672992066e-05
in O 0 5.887236511625815e-06
vivo O 0 0.0003683386603370309
footprinting O 0 0.01489270105957985
data O 0 5.990105819364544e-06
gave O 0 1.478032800150686e-06
evidence O 0 4.64369691144384e-07
for O 0 8.476392565626156e-08
protein O 0 5.483134941641765e-07
- O 0 2.5036326405825093e-05
DNA O 0 2.057797928500804e-06
contact O 0 1.730559660018116e-07
in O 0 2.8605493085365197e-08
normal O 0 1.3115202079916344e-07
genes O 0 7.035557558765504e-08
at O 0 9.000125800184833e-08
an O 0 1.7592368450891627e-08
Sp1 O 0 5.083717496745521e-06
consensus O 0 6.405679187082569e-08
binding O 0 1.5773161976539996e-07
site O 0 3.310276781576249e-07
upstream O 0 1.0514388293358934e-07
of O 0 9.976373505082847e-09
the O 0 4.347290172290741e-08
CTG O 0 6.578674219781533e-05
repeat O 0 7.546093456767267e-07
and O 0 2.8470502400068654e-08
for O 0 1.8064156392938457e-08
a O 0 7.026223869388559e-08
significant O 0 2.1119022619586758e-07
reduction O 0 2.4472808490827447e-07
of O 0 1.0845830011874114e-08
this O 0 1.3052658509593584e-08
interaction O 0 5.2838018405054754e-08
in O 0 4.4936712129128864e-08
cells O 0 5.817610713165777e-07
with O 0 6.42849400378509e-08
a O 0 3.570987985312968e-07
hypermethylated O 0 0.0013634981587529182
DMPK O 0 0.001331197563558817
gene O 0 1.6680796761647798e-06
. O 0 4.358399223747256e-07
. O 0 2.362522764087771e-06

The O 0 0.00010025464871432632
hemochromatosis B-Disease 1 0.9998544454574585
gene O 0 2.7857127861352637e-05
product O 0 1.2113157936255448e-05
complexes O 0 1.1346163773851003e-05
with O 0 7.515900790622254e-08
the O 0 6.972915400638158e-08
transferrin O 0 4.362723120721057e-05
receptor O 0 9.763040225152508e-07
and O 0 1.9534269313226105e-07
lowers O 0 2.6579123186820652e-06
its O 0 5.408360692626957e-08
affinity O 0 3.5684891486198467e-07
for O 0 1.1170285318939932e-07
ligand O 0 5.277977834339254e-06
binding O 0 6.23035748503753e-06
. O 0 4.364402684586821e-06

We O 0 4.336748315836303e-05
recently O 0 2.96231792162871e-05
reported O 0 1.3883430938221863e-06
the O 0 2.5651189616837655e-08
positional O 0 9.837895049713552e-07
cloning O 0 3.1252864118869184e-06
of O 0 1.360590289323227e-07
a O 0 7.58033877445996e-07
candidate O 0 9.931010936270468e-06
gene O 0 1.0492552974028513e-05
for O 0 0.0004522251256275922
hereditary B-Disease 1 0.9999986886978149
hemochromatosis I-Disease 1 0.9999998807907104
called O 0 0.17519207298755646
HFE O 1 0.9825423955917358
. O 0 6.80178272887133e-05

The O 0 4.3355589696147945e-06
gene O 0 5.905004854867002e-06
product O 0 3.014497906406177e-06
, O 0 2.051504850442143e-07
a O 0 7.079467678750007e-08
member O 0 6.088140480642323e-08
of O 0 2.8573756694072472e-08
the O 0 2.100565268392529e-07
major O 0 1.2444871572370175e-05
histocompatibility O 0 0.4512750506401062
complex O 0 2.525873605918605e-05
class O 0 2.865950818886631e-06
I O 0 3.7246636566123925e-06
- O 0 1.646384953346569e-05
like O 0 9.488634304943844e-07
family O 0 3.7553445508820005e-07
, O 0 2.0952475665581005e-07
was O 0 8.130460855682031e-07
found O 0 1.2474386323901854e-07
to O 0 2.5423334548690946e-08
have O 0 2.545613497773047e-08
a O 0 5.71116913761216e-08
mutation O 0 2.3871496068750275e-07
, O 0 2.0515106768925762e-07
Cys O 0 0.00010859297617571428
- O 0 1.6348976714652963e-05
282 O 0 5.765208243246889e-06
- O 0 0.00021353093325160444
- O 0 0.00019405064813327044
> O 0 1.443500877940096e-05
Tyr O 0 8.458754746243358e-05
( O 0 1.6806303904104425e-07
C282Y O 0 2.323077978871879e-06
) O 0 2.0749364892935773e-08
, O 0 8.972766529780074e-09
in O 0 1.7702266319474802e-08
85 O 0 2.385147013228561e-07
% O 0 6.54314220582819e-08
of O 0 1.6185262552426138e-07
patient O 0 2.9110329705872573e-05
chromosomes O 0 2.1711930457968265e-05
. O 0 7.845191248634364e-06

This O 0 9.149807738140225e-06
mutation O 0 1.5121631804504432e-05
eliminates O 0 1.5873220036155544e-05
the O 0 4.760960337080178e-07
ability O 0 2.8305689170338155e-07
of O 0 1.3252120822926372e-07
HFE O 0 0.0009118274901993573
to O 0 1.4328369957183895e-07
associate O 0 4.288132515739562e-07
with O 0 1.436012126987407e-07
beta2 O 0 0.003484629560261965
- O 0 0.018269022926688194
microglobulin O 0 0.0031533977016806602
( O 0 1.2689815775956959e-07
beta2m O 0 2.7261601644568145e-05
) O 0 4.87991833608703e-08
and O 0 6.306464683802915e-08
prevents O 0 9.764454489413765e-07
cell O 0 3.911763269570656e-05
- O 0 0.00015233384328894317
surface O 0 5.3519801440415904e-05
expression O 0 1.8170122757510399e-06
. O 0 3.1975303045328474e-06

A O 0 2.082151513604913e-05
second O 0 5.9884673646593e-06
mutation O 0 5.310410870151827e-06
that O 0 2.067896787139034e-07
has O 0 2.680593524928554e-07
no O 0 1.8292057291091623e-07
effect O 0 3.0093943337305973e-07
on O 0 9.194989729621739e-07
beta2m O 0 0.00038777917507104576
association O 0 4.4540348653754336e-07
, O 0 3.023392025625071e-07
H63D O 0 0.0025372111704200506
, O 0 4.457383511180524e-07
was O 0 1.4777425576539827e-06
found O 0 2.2969169322095695e-07
in O 0 1.1824978329855185e-08
eight O 0 2.7105306443786503e-08
out O 0 1.6433146399208454e-08
of O 0 4.356495253432513e-08
nine O 0 2.7857865916303126e-06
patients O 0 4.725667167804204e-06
heterozygous O 0 3.028363835255732e-07
for O 0 6.471033486832312e-08
the O 0 3.352023156821815e-07
C282Y O 0 7.504203676944599e-05
mutant O 0 2.4357641450478695e-05
. O 0 4.021064796688734e-06

In O 0 4.759380317409523e-06
this O 0 5.140677785675507e-07
report O 0 5.980210175948741e-07
, O 0 1.2269141791421134e-07
we O 0 2.751078831408904e-08
demonstrate O 0 1.458765126471917e-07
in O 0 2.4954152522127515e-08
cultured O 0 4.824082679988351e-06
293 O 0 8.220652489399072e-06
cells O 0 2.946408585557947e-06
overexpressing O 0 5.84083391004242e-05
wild O 0 5.650605544360587e-06
- O 0 5.4407639254350215e-05
type O 0 4.305229595047422e-06
or O 0 2.1064792576908076e-07
mutant O 0 3.908292910637101e-06
HFE O 0 7.240263948915526e-05
proteins O 0 1.210939899465302e-07
that O 0 2.2283504819142763e-08
both O 0 1.4290196581612236e-08
the O 0 2.825918166138308e-08
wild O 0 1.5303671716537792e-06
- O 0 5.910828986088745e-05
type O 0 6.3908119045663625e-06
and O 0 6.054396521903982e-07
H63D O 0 0.01032502856105566
HFE O 0 0.0004207634774502367
proteins O 0 1.42681827242086e-07
form O 0 7.265677481882449e-08
stable O 0 1.0557085943219136e-06
complexes O 0 1.5275093119271332e-06
with O 0 8.740158818909549e-08
the O 0 2.497006050816708e-07
transferrin O 0 0.0005414619226939976
receptor O 0 7.119608198991045e-06
( O 0 6.361748319250182e-07
TfR O 0 2.6910311134997755e-05
) O 0 3.1260802302313095e-07
. O 0 1.6045239590312121e-06

The O 0 2.0482748368522152e-05
C282Y O 0 0.0005911863408982754
mutation O 0 2.2984007955528796e-05
nearly O 0 2.3157983832788887e-06
completely O 0 2.2987890133663313e-06
prevents O 0 8.318913273797079e-07
the O 0 1.0426954588638182e-07
association O 0 1.3621287564546947e-07
of O 0 2.921099806485472e-08
the O 0 1.7245776007257518e-07
mutant O 0 1.801649523258675e-05
HFE O 0 0.0006657404010184109
protein O 0 6.544035500155587e-07
with O 0 1.976225263433662e-07
the O 0 1.4163589412419242e-06
TfR O 0 0.0005772705771960318
. O 0 1.070481630449649e-05

Studies O 0 3.581307828426361e-05
on O 0 8.526977580913808e-06
cell O 0 0.0002605866175144911
- O 0 0.00016131476149894297
associated O 0 1.7097993350034812e-06
transferrin O 0 1.3404256606008857e-05
at O 0 1.5842344680550013e-07
37 O 0 3.037921203485894e-07
degrees O 0 5.845345185662154e-07
C O 0 6.545791165990522e-06
suggest O 0 1.9873799317338126e-07
that O 0 1.0525861959820304e-08
the O 0 3.1866477456787834e-08
overexpressed O 0 5.286793566483539e-06
wild O 0 9.22259175695217e-07
- O 0 3.5541641409508884e-05
type O 0 3.906377514795167e-06
HFE O 0 3.611608917708509e-05
protein O 0 1.7215425884842261e-07
decreases O 0 2.2608105609833729e-07
the O 0 2.2584222492127992e-08
affinity O 0 3.4507911550463177e-07
of O 0 5.4375497882119816e-08
the O 0 4.264524022801197e-07
TfR O 0 4.541076850728132e-05
for O 0 1.0979726994264638e-06
transferrin O 0 0.0010314327664673328
. O 0 1.2908960343338549e-05

The O 0 2.7329597287462093e-05
overexpressed O 0 0.0006256491760723293
H63D O 0 0.0007632995257154107
protein O 0 1.939012463481049e-06
does O 0 3.2972238273032417e-07
not O 0 3.406420390206222e-08
have O 0 1.3300557100137667e-08
this O 0 8.58676507675682e-09
effect O 0 7.762945131162269e-08
, O 0 2.1817269768575898e-08
providing O 0 2.0363488673069696e-08
the O 0 8.132670537008835e-09
first O 0 8.265910622640149e-09
direct O 0 3.30313980612118e-08
evidence O 0 3.380208397629758e-07
for O 0 5.323994400896481e-08
a O 0 4.820444701181259e-07
functional O 0 3.5058928915532306e-06
consequence O 0 7.83340055932058e-07
of O 0 2.0518297105809324e-07
the O 0 1.6179906197066884e-06
H63D O 0 0.02167944237589836
mutation O 0 1.0884222319873516e-05
. O 0 6.779930117772892e-06

Addition O 0 1.4604158423026092e-05
of O 0 2.394272769379313e-06
soluble O 0 7.07585277268663e-05
wild O 0 1.0442600796523038e-05
- O 0 0.00042884753202088177
type O 0 0.00011478507803985849
HFE O 0 0.01187941525131464
/ O 0 0.00026521438849158585
beta2m O 0 0.0002998017589561641
heterodimers O 0 1.532025999040343e-05
to O 0 1.0711647746575181e-07
cultured O 0 4.5084643716108985e-06
cells O 0 7.842265290491923e-07
also O 0 5.3924775755831433e-08
decreased O 0 1.3678334198630182e-06
the O 0 5.207145648000733e-08
apparent O 0 3.290125960120349e-06
affinity O 0 2.0607858175480942e-07
of O 0 3.3406362121013444e-08
the O 0 8.988614297322783e-08
TfR O 0 5.4574124987993855e-06
for O 0 1.3121902675550245e-08
its O 0 1.726339249330522e-08
ligand O 0 2.2838810309622204e-07
under O 0 1.6681386227901385e-07
steady O 0 4.44083752881852e-06
- O 0 2.703434438444674e-05
state O 0 1.6809190128697082e-07
conditions O 0 6.8387384999368805e-06
, O 0 4.0294992231793e-08
both O 0 6.593590562431473e-09
in O 0 1.5798779173792354e-08
293 O 0 1.4961998431317625e-06
cells O 0 2.946061385955545e-07
and O 0 1.0892146207197584e-07
in O 0 7.00399823472253e-07
HeLa O 0 0.008211766369640827
cells O 0 1.164835975941969e-05
. O 0 3.2734135402279207e-06

Furthermore O 0 3.950477548642084e-05
, O 0 1.0038716027338523e-06
at O 0 1.5577778356146155e-07
4 O 0 2.740056288530468e-07
degrees O 0 7.081263220243272e-07
C O 0 2.740057789196726e-05
, O 0 4.2191835802896094e-08
the O 0 2.742800475630247e-08
added O 0 1.9803420059361088e-07
soluble O 0 1.6406889926656731e-06
complex O 0 4.508962376803538e-07
of O 0 2.538845080835017e-07
HFE O 0 0.036973774433135986
/ O 0 4.211768464301713e-05
beta2m O 0 6.113552080933005e-05
inhibited O 0 1.3846671436112956e-06
binding O 0 1.9863946931764076e-07
of O 0 9.944745471557326e-08
transferrin O 0 4.356918725534342e-05
to O 0 3.2632883062433393e-07
HeLa O 0 0.0006211101426742971
cell O 0 4.465793972485699e-05
TfR O 0 1.8914286556537263e-05
in O 0 1.0376363945852063e-07
a O 0 5.061837669018132e-07
concentration O 0 7.338376599363983e-05
- O 0 0.00027315804618410766
dependent O 0 5.399143446993548e-06
manner O 0 4.758658633363666e-06
. O 0 4.4572402657649945e-06

Scatchard O 0 0.0005384795949794352
plots O 0 2.561050860094838e-05
of O 0 3.614066770296631e-07
these O 0 1.2025205364807334e-07
data O 0 4.499108570144017e-07
indicate O 0 3.7095730931469006e-07
that O 0 1.945419114690594e-08
the O 0 4.0634120068716584e-08
added O 0 7.561466190963984e-07
heterodimer O 0 2.2562308004125953e-05
substantially O 0 2.2549095319845947e-06
reduced O 0 2.6195814939455886e-07
the O 0 2.0958664137538108e-08
affinity O 0 3.4871021625804133e-07
of O 0 3.2497692359356734e-07
TfR O 0 0.0002536671527195722
for O 0 2.6495354177313857e-06
transferrin O 0 0.004325807560235262
. O 0 2.238952583866194e-05

These O 0 3.4218385280837538e-06
results O 0 2.7970020255452255e-06
establish O 0 1.3737069366470678e-06
a O 0 6.680547812720761e-07
molecular O 0 2.803772258630488e-05
link O 0 1.3457924069371074e-05
between O 0 1.9809322111541405e-06
HFE O 0 0.15797771513462067
and O 0 5.004550303056021e-07
a O 0 1.9125684502796503e-07
key O 0 4.200647083507647e-07
protein O 0 4.88558100641967e-08
involved O 0 1.0850219922531323e-07
in O 0 1.0549622686539806e-07
iron O 0 4.167904990026727e-05
transport O 0 4.5408837650029454e-06
, O 0 6.755107762046464e-08
the O 0 2.715084157500769e-08
TfR O 0 1.1155961146869231e-05
, O 0 4.6267043529724106e-08
and O 0 3.716094809647075e-08
raise O 0 1.6165795102551783e-07
the O 0 1.588871256785751e-08
possibility O 0 1.9482064317344339e-07
that O 0 2.3375282154347587e-08
alterations O 0 1.5892613873802475e-06
in O 0 5.304947592321696e-08
this O 0 1.8293937031899077e-08
regulatory O 0 2.5036615625140257e-06
mechanism O 0 4.6433646616605984e-07
may O 0 1.6095324895104568e-07
play O 0 2.0455903637639494e-08
a O 0 5.7139690312624225e-08
role O 0 7.916840871757813e-08
in O 0 6.860137347075579e-08
the O 0 4.2168429104094685e-07
pathogenesis O 0 0.006546511314809322
of O 0 0.0007226011366583407
hereditary B-Disease 1 0.9999995231628418
hemochromatosis I-Disease 1 0.9999998807907104
. O 0 8.381297811865807e-05
. O 0 3.98456359107513e-05

Genomic O 0 0.00033039425034075975
organization O 0 1.6901463823160157e-05
of O 0 1.98289421859954e-06
the O 0 2.215534095739713e-06
UBE3A O 0 0.012356490828096867
/ O 0 0.0004187228041701019
E6 O 0 0.009262563660740852
- O 0 0.02868768759071827
AP O 0 6.092705007176846e-05
gene O 0 1.5580853869323619e-06
and O 0 1.152069671661593e-06
related O 0 2.0378551198518835e-05
pseudogenes O 0 0.00022768808412365615
. O 0 1.7711165128275752e-05

The O 0 2.2054213332012296e-05
UBE3A O 0 0.0008308640099130571
gene O 0 8.774917660048231e-06
encodes O 0 1.5551713659078814e-06
the O 0 2.881660918774287e-07
E6 O 0 0.0002505713782738894
- O 0 0.003559286007657647
AP O 0 1.7373444279655814e-05
ubiquitin O 0 5.940788469160907e-06
- O 0 9.85560745903058e-06
protein O 0 1.6907372923924413e-07
ligase O 0 9.99121880340681e-07
and O 0 4.476493487004518e-08
has O 0 3.242935875391595e-08
recently O 0 2.4519977159798145e-07
been O 0 1.855291209551524e-08
shown O 0 1.8226021580858287e-08
to O 0 2.3668874860049982e-08
be O 0 5.35753940766881e-07
mutated O 0 0.0001020554918795824
in O 0 0.27756595611572266
Angelman B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
patients O 0 0.0375371091067791
who O 0 6.465909791586455e-06
lack O 0 5.1473966777848545e-06
15q11 O 0 0.000572080141864717
- O 0 0.002917555160820484
q13 O 0 0.00012798169336747378
deletions O 0 9.945474630512763e-06
or O 0 9.158800935438194e-07
chromosome O 0 9.759067324921489e-06
15 O 0 3.030900188605301e-06
paternal O 0 0.00010758524877019227
uniparental B-Disease 0 0.09852822124958038
disomy I-Disease 0 0.03166563808917999
. O 0 2.5636289137764834e-05

Previous O 0 6.704671250190586e-05
UBE3A O 0 0.0006963569903746247
cDNA O 0 5.2857183618471026e-05
analysis O 0 9.584432518749963e-06
has O 0 7.586732522213424e-07
shown O 0 3.3706092494867335e-07
a O 0 3.158137076297862e-07
coding O 0 1.2706305824394803e-05
region O 0 1.2616270623766468e-06
of O 0 1.8201778573256888e-07
approximately O 0 1.2953499890500098e-06
2 O 0 3.801329285124666e-06
. O 0 3.693310418384499e-06

6 O 0 9.145343938143924e-05
kb O 0 0.0007574474439024925
and O 0 1.4811201936026919e-06
a O 0 7.123746286197274e-07
3 O 0 3.1867443794908468e-06
- O 0 0.0013376690912991762
untranslated O 0 0.0011320447083562613
region O 0 3.825965904979967e-06
( O 0 8.78984423025031e-08
UTR O 0 3.249262590543367e-06
) O 0 9.127462341496084e-09
of O 0 1.0524315641191606e-08
< O 0 9.513219993095845e-06
50 O 0 1.6946972891673795e-07
bp O 0 3.0831602089165244e-06
, O 0 4.220463267756713e-08
whereas O 0 8.618665958692873e-08
Northern O 0 5.2747793688467937e-08
analysis O 0 6.511544370368938e-08
has O 0 5.418479531726916e-08
indicated O 0 2.055972458947508e-07
mRNA O 0 5.1288708391439286e-08
sizes O 0 1.827657314379394e-07
of O 0 2.8910573490747993e-08
5 O 0 7.796196541676181e-07
- O 0 4.68927864858415e-05
8 O 0 7.94296011008555e-06
kb O 0 0.0002846115385182202
. O 0 7.132731752790278e-06

We O 0 1.4065170034882613e-05
have O 0 5.37193500349531e-07
analyzed O 0 7.977379254953121e-07
additional O 0 1.4854117580398452e-07
cDNA O 0 1.2583491297846194e-06
clones O 0 6.2415974753093906e-06
and O 0 1.0901749192271382e-07
provide O 0 8.435249299054703e-08
evidence O 0 1.2964544282567658e-07
for O 0 3.3080706174359875e-08
an O 0 5.700938743302686e-08
additional O 0 6.528930498461705e-07
0 O 0 1.176494697574526e-05
. O 0 7.098517016856931e-06

5 O 0 2.179678085667547e-05
kb O 0 5.835722549818456e-05
of O 0 5.38012272954802e-07
5 O 0 2.1102000573591795e-06
- O 0 9.756437793839723e-05
UTR O 0 2.9035578336333856e-05
and O 0 9.499248676547722e-08
> O 0 9.252163977180317e-07
2 O 0 3.3665645560176927e-07
kb O 0 5.712568963645026e-06
of O 0 9.127796118946208e-08
3 O 0 2.3260683974513086e-06
- O 0 0.0001835637231124565
UTR O 0 0.0004240690323058516
. O 0 7.218743576231645e-06

We O 0 2.133815360139124e-05
have O 0 7.569171316390566e-07
established O 0 1.155416384790442e-07
the O 0 3.308183949002341e-08
genomic O 0 4.846100409849896e-07
organization O 0 1.197037562405967e-07
of O 0 9.454457483570877e-08
UBE3A O 0 0.00017942085105460137
and O 0 5.9172837296728176e-08
the O 0 1.4436103867865313e-08
sequence O 0 1.0045020104598734e-07
of O 0 1.7454006240313902e-07
intron O 0 0.0021515388507395983
- O 0 0.0003013877139892429
exon O 0 9.474913531448692e-05
borders O 0 8.227036232710816e-06
. O 0 4.741331395052839e-06

We O 0 1.3486935131368227e-05
have O 0 8.709163239473128e-07
also O 0 2.3115366332149279e-07
mapped O 0 7.154559170885477e-06
two O 0 6.627585946716863e-08
highly O 0 1.2001649452031415e-07
homologous O 0 4.815730676455132e-07
processed O 0 6.235239311536134e-07
pseudogenes O 0 3.2726238714531064e-06
, O 0 1.8911445920366532e-07
UBE3AP1 O 0 0.00012376377708278596
and O 0 3.8170955463101564e-07
UBE3AP2 O 0 0.0001579447853146121
, O 0 4.6253987306954514e-08
to O 0 7.46597539347249e-09
chromosomes O 0 1.2909481483802665e-07
2 O 0 2.0627933849937108e-07
and O 0 6.983736255961048e-08
21 O 0 1.9249492311246286e-07
, O 0 5.116823231787748e-08
respectively O 0 3.0058404831834196e-07
, O 0 1.4227568101432553e-07
and O 0 1.0894099489178188e-07
determined O 0 4.4007839505866286e-07
their O 0 7.208833352478905e-08
genomic O 0 6.709869467158569e-06
organization O 0 3.5647444747155532e-06
. O 0 3.010573436768027e-06

These O 0 3.460457492110436e-06
results O 0 3.338825536047807e-06
will O 0 1.864725049927074e-07
form O 0 3.893208244676316e-08
the O 0 9.084769381217939e-09
basis O 0 2.797585807456926e-08
for O 0 2.64836259589174e-08
studies O 0 2.95620914414485e-08
of O 0 5.017596649281586e-08
mutation O 0 9.416750117452466e-07
and O 0 2.037064206206196e-07
imprinting O 0 2.9999522666912526e-05
of O 0 4.826940312341321e-06
UBE3A O 0 0.025737648829817772
. O 0 1.1052236914110836e-05

Mutation O 0 0.00015937548596411943
spectrum O 0 0.0001716993428999558
and O 0 1.0132424904440995e-05
genotype O 0 0.0006651271251030266
- O 0 0.0007584235281683505
phenotype O 0 3.273546462878585e-05
analyses O 0 2.2606847778661177e-05
in O 0 3.701616878970526e-05
Cowden B-Disease 1 0.9998722076416016
disease I-Disease 0 0.01356600970029831
and O 0 7.580934470752254e-05
Bannayan B-Disease 1 0.9995489716529846
- I-Disease 1 0.9999953508377075
Zonana I-Disease 1 0.9999980926513672
syndrome I-Disease 1 0.9999599456787109
, O 0 5.6244343795697205e-06
two O 0 3.164535519317724e-05
hamartoma B-Disease 1 0.9997426867485046
syndromes I-Disease 1 0.8876093626022339
with O 0 2.9472794267348945e-05
germline O 0 0.4890214204788208
PTEN O 0 0.37398284673690796
mutation O 0 8.684992644703016e-05
. O 0 2.168291757698171e-05

The O 0 7.971122249728069e-05
tumour B-Disease 1 0.9992372989654541
suppressor O 0 0.0019982594531029463
gene O 0 6.346630834741518e-05
PTEN O 0 0.002345909597352147
, O 0 7.945141646814591e-07
which O 0 1.3074340188268252e-07
maps O 0 4.662405899580335e-06
to O 0 1.5974943607943715e-06
10q23 O 0 0.0001872920838650316
. O 0 6.3547358877258375e-06

3 O 0 9.96140170173021e-06
and O 0 6.237154366317554e-07
encodes O 0 4.4213635419509956e-07
a O 0 1.7131866059116874e-07
403 O 0 6.91765421834134e-07
amino O 0 2.2629677687291405e-07
acid O 0 1.3799699161154422e-07
dual O 0 2.384678623457148e-07
specificity O 0 6.824208753641869e-07
phosphatase O 0 8.463289123028517e-05
( O 0 8.176347421340324e-08
protein O 0 7.638919186092608e-08
tyrosine O 0 7.690289294259856e-07
phosphatase O 0 3.5625864256871864e-05
; O 0 9.930283084713665e-08
PTPase O 0 7.134337465686258e-06
) O 0 1.8654182198929448e-08
, O 0 2.0019125912540403e-08
was O 0 1.4915697477135836e-07
shown O 0 6.225150883665265e-08
recently O 0 3.0287336016954214e-07
to O 0 1.9395208994410496e-08
play O 0 2.9784690269707426e-08
a O 0 9.409050960584864e-08
broad O 0 5.728565156459808e-06
role O 0 6.499893174805038e-07
in O 0 7.31982822799182e-07
human O 0 1.2035055078740697e-05
malignancy B-Disease 1 0.5024938583374023
. O 0 2.5223205739166588e-05

Somatic O 0 0.0026902398094534874
PTEN O 0 0.014077572152018547
deletions O 0 0.0004352155374363065
and O 0 1.0559116162767168e-05
mutations O 0 9.73141777649289e-06
were O 0 6.373043106577825e-07
observed O 0 6.816260338382563e-07
in O 0 2.3935004378472513e-07
sporadic B-Disease 0 0.0002602511958684772
breast I-Disease 0 0.35474714636802673
, I-Disease 0 1.1564261512830853e-05
brain I-Disease 0 0.004634796641767025
, I-Disease 0 5.733994839829393e-05
prostate I-Disease 1 0.9984521865844727
and I-Disease 0 0.41210874915122986
kidney I-Disease 1 0.9999876022338867
cancer I-Disease 1 0.9718753695487976
cell O 0 0.0036003978457301855
lines O 0 1.2303840776439756e-05
and O 0 2.9387487643361965e-07
in O 0 1.282583923511993e-07
several O 0 2.3387931946672325e-07
primary O 0 0.0001286340702790767
tumours B-Disease 1 0.9920680522918701
such O 0 9.127802513830829e-07
as O 0 3.1365758331958205e-05
endometrial B-Disease 1 0.9998955726623535
carcinomas I-Disease 1 0.9999994039535522
, O 1 0.9957713484764099
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9992955923080444
thyroid B-Disease 1 0.9999990463256836
tumours I-Disease 1 0.999992847442627
. O 0 0.0003495512355584651

In O 0 6.118213605077472e-06
addition O 0 1.9259423424955457e-06
, O 0 8.88289207523485e-07
PTEN O 0 0.000859241874422878
was O 0 4.45368823420722e-06
identified O 0 6.527661184918543e-07
as O 0 2.2455319381720074e-08
the O 0 4.5136687276681187e-08
susceptibility O 0 6.301550001808209e-06
gene O 0 3.602133915592276e-07
for O 0 4.3561882989706646e-07
two O 0 3.675741027109325e-05
hamartoma B-Disease 1 0.9999598264694214
syndromes I-Disease 1 0.9999669790267944
Cowden B-Disease 1 0.999992847442627
disease I-Disease 1 0.5356760621070862
( O 0 1.209401943924604e-06
CD B-Disease 0 8.64472021930851e-05
; O 0 2.2796775738243014e-06
MIM O 0 0.0007233076612465084
158350 O 0 3.233688767068088e-05
) O 0 6.979688293995423e-08
and O 0 1.3538236487420363e-07
Bannayan B-Disease 0 0.001223381725139916
- I-Disease 0 0.1404317170381546
Zonana I-Disease 0 0.13806888461112976
( I-Disease 0 3.6676283343695104e-07
BZS I-Disease 0 1.9238281311118044e-05
) I-Disease 0 5.799203961487365e-08
or I-Disease 0 1.4290324656940356e-07
Ruvalcaba I-Disease 0 7.602290133945644e-05
- I-Disease 0 0.00019919508486054838
Riley I-Disease 0 8.130814967444167e-05
- I-Disease 1 0.9569403529167175
Smith I-Disease 1 0.9025459885597229
syndrome I-Disease 1 0.9888976216316223
( O 0 1.7915397165779723e-06
MIM O 0 0.0024338746443390846
153480 O 0 0.00019522129150573164
) O 0 1.97542749447166e-06
. O 0 3.1714093893242534e-06

Constitutive O 0 0.0002665368374437094
DNA O 0 0.00010274232045048848
from O 0 1.3268702332425164e-06
37 O 0 1.7124201576734777e-06
CD B-Disease 0 1.2947079994773958e-05
families O 0 1.1176140333191142e-06
and O 0 2.3884155098130577e-07
seven O 0 1.111820438381983e-06
BZS B-Disease 0 0.0008860910311341286
families O 0 5.583979145740159e-07
was O 0 9.170442467620887e-07
screened O 0 5.280132427287754e-06
for O 0 1.4092678384258761e-06
germline O 0 0.0046057444997131824
PTEN O 0 0.03330051526427269
mutations O 0 3.2044947147369385e-05
. O 0 8.287054697575513e-06

PTEN O 0 0.20704053342342377
mutations O 0 0.0002082909777527675
were O 0 5.2240543482184876e-06
identified O 0 4.597087354341056e-06
in O 0 1.2912904878703557e-07
30 O 0 6.653664996747466e-08
of O 0 2.3278289518202655e-08
37 O 0 8.025820079637924e-07
( O 0 4.847024470677752e-08
81 O 0 7.425531975968624e-07
% O 0 4.034544431874565e-08
) O 0 2.301538515325774e-08
CD B-Disease 0 5.402413989941124e-06
families O 0 4.586563875363936e-07
, O 0 7.288245740255661e-08
including O 0 1.5737433045615035e-07
missense O 0 1.4042961993254721e-05
and O 0 5.496747235156363e-07
nonsense O 0 1.777848410711158e-05
point O 0 2.0947170469298726e-06
mutations O 0 7.90982085163705e-07
, O 0 8.1340999713575e-08
deletions O 0 8.638824624540575e-07
, O 0 1.733053665020634e-07
insertions O 0 2.6763123059936333e-06
, O 0 2.375753069827624e-07
a O 0 5.990586942061782e-07
deletion O 0 1.834845716075506e-05
/ O 0 7.132114842534065e-05
insertion O 0 5.857186351931887e-06
and O 0 1.2264384849913768e-06
splice O 0 0.0001494958996772766
site O 0 2.435401620459743e-05
mutations O 0 1.3913895600126125e-05
. O 0 7.940483556012623e-06

These O 0 2.825476258294657e-06
mutations O 0 5.76151524001034e-06
were O 0 3.4860113373724744e-07
scattered O 0 1.6797986290839617e-06
over O 0 1.0803961458805134e-07
the O 0 3.101261469851124e-08
entire O 0 1.6631682342449494e-07
length O 0 5.934910518590186e-07
of O 0 2.4431534484392614e-07
PTEN O 0 0.004081340506672859
, O 0 2.493565034455969e-07
with O 0 5.5878153659705276e-08
the O 0 3.477914845007035e-08
exception O 0 4.356578386932597e-08
of O 0 7.346946606645588e-09
the O 0 1.9399795547769827e-08
first O 0 5.8978805839160486e-08
, O 0 1.32273100916791e-07
fourth O 0 1.1934233725696686e-06
and O 0 3.01654608847457e-07
last O 0 1.7232226809937856e-06
exons O 0 2.366347507631872e-05
. O 0 3.584435035008937e-06

A O 0 3.556202136678621e-05
hot O 0 9.894550748867914e-05
spot O 0 1.4482551705441438e-05
for O 0 1.207038621942047e-06
PTEN O 0 0.0010778516298159957
mutation O 0 1.8633612626217655e-06
in O 0 1.1054770965301941e-07
CD B-Disease 0 1.307610364165157e-05
was O 0 4.016618731839117e-06
identified O 0 1.465049081161851e-06
in O 0 3.7815251374695436e-08
exon O 0 2.2506255845655687e-06
5 O 0 1.5268408048996207e-07
that O 0 1.2098474222455025e-08
contains O 0 2.5035197026568312e-08
the O 0 2.7794545331971676e-08
PTPase O 0 7.828748493921012e-06
core O 0 9.507384106655081e-07
motif O 0 1.4676891169074224e-07
, O 0 1.0166816721834948e-08
with O 0 5.9191322954177394e-09
13 O 0 3.691419081519598e-08
of O 0 1.3649200880649914e-08
30 O 0 1.7802312868298031e-07
( O 0 2.5571370798616044e-08
43 O 0 2.7868259167007636e-07
% O 0 4.463381131358801e-08
) O 0 2.0684089108158332e-08
CD B-Disease 0 2.732816938078031e-06
mutations O 0 1.217590806845692e-06
identified O 0 1.9476361501347128e-07
in O 0 5.2180020304604113e-08
this O 0 2.262328848701145e-07
exon O 0 0.00011999358684988692
. O 0 1.0811442734848242e-05

Seven O 0 1.9391218302189372e-05
of O 0 7.979920724210388e-07
30 O 0 1.250756668014219e-06
( O 0 1.684952337654977e-07
23 O 0 5.112448207000853e-07
% O 0 1.1267368194012306e-07
) O 0 1.509221725370935e-08
were O 0 1.8768600895668897e-08
within O 0 8.224360747988158e-09
the O 0 1.3646545227175011e-08
core O 0 8.180400641322194e-07
motif O 0 1.1558439894088224e-07
, O 0 1.4479287102631133e-08
the O 0 1.0194273869501558e-08
majority O 0 9.552702096016219e-08
( O 0 8.459542399918973e-09
five O 0 8.848124011251457e-09
of O 0 8.505393722657573e-09
seven O 0 5.8177722195296155e-08
) O 0 7.838465876375267e-09
of O 0 4.213720927737086e-09
which O 0 4.227488759056541e-08
were O 0 2.431633276955836e-07
missense O 0 1.5351384718087502e-05
mutations O 0 5.937769174124696e-07
, O 0 1.6818634662740806e-07
possibly O 0 4.164032816333929e-07
pointing O 0 1.8365715277468553e-06
to O 0 2.8069875313008197e-08
the O 0 3.487280864078457e-08
functional O 0 3.002814707997459e-07
significance O 0 2.1651766246577608e-07
of O 0 1.531450521952138e-07
this O 0 4.2094654872926185e-07
region O 0 1.1112014362879563e-05
. O 0 6.6253192017029505e-06

Germline O 0 0.16750884056091309
PTEN O 0 0.3237674832344055
mutations O 0 0.0002977372787427157
were O 0 5.4308975450112484e-06
identified O 0 3.5599000511865597e-06
in O 0 6.877509406422178e-08
four O 0 3.432403872238865e-08
of O 0 4.539293385619203e-08
seven O 0 4.780496851708449e-07
( O 0 1.1595712834377991e-07
57 O 0 2.735836460487917e-06
% O 0 2.492409691967623e-07
) O 0 1.2577572761074407e-07
BZS B-Disease 0 0.00014329375699162483
families O 0 1.5949733551678946e-06
studied O 0 3.3474148040113505e-06
. O 0 3.920993549400009e-06

Interestingly O 0 0.0004663263098336756
, O 0 4.89193052999326e-06
none O 0 8.447595973848365e-07
of O 0 5.5399439702341624e-08
these O 0 5.507777700586303e-08
mutations O 0 1.015301904772059e-06
was O 0 2.8917918371007545e-07
observed O 0 2.560551877195394e-07
in O 0 4.2933088195695746e-08
the O 0 1.8705867432800005e-07
PTPase O 0 0.0002617270511109382
core O 0 1.895784225780517e-05
motif O 0 9.752545338415075e-06
. O 0 3.4047425288008526e-06

It O 0 4.296447968954453e-06
is O 0 4.6407791387537145e-07
also O 0 7.71447261627145e-08
worthy O 0 3.482661838916101e-07
of O 0 1.6488441190176673e-07
note O 0 2.25834423872584e-06
that O 0 3.139206938840289e-08
a O 0 4.9245844735423816e-08
single O 0 5.44326667295536e-07
nonsense O 0 1.0554414075159002e-05
point O 0 4.336284860073647e-07
mutation O 0 1.9011987717476586e-07
, O 0 6.312782829809294e-08
R233X O 0 9.159516594081651e-06
, O 0 9.085744068215718e-08
was O 0 3.1197515681924415e-07
observed O 0 1.8807776314133662e-07
in O 0 2.025966239216359e-08
the O 0 4.155442923092778e-08
germline O 0 2.4616143491584808e-05
DNA O 0 2.62841535914049e-06
from O 0 5.272054082183786e-08
two O 0 3.497659406548337e-08
unrelated O 0 2.2818614979769336e-06
CD B-Disease 0 1.8724353139987215e-05
families O 0 7.679039981667302e-07
and O 0 3.378767701178731e-07
one O 0 1.1842763569802628e-06
BZS B-Disease 0 0.003239647252485156
family O 0 1.4993200238677673e-05
. O 0 8.469170097669121e-06

Genotype O 0 0.009521473199129105
- O 0 0.00444511603564024
phenotype O 0 7.738143904134631e-05
studies O 0 7.40061864235031e-07
were O 0 1.5705631994933356e-07
not O 0 3.264071679609515e-08
performed O 0 1.0851627507690864e-07
on O 0 4.627710481486247e-08
this O 0 1.8770391463363012e-08
small O 0 2.068490374540488e-07
group O 0 4.2210112383145315e-07
of O 0 5.646165845973883e-07
BZS B-Disease 0 0.0019403306068852544
families O 0 3.3083940707001602e-06
. O 0 5.214567408984294e-06

However O 0 2.79825344478013e-05
, O 0 4.34396451964858e-06
genotype O 0 0.00010623895650496706
- O 0 0.00016838697774801403
phenotype O 0 6.653996479144553e-06
analysis O 0 4.648739206913888e-07
inthe O 0 3.697421925608069e-05
group O 0 4.552932750812033e-07
of O 0 6.223025650342606e-08
CD B-Disease 0 5.696470179827884e-05
families O 0 1.6121745147756883e-06
revealed O 0 3.859571279463125e-06
two O 0 5.216151421905124e-08
possible O 0 1.6257538959507656e-07
associations O 0 2.854592118239907e-08
worthy O 0 8.741059076555757e-08
of O 0 2.549558963949039e-08
follow O 0 2.543461903314892e-07
- O 0 2.6237165002385154e-05
up O 0 2.2729905424512253e-07
in O 0 6.051752166058577e-08
independent O 0 3.5121533414894657e-07
analyses O 0 4.3176510189368855e-06
. O 0 4.89862986796652e-06

The O 0 3.3374567465216387e-06
first O 0 1.2371484672257793e-06
was O 0 1.2583874422489316e-06
an O 0 5.0142482166393165e-08
association O 0 3.49662286680541e-07
noted O 0 3.847183620564465e-07
in O 0 2.287001699130542e-08
the O 0 4.7493507793205936e-08
group O 0 2.4047389501902217e-07
of O 0 4.5544787496965e-08
CD B-Disease 0 7.67885212553665e-05
families O 0 7.703077244514134e-06
with O 0 0.0003899518633261323
breast B-Disease 1 0.9999184608459473
disease I-Disease 0 0.11003832519054413
. O 0 3.897973874700256e-05

A O 0 1.9917351892217994e-05
correlation O 0 1.550766683067195e-05
was O 0 1.845235487962782e-06
observed O 0 7.035684461698111e-07
between O 0 1.1070195427009821e-07
the O 0 6.426397902714598e-08
presence O 0 5.977119599265279e-07
/ O 0 1.539962613605894e-05
absence O 0 2.973993957766652e-07
of O 0 7.332138807214506e-08
a O 0 2.9633617941726698e-06
PTEN O 0 0.025325017049908638
mutation O 0 4.80780101952405e-07
and O 0 4.575226952852063e-08
the O 0 3.699073047869206e-08
type O 0 7.2425468715664465e-06
of O 0 7.471277285731048e-07
breast O 0 0.18305140733718872
involvement O 0 4.649718539440073e-05
( O 0 1.7694859479888692e-06
unaffected O 0 0.00011108386388514191
versus O 0 0.012090259231626987
benign O 1 0.7922467589378357
versus O 1 0.7835620641708374
malignant O 1 0.999485969543457
) O 0 1.3726547877013218e-05
. O 0 1.4223502148524858e-05

Specifically O 0 2.7476960895000957e-05
and O 0 1.195470417769684e-06
more O 0 6.928119944404898e-08
directly O 0 1.6690185589141038e-07
, O 0 7.31240490381424e-08
an O 0 1.784079906030911e-08
association O 0 2.3607721288954053e-07
was O 0 1.2022306918879622e-06
also O 0 1.0259838489901085e-07
observed O 0 2.6641703243512893e-07
between O 0 3.723707919789376e-08
the O 0 2.1559637630730322e-08
presence O 0 2.988381808677332e-08
of O 0 1.673748784014606e-08
a O 0 1.6408267811129917e-06
PTEN O 0 0.052409786731004715
mutation O 0 4.42763848695904e-05
and O 0 0.002089297864586115
malignant B-Disease 1 0.999997615814209
breast I-Disease 1 0.9999711513519287
disease I-Disease 0 0.42958763241767883
. O 0 5.5076296121114865e-05

Secondly O 0 0.008873931132256985
, O 0 1.3237509847385809e-05
there O 0 9.303225851908792e-07
appeared O 0 1.0106668923981488e-06
to O 0 8.23895121015994e-08
be O 0 4.577417911377779e-08
an O 0 4.132679265467232e-08
interdependent O 0 2.14385254366789e-05
association O 0 3.659850449366786e-07
between O 0 2.3819737293706567e-07
mutations O 0 5.658434361066611e-07
upstream O 0 5.574763122240256e-07
and O 0 8.365136494603576e-08
within O 0 3.232178968914923e-08
the O 0 5.982240480761902e-08
PTPase O 0 0.00011353007721481845
core O 0 3.363825044289115e-06
motif O 0 4.169791054664529e-07
, O 0 3.816618132645999e-08
the O 0 2.9221641995036407e-08
core O 0 1.4957633993617492e-06
motif O 0 2.607530404930003e-07
containing O 0 7.709942195788244e-08
the O 0 2.4989303071265567e-08
majority O 0 1.2542608374133124e-07
of O 0 6.748577874304829e-08
missense O 0 5.247758235782385e-05
mutations O 0 1.0582720051388605e-06
, O 0 7.529416734541883e-08
and O 0 4.629317373883168e-08
the O 0 1.9561426256586856e-08
involvement O 0 2.0525283161987318e-07
of O 0 2.1974381425593492e-08
all O 0 4.1260634020545695e-08
major O 0 2.8204876798554324e-06
organ O 0 3.2987361919367686e-05
systems O 0 3.860079596051946e-05
( O 0 1.1715159331515679e-07
central O 0 1.5977778389242303e-07
nervous O 0 3.3090409488067962e-06
system O 0 2.7200967451790348e-06
, O 0 1.3636533367389347e-05
thyroid O 1 0.9598485827445984
, O 0 1.5004414308350533e-05
breast O 1 0.5000185966491699
, O 0 5.1825882110279053e-05
skin O 1 0.7836679220199585
and O 0 0.10156847536563873
gastrointestinal O 1 0.9999614953994751
tract O 1 0.9853734374046326
) O 0 1.677593718341086e-05
. O 0 2.0315817891969346e-05

However O 0 2.1988797016092576e-05
, O 0 7.022853765192849e-07
these O 0 3.7231181693186954e-08
observations O 0 1.3616794092286e-07
would O 0 6.858724788116888e-08
need O 0 2.6806031172554867e-08
to O 0 1.506725055833158e-08
be O 0 2.7833696236712058e-08
confirmed O 0 1.7498138049631962e-07
by O 0 3.132956294393807e-08
studying O 0 8.143414476080579e-08
a O 0 6.081432246674012e-08
larger O 0 1.1364384988610254e-07
number O 0 2.246273211881089e-08
of O 0 4.222057370384391e-08
CD B-Disease 0 4.057042679050937e-05
families O 0 2.999396883751615e-06
. O 0 3.964709321735427e-06

Molecular O 1 0.7132301330566406
defects O 1 0.9949238896369934
leading O 0 1.5956238712533377e-05
to O 0 4.6398275799219846e-07
human O 0 1.3637162510349299e-06
complement B-Disease 0 3.033939174201805e-05
component I-Disease 0 0.42296943068504333
C6 I-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.999968409538269
in O 0 2.484841274963401e-07
an O 0 6.38584367607109e-08
African O 0 3.4117786640308623e-07
- O 0 0.00025360958534292877
American O 0 1.4732227100466844e-06
family O 0 1.0129237125511281e-05
. O 0 1.0513227607589215e-05

Complement B-Disease 0 0.0026324826758354902
component I-Disease 1 0.8350784778594971
C6 I-Disease 1 0.9999954700469971
deficiency I-Disease 1 0.9999938011169434
( O 0 1.95665215869667e-05
C6D B-Disease 0 0.3676740825176239
) O 0 3.898130671586841e-06
was O 0 0.0001805001520551741
diagnosed O 0 0.035549480468034744
in O 0 8.221667258112575e-08
a O 0 2.5531704750392237e-07
16 O 0 7.538957902397669e-07
- O 0 1.884036828414537e-05
year O 0 3.8775942812208086e-07
- O 0 1.7715963622322306e-05
old O 0 3.1671961551182903e-06
African O 0 2.1439919350996206e-07
- O 0 3.012420165759977e-05
American O 0 6.026331789144024e-07
male O 0 4.844639988732524e-06
with O 0 0.00017785515228752047
meningococcal B-Disease 1 0.9999741315841675
meningitis I-Disease 1 0.9996312856674194
. O 0 7.72098355810158e-05

The O 0 5.884014899493195e-05
patients O 0 0.0011817951453849673
father O 0 3.261493475292809e-05
and O 0 1.1415191920605139e-06
two O 0 7.253685794239573e-07
brothers O 0 4.860886838287115e-05
also O 0 2.2890031914357678e-07
had O 0 6.633813995904347e-07
C6D B-Disease 0 0.0031714446377009153
, O 0 2.0590766780514969e-07
but O 0 1.231628061759693e-07
gave O 0 1.8780514210448018e-07
no O 0 6.436862065584137e-08
history O 0 1.3976433876905503e-07
of O 0 4.150891072640661e-06
meningitis B-Disease 1 0.9976623058319092
or O 0 2.604501105452073e-06
other O 0 3.2644011298543774e-06
neisserial B-Disease 1 0.8695163130760193
infection I-Disease 0 0.001625433680601418
. O 0 2.011248034250457e-05

By O 0 1.1579944839468226e-05
using O 0 5.190820502321003e-06
exon O 0 4.8406167479697615e-05
- O 0 1.850520675361622e-05
specific O 0 4.85351904444542e-07
polymerase O 0 1.1086673112004064e-05
chain O 0 1.1825217370642349e-05
reaction O 0 3.5233313155913493e-07
( O 0 4.746950565959196e-08
PCR O 0 1.262451519323804e-06
) O 0 4.2693660162740343e-08
/ O 0 4.6190066882445535e-07
single O 0 8.456787270461064e-08
- O 0 9.378442882734817e-06
strand O 0 1.2034777228109306e-06
conformation O 0 3.460955326772819e-07
polymorphism O 0 1.0064291018352378e-06
as O 0 2.924790543090694e-08
a O 0 3.958750838251035e-08
screening O 0 3.333132667648897e-07
step O 0 2.5531218739160977e-07
and O 0 1.9429309716656462e-08
nucleotide O 0 2.8777547456115826e-08
sequencing O 0 3.7431906463325504e-08
of O 0 7.38947303347004e-09
target O 0 1.1597051496892163e-07
exons O 0 2.0731728511691472e-07
, O 0 2.6404739728036475e-08
we O 0 1.5547612974842195e-08
determined O 0 9.922293031650042e-08
that O 0 1.4707526752033573e-08
the O 0 4.812984499835693e-08
proband O 0 0.00011449449812062085
was O 0 5.55592691853235e-07
a O 0 1.5798410402112495e-07
compound O 0 1.6629730907880003e-06
heterozygote O 0 1.7833438050729455e-06
for O 0 5.3379345388293586e-08
two O 0 3.314506784590776e-07
C6 O 0 0.002298646606504917
gene O 0 8.312803402077407e-06
mutations O 0 1.2174898074590601e-05
. O 0 6.750664397259243e-06

The O 0 4.11494511354249e-06
first O 0 1.3537722907130956e-06
, O 0 3.782413102726423e-07
1195delC O 0 6.783772278140532e-06
located O 0 5.149858566255716e-07
in O 0 8.115070926351109e-08
exon O 0 7.59873319111648e-06
7 O 0 2.397332082182402e-06
, O 0 1.4385301483343937e-07
is O 0 4.463381131358801e-08
a O 0 8.733810119565533e-08
novel O 0 7.032176085886022e-07
mutation O 0 2.8529518658615416e-07
, O 0 3.8987963080217014e-08
while O 0 2.1626686219633484e-08
the O 0 1.5746373094316368e-08
second O 0 2.6003414177466766e-07
, O 0 7.81711833042209e-08
1936delG O 0 4.3818686208396684e-06
in O 0 3.5461724223750934e-08
exon O 0 3.120583642157726e-06
12 O 0 5.925635377934668e-07
, O 0 2.1053986642982636e-07
has O 0 8.301685028300199e-08
been O 0 5.851603646078729e-08
described O 0 3.873188916259096e-07
before O 0 7.3323910498857e-08
to O 0 5.8733629515472785e-08
cause O 0 1.5303891132134595e-06
C6D B-Disease 0 0.00020853045862168074
in O 0 5.016228143972512e-08
an O 0 3.986703944747205e-08
unrelated O 0 3.5623793337435927e-06
African O 0 5.876343607269519e-07
- O 0 5.383182724472135e-05
American O 0 9.121632729147677e-07
individual O 0 1.1363836165401153e-06
. O 0 5.052610049460782e-06

Both O 0 2.8404487238731235e-05
mutations O 0 6.37860648566857e-05
result O 0 5.245181455393322e-06
in O 0 1.570799895489472e-06
premature O 0 0.0004913702723570168
termination O 0 0.0003534680581651628
codons O 0 3.4894597774837166e-05
and O 0 6.23832420387771e-06
C6 O 0 0.024882847443223
null O 0 0.0004940733197145164
alleles O 0 2.9898703360231593e-05
. O 0 8.48835043143481e-06

Allele O 0 0.00024979893350973725
- O 0 4.620993786375038e-05
specific O 0 6.500810627585452e-07
PCR O 0 6.679109901597258e-06
indicated O 0 1.5914135929051554e-06
that O 0 2.0460666050325926e-08
the O 0 5.217345488972569e-08
probands O 0 4.8164056352106854e-05
two O 0 1.7681303177141672e-07
brothers O 0 2.2222138795768842e-05
also O 0 6.610328000533627e-07
inherited O 0 2.8909147658850998e-05
the O 0 1.666327591465233e-07
1195delC O 0 5.695535946870223e-05
mutation O 0 3.8137153524075984e-07
from O 0 3.015055582977766e-08
their O 0 4.0133002698894416e-08
heterozygous O 0 1.5631516134817502e-06
mother O 0 3.997248313680757e-06
and O 0 8.845309906746479e-08
the O 0 9.144577006736654e-08
1936delG O 0 8.762967627262697e-05
mutation O 0 7.504389714085846e-07
from O 0 5.116569568031082e-08
their O 0 1.1111022502063861e-07
homozygous O 0 4.133107722736895e-06
father O 0 5.095201231597457e-06
. O 0 5.533870535145979e-07
. O 0 4.81533561469405e-06

PAX6 O 1 0.7299146056175232
mutations O 0 0.004328558221459389
reviewed O 0 0.001016569440253079
. O 0 0.00013986822159495205

Mutations O 0 0.0003126593364868313
in O 0 5.096814675198402e-06
PAX6 O 0 0.002983630169183016
are O 0 4.154255464072776e-07
responsible O 0 2.0751463125634473e-06
for O 0 3.2615770351185347e-07
human O 0 3.0310388865473215e-06
aniridia B-Disease 1 0.9997742772102356
and O 0 4.883494057139615e-06
have O 0 3.940062640594988e-07
also O 0 1.229629305044e-07
been O 0 9.793610900032945e-08
found O 0 4.81367351312656e-07
in O 0 9.54286520027381e-07
patients O 0 1.9474522559903562e-05
with O 0 7.595994247822091e-06
Peters B-Disease 1 0.9998840093612671
anomaly I-Disease 1 0.9999009370803833
, O 0 0.0014172802912071347
with O 1 0.5118832588195801
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.999998927116394
, O 0 0.005216070916503668
with O 0 0.0005500524421222508
autosomal B-Disease 0 0.1972014456987381
dominant I-Disease 0 0.008511198684573174
keratitis I-Disease 1 0.9782463312149048
, O 0 1.4684909729112405e-05
and O 0 1.123837773775449e-05
with O 0 9.446891635889187e-05
isolated B-Disease 1 0.7764430642127991
foveal I-Disease 1 0.999967098236084
hypoplasia I-Disease 1 0.9999724626541138
. O 0 9.8527452792041e-05

No O 0 2.3009273718344048e-05
locus O 0 1.9758304915740155e-05
other O 0 3.929967817839497e-07
than O 0 3.765091491914063e-07
chromosome O 0 1.0002239832829218e-05
11p13 O 0 0.00011398415517760441
has O 0 3.1689501156506594e-07
been O 0 2.3175384455953463e-07
implicated O 0 9.422164112038445e-06
in O 0 7.267755677276e-07
aniridia B-Disease 1 0.9992303848266602
, O 0 1.939104777193279e-06
and O 0 2.671344873306225e-06
PAX6 O 0 0.005470148753374815
is O 0 1.8070070950670925e-07
clearly O 0 2.1155346985324286e-07
the O 0 2.4595593117737735e-08
major O 0 7.090480380611552e-07
, O 0 1.7982104338898353e-07
if O 0 7.3391348109908e-08
not O 0 1.890296630335797e-08
only O 0 1.5175869449990387e-08
, O 0 1.0402541761322937e-07
gene O 0 6.240212542252266e-07
responsible O 0 6.399929588951636e-06
. O 0 5.595105903921649e-06

Twenty O 0 4.328926661401056e-05
- O 0 8.548235928174108e-05
eight O 0 1.2556974979816005e-06
percent O 0 1.3398864666669397e-06
of O 0 1.505392930312155e-07
identified O 0 7.550515420007287e-06
PAX6 O 0 0.002000899286940694
mutations O 0 2.3530114958703052e-06
are O 0 2.563598684446333e-07
C O 0 0.002998062176629901
- O 0 0.01711963303387165
T O 0 0.0010219382820650935
changes O 0 8.411775809236133e-08
at O 0 1.9339324808242964e-07
CpG O 0 1.075728505384177e-05
dinucleotides O 0 2.1097548597026616e-05
, O 0 5.238904776661002e-08
20 O 0 4.7820648774177243e-08
% O 0 1.362181478725688e-08
are O 0 5.073477193917597e-09
splicing O 0 1.680297145867371e-07
errors O 0 4.818266461370513e-06
, O 0 1.556620929932251e-07
and O 0 3.8370480126559414e-08
more O 0 8.775333348864933e-09
than O 0 2.3412496830133023e-08
30 O 0 1.718075282042264e-07
% O 0 1.0236519187856175e-07
are O 0 5.222303300911335e-08
deletion O 0 1.5796059642525506e-06
or O 0 2.7740742325477186e-07
insertion O 0 2.2330023057293147e-06
events O 0 1.8458621298123035e-06
. O 0 5.975750809739111e-06

There O 0 1.5646293832105584e-05
is O 0 1.8634217440194334e-06
a O 0 9.792898936211714e-07
noticeably O 0 2.732735447352752e-05
elevated O 0 3.622668009484187e-05
level O 0 2.0287897939397226e-07
of O 0 4.5601375120440935e-08
mutation O 0 4.5431130502038286e-07
in O 0 3.711999951860889e-08
the O 0 3.5668485054429766e-08
paired O 0 4.767030077346135e-07
domain O 0 1.1867302163182103e-07
compared O 0 1.3091087112115929e-06
with O 0 5.8920790024785674e-08
the O 0 3.967542383520595e-08
rest O 0 9.548767820888315e-08
of O 0 2.537140453284792e-08
the O 0 1.2189032361220598e-07
gene O 0 2.4963255782495253e-06
. O 0 3.0924659313313896e-06

Increased O 0 6.480864249169827e-05
mutation O 0 2.7241227144259028e-05
in O 0 3.911798955869017e-07
the O 0 1.659395962860799e-07
homeodomain O 0 3.1917279557092115e-05
is O 0 1.2996247278351802e-07
accounted O 0 5.358704129321268e-07
for O 0 4.1007687912042456e-08
by O 0 9.822419855254338e-08
the O 0 2.74518271226043e-07
hypermutable O 0 0.0021503996104002
CpG O 0 0.0001120851156883873
dinucleotide O 0 2.3985005100257695e-05
in O 0 2.2514080910696066e-07
codon O 0 4.479825747694122e-06
240 O 0 6.439381650125142e-06
. O 0 6.9912252911308315e-06

Very O 0 1.3159195077605546e-05
nearly O 0 1.4285175211625756e-06
all O 0 1.0908779302098992e-07
mutations O 0 1.4579768503608648e-06
appear O 0 7.16390843535919e-07
to O 0 4.794531491825182e-07
cause O 0 4.593613266479224e-05
loss O 0 1.6274758309009485e-05
of O 0 7.238814703214302e-08
function O 0 1.260408595271656e-07
of O 0 2.681001731730248e-08
the O 0 5.283761339569537e-08
mutant O 0 1.5505582950936514e-06
allele O 0 2.700453194393049e-07
, O 0 3.347313892732018e-08
and O 0 1.1715243886101234e-08
more O 0 3.849566887481615e-09
than O 0 1.5801793651348817e-08
80 O 0 7.389603240426368e-08
% O 0 1.637288882250232e-08
of O 0 2.9737631024318034e-08
exonic O 0 7.169906893977895e-05
substitutions O 0 9.645864338381216e-07
result O 0 6.197251423145644e-07
in O 0 2.7403334001974144e-07
nonsense O 0 1.9636863726191223e-05
codons O 0 1.361474278382957e-05
. O 0 3.872833985951729e-06

In O 0 7.679533155169338e-06
a O 0 1.4134888033368043e-06
gene O 0 1.1335154113112367e-06
with O 0 1.505232205545326e-07
such O 0 2.632228017773741e-07
extraordinarily O 0 0.00035756887518800795
high O 0 4.943264684698079e-06
sequence O 0 1.6517086010026105e-07
conservation O 0 1.913177669621291e-07
throughout O 0 1.2129135917859912e-08
evolution O 0 6.472095037679537e-08
, O 0 7.968257165202886e-08
there O 0 5.829368632248588e-08
are O 0 1.1244483033578945e-07
presumed O 0 0.0002262272173538804
undiscovered O 0 0.001328718732111156
missense O 0 0.00013296771794557571
mutations O 0 1.3224336044004303e-06
, O 0 6.315853795513249e-08
these O 0 8.955753472150718e-09
are O 0 8.956214436750543e-09
hypothesized O 0 1.225869681320546e-07
to O 0 1.8525684097880912e-08
exist O 0 3.720732877354749e-08
in O 0 4.0007808621567165e-08
as O 0 1.3100701323764952e-07
- O 0 0.0006394555093720555
yet O 0 3.2294603897753404e-06
unidentified O 0 9.392020729137585e-06
phenotypes O 0 7.943854143377393e-06
. O 0 7.366073759840219e-07
. O 0 4.71619523523259e-06

Genetic O 0 0.0015944306505843997
heterogeneity O 0 0.0007428458193317056
and O 0 7.88622310210485e-06
penetrance O 0 9.876808326225728e-05
analysis O 0 8.599927241448313e-07
of O 0 1.9616167890035285e-07
the O 0 6.325450385702425e-07
BRCA1 O 0 8.107758912956342e-05
and O 0 2.605395366117591e-06
BRCA2 O 0 0.00011705834185704589
genes O 0 3.4365750707365805e-06
in O 0 2.5369297873112373e-05
breast B-Disease 1 0.99968421459198
cancer I-Disease 1 0.9393681287765503
families O 0 4.576564970193431e-05
. O 0 5.648047590511851e-05

The O 0 0.003475144738331437
Breast B-Disease 1 0.9999921321868896
Cancer I-Disease 1 0.9999498128890991
Linkage O 0 0.007086530793458223
Consortium O 0 0.0005226916982792318
. O 0 3.351435952936299e-05

The O 0 3.931567334802821e-06
contribution O 0 3.1999798011383973e-06
of O 0 8.871040222402371e-07
BRCA1 O 0 0.0001591187174199149
and O 0 8.587457159592304e-06
BRCA2 O 0 0.0029424403328448534
to O 0 0.001176317106001079
inherited B-Disease 1 0.9999995231628418
breast I-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999974966049194
was O 0 0.00017834678874351084
assessed O 0 0.00011411390005378053
by O 0 4.577632068958337e-07
linkage O 0 1.2640413842746057e-05
and O 0 1.819448840478799e-07
mutation O 0 1.3513223962036136e-07
analysis O 0 5.1903974451761314e-08
in O 0 7.563731685422681e-08
237 O 0 3.76783555111615e-06
families O 0 4.0220058394879743e-07
, O 0 4.151870314217376e-08
each O 0 5.625089727345767e-09
with O 0 3.24700231146835e-08
at O 0 1.7844178046289016e-07
least O 0 2.6786658224864368e-08
four O 0 3.354146116407719e-08
cases O 0 1.284029167436529e-07
of O 0 2.5228000595234334e-06
breast B-Disease 1 0.9985328912734985
cancer I-Disease 0 0.16192834079265594
, O 0 1.3433867707135505e-07
collected O 0 2.4925950015131093e-07
by O 0 7.305043254746124e-07
the O 0 0.0001593124179635197
Breast B-Disease 1 0.9999980926513672
Cancer I-Disease 1 0.9997994303703308
Linkage O 0 0.0008641922031529248
Consortium O 0 0.00020620549912564456
. O 0 1.9056304154219106e-05

Families O 0 5.355921894079074e-05
were O 0 1.2801145885532605e-06
included O 0 3.6364323818816047e-07
without O 0 1.9731800193767413e-07
regard O 0 2.877829388125974e-07
to O 0 6.182363421203263e-08
the O 0 9.881424034574593e-08
occurrence O 0 1.2371529919619206e-05
of O 0 2.2736439859727398e-05
ovarian B-Disease 1 0.9995299577713013
or I-Disease 0 1.1502613233460579e-05
other I-Disease 0 2.8288304747547954e-06
cancers I-Disease 0 0.2488858550786972
. O 0 1.8371640180703253e-05

Overall O 0 0.0020492852199822664
, O 0 0.0007578824297524989
disease O 0 0.01457252912223339
was O 0 7.998884939297568e-06
linked O 0 2.1765372366644442e-05
to O 0 1.8696754011671146e-07
BRCA1 O 0 4.3595417082542554e-05
in O 0 1.160242817377366e-07
an O 0 3.669026682473486e-08
estimated O 0 1.0921953617071267e-06
52 O 0 1.2233056168042822e-06
% O 0 3.08681471494765e-08
of O 0 1.7244337513488972e-08
families O 0 1.8927900669041264e-07
, O 0 8.394098216513157e-08
to O 0 9.296541492176402e-08
BRCA2 O 0 3.483383579805377e-06
in O 0 4.348708415591318e-08
32 O 0 4.921664640278323e-07
% O 0 3.3032282686917824e-08
of O 0 2.7320655959783835e-08
families O 0 3.350610597863124e-07
, O 0 1.2462793108625192e-07
and O 0 7.10227041622602e-08
to O 0 2.3252196612588705e-08
neither O 0 2.1827639784532948e-07
gene O 0 7.383981426301034e-08
in O 0 2.2493429341352567e-08
16 O 0 1.2599819854131056e-07
% O 0 5.09679658478035e-08
( O 0 1.248533099129645e-08
95 O 0 1.1948179690079996e-07
% O 0 4.397276498480096e-08
confidence O 0 2.941064565220586e-07
interval O 0 9.141976420323772e-07
[ O 0 1.0980962770190672e-06
CI O 0 0.00013433481217361987
] O 0 2.970855916828441e-07
6 O 0 8.86135254063447e-08
% O 0 3.1099393282829624e-08
- O 0 6.085184850235237e-06
28 O 0 2.975818063077895e-07
% O 0 2.286465239365043e-08
) O 0 1.0844960485201227e-08
, O 0 2.9207599894220948e-08
suggesting O 0 4.147668164478091e-07
other O 0 8.45819059236419e-08
predisposition O 0 8.200303273042664e-05
genes O 0 3.3295725643256446e-06
. O 0 4.607304617820773e-06

The O 0 5.491248430189444e-06
majority O 0 6.706485237373272e-06
( O 0 4.6535120645785355e-07
81 O 0 3.7084871564729838e-06
% O 0 7.443456695455097e-08
) O 0 1.1814404565768655e-08
of O 0 2.630129536385084e-08
the O 0 2.976160430989694e-06
breast B-Disease 1 0.9997244477272034
- I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999943971633911
families O 0 4.516426088230219e-06
were O 0 5.47157981145574e-07
due O 0 1.1485275308587006e-06
to O 0 3.8893716691745794e-07
BRCA1 O 0 7.61763149057515e-05
, O 0 3.65561589887875e-07
with O 0 1.2828651563268068e-07
most O 0 8.982118515632465e-08
others O 0 1.4668593451006018e-07
( O 0 3.1280062984251344e-08
14 O 0 2.3827371364859573e-07
% O 0 1.1639544084118825e-07
) O 0 2.6370715389134602e-08
due O 0 5.049230367148994e-07
to O 0 8.216554761020234e-07
BRCA2 O 0 0.0002129267086274922
. O 0 6.750973170710495e-06

Conversely O 0 0.00038868811680004
, O 0 2.180551291530719e-06
the O 0 1.5847255951939587e-07
majority O 0 4.332473793056124e-07
of O 0 8.157810071907079e-08
families O 0 8.449723054582137e-07
with O 0 4.935746460432711e-07
male B-Disease 0 5.313055225997232e-06
and I-Disease 0 1.1653482033580076e-05
female I-Disease 0 0.0005214073462411761
breast I-Disease 1 0.9970658421516418
cancer I-Disease 0 0.22337962687015533
were O 0 7.515698712268204e-07
due O 0 2.2429824184655445e-06
to O 0 6.491109161288477e-07
BRCA2 O 0 5.716375744668767e-05
( O 0 1.9248390970005858e-07
76 O 0 1.199500729853753e-05
% O 0 6.116552526691521e-07
) O 0 3.709898521719879e-07
. O 0 1.9003772422365728e-06

The O 0 7.794748853484634e-06
largest O 0 1.3874291653337423e-05
proportion O 0 3.4158035759901395e-06
( O 0 2.5523672775307205e-07
67 O 0 1.1055631148337852e-06
% O 0 8.625605829593042e-08
) O 0 1.0353427448706043e-08
of O 0 1.8560662340405543e-08
families O 0 1.909604918637342e-07
due O 0 4.173442675892147e-07
to O 0 2.5810201975673408e-08
other O 0 1.3130866172161859e-08
genes O 0 6.775147198823106e-08
was O 0 6.250999149415293e-07
found O 0 2.4048677005339414e-07
in O 0 5.9555095077712394e-08
families O 0 1.4108194079653913e-07
with O 0 5.051310836279299e-08
four O 0 1.1069836602928262e-07
or O 0 2.1607931444123096e-07
five O 0 5.5942781074236336e-08
cases O 0 1.2292132112179388e-07
of O 0 3.724013311057206e-07
female O 0 0.002656079363077879
breast B-Disease 1 0.9998894929885864
cancer I-Disease 1 0.6967901587486267
only O 0 1.4786756992180017e-06
. O 0 1.3981292795506306e-05

These O 0 5.19373270435608e-06
estimates O 0 1.1075280781369656e-05
were O 0 5.425076778919902e-07
not O 0 1.8279327207437746e-07
substantially O 0 1.9141500615660334e-06
affected O 0 2.8824496212109807e-07
either O 0 6.901741045339804e-08
by O 0 4.0207165596939376e-08
changing O 0 2.253882911418259e-07
the O 0 5.050173967902083e-08
assumed O 0 7.650576208106941e-07
penetrance O 0 1.1001216080330778e-05
model O 0 4.6761024918851035e-07
for O 0 1.7814082298173162e-07
BRCA1 O 0 2.620735722302925e-05
or O 0 1.2198114518469083e-07
by O 0 3.651531699233601e-08
including O 0 1.6561912730139738e-07
or O 0 2.2903853391653684e-07
excluding O 0 2.069600304821506e-05
BRCA1 O 0 0.00018499893485568464
mutation O 0 3.2245977763523115e-06
data O 0 4.739333689940395e-06
. O 0 5.161037279322045e-06

Among O 0 3.523184932419099e-05
those O 0 5.0415205805620644e-06
families O 0 9.31757313082926e-06
with O 0 2.32912407227559e-05
disease O 0 0.007880798541009426
due O 0 4.2815149754460435e-06
to O 0 1.3814751582685858e-06
BRCA1 O 0 0.00028680372633971274
that O 0 4.3499943558344967e-07
were O 0 1.4282669553722371e-06
tested O 0 1.8686768044062774e-06
by O 0 3.8535212354418036e-08
one O 0 1.1879866868014233e-08
of O 0 8.359582359673823e-09
the O 0 2.040135527181519e-08
standard O 0 2.828415688327368e-07
screening O 0 2.1170282593629963e-07
methods O 0 1.5358455129899085e-07
, O 0 7.523817657784093e-08
mutations O 0 1.2572679963795963e-07
were O 0 4.698220124055297e-08
detected O 0 1.1344995982653927e-06
in O 0 1.2879889155215096e-08
the O 0 7.096688570129572e-09
coding O 0 2.350924717120506e-07
sequence O 0 2.9495803133272602e-08
or O 0 9.872302086932905e-09
splice O 0 2.105715992684054e-07
sites O 0 4.1978399423214796e-08
in O 0 4.2946002309918185e-09
an O 0 4.409645981695576e-09
estimated O 0 7.626807274618841e-08
63 O 0 8.242115541179373e-07
% O 0 3.2152083662140285e-08
( O 0 8.847719001892074e-09
95 O 0 1.400680247343189e-07
% O 0 6.287080367428644e-08
CI O 0 3.3812557376222685e-05
51 O 0 9.925471431415644e-07
% O 0 1.3555160194300697e-07
- O 0 2.0451419914024882e-05
77 O 0 3.9276851566683035e-06
% O 0 3.0355522540048696e-07
) O 0 3.926431304535072e-07
. O 0 1.397666210323223e-06

The O 0 1.0282960829499643e-05
estimated O 0 1.536984200356528e-05
sensitivity O 0 1.2339291060925461e-05
was O 0 1.8939922483696137e-06
identical O 0 8.495943006892048e-07
for O 0 2.5812317616669134e-08
direct O 0 3.394201542050723e-08
sequencing O 0 3.9203547430588515e-07
and O 0 1.499824264783456e-07
other O 0 8.049723021485988e-08
techniques O 0 5.6734515965217724e-06
. O 0 4.230491867929231e-06

The O 0 2.283988578710705e-05
penetrance O 0 0.0011878837831318378
of O 0 7.75565695221303e-06
BRCA2 O 0 0.0003237153869122267
was O 0 3.884473699145019e-06
estimated O 0 1.0284569498253404e-06
by O 0 1.0726613908218496e-07
maximizing O 0 1.5727486015748582e-06
the O 0 1.7334123469936458e-07
LOD O 0 0.0006137084565125406
score O 0 7.083451691869413e-07
in O 0 2.670886658506788e-07
BRCA2 O 0 3.5975601349491626e-05
- O 0 0.00013301985745783895
mutation O 0 1.571324219185044e-06
families O 0 2.3571165286284668e-07
, O 0 5.374118572376574e-08
over O 0 1.5195108460375195e-07
all O 0 6.662008900093497e-08
possible O 0 2.673618382686982e-06
penetrance O 0 0.0001163683264167048
functions O 0 1.6513320133526577e-06
. O 0 6.9301281655498315e-06

The O 0 3.646134928203537e-06
estimated O 0 6.925562956894282e-06
cumulative O 0 1.2202353900647722e-05
risk O 0 1.4839797586319037e-05
of O 0 4.877229457633803e-06
breast B-Disease 1 0.9982548356056213
cancer I-Disease 1 0.8336004614830017
reached O 0 1.5261321095749736e-05
28 O 0 3.46239880855137e-06
% O 0 9.26771903664303e-08
( O 0 2.690453015929961e-08
95 O 0 2.3267865856269054e-07
% O 0 2.1139575778761355e-07
CI O 0 0.0002446303842589259
9 O 0 6.991272698542161e-07
% O 0 6.44773621161221e-08
- O 0 4.866705239692237e-06
44 O 0 2.413538311429875e-07
% O 0 3.639391366050404e-08
) O 0 5.714816619928342e-09
by O 0 1.2131772919588002e-08
age O 0 5.918796119885883e-08
50 O 0 2.9489221731182624e-08
years O 0 1.85116260098539e-08
and O 0 3.0687164809251044e-08
84 O 0 4.3348870804038597e-07
% O 0 3.0752616453355586e-08
( O 0 7.077331609650628e-09
95 O 0 1.1133848687450154e-07
% O 0 8.348066415919675e-08
CI O 0 5.495290315593593e-05
43 O 0 2.4226244477176806e-07
% O 0 3.8652473222100525e-08
- O 0 2.2391823222278617e-06
95 O 0 3.9230104675880284e-07
% O 0 2.425277578765872e-08
) O 0 7.808531599096113e-09
by O 0 1.6966888338743047e-08
age O 0 2.959346829811693e-07
70 O 0 4.363514847227634e-07
years O 0 8.055480407165305e-07
. O 0 2.2634044398728292e-06

The O 0 0.00014698160521220416
corresponding O 1 0.7658472061157227
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999958276748657
risks O 0 0.0031593376770615578
were O 0 7.204610938060796e-06
0 O 0 2.781346302072052e-05
. O 0 1.2744680134346709e-05

4 O 0 3.685238698380999e-05
% O 0 2.5830547656369163e-06
( O 0 1.2538900762137928e-07
95 O 0 4.4658722231361025e-07
% O 0 2.1355988621962751e-07
CI O 0 9.518962178844959e-05
0 O 0 2.4392281261498283e-07
% O 0 4.609827186641269e-08
- O 0 2.62551679952594e-06
1 O 0 5.4214257971807456e-08
% O 0 1.3714545943344092e-08
) O 0 6.4861067627930424e-09
by O 0 1.1040607539314351e-08
age O 0 6.156910359322865e-08
50 O 0 3.026596573363349e-08
years O 0 2.886831218518182e-08
and O 0 3.429066453009e-08
27 O 0 3.385150648682611e-07
% O 0 1.8228664799835315e-08
( O 0 8.620404834402962e-09
95 O 0 1.1514607223261919e-07
% O 0 6.066649405056523e-08
CI O 0 4.728069689008407e-05
0 O 0 1.9819857755010162e-07
% O 0 6.882653735829081e-08
- O 0 4.79645268569584e-06
47 O 0 7.264637815751485e-07
% O 0 3.1758780494328676e-08
) O 0 6.124359241965749e-09
by O 0 1.589786791100778e-08
age O 0 2.699402728012501e-07
70 O 0 3.792649465594877e-07
years O 0 8.58149405758013e-07
. O 0 2.796609805955086e-06

The O 0 1.4680317690363154e-05
lifetime O 0 0.00017711054533720016
risk O 0 0.00017979656695388258
of O 0 5.865628190804273e-05
breast B-Disease 1 0.9999723434448242
cancer I-Disease 1 0.9985729455947876
appears O 0 2.6080550014739856e-05
similar O 0 8.608838584223122e-07
to O 0 1.3448453728415188e-07
the O 0 1.6837491045862407e-07
risk O 0 8.262741175713018e-06
in O 0 1.665909650228059e-07
BRCA1 O 0 2.4398183086304925e-05
carriers O 0 3.564411372281029e-06
, O 0 2.7533263846635236e-07
but O 0 1.1866068660992823e-07
there O 0 3.565692097140527e-08
was O 0 1.3903978413054574e-07
some O 0 5.304499506308957e-09
suggestion O 0 1.0240405856620782e-07
of O 0 1.7492292059273495e-08
a O 0 3.3610470495659683e-07
lower O 0 7.215581717900932e-05
risk O 0 4.54081418865826e-06
in O 0 1.0302176178811351e-07
BRCA2 O 0 1.0558924259385094e-05
carriers O 0 1.0602529982861597e-06
< O 0 1.770434209902305e-05
50 O 0 2.690674421046424e-07
years O 0 1.0444809817045098e-07
of O 0 1.288972413249212e-07
age O 0 2.6399059152026894e-06
. O 0 5.102704108139733e-06

Eye B-Disease 1 0.5930048227310181
movement I-Disease 0 0.004308382980525494
abnormalities I-Disease 1 0.9061460494995117
correlate O 0 0.0003104704665020108
with O 0 7.144277788029285e-06
genotype O 0 0.004350342787802219
in O 0 4.0647802961757407e-05
autosomal O 0 0.4598371982574463
dominant O 1 0.5100313425064087
cerebellar B-Disease 1 0.999808132648468
ataxia I-Disease 1 0.9998593330383301
type I-Disease 0 0.3158493936061859
I I-Disease 0 0.0014620701549574733
. O 0 3.640729482867755e-05

We O 0 2.307229078724049e-05
compared O 0 2.5014036509674042e-05
horizontal O 0 0.0001488827692810446
eye O 0 0.0005560668651014566
movements O 0 9.653784218244255e-06
( O 0 2.819528219788481e-07
visually O 0 2.8945805752300657e-06
guided O 0 5.254533334664302e-06
saccades O 0 0.0009856269462034106
, O 0 1.0499593372514937e-06
antisaccades O 0 0.00012518999574240297
, O 0 1.3440273960441118e-07
and O 0 8.942596707584016e-08
smooth O 0 1.0666246453183703e-05
pursuit O 0 2.8686232326435857e-05
) O 0 4.9402203217141505e-08
in O 0 2.4193084868784354e-08
control O 0 3.7988036183378426e-07
subjects O 0 5.223987500357907e-07
( O 0 1.504191686763079e-07
n O 0 9.682136442279443e-05
= O 0 2.3412821974488907e-06
14 O 0 1.0098597869045989e-07
) O 0 1.4969229411576634e-08
and O 0 9.807874334910593e-08
patients O 0 1.0482644938747399e-06
with O 0 2.8981244071246692e-08
three O 0 8.409754315152895e-08
forms O 0 8.677616847307945e-07
of O 0 2.6343127501604613e-06
autosomal O 0 0.0029013347811996937
dominant O 0 0.00024417927488684654
cerebellar B-Disease 0 0.26464250683784485
ataxias I-Disease 0 0.4669322669506073
type I-Disease 0 0.0023893904872238636
I I-Disease 0 0.0002592862874735147
spinocerebellar B-Disease 0 0.23507678508758545
ataxias I-Disease 0 0.0004123469698242843
1 I-Disease 0 6.289958491834113e-07
and I-Disease 0 1.2152921158303798e-07
2 I-Disease 0 2.940616070645774e-07
( O 0 5.5553716293843536e-08
SCA1 B-Disease 0 4.0084636566461995e-05
, O 0 9.264379485784957e-08
n O 0 1.6730529750930145e-05
= O 0 9.804607543628663e-07
11 O 0 6.916975792137237e-08
; O 0 5.00502714828599e-08
SCA2 B-Disease 0 2.4005166778806597e-05
, O 0 1.272551770625796e-07
n O 0 1.3356187082536053e-05
= O 0 5.100842486172041e-07
10 O 0 2.618946304266956e-08
) O 0 1.5639068706718717e-08
and O 0 8.358278336118019e-08
SCA3 B-Disease 1 0.7874954342842102
/ O 0 7.219965482363477e-05
Machado B-Disease 0 0.00013170346210245043
- I-Disease 0 0.06403166055679321
Joseph I-Disease 0 0.09079508483409882
disease I-Disease 0 0.0002881932014133781
( O 0 5.894573860132368e-07
MJD B-Disease 1 0.9989696741104126
) O 0 3.812264139924082e-07
( O 0 1.566174745448734e-07
n O 0 3.067539000767283e-05
= O 0 3.4246397717652144e-06
16 O 0 4.122952930174506e-07
) O 0 2.6679740017243603e-07
. O 0 1.1186558594999951e-06

In O 0 8.866211828717496e-06
SCA1 B-Disease 0 0.0006484176847152412
, O 0 7.872763490013313e-07
saccade O 0 1.5654368326067924e-05
amplitude O 0 1.6876601875992492e-06
was O 0 4.453737858511886e-07
significantly O 0 7.424512205034262e-07
increased O 0 1.8990552064224175e-07
, O 0 1.295216094376883e-07
resulting O 0 8.303900358441751e-07
in O 0 1.0208592584604048e-06
hypermetria B-Disease 0 0.0012420706916600466
. O 0 7.851897862565238e-06

The O 0 1.485268057876965e-05
smooth O 0 5.479058381752111e-05
pursuit O 0 0.00020345859229564667
gain O 0 0.0001303613098571077
was O 0 2.1923928215983324e-05
decreased O 0 0.00010938522609649226
. O 0 1.2753117516695056e-05

In O 0 4.3730324250645936e-05
SCA2 B-Disease 0 0.0023813112638890743
, O 0 7.459390417352552e-06
saccade O 0 0.0001838511525420472
velocity O 0 5.6748962379060686e-05
was O 0 1.4168968846206553e-05
markedly O 0 8.52386438054964e-05
decreased O 0 5.60015432711225e-05
. O 0 1.1416060260671657e-05

The O 0 8.580809662817046e-06
percentage O 0 1.4756139535165858e-05
of O 0 4.43146518591675e-07
errors O 0 1.3873867828806397e-05
in O 0 2.674750874120946e-07
antisaccades O 0 0.00028661408578045666
was O 0 7.134324846447271e-07
greatly O 0 2.3640615154363331e-07
increased O 0 6.575207578407571e-08
and O 0 3.0929793837231045e-08
was O 0 2.861723373825953e-07
significantly O 0 4.892901301900565e-07
correlated O 0 6.57518171465199e-07
with O 0 2.790141877540009e-07
age O 0 1.1640663615253288e-05
at O 0 0.00010363114415667951
disease O 0 0.0021514149848371744
onset O 0 0.007558778859674931
. O 0 1.1886973879882134e-05

In O 0 4.9932123147300445e-06
addition O 0 2.0433169538591756e-06
, O 0 2.541039805237233e-07
a O 0 7.400492307851891e-08
correlation O 0 2.4507281182195584e-07
between O 0 8.208363766470939e-08
smooth O 0 5.623061042570043e-06
pursuit O 0 4.1003411752171814e-05
gain O 0 9.537002370052505e-06
and O 0 8.929814043767692e-08
the O 0 1.7623500880858955e-08
number O 0 1.6596374052824103e-08
of O 0 1.1151445988843989e-07
trinucleotide O 0 0.0003079461748711765
repeats O 0 4.179929874226218e-06
was O 0 2.3861396130087087e-06
found O 0 1.5314973325075698e-06
. O 0 3.5056352771789534e-06

In O 0 0.00010608183220028877
SCA3 B-Disease 1 0.9961722493171692
, O 0 1.2215511560498271e-05
gaze B-Disease 0 6.114788266131654e-05
- I-Disease 0 0.0006077094003558159
evoked I-Disease 0 0.00037959314067848027
nystagmus I-Disease 0 0.004226595163345337
was O 0 3.947075583710102e-06
often O 0 1.885351537112001e-07
present O 0 1.2089009260307648e-07
as O 0 5.241502876174309e-08
was O 0 5.269374696581508e-07
saccade O 0 2.265199327666778e-05
hypometria O 0 3.703558832057752e-05
and O 0 1.4864788511204097e-07
smooth O 0 5.146930107002845e-06
pursuit O 0 3.2228090276475996e-05
gain O 0 2.2547035769093782e-05
was O 0 7.857530363253318e-06
markedly O 0 7.50313192838803e-05
decreased O 0 4.401738624437712e-05
. O 0 4.850695859204279e-06

Three O 0 1.686144241830334e-05
major O 0 8.530498234904371e-06
criteria O 0 1.7212106513397885e-06
, O 0 2.644537175910955e-07
saccade O 0 1.454967787140049e-05
amplitude O 0 1.570075028212159e-06
, O 0 8.289564590313603e-08
saccade O 0 3.614184834077605e-06
velocity O 0 9.153945939033292e-07
, O 0 6.250349571246261e-08
and O 0 2.849723301778795e-08
presence O 0 2.918621433423141e-08
of O 0 2.2212214290107113e-08
gaze B-Disease 0 3.96049927076092e-06
- I-Disease 0 3.1642219255445525e-05
evoked I-Disease 0 2.15671825571917e-05
nystagmus I-Disease 0 0.00012989476090297103
, O 0 1.221125387473876e-07
permitted O 0 6.612093983449085e-08
the O 0 1.6404053226892756e-08
correct O 0 2.4200983261835063e-07
assignment O 0 1.3412628163678164e-07
of O 0 1.7720170220059117e-08
90 O 0 1.858748817085143e-07
% O 0 2.6217202631073633e-08
of O 0 7.116668143680727e-09
the O 0 7.599826545856558e-08
SCA1 B-Disease 0 0.0006227846606634557
, O 0 5.878204589748748e-08
90 O 0 6.140362529549748e-08
% O 0 1.3419481526000254e-08
of O 0 7.876833407749473e-09
the O 0 5.577146211521722e-08
SCA2 B-Disease 0 0.001740544568747282
, O 0 4.935257180704866e-08
and O 0 3.566080053474252e-08
93 O 0 3.777326753606758e-07
% O 0 1.594481524591629e-08
of O 0 2.1369917391211857e-08
the O 0 3.937451822366711e-07
patients O 0 1.103255544876447e-05
with O 0 8.147801509039709e-07
SCA3 B-Disease 1 0.9997331500053406
to O 0 1.6943693026405526e-07
their O 0 5.136399394700675e-08
genetically O 0 3.4664094528125133e-06
confirmed O 0 4.526490101852687e-06
patient O 0 7.792682481522206e-06
group O 0 8.35113837638346e-07
and O 0 2.3260231785116048e-07
, O 0 1.4857815244795347e-07
therefore O 0 1.3449916025365383e-07
, O 0 1.5593117552725744e-07
may O 0 2.3139473626088147e-07
help O 0 3.3741662264219485e-07
orient O 0 9.524192137178034e-05
diagnoses O 0 4.036719838040881e-05
of O 0 2.6598038971314963e-07
SCA1 B-Disease 0 0.01943071000277996
, O 0 7.026618504824e-07
SCA2 B-Disease 0 0.00022364206961356103
, O 0 1.7114376760218875e-07
and O 0 7.797096372996748e-07
SCA3 B-Disease 1 0.9584119319915771
at O 0 6.836116313024831e-07
early O 0 5.424197411230125e-07
clinical O 0 1.4567203834303655e-06
stages O 0 1.820273155317409e-06
of O 0 3.3692978718136146e-07
the O 0 1.4480591744359117e-05
diseases O 0 0.040605418384075165
. O 0 1.5620399835825083e-06
. O 0 6.091531304264208e-06

Genetic O 0 0.00018317086505703628
basis O 0 9.338335985376034e-06
and O 0 2.59847456618445e-06
molecular O 0 4.459384945221245e-05
mechanism O 0 4.092255039722659e-05
for O 0 0.0003350178012624383
idiopathic B-Disease 1 0.999998927116394
ventricular I-Disease 1 0.9999427795410156
fibrillation I-Disease 1 0.9999475479125977
. O 0 0.0007727340562269092

Ventricular B-Disease 1 0.9981992840766907
fibrillation I-Disease 1 0.9981377124786377
causes O 0 0.00021748094877693802
more O 0 3.5288999811200483e-07
than O 0 1.8328273654333316e-07
300 O 0 4.0595665495857247e-07
, O 0 1.436788750197593e-07
000 O 0 8.010167107386224e-07
sudden O 0 7.275846201082459e-06
deaths O 0 1.2662967492360622e-06
each O 0 3.401206782882582e-08
year O 0 1.7512563488253363e-07
in O 0 5.370409184024538e-08
the O 0 1.2721925202185957e-07
USA O 0 7.021734290901804e-06
alone O 0 5.820768819830846e-06
. O 0 4.98341205457109e-06

In O 0 3.149191570628318e-06
approximately O 0 1.2269871376702213e-06
5 O 0 8.184396733668109e-07
- O 0 5.0304938667977694e-06
12 O 0 8.002404427998044e-08
% O 0 1.6958541237954705e-08
of O 0 4.80915574030405e-09
these O 0 2.8806542928805356e-08
cases O 0 2.4522876174160047e-07
, O 0 1.363930408615488e-07
there O 0 9.132062928074447e-08
are O 0 4.9821682779338516e-08
no O 0 6.30268914392218e-07
demonstrable O 0 0.006477501709014177
cardiac O 0 0.09722369909286499
or O 0 2.259936081827618e-06
non O 0 2.7271067665424198e-05
- O 1 0.9730128049850464
cardiac O 1 0.8807244300842285
causes O 0 4.0816617001837585e-06
to O 0 5.1265139688894124e-08
account O 0 5.4244562619487624e-08
for O 0 2.5566690098344225e-08
the O 0 2.1623304036211266e-08
episode O 0 7.633645964233438e-07
, O 0 8.276988694433385e-08
which O 0 6.751049852482538e-08
is O 0 1.442291193143319e-07
therefore O 0 4.944952820551407e-07
classified O 0 7.942903903312981e-05
as O 0 0.0003329913306515664
idiopathic B-Disease 1 0.9999996423721313
ventricular I-Disease 1 0.9999798536300659
fibrillation I-Disease 1 0.9999915361404419
( O 0 0.0002594000252429396
IVF B-Disease 1 0.9992984533309937
) O 0 9.5831173894112e-06
. O 0 1.2110744137316942e-05

A O 0 3.455642581684515e-05
distinct O 0 7.631697371834889e-06
group O 0 2.3648806291021174e-06
of O 0 1.9094059098279104e-06
IVF B-Disease 1 0.9999748468399048
patients O 0 0.04174016788601875
has O 0 1.3600185866380343e-06
been O 0 3.85166970318096e-07
found O 0 2.285938194290793e-07
to O 0 5.384727685964208e-08
present O 0 3.395173564513243e-07
with O 0 5.571127985604107e-07
a O 0 4.312252258387161e-06
characteristic O 0 2.252661761303898e-05
electrocardiographic O 0 0.0011131151113659143
pattern O 0 6.022025627316907e-05
. O 0 1.066824006556999e-05

Because O 0 1.1279220416327007e-05
of O 0 3.090037523634237e-07
the O 0 1.041375767840691e-07
small O 0 3.2903193414313137e-07
size O 0 5.344918463379145e-07
of O 0 4.683975518560146e-08
most O 0 3.9766185011558264e-08
pedigrees O 0 2.317738108104095e-06
and O 0 1.294441887011999e-07
the O 0 8.796670414312757e-08
high O 0 2.448279337841086e-05
incidence O 0 0.0001015081797959283
of O 0 4.894292260360089e-07
sudden B-Disease 0 0.006575506180524826
death I-Disease 0 6.247466808417812e-05
, O 0 5.330090289135114e-07
however O 0 9.15943232371319e-08
, O 0 6.105886285467932e-08
molecular O 0 1.2458151559258113e-06
genetic O 0 4.4797221221415384e-07
studies O 0 7.801389045880569e-08
of O 0 3.804154573572305e-07
IVF B-Disease 1 0.9968271851539612
have O 0 1.0512377457416733e-06
not O 0 1.1647283315596724e-07
yet O 0 4.45840811380549e-07
been O 0 3.1952666290635534e-07
done O 0 1.593845240677183e-06
. O 0 2.607518126751529e-06

Because O 0 0.001591603155247867
IVF B-Disease 1 0.9996607303619385
causes O 0 0.15311479568481445
cardiac O 1 0.9858109951019287
rhythm O 0 0.04200536757707596
disturbance O 0 0.10495693236589432
, O 0 1.8215649788544397e-06
we O 0 3.217564881197177e-07
investigated O 0 4.104132585780462e-06
whether O 0 4.188090940715483e-07
malfunction O 0 0.00014136687968857586
of O 0 1.2889503864244034e-07
ion O 0 5.96746540395543e-05
channels O 0 4.190330855635693e-06
could O 0 4.899615305475891e-06
cause O 0 9.066837264981586e-06
the O 0 1.1485362847452052e-06
disorder O 0 0.0003443561145104468
by O 0 5.2765305014190744e-08
studying O 0 2.4525940034436644e-07
mutations O 0 4.6898176719878393e-07
in O 0 6.703983501665789e-08
the O 0 2.3242758118158235e-07
cardiac O 0 0.00033616702421568334
sodium O 0 1.0386228495917749e-05
channel O 0 1.6995354599202983e-05
gene O 0 1.0435651347506791e-05
SCN5A O 0 0.0008732353453524411
. O 0 1.721472290228121e-05

We O 0 1.9286353563074954e-05
have O 0 2.453787374179228e-06
now O 0 1.3983035387354903e-06
identified O 0 1.2073484185748384e-06
a O 0 4.0492236053069064e-07
missense O 0 5.5562370107509196e-05
mutation O 0 1.726079517538892e-06
, O 0 1.1756480944313807e-07
a O 0 1.54491090142983e-07
splice O 0 2.0330739062046632e-05
- O 0 0.00013833939738105983
donor O 0 4.413996066432446e-06
mutation O 0 6.193470198923023e-07
, O 0 2.3802117254945188e-07
and O 0 2.0572237247051817e-07
a O 0 9.214178362526582e-07
frameshift O 0 0.0006240467191673815
mutation O 0 6.646662882303644e-07
in O 0 5.7629048200169564e-08
the O 0 8.310841792535939e-08
coding O 0 5.291328307066578e-06
region O 0 3.7886729842284694e-07
of O 0 9.48456531091324e-08
SCN5A O 0 0.001131550408899784
in O 0 4.337885286531673e-07
three O 0 1.2940249689563643e-06
IVF B-Disease 1 0.9942973256111145
families O 0 1.4073274542170111e-05
. O 0 1.1826593436126132e-05

We O 0 3.401185722395894e-06
show O 0 5.28285454493016e-07
that O 0 7.110877220384282e-08
sodium O 0 5.093103823128331e-07
channels O 0 2.557723064455786e-07
with O 0 4.246107465633031e-08
the O 0 8.534453144193321e-08
missense O 0 2.1861878849449567e-05
mutation O 0 8.080918405539705e-07
recover O 0 4.5311026042327285e-06
from O 0 6.039609701247173e-08
inactivation O 0 0.00010984596883645281
more O 0 4.48643433514917e-08
rapidly O 0 2.56633825301833e-07
than O 0 2.4903940243348188e-08
normal O 0 1.2548171923754126e-07
and O 0 3.9494970849318634e-08
that O 0 1.758445122845842e-08
the O 0 1.1318266501803009e-07
frameshift O 0 0.0004174267523922026
mutation O 0 6.568882895408024e-07
causes O 0 1.2596994736213674e-07
the O 0 2.116296826670805e-08
sodium O 0 4.195638609871821e-07
channel O 0 5.11914663547941e-07
to O 0 5.308004347170936e-08
be O 0 8.028317921571215e-08
non O 0 1.278082322642149e-06
- O 0 8.932471973821521e-05
functional O 0 2.2525671738549136e-05
. O 0 6.826448952779174e-06

Our O 0 1.7771093553164974e-05
results O 0 6.217310783540597e-06
indicate O 0 2.4513317384844413e-06
that O 0 1.6325573426456685e-07
mutations O 0 1.103567001337069e-06
in O 0 1.955031621037051e-07
cardiac O 0 0.00024643767392262816
ion O 0 0.00020767665409948677
- O 0 4.0744198486208916e-05
channel O 0 1.3673378589373897e-06
genes O 0 1.1951964040690655e-07
contribute O 0 6.99561439887475e-08
to O 0 3.6523392310527925e-08
the O 0 9.897438246753154e-08
risk O 0 8.100640229713463e-07
of O 0 7.718858796579298e-08
developing O 0 2.63502515736036e-05
IVF B-Disease 1 0.9917694330215454
. O 0 3.3267540402448503e-06
. O 0 7.135357918741647e-06

Molecular O 0 0.0002130347565980628
heterogeneity O 0 0.0002777962072286755
in O 0 8.078783139353618e-06
mucopolysaccharidosis B-Disease 0 0.10710901021957397
IVA I-Disease 1 0.711634635925293
in O 0 8.477109645355085e-07
Australia O 0 4.1435131947764603e-07
and O 0 1.7762410209343216e-07
Northern O 0 6.603989390896459e-07
Ireland O 0 6.088826012273785e-07
: O 0 1.174310213514218e-07
nine O 0 1.9134751028104802e-07
novel O 0 4.472286434520356e-07
mutations O 0 3.6066438724446925e-07
including O 0 2.740863749295386e-07
T312S O 0 0.00010381024912931025
, O 0 4.755070506234915e-07
a O 0 2.2532402965680376e-07
common O 0 4.4938684595763334e-07
allele O 0 1.8102393823937746e-06
that O 0 3.280052567333769e-07
confers O 0 1.1731146514648572e-05
a O 0 1.68988699442707e-05
mild O 0 0.29007378220558167
phenotype O 0 0.0008412760216742754
. O 0 2.6558180252322927e-05

Mucopolysaccharidosis B-Disease 1 0.9850534796714783
IVA I-Disease 1 0.9988948702812195
( O 0 0.0006774814100936055
MPS B-Disease 1 0.9977331161499023
IVA I-Disease 1 0.9999876022338867
) O 0 1.5044132851471659e-05
is O 0 3.050496843570727e-06
an O 0 8.557421097066253e-06
autosomal B-Disease 1 0.9853288531303406
recessive I-Disease 1 0.9996310472488403
lysosomal I-Disease 1 0.9999948740005493
storage I-Disease 1 0.9999957084655762
disorder I-Disease 1 0.9998718500137329
caused O 0 0.000991318840533495
by O 0 5.279085144138662e-06
a O 0 9.037134441314265e-05
genetic B-Disease 1 0.9972418546676636
defect I-Disease 1 0.9901641011238098
in O 0 1.2665044550885796e-06
N O 0 0.010448921471834183
- O 0 0.00039840370300225914
acetylgalactosamine O 0 0.000615199445746839
- O 0 0.00017971637134905905
6 O 0 1.5294906916096807e-05
- O 0 0.022325586527585983
sulfate O 0 0.017699096351861954
sulfatase O 0 0.0014185423497110605
( O 0 8.268072519967973e-07
GALNS O 0 0.00011810441355919465
) O 0 8.123090537992539e-07
. O 0 1.925679725900409e-06

Previous O 0 1.4900237147230655e-05
studies O 0 2.31980811804533e-06
of O 0 1.3939935570306261e-06
patients O 0 2.0282501282054e-05
from O 0 1.9877779777743854e-07
a O 0 4.97852056469128e-07
British O 0 7.174483471317217e-06
- O 0 0.011679241433739662
Irish O 0 8.836455890559591e-06
population O 0 1.2369285684599163e-07
showed O 0 1.1709869340847945e-06
that O 0 3.365077816397388e-08
the O 0 5.421498272539793e-08
I113F O 0 2.165857222280465e-05
mutation O 0 2.4753282445999503e-07
is O 0 1.8332917406382876e-08
the O 0 1.9536704698452922e-08
most O 0 4.13483967065531e-08
common O 0 1.7176346034375456e-07
single O 0 4.2429988411640807e-07
mutation O 0 1.337662297373754e-06
among O 0 4.109039764443878e-06
MPS B-Disease 1 0.9984490871429443
IVA I-Disease 1 0.9999994039535522
patients O 0 0.008969040587544441
and O 0 4.074699972989038e-06
produces O 0 3.4273914934601635e-05
a O 0 5.136819163453765e-05
severe O 0 0.38186702132225037
clinical O 0 0.00657377066090703
phenotype O 0 0.004359067417681217
. O 0 4.700623685494065e-05

We O 0 1.8987660951097496e-05
studied O 0 4.582721430779202e-06
mutations O 0 3.393377937754849e-06
in O 0 1.2686608386047737e-07
the O 0 1.427734304115802e-07
GALNS O 0 0.00018979758897330612
gene O 0 4.4163314782963425e-07
from O 0 6.422610709932997e-08
23 O 0 3.325430100176163e-07
additional O 0 5.870366521776305e-07
MPS B-Disease 1 0.992693305015564
IVA I-Disease 1 0.9999994039535522
patients O 0 0.001373862731270492
( O 0 9.316208604559506e-08
15 O 0 5.928060531346091e-08
from O 0 1.892186674012919e-08
Australia O 0 3.359139810754641e-08
, O 0 2.0436795367118066e-08
8 O 0 4.010896859085733e-08
from O 0 9.230562980633295e-09
Northern O 0 6.702526178514745e-08
Ireland O 0 8.926374306383877e-08
) O 0 9.07306407782471e-09
, O 0 1.7492657988782412e-08
with O 0 1.6240143452250777e-08
various O 0 6.740268077010114e-08
clinical O 0 0.00010374870180385187
phenotypes O 0 0.00019917779718525708
( O 0 1.6468151216031401e-06
severe O 0 0.0001863929210230708
, O 0 4.762871981256467e-07
16 O 0 7.684219553993898e-07
cases O 0 3.0005361395524233e-07
; O 0 2.6016707010967366e-07
intermediate O 0 8.75107446063339e-07
, O 0 1.0534220251656734e-07
4 O 0 1.3573959449786344e-06
cases O 0 6.210101446413319e-07
; O 0 1.890879048005445e-06
mild O 0 0.0017073090421035886
, O 0 1.1313188679196173e-06
3 O 0 6.556286734848982e-06
cases O 0 1.8803214061335893e-06
) O 0 5.460502734422334e-07
. O 0 1.7856141312222462e-06

We O 0 1.9048162357648835e-05
found O 0 2.7186626994080143e-06
two O 0 2.0719987503525772e-07
common O 0 5.462466106109787e-07
mutations O 0 7.209121122286888e-07
that O 0 1.4366855261016553e-08
together O 0 7.865201467893712e-08
accounted O 0 1.583772132107697e-06
for O 0 7.961466508277226e-08
32 O 0 2.423909393201029e-07
% O 0 1.3949715160777032e-08
of O 0 7.2392261074583075e-09
the O 0 4.642447848368647e-08
44 O 0 7.327740831897245e-07
unrelated O 0 1.9114866063318914e-06
alleles O 0 3.3900482776516583e-07
in O 0 1.9144296459217003e-07
these O 0 8.815118803795485e-07
patients O 0 3.924762859242037e-05
. O 0 7.5296838986105286e-06

One O 0 1.139255709858844e-05
is O 0 1.0350149750593118e-06
the O 0 2.5260425218220917e-07
T312S O 0 6.303444388322532e-05
mutation O 0 1.273489260711358e-06
, O 0 1.8525690848036902e-07
a O 0 2.139402397460799e-07
novel O 0 2.142078074029996e-06
mutation O 0 1.2079208318027668e-06
found O 0 1.3763740014383075e-07
exclusively O 0 1.589037168514551e-07
in O 0 1.1103888937213924e-06
milder O 0 0.042359720915555954
patients O 0 0.00023096034419722855
. O 0 1.1627550520643126e-05

The O 0 4.339190581958974e-06
other O 0 5.353882102099305e-07
is O 0 2.1757890067419794e-07
the O 0 1.0967989538812617e-07
previously O 0 8.107055009531905e-07
described O 0 6.093739557400113e-06
I113F O 0 7.368143269559368e-05
that O 0 2.908608394136536e-07
produces O 0 8.33082685858244e-06
a O 0 1.308943046751665e-05
severe O 0 0.007217638660222292
phenotype O 0 0.001069850753992796
. O 0 3.430210199439898e-05

The O 0 1.072327904694248e-05
I113F O 0 0.00010450071567902341
and O 0 1.7888354477690882e-06
T312S O 0 8.856881322572008e-05
mutations O 0 2.267455329274526e-06
accounted O 0 9.287765010412841e-07
for O 0 3.420385397134851e-08
8 O 0 3.9818181107875716e-07
( O 0 2.5009663673358773e-08
18 O 0 8.162370335185187e-08
% O 0 2.4073724347317693e-08
) O 0 1.862041187905561e-08
and O 0 5.316647389008722e-08
6 O 0 7.008890179349692e-07
( O 0 3.068160481234372e-08
14 O 0 8.465873690965964e-08
% O 0 2.8020716413834634e-08
) O 0 4.995773128513292e-09
of O 0 1.6561273241677554e-08
44 O 0 3.943430897379585e-07
unrelated O 0 1.6090965573312133e-06
alleles O 0 6.115747055446263e-07
, O 0 5.13091606535454e-07
respectively O 0 3.768496753764339e-06
. O 0 6.566699084942229e-06

The O 0 8.170021828846075e-06
relatively O 0 1.4794015442021191e-05
high O 0 8.619817890576087e-06
residual O 0 3.9946949982549995e-05
GALNS O 0 0.000592435710132122
activity O 0 1.7337160898023285e-06
seen O 0 1.0143165809495258e-06
when O 0 6.50281961611654e-08
the O 0 2.7478169073447134e-08
T312S O 0 2.8549407034006435e-06
mutant O 0 4.6918350449232094e-07
cDNA O 0 5.052230562796467e-07
is O 0 6.384187400954033e-08
overexpressed O 0 1.6911790226004086e-06
in O 0 4.723504432035952e-08
mutant O 0 1.4758636552869575e-06
cells O 0 3.9319621691902285e-07
provides O 0 3.120325331451568e-08
an O 0 1.2942487970235561e-08
explanation O 0 1.4378908019807568e-07
for O 0 9.85776154038831e-08
the O 0 1.0272101462760475e-06
mild O 0 0.13274483382701874
phenotype O 0 0.00046804980956949294
in O 0 1.104469265555963e-05
patients O 0 4.115082265343517e-05
with O 0 2.1976188691041898e-07
this O 0 4.4099428464505763e-07
mutation O 0 9.560789294482674e-06
. O 0 6.0460461099864915e-06

The O 0 2.7848195713886525e-06
distribution O 0 2.2539654764841544e-06
and O 0 1.9303871567899478e-07
relative O 0 5.365135962165368e-07
frequencies O 0 6.225317150665433e-08
of O 0 1.2116255554417421e-08
the O 0 4.024813904379698e-08
I113F O 0 9.103226147999521e-06
and O 0 1.4414331417356152e-07
T312S O 0 1.556029928906355e-05
mutations O 0 3.8215284803300165e-07
in O 0 3.094277545301338e-08
Australia O 0 3.5279569488011475e-08
corresponded O 0 9.264555700383426e-08
to O 0 1.9911432502794923e-08
those O 0 2.1822222251444146e-08
observed O 0 1.0793436899803055e-07
in O 0 3.1270520395310086e-08
Northern O 0 2.731748907081055e-07
Ireland O 0 2.454941068208427e-07
and O 0 7.968515802758702e-08
are O 0 1.4556238880913952e-08
unique O 0 1.223310430731317e-08
to O 0 4.376180751108905e-09
these O 0 5.406068481761395e-09
two O 0 2.083399230912164e-08
populations O 0 1.4921573665560572e-07
, O 0 6.727539414441708e-08
suggesting O 0 3.7007569630986836e-07
that O 0 2.6092685345702193e-08
both O 0 3.46893820335481e-08
mutations O 0 1.8805658896781097e-07
were O 0 7.845319061061673e-08
probably O 0 1.1000357602597433e-07
introduced O 0 6.717308309589498e-08
to O 0 3.917700652777967e-08
Australia O 0 6.197771540428221e-08
by O 0 8.709821486263536e-08
Irish O 0 3.6307457662587694e-07
migrants O 0 1.3656341479872935e-07
during O 0 1.0641880976436369e-07
the O 0 5.6565301775890475e-08
19th O 0 1.7128805893662502e-06
century O 0 7.246754648804199e-06
. O 0 5.793151103716809e-06

Haplotype O 0 0.0006213244632817805
analysis O 0 1.289060583076207e-05
using O 0 2.287976030856953e-06
6 O 0 2.9792956866003806e-06
RFLPs O 0 3.664862742880359e-05
provides O 0 1.5369708705748053e-07
additional O 0 7.038295279926388e-08
data O 0 1.3080027372325276e-07
that O 0 2.0497108010886222e-08
the O 0 4.879862558482273e-08
I113F O 0 1.6191688700928353e-05
mutation O 0 2.9781460852973396e-07
originated O 0 5.990575147052368e-08
from O 0 2.86973040886096e-08
a O 0 3.019810321802652e-07
common O 0 1.1766368288590456e-06
ancestor O 0 8.673002412251662e-06
. O 0 8.622703717264812e-06

The O 0 4.967962013324723e-06
other O 0 6.790832571823557e-07
9 O 0 3.61395404979703e-06
novel O 0 1.2284319836908253e-06
mutations O 0 2.2477577203972032e-06
identified O 0 6.200076541063027e-07
in O 0 3.9965250664408813e-08
these O 0 4.9791093914564044e-08
23 O 0 9.587384738551918e-06
patients O 0 1.5148576721912832e-06
were O 0 2.6644951134358053e-08
each O 0 5.298493199745735e-09
limited O 0 8.301922349573942e-08
to O 0 3.546537641341274e-08
a O 0 1.7855991529813764e-07
single O 0 1.966130184882786e-06
family O 0 7.3557371251808945e-06
. O 0 3.5937243865191704e-06

These O 0 4.8240917749353684e-06
data O 0 2.512696028134087e-06
provide O 0 4.301029719044891e-07
further O 0 1.2542045624286402e-07
evidence O 0 3.377682276095584e-07
for O 0 1.2001351024082396e-07
extensive O 0 4.411752797750523e-06
allelic O 0 9.391303319716826e-05
heterogeneity O 0 0.0002931681810878217
in O 0 9.329773092758842e-06
MPS B-Disease 1 0.9541481137275696
IVA I-Disease 1 0.999921441078186
in O 0 1.2724185580736957e-06
British O 0 1.5014276868896559e-05
- O 0 0.10172422230243683
Irish O 0 0.00020795047748833895
patients O 0 2.7137668439536355e-05
and O 0 1.564416294286275e-07
provide O 0 9.56294812226588e-08
evidence O 0 3.7419917475745024e-07
for O 0 3.834926332046962e-08
their O 0 3.0203970879938424e-08
transmission O 0 1.0080121910505113e-06
to O 0 4.542047449263009e-08
Australia O 0 6.173726063707363e-08
by O 0 1.280735801856281e-07
British O 0 2.2471447209682083e-06
- O 0 0.00044232196523807943
Irish O 0 4.0058689592115115e-06
migrants O 0 1.4242978068068624e-06
. O 0 4.698645739154017e-07
. O 0 2.3103584680939093e-06

Identification O 0 2.4763867259025574e-05
of O 0 3.2988953080348438e-06
constitutional O 0 3.976580046582967e-05
WT1 O 0 0.3293233811855316
mutations O 0 0.00014199766155797988
, O 0 2.370941501794732e-06
in O 0 1.7770147451301455e-06
patients O 0 3.538492455845699e-05
with O 0 3.3823216654127464e-06
isolated O 0 0.0568375438451767
diffuse B-Disease 1 0.998781144618988
mesangial I-Disease 1 0.9999998807907104
sclerosis I-Disease 1 0.9999992847442627
, O 0 3.947128789150156e-06
and O 0 1.4223552113890037e-07
analysis O 0 2.3523870140707004e-07
of O 0 5.195736321184086e-07
genotype O 0 0.012370506301522255
/ O 0 0.010121139697730541
phenotype O 0 5.304289879859425e-05
correlations O 0 1.4495788491331041e-05
by O 0 1.3384287456119637e-07
use O 0 1.3710078405893e-07
of O 0 1.161366469659697e-07
a O 0 2.2797776182414964e-06
computerized O 0 0.0002229146339232102
mutation O 0 2.2845375497126952e-05
database O 0 1.2992821211810224e-05
. O 0 7.471301614714321e-06

Constitutional O 0 0.0001124213304137811
mutations O 0 2.3072114345268346e-05
of O 0 4.2283841139578726e-07
the O 0 4.2240071707055904e-07
WT1 O 0 0.0006775085930712521
gene O 0 1.0174273938901024e-06
, O 0 1.2075055622062791e-07
encoding O 0 1.602571160219668e-07
a O 0 5.627200607705163e-07
zinc O 0 0.00044630319462157786
- O 0 0.00010256944369757548
finger O 0 9.243739441444632e-06
transcription O 0 2.1195170063492696e-07
factor O 0 1.1932387167234992e-07
involved O 0 2.5178411533488543e-07
in O 0 1.8581971517050988e-06
renal O 1 0.9974309802055359
and O 0 3.189918970747385e-06
gonadal O 0 0.05663224682211876
development O 0 2.5265319436584832e-06
, O 0 3.1334826644524583e-07
are O 0 3.3775460650531386e-08
found O 0 1.455997988841773e-07
in O 0 7.280812752696875e-08
most O 0 3.468601335043786e-07
patients O 0 2.346297833355493e-06
with O 0 2.794263991745538e-06
Denys B-Disease 1 0.9994221925735474
- I-Disease 1 0.9999840259552002
Drash I-Disease 1 0.9999961853027344
syndrome I-Disease 1 0.999969482421875
( O 0 2.47181214945158e-05
DDS B-Disease 1 0.9999736547470093
) O 0 7.08160712292738e-07
, O 0 7.48789773297176e-07
or O 0 2.502377174096182e-05
diffuse B-Disease 1 0.997090220451355
mesangial I-Disease 1 0.9999998807907104
sclerosis I-Disease 1 0.9999997615814209
( O 0 0.0001680729037616402
DMS B-Disease 1 0.9742514491081238
) O 0 7.005989459685225e-07
associated O 0 8.377141966775525e-07
with O 0 6.781008892176033e-07
pseudohermaphroditism B-Disease 1 0.9990299940109253
and O 0 2.5053765057236888e-05
/ O 0 0.020961401984095573
or O 0 0.0009241336956620216
Wilms B-Disease 1 0.9999170303344727
tumor I-Disease 1 0.9266021251678467
( O 0 1.7108748579630628e-05
WT B-Disease 1 0.983349084854126
) O 0 1.6401477296312805e-06
. O 0 4.609906682162546e-06

Most O 0 3.317791924928315e-05
mutations O 0 0.00012022425653412938
in O 0 3.711847239173949e-05
DDS B-Disease 1 0.9999964237213135
patients O 0 0.24884191155433655
lie O 0 0.0019422031473368406
in O 0 3.455322428180807e-07
exon O 0 2.4983377443277277e-05
8 O 0 6.974137818360759e-07
or O 0 8.043645749467032e-08
exon O 0 1.2103803328500362e-06
9 O 0 3.420059897507599e-07
, O 0 4.4364753648551414e-08
encoding O 0 1.8660787759472441e-07
zinc O 0 5.157610939932056e-05
finger O 0 1.0271317478327546e-05
2 O 0 3.8721918826922774e-07
or O 0 3.0192745725798886e-07
zinc O 0 6.110398680903018e-05
finger O 0 4.5556271288660355e-06
3 O 0 1.5805628095222346e-07
, O 0 2.5562298944237227e-08
respectively O 0 1.1755280837633109e-07
, O 0 3.4214227895290605e-08
with O 0 2.205533711219232e-08
a O 0 1.3122408404342423e-07
hot O 0 4.503656236920506e-05
spot O 0 1.1376067050150596e-05
( O 0 1.4177102514167927e-07
R394W O 0 3.7326396977732657e-06
) O 0 4.337293546541332e-08
in O 0 5.915286394042596e-08
exon O 0 1.0615282917569857e-05
9 O 0 5.416079602582613e-06
. O 0 4.051829364470905e-06

We O 0 1.0953018318105023e-05
analyzed O 0 6.779516752430936e-06
a O 0 2.9671750212401093e-07
series O 0 2.388196946867538e-07
of O 0 1.88258823641263e-07
24 O 0 1.5555047866655514e-05
patients O 0 1.1585689208004624e-05
, O 0 2.1576714459570212e-07
10 O 0 3.5252301699983946e-07
with O 0 1.9275114482297795e-06
isolated B-Disease 0 0.007901869714260101
DMS I-Disease 1 0.9405789375305176
( O 0 1.583917082825792e-06
IDMS B-Disease 0 0.003481160616502166
) O 0 1.8006628010880377e-07
, O 0 1.1712970149346802e-07
10 O 0 1.5258743246704398e-07
with O 0 9.423937967767415e-07
DDS B-Disease 1 0.9998677968978882
, O 0 6.814896096329903e-07
and O 0 2.84674712247579e-07
4 O 0 3.551459940354107e-06
with O 0 3.955007287004264e-06
urogenital B-Disease 1 0.9909710884094238
abnormalities I-Disease 1 0.8537861108779907
and O 0 2.0418176063685678e-05
/ O 0 0.014308663085103035
or O 0 9.987067460315302e-05
WT B-Disease 1 0.99858558177948
. O 0 2.9590795747935772e-05

We O 0 2.1438137991935946e-05
report O 0 1.0895407285715919e-05
WT1 O 0 0.0008648915681988001
heterozygous O 0 1.320709543506382e-05
mutations O 0 3.028675337191089e-06
in O 0 4.944104148307815e-07
16 O 0 6.909933745191665e-06
patients O 0 8.040137799980585e-06
, O 0 1.6379766520913108e-07
4 O 0 8.687039212418313e-07
of O 0 4.390103072182683e-07
whom O 0 9.555984433973208e-06
presented O 0 1.0286070391885005e-05
with O 0 2.1386436856118962e-05
IDMS B-Disease 1 0.7173827290534973
. O 0 1.4408794413611759e-05

One O 0 1.1631864254013635e-05
male O 0 8.133780283969827e-06
and O 0 1.1808298268078943e-06
two O 0 1.1453619208623422e-06
female O 0 8.83774773683399e-05
IDMS B-Disease 1 0.9993608593940735
patients O 0 0.0003914622066076845
with O 0 1.0262426258123014e-05
WT1 O 1 0.6858910322189331
mutations O 0 8.085768786258996e-05
underwent O 0 0.0009391542989760637
normal O 0 5.552973743760958e-05
puberty O 0 0.0007446574163623154
. O 0 1.9006358343176544e-05

Two O 0 3.452809323789552e-05
mutations O 0 0.00026706926291808486
associated O 0 1.7287735317950137e-05
with O 0 3.572197556422907e-06
IDMS B-Disease 0 0.20133672654628754
are O 0 9.102743092626042e-08
different O 0 3.8184893469406234e-08
from O 0 6.79366465305975e-08
those O 0 1.668916809194343e-07
described O 0 3.9081314753275365e-05
in O 0 5.2233037422411144e-05
DDS B-Disease 1 0.9999964237213135
patients O 0 0.0020557234529405832
. O 0 1.77205256477464e-05

No O 0 0.00012932895333506167
WT1 O 0 0.009737087413668633
mutations O 0 3.910062514478341e-05
were O 0 9.482718041908811e-07
detected O 0 8.37329662317643e-06
in O 0 5.879146414144998e-08
the O 0 6.644989980486571e-08
six O 0 5.285656925479998e-07
other O 0 2.174802602894488e-06
IDMS B-Disease 1 0.9989908337593079
patients O 0 0.00014192696835380048
, O 0 6.609332103835186e-07
suggesting O 0 7.37954269425245e-06
genetic O 0 1.1945646292588208e-05
heterogeneity O 0 6.143581413198262e-05
of O 0 1.5595735476381378e-06
this O 0 2.166659032809548e-05
disease O 0 0.004030961077660322
. O 0 1.4550068044627551e-05

We O 0 1.562638681207318e-05
analyzed O 0 4.960736623615958e-05
genotype O 0 0.0007336297421716154
/ O 0 0.000500133668538183
phenotype O 0 6.12675430602394e-05
correlations O 0 6.97597861289978e-05
, O 0 7.799037007316656e-07
on O 0 1.9430001430009725e-07
the O 0 3.277784799138317e-08
basis O 0 9.068811124279819e-08
of O 0 3.369817846987644e-08
the O 0 7.254931944089549e-08
constitution O 0 7.018964254257298e-08
of O 0 4.821253796194469e-08
a O 0 1.1777302688642521e-06
WT1 O 0 0.0014005328994244337
mutation O 0 3.595811790546577e-07
database O 0 1.4481585708381317e-07
of O 0 6.684754083607913e-08
84 O 0 1.0712618859543e-05
germ O 0 0.0013694168301299214
- O 0 0.00034510064870119095
line O 0 1.0966104127874132e-05
mutations O 0 4.308698748900497e-07
, O 0 3.57796885452899e-08
to O 0 1.9543747953321144e-08
compare O 0 2.037507300656216e-07
the O 0 7.554485925709287e-09
distribution O 0 1.197599317492859e-07
and O 0 5.658655766183074e-08
type O 0 5.651720016430772e-07
of O 0 3.0563271025130234e-08
mutations O 0 6.066690048101009e-07
, O 0 6.361675985999682e-08
according O 0 5.6107342771838375e-08
to O 0 2.5024789351846266e-08
the O 0 1.335617270115108e-07
different O 0 7.571669584649499e-07
symptoms O 0 4.685568273998797e-05
. O 0 8.283895112981554e-06

This O 0 7.400481081276666e-06
demonstrated O 0 6.994332579779439e-06
( O 0 1.4050444008262275e-07
1 O 0 1.7151678832760808e-07
) O 0 2.1688318696533315e-08
the O 0 1.4098194611733561e-08
association O 0 6.204051317126869e-08
between O 0 5.038397432599595e-08
mutations O 0 3.071574496971152e-07
in O 0 1.7982717537279314e-08
exons O 0 5.467239816425717e-07
8 O 0 2.843979132194363e-07
and O 0 5.3902972751984635e-08
9 O 0 6.22243817360868e-07
and O 0 4.48991471557747e-07
DMS B-Disease 0 0.09255340695381165
; O 0 1.951697043978129e-07
( O 0 3.7124884499917243e-08
2 O 0 1.7684185138477915e-07
) O 0 2.7797511847893475e-08
among O 0 2.1373428182869247e-07
patients O 0 1.8167108919442398e-06
with O 0 5.403575755735801e-07
DMS B-Disease 0 0.165683776140213
, O 0 5.851156714697936e-08
a O 0 1.9998479316996054e-08
higher O 0 3.122956826473455e-08
frequency O 0 3.885715571527726e-08
of O 0 2.200634163784798e-08
exon O 0 2.398171545792138e-06
8 O 0 1.159668045147555e-06
mutations O 0 6.58377814488631e-07
among O 0 1.6010038450531283e-07
46 O 0 5.186743237572955e-06
, O 0 2.7535413664736552e-06
XY O 1 0.8288310170173645
patients O 0 0.00010737904813140631
with O 0 5.689217346116493e-07
female O 0 9.089077366297715e-07
phenotype O 0 5.506492925633211e-06
than O 0 1.646780845021567e-07
among O 0 4.0458576222590636e-07
46 O 0 2.5163933969452046e-05
, O 0 1.2678709026658908e-05
XY O 1 0.9921567440032959
patients O 0 0.00014438565995078534
with O 0 6.520829174405662e-07
sexual O 0 5.4693964557372965e-06
ambiguity O 0 1.3029724868829362e-05
or O 0 1.2841268471674994e-05
male O 0 5.0143762564403005e-06
phenotype O 0 2.4509516151738353e-05
; O 0 5.107804099679925e-07
and O 0 4.4663534026767593e-07
( O 0 7.179235694820818e-08
3 O 0 2.3566309437228483e-07
) O 0 1.775200253462117e-08
statistically O 0 3.2314704867530963e-07
significant O 0 1.561076317102561e-07
evidence O 0 1.6553796911011887e-07
that O 0 3.792822766968129e-08
mutations O 0 1.7325034207260614e-07
in O 0 2.886858752049193e-08
exons O 0 7.098572609720577e-07
8 O 0 1.936545857006422e-07
and O 0 8.217966751544736e-08
9 O 0 2.3128265524974267e-07
preferentially O 0 3.4419662142681773e-07
affect O 0 8.513448079838781e-08
amino O 0 2.4162048362086352e-08
acids O 0 1.2926254733258702e-08
with O 0 5.333270713947513e-09
different O 0 7.559458836681188e-09
functions O 0 5.589307860986992e-08
. O 0 1.5906140049537498e-07
. O 0 2.075686325042625e-06

The O 0 2.309115370735526e-05
185delAG O 0 0.0018127424409613013
BRCA1 O 0 0.0009288546862080693
mutation O 0 8.196947419492062e-06
originated O 0 7.198994467216835e-07
before O 0 1.7161610799121263e-07
the O 0 3.828619199452987e-08
dispersion O 0 2.3533209514425835e-06
of O 0 6.112411909953153e-08
Jews O 0 5.770218649558956e-07
in O 0 4.023463162639018e-08
the O 0 2.5386313495801005e-08
diaspora O 0 7.759768436699233e-07
and O 0 2.145139319509326e-07
is O 0 1.0188892929363647e-07
not O 0 6.288699694323441e-08
limited O 0 5.020554567636282e-07
to O 0 1.336666286988475e-06
Ashkenazim O 0 0.0005291310953907669
. O 0 7.5472116805030964e-06

The O 0 8.201639502658509e-06
185delAG O 0 0.000470629456685856
mutation O 0 1.678316948527936e-05
in O 0 9.428153475710133e-07
BRCA1 O 0 6.0096797824371606e-05
is O 0 5.796063078378211e-07
detected O 0 9.636187314754352e-06
in O 0 1.7043052480403276e-07
Ashkenazi O 0 1.694255115580745e-05
Jews O 0 5.011838766222354e-07
both O 0 6.771503535674128e-08
in O 0 1.107075036088645e-06
familial B-Disease 1 0.8936803340911865
breast I-Disease 1 0.9998410940170288
and I-Disease 1 0.998216450214386
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999929666519165
and O 0 8.786976650299039e-06
in O 0 4.2685684320531436e-07
the O 0 2.897727142681106e-07
general O 0 2.236134832855896e-06
population O 0 9.22521337543003e-07
. O 0 4.734089088742621e-06

All O 0 2.90166208287701e-05
tested O 0 0.00011286591325188056
Ashkenazi O 0 0.00039400282548740506
mutation O 0 9.644581041357014e-06
carriers O 0 3.566492523532361e-06
share O 0 3.596796034344152e-07
the O 0 9.412030976818642e-08
same O 0 1.5424890875692654e-07
allelic O 0 1.215241809404688e-05
pattern O 0 3.4063923521898687e-06
at O 0 8.016946253519563e-07
the O 0 5.907821787332068e-07
BRCA1 O 0 0.00013216921070124954
locus O 0 6.551403930643573e-05
. O 0 1.5331281247199513e-05

Our O 0 1.3852132724423427e-05
previous O 0 3.3187116059707478e-06
study O 0 6.636105354118627e-07
showed O 0 1.6667009958837298e-06
that O 0 5.519556367516998e-08
this O 0 5.652604428973973e-08
Ashkenazi O 0 3.503821790218353e-05
mutation O 0 8.825541044643614e-07
also O 0 9.628727326571607e-08
occurs O 0 1.0514187209764714e-07
in O 0 4.125496744222801e-08
Iraqi O 0 3.608143686051335e-07
Jews O 0 4.701277021013084e-07
with O 0 9.706171510970307e-08
a O 0 6.157204666124017e-07
similar O 0 5.125250936544035e-06
allelic O 0 0.0002489532344043255
pattern O 0 5.578912896453403e-05
. O 0 8.43560428620549e-06

We O 0 5.5936493481567595e-06
extended O 0 1.2091920780221699e-06
our O 0 1.5145398890581419e-07
analysis O 0 1.1030529378786014e-07
to O 0 2.574372892638621e-08
other O 0 2.629818496302505e-08
non O 0 1.08376093521656e-06
- O 0 4.970292138750665e-05
Ashkenazi O 0 2.6381239877082407e-06
subsets O 0 9.89615159596724e-07
354 O 0 5.944347662989458e-07
of O 0 2.9330079698297595e-08
Moroccan O 0 2.6560271635389654e-06
origin O 0 1.526510260418945e-07
, O 0 5.084397614041336e-08
200 O 0 1.3441787416468287e-07
Yemenites O 0 4.894590347248595e-06
and O 0 7.131836099460998e-08
150 O 0 5.056834879724192e-07
Iranian O 0 1.7807333279051818e-06
Jews O 0 4.032585366076091e-06
. O 0 3.689747700263979e-06

Heteroduplex O 0 0.0013105999678373337
analysis O 0 8.535210326954257e-06
complemented O 0 4.819718469661893e-06
by O 0 1.8247001776217076e-07
direct O 0 1.878257336329625e-07
DNA O 0 9.625400707591325e-07
sequencing O 0 7.518502229686419e-07
of O 0 2.599622064280993e-07
abnormally O 0 5.2973646234022453e-05
migrating O 0 1.1733983455997077e-06
bands O 0 1.8049918253382202e-06
were O 0 4.105386892661045e-07
employed O 0 4.389568402984878e-06
. O 0 4.3188124436710496e-06

Four O 0 6.6480215537012555e-06
of O 0 7.645754749319167e-07
Moroccan O 0 1.9282841094536707e-05
origin O 0 4.786472800333286e-07
( O 0 7.12153251924974e-08
1 O 0 8.845125165635181e-08
. O 0 1.7709458788317534e-08
1 O 0 1.4789775093504431e-07
% O 0 3.7016562259850616e-08
) O 0 1.5095528382857992e-08
and O 0 3.661015668399159e-08
none O 0 6.977690958365201e-08
of O 0 1.3363059991888804e-08
the O 0 1.0790287774398166e-07
Yemenites O 0 4.560814704746008e-05
or O 0 2.1521228177334706e-07
Iranians O 0 5.023624680688954e-07
was O 0 3.2458663667966903e-07
a O 0 1.965069458265134e-07
carrier O 0 3.8003611280146288e-06
of O 0 5.835820715560658e-08
the O 0 5.368237339098414e-07
185delAG O 0 0.0005493519129231572
mutation O 0 2.1758460206910968e-05
. O 0 6.006495368637843e-06

BRCA1 O 0 0.008106468245387077
allelic O 0 0.0016666679875925183
patterns O 0 0.0001074467581929639
were O 0 2.4082144136627903e-06
determined O 0 4.646744855563156e-06
for O 0 9.510107190635608e-08
four O 0 4.733344027840758e-08
of O 0 2.1685091056156125e-08
these O 0 3.426699635156183e-08
individuals O 0 3.193840569792883e-08
and O 0 4.204795445161835e-08
for O 0 2.112727592873398e-08
12 O 0 8.661529449227601e-08
additional O 0 4.531205277658046e-08
non O 0 1.8006265918302233e-06
- O 0 0.0005532109062187374
Ashkenazi O 0 7.430717232637107e-05
185delAG O 0 6.719943485222757e-05
mutation O 0 1.984933760468266e-06
carriers O 0 2.7365881578589324e-06
who O 0 2.985211267514387e-06
had O 0 0.00022771758085582405
breast B-Disease 1 0.9999555349349976
/ I-Disease 1 0.9999942779541016
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999984622001648
. O 0 0.0002234338317066431

Six O 0 3.488595029921271e-05
non O 0 4.1603601857787e-05
- O 0 0.00438437145203352
Ashkenazi O 0 0.0002551380021031946
individuals O 0 2.6980796974385157e-07
shared O 0 2.0126637423345528e-07
the O 0 1.4857646135624236e-07
common O 0 2.679300223462633e-06
Ashkenazi O 0 0.0004201181582175195
haplotype O 0 8.066392183536664e-05
, O 0 6.288051395131333e-07
four O 0 1.6194989882478694e-07
had O 0 2.7828716042677115e-07
a O 0 3.171556102188333e-07
closely O 0 1.169006509371684e-06
related O 0 5.041467829869362e-06
pattern O 0 1.0486481187399477e-05
, O 0 2.529641847104358e-07
and O 0 8.692412478694678e-08
the O 0 4.1637736813981974e-08
rest O 0 5.096650852465245e-07
( O 0 1.6163944849267864e-07
n O 0 9.965625213226303e-05
= O 0 6.347728231048677e-06
6 O 0 2.3702921225776663e-07
) O 0 3.074217502785359e-08
displayed O 0 2.647125825205876e-07
a O 0 2.9201649454080325e-07
distinct O 0 3.0395176509045996e-06
BRCA1 O 0 0.0002763174707069993
allelic O 0 0.00022107652330305427
pattern O 0 0.0001036297544487752
. O 0 1.681455432844814e-05

We O 0 1.4639213986811228e-05
conclude O 0 1.0505469617783092e-05
that O 0 2.636787996834755e-07
the O 0 3.361672042956343e-07
185delAG O 0 0.0004159322415944189
BRCA1 O 0 0.0003891302039846778
mutation O 0 3.830310561170336e-06
occurs O 0 2.3043503460939974e-07
in O 0 2.070311211355147e-08
some O 0 1.2959681328084116e-08
non O 0 1.0182748155784793e-06
- O 0 0.00029999794787727296
Ashkenazi O 0 3.744316927623004e-05
populations O 0 1.9443217524894862e-07
at O 0 1.7854084433110984e-07
rates O 0 3.9490757330895576e-07
comparable O 0 6.262909550969198e-07
with O 0 4.4919143959987196e-08
that O 0 6.486579451348007e-08
of O 0 7.58513351684087e-07
Ashkenazim O 0 0.0005889154272153974
. O 0 8.711315786058549e-06

The O 0 6.788315204175888e-06
majority O 0 3.965310497733299e-06
of O 0 5.636605351355684e-07
Jewish O 0 5.087485988042317e-06
185delAG O 0 0.0006531861727125943
mutation O 0 1.1824744433397427e-05
carriers O 0 3.4092167879862245e-06
have O 0 7.804514723375178e-08
a O 0 2.3881628408162214e-07
common O 0 4.300808313928428e-07
allelic O 0 3.911957173841074e-05
pattern O 0 3.0063503800192848e-05
, O 0 3.5227333228249336e-07
supporting O 0 3.755914121938986e-07
the O 0 7.427756543165742e-08
founder O 0 5.769888957729563e-06
effect O 0 2.3204178489777405e-07
notion O 0 2.0495552632837644e-07
, O 0 9.15400093504104e-08
but O 0 3.9644859839427227e-08
dating O 0 4.420646746439161e-07
the O 0 3.4526667747059037e-08
mutations O 0 1.3995826009249868e-07
origin O 0 1.200409460722085e-08
to O 0 1.457224030332327e-08
an O 0 1.287031103913705e-08
earlier O 0 4.000644366897177e-07
date O 0 7.403823474305682e-07
than O 0 8.120552053014762e-08
currently O 0 3.23579996575063e-07
estimated O 0 3.946450760849984e-06
. O 0 3.534164534357842e-06

However O 0 2.2472631826531142e-05
, O 0 9.681299388830666e-07
the O 0 6.000432506425568e-08
different O 0 3.573985551952319e-08
allelic O 0 6.138926892162999e-06
pattern O 0 6.6862603489425965e-06
at O 0 3.631899119227455e-07
the O 0 9.766599617933025e-08
BRCA1 O 0 1.910889841383323e-05
locus O 0 1.7624730617171736e-06
even O 0 3.7454123003044515e-07
in O 0 2.903430207368274e-08
some O 0 1.4171878781610303e-08
Jewish O 0 2.722515830555494e-07
mutation O 0 1.835426530760742e-07
carriers O 0 7.19753870725981e-07
, O 0 1.5267927722106833e-07
might O 0 2.312061297971013e-07
suggest O 0 2.850172222679248e-07
that O 0 3.911279478074903e-08
the O 0 1.1245985120922342e-07
mutation O 0 1.0183738368141348e-06
arose O 0 1.0445561429150985e-06
independently O 0 3.9262292261810217e-07
. O 0 3.2055066867542337e-07
. O 0 2.819503606588114e-06

Crystal O 0 0.03508178889751434
structure O 0 2.2938638721825555e-05
of O 0 2.0637294255720917e-06
the O 0 5.2453310672717635e-06
hemochromatosis B-Disease 1 0.999927282333374
protein O 0 1.4302748240879737e-05
HFE O 0 0.0032752840779721737
and O 0 4.1260875605075853e-07
characterization O 0 1.8324374195799464e-06
of O 0 4.083924665110317e-08
its O 0 9.186533844740552e-08
interaction O 0 3.0453935551122413e-07
with O 0 4.467162852961337e-07
transferrin O 0 0.0004998320364393294
receptor O 0 1.7772719729691744e-05
. O 0 3.883551471517421e-06

HFE O 0 0.24817055463790894
is O 0 1.341527695331024e-05
an O 0 8.681838039592549e-07
MHC O 0 0.009310122579336166
- O 0 0.0005345037789084017
related O 0 7.130997346393997e-06
protein O 0 1.933482423055466e-07
that O 0 2.3413388561266402e-08
is O 0 3.413196836277166e-08
mutated O 0 2.8813087737944443e-07
in O 0 1.035673022897754e-07
the O 0 1.6553937030039378e-06
iron B-Disease 1 0.9136547446250916
- I-Disease 1 0.9998685121536255
overload I-Disease 1 0.9999403953552246
disease I-Disease 1 0.9998800754547119
hereditary B-Disease 1 0.9999970197677612
hemochromatosis I-Disease 1 0.9999994039535522
. O 0 0.0022264376748353243

HFE O 0 0.015209581702947617
binds O 0 0.00011907966836588457
to O 0 9.9196904557175e-06
transferrin O 0 0.0006945886998437345
receptor O 0 2.9131351766409352e-05
( O 0 7.465450835297816e-07
TfR O 0 2.1875326638109982e-05
) O 0 9.269787426546827e-08
and O 0 8.180605703955734e-08
reduces O 0 4.411414806781977e-07
its O 0 4.701608702362137e-08
affinity O 0 3.258542733419745e-07
for O 0 8.942767237840599e-08
iron O 0 3.887201091856696e-05
- O 0 2.8964368539163843e-05
loaded O 0 1.0137838216905948e-05
transferrin O 0 5.110737038194202e-05
, O 0 3.430411652516341e-07
implicating O 0 6.854747334728017e-05
HFE O 0 0.005258317571133375
in O 0 3.6699480006063823e-06
iron O 0 0.0021682935766875744
metabolism O 0 5.254468123894185e-05
. O 0 8.59111787576694e-06

The O 0 1.7662641766946763e-05
2 O 0 3.0367904400918633e-05
. O 0 2.00344711629441e-05

6 O 0 0.0002005068672588095
A O 0 2.25183684960939e-05
crystal O 0 0.0011817433405667543
structure O 0 2.670631829460035e-06
of O 0 6.018772751303914e-07
HFE O 0 0.043931569904088974
reveals O 0 1.0957615813822486e-05
the O 0 1.22183024586775e-07
locations O 0 2.125744913428207e-06
of O 0 1.1291822374914773e-05
hemochromatosis B-Disease 1 0.9999974966049194
mutations O 0 6.557597953360528e-05
and O 0 3.7487679946934804e-06
a O 0 4.443222223926568e-06
patch O 1 0.7124509215354919
of O 0 1.6081637568277074e-06
histidines O 0 0.008185625076293945
that O 0 1.437885401855965e-07
could O 0 1.5450804369265825e-07
be O 0 1.6743268105301468e-08
involved O 0 6.201211988354771e-08
in O 0 2.1176259679123177e-07
pH O 0 0.0008680488099344075
- O 0 0.00010178705269936472
dependent O 0 3.5260477488918696e-06
interactions O 0 2.4544615371269174e-06
. O 0 2.6723284918261925e-06

We O 0 1.2304320989642292e-05
also O 0 7.849777148294379e-07
demonstrate O 0 1.935118234541733e-06
that O 0 3.625078761615441e-07
soluble O 0 5.563118611462414e-05
TfR O 0 5.543016595765948e-05
and O 0 5.688219175681297e-07
HFE O 0 0.0009188929107040167
bind O 0 2.3882478217274183e-06
tightly O 0 1.814186589399469e-06
at O 0 2.563439807090617e-07
the O 0 3.8501564603166116e-08
basic O 0 2.208085163601936e-07
pH O 0 7.916183676570654e-06
of O 0 3.401381931666947e-08
the O 0 7.286202929890351e-08
cell O 0 2.1690488210879266e-05
surface O 0 2.6645142497727647e-05
, O 0 6.031896759850497e-08
but O 0 2.3110709790330475e-08
not O 0 1.4363293665553556e-08
at O 0 6.493758775150127e-08
the O 0 1.175092165794922e-07
acidic O 0 0.0001385453506372869
pH O 0 2.7088024580734782e-05
of O 0 2.3779200830631453e-07
intracellular O 0 3.488115908112377e-05
vesicles O 0 0.00018374479259364307
. O 0 8.85368172021117e-06

TfR O 0 0.1656045913696289
HFE O 0 0.04759872704744339
stoichiometry O 0 0.0002228181401733309
( O 0 1.982173898795736e-06
2 O 0 1.0091874855788774e-06
1 O 0 2.5948912707463023e-07
) O 0 4.358980731922202e-08
differs O 0 1.130573110685873e-07
from O 0 1.3105824336889782e-07
TfR O 0 3.695296618388966e-05
transferrin O 0 2.185383164032828e-05
stoichiometry O 0 2.188029611716047e-06
( O 0 3.653036273476573e-08
2 O 0 1.089401706622084e-07
2 O 0 1.9362079228812945e-07
) O 0 1.5382077833692165e-08
, O 0 2.5134715642138872e-08
implying O 0 1.1334058314105278e-07
a O 0 1.26888419771376e-08
different O 0 3.439565077201223e-09
mode O 0 3.011147953202453e-08
of O 0 9.143788837207012e-09
binding O 0 2.955671902782342e-07
for O 0 1.1791625809109973e-07
HFE O 0 0.0005727209500037134
and O 0 8.704471383680357e-07
transferrin O 0 7.118185749277472e-05
to O 0 4.134122946197749e-07
TfR O 0 8.63759996718727e-05
, O 0 1.5796631203102152e-07
consistent O 0 1.9293528907837754e-07
with O 0 4.8983640255073624e-08
our O 0 5.683155279712082e-08
demonstration O 0 1.0500124290047097e-06
that O 0 9.829391700577617e-08
HFE O 0 0.00017886757268570364
, O 0 2.536797580887651e-07
transferrin O 0 4.537302447715774e-05
, O 0 2.0606698569736182e-07
and O 0 5.660922397510149e-07
TfR O 0 0.00011862248356919736
form O 0 3.904508503183024e-07
a O 0 1.22889480280719e-06
ternary O 0 0.00012853622320108116
complex O 0 0.00010851493425434455
. O 0 1.6582203897996806e-05

Identification O 0 2.45523751800647e-05
of O 0 8.891402103472501e-07
three O 0 5.576113721872389e-07
novel O 0 2.559893118814216e-06
mutations O 0 1.4408396964427084e-06
and O 0 9.119147392766536e-08
a O 0 1.1287168888429733e-07
high O 0 3.943727904243133e-07
frequency O 0 1.1349763440193783e-07
of O 0 3.1674751710397686e-08
the O 0 1.0527833183004986e-07
Arg778Leu O 0 6.912190292496234e-05
mutation O 0 6.250576234378968e-07
in O 0 4.3694194573618006e-07
Korean O 0 6.998667231528088e-05
patients O 0 4.372998955659568e-05
with O 0 1.608262573427055e-05
Wilson B-Disease 0 0.0931825190782547
disease I-Disease 0 0.0015332133043557405
. O 0 1.3307289918884635e-05

Four O 0 1.770339804352261e-05
mutations O 0 5.675416105077602e-05
- O 0 0.0002972786023747176
- O 0 0.00010774171823868528
R778L O 0 2.3542603230453096e-05
, O 0 2.1405658401363326e-07
A874V O 0 4.306346454541199e-06
, O 0 1.234336082234222e-07
L1083F O 0 5.9646422414516564e-06
, O 0 5.0663821582475066e-08
and O 0 4.796653385596983e-08
2304delC O 0 1.2651485121750738e-05
- O 0 2.013312951021362e-05
- O 0 1.1819760402431712e-05
in O 0 3.125710179574526e-08
the O 0 3.762058042866556e-08
copper O 0 1.4996803656686097e-05
- O 0 2.0291122382332105e-06
transporting O 0 6.12471239946899e-07
enzyme O 0 1.6403403435560904e-07
, O 0 6.964634025052874e-08
P O 0 4.259272100171074e-05
- O 0 2.062477960862452e-06
type O 0 4.4551563860295573e-07
ATPase O 0 2.274240159749752e-06
( O 0 3.6237302936115157e-08
ATP7B O 0 6.879896773170913e-06
) O 0 1.2463536869233849e-08
, O 0 7.1852466199118226e-09
were O 0 2.206804516902139e-08
identified O 0 1.937471267865476e-07
in O 0 1.0241030423685515e-07
Korean O 0 4.143390106037259e-05
Patients O 0 1.696090112091042e-05
with O 0 7.556653599749552e-06
Wilson B-Disease 0 0.0966896042227745
disease I-Disease 0 0.0013777678832411766
. O 0 1.063349009200465e-05

Arg778Leu O 0 0.008660579100251198
, O 0 4.326542239141418e-06
the O 0 2.4543675181121216e-07
most O 0 1.7328652290871105e-07
frequently O 0 4.07338404784241e-07
reported O 0 5.087861154606799e-07
mutation O 0 8.731277745255284e-08
of O 0 1.2901772095119668e-08
this O 0 1.6549906334262232e-08
enzyme O 0 1.683543615627059e-07
, O 0 1.231522333000612e-07
was O 0 3.25809537571331e-07
found O 0 7.360330300798523e-08
in O 0 1.024600848609225e-08
six O 0 3.0276588347533107e-08
of O 0 2.0046789117600383e-08
eight O 0 6.523503657263063e-07
unrelated O 0 7.518981874454767e-05
patients O 0 8.779120435065124e-06
studied O 0 2.6105860229108657e-07
, O 0 4.533219311042558e-08
an O 0 1.0668235184141395e-08
allele O 0 2.266297940423101e-07
frequency O 0 1.5447739087903756e-07
of O 0 1.5276143017217692e-07
37 O 0 4.169840849499451e-06
. O 0 3.90668674299377e-06

5 O 0 2.873995981644839e-05
% O 0 1.8544794784247642e-06
, O 0 3.3945906352528255e-07
which O 0 7.130149271006303e-08
is O 0 4.556468269356628e-08
considerably O 0 3.425948875701579e-07
higher O 0 7.882096753064616e-08
than O 0 1.7356960313463787e-08
those O 0 9.572890036224635e-09
in O 0 1.9215299573716038e-08
other O 0 4.2974377834070765e-08
Asian O 0 6.500265499198576e-07
populations O 0 1.3785324881609995e-06
. O 0 2.9599837034766097e-06

The O 0 4.2314886741223745e-06
novel O 0 2.0968116132280556e-06
single O 0 3.487620858777518e-07
nucleotide O 0 1.0580348543953733e-06
deletion O 0 3.094259454883286e-06
, O 0 2.601645974209532e-07
2304delC O 0 2.616258461785037e-05
, O 0 2.499445770354214e-07
was O 0 6.002905479363108e-07
found O 0 2.97648796276917e-07
in O 0 1.2700893137207458e-07
one O 0 6.387500093296694e-07
patient O 0 9.22174149309285e-05
. O 0 8.349238669325132e-06

Since O 0 3.47249697369989e-05
a O 0 1.9017315935343504e-06
mutation O 0 1.2298315823500161e-06
at O 0 2.2209847827525664e-07
cDNA O 0 2.115586312356754e-06
nucleotide O 0 1.9878436887665885e-06
2302 O 0 0.0001390790130244568
( O 0 6.756331316637443e-08
2302insC O 0 3.1532968023384456e-06
) O 0 3.53856464130331e-08
had O 0 5.371515499064117e-08
been O 0 3.015067306932906e-08
previously O 0 2.3297930340504536e-07
described O 0 1.5919159750410472e-06
, O 0 6.636858529418532e-08
this O 0 1.7248053651996997e-08
region O 0 1.3858651470854966e-07
of O 0 1.4209255994046543e-08
the O 0 8.051611644077639e-08
ATP7B O 0 0.0005772760487161577
gene O 0 1.0723081231844844e-06
may O 0 1.8443121518885164e-07
be O 0 3.438327311755529e-08
susceptible O 0 4.231178081681719e-06
to O 0 1.270989571366954e-07
gene O 0 6.144186045276001e-06
rearrangements O 0 0.00895651988685131
causing O 0 0.008133351802825928
Wilson B-Disease 0 0.0586821623146534
disease I-Disease 0 0.00157650385517627
. O 0 1.7768805264495313e-05

Disruption O 0 0.00011634758266154677
of O 0 1.1349334272381384e-06
splicing O 0 8.150163012032863e-06
regulated O 0 2.0358652363938745e-06
by O 0 1.560890297014339e-07
a O 0 3.991467565356288e-07
CUG O 0 0.0007794051198288798
- O 0 5.257455268292688e-05
binding O 0 4.182517386652762e-06
protein O 0 3.4706570204434684e-06
in O 0 1.1337120668031275e-05
myotonic B-Disease 1 0.9999661445617676
dystrophy I-Disease 1 0.9998633861541748
. O 0 9.581234189681709e-05

Myotonic B-Disease 1 0.9999889135360718
dystrophy I-Disease 1 0.999991774559021
( O 0 0.030338751152157784
DM B-Disease 1 0.9999959468841553
) O 0 2.3442591555067338e-05
is O 0 1.8717677221502527e-06
caused O 0 3.784985437960131e-06
by O 0 8.953433905389829e-08
a O 0 2.748724625689647e-07
CTG O 0 8.437872747890651e-05
expansion O 0 8.201288892450975e-07
in O 0 4.605810488556017e-08
the O 0 4.814738119307549e-08
3 O 0 5.007319145988731e-07
untranslated O 0 4.247152537573129e-05
region O 0 4.2742144046314934e-07
of O 0 1.3268446252823196e-07
the O 0 2.219615453213919e-06
DM B-Disease 1 0.9999464750289917
gene O 0 2.5624362024245784e-05
. O 0 9.457498890697025e-06

One O 0 6.025996754033258e-06
model O 0 1.0814248526003212e-05
of O 0 5.675865395460278e-06
DM B-Disease 1 0.9999957084655762
pathogenesis O 0 0.3624188005924225
suggests O 0 1.5789606550242752e-05
that O 0 2.547663768837083e-07
RNAs O 0 6.81118035572581e-06
from O 0 2.0531579991711624e-08
the O 0 1.8462120721096653e-08
expanded O 0 7.391534495582164e-08
allele O 0 1.7380953920564934e-07
create O 0 4.9297440796181036e-08
a O 0 7.348687347530358e-08
gain O 0 1.601267967998865e-06
- O 0 6.038117589923786e-06
of O 0 9.811485313093726e-08
- O 0 5.4494303185492754e-05
function O 0 1.532647218027705e-07
mutation O 0 7.657007472516852e-08
by O 0 1.9632219405707474e-08
the O 0 1.6408526093414366e-08
inappropriate O 0 2.3080234257122356e-07
binding O 0 1.0940994599195619e-07
of O 0 1.387620862658423e-08
proteins O 0 3.754431077140907e-08
to O 0 5.237166078586597e-08
the O 0 4.95191841309861e-07
CUG O 0 0.000751167070120573
repeats O 0 1.6123289242386818e-05
. O 0 4.366330358607229e-06

Data O 0 8.710920519661158e-05
presented O 0 1.9153925677528605e-05
here O 0 2.312589231223683e-06
indicate O 0 1.407760578331363e-06
that O 0 4.6531123842896704e-08
the O 0 6.940552310652492e-08
conserved O 0 1.0953549463010859e-06
heterogeneous O 0 1.0912022844422609e-05
nuclear O 0 0.00014694307174067944
ribonucleoprotein O 0 0.00011427798744989559
, O 0 2.9165801151975757e-07
CUG O 0 6.547038356075063e-05
- O 0 6.278144610405434e-06
binding O 0 4.5234941126182093e-07
protein O 0 1.1781712316860649e-07
( O 0 6.154256482204801e-08
CUG O 0 1.826660991355311e-05
- O 0 2.2781130610383116e-05
BP O 0 4.7251087380573153e-05
) O 0 3.8392006018739266e-08
, O 0 4.907874640025511e-08
may O 0 5.691747162472893e-08
mediate O 0 1.3484570899890969e-06
the O 0 1.3613743021778646e-07
trans O 0 2.1879124687984586e-05
- O 0 0.0006214958848431706
dominant O 0 2.273546215292299e-06
effect O 0 1.2624897749446973e-07
of O 0 4.571249334617278e-08
the O 0 3.4408867577440105e-07
RNA O 0 4.553542112262221e-06
. O 0 3.631809704529587e-06

CUG O 0 0.04085918515920639
- O 0 0.003090405836701393
BP O 0 0.0009806645102798939
was O 0 2.5417962206120137e-06
found O 0 2.010430790733153e-07
to O 0 2.0239424358692304e-08
bind O 0 9.86022499205319e-08
to O 0 1.5208760473228722e-08
the O 0 4.9888626563188154e-08
human O 0 1.753312858454592e-06
cardiac O 0 0.07550376653671265
troponin O 1 0.9995569586753845
T O 1 0.8480908870697021
( O 0 2.465075965574215e-07
cTNT O 0 9.026340194395743e-06
) O 0 7.456244333070572e-08
pre O 0 7.818272933945991e-06
- O 0 1.0791541171784047e-05
messenger O 0 3.93623935224241e-07
RNA O 0 5.777289402431052e-08
and O 0 1.7052734335720743e-08
regulate O 0 1.0004693962173405e-07
its O 0 6.085981141268348e-08
alternative O 0 7.849178587093775e-07
splicing O 0 8.828167665342335e-06
. O 0 4.1446373870712705e-06

Splicing O 0 0.00012803517165593803
of O 0 5.921510819462128e-06
cTNT O 0 0.0005139329587109387
was O 0 7.111702871043235e-06
disrupted O 0 5.413762846728787e-05
in O 0 5.473502824315801e-06
DM B-Disease 1 0.9999711513519287
striated O 0 0.03471007198095322
muscle O 0 0.00013309140922501683
and O 0 7.129652317416912e-07
in O 0 1.7898459248044674e-07
normal O 0 9.241063025910989e-07
cells O 0 1.1558544201761833e-06
expressing O 0 5.146092689756188e-07
transcripts O 0 2.6201287255389616e-06
that O 0 3.6252032487027464e-07
contain O 0 3.4715174024313455e-06
CUG O 0 0.0011632972164079547
repeats O 0 2.1047870177426375e-05
. O 0 8.88202885107603e-06

Altered O 0 9.551186667522416e-05
expression O 0 4.647587047656998e-06
of O 0 2.805238068503968e-07
genes O 0 1.1275338920313516e-06
regulated O 0 1.7336202517981292e-06
posttranscriptionally O 0 4.340165469329804e-05
by O 0 5.631823114526924e-07
CUG O 0 0.001916959648951888
- O 0 0.0005326515529304743
BP O 0 0.0002770672144833952
therefore O 0 3.4408867577440105e-07
may O 0 2.153362714807372e-07
contribute O 0 3.4951659699800075e-07
to O 0 3.900521733157802e-06
DM B-Disease 1 0.9999880790710449
pathogenesis O 0 0.01985015533864498
. O 0 4.2540864342299756e-06
. O 0 5.899145889998181e-06

Identification O 0 4.354750853963196e-05
of O 0 1.9693329704750795e-06
a O 0 3.5596556244854582e-06
novel O 0 9.442781447432935e-06
nonsense O 0 0.0001998628576984629
mutation O 0 2.955039235530421e-06
and O 0 1.4224745825686114e-07
a O 0 1.5499490757520107e-07
missense O 0 2.337114892725367e-06
substitution O 0 9.384997667893913e-08
in O 0 2.687242428578429e-08
the O 0 2.5356696298217685e-08
vasopressin O 0 1.5389480267913314e-06
- O 0 7.028074469417334e-05
neurophysin O 0 0.00011235434067202732
II O 0 0.00011466276919236407
gene O 0 2.832710777056491e-07
in O 0 4.329557157234376e-08
two O 0 8.9865402230771e-08
Spanish O 0 7.959187087180908e-07
kindreds O 0 6.370989285642281e-05
with O 0 4.940677172271535e-06
familial B-Disease 1 0.9621008038520813
neurohypophyseal I-Disease 1 0.9998151659965515
diabetes I-Disease 1 0.9999442100524902
insipidus I-Disease 1 0.9988817572593689
. O 0 0.0001468929258408025

Familial B-Disease 1 0.9985231757164001
neurohypophyseal I-Disease 1 0.9998883008956909
diabetes I-Disease 1 0.9999954700469971
insipidus I-Disease 1 0.9999570846557617
( O 0 0.0045284428633749485
FNDI B-Disease 1 0.999972939491272
) O 0 5.8639043345465325e-06
is O 0 1.3677368997377926e-06
an O 0 4.305217316868948e-06
autosomal B-Disease 1 0.714838981628418
dominant I-Disease 1 0.9852946996688843
disease I-Disease 1 0.9898486733436584
caused O 0 0.041203077882528305
by O 0 0.01842537522315979
deficiency O 1 0.9653864502906799
in O 0 7.193668807303766e-07
the O 0 1.0103199201694224e-06
antidiuretic O 0 0.0002659289166331291
hormone O 0 1.7344569869237603e-06
arginine O 0 2.0075349311809987e-06
vasopressin O 0 3.079810085182544e-06
( O 0 1.559552629259997e-07
AVP O 0 8.984816304291598e-06
) O 0 1.6888431986217256e-08
encoded O 0 2.0053366966976682e-08
by O 0 1.0813894668615376e-08
the O 0 2.732138604244483e-08
AVP O 0 5.3455227316590026e-05
- O 0 0.0003134678991045803
neurophysin O 0 0.0015750142047181726
II O 0 0.00289428373798728
( O 0 3.315878984722076e-07
AVP O 0 0.0001296104455832392
- O 0 0.0002468143356963992
NPII O 0 0.00035769128589890897
) O 0 1.4275300941335445e-07
gene O 0 4.047493860070972e-07
on O 0 7.460995448127505e-07
chromosome O 0 2.926294291683007e-05
20p13 O 0 0.0002164007892133668
. O 0 7.983156137925107e-06

In O 0 2.259315351693658e-06
this O 0 1.9359919178896234e-07
study O 0 2.3559209694212768e-07
, O 0 9.13342148578522e-08
we O 0 3.2047267950474634e-08
analyzed O 0 4.3905720303882845e-07
two O 0 5.3095838836725306e-08
families O 0 3.162157327096793e-07
with O 0 8.619296636425133e-07
FNDI B-Disease 1 0.9211402535438538
using O 0 1.353196097397813e-07
direct O 0 6.692204834735094e-08
automated O 0 1.0321446097805165e-06
fluorescent O 0 7.466946385648043e-07
, O 0 4.252656538028532e-08
solid O 0 3.8004486668796744e-07
phase O 0 2.3575578325107927e-06
, O 0 6.692945220265756e-08
single O 0 7.714560723570685e-08
- O 0 9.593476534064393e-06
stranded O 0 4.978535343980184e-07
DNA O 0 1.1008711453541764e-07
sequencing O 0 6.846412503591637e-08
of O 0 2.782329389106053e-08
PCR O 0 1.5438048421856365e-06
- O 0 3.962773917010054e-06
amplified O 0 4.995884410163853e-06
AVP O 0 9.542228508507833e-05
- O 0 0.00012191762652946636
NPII O 0 0.0005065100849606097
DNA O 0 2.6381632778793573e-05
. O 0 8.734058610571083e-06

In O 0 5.910227628191933e-06
one O 0 1.9043254440020974e-07
of O 0 8.46464587311857e-08
the O 0 2.2895947893175617e-07
families O 0 1.8294166466148454e-06
, O 0 1.3395848554864642e-06
affected O 0 2.2534670733875828e-06
individuals O 0 1.2614570721325435e-07
presented O 0 1.108035121433204e-06
a O 0 1.0653928939063917e-06
novel O 0 3.869736701744841e-06
nonsense O 0 2.4103761461446993e-05
mutation O 0 2.5755252863746136e-07
in O 0 5.55845574012892e-08
exon O 0 1.7787237993616145e-06
3 O 0 1.6138714897806494e-07
of O 0 1.023487516960131e-08
the O 0 2.892612904759062e-08
gene O 0 8.143880592115238e-08
, O 0 2.2831226687003436e-08
consisting O 0 5.256921653540303e-08
in O 0 2.321417724715502e-08
a O 0 3.189099118117156e-07
G O 0 0.00042431530891917646
to O 0 7.988649031176465e-08
T O 0 0.00010102486703544855
transition O 0 2.0622445617846097e-07
at O 0 8.125277162207567e-08
nucleotide O 0 2.9783620902890107e-07
2101 O 0 2.014749770751223e-05
, O 0 2.155042722051803e-08
which O 0 1.086894130253313e-08
produces O 0 3.466384868033856e-08
a O 0 2.184566838536739e-08
stop O 0 9.748546858645568e-08
signal O 0 1.3615715488413116e-07
in O 0 2.189773162797337e-08
codon O 0 2.9191346584411804e-07
82 O 0 9.6188853149215e-07
( O 0 1.7453989187288244e-07
Glu O 0 8.372454612981528e-05
) O 0 6.79765648214925e-08
of O 0 2.0048304349984392e-07
NPII O 0 0.0008008338627405465
. O 0 7.135017767723184e-06

The O 0 2.129686254193075e-05
premature O 0 0.0010611831676214933
termination O 0 0.00036124896723777056
eliminates O 0 1.9771387087530456e-05
part O 0 4.341614214808942e-07
of O 0 9.059821337586982e-08
the O 0 1.3766705819762137e-07
C O 0 0.0003012963570654392
- O 0 2.5495854060864076e-05
terminal O 0 1.735233013278048e-06
domain O 0 2.8846349309219477e-08
of O 0 1.6937690361373825e-08
NPII O 0 0.0006748580490238965
, O 0 1.0141158668375283e-07
including O 0 2.897450102068433e-08
a O 0 5.184549678460826e-08
cysteine O 0 1.0372347958309547e-07
residue O 0 2.2876565708429553e-07
in O 0 1.552408512850434e-08
position O 0 5.006430825460484e-08
85 O 0 1.197202976754852e-07
, O 0 2.1888629575528284e-08
which O 0 2.38725377244009e-08
could O 0 6.325016244090875e-08
be O 0 1.592226617219694e-08
involved O 0 6.905270311108325e-08
in O 0 3.0607665735260525e-08
the O 0 6.051140388763088e-08
correct O 0 3.760361778404331e-06
folding O 0 7.463980182365049e-06
of O 0 1.3956559996586293e-07
the O 0 9.866128038993338e-07
prohormone O 0 0.0031490165274590254
. O 0 8.836793313093949e-06

In O 0 7.69125108490698e-06
the O 0 9.602030104360892e-07
second O 0 2.7975115699518938e-06
family O 0 3.69626332030748e-06
, O 0 1.35492271624571e-07
a O 0 8.719994326611413e-08
G279A O 0 1.9649060050141998e-06
substitution O 0 1.1217748863145971e-07
at O 0 9.736171335816834e-08
position O 0 6.581694123042325e-08
- O 0 7.807930160197429e-07
1 O 0 1.9361351633051527e-08
of O 0 3.4042360042008113e-09
the O 0 7.68846852849947e-09
signal O 0 1.888916756342951e-07
peptide O 0 1.492015115900358e-07
was O 0 4.253500307527247e-08
observed O 0 6.964739895920502e-08
in O 0 1.7416020625660167e-08
all O 0 3.738610132586473e-08
affected O 0 8.918186154005525e-07
individuals O 0 4.395121493416809e-07
. O 0 2.2804779291618615e-06

This O 0 1.1017562428605743e-05
missense O 0 0.000564076064620167
mutation O 0 2.4624359866720624e-05
, O 0 9.553318705002312e-07
which O 0 8.270611147054296e-07
replaces O 0 0.0002669394016265869
Ala O 0 0.028585726395249367
with O 0 3.1614927138434723e-06
Thr O 0 0.007179342210292816
, O 0 5.483725544763729e-07
is O 0 2.0080373985820188e-07
frequent O 0 3.114218543487368e-06
among O 0 1.1159228051838e-05
FNDI B-Disease 1 0.9999963045120239
patients O 0 0.00013171679165679961
and O 0 4.0606778384244535e-07
is O 0 7.652131728264067e-08
thought O 0 1.0201843991808346e-07
to O 0 1.7596427426269656e-08
reduce O 0 1.1498114815822191e-07
the O 0 9.840568360175439e-09
efficiency O 0 2.2197968974069227e-07
of O 0 5.4283066930338464e-08
cleavage O 0 4.3790416384581476e-05
by O 0 1.8865458173422667e-07
signal O 0 3.6711171560455114e-06
peptidases O 0 5.692369813914411e-05
. O 0 4.982505856787611e-07
. O 0 3.3052403978217626e-06

Genetic O 0 0.00024126800417434424
heterogeneity O 0 0.00013759637658949941
of O 0 7.398413345072186e-06
Saethre B-Disease 1 0.9424091577529907
- I-Disease 1 0.9998762607574463
Chotzen I-Disease 1 0.9999761581420898
syndrome I-Disease 1 0.999782145023346
, O 0 2.429121650493471e-06
due O 0 8.975985110737383e-07
to O 0 1.5626686433733994e-07
TWIST O 0 8.738334145164117e-05
and O 0 8.546899152861442e-06
FGFR O 0 0.2473389357328415
mutations O 0 3.219620339223184e-05
. O 0 8.596774023317266e-06

Thirty O 0 0.0001082597445929423
- O 0 0.0003903376928064972
two O 0 1.0318807426301646e-06
unrelated O 0 0.00013618481170851737
patients O 0 1.0536594345467165e-05
with O 0 6.985867173625593e-08
features O 0 5.080995038042602e-07
of O 0 1.4689187537442194e-06
Saethre B-Disease 1 0.9832274913787842
- I-Disease 1 0.9999451637268066
Chotzen I-Disease 1 0.9999909400939941
syndrome I-Disease 1 0.9998593330383301
, O 0 3.5563643905334175e-06
a O 0 7.861233825678937e-06
common O 0 8.253193664131686e-05
autosomal B-Disease 0 0.010203582234680653
dominant I-Disease 0 0.011757236905395985
condition I-Disease 0 0.0029887380078434944
of O 0 2.0978293832740746e-05
craniosynostosis B-Disease 1 0.999785840511322
and O 0 0.0017547830939292908
limb B-Disease 1 0.9741305112838745
anomalies I-Disease 1 0.7290725111961365
, O 0 4.085934051545337e-06
were O 0 9.378624099554145e-07
screened O 0 3.4146473808505107e-06
for O 0 2.138627479553179e-07
mutations O 0 1.1225266689507407e-06
in O 0 1.1969895297170297e-07
TWIST O 0 1.4892877516103908e-05
, O 0 1.6637599173918716e-06
FGFR2 O 0 0.0011211450910195708
, O 0 7.9822802945273e-07
and O 0 2.7106370907858945e-06
FGFR3 O 0 0.0031986546237021685
. O 0 9.681608389655594e-06

Nine O 0 2.9613804144901223e-05
novel O 0 6.36070853943238e-06
and O 0 1.2332152437011246e-06
three O 0 1.0815812174769235e-06
recurrent O 0 0.0014123630244284868
TWIST O 0 0.0005195583798922598
mutations O 0 2.7952610253123567e-05
were O 0 1.040652591655089e-06
found O 0 6.473607641055423e-07
in O 0 2.0166754666206543e-07
12 O 0 1.4217573607311351e-06
families O 0 3.0132448500808096e-06
. O 0 3.579853910196107e-06

Seven O 0 4.97044347866904e-05
families O 0 1.8187414752901532e-05
were O 0 1.991902763620601e-06
found O 0 5.97981056671415e-07
to O 0 1.0150893103855196e-07
have O 0 5.864709962111192e-08
the O 0 7.092916121109738e-08
FGFR3 O 0 0.0015117108123376966
P250R O 0 6.0843962273793295e-05
mutation O 0 4.789449690179026e-07
, O 0 3.793842751065313e-08
and O 0 4.8259554574769936e-08
one O 0 1.7211609915079862e-08
individual O 0 2.281803546111405e-08
was O 0 6.335060902529221e-07
found O 0 1.3389023933996214e-07
to O 0 2.988415914728648e-08
have O 0 4.273896081485873e-08
an O 0 7.113155930937864e-08
FGFR2 O 0 0.001030698069371283
VV269 O 0 9.643896191846579e-05
- O 0 4.6769611799390987e-05
270 O 0 1.7443902834202163e-05
deletion O 0 4.4192856876179576e-05
. O 0 1.293872446694877e-05

To O 0 3.885244495904772e-06
date O 0 8.952885764301755e-06
, O 0 4.6962446731413365e-07
our O 0 1.4321211949663848e-07
detection O 0 1.7990834066949901e-06
rate O 0 3.4600643061821756e-07
for O 0 5.659055801743307e-08
TWIST O 0 5.844592578796437e-06
or O 0 6.089964017519378e-07
FGFR O 0 0.00019909597176592797
mutations O 0 4.3209115574427415e-07
is O 0 4.258354380226592e-08
68 O 0 7.474284302588785e-07
% O 0 5.4009898775575493e-08
in O 0 2.4146107335809575e-08
our O 0 4.918624085803458e-07
Saethre B-Disease 0 0.16288678348064423
- I-Disease 1 0.999383807182312
Chotzen I-Disease 1 0.9999760389328003
syndrome I-Disease 1 0.9998688697814941
patients O 0 3.462837776169181e-05
, O 0 2.7503293154040875e-07
including O 0 2.715944731335185e-07
our O 0 2.1312609987944597e-07
five O 0 1.029572786137578e-06
patients O 0 2.1262812879285775e-05
elsewhere O 0 2.5177957923006034e-06
reported O 0 4.3537393139558844e-06
with O 0 1.1094202818640042e-06
TWIST O 0 0.00023324524227064103
mutations O 0 5.181106098461896e-05
. O 0 1.0467168067407329e-05

More O 0 2.6248908397974446e-06
than O 0 4.536549340627971e-07
35 O 0 3.473901415418368e-07
different O 0 4.666853570256535e-08
TWIST O 0 3.7466770663741045e-06
mutations O 0 1.1729999869203311e-06
are O 0 4.668073216862467e-08
now O 0 1.5136964748307946e-07
known O 0 1.984588209325011e-07
in O 0 3.332045395154637e-08
the O 0 9.844102066836058e-08
literature O 0 1.4602993587686797e-06
. O 0 3.4401948596496368e-06

The O 0 4.596289727487601e-06
most O 0 6.300297172856517e-07
common O 0 5.195141739022802e-07
phenotypic O 0 2.95557219942566e-06
features O 0 5.8599748626875225e-06
, O 0 5.786828296550084e-07
present O 0 2.0722596616451483e-07
in O 0 4.764766714515645e-08
more O 0 2.3751995925636038e-08
than O 0 4.0900204112404026e-08
a O 0 9.821707891433107e-08
third O 0 2.9305653015399e-07
of O 0 1.2403140203787189e-07
our O 0 1.8653312281458057e-06
patients O 0 5.51318726138561e-06
with O 0 1.3752389804722043e-07
TWIST O 0 2.8289679903537035e-05
mutations O 0 2.315003484909539e-06
, O 0 1.1908297636864518e-07
are O 0 4.8189832568823476e-08
coronal B-Disease 0 0.00014873007603455335
synostosis I-Disease 0 0.0006061990279704332
, O 0 5.999660857014533e-07
brachycephaly B-Disease 0 0.00023992829665075988
, O 0 1.0650037438608706e-06
low B-Disease 0 0.001621830160729587
frontal I-Disease 1 0.9989585876464844
hairline I-Disease 1 0.9998492002487183
, O 0 3.3375494240317494e-05
facial B-Disease 0 0.02277183160185814
asymmetry I-Disease 0 0.0010483928490430117
, O 0 5.392842649598606e-05
ptosis B-Disease 1 0.9907243847846985
, O 0 1.4551274944096804e-05
hypertelorism B-Disease 0 0.26841768622398376
, O 0 3.1349670734925894e-06
broad B-Disease 0 8.585930481785908e-05
great I-Disease 0 1.5716190318926238e-05
toes I-Disease 0 0.0003263965481892228
, O 0 7.964456472109305e-07
and O 0 2.871811147997505e-06
clinodactyly B-Disease 0 0.0034282917622476816
. O 0 2.035638681263663e-05

Significant O 0 6.26633336651139e-05
intra O 0 0.00018111769168172032
- O 0 0.0005686620716005564
and O 0 2.206789076808491e-06
interfamilial O 0 0.0002499218680895865
phenotypic O 0 2.1677087715943344e-05
variability O 0 0.00018870730127673596
is O 0 2.731024437707674e-07
present O 0 2.1214118817169947e-07
for O 0 2.3358821010788233e-07
either O 0 1.3566194638769957e-06
TWIST O 0 0.00012629535922314972
mutations O 0 2.8964643206563778e-05
or O 0 7.09788037056569e-06
FGFR O 0 0.01210816204547882
mutations O 0 4.7833531425567344e-05
. O 0 7.438882221322274e-06

The O 0 2.7609146400209283e-06
overlap O 0 3.3796777643146925e-06
in O 0 5.983632718198351e-07
clinical O 0 5.923962362430757e-06
features O 0 1.428787300028489e-06
and O 0 5.566300274040259e-07
the O 0 8.462676959197779e-08
presence O 0 5.645471219395404e-07
, O 0 9.635046183120721e-08
in O 0 3.769887513271897e-08
the O 0 1.9412231822002468e-08
same O 0 6.306007094281085e-08
genes O 0 1.0469961608805534e-07
, O 0 2.295869450108512e-08
of O 0 1.623394929595179e-08
mutations O 0 1.0291530827544193e-07
for O 0 1.3802799792017595e-08
more O 0 9.122484101453665e-09
than O 0 4.7204874675799147e-08
one O 0 1.4364367473262973e-07
craniosynostotic B-Disease 0 0.006689073052257299
condition I-Disease 0 3.9998485590331256e-05
- O 0 1.2222816621942911e-05
such O 0 4.063528535880323e-08
as O 0 8.593223554953511e-08
Saethre B-Disease 0 4.95805470563937e-05
- I-Disease 0 5.0196307711303234e-05
Chotzen I-Disease 0 7.142459799069911e-05
, I-Disease 0 2.81481590036492e-07
Crouzon I-Disease 0 3.783029387705028e-05
, I-Disease 0 4.105097275441949e-07
and I-Disease 0 9.776785191206727e-06
Pfeiffer I-Disease 1 0.6560696959495544
syndromes I-Disease 0 0.09564231336116791
- O 0 0.0005485806614160538
support O 0 6.517391284432961e-07
the O 0 6.831815824170917e-08
hypothesis O 0 6.110454364716134e-07
that O 0 3.3783642550133663e-08
TWIST O 0 2.685321760509396e-06
and O 0 3.718285768172791e-07
FGFRs O 0 3.5827557439915836e-05
are O 0 2.946628008260177e-08
components O 0 1.4972047779338027e-07
of O 0 7.49325312909832e-09
the O 0 1.1850718628636514e-08
same O 0 2.760024209180756e-08
molecular O 0 9.158067086900701e-07
pathway O 0 1.4166762696277146e-07
involved O 0 6.922373785300806e-08
in O 0 1.7332446589080064e-08
the O 0 1.4716927232427679e-08
modulation O 0 4.132632795972313e-07
of O 0 6.388329438777873e-07
craniofacial O 1 0.9854660034179688
and O 0 1.4508955246128608e-05
limb O 0 0.01264459639787674
development O 0 1.9715389498742297e-06
in O 0 5.641369966724596e-07
humans O 0 9.873460840026382e-07
. O 0 5.05876357692614e-07
. O 0 5.12790074935765e-06

Mutation O 0 0.00020946045697201043
analysis O 0 2.14060019061435e-05
of O 0 2.353750642214436e-05
UBE3A O 1 0.9979003667831421
in O 1 0.9877947568893433
Angelman B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999997615814209
patients O 0 0.245188906788826
. O 0 0.00012822748976759613

Angelman B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999997615814209
( O 0 0.0006906217895448208
AS B-Disease 0 0.003150360658764839
) O 0 8.883722557584406e-07
is O 0 5.845735699949728e-07
caused O 0 4.300252385291969e-06
by O 0 2.578221369731182e-07
chromosome O 0 2.767342266452033e-05
15q11 O 0 0.0002475767978467047
- O 0 0.00019683394930325449
q13 O 0 1.4122914762992878e-05
deletions O 0 1.8996489643541281e-06
of O 0 2.1573256958618003e-07
maternal O 0 5.791338935523527e-06
origin O 0 2.2178141989570577e-07
, O 0 3.8757087850171956e-07
by O 0 7.696929742451175e-07
paternal O 0 0.00019686640007421374
uniparental B-Disease 0 0.2829302251338959
disomy I-Disease 0 0.49788549542427063
( O 0 1.1985664968960918e-05
UPD B-Disease 1 0.9990041851997375
) O 0 2.467637330028083e-07
15 O 0 2.3666150639201078e-07
, O 0 5.248145384939562e-08
by O 0 1.4853054608465754e-07
imprinting O 0 0.0030844444409012794
defects O 1 0.8231847882270813
, O 0 1.4322416745926603e-06
and O 0 3.2433939622933394e-07
by O 0 3.3353964568050287e-07
mutations O 0 7.40462894555094e-07
in O 0 9.803441258782186e-08
the O 0 9.393044706484943e-07
UBE3A O 0 0.0014953170903027058
gene O 0 7.840194484742824e-06
. O 0 5.434218110167421e-06

UBE3A O 0 0.008812183514237404
encodes O 0 3.630584251368418e-05
a O 0 3.3718997656251304e-06
ubiquitin O 0 3.3561438613105565e-05
- O 0 3.607344115152955e-05
protein O 0 8.984163173408888e-07
ligase O 0 4.563070888252696e-06
and O 0 2.276418200608532e-07
shows O 0 1.5561163309030235e-06
brain O 0 3.503761763568036e-05
- O 0 1.179667469841661e-05
specific O 0 8.564160793866904e-07
imprinting O 0 9.000025602290407e-05
. O 0 1.0521633157623e-05

Here O 0 2.2183665350894444e-05
we O 0 2.042341066044173e-06
describe O 0 1.0373082659498323e-05
UBE3A O 0 0.0011562940198928118
coding O 0 0.00011945906589971855
- O 0 0.0011253238189965487
region O 0 7.578787517559249e-06
mutations O 0 3.348034169903258e-06
detected O 0 3.278765234426828e-06
by O 0 1.2212755962082156e-07
SSCP O 0 7.297664706129581e-05
analysis O 0 3.861430855067738e-07
in O 0 1.903927824287166e-07
13 O 0 3.2038519748311955e-06
AS B-Disease 0 1.8576780348666944e-05
individuals O 0 4.421228254614107e-07
or O 0 1.0182029654970393e-06
families O 0 3.830149580608122e-06
. O 0 5.549753950617742e-06

Two O 0 4.964760137227131e-06
identical O 0 1.3832449440087657e-05
de O 0 2.4523076717741787e-05
novo O 0 1.7645283151068725e-05
5 O 0 1.5423111108248122e-06
- O 0 1.7039723388734274e-05
bp O 0 4.292655830795411e-06
duplications O 0 2.728410436247941e-06
in O 0 1.2498452406362048e-07
exon O 0 9.782586857909337e-06
16 O 0 5.943168162048096e-07
were O 0 3.7951025433358154e-07
found O 0 1.7968372958421241e-06
. O 0 3.945840944652446e-06

Among O 0 1.6375472114305012e-05
the O 0 4.469110024274414e-07
other O 0 1.3294526013396535e-07
11 O 0 2.8533136742225906e-07
unique O 0 1.2906330937312305e-07
mutations O 0 1.0556401548456051e-06
, O 0 1.1662277188406733e-07
8 O 0 3.7257115081956726e-07
were O 0 9.084738650244617e-08
small O 0 2.0147281531990302e-07
deletions O 0 8.860792490850145e-07
or O 0 7.396216261668087e-08
insertions O 0 2.0245890937076183e-06
predicted O 0 9.811223208089359e-06
to O 0 1.1680297973271081e-07
cause O 0 3.374215793883195e-06
frameshifts O 0 0.0008469565655104816
, O 0 1.9999781386559334e-07
1 O 0 2.652612351994321e-07
was O 0 2.865054966605385e-07
a O 0 6.311795175406587e-08
mutation O 0 7.678917057774015e-08
to O 0 8.89038265228237e-09
a O 0 3.5649712515350984e-08
stop O 0 1.660701940409126e-07
codon O 0 1.1688488399386188e-07
, O 0 2.9474938045837007e-08
1 O 0 6.115420347896361e-08
was O 0 7.652948852410191e-08
a O 0 7.964671056015504e-08
missense O 0 3.658919013105333e-06
mutation O 0 1.5744564052511123e-07
, O 0 2.6636717720407432e-08
and O 0 4.3648874736845755e-08
1 O 0 3.6474182252277387e-07
was O 0 1.265097012037586e-06
predicted O 0 1.3084912097838242e-05
to O 0 6.552158993144985e-08
cause O 0 3.1817532430977735e-07
insertion O 0 2.425997536192881e-07
of O 0 2.2748201544686708e-08
an O 0 4.1448831922252793e-08
isoleucine O 0 0.00014821843069512397
in O 0 5.572595540570546e-08
the O 0 3.2931755100662485e-08
hect O 0 7.777781320328359e-06
domain O 0 3.908207091285476e-08
of O 0 1.5491282923107974e-08
the O 0 5.626669974390097e-08
UBE3A O 0 7.26155994925648e-05
protein O 0 8.580907007171845e-08
, O 0 7.347451091987978e-09
which O 0 3.5314495772098553e-09
functions O 0 7.529528112115713e-09
in O 0 1.698625062829251e-08
E2 O 0 5.376668923418038e-06
binding O 0 5.04398428802233e-07
and O 0 3.05711466808134e-07
ubiquitin O 0 2.506461532902904e-05
transfer O 0 6.477291208284441e-06
. O 0 5.930389761488186e-06

Eight O 0 1.3931435205449816e-05
of O 0 1.1995600743830437e-06
the O 0 9.448576747672632e-07
cases O 0 4.310599251766689e-06
were O 0 2.5685860691737616e-06
familial O 0 0.014646632596850395
, O 0 2.671671154530486e-06
and O 0 5.408504080151033e-07
five O 0 4.4610746385842504e-07
were O 0 1.2933452353536268e-06
sporadic O 0 4.402809281600639e-05
. O 0 6.541035872942302e-06

In O 0 1.0321078661945648e-05
two O 0 2.3606085051142145e-06
familial O 0 0.030145829543471336
cases O 0 1.014017834677361e-05
and O 0 1.0356824304835754e-06
one O 0 3.919850257716462e-07
sporadic O 0 0.00010873016435652971
case O 0 2.8530292183859274e-05
, O 0 1.3398519058682723e-06
mosaicism O 0 0.002616297919303179
for O 0 2.663692612259183e-06
UBE3A O 0 0.17390176653862
mutations O 0 7.591424946440384e-06
was O 0 8.976772392088606e-07
detected O 0 2.751535930656246e-06
in O 0 4.1429547792404264e-08
the O 0 8.662867401199037e-08
mother O 0 2.3298205178434728e-06
of O 0 3.630973921531222e-08
three O 0 2.650895112310536e-07
AS B-Disease 0 0.0020851583685725927
sons O 0 0.0012546349316835403
, O 0 2.7262728963250993e-07
in O 0 3.829364203511432e-08
the O 0 1.1092345886254407e-07
maternal O 0 1.728971255943179e-05
grandfather O 0 7.265050498972414e-06
of O 0 2.603745308249472e-08
two O 0 1.7314098954557267e-07
AS B-Disease 0 9.965914614440408e-06
first O 0 1.408941159297683e-07
cousins O 0 1.2805913684132975e-05
, O 0 2.6974933575729665e-07
and O 0 9.862782945901927e-08
in O 0 2.717130342944074e-08
the O 0 7.29895788253998e-08
mother O 0 1.512933067715494e-06
of O 0 3.466212916691802e-08
an O 0 1.818560804167646e-07
AS B-Disease 0 0.001463100896216929
daughter O 0 0.014463056810200214
. O 0 2.5920326152117923e-05

The O 0 3.6567143979482353e-06
frequencies O 0 2.776747351163067e-06
with O 0 2.939780188171426e-07
which O 0 8.6337038851525e-08
we O 0 1.1203400873682767e-07
detected O 0 8.358038030564785e-07
mutations O 0 2.1595199939383747e-07
were O 0 5.002831926503859e-08
5 O 0 1.1422429224694497e-07
( O 0 1.7844579147663353e-08
14 O 0 6.300285093630009e-08
% O 0 1.4345443055674423e-08
) O 0 3.2148019801780947e-09
of O 0 2.956241695883932e-09
35 O 0 7.025661119541837e-08
in O 0 2.0078436691051138e-08
sporadic O 0 2.914221568062203e-06
cases O 0 2.2874560556829238e-07
and O 0 7.252385358924585e-08
8 O 0 3.8322141904245655e-07
( O 0 3.0710292975300035e-08
80 O 0 4.642492612561e-08
% O 0 1.1550656431325024e-08
) O 0 3.079368537939331e-09
of O 0 6.919480100009423e-09
10 O 0 1.5157999655457388e-07
in O 0 4.2981838532796246e-07
familial O 0 0.0012914004037156701
cases O 0 8.647250979265664e-06
. O 0 3.159102561767213e-06
. O 0 1.1423410796851385e-05

The O 0 0.000406344304792583
hemochromatosis B-Disease 1 0.9995673298835754
845 O 0 0.01268361322581768
G O 0 0.17539289593696594
- O 0 0.0013389767846092582
- O 0 0.00014285321231000125
> O 0 3.59661498805508e-06
A O 0 1.0402084882343843e-07
and O 0 2.7481315001409712e-08
187 O 0 9.088202546081448e-07
C O 0 2.4905401005526073e-05
- O 0 3.9420698158210143e-05
- O 0 0.0001539602963021025
> O 0 2.4258608391392045e-05
G O 0 0.0001270476495847106
mutations O 0 6.026158985150687e-07
: O 0 1.0919792003960538e-07
prevalence O 0 8.880878340278286e-06
in O 0 1.737629560238929e-07
non O 0 1.0718290468503255e-05
- O 0 0.014489634893834591
Caucasian O 0 0.00019501942733768374
populations O 0 1.0306424883310683e-05
. O 0 6.1581827139889356e-06

Hemochromatosis B-Disease 1 0.9984978437423706
, O 0 0.0002676835865713656
the O 0 0.0008327615214511752
inherited B-Disease 1 0.9999979734420776
disorder I-Disease 1 0.9999841451644897
of I-Disease 0 1.4663611182186287e-05
iron I-Disease 1 0.7583461999893188
metabolism I-Disease 0 5.5046260968083516e-05
, O 0 1.40320753416745e-06
leads O 0 4.291329787520226e-06
, O 0 1.2635391613002867e-06
if O 0 3.1303543437388726e-06
untreated O 0 0.00017542947898618877
, O 0 2.002122982958099e-07
to O 0 3.42753708082455e-07
progressive O 0 0.00145484390668571
iron B-Disease 0 0.41589289903640747
overload I-Disease 0 0.03131217509508133
and O 0 1.6761303413659334e-05
premature B-Disease 0 0.002141431672498584
death I-Disease 0 2.104469785990659e-05
. O 0 7.423036095133284e-06

The O 0 7.471017306670547e-05
hemochromatosis B-Disease 1 0.9998577833175659
gene O 0 7.176801591413096e-05
, O 0 4.840783276449656e-06
HFE O 0 0.015579244121909142
, O 0 3.141057050015661e-06
recently O 0 7.556682248832658e-06
has O 0 2.862400094727491e-07
been O 0 1.9664942385588802e-07
identified O 0 2.6660131879907567e-06
, O 0 1.318127118565826e-07
and O 0 7.269392199305003e-08
characterization O 0 1.0631406439642888e-06
of O 0 2.2301321678241948e-08
this O 0 4.525237073949029e-08
gene O 0 2.588880079201772e-07
has O 0 4.1734260491921304e-08
shown O 0 4.2090480434353594e-08
that O 0 8.718925137429778e-09
it O 0 9.192068439745071e-09
contains O 0 3.261700953771651e-08
two O 0 2.899611573070615e-08
mutations O 0 2.0942167111570598e-07
that O 0 1.6143234304877296e-08
result O 0 6.87155647938198e-08
in O 0 2.2482362638243103e-08
amino O 0 6.064844626507693e-08
acid O 0 4.4603002180565454e-08
substitutions O 0 6.862912016458722e-08
- O 0 2.2373627928118367e-07
cDNA O 0 3.7503303929042886e-07
nucleotides O 0 2.1420382267933746e-07
845 O 0 1.3271638863443513e-06
G O 0 1.3041684724157676e-05
- O 0 2.1220270355115645e-05
- O 0 2.8046333682141267e-05
> O 0 2.0725615286210086e-06
A O 0 9.075992579710146e-08
( O 0 1.6474697162038865e-08
C282Y O 0 4.0861456795937556e-07
) O 0 6.551857278935813e-09
and O 0 1.1034670066578656e-08
187 O 0 1.8603235218961345e-07
C O 0 7.612993613292929e-06
- O 0 4.233416620991193e-05
- O 0 0.0003479609440546483
> O 0 3.663800089270808e-05
G O 0 8.148108463501558e-05
( O 0 2.715649429774203e-07
H63D O 0 8.801499643595889e-05
) O 0 3.6434826711229107e-07
. O 0 1.5829356243557413e-06

Although O 0 0.0061836582608520985
hemochromatosis B-Disease 1 0.9999798536300659
is O 0 1.0606044270389248e-05
common O 0 2.325314426343539e-06
in O 0 4.914966211799765e-07
Caucasians O 0 8.902855370251928e-06
, O 0 2.4456008418383135e-07
affecting O 0 1.2373513982311124e-06
> O 0 3.2842970540514216e-05
= O 0 4.869375061389292e-06
1 O 0 2.8234083515599195e-07
/ O 0 1.114761175813328e-06
300 O 0 4.661897889945976e-08
individuals O 0 5.22662535473728e-09
of O 0 4.3614902800470645e-09
northern O 0 9.930396771551386e-08
European O 0 4.1874116618600965e-08
origin O 0 2.5431335259895604e-08
, O 0 4.266223996296503e-08
it O 0 1.6761990906388746e-08
has O 0 4.563147726344141e-08
not O 0 3.2659027482395686e-08
been O 0 7.54993791929337e-08
recognized O 0 6.483808334678542e-08
in O 0 3.369663659213984e-08
other O 0 1.3088849470932473e-07
populations O 0 2.236717136838706e-06
. O 0 3.732686082003056e-06

The O 0 6.807576028222684e-06
present O 0 1.3852588836016366e-06
study O 0 3.024023556008615e-07
used O 0 9.630011987837861e-08
PCR O 0 2.083599838442751e-06
and O 0 6.14758164374507e-08
restriction O 0 3.5564150380196224e-07
- O 0 2.6024006274383282e-06
enzyme O 0 9.551828128451234e-08
digestion O 0 4.16218654208933e-07
to O 0 1.4997178610087758e-08
analyze O 0 1.4072382725771604e-07
the O 0 4.357955774025868e-09
frequency O 0 2.3840502905159155e-08
of O 0 7.290328341014174e-09
the O 0 1.8652333011459632e-08
845 O 0 6.6121338022639975e-06
G O 0 8.914320642361417e-05
- O 0 3.795702286879532e-05
- O 0 1.8118413208867423e-05
> O 0 5.362855404200673e-07
A O 0 1.960355788810375e-08
and O 0 3.258927350202612e-08
187 O 0 5.932619160375907e-07
C O 0 1.7475606000516564e-05
- O 0 2.6104240532731637e-05
- O 0 9.37874719966203e-05
> O 0 8.760336640989408e-06
G O 0 1.375099782308098e-05
mutations O 0 1.4294427330696635e-07
in O 0 4.74154866481058e-08
HLA O 0 7.685759919695556e-05
- O 0 7.571931746497285e-06
typed O 0 4.730744649350527e-07
samples O 0 1.2782440705905174e-07
from O 0 2.0024394586926064e-08
non O 0 4.850289201385749e-07
- O 0 4.43115241068881e-05
Caucasian O 0 9.228388989868108e-06
populations O 0 3.042775063022418e-07
, O 0 3.207013676842507e-08
comprising O 0 9.809127021753739e-08
Australian O 0 1.4897756273057894e-07
Aboriginal O 0 2.03453069502757e-07
, O 0 5.0173376564544014e-08
Chinese O 0 1.322229703504263e-08
, O 0 6.42690025642878e-08
and O 0 3.334099005769531e-07
Pacific O 0 1.0949947863991838e-05
Islanders O 0 1.7102143829106353e-05
. O 0 5.016580871597398e-06

Results O 0 5.949969636276364e-05
showed O 0 1.3235363439889625e-05
that O 0 2.731391646193515e-07
the O 0 1.617658966779345e-07
845 O 0 7.889007247285917e-05
G O 0 0.011077498085796833
- O 0 0.0007715350948274136
- O 0 0.00038052318268455565
> O 0 4.926200290356064e-06
A O 0 2.203810254286509e-07
mutation O 0 1.9848948795697652e-07
was O 0 7.773228105634189e-08
present O 0 1.7156871479073743e-08
in O 0 1.832312968019778e-08
these O 0 2.1326837185142722e-08
populations O 0 5.361157207062206e-08
( O 0 4.956612009721084e-09
allele O 0 3.547471294496063e-08
frequency O 0 3.732959541480341e-08
0 O 0 4.682206977690839e-08
. O 0 8.729609035640351e-09
32 O 0 6.426360243949603e-08
% O 0 1.5040319212289432e-08
) O 0 9.884021601180848e-09
, O 0 1.5953332876961213e-08
and O 0 4.4139650157148935e-08
, O 0 5.3709626968156954e-08
furthermore O 0 1.3055476699719293e-07
, O 0 4.0758781238992015e-08
it O 0 1.6810338010486703e-08
was O 0 2.4701000711502274e-07
always O 0 7.297009574358526e-08
seen O 0 1.7286266995597543e-07
in O 0 1.5254691732025094e-08
conjunction O 0 1.7911419547544938e-07
with O 0 5.693244133908593e-07
HLA O 0 0.02848653495311737
haplotypes O 0 1.788244662748184e-05
common O 0 2.872359630146093e-07
in O 0 1.0503023162300451e-07
Caucasians O 0 7.261199243657757e-06
, O 0 2.294539171998622e-07
suggesting O 0 6.851742000435479e-07
that O 0 9.429028580143495e-08
845 O 0 5.248128582024947e-05
G O 0 0.019446678459644318
- O 0 0.005209651775658131
- O 0 0.0020912603940814734
> O 0 1.0842501978913788e-05
A O 0 5.71695579765219e-07
may O 0 3.211733883290435e-07
have O 0 1.3341057147897573e-08
been O 0 1.3044395785755114e-08
introduced O 0 3.466391618189846e-08
into O 0 3.615604171613995e-08
these O 0 4.794321384338218e-08
populations O 0 3.087383504407626e-07
by O 0 5.083302312414162e-07
Caucasian O 0 6.240190850803629e-05
admixture O 0 0.00012905029871035367
. O 0 2.1642921637976542e-05

187 O 0 0.0002579361025709659
C O 0 0.0006113321287557483
- O 0 0.0003233415191061795
- O 0 0.0002448329178150743
> O 0 1.5747291399748065e-05
G O 0 4.488747435971163e-05
was O 0 1.9168777498634881e-07
present O 0 3.989038788176913e-08
at O 0 4.247031171189519e-08
an O 0 1.424803830474275e-08
allele O 0 2.3164909634942887e-07
frequency O 0 1.6044765516198822e-07
of O 0 9.870893791230628e-08
2 O 0 1.9952203729189932e-06
. O 0 3.2292014111590106e-06

68 O 0 0.00022655616339761764
% O 0 2.2899405394127825e-06
in O 0 3.71663020359847e-07
the O 0 1.0953898765819758e-07
two O 0 1.0948635065233248e-07
populations O 0 4.844935688197438e-07
analyzed O 0 9.480547760176705e-07
( O 0 5.9157940768272965e-08
Australian O 0 1.4571078565950302e-07
Aboriginal O 0 4.3887968104172614e-07
and O 0 1.3160533285372367e-07
Chinese O 0 9.552720570127349e-08
) O 0 3.160514268074621e-07
. O 0 2.2278588858171133e-06

In O 0 8.249710845120717e-06
the O 0 9.927250630425988e-07
Australian O 0 1.0200681117567e-06
Aboriginal O 0 7.124996272978024e-07
samples O 0 3.035051463484706e-07
, O 0 3.6064161434978814e-08
187 O 0 5.757422059105011e-07
C O 0 1.2425352906575426e-05
- O 0 8.279063331428915e-05
- O 0 0.0005008125444874167
> O 0 9.57893189479364e-06
G O 0 6.048113573342562e-05
was O 0 5.329602572601289e-07
found O 0 5.273833636465497e-08
to O 0 1.253281034507836e-08
be O 0 3.095989598023152e-08
associated O 0 4.1785759208323725e-07
with O 0 8.005974905245239e-07
HLA O 0 0.06761860102415085
haplotypes O 0 3.05749817925971e-05
common O 0 4.0250256461149547e-07
in O 0 2.471207380949636e-07
Caucasians O 0 1.945666372193955e-05
, O 0 2.1433316987895523e-07
suggesting O 0 6.713631819366128e-07
that O 0 2.3695525541711504e-08
it O 0 3.902307810221828e-08
was O 0 2.6709477651820634e-07
introduced O 0 3.8596635931753553e-07
by O 0 1.828832409955794e-07
recent O 0 1.7253998976229923e-06
admixture O 0 6.439018034143373e-05
. O 0 1.0766644663817715e-05

In O 0 2.833495955201215e-06
the O 0 2.8847594535363896e-07
Chinese O 0 4.243257833991265e-08
samples O 0 9.354972974051634e-08
analyzed O 0 1.2571253193982557e-07
, O 0 1.8206565144396336e-08
187 O 0 2.8950756814083434e-07
C O 0 7.003650807746453e-06
- O 0 2.271299308631569e-05
- O 0 8.180878649000078e-05
> O 0 1.0909546290349681e-05
G O 0 2.2226058717933483e-05
was O 0 2.014269000483182e-07
present O 0 3.77449218547099e-08
in O 0 3.9398443618665624e-08
association O 0 9.562181446653994e-08
with O 0 7.089575149166194e-08
a O 0 2.2441498970238172e-07
wide O 0 2.1893508801440476e-06
variety O 0 1.2971148066753813e-07
of O 0 1.4020635319411667e-07
HLA O 0 0.012752857059240341
haplotypes O 0 1.340888502454618e-05
, O 0 2.3547596583739505e-07
showing O 0 1.714053951218375e-06
this O 0 2.741817439755323e-08
mutation O 0 1.461608718500429e-07
to O 0 2.8232514992510005e-08
be O 0 3.2830282492568585e-08
widespread O 0 7.025352033451782e-07
and O 0 2.5382107082805305e-07
likely O 0 8.543441367692139e-07
to O 0 4.2596866478561424e-08
predate O 0 5.233184765529586e-06
the O 0 2.5146224658101346e-08
more O 0 4.2559992863289153e-08
genetically O 0 1.0827969845195184e-06
restricted O 0 5.346830675989622e-07
845 O 0 3.275173367001116e-05
G O 0 0.008902064524590969
- O 0 0.0012976941652595997
- O 0 0.00027175116701982915
> O 0 1.5862233340158127e-05
A O 0 1.3888834473618772e-06
mutation O 0 5.216547378950054e-06
. O 0 2.3329464511334663e-06

Genotype O 0 0.01944946125149727
- O 0 0.012282555922865868
phenotype O 0 0.0017342683859169483
correlations O 0 0.002246362389996648
in O 0 0.0002487558522261679
attenuated B-Disease 1 0.9953165054321289
adenomatous I-Disease 1 0.9999632835388184
polyposis I-Disease 1 0.9999321699142456
coli I-Disease 1 0.9991316199302673
. O 0 0.0004677442484535277

Germ O 0 0.2846135199069977
- O 0 0.0015085426857694983
line O 0 2.1852936697541736e-05
mutations O 0 1.3031783510086825e-06
of O 0 8.524659023123604e-08
the O 0 3.852242969060171e-07
tumor B-Disease 0 0.0021331810858100653
suppressor O 0 0.00013161559763830155
APC O 0 1.69589930010261e-05
are O 0 2.243683354663517e-07
implicated O 0 1.9956369214924052e-05
in O 0 1.1278531928837765e-05
attenuated B-Disease 1 0.9829047918319702
adenomatous I-Disease 1 0.999996542930603
polyposis I-Disease 1 0.9999940395355225
coli I-Disease 1 0.9999390840530396
( O 0 0.00016771430091466755
AAPC B-Disease 1 0.9999045133590698
) O 0 2.298179879289819e-06
, O 0 4.681858456478949e-07
a O 0 1.1541084177224548e-06
variant O 0 8.904762944439426e-05
of O 0 0.0003052717656828463
familial B-Disease 1 0.9999946355819702
adenomatous I-Disease 1 0.9999908208847046
polyposis I-Disease 1 0.9999982118606567
( O 0 0.0004091007576789707
FAP B-Disease 0 0.0072577940300107
) O 0 8.134175914165098e-06
. O 0 1.8964678019983694e-05

AAPC B-Disease 1 0.9994578957557678
is O 0 2.8178072170703672e-05
recognized O 0 2.3953600702952826e-06
by O 0 1.8110286248429475e-07
the O 0 1.0447898546317447e-07
occurrence O 0 7.596912610097206e-07
of O 0 2.4600501546956366e-07
< O 0 0.00141090527176857
100 O 0 1.3799398175251554e-06
colonic B-Disease 0 0.05509142950177193
adenomas I-Disease 0 0.0172320194542408
and O 0 2.4765679995653045e-07
a O 0 1.828070566034512e-07
later O 0 1.0251110325043555e-06
onset O 0 0.03866637125611305
of O 0 0.23056632280349731
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
( O 0 4.655985321733169e-06
age O 0 3.8684784158249386e-06
> O 0 1.9098204575129785e-05
40 O 0 4.78338790799171e-07
years O 0 5.446974569167651e-07
) O 0 5.929230724177614e-07
. O 0 2.61939680967771e-06

The O 0 2.4304029011545936e-06
aim O 0 2.963206497952342e-06
of O 0 9.036504877713014e-08
this O 0 4.104955664274712e-08
study O 0 1.0062700539492653e-07
was O 0 1.9348972557509114e-07
to O 0 6.858266488052323e-08
assess O 0 1.3193674931244459e-05
genotype O 0 0.00011720443580998108
- O 0 0.00040256083593703806
phenotype O 0 2.0939156456734054e-05
correlations O 0 6.508189107989892e-05
in O 0 1.090295427275123e-05
AAPC B-Disease 1 0.9987188577651978
families O 0 2.2915462977834977e-05
. O 0 1.84846758202184e-05

By O 0 9.038364623847883e-06
protein O 0 3.00186957247206e-06
- O 0 1.070776670530904e-05
truncation O 0 6.546240911120549e-06
test O 0 1.1078270745201735e-06
( O 0 4.3119211312614425e-08
PTT O 0 4.056958005094202e-07
) O 0 1.2049836684013826e-08
assay O 0 2.38330983393098e-07
, O 0 1.2628409429282783e-08
the O 0 4.5394816794441795e-09
entire O 0 8.687837294019118e-08
coding O 0 5.840163339598803e-07
region O 0 7.284562997256216e-08
of O 0 7.414080460677042e-09
the O 0 3.463787479063285e-08
APC B-Disease 0 1.6623546343907947e-06
gene O 0 1.8077913921388244e-07
was O 0 1.6509683575804956e-07
screened O 0 1.4554581184711424e-06
in O 0 1.517117311777838e-07
affected O 0 8.39046151668299e-07
individuals O 0 1.2444586161564075e-07
from O 0 3.1453839710593456e-07
11 O 0 2.573966958152596e-05
AAPC B-Disease 1 0.9991293549537659
kindreds O 0 0.001505532767623663
, O 0 7.816356628609356e-07
and O 0 1.265262028482539e-07
their O 0 5.684326254140615e-08
phenotypic O 0 2.581429498604848e-06
differences O 0 5.311018867359962e-06
were O 0 2.4332346129085636e-06
examined O 0 0.00012755846546497196
. O 0 1.5183104551397264e-05

Five O 0 1.886417157948017e-05
novel O 0 1.6137471902766265e-05
germ O 0 0.005467609502375126
- O 0 0.0012117564911022782
line O 0 6.015665712766349e-05
APC B-Disease 0 2.8721709895762615e-05
mutations O 0 1.1304991858196445e-06
were O 0 1.379850118610193e-07
identified O 0 1.006702632366796e-06
in O 0 1.7952632447304495e-07
seven O 0 2.6618999982019886e-06
kindreds O 0 0.00040143931983038783
. O 0 1.0971931260428391e-05

Mutations O 0 0.000262494693743065
were O 0 2.721352757362183e-06
located O 0 2.245730684080627e-06
in O 0 4.415910126454037e-08
three O 0 1.6901257282597726e-08
different O 0 1.5586509860554543e-08
regions O 0 7.788068501213274e-08
of O 0 1.2123885007042645e-08
the O 0 6.766442339767309e-08
APC B-Disease 0 9.407806828676257e-06
gene O 0 3.4117070413230977e-07
( O 0 2.2325878035189817e-08
1 O 0 6.03038969870795e-08
) O 0 1.2216643696660867e-08
at O 0 2.7784421874343934e-08
the O 0 6.51271037099832e-09
5 O 0 6.481310776962346e-08
end O 0 6.748977199322326e-08
spanning O 0 1.7802889828999469e-07
exons O 0 3.655047180473048e-07
4 O 0 9.843012804822138e-08
and O 0 2.8603091450918328e-08
5 O 0 7.348238995064094e-08
, O 0 2.657384357007686e-08
( O 0 9.61842605562424e-09
2 O 0 4.252445506836011e-08
) O 0 4.580777979157347e-09
within O 0 9.481287754908863e-09
exon O 0 5.419119588623289e-07
9 O 0 4.776568403030979e-07
, O 0 4.1626776692282874e-08
and O 0 2.8723587064405365e-08
( O 0 1.6081523668276532e-08
3 O 0 5.276993064740054e-08
) O 0 9.133104938996439e-09
at O 0 3.138351090115066e-08
the O 0 9.25353216274516e-09
3 O 0 2.914066783432645e-07
distal O 0 1.8484710381017067e-05
end O 0 3.973070761276176e-07
of O 0 6.945796826585138e-08
the O 0 3.024969714715553e-07
gene O 0 5.351092113414779e-06
. O 0 5.168504230823601e-06

Variability O 0 0.0014604420866817236
in O 0 1.5923744740575785e-06
the O 0 3.177393068654055e-07
number O 0 4.723819699847809e-07
of O 0 0.0015884088352322578
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999995231628418
was O 0 0.0032661340665072203
most O 0 1.5594916931149783e-06
apparent O 0 8.226635691244155e-05
in O 0 2.84146892681747e-07
individuals O 0 1.3455188252464723e-07
with O 0 8.893286462807737e-08
mutations O 0 3.749500478988921e-07
in O 0 3.873402221188371e-08
region O 0 6.266105856411741e-07
1 O 0 2.2343989769524342e-07
, O 0 1.1423757939610368e-07
and O 0 6.085592758608982e-07
upper O 0 0.015847546979784966
- O 1 0.8918994665145874
gastrointestinal O 1 0.5049635767936707
manifestations O 0 3.7569887354038656e-05
were O 0 9.037209451889794e-07
more O 0 3.8991424844425637e-07
severe O 0 0.00012101927131880075
in O 0 4.855315296481422e-07
them O 0 1.0019166438723914e-06
. O 0 6.9161842475296e-06

In O 0 6.771193966415012e-06
individuals O 0 2.208309069828829e-06
with O 0 8.79078129401023e-07
mutations O 0 4.5952156142448075e-06
in O 0 1.327147032270659e-07
either O 0 2.3348910360709851e-07
region O 0 1.3340925306692952e-06
2 O 0 7.823873602319509e-07
or O 0 8.184164101976421e-08
region O 0 2.84743123302178e-07
3 O 0 2.0989673998883518e-07
, O 0 2.2438580771222405e-08
the O 0 9.393035682592199e-09
average O 0 1.3929434317105915e-07
number O 0 1.1229881913266127e-08
of O 0 3.585921248827617e-08
adenomas B-Disease 0 0.00048684905050322413
tended O 0 5.675328793586232e-07
to O 0 1.555847006784461e-08
be O 0 1.5651931306592815e-08
lower O 0 7.544927598246431e-07
than O 0 2.082398253833162e-08
those O 0 2.7487500275924504e-08
in O 0 3.579757290594898e-08
individuals O 0 3.6275544346153765e-08
with O 0 5.789511448028861e-08
mutations O 0 4.716050625575008e-07
in O 0 4.0069057405389685e-08
region O 0 2.877200984130468e-07
1 O 0 2.1697407248666423e-07
, O 0 7.763152609641111e-08
although O 0 1.2992529718758306e-07
age O 0 6.946226562831725e-07
at O 0 4.035971414850792e-06
diagnosis O 0 0.0004890383570455015
was O 0 6.78312517266022e-06
similar O 0 6.143740392872132e-06
. O 0 7.722775080765132e-06

In O 0 3.301857941551134e-05
all O 0 8.433979928668123e-06
AAPC B-Disease 1 0.9980496168136597
kindreds O 0 0.00326979486271739
, O 0 1.569748746987898e-06
a O 0 7.168035836002673e-07
predominance O 0 1.9801202142843977e-05
of O 0 1.8990076569025405e-06
right O 0 0.0012913750251755118
- O 1 0.999785840511322
sided O 1 0.9999972581863403
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999986886978149
and O 0 0.082472063601017
rectal B-Disease 1 0.9999922513961792
polyp I-Disease 1 0.9988725781440735
sparing O 0 0.0006108644884079695
was O 0 4.6521221520379186e-05
observed O 0 2.3257947759702802e-05
. O 0 1.304977104155114e-05

No O 0 0.00043689479934982955
desmoid B-Disease 1 0.9935269355773926
tumors I-Disease 1 0.9999517202377319
were O 0 6.9849006649747025e-06
found O 0 1.2888855280834832e-06
in O 0 2.6092817506651045e-07
these O 0 6.658324309682939e-07
kindreds O 0 0.0007239027763716877
. O 0 1.5157902453211136e-05

Our O 0 1.2052444617438596e-05
data O 0 5.54820871911943e-06
suggest O 0 1.7968750398722477e-06
that O 0 2.3373237922896806e-07
, O 0 3.939070722935867e-07
in O 0 1.0894895012825145e-06
AAPC B-Disease 1 0.9995635151863098
families O 0 4.690440164267784e-06
, O 0 1.8630079523518361e-07
the O 0 2.67798654363105e-08
location O 0 2.757160189048591e-07
of O 0 3.6696569338801055e-08
the O 0 3.1599807925886125e-07
APC B-Disease 0 0.00014729786198586226
mutation O 0 3.3051237551262602e-06
may O 0 7.12320911588904e-07
partially O 0 4.241111582814483e-06
predict O 0 6.307604508037912e-06
specific O 0 3.95711367673357e-07
phenotypic O 0 6.753780780854868e-06
expression O 0 3.628140120781609e-06
. O 0 8.914971658668946e-06

This O 0 3.5295299767312827e-06
should O 0 1.340328594778839e-06
help O 0 4.349646189893974e-07
in O 0 5.231994038012999e-08
the O 0 2.819156463829131e-08
design O 0 7.625009175171726e-07
of O 0 2.1329488220089843e-07
tailored O 0 0.0003557245363481343
clinical O 0 0.0006905628251843154
- O 0 0.12556661665439606
management O 0 1.1796775652328506e-05
protocols O 0 2.8330257464403985e-06
in O 0 2.9581157079405784e-08
this O 0 2.4323513869717317e-08
subset O 0 1.8983721474796766e-06
of O 0 1.1021187447113334e-06
FAP B-Disease 0 0.01667138561606407
patients O 0 2.14308820432052e-05
. O 0 5.120660375723673e-07
. O 0 4.6748814384045545e-06

Wilms B-Disease 1 0.9975685477256775
' I-Disease 0 0.0022008889354765415
tumor I-Disease 0 0.0015650450950488448
1 O 0 1.4715167253598338e-06
and O 0 5.073954412182502e-07
Dax O 0 0.020484426990151405
- O 0 3.446315895416774e-05
1 O 0 3.1118386800699227e-07
modulate O 0 6.087839210522361e-07
the O 0 5.1703398895597275e-08
orphan O 0 4.221359631628729e-06
nuclear O 0 1.093732953449944e-05
receptor O 0 6.863081694064022e-07
SF O 0 0.000771882536355406
- O 0 5.108936875330983e-06
1 O 0 8.566092191131247e-08
in O 0 2.971495227654941e-08
sex O 0 3.4392985526210396e-07
- O 0 1.0721459148044232e-05
specific O 0 1.4336531251046836e-07
gene O 0 9.501021622781991e-07
expression O 0 1.0922506135102594e-06
. O 0 4.300621185393538e-06

Products O 0 4.741041630040854e-05
of O 0 2.232276074209949e-06
steroidogenic O 0 0.001592522719874978
factor O 0 4.639921826310456e-06
1 O 0 9.54739789449377e-07
( O 0 1.5677363762733876e-07
SF O 0 0.06893711537122726
- O 0 5.46892115380615e-05
1 O 0 2.668371053005103e-07
) O 0 4.820812549155562e-08
and O 0 4.247407900948019e-07
Wilms B-Disease 1 0.7859002351760864
tumor I-Disease 0 0.000506116368342191
1 O 0 5.302904355630744e-07
( O 0 1.1547675882184194e-07
WT1 O 0 4.142916077398695e-05
) O 0 3.266943338076089e-08
genes O 0 3.233689582771149e-08
are O 0 4.2860408555611684e-09
essential O 0 1.8168336168855603e-08
for O 0 1.964926532593836e-08
mammalian O 0 8.485772582389473e-07
gonadogenesis O 0 3.192491931258701e-05
prior O 0 4.494940242238954e-07
to O 0 1.844002497364272e-07
sexual O 0 1.9814840470644413e-06
differentiation O 0 2.3127937311073765e-05
. O 0 6.509888862638036e-06

In O 0 9.10339986148756e-06
males O 0 1.0657979146344587e-05
, O 0 1.4685167570860358e-06
SF O 0 0.18032802641391754
- O 0 6.66929263388738e-05
1 O 0 2.6259547780682624e-07
participates O 0 1.1494430651737275e-07
in O 0 1.7620811476604104e-08
sexual O 0 6.832844690052298e-08
development O 0 5.973757311039662e-08
by O 0 1.8964501080631635e-08
regulating O 0 2.447929716709041e-07
expression O 0 2.7610141728473536e-08
of O 0 1.4257118152727344e-08
the O 0 1.3064119741557079e-07
polypeptide O 0 5.2775987569475546e-05
hormone O 0 6.144619419501396e-06
Mullerian O 0 6.258629582589492e-05
inhibiting O 0 5.797124686068855e-06
substance O 0 3.421675501158461e-06
( O 0 4.758082354783255e-07
MIS O 0 6.970452523091808e-05
) O 0 1.2603763934748713e-06
. O 0 2.626511104608653e-06

Here O 0 2.3032720491755754e-05
, O 0 1.1761252380892984e-06
we O 0 1.9065952017172094e-07
show O 0 3.14961312142259e-07
that O 0 2.0890382756988402e-07
WT1 O 0 0.0006267721764743328
- O 0 0.00016836995200719684
KTS O 0 0.0004399666504468769
isoforms O 0 3.587624917145149e-07
associate O 0 4.126095518586226e-07
and O 0 9.68553308666742e-08
synergize O 0 0.0001370451063849032
with O 0 9.80823529062036e-07
SF O 1 0.8068881034851074
- O 0 9.86692393780686e-05
1 O 0 5.031425871493411e-07
to O 0 9.606036144305108e-08
promote O 0 1.4172412647894816e-06
MIS O 0 0.0004459555493667722
expression O 0 8.145827450789511e-06
. O 0 8.386186891584657e-06

In O 0 2.801364280458074e-05
contrast O 0 5.1645412895595655e-05
, O 0 1.1602936865529045e-05
WT1 O 0 0.017946962267160416
missense O 0 0.0009377754759043455
mutations O 0 5.194993718760088e-05
, O 0 2.2827539396530483e-06
associated O 0 1.8722533923209994e-06
with O 0 1.2805187452613609e-06
male B-Disease 0 8.427467946603429e-06
pseudohermaphroditism I-Disease 1 0.9983114004135132
in O 0 2.538323860790115e-05
Denys B-Disease 1 0.9986605644226074
- I-Disease 1 0.9999178647994995
Drash I-Disease 1 0.9999792575836182
syndrome I-Disease 1 0.9997164607048035
, O 0 4.667290340876207e-06
fail O 0 1.4250356798584107e-05
to O 0 3.622524786806025e-07
synergize O 0 0.0007471616845577955
with O 0 4.700865247286856e-06
SF O 1 0.993165910243988
- O 0 0.001160169718787074
1 O 0 7.506582733185496e-06
. O 0 7.783100954839028e-06

Additionally O 0 3.048571124963928e-05
, O 0 1.5940671573844156e-06
the O 0 2.802195240292349e-07
X O 0 0.0013324019964784384
- O 0 0.0006631611031480134
linked O 0 2.2195916244527325e-05
, O 0 1.6444440120721993e-07
candidate O 0 1.3642247722600587e-06
dosage O 0 7.328626452363096e-06
- O 0 3.172303695464507e-05
sensitive O 0 6.33472018307657e-06
sex O 0 8.809016662780778e-07
- O 0 1.363272349408362e-05
reversal O 0 1.997451818169793e-06
gene O 0 1.9224688685426372e-07
, O 0 9.754610630352545e-08
Dax O 0 0.0011346396058797836
- O 0 2.4696137188584544e-05
1 O 0 2.310994489107543e-07
, O 0 7.166553217530236e-08
antagonizes O 0 2.3069062535796547e-06
synergy O 0 7.521061888837721e-07
between O 0 2.4019840338951326e-07
SF O 0 0.30604422092437744
- O 0 0.00016809148655738682
1 O 0 4.7483456455665873e-07
and O 0 1.5506218176142283e-07
WT1 O 0 0.00010127218411071226
, O 0 7.031425752757059e-08
most O 0 2.3513727853696764e-08
likely O 0 7.909203958433864e-08
through O 0 1.1924544018881988e-08
a O 0 2.9197739337405437e-08
direct O 0 4.760642369205925e-08
interaction O 0 1.4591992680834664e-07
with O 0 4.323236169057054e-07
SF O 1 0.9835482239723206
- O 0 0.0013597749639302492
1 O 0 7.3078695095318835e-06
. O 0 3.4815104754670756e-06

We O 0 8.97367499419488e-06
propose O 0 1.557769974169787e-05
that O 0 6.552422178174311e-07
WT1 O 0 0.0001622525160200894
and O 0 1.1909040722457576e-06
Dax O 0 0.22868940234184265
- O 0 0.0002784020616672933
1 O 0 6.967835588511662e-07
functionally O 0 2.130743951056502e-06
oppose O 0 3.006792326232244e-07
each O 0 9.234965681059748e-09
other O 0 1.306591013161551e-08
in O 0 8.228209225080718e-08
testis O 0 2.2996242478257045e-05
development O 0 1.7715008482355188e-07
by O 0 1.9245013049840054e-07
modulating O 0 3.6920908314641565e-05
SF O 1 0.7756941914558411
- O 0 0.0002460683463141322
1 O 0 1.99811461243371e-06
- O 0 4.099356010556221e-05
mediated O 0 2.8420799935702235e-05
transactivation O 0 9.684592805569991e-05
. O 0 7.333242706408782e-07
. O 0 3.106731355728698e-06

A O 0 3.7141693610465154e-05
mouse O 0 0.00014066402218304574
model O 0 4.404744686326012e-05
for O 0 0.00011020278907380998
Prader B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999977350234985
Willi I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999501705169678
imprinting O 0 0.07966409623622894
- O 0 0.224910706281662
centre O 0 0.00033844306017272174
mutations O 0 0.00010140446829609573
. O 0 1.625092227186542e-05

Imprinting O 0 0.0005255884025245905
in O 0 3.855627710436238e-06
the O 0 7.036717875053e-07
15q11 O 0 0.00013342918828129768
- O 0 0.0002855492348317057
q13 O 0 4.1296472772955894e-05
region O 0 6.064578883524518e-07
involves O 0 2.8809546392949414e-07
an O 0 5.2629211211296933e-08
imprinting O 0 2.788253732433077e-05
centre O 0 1.3189901437726803e-05
( O 0 1.8254590372634993e-07
IC O 0 2.4914856112445705e-05
) O 0 3.608108656294462e-08
, O 0 2.2697147272765505e-08
mapping O 0 3.751374890725856e-07
in O 0 1.6784705181294157e-08
part O 0 3.942949078350466e-08
to O 0 1.0575185172001511e-08
the O 0 4.756140725703517e-08
promoter O 0 1.2637206964427605e-05
and O 0 8.541520912785927e-08
first O 0 2.130994829485644e-07
exon O 0 7.610874035890447e-06
of O 0 1.5704119959991658e-06
SNRPN O 0 0.004128801170736551
. O 0 7.108312274795026e-06

Deletion O 0 0.00019412205438129604
of O 0 2.04304228645924e-06
this O 0 9.428594012206304e-07
IC O 0 0.00012856673856731504
abolishes O 0 2.4232065698015504e-05
local O 0 4.862636728830694e-07
paternally O 0 5.079123184259515e-06
derived O 0 9.596036676384756e-08
gene O 0 2.1642330239046714e-07
expression O 0 5.6136993720201644e-08
and O 0 8.765401560140162e-08
results O 0 1.9961757971032057e-06
in O 0 8.995709504233673e-05
Prader B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999996423721313
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999982118606567
( O 0 0.0005613987450487912
PWS B-Disease 1 0.9998942613601685
) O 0 1.3657680938194972e-05
. O 0 1.5795780200278386e-05

We O 0 1.1728809113265015e-05
have O 0 3.796576208969782e-07
created O 0 2.623874593155051e-07
two O 0 9.417453838977963e-08
deletion O 0 8.311963028972968e-06
mutations O 0 2.611843683553161e-06
in O 0 3.2071059763438825e-07
mice O 0 6.535798092954792e-06
to O 0 6.794246587560338e-07
understand O 0 3.255925184930675e-05
PWS B-Disease 1 0.9998651742935181
and O 0 7.707536724410602e-07
the O 0 1.5131625730191445e-07
mechanism O 0 3.2966670460155e-07
of O 0 1.6154127990830602e-07
this O 0 6.549573186021007e-07
IC O 0 0.0006090565002523363
. O 0 8.659118066134397e-06

Mice O 0 0.0057692816480994225
harbouring O 0 0.0026305601932108402
an O 0 1.9997999061160954e-06
intragenic O 0 0.0008099820697680116
deletion O 0 3.099053355981596e-05
in O 0 6.477479814748222e-07
Snrpn O 0 0.0003515414719004184
are O 0 1.3291356992795045e-07
phenotypically O 0 1.6107565897982568e-05
normal O 0 1.0141541224584216e-06
, O 0 2.0144688051004778e-07
suggesting O 0 9.180908477901539e-07
that O 0 3.5629660999347834e-08
mutations O 0 3.6950649473510566e-07
of O 0 7.789925149381816e-08
SNRPN O 0 0.002894541947171092
are O 0 4.443682399823956e-08
not O 0 3.852948182725413e-08
sufficient O 0 4.0270643353323976e-07
to O 0 8.542349405615823e-07
induce O 0 0.00020452543685678393
PWS B-Disease 1 0.9987712502479553
. O 0 3.2166710298042744e-05

Mice O 0 0.001655341824516654
with O 0 5.123604296386475e-06
a O 0 1.72562704392476e-06
larger O 0 1.7658278466115007e-06
deletion O 0 4.653037649404723e-06
involving O 0 1.4732564750374877e-06
both O 0 4.424598500918364e-07
Snrpn O 0 0.0008311883429996669
and O 0 1.3233243407739792e-06
the O 0 5.367899689190381e-07
putative O 0 0.0015866373432800174
PWS O 1 0.999829888343811
- O 0 0.00370483729057014
IC O 0 0.00020003043755423278
lack O 0 4.7614142317797814e-07
expression O 0 7.97522119455607e-08
of O 0 2.573253432558431e-08
the O 0 1.881868456621305e-07
imprinted O 0 4.661465573008172e-05
genes O 0 7.41129781545169e-07
Zfp127 O 0 6.367509195115417e-05
( O 0 7.218767450467567e-08
mouse O 0 1.1244585493841441e-06
homologue O 0 2.73828231911466e-06
of O 0 2.1685160334072862e-07
ZNF127 O 0 0.002324793254956603
) O 0 1.2966251006218954e-07
, O 0 1.8195756013028586e-07
Ndn O 0 0.00020975245570298284
and O 0 1.773766058477122e-07
Ipw O 0 5.515395969268866e-06
, O 0 2.5814787818490004e-07
and O 0 2.3179053698640928e-07
manifest O 0 2.6805219022207893e-06
several O 0 3.3661922316241544e-07
phenotypes O 0 2.5667162844911218e-05
common O 0 1.5320290458475938e-06
to O 0 2.5173609174089506e-05
PWS B-Disease 1 0.9999701976776123
infants O 0 0.006435571704059839
. O 0 3.4275126381544396e-05

These O 0 2.651860995683819e-06
data O 0 2.603398343126173e-06
demonstrate O 0 1.0681366120479652e-06
that O 0 8.265188711220617e-08
both O 0 4.0005673440646206e-08
the O 0 2.1143764072917293e-08
position O 0 7.980212046732049e-08
of O 0 2.4358801198332003e-08
the O 0 5.236147515574885e-08
IC O 0 7.747431664029136e-05
and O 0 6.498368065877003e-08
its O 0 2.0546860213244145e-08
role O 0 4.92701808241236e-08
in O 0 8.304437137951481e-09
the O 0 5.875534281329919e-09
coordinate O 0 1.8232998399980715e-07
expression O 0 2.2855669357113584e-08
of O 0 1.2021186712729559e-08
genes O 0 2.953132316463325e-08
is O 0 1.0804658501228914e-08
conserved O 0 4.310868817469782e-08
between O 0 8.606378543163373e-08
mouse O 0 4.917329079034971e-06
and O 0 2.157515126555154e-07
human O 0 1.7859908041373274e-07
, O 0 1.7618619096992916e-07
and O 0 1.877895527968576e-07
indicate O 0 3.643652917162399e-07
that O 0 2.34776074137244e-08
the O 0 3.3795370057987384e-08
mouse O 0 5.302962563291658e-06
is O 0 5.0581459021259434e-08
a O 0 8.872345347299415e-08
suitable O 0 1.959520204763976e-06
model O 0 1.383545168209821e-06
system O 0 4.085202931491949e-07
in O 0 1.4678857240824073e-08
which O 0 1.6490950827119377e-08
to O 0 4.338369308243273e-08
investigate O 0 1.299742848459573e-06
the O 0 2.733796478082695e-08
molecular O 0 1.7238274949704646e-06
mechanisms O 0 7.557041215022764e-08
of O 0 1.8583937944072204e-08
imprinting O 0 7.274133167811669e-06
in O 0 5.712432837867709e-08
this O 0 2.3460058784507964e-08
region O 0 1.733724843688833e-07
of O 0 2.3102378676753688e-08
the O 0 1.3624055839045468e-07
genome O 0 2.9856125820515445e-06
. O 0 5.223997163739114e-07
. O 0 3.552127282091533e-06

Mutations O 0 6.297027721302584e-05
of O 0 1.1217807696084492e-06
the O 0 6.799017455705325e-07
ATM O 0 3.4772423532558605e-05
gene O 0 2.151112312276382e-06
detected O 0 4.621708740160102e-06
in O 0 6.08753737196821e-07
Japanese O 0 0.0006102525512687862
ataxia B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999902248382568
telangiectasia I-Disease 1 0.9999988079071045
patients O 0 0.0052205962128937244
: O 0 4.4720641767526104e-07
possible O 0 1.2872885690740077e-06
preponderance O 0 2.985044557135552e-05
of O 0 1.1579788861126872e-07
the O 0 1.3589071556907584e-07
two O 0 2.7011176939595316e-07
founder O 0 7.720866415183991e-05
mutations O 0 3.834243216260802e-06
4612del165 O 0 3.877323615597561e-05
and O 0 2.5368026399519295e-06
7883del5 O 0 0.0001904345554066822
. O 0 8.328833246196155e-06

The O 0 1.1765349881898146e-05
ATM O 0 0.0008770732674747705
( O 0 3.942644070775714e-06
A O 0 0.0017868083668872714
- O 1 0.9939084053039551
T O 1 0.9999760389328003
, O 0 1.0490865633983049e-06
mutated O 0 7.102086669874552e-07
) O 0 4.64890774765081e-08
gene O 0 1.6745765663017664e-07
on O 0 3.318745029901038e-07
human O 0 1.1543561413418502e-06
chromosome O 0 9.295639029005542e-05
11q22 O 0 0.0005888284649699926
. O 0 1.4650861885456834e-05

3 O 0 5.3496532927965745e-05
has O 0 2.3524796688434435e-06
recently O 0 2.9870479920646176e-06
been O 0 2.2386069531421526e-07
identified O 0 4.737308927360573e-07
as O 0 1.5048813750695444e-08
the O 0 1.51503609657766e-08
gene O 0 1.1120329190816847e-07
responsible O 0 2.1273824302170397e-07
for O 0 5.3722125414878974e-08
the O 0 7.789894311827084e-07
human O 0 0.0006302818655967712
recessive B-Disease 1 0.9997332692146301
disease I-Disease 1 0.9998282194137573
ataxia B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999948740005493
telangiectasia I-Disease 1 0.9999978542327881
( O 0 0.00012565798533614725
A B-Disease 1 0.6882482767105103
- I-Disease 1 0.9995266199111938
T I-Disease 1 0.9999532699584961
) O 0 3.0822752705716994e-06
. O 0 4.2417022996232845e-06

In O 0 3.7721213175245794e-06
order O 0 4.7386285473294265e-07
to O 0 7.894252718188e-08
define O 0 3.3823044987002504e-07
the O 0 5.0462357847891326e-08
types O 0 1.3224550912127597e-06
of O 0 2.313639470230555e-06
disease O 0 0.018276266753673553
- O 0 0.03506645932793617
causing O 0 4.205066215945408e-05
ATM O 0 0.00011942489800276235
mutations O 0 7.31109309981548e-07
in O 0 1.180533146794005e-07
Japanese O 0 7.493664725188864e-06
A B-Disease 0 0.1758035123348236
- I-Disease 1 0.9998953342437744
T I-Disease 1 0.9999992847442627
patients O 0 7.675499364268035e-05
as O 0 5.120982748962888e-08
well O 0 3.990370700535095e-08
as O 0 1.3064066273216213e-08
to O 0 1.7571107235880845e-08
look O 0 2.591404211216286e-07
for O 0 3.555301830715507e-08
possible O 0 4.768594408233184e-07
mutational O 0 3.704586561070755e-05
hotspots O 0 1.9304554371046834e-05
, O 0 2.653713124800561e-07
reverse O 0 1.3904927982366644e-05
- O 0 3.317570372018963e-05
transcribed O 0 3.54764807752872e-07
RNA O 0 8.291778641478231e-08
derived O 0 2.3236149004901563e-08
from O 0 1.9941611029139494e-08
ten O 0 1.038501693528815e-07
patients O 0 5.433054752757016e-07
belonging O 0 4.75419057011095e-07
to O 0 2.1657397653029875e-08
eight O 0 9.879482831820496e-08
unrelated O 0 2.7214668989472557e-06
Japanese O 0 6.561740974575514e-06
A B-Disease 0 0.024828165769577026
- I-Disease 1 0.9993398785591125
T I-Disease 1 0.9999873638153076
families O 0 2.1943487809039652e-06
was O 0 6.795801823500369e-07
analyzed O 0 6.872775202282355e-07
for O 0 1.213358160612188e-07
mutations O 0 6.656006803495984e-07
by O 0 7.716297290016882e-08
the O 0 1.1986951164999482e-07
restriction O 0 1.4547324553859653e-06
endonuclease O 0 6.463583849836141e-05
fingerprinting O 0 5.9670328482752666e-05
method O 0 6.460615622927435e-06
. O 0 7.339634521486005e-06

As O 0 8.44790611154167e-06
has O 0 9.481144047640555e-07
been O 0 2.4088453187687264e-07
reported O 0 1.3338483313418692e-06
by O 0 2.1421463713977573e-07
others O 0 5.531517786039331e-07
, O 0 2.14706318502067e-07
mutations O 0 2.8007710284327914e-07
that O 0 2.988945979609525e-08
lead O 0 3.2095263691189757e-07
to O 0 5.667869729109043e-08
exon O 0 8.389059075852856e-06
skipping O 0 6.756164111720864e-06
or O 0 4.927154009237711e-07
premature O 0 3.91292451240588e-06
protein O 0 1.1907048502735051e-07
truncation O 0 1.3288876061778865e-06
were O 0 1.1882318773359657e-07
also O 0 4.446335921670652e-08
predominant O 0 3.461552751105046e-07
in O 0 7.670514179380916e-08
our O 0 3.8614751929344493e-07
mutants O 0 1.7072550690500066e-05
. O 0 5.643798431265168e-06

Six O 0 1.224357129103737e-05
different O 0 1.0218060424449504e-06
mutations O 0 2.3232619241753127e-06
were O 0 4.669471422857896e-07
identified O 0 6.657307949353708e-07
on O 0 1.2782648184384016e-07
12 O 0 1.419390400769771e-07
of O 0 3.450823271577974e-08
the O 0 7.941098800756663e-08
16 O 0 6.085975314817915e-07
alleles O 0 1.8017517504631542e-06
examined O 0 1.897195033961907e-05
. O 0 5.864447302883491e-06

Four O 0 1.9605035049607977e-05
were O 0 3.879483301716391e-06
deletions O 0 1.711020195216406e-05
involving O 0 1.1873637959070038e-05
a O 0 5.5846894611022435e-06
loss O 0 4.015487866126932e-05
of O 0 6.990199352685522e-08
a O 0 2.4846869450811937e-07
single O 0 3.3352503692185564e-07
exon O 0 4.41178690380184e-06
exon O 0 4.4371540752763394e-06
7 O 0 3.433046060763445e-07
, O 0 4.437152512082321e-08
exon O 0 1.1462186648714123e-06
16 O 0 1.976006700488142e-07
, O 0 7.036496896262179e-08
exon O 0 2.4787091206235345e-06
33 O 0 1.116457156058459e-06
or O 0 4.2485382323320664e-07
exon O 0 1.5259036445058882e-05
35 O 0 7.187440587586025e-06
. O 0 4.605578396876808e-06

The O 0 1.1947845450777095e-05
others O 0 2.3567281459691003e-06
were O 0 2.674944710179261e-07
minute O 0 8.079331337285112e-07
deletions O 0 5.311738277669065e-06
, O 0 3.514180377806042e-07
4649delA O 0 6.017985924700042e-06
in O 0 8.898462056095013e-08
exon O 0 3.0639437227364397e-06
33 O 0 1.0045122280644136e-06
and O 0 1.5307773537642788e-07
7883del5 O 0 6.694453077216167e-06
in O 0 2.6710495149018243e-07
exon O 0 2.6216954211122356e-05
55 O 0 9.69467237155186e-06
. O 0 3.466019506959128e-06

The O 0 4.808663561561843e-06
mutations O 0 8.991836693894584e-06
4612del165 O 0 4.4545988203026354e-05
and O 0 4.6521006424882216e-07
7883del5 O 0 3.281385579612106e-05
were O 0 3.6642367717831803e-07
found O 0 9.709948756153608e-08
in O 0 1.341751154626536e-08
more O 0 7.0531558371556e-09
than O 0 1.124154103138153e-08
two O 0 1.8361403064659498e-08
unrelated O 0 1.7582827922524302e-06
families O 0 3.925832174900279e-07
; O 0 1.6171807715181785e-07
44 O 0 5.136634513291938e-07
% O 0 7.966950477111823e-08
( O 0 1.483625844400649e-08
7 O 0 8.887758440323523e-08
of O 0 1.206025146416323e-08
16 O 0 5.828123050832801e-08
) O 0 5.480947251612633e-09
of O 0 3.766586598175081e-09
the O 0 1.2890014389199678e-08
mutant O 0 7.218271207420912e-07
alleles O 0 1.0988530618760706e-07
had O 0 3.45271935486835e-08
one O 0 7.644191946099e-09
of O 0 1.0527347882316462e-08
the O 0 8.05889470711918e-08
two O 0 4.5080849986334215e-07
mutations O 0 7.361948064499302e-06
. O 0 4.591890501615126e-06

The O 0 7.123323939595139e-06
4612del165 O 0 0.00038347835652530193
mutations O 0 1.0315509825886693e-05
in O 0 1.8381241773113288e-07
three O 0 5.3286168366639686e-08
different O 0 2.983307467729901e-08
families O 0 8.844686050224482e-08
were O 0 4.1949583362566045e-08
all O 0 8.687087493797208e-09
ascribed O 0 1.4363983780185663e-07
to O 0 1.6532300861626936e-08
the O 0 2.526969389293754e-08
same O 0 3.918045194950537e-07
T O 0 0.04815186560153961
- O 0 0.00012008607882307842
- O 0 3.170035779476166e-05
> O 0 9.111433882935671e-07
A O 0 2.9590523809019942e-08
substitution O 0 5.447536111091722e-08
at O 0 5.811195791238788e-08
the O 0 2.7984130568370347e-08
splice O 0 3.209839860573993e-06
donor O 0 7.898852345533669e-07
site O 0 9.299855037170346e-07
in O 0 2.066244775278392e-07
intron O 0 0.00021733729226980358
33 O 0 7.022691988822771e-06
. O 0 3.450624035394867e-06

Microsatellite O 0 0.007806044537574053
genotyping O 0 0.0007687730831094086
around O 0 4.148437710682629e-06
the O 0 6.209934895196056e-07
ATM O 0 2.4913430024753325e-05
locus O 0 5.246491582511226e-06
also O 0 2.4280274146804004e-07
indicated O 0 1.7630378579269745e-06
that O 0 6.010558450952885e-08
a O 0 3.693426720019488e-07
common O 0 1.1549024065971025e-06
haplotype O 0 6.122115883044899e-05
was O 0 5.573579528572736e-06
shared O 0 2.2381844644314697e-07
by O 0 5.466667118980695e-08
the O 0 7.161619919315854e-08
mutant O 0 1.782274466677336e-06
alleles O 0 4.619434150754387e-07
in O 0 1.8360672981998505e-07
both O 0 7.341835726037971e-07
mutations O 0 1.5031197108328342e-05
. O 0 6.870980087114731e-06

This O 0 3.3186797736561857e-06
suggests O 0 2.7857388431584695e-06
that O 0 7.182837435948386e-08
these O 0 3.116500835176339e-08
two O 0 1.3640240581480612e-07
founder O 0 6.585805385839194e-05
mutations O 0 3.460969082880183e-06
may O 0 3.30092035483176e-07
be O 0 6.972117461145899e-08
predominant O 0 9.152575444204558e-07
among O 0 3.121040208498016e-07
Japanese O 0 3.101533138760715e-06
ATM O 0 2.4112565370160155e-05
mutant O 0 1.6481020793435164e-05
alleles O 0 7.367742455244297e-06
. O 0 4.848883236263646e-06

W474C O 0 0.0007666338351555169
amino O 0 1.4888914847688284e-05
acid O 0 4.5228398448671214e-06
substitution O 0 6.341099378914805e-07
affects O 0 6.483610945906548e-07
early O 0 1.2099251023300894e-07
processing O 0 1.832607097185246e-07
of O 0 7.007764590838406e-09
the O 0 9.223928287838135e-09
alpha O 0 7.8804134773236e-08
- O 0 9.125550803901206e-08
subunit O 0 1.8268412560473735e-08
of O 0 5.145770920478299e-09
beta O 0 1.5183130130935751e-07
- O 0 3.0985590910859173e-06
hexosaminidase O 0 6.344617759168614e-06
A O 0 7.457254724840823e-08
and O 0 6.043181599579839e-08
is O 0 7.418228165079199e-08
associated O 0 6.637757223870722e-07
with O 0 3.0367737053893507e-06
subacute O 1 0.9915516376495361
G B-Disease 1 0.671029806137085
( I-Disease 0 3.294462203484727e-06
M2 I-Disease 0 0.002100002719089389
) I-Disease 0 3.1630547709937673e-06
gangliosidosis I-Disease 0 0.00020806114480365068
. O 0 9.851613867795095e-06

Mutations O 0 0.00016608470468781888
in O 0 1.542196400805551e-06
the O 0 7.651283908671758e-07
HEXA O 0 0.005539544392377138
gene O 0 1.7384512602802715e-06
, O 0 4.7113214662886094e-08
encoding O 0 6.08226713438853e-08
the O 0 1.1470389971179884e-08
alpha O 0 1.0637435821081453e-07
- O 0 2.0650864485105558e-07
subunit O 0 5.944501069166108e-08
of O 0 2.4514381635754035e-08
beta O 0 3.564394148725114e-07
- O 0 1.0467826541571412e-05
hexosaminidase O 0 1.8217237084172666e-05
A O 0 1.6751947384818777e-07
( O 0 3.699440398463594e-08
Hex O 0 9.820787454373203e-07
A O 0 6.619488601700141e-08
) O 0 1.617121725416837e-08
, O 0 7.597591000774173e-09
that O 0 5.73629721500879e-09
abolish O 0 3.1137622613641724e-07
Hex O 0 1.182576625069487e-06
A O 0 5.71171376861912e-08
enzyme O 0 2.0929347499532014e-07
activity O 0 1.5438092759723077e-06
cause O 0 0.000141566910315305
Tay B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999648332595825
Sachs I-Disease 1 0.9999912977218628
disease I-Disease 0 0.004495771136134863
( O 0 3.1188412208393856e-07
TSD B-Disease 0 0.008843325078487396
) O 0 1.8782967003971862e-07
, O 0 2.3060387377427105e-07
the O 0 4.495394421155652e-07
fatal O 0 0.036851171404123306
infantile B-Disease 0 0.00028290582122281194
form I-Disease 0 2.141413233403e-07
of I-Disease 0 5.076539082438103e-07
G I-Disease 0 0.04963871091604233
( I-Disease 0 4.3210516764702334e-07
M2 I-Disease 0 0.000462429627077654
) I-Disease 0 2.795028990476567e-07
gangliosidosis I-Disease 0 3.864116661134176e-05
, I-Disease 0 2.4959538791335945e-07
Type I-Disease 0 2.6892889763985295e-06
1 I-Disease 0 2.0159959603915922e-06
. O 0 4.697924850916024e-06

Less O 0 0.00043631959124468267
severe O 0 0.20884336531162262
, O 0 3.775233926717192e-05
subacute O 1 0.9718788266181946
( O 0 2.2763560991734266e-05
juvenile O 1 0.8222730159759521
- O 1 0.742759108543396
onset O 1 0.7339690327644348
) O 0 5.822600542160217e-06
and O 0 0.0001090527803171426
chronic O 1 0.9317306876182556
( O 0 7.474883432223578e-07
adult O 0 1.864248224592302e-05
- O 0 0.3625827431678772
onset O 0 0.037926170974969864
) O 0 1.8847529759113968e-07
variants O 0 5.154693667464016e-07
are O 0 6.556409459790302e-08
characterized O 0 7.041886647130013e-07
by O 0 4.2759264573533073e-08
a O 0 1.2442461638784152e-07
broad O 0 7.830733920854982e-06
spectrum O 0 1.1324197657813784e-05
of O 0 4.943924523104215e-07
clinical O 0 4.761912350659259e-05
manifestations O 0 1.6905962183955126e-05
and O 0 1.276585180676193e-06
are O 0 9.022537739156178e-08
associated O 0 4.4220422523721936e-07
with O 0 1.5708164369243605e-07
residual O 0 3.4341512218816206e-05
levels O 0 1.8471776286332897e-07
of O 0 5.768755428903205e-08
Hex O 0 4.058171725773718e-06
A O 0 2.9669936907339434e-07
enzyme O 0 6.796793172725302e-07
activity O 0 1.5926023024803726e-06
. O 0 1.7471804767410504e-06

We O 0 1.9501840142766014e-05
identified O 0 1.4233422007237095e-05
a O 0 1.7978965161091764e-06
1422 O 0 0.0004760655283462256
G O 0 0.004998415242880583
- O 0 0.003161009168252349
- O 0 0.003771487856283784
> O 0 9.151257836492732e-05
C O 0 3.5464308894006535e-05
( O 0 3.148429073007719e-08
amino O 0 2.4500405260141633e-08
acid O 0 3.5408465492992036e-08
W474C O 0 1.395305986306994e-07
) O 0 2.9301938653247817e-09
substitution O 0 4.383750251690799e-09
in O 0 2.697141399110592e-09
the O 0 1.90657556409235e-09
first O 0 8.733072931477182e-09
position O 0 2.084341232944098e-08
of O 0 1.158487705765765e-08
exon O 0 1.353022298644646e-06
13 O 0 1.0025420493775528e-07
of O 0 3.003421866765166e-08
HEXA O 0 0.00017349117842968553
of O 0 3.936982295726921e-08
a O 0 2.806249597142596e-07
non O 0 2.2989797798800282e-06
- O 0 7.385405478999019e-05
Jewish O 0 4.653690211853245e-06
proband O 0 0.005614629480987787
who O 0 1.5231685210892465e-06
manifested O 0 2.6766213068185607e-06
a O 0 7.130107633201987e-07
subacute O 0 0.07125081866979599
variant O 0 1.1139983143948484e-05
of O 0 6.499905680357188e-07
G B-Disease 0 0.04119451716542244
( I-Disease 0 1.306904664488684e-06
M2 I-Disease 0 0.0023227825295180082
) I-Disease 0 2.170501375076128e-06
gangliosidosis I-Disease 0 0.0002407819702057168
. O 0 1.0077784281747881e-05

On O 0 6.987238975852961e-06
the O 0 6.302989277173765e-07
second O 0 4.375851403892739e-06
maternally O 0 0.0014331736601889133
inherited O 0 0.0028756107203662395
allele O 0 5.53798008695594e-06
, O 0 3.0375619530786935e-07
we O 0 2.0633913777601265e-07
identified O 0 8.80880747899937e-07
the O 0 2.114078654358309e-07
common O 0 4.3672356696333736e-05
infantile O 1 0.9624371528625488
disease O 0 0.04143921658396721
- O 0 0.015834679827094078
causing O 0 2.2417450963985175e-05
4 O 0 2.5764466045075096e-06
- O 0 3.217818448320031e-05
bp O 0 7.847735105315223e-06
insertion O 0 8.460996241410612e-07
, O 0 1.6078280395959155e-07
+ O 0 3.445836227911059e-06
TATC O 0 8.20369750726968e-05
1278 O 0 9.737598156789318e-05
, O 0 1.9904489079181076e-07
in O 0 2.87811502630575e-07
exon O 0 4.484879900701344e-05
11 O 0 4.654391432268312e-06
. O 0 4.369825546746142e-06

Pulse O 0 0.0002364586543990299
- O 0 0.00011728705430869013
chase O 0 1.4388032468559686e-05
analysis O 0 2.7843898919854837e-07
using O 0 1.5912253559235978e-07
proband O 0 3.9292452129302546e-05
fibroblasts O 0 1.0794381523737684e-05
revealed O 0 3.226744865969522e-06
that O 0 1.8257058087556288e-08
the O 0 3.1768411901111904e-08
W474C O 0 6.172164830786642e-06
- O 0 1.5221128251141636e-06
containing O 0 3.476999665963376e-08
alpha O 0 3.972176543243222e-08
- O 0 1.207996263019595e-07
subunit O 0 3.1555835278140876e-08
precursor O 0 3.178683627425016e-08
was O 0 2.489738726296764e-08
normally O 0 2.0693164515250828e-08
synthesized O 0 4.3719868614289226e-08
, O 0 1.081841372041481e-08
but O 0 6.633160687385953e-09
not O 0 5.224472410247927e-09
phosphorylated O 0 2.6202712888334645e-07
or O 0 4.2157004997989134e-08
secreted O 0 7.787771494349727e-08
, O 0 2.088452077941838e-08
and O 0 3.000919335249819e-08
the O 0 2.22235705393814e-08
mature O 0 8.612961437393096e-07
lysosomal O 0 2.4649172701174393e-05
alpha O 0 4.278173832972243e-07
- O 0 1.2096234058844857e-06
subunit O 0 3.8090917087174603e-07
was O 0 1.978539074798391e-07
not O 0 1.2323906162237108e-07
detected O 0 4.006274139101151e-06
. O 0 1.5688448229411733e-06

When O 0 1.1269317838014103e-05
the O 0 8.840719942782016e-07
W474C O 0 2.0395094907144085e-05
- O 0 2.2315844034892507e-06
containing O 0 1.3036093093887757e-07
alpha O 0 1.752893865614169e-07
- O 0 4.3515629499779607e-07
subunit O 0 1.2953063333043247e-07
was O 0 1.6177082784452068e-07
transiently O 0 2.913343223553966e-06
co O 0 2.1692969767173054e-06
- O 0 5.976291959086666e-06
expressed O 0 3.4500995838016024e-08
with O 0 1.1388726406380556e-08
the O 0 1.3243094620918328e-08
beta O 0 1.4113133772752917e-07
- O 0 4.126221710976097e-07
subunit O 0 4.604238412753148e-08
to O 0 1.0832350127998325e-08
produce O 0 5.1498382447334734e-08
Hex O 0 1.187736074825807e-06
A O 0 9.60775849989659e-08
( O 0 6.220723491878744e-08
alphabeta O 0 5.153059646545444e-06
) O 0 2.5510475509804564e-08
in O 0 3.6403079661795346e-08
COS O 0 0.00020742336346302181
- O 0 1.7612395822652616e-05
7 O 0 6.435247428271396e-07
cells O 0 2.0698618641290523e-07
, O 0 1.3439178658813944e-08
the O 0 5.113620193952784e-09
mature O 0 7.376971211670025e-08
alpha O 0 9.646612397773424e-08
- O 0 2.4770830009401834e-07
subunit O 0 6.825225540296742e-08
was O 0 3.8563001680813613e-08
present O 0 2.1329929822400118e-08
, O 0 1.939735483347249e-08
but O 0 7.338235796794379e-09
its O 0 5.862101470910375e-09
level O 0 4.004987630423784e-08
was O 0 4.221960736572328e-08
much O 0 4.5568942397267165e-08
lower O 0 3.233850236483704e-07
than O 0 7.823887315794309e-09
that O 0 6.094981408466538e-09
from O 0 4.412018306254595e-09
normal O 0 2.0826524504968802e-08
alpha O 0 9.027719727328076e-08
- O 0 3.223258886464464e-07
subunit O 0 1.1703814095653797e-07
transfections O 0 4.130089564569062e-06
, O 0 2.7221517484576907e-08
although O 0 1.6944380121231006e-08
higher O 0 4.484133242499411e-08
than O 0 1.3206821414257774e-08
in O 0 1.5079699267062097e-08
those O 0 4.281524823568361e-08
cells O 0 3.489803646061773e-07
transfected O 0 3.7106096897332463e-06
with O 0 1.6930616908439333e-08
an O 0 7.424113768195184e-09
alpha O 0 1.6289726545437588e-07
- O 0 1.3308242614584742e-06
subunit O 0 5.936812499385269e-07
associated O 0 5.283187647364684e-07
with O 0 1.1109618753835093e-06
infantile O 0 0.00813869945704937
TSD B-Disease 0 0.11236921697854996
. O 0 1.6909849364310503e-05

Furthermore O 0 5.0672348152147606e-05
, O 0 1.1218085091968533e-06
the O 0 1.3274116383854562e-07
precursor O 0 5.282965389596939e-07
level O 0 1.5103397288385167e-07
of O 0 1.1434610591720684e-08
the O 0 1.804676408312389e-08
W474C O 0 9.836853678280022e-07
alpha O 0 8.22312600234909e-08
- O 0 2.455519449995336e-07
subunit O 0 7.561222048479976e-08
was O 0 6.330833457468543e-08
found O 0 1.3480563332279871e-08
to O 0 7.076575325726253e-09
accumulate O 0 1.3552719337894814e-06
in O 0 8.303011611587863e-09
comparison O 0 7.246592303999932e-08
to O 0 7.839452642599554e-09
the O 0 8.643817217546257e-09
normal O 0 5.836555416749434e-08
alpha O 0 2.1315496212537255e-07
- O 0 1.1314882613078225e-06
subunit O 0 6.0962400993958e-07
precursor O 0 9.86676809588971e-07
levels O 0 4.4936200538359117e-07
. O 0 1.2966378335477202e-06

We O 0 5.2428358685574494e-06
conclude O 0 7.972489584062714e-06
that O 0 1.439396015712191e-07
the O 0 1.7856059741916397e-07
1422 O 0 0.0002972545044030994
G O 0 0.0034853562247008085
- O 0 0.001175170880742371
- O 0 0.0019192977342754602
> O 0 4.516955596045591e-05
C O 0 6.0642614698736e-05
mutation O 0 2.790173994071665e-07
is O 0 2.145470467951327e-08
the O 0 3.008323545827807e-08
cause O 0 5.995673859615636e-07
of O 0 2.558128073815169e-07
Hex B-Disease 0 0.005187766160815954
A I-Disease 0 0.001240963814780116
enzyme I-Disease 1 0.9995359182357788
deficiency I-Disease 1 0.9994163513183594
in O 0 5.529850568564143e-07
the O 0 2.323895614608773e-06
proband O 0 0.0035919465590268373
. O 0 1.276460534427315e-05

The O 0 9.168158612737898e-06
resulting O 0 6.607040631934069e-06
W474C O 0 3.0333145332406275e-05
substitution O 0 1.548245791127556e-06
clearly O 0 1.2757174090438639e-06
interferes O 0 1.1547746225915034e-06
with O 0 6.701937849129536e-08
alpha O 0 1.8548389846273494e-07
- O 0 3.927584941720852e-07
subunit O 0 5.8635354349689806e-08
processing O 0 1.2776384039625555e-07
, O 0 2.266941478978879e-08
but O 0 2.052163594612466e-08
because O 0 8.054311884109211e-09
the O 0 7.6378530167176e-09
base O 0 1.0552923868090147e-07
substitution O 0 1.2627282330868184e-07
falls O 0 5.579711341852089e-06
at O 0 1.8022822345642453e-08
the O 0 2.764421802581296e-09
first O 0 7.2633885572770396e-09
position O 0 2.252090425258757e-08
of O 0 9.09610964328067e-09
exon O 0 1.760875306899834e-06
13 O 0 2.0402782752171333e-07
, O 0 3.711879514867178e-08
aberrant O 0 5.604914576906594e-07
splicing O 0 6.940789489817689e-07
may O 0 1.688668334054455e-07
also O 0 1.480106970319639e-08
contribute O 0 5.575402184376799e-08
to O 0 1.3020239464367478e-07
Hex B-Disease 0 0.0017765386728569865
A I-Disease 0 0.00033590427483431995
deficiency I-Disease 0 0.0951094850897789
in O 0 1.2327643617027206e-07
this O 0 2.1607087319353013e-07
proband O 0 0.0004440934571903199
. O 0 7.698280910517497e-07
. O 0 3.786220077017788e-06

Two O 0 4.4854870793642476e-05
frequent O 0 0.0002512514765840024
missense O 0 0.006344690918922424
mutations O 0 0.0022972538135945797
in O 0 0.002736413385719061
Pendred B-Disease 1 0.999994158744812
syndrome I-Disease 1 0.9999932050704956
. O 0 0.00041663763113319874

Pendred B-Disease 1 0.9999979734420776
syndrome I-Disease 1 0.9999995231628418
is O 0 0.052626628428697586
an O 1 0.7157828211784363
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.8943414688110352
by O 0 0.00016231162589974701
early O 0 0.05843912065029144
childhood O 1 0.9996398687362671
deafness B-Disease 1 0.9999997615814209
and O 1 0.9908816814422607
goiter B-Disease 1 0.9999990463256836
. O 0 0.0004115562769584358

A O 0 2.804184077831451e-05
century O 0 6.286351890594233e-06
after O 0 9.484399470238714e-07
its O 0 1.0745309708681816e-07
recognition O 0 4.973433647137426e-07
as O 0 5.843477879352577e-07
a O 0 5.204707485972904e-05
syndrome O 0 0.17254501581192017
by O 0 3.6565779737429693e-07
Vaughan O 0 0.002099165692925453
Pendred O 0 0.002922172425314784
, O 0 5.276651791064069e-07
the O 0 9.433729246666189e-07
disease O 0 9.459033026359975e-05
gene O 0 2.1976766220177524e-06
( O 0 5.58667409222835e-07
PDS O 0 9.24130217754282e-05
) O 0 1.1849705572331004e-07
was O 0 2.323243251112217e-07
mapped O 0 3.3165729291795287e-06
to O 0 2.223044646143535e-07
chromosome O 0 1.7718430171953514e-05
7q22 O 0 0.00024360534735023975
- O 0 0.0004474491288419813
q31 O 0 0.0003191612777300179
. O 0 1.0353750440117437e-05

1 O 0 1.3618429875350557e-05
and O 0 1.3956707789475331e-06
, O 0 6.789725262024149e-07
recently O 0 1.8916221051767934e-06
, O 0 1.4258156966207025e-07
found O 0 8.100487747242369e-08
to O 0 5.363734700836176e-08
encode O 0 1.088252702174941e-06
a O 0 1.6348318467862555e-06
putative O 0 0.0004121492966078222
sulfate O 0 0.0011967140017077327
transporter O 0 0.0015718737849965692
. O 0 1.1039406672352925e-05

We O 0 1.628057907510083e-05
performed O 0 5.972132839815458e-06
mutation O 0 1.6787831782494322e-06
analysis O 0 2.7981948846900195e-07
of O 0 1.1268228661265312e-07
the O 0 1.9581626986564515e-07
PDS B-Disease 0 0.00014058666420169175
gene O 0 1.6820026758068707e-06
in O 0 3.6141568671155255e-07
patients O 0 3.035369218196138e-06
from O 0 1.2248121095126407e-07
14 O 0 1.0718335943238344e-06
Pendred B-Disease 0 7.787519280100241e-05
families O 0 1.5074314774210507e-07
originating O 0 5.518798218417942e-08
from O 0 3.280036153796573e-08
seven O 0 5.611890330214919e-08
countries O 0 1.787663528318717e-08
and O 0 1.3646655361299054e-07
identified O 0 9.157805038739752e-07
all O 0 2.6400414299132535e-07
mutations O 0 5.91197522226139e-06
. O 0 5.461150976771023e-06

The O 0 1.6701231288607232e-05
mutations O 0 4.757808710564859e-05
include O 0 1.0559743941485067e-06
three O 0 2.076841809639518e-07
single O 0 3.653217959254107e-07
base O 0 8.425727742178424e-07
deletions O 0 1.5297777054001926e-06
, O 0 6.045464573389836e-08
one O 0 3.3056483772497813e-08
splice O 0 5.652195795846637e-06
site O 0 1.6710156387489405e-06
mutation O 0 3.914138630989328e-07
and O 0 1.7323529277746275e-07
10 O 0 9.618646572562284e-07
missense O 0 0.00010583590483292937
mutations O 0 2.1559306333074346e-05
. O 0 6.936191766726552e-06

One O 0 3.2440733775729313e-05
missense O 0 0.0008491371991112828
mutation O 0 2.0781801140401512e-05
( O 0 8.973323133432132e-07
L236P O 0 3.692731843329966e-05
) O 0 1.5301598921269033e-07
was O 0 1.1298848221485969e-06
found O 0 6.307607804956206e-07
in O 0 6.545875663732659e-08
a O 0 3.022109353878477e-07
homozygous O 0 8.030169169614965e-07
state O 0 5.650771939258448e-08
in O 0 3.258212544210437e-08
two O 0 5.931430990813169e-08
consanguineous O 0 0.0003591128333937377
families O 0 9.042727242558612e-07
and O 0 2.7110226596960274e-07
in O 0 3.7994769996885225e-08
a O 0 1.565325078445312e-07
heterozygous O 0 2.5471706521784654e-07
state O 0 3.1996204796769234e-08
in O 0 1.1626914542262057e-08
five O 0 3.009086668726013e-08
additional O 0 9.934072409123473e-08
non O 0 2.1645314518536907e-06
- O 0 0.00020123965805396438
consanguineous O 0 0.0016164497938007116
families O 0 6.974962161621079e-06
. O 0 8.456167961412575e-06

Another O 0 0.00011518396786414087
missense O 0 0.002691204659640789
mutation O 0 2.724086334637832e-05
( O 0 1.4159280681269593e-06
T416P O 0 4.372477633296512e-05
) O 0 1.4802502334987366e-07
was O 0 5.97727876083809e-07
found O 0 1.5327904634432343e-07
in O 0 2.598867965275531e-08
a O 0 1.7943389707397728e-07
homozygous O 0 1.134149101744697e-06
state O 0 4.993403734943058e-08
in O 0 2.7739568864149078e-08
one O 0 7.698435666725345e-08
family O 0 6.639137382080662e-07
and O 0 2.0980908743695181e-07
in O 0 7.862021789151186e-08
a O 0 1.650184486834405e-07
heterozygous O 0 4.3263463567200233e-07
state O 0 8.909211857144328e-08
in O 0 5.979296702207648e-08
four O 0 3.978652500791213e-07
families O 0 4.421583980729338e-06
. O 0 5.808928563055815e-06

Pendred B-Disease 1 0.7929584383964539
patients O 0 0.0020463860128074884
in O 0 9.307254913437646e-07
three O 0 3.4828912021112046e-07
non O 0 6.332225439109607e-06
- O 0 0.004059447441250086
consanguineous O 0 0.00587103795260191
families O 0 6.789013013985823e-07
were O 0 1.0421149454487022e-07
shown O 0 1.2160874973687896e-07
to O 0 5.169343708644192e-08
be O 0 4.6357232719174135e-08
compound O 0 1.2283113619560027e-06
heterozygotes O 0 2.1857333649677457e-06
for O 0 1.2494673740093276e-07
L236P O 0 3.0045563107705675e-05
and O 0 9.049231266544666e-07
T416P O 0 7.925803947728127e-05
. O 0 5.376007266022498e-06

In O 0 5.1269817049615085e-06
total O 0 2.3785466964909574e-06
, O 0 5.11016651216778e-07
one O 0 9.82301955332332e-08
or O 0 8.812085638965073e-08
both O 0 1.231227209075314e-08
of O 0 1.2622195733058561e-08
these O 0 2.127426590448067e-08
mutations O 0 2.3466084542178578e-07
were O 0 1.312712640810787e-07
found O 0 1.321780160878916e-07
in O 0 1.6791494417134345e-08
nine O 0 4.516097007467579e-08
of O 0 2.80110441508441e-08
the O 0 1.2267608440197364e-07
14 O 0 2.0101444988540607e-06
families O 0 9.800390898817568e-07
analyzed O 0 8.835749213176314e-06
. O 0 4.475158675631974e-06

The O 0 4.061621439177543e-06
identification O 0 4.410255314724054e-06
of O 0 3.2178010656025435e-07
two O 0 6.270421977205842e-07
frequent O 0 2.0719306121463887e-05
PDS B-Disease 0 0.004538929555565119
mutations O 0 1.3300070804689312e-06
will O 0 7.736500862165485e-08
facilitate O 0 4.3929426851718745e-07
the O 0 4.6137503773024946e-07
molecular O 0 0.0007259532576426864
diagnosis O 0 0.22126521170139313
of O 0 0.011115306988358498
Pendred B-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999980926513672
. O 0 0.0003956264699809253

Insertional O 0 0.02028574049472809
mutation O 0 0.00012583016359712929
by O 0 3.5034829579672078e-06
transposable O 0 0.00019819365115836263
element O 0 7.336750968534034e-06
, O 0 3.0198900731193135e-06
L1 O 0 0.0003592189750634134
, O 0 3.139369084692589e-07
in O 0 6.404201258192188e-08
the O 0 3.8713869798812084e-07
DMD B-Disease 1 0.9946756362915039
gene O 0 1.175259626506886e-06
results O 0 1.366078663522785e-06
in O 0 1.029284135256603e-06
X B-Disease 1 0.9411536455154419
- I-Disease 1 0.9893631339073181
linked I-Disease 1 0.9569036960601807
dilated I-Disease 1 0.9983068704605103
cardiomyopathy I-Disease 1 0.9998416900634766
. O 0 9.427597251487896e-05

X B-Disease 1 0.9797363877296448
- I-Disease 1 0.9948269724845886
linked I-Disease 1 0.9805039167404175
dilated I-Disease 1 0.9997488856315613
cardiomyopathy I-Disease 1 0.9999929666519165
( O 0 1.7301621483056806e-05
XLDCM B-Disease 0 0.4269615411758423
) O 0 9.417989303983632e-07
is O 0 1.6982794193154405e-07
a O 0 4.544941987205675e-07
clinical O 0 2.6708694349508733e-05
phenotype O 0 1.5647443433408625e-05
of O 0 5.227276460573194e-07
dystrophinopathy B-Disease 0 0.1252584457397461
which O 0 1.3560761544795241e-06
is O 0 6.708780233566358e-07
characterized O 0 8.207116479752585e-06
by O 0 9.349333254249359e-07
preferential O 0 0.000140993288368918
myocardial B-Disease 1 0.9958420395851135
involvement I-Disease 0 4.906120375380851e-05
without O 0 7.686352319069556e-07
any O 0 5.67058407341392e-07
overt O 0 2.6035200789920054e-05
clinical O 0 0.0005666426150128245
signs O 0 0.0004639078106265515
of O 0 0.0011841468513011932
skeletal B-Disease 1 0.99998939037323
myopathy I-Disease 1 0.9999985694885254
. O 0 0.0011742187198251486

To O 0 1.1188959433638956e-05
date O 0 8.86649104359094e-06
, O 0 6.354047741297109e-07
several O 0 1.8082018016229995e-07
mutations O 0 1.6400757658630027e-06
in O 0 2.3628240342077333e-07
the O 0 1.102268106478732e-05
Duchenne B-Disease 1 0.9998624324798584
muscular I-Disease 1 0.9973279237747192
dystrophy I-Disease 1 0.9816235303878784
gene O 0 0.00016704906011000276
, O 0 0.00022717112733516842
DMD O 1 0.9999860525131226
, O 0 2.1172969354665838e-05
have O 0 3.9309125554609636e-07
been O 0 5.852596700606227e-07
identified O 0 4.770341092807939e-06
in O 0 1.069585209734214e-06
patients O 0 5.119398792885477e-06
with O 0 3.647265032213909e-07
XLDCM B-Disease 0 0.34937697649002075
, O 0 7.812853937139153e-07
but O 0 7.169533233764014e-08
a O 0 9.586305083075786e-08
pathogenic O 0 1.6531330970792624e-07
correlation O 0 1.0328362520795054e-07
of O 0 1.9143341134508773e-08
these O 0 8.223110370408904e-08
cardiospecific O 0 0.0002569008502177894
mutations O 0 3.2049701985670254e-06
in O 0 8.946636853579548e-07
DMD O 1 0.9990289211273193
with O 0 3.577501672680228e-07
the O 0 5.134332354828075e-07
XLDCM B-Disease 0 0.08066312223672867
phenotype O 0 4.982213067705743e-05
has O 0 3.852999839182303e-07
remained O 0 1.0885620440603816e-06
to O 0 9.278402757217918e-08
be O 0 5.854114988324e-07
elucidated O 0 0.00011908807209692895
. O 0 9.9689377748291e-06

We O 0 1.4173523595673032e-05
report O 0 3.842061687464593e-06
here O 0 3.2021731044551416e-07
the O 0 5.6469364295708147e-08
identification O 0 2.3649995739560836e-07
of O 0 4.27084820842083e-08
a O 0 2.2660687193365447e-07
unique O 0 4.902607884105237e-07
de O 0 1.5696014088462107e-05
novo O 0 1.610778235772159e-05
L1 O 0 5.590507134911604e-05
insertion O 0 1.4720782246513409e-06
in O 0 5.5910351903776245e-08
the O 0 5.4256464210311606e-08
muscle O 0 1.6964239648586954e-06
exon O 0 4.013762008980848e-06
1 O 0 7.694295049986977e-07
in O 0 4.803465003533347e-07
DMD O 1 0.9977643489837646
in O 0 5.769052222603932e-07
three O 0 2.714965376071632e-06
XLDCM B-Disease 1 0.8900305032730103
patients O 0 2.2372983949026093e-05
from O 0 1.9066351342189591e-07
two O 0 2.309260622723741e-07
unrelated O 0 1.8481043298379518e-05
Japanese O 0 9.287055036111269e-06
families O 0 7.257675406435737e-06
. O 0 7.957753041409887e-06

The O 0 4.0559357330494095e-06
insertion O 0 1.601749681867659e-05
was O 0 1.5327275377785554e-06
a O 0 2.9889466190979874e-07
5 O 0 5.290750095809926e-07
- O 0 1.5066588275658432e-05
truncated O 0 6.417009217329905e-07
form O 0 6.2445344894968e-08
of O 0 3.2801491300915586e-08
human O 0 1.9518273575158673e-07
L1 O 0 2.450666215736419e-05
inversely O 0 5.27464680999401e-06
integrated O 0 1.0229605322820134e-06
in O 0 2.2147277789485997e-08
the O 0 2.1743407074836796e-08
5 O 0 5.833272211930307e-07
- O 0 0.00013263709843158722
untranslated O 0 9.80511395027861e-05
region O 0 6.583012464034255e-07
in O 0 3.4830200945634715e-08
the O 0 4.0831846348510226e-08
muscle O 0 6.864573833809118e-07
exon O 0 3.3472424547653645e-06
1 O 0 4.221244580548955e-07
, O 0 6.36977404155914e-08
which O 0 2.2854187875509524e-08
affected O 0 4.995299462962066e-08
the O 0 7.504723953388748e-09
transcription O 0 1.5130586916711763e-07
or O 0 3.118873337371042e-08
the O 0 2.3228615475545666e-08
stability O 0 2.248481507649558e-07
of O 0 5.105553313455857e-08
the O 0 1.160064684313511e-07
muscle O 0 1.923185664054472e-06
form O 0 5.2423832386239155e-08
of O 0 6.163924837210288e-08
dystrophin O 0 3.389098128536716e-05
transcripts O 0 8.43394809635356e-06
but O 0 2.0456458571516123e-07
not O 0 1.665535620531955e-08
that O 0 5.9997207202400205e-09
of O 0 1.8719907401987257e-08
the O 0 5.828712232869293e-07
brain O 0 0.0004120601515751332
or O 0 1.6052401861088583e-06
Purkinje O 0 0.06069660931825638
cell O 0 0.00010185094288317487
form O 0 2.194222048501615e-07
, O 0 2.7873176122739096e-07
probably O 0 1.2027227285216213e-06
due O 0 4.0386717614637746e-07
to O 0 2.7313049599797523e-08
its O 0 3.635589251871352e-08
unique O 0 1.0128323424396513e-07
site O 0 8.224723728744721e-07
of O 0 3.255892977449548e-07
integration O 0 1.968781180039514e-05
. O 0 7.990536687429994e-06

We O 0 8.850000995153096e-06
speculate O 0 2.976935093101929e-06
that O 0 5.378261391797423e-08
this O 0 1.4986371255076847e-08
insertion O 0 6.017257874191273e-07
of O 0 5.207165187925966e-08
an O 0 7.653182620970256e-08
L1 O 0 0.0003927682409994304
sequence O 0 5.643490226248105e-07
in O 0 1.4250532558435225e-06
DMD O 1 0.9991469383239746
is O 0 3.147490303945233e-07
responsible O 0 2.703076233956381e-07
for O 0 2.160252776661764e-08
some O 0 6.357949278168462e-09
of O 0 9.75464420349681e-09
the O 0 2.528044618088643e-08
population O 0 2.4411077603758713e-08
of O 0 4.797742292339535e-08
Japanese O 0 1.3793444850307424e-05
patients O 0 1.1284555512247607e-05
with O 0 6.420773956961057e-07
XLDCM B-Disease 0 0.017386186867952347
. O 0 1.6220336647165823e-06
. O 0 4.7646844905102625e-06

Severe O 0 0.03548930212855339
early O 0 0.00028938869945704937
- O 1 0.9849998950958252
onset O 1 0.9999126195907593
obesity B-Disease 1 0.9999969005584717
, O 0 0.4486403465270996
adrenal B-Disease 1 0.9999978542327881
insufficiency I-Disease 1 0.9999960660934448
and O 0 0.0002688734675757587
red O 0 0.264457643032074
hair O 1 0.9304822087287903
pigmentation O 0 0.42048248648643494
caused O 0 0.00017735794244799763
by O 0 7.848065251891967e-06
POMC O 1 0.8156120777130127
mutations O 0 1.8214490410173312e-05
in O 0 1.0791887916639098e-06
humans O 0 4.214440650684992e-06
. O 0 6.108634352131048e-06

Sequential O 0 7.060788630042225e-05
cleavage O 0 0.0003327476151753217
of O 0 8.431273954556673e-07
the O 0 3.508444308408798e-07
precursor O 0 7.244214543788985e-07
protein O 0 3.548609015524562e-07
pre O 0 1.7584503439138643e-05
- O 0 5.721263005398214e-05
pro O 0 2.9129214453860186e-05
- O 0 0.00011098434333689511
opiomelanocortin O 0 0.00014015953638590872
( O 0 4.121557140024379e-07
POMC O 0 4.529295983957127e-05
) O 0 5.833394922660773e-08
generates O 0 1.1770325158977357e-07
the O 0 5.78720396049448e-08
melanocortin O 0 0.0001317862479481846
peptides O 0 4.794801498064771e-06
adrenocorticotrophin O 0 0.00010285112512065098
( O 0 1.1750427830747867e-07
ACTH O 0 4.410137535160175e-06
) O 0 2.815652955234782e-08
, O 0 4.620328653004435e-08
melanocyte O 0 3.373625804670155e-05
- O 0 2.560772372817155e-05
stimulating O 0 2.5122433271462796e-06
hormones O 0 3.3769669016692205e-07
( O 0 5.1583914029151856e-08
MSH O 0 2.0465975467232056e-05
) O 0 1.8175684957100202e-08
alpha O 0 6.465087665219471e-08
, O 0 1.0701515229527558e-08
beta O 0 2.675872678992164e-08
and O 0 8.046327160116107e-09
gamma O 0 7.040497251864508e-08
as O 0 3.5221128236173627e-09
well O 0 4.960962751709985e-09
as O 0 3.5047096336171535e-09
the O 0 9.704835157720026e-09
opioid O 0 2.392807573414757e-06
- O 0 4.022798293590313e-06
receptor O 0 1.2771159845215152e-06
ligand O 0 1.6693065845174715e-06
beta O 0 2.185039420510293e-06
- O 0 1.3214553291618358e-05
endorphin O 0 0.00012831712956540287
. O 0 2.905723931689863e-06

While O 0 1.920171416713856e-05
a O 0 3.02803709928412e-06
few O 0 1.1823667591670528e-06
cases O 0 8.425180908488983e-07
of O 0 1.7490358459326671e-06
isolated O 1 0.9631624817848206
ACTH B-Disease 1 0.999735414981842
deficiency I-Disease 1 0.9896563291549683
have O 0 6.803583119108225e-07
been O 0 2.724250634855707e-06
reported O 0 3.527602893882431e-05
( O 0 1.2348275504336925e-06
OMIM O 0 0.01963885873556137
201400 O 0 0.0001552275789435953
) O 0 2.1832636321050813e-07
, O 0 2.1292171936693194e-07
an O 0 5.2861258836856e-07
inherited O 0 0.43161332607269287
POMC O 1 0.9929163455963135
defect O 0 0.03033865988254547
has O 0 8.846658374750405e-07
not O 0 2.2481746952962567e-07
been O 0 3.5680776022672944e-07
described O 0 5.4664446906826925e-06
so O 0 6.237285106180934e-07
far O 0 2.033612418017583e-06
. O 0 4.342697138781659e-06

Recent O 0 4.387255467008799e-05
studies O 0 6.8787680902460124e-06
in O 0 6.929229243723967e-07
animal O 0 1.1523630973897525e-06
models O 0 4.101186277694069e-06
elucidated O 0 5.49216974832234e-06
a O 0 1.3600792669876682e-07
central O 0 6.939983165921149e-08
role O 0 2.559762357634554e-08
of O 0 2.3933447224067095e-08
alpha O 0 1.4132178876025137e-06
- O 0 0.00016444397624582052
MSH O 0 8.004753181012347e-05
in O 0 1.2840349228326886e-08
the O 0 5.212965614731502e-09
regulation O 0 2.3513905489380704e-08
of O 0 1.3303931289954107e-08
food O 0 1.1912931086044409e-07
intake O 0 1.317889513074988e-07
by O 0 1.178548370006638e-08
activation O 0 9.077636775600695e-08
of O 0 1.4050921315345022e-08
the O 0 5.583617834759025e-08
brain O 0 7.254927822941681e-06
melanocortin O 0 3.1123960070544854e-05
- O 0 5.3691674111178145e-06
4 O 0 6.45159332179901e-07
- O 0 8.913032615964767e-06
receptor O 0 6.871005666653218e-07
( O 0 6.463583446247867e-08
MC4 O 0 5.933181455475278e-05
- O 0 4.860413901042193e-05
R O 0 6.779300019843504e-05
; O 0 4.783123230822639e-08
refs O 0 4.5255910663399845e-07
3 O 0 1.864143541752128e-07
- O 0 3.417031848584884e-06
5 O 0 5.426878146863601e-08
) O 0 4.558413202460088e-09
and O 0 4.065642933426261e-09
the O 0 4.076809112518731e-09
linkage O 0 3.189953758919728e-07
of O 0 5.740393760333973e-08
human O 0 2.477343286955147e-06
obesity B-Disease 0 0.40722739696502686
to O 0 1.9225660707888892e-07
chromosome O 0 1.0035796549345832e-05
2 O 0 6.614351377720595e-07
in O 0 8.127277340008732e-08
close O 0 6.000512939863256e-07
proximity O 0 4.771205226461461e-07
to O 0 4.957900401336701e-08
the O 0 1.1449608194880057e-07
POMC O 0 0.0002513698418624699
locus O 0 1.084653263205837e-06
, O 0 1.1048574322103377e-07
led O 0 1.4026961991930875e-07
to O 0 1.543291894279264e-08
the O 0 1.4513378943092903e-08
proposal O 0 3.065183875605726e-07
of O 0 2.610388705193145e-08
an O 0 2.491163719753331e-08
association O 0 2.610812543935026e-07
of O 0 5.642844485009846e-07
POMC O 0 0.14803120493888855
with O 0 4.2093674892385025e-06
human O 0 7.648829341633245e-05
obesity B-Disease 1 0.9935891628265381
. O 0 5.768321716459468e-05

The O 0 4.411955160321668e-06
dual O 0 6.178489456942771e-06
role O 0 6.371244580805069e-07
of O 0 2.0139272294272814e-07
alpha O 0 3.4879776649177074e-06
- O 0 0.00015772206825204194
MSH O 0 8.19084671093151e-05
in O 0 3.116459268426297e-08
regulating O 0 2.740835043368861e-07
food O 0 1.4286059979440324e-07
intake O 0 2.821438158662204e-07
and O 0 1.042924253624733e-07
influencing O 0 1.6114120171550894e-06
hair O 0 0.0005672824918292463
pigmentation O 0 0.0011851026210933924
predicts O 0 0.001584656536579132
that O 0 1.5862994473536673e-07
the O 0 2.5316884944004414e-07
phenotype O 0 2.264141039631795e-05
associated O 0 6.528208587042172e-07
with O 0 4.198416547751549e-07
a O 0 2.1248864868539385e-05
defect O 0 0.00598152307793498
in O 0 4.1105386117124e-07
POMC O 0 0.0015222199726849794
function O 0 2.474575353517139e-07
would O 0 1.7987525779972202e-07
include O 0 9.578859135217499e-06
obesity B-Disease 1 0.9929524064064026
, O 0 2.3113720999390353e-06
alteration O 0 4.100927981198765e-05
in O 0 5.138033884577453e-06
pigmentation O 1 0.5813934206962585
and O 0 0.015251852571964264
ACTH B-Disease 1 0.9995015859603882
deficiency I-Disease 1 0.98903489112854
. O 0 2.3977916498552077e-05

The O 0 6.8792405727435835e-06
observation O 0 1.4039198504178785e-05
of O 0 8.592172662247322e-07
these O 0 1.090338741960295e-06
symptoms O 0 2.935951852123253e-05
in O 0 7.431298598703506e-08
two O 0 1.8660183798147045e-07
probands O 0 0.0007988947327248752
prompted O 0 1.5489532643186976e-06
us O 0 1.2647383584862837e-07
to O 0 3.251011904126244e-08
search O 0 3.385044067272247e-07
for O 0 7.818609759624451e-08
mutations O 0 8.11028712632833e-07
within O 0 1.4354206712141604e-07
their O 0 4.5118056846149557e-07
POMC O 0 0.0022280134726315737
genes O 0 8.038834494072944e-06
. O 0 5.274616341921501e-06

Patient O 0 0.002880870131775737
1 O 0 1.2734037227346562e-05
was O 0 4.497960162552772e-06
found O 0 2.9308057492016815e-07
to O 0 3.205142107276515e-08
be O 0 2.439604429582687e-08
a O 0 9.15333728812584e-08
compound O 0 8.149207815222326e-07
heterozygote O 0 1.3308953157320502e-06
for O 0 3.782145441277862e-08
two O 0 4.2906727060199046e-08
mutations O 0 3.013828688835929e-07
in O 0 4.473608683497332e-08
exon O 0 4.153770078119123e-06
3 O 0 9.300653118771152e-07
( O 0 1.0895097091179196e-07
G7013T O 0 1.1136095963593107e-05
, O 0 2.207642921803199e-07
C7133delta O 0 1.2775760296790395e-05
) O 0 1.663148552211169e-08
which O 0 7.929018330798954e-09
interfere O 0 4.8498730365054143e-08
with O 0 7.242568322851639e-09
appropriate O 0 2.0323213334449974e-08
synthesis O 0 6.678535413584541e-08
of O 0 8.475324619894309e-08
ACTH O 0 2.7826676159747876e-05
and O 0 4.6540534981431847e-07
alpha O 0 7.79235597292427e-06
- O 0 0.0001704082387732342
MSH O 0 0.0010698609985411167
. O 0 3.3376732062606607e-06

Patient O 0 0.001593089080415666
2 O 0 1.2739211342704948e-05
was O 0 1.7744913520800765e-06
homozygous O 0 1.3657127055921592e-06
for O 0 7.448355887618163e-08
a O 0 1.8938210644137143e-07
mutation O 0 5.689781801265781e-07
in O 0 9.038349446655047e-08
exon O 0 1.1122891919512767e-05
2 O 0 1.7854692941909889e-06
( O 0 2.394591831489379e-07
C3804A O 0 1.1920645192731172e-05
) O 0 1.5643745143734122e-07
which O 0 5.22123798418761e-07
abolishes O 0 5.481410335050896e-05
POMC O 0 0.0009340125834569335
translation O 0 9.26958819036372e-06
. O 0 7.954535249155015e-06

These O 0 9.226865586242639e-06
findings O 0 5.554233666771324e-06
represent O 0 3.688931258238881e-07
the O 0 8.220052905016928e-08
first O 0 1.2687588935023086e-07
examples O 0 3.91962231560683e-07
of O 0 3.5296741884849325e-07
a O 0 0.0004690603236667812
genetic B-Disease 1 0.9997730851173401
defect I-Disease 1 0.9979822635650635
within O 0 4.1687650309540913e-07
the O 0 2.391770976828411e-07
POMC O 0 0.004375303629785776
gene O 0 7.598999332003586e-07
and O 0 1.3714550561871874e-07
define O 0 8.700910711922916e-07
a O 0 9.451650271330436e-07
new O 0 0.00011177580017829314
monogenic B-Disease 1 0.9999150037765503
endocrine I-Disease 1 0.9998569488525391
disorder I-Disease 0 0.06793403625488281
resulting O 0 2.602725771794212e-06
in O 0 3.5825101463160536e-07
early O 0 1.3700365343538579e-05
- O 1 0.9384620189666748
onset O 1 0.9997789263725281
obesity B-Disease 1 0.9999969005584717
, O 0 0.33744972944259644
adrenal B-Disease 1 0.999995231628418
insufficiency I-Disease 1 0.9999903440475464
and O 0 0.00011558202095329762
red O 0 0.014144032262265682
hair O 0 0.40135788917541504
pigmentation O 0 0.042414624243974686
. O 0 8.250308383139782e-06
. O 0 1.537108801130671e-05

A O 0 4.597618317347951e-05
European O 0 1.141813936555991e-05
multicenter O 0 0.009823114611208439
study O 0 1.2201749086671043e-05
of O 0 8.12216749181971e-05
phenylalanine B-Disease 1 0.9999845027923584
hydroxylase I-Disease 1 0.9999966621398926
deficiency I-Disease 1 0.9999961853027344
: O 0 2.3285188035515603e-06
classification O 0 3.3997264381468995e-06
of O 0 7.497258991406852e-08
105 O 0 3.446421033004299e-06
mutations O 0 7.745005063952703e-07
and O 0 8.142979623926294e-08
a O 0 1.4620492549966002e-07
general O 0 5.150437800693908e-07
system O 0 4.83411270124634e-07
for O 0 1.645151428419922e-07
genotype O 0 2.5000252207973972e-05
- O 0 2.1699135686503723e-05
based O 0 5.696204539162864e-07
prediction O 0 6.100548034737585e-06
of O 0 1.6698065792297712e-06
metabolic O 0 0.017208050936460495
phenotype O 0 0.0004406138032209128
. O 0 1.3849939932697453e-05

Phenylketonuria B-Disease 1 0.9932729005813599
( O 0 0.0001336726563749835
PKU B-Disease 0 0.09641975909471512
) O 0 4.649462425732054e-06
and O 0 1.4368752999871504e-05
mild B-Disease 1 0.9019060134887695
hyperphenylalaninemia I-Disease 1 0.999996542930603
( O 0 0.00048714340664446354
MHP B-Disease 1 0.9999896287918091
) O 0 1.019948513203417e-06
are O 0 9.368648079544073e-07
allelic B-Disease 1 0.5617741346359253
disorders I-Disease 1 0.9809556603431702
caused O 0 3.8780486647738144e-05
by O 0 8.080425573098182e-07
mutations O 0 1.360454461973859e-06
in O 0 5.598761276814912e-08
the O 0 1.0057922139594666e-07
gene O 0 7.405108704006125e-07
encoding O 0 2.7965886602032697e-06
phenylalanine O 0 0.00013940698408987373
hydroxylase O 0 0.004789415281265974
( O 0 9.551201401336584e-06
PAH O 0 0.022195082157850266
) O 0 1.2450869917302043e-06
. O 0 2.2677645574731287e-06

Previous O 0 2.878368104575202e-05
studies O 0 4.638855443772627e-06
have O 0 4.798731083610619e-07
suggested O 0 5.064846391178435e-07
that O 0 2.932790010845565e-08
the O 0 7.004159385815001e-08
highly O 0 2.640187858560239e-06
variable O 0 5.899983079871163e-05
metabolic O 0 0.00332290749065578
phenotypes O 0 0.0003699659137055278
of O 0 0.0004754072579089552
PAH B-Disease 1 0.9999912977218628
deficiency I-Disease 1 0.9889543056488037
correlate O 0 0.0003801308630499989
with O 0 0.00013297521218191832
PAH O 1 0.9979380965232849
genotypes O 0 0.0008641049498692155
. O 0 1.3457872228173073e-05

We O 0 2.541562389524188e-05
identified O 0 1.1499410902615637e-05
both O 0 8.522893040208146e-07
causative O 0 1.652309947530739e-05
mutations O 0 2.7644662168313516e-06
in O 0 1.2365669590508332e-06
686 O 0 0.06282615661621094
patients O 0 7.768730574753135e-05
from O 0 3.2912922165451164e-07
seven O 0 6.383706931956112e-07
European O 0 2.0412835510796867e-06
centers O 0 6.453768037317786e-06
. O 0 4.243438070261618e-06

On O 0 7.95135747466702e-06
the O 0 4.661240495806851e-07
basis O 0 2.606946054584114e-07
of O 0 7.654174538629377e-08
the O 0 6.348245307208344e-08
phenotypic O 0 1.1552426713024033e-06
characteristics O 0 3.2846728004187753e-07
of O 0 1.0093475566463894e-07
297 O 0 2.497884997865185e-05
functionally O 0 0.0002586995833553374
hemizygous O 0 0.16962693631649017
patients O 0 1.446576789021492e-05
, O 0 6.65216788320322e-08
105 O 0 1.2331464915860124e-07
of O 0 1.1324221560471415e-08
the O 0 2.522135034155326e-08
mutations O 0 1.3210340910063678e-07
were O 0 4.0581451088428366e-08
assigned O 0 9.041315962576846e-08
to O 0 1.5609417758355448e-08
one O 0 1.0666851402163502e-08
of O 0 1.7063470636458078e-08
four O 0 1.0488309953871067e-07
arbitrary O 0 3.222820623705047e-06
phenotype O 0 3.567390376701951e-05
categories O 0 8.483591045660432e-06
. O 0 4.717827778222272e-06

We O 0 7.720514986431226e-06
proposed O 0 9.003744708024897e-06
and O 0 1.2699370017799083e-06
tested O 0 2.2377093955583405e-06
a O 0 9.609425433154684e-08
simple O 0 1.7950304709302145e-07
model O 0 1.7078946257242933e-07
for O 0 4.084095905909635e-08
correlation O 0 5.278654384710535e-07
between O 0 2.644325149958604e-07
genotype O 0 1.1651259228528943e-05
and O 0 6.201963174135017e-07
phenotypic O 0 1.240673827851424e-05
outcome O 0 4.120929224882275e-05
. O 0 2.0403225789777935e-05

The O 0 8.307184543809853e-06
observed O 0 1.1399285540392157e-05
phenotype O 0 3.0289957066997886e-05
matched O 0 5.276296633383026e-06
the O 0 2.0986230708786024e-07
predicted O 0 2.764259079413023e-05
phenotype O 0 3.3309001992165577e-06
in O 0 7.010882541180763e-08
79 O 0 3.7107583921169862e-06
% O 0 4.607225179142915e-08
of O 0 1.7053709555625574e-08
the O 0 7.542640645397114e-08
cases O 0 3.874400533732114e-07
, O 0 1.9676723184147704e-07
and O 0 6.581757361345808e-08
in O 0 1.1098923557995022e-08
only O 0 4.8449146916595964e-09
5 O 0 2.4635971485054142e-08
of O 0 3.316517194207336e-08
184 O 0 2.4176390070351772e-05
patients O 0 1.1714880201907363e-05
was O 0 4.3007506178582844e-07
the O 0 5.479444453726501e-08
observed O 0 7.824963859093259e-07
phenotype O 0 5.731498617933539e-07
more O 0 9.527805211462237e-09
than O 0 1.3649253283176677e-08
one O 0 3.4727577258308884e-08
category O 0 9.883862048809533e-07
away O 0 7.301965609940453e-08
from O 0 2.12827071521815e-08
that O 0 4.782430096383905e-08
expected O 0 2.5814590571826557e-06
. O 0 4.384799012768781e-06

Among O 0 1.1875756172230467e-05
the O 0 5.602574333352095e-07
seven O 0 4.142781904192816e-07
contributing O 0 5.457342240333674e-07
centers O 0 4.5455053054865857e-07
, O 0 4.57490401117866e-08
the O 0 1.7917939132416905e-08
proportion O 0 2.5718216534187377e-07
of O 0 2.8285666076044436e-07
patients O 0 9.578768185747322e-06
for O 0 4.1522156379869557e-07
whom O 0 1.395362119183119e-06
the O 0 8.751401736617481e-08
observed O 0 2.926592742369394e-06
phenotype O 0 4.7500529944954906e-06
did O 0 7.758431053161985e-08
not O 0 1.8594858985920837e-08
match O 0 2.0302491066104267e-07
the O 0 1.1019867685035933e-07
predicted O 0 5.8107230870518833e-05
phenotype O 0 2.6242673811793793e-06
was O 0 1.795554425143564e-07
4 O 0 2.291101992568656e-07
% O 0 1.0783477932818641e-07
- O 0 2.3575357772642747e-05
23 O 0 1.130764417212049e-06
% O 0 1.4678752791041916e-07
( O 0 1.0564865959850067e-07
P O 0 0.0009015523246489465
< O 0 1.4721143088536337e-05
. O 0 3.585797969662963e-08
0001 O 0 1.9607691683631856e-06
) O 0 1.7294008003432282e-08
, O 0 2.3386878211795192e-08
suggesting O 0 1.1491538032259996e-07
that O 0 2.9451671323954542e-08
differences O 0 3.726599970832467e-07
in O 0 2.3646766322826807e-08
methods O 0 1.0755766766123998e-07
used O 0 4.340496317922771e-08
for O 0 5.489654242296638e-08
mutation O 0 4.1825947505458316e-07
detection O 0 1.1935456313949544e-05
or O 0 1.8771913801174378e-06
phenotype O 0 3.272772300988436e-05
classification O 0 2.9147438908694312e-05
may O 0 6.959189136068744e-07
account O 0 9.669215472740689e-08
for O 0 3.6348403398278606e-08
a O 0 1.0554251872463283e-07
considerable O 0 3.2886535450415977e-07
proportion O 0 1.4037709661351983e-06
of O 0 5.841333177158958e-07
genotype O 0 0.0012734854826703668
- O 0 0.05071241408586502
phenotype O 0 0.0003786638844758272
inconsistencies O 0 0.0002688111853785813
. O 0 2.203520853072405e-05

Our O 0 1.7129825209849514e-05
data O 0 4.963458195561543e-06
indicate O 0 1.935103455252829e-06
that O 0 1.4048193008875387e-07
the O 0 7.084843218763126e-07
PAH O 1 0.8325183987617493
- O 0 0.00035119091626256704
mutation O 0 5.428512963590038e-07
genotype O 0 9.495078643340094e-07
is O 0 1.8747993379975014e-08
the O 0 1.66301514781253e-08
main O 0 2.8755002290381526e-07
determinant O 0 1.5235956425385666e-06
of O 0 3.0589578159379016e-07
metabolic O 0 0.0006059775478206575
phenotype O 0 1.9938086552429013e-05
in O 0 5.017050739297702e-07
most O 0 9.484522706770804e-06
patients O 0 0.0022270765621215105
with O 0 0.011419356800615788
PAH B-Disease 1 0.9999943971633911
deficiency I-Disease 1 0.9957985281944275
. O 0 2.411123386991676e-05

In O 0 4.1527441680955235e-06
the O 0 3.338152509968495e-07
present O 0 2.9823235081494204e-07
study O 0 3.655448495010205e-07
, O 0 1.1430765312070434e-07
the O 0 4.050643909181417e-08
classification O 0 1.395372692059027e-06
of O 0 1.0736889777263059e-07
105 O 0 0.000205138698220253
PAH O 1 0.9593952894210815
mutations O 0 3.515327534842072e-06
may O 0 1.593944034539163e-07
allow O 0 5.899793364960715e-08
the O 0 2.794721787324761e-08
prediction O 0 2.195449951614137e-06
of O 0 3.099369294545795e-08
the O 0 1.3729599857015273e-07
biochemical O 0 6.397641300281975e-06
phenotype O 0 5.177206276130164e-06
in O 0 1.4065003028918e-07
> O 0 5.819131274620304e-06
10 O 0 1.2403660321069765e-07
, O 0 6.598813939717729e-08
000 O 0 2.9237790499792027e-07
genotypes O 0 2.578113026174833e-06
, O 0 1.1375966835203144e-07
which O 0 8.377782734214634e-08
may O 0 2.162504273428567e-07
be O 0 1.025347629024509e-08
useful O 0 2.940822518837649e-08
for O 0 1.951618244788733e-08
the O 0 5.740623620908991e-08
management O 0 9.486100225331029e-07
of O 0 5.61917318009364e-07
hyperphenylalaninemia B-Disease 1 0.9992087483406067
in O 0 1.9403409169171937e-05
newborns O 0 0.0012469193898141384
. O 0 9.704191143100616e-06

Somatic O 0 0.0007184999412856996
instability O 0 9.758038504514843e-05
of O 0 7.798962542437948e-07
the O 0 1.3756773569184588e-06
CTG O 0 0.0019903830252587795
repeat O 0 1.2249294741195627e-05
in O 0 3.5328199032846896e-07
mice O 0 5.631830390484538e-06
transgenic O 0 8.219084520533215e-06
for O 0 1.132758939093037e-06
the O 0 0.00012753583723679185
myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.999992847442627
region O 0 0.00027553748805075884
is O 0 1.2376854101603385e-06
age O 0 1.5535332522631506e-06
dependent O 0 1.2707631640296313e-06
but O 0 1.0968365415919834e-07
not O 0 3.298254469541462e-08
correlated O 0 3.7123547258488543e-07
to O 0 2.7418485260000125e-08
the O 0 4.673177755876168e-08
relative O 0 1.9720994259841973e-06
intertissue O 0 4.4105119741288945e-05
transcription O 0 1.5080123603183893e-06
levels O 0 6.238296350602468e-07
and O 0 9.474680950916081e-07
proliferative O 0 0.2309415191411972
capacities O 0 6.881771696498618e-05
. O 0 8.582414011470973e-06

A O 0 5.555675670620985e-05
( O 0 3.18421689371462e-06
CTG O 0 0.000236791223869659
) O 0 3.372120431777148e-07
nexpansion O 0 1.2667832379520405e-05
in O 0 3.6625245058985456e-08
the O 0 3.3394190523949874e-08
3 O 0 1.095852326216118e-06
- O 0 0.0036432163324207067
untranslated O 0 0.0019166632555425167
region O 0 3.450821623118827e-06
( O 0 7.427232162626751e-08
UTR O 0 4.542100668913918e-06
) O 0 9.067389505901247e-09
of O 0 9.417162161184933e-09
the O 0 1.628599903824579e-07
DM O 1 0.9997431635856628
protein O 0 1.0292271781509044e-06
kinase O 0 1.4994025150372181e-06
gene O 0 3.3851054581646167e-07
( O 0 6.744602387698251e-08
DMPK O 0 2.2807609639130533e-05
) O 0 2.9773726595294647e-08
is O 0 2.5606610165596067e-08
responsible O 0 3.501484684420575e-07
for O 0 3.692039172165096e-06
causing O 1 0.7371388673782349
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999961853027344
( O 0 0.003986726514995098
DM B-Disease 1 0.9999936819076538
) O 0 1.6730944480514154e-05
. O 0 1.6280564523185603e-05

Major O 0 0.00028677424415946007
instability O 0 0.000419963471358642
, O 0 2.0296349703130545e-06
with O 0 1.6568642990932858e-07
very O 0 1.9039096343931305e-07
large O 0 2.6074459924529947e-07
expansions O 0 1.0985131666529924e-06
between O 0 1.7572925514741655e-07
generations O 0 3.31494618421857e-07
and O 0 2.0417458301835723e-07
high O 0 2.6570100999379065e-06
levels O 0 9.160480374248436e-08
of O 0 1.2786922631846664e-08
somatic O 0 4.753732810058864e-06
mosaicism O 0 0.0009088862570933998
, O 0 2.068594966431192e-07
is O 0 1.2603773313912825e-07
observed O 0 1.4873170357532217e-06
in O 0 9.316881346421724e-07
patients O 0 3.886148624587804e-05
. O 0 5.6509616115363315e-06

There O 0 1.0633034435159061e-05
is O 0 3.8615416997345164e-07
a O 0 2.60949803987387e-07
good O 0 5.122452648720355e-07
correlation O 0 7.913947683846345e-07
between O 0 2.559511642630241e-07
repeat O 0 6.023078185535269e-06
size O 0 5.448447154776659e-06
( O 0 7.553092729040145e-08
at O 0 1.2988070352548675e-07
least O 0 2.8828640807887496e-08
in O 0 5.0290459796542564e-08
leucocytes O 0 6.095226854085922e-05
) O 0 1.2448050767943641e-07
, O 0 2.1741109890172083e-07
clinical O 0 1.3247688912088051e-05
severity O 0 0.00018565911159384996
and O 0 1.2490021390476613e-06
age O 0 1.3538445955418865e-06
of O 0 1.3570244163929601e-06
onset O 0 0.08513561636209488
. O 0 2.6271565729985014e-05

The O 0 0.00010041730274679139
trinucleotide O 0 0.028587903827428818
repeat O 0 0.0003414855746086687
instability O 0 5.941425115452148e-05
mechanisms O 0 8.047701157920528e-06
involved O 0 2.8658550945692696e-06
in O 0 4.561674359138124e-06
DM B-Disease 1 0.9999974966049194
and O 0 1.5247223927872255e-05
other O 0 2.7869957648363197e-06
human O 0 0.0005256233853287995
genetic B-Disease 1 0.9999523162841797
diseases I-Disease 1 0.9999568462371826
are O 0 4.112850092496956e-06
unknown O 0 2.2306388927972876e-05
. O 0 1.2636267456400674e-05

We O 0 1.0161921636608895e-05
studied O 0 8.184643775166478e-06
somatic O 0 3.1834533729124814e-05
instability O 0 1.723952664178796e-05
by O 0 4.964600179846457e-07
measuring O 0 5.3841995395487174e-05
the O 0 3.5872420767191215e-07
CTG O 0 0.0005625355988740921
repeat O 0 3.3915596304723294e-06
length O 0 8.934700872487156e-07
at O 0 2.0279850332372007e-07
several O 0 4.0045982530045876e-08
ages O 0 1.5980475609467248e-07
in O 0 1.954151152006034e-08
various O 0 3.3173584768064757e-08
tissues O 0 5.040396899858024e-07
of O 0 5.3780560449467885e-08
transgenic O 0 3.135831138934009e-05
mice O 0 1.3134295841155108e-05
carrying O 0 1.3435522987492732e-06
a O 0 4.177205141786544e-07
( O 0 2.91633540427938e-07
CTG O 0 9.384652366861701e-05
) O 0 1.66220416986107e-07
55expansion O 0 4.519114372669719e-05
surrounded O 0 2.011574906646274e-06
by O 0 5.4362228496529497e-08
45 O 0 1.891867924541657e-07
kb O 0 6.872932772239437e-06
of O 0 4.31849755955227e-08
the O 0 1.4858410679607914e-07
human O 0 6.910500815138221e-06
DM B-Disease 1 0.9999885559082031
region O 0 7.963378266140353e-06
, O 0 7.77168622789759e-08
using O 0 1.04158239366825e-07
small O 0 8.430840239270765e-07
- O 0 3.7202811654424295e-05
pool O 0 1.4235633898351807e-05
PCR O 0 4.1504772525513545e-05
. O 0 7.067964361340273e-06

These O 0 9.126260010816623e-06
mice O 0 7.834639109205455e-05
have O 0 4.0581147686680197e-07
been O 0 1.3775398599591426e-07
shown O 0 8.467859657912413e-08
to O 0 4.188977698049712e-08
reproduce O 0 7.381305522358161e-07
the O 0 3.190412556364208e-08
intergenerational O 0 1.8301987438462675e-05
and O 0 3.3698185575303796e-07
somatic O 0 5.655641416524304e-06
instability O 0 1.8604793012855225e-06
of O 0 6.76739730920417e-08
the O 0 1.679480021721247e-07
55 O 0 5.55850965611171e-06
CTG O 0 0.000489598314743489
repeat O 0 5.120922196510946e-06
suggesting O 0 7.541460149695922e-07
that O 0 4.097672601233171e-08
surrounding O 0 4.5535969661614217e-07
sequences O 0 1.3146760124982393e-07
and O 0 5.323770579934717e-08
the O 0 2.277911548276279e-08
chromatin O 0 1.3271207990328548e-06
environment O 0 8.929811201596749e-07
are O 0 3.4707316132198684e-08
involved O 0 4.0289236835633346e-07
in O 0 5.109264975544647e-07
instability O 0 4.0764101868262514e-05
mechanisms O 0 8.980729944596533e-06
. O 0 9.036994015332311e-06

As O 0 6.576469786523376e-06
observed O 0 3.2942484722298104e-06
in O 0 9.56086836367831e-08
some O 0 1.6241600064859085e-08
of O 0 2.395623610595976e-08
the O 0 8.788452987573692e-08
tissues O 0 2.943937033705879e-06
of O 0 1.0526370715524536e-05
DM B-Disease 1 1.0
patients O 0 0.022444335743784904
, O 0 5.42500401934376e-07
there O 0 7.281493452637733e-08
is O 0 3.652827018640892e-08
a O 0 1.1933103394312639e-07
tendency O 0 5.323638561094413e-07
for O 0 4.0761737096772777e-08
repeat O 0 1.969581035154988e-06
length O 0 6.266506034080521e-07
and O 0 7.815657454557368e-08
somatic O 0 2.4659582322783535e-06
mosaicism O 0 0.0001498629862908274
to O 0 4.113051232934595e-08
increase O 0 2.5899367983583943e-07
with O 0 5.780628953289124e-08
the O 0 5.4129635884692107e-08
age O 0 2.0012755896914314e-07
of O 0 6.67603856641108e-08
the O 0 4.51932010037126e-07
mouse O 0 7.068913691909984e-05
. O 0 8.020701898203697e-06

Furthermore O 0 0.00013882781786378473
, O 0 2.8962292617507046e-06
we O 0 3.09947608911898e-07
observed O 0 3.882252599396452e-07
no O 0 6.579962530395278e-08
correlation O 0 1.5380912543605518e-07
between O 0 6.27340099867979e-08
the O 0 5.3124807664062246e-08
somatic O 0 1.0189558452111669e-05
mutation O 0 2.7297198812448187e-06
rate O 0 1.4507837704513804e-06
and O 0 1.6483770650665974e-06
tissue O 0 0.0006853208178654313
proliferation O 0 0.0004047221736982465
capacity O 0 7.171610377554316e-06
. O 0 4.236668701196322e-06

The O 0 6.05546392762335e-06
somatic O 0 0.0001136579958256334
mutation O 0 2.268018215545453e-05
rates O 0 1.289037982132868e-06
in O 0 4.427371536053215e-08
different O 0 2.3153154060651104e-08
tissues O 0 1.2368570878606988e-06
were O 0 1.3266485154872498e-07
also O 0 2.214119554366789e-08
not O 0 1.3641965779243037e-08
correlated O 0 1.415365034063143e-07
to O 0 1.4183939356371411e-08
the O 0 2.156440714884411e-08
relative O 0 1.3267183476273203e-06
inter O 0 8.074053766904399e-06
- O 0 0.0002815805491991341
tissue O 0 1.5062695638334844e-05
difference O 0 2.4413483856733365e-07
in O 0 1.1142809341890825e-08
transcriptional O 0 1.7035966948242276e-07
levels O 0 2.7756401621559235e-08
of O 0 4.3668006988184516e-09
the O 0 8.790292937987942e-09
three O 0 2.127142550989447e-08
genes O 0 4.02237354535373e-08
( O 0 2.9769243070632e-08
DMAHP O 0 2.3912467440823093e-05
, O 0 9.547310497737271e-08
DMPK O 0 8.238395093940198e-05
and O 0 2.720117890930851e-07
59 O 0 2.6256593628204428e-06
) O 0 2.9318391270294342e-08
surrounding O 0 3.110559987362649e-07
the O 0 8.829752573547012e-08
repeat O 0 2.8080160063836956e-06
. O 0 2.850675286936166e-07
. O 0 2.6712075396062573e-06

A O 0 7.534751057391986e-05
novel O 0 6.602078792639077e-05
missense O 0 0.002260620705783367
mutation O 0 7.630704203620553e-05
in O 0 8.428866749454755e-06
patients O 0 4.626395821105689e-05
from O 0 2.418462372588692e-07
a O 0 1.948265662576887e-06
retinoblastoma B-Disease 0 0.040847040712833405
pedigree O 0 0.00011500068649183959
showing O 0 1.1889219422300812e-05
only O 0 1.8422939263018634e-07
mild O 0 4.321188680478372e-05
expression O 0 1.8732146145339357e-07
of O 0 1.6957935145001102e-07
the O 0 7.984161129570566e-06
tumor B-Disease 0 0.39367735385894775
phenotype O 0 0.00015030604845378548
. O 0 9.299347766500432e-06

We O 0 1.705419344943948e-05
have O 0 3.1053610882736393e-07
used O 0 7.240306132416663e-08
single O 0 1.2742154353873048e-07
strand O 0 8.356029184142244e-07
conformation O 0 4.4163482471049065e-07
polymorphism O 0 8.796550332590414e-07
analysis O 0 9.865114947160691e-08
to O 0 2.5957122673503363e-08
study O 0 8.451030453215935e-08
the O 0 2.3225338097176973e-08
27 O 0 3.409046769320412e-07
exons O 0 3.91909139807467e-07
of O 0 4.259507591086731e-08
the O 0 1.8562582226877566e-07
RB1 O 0 0.0010335225379094481
gene O 0 3.954910425818525e-07
in O 0 5.373852118850664e-08
individuals O 0 7.355474451742339e-08
from O 0 5.355127541406546e-08
a O 0 1.0238662753181416e-06
family O 0 8.761188837524969e-06
showing O 0 0.00015225165407173336
mild O 0 0.0007732806261628866
expression O 0 3.3422108458580624e-07
of O 0 2.3901884560473263e-07
the O 0 2.632373934829957e-06
retinoblastoma B-Disease 0 0.22623585164546967
phenotype O 0 0.0004055343451909721
. O 0 1.3092951121507213e-05

In O 0 8.643177352496423e-06
this O 0 8.518025538251095e-07
family O 0 5.536876415135339e-06
affected O 0 4.61921445094049e-06
individuals O 0 4.81765084714425e-07
developed O 0 1.6220279576373287e-05
unilateral B-Disease 0 0.14611008763313293
tumors I-Disease 1 0.9999942779541016
and O 0 9.867080734693445e-06
, O 0 9.280531685362803e-07
as O 0 5.359143528949062e-08
a O 0 7.813302715931059e-08
result O 0 7.664269929819056e-08
of O 0 4.281312726561737e-08
linkage O 0 7.849232133594342e-06
analysis O 0 1.0646351711329771e-06
, O 0 7.99922815986065e-07
unaffected O 0 1.556821007397957e-05
mutation O 0 7.721382644376718e-07
carriers O 0 5.370567350837518e-07
were O 0 1.2573542562677176e-07
also O 0 1.935426894306147e-07
identified O 0 5.871458483852621e-07
within O 0 1.337044608362703e-07
the O 0 5.759042096542544e-07
pedigree O 0 0.0001725261245155707
. O 0 9.828332622419111e-06

A O 0 1.9542761947377585e-05
single O 0 3.4222236990899546e-06
band O 0 1.5384270000140532e-06
shift O 0 8.381232987630938e-07
using O 0 2.412148489838728e-07
SSCP O 0 0.0001821231417125091
was O 0 8.024442763598927e-07
identified O 0 3.6008836445944326e-07
in O 0 3.17113837411398e-08
exon O 0 4.301076387491776e-06
21 O 0 3.6717435136779386e-07
which O 0 3.5278091559121094e-08
resulted O 0 2.6077617576447665e-07
in O 0 5.004817182907573e-08
a O 0 2.979751343445969e-07
missense O 0 8.352862096216995e-06
mutation O 0 2.19697767533944e-07
converting O 0 2.0332602446160308e-07
a O 0 4.5991654928911885e-07
cys O 0 0.0008854521438479424
- O 0 0.00016449713439214975
- O 0 5.107823744765483e-05
> O 0 2.4507612579327542e-06
arg O 0 2.2781130155635765e-06
at O 0 6.19872864149329e-08
nucleotide O 0 1.6749662279380573e-07
position O 0 7.9052227874854e-08
28 O 0 1.273165963766587e-07
in O 0 3.744868948274416e-08
the O 0 2.4508918272658775e-07
exon O 0 9.23546904232353e-05
. O 0 8.801016520010307e-06

The O 0 1.433962370356312e-05
mutation O 0 1.9635383068816736e-05
destroyed O 0 1.7269952877541073e-05
an O 0 3.72303361473314e-07
NdeI O 0 0.0001069374120561406
restriction O 0 5.1414208428468555e-06
enzyme O 0 3.2149162052519387e-06
site O 0 6.333276814984856e-06
. O 0 3.3082269510487095e-06

Analysis O 0 1.0367959475843236e-05
of O 0 1.0392144531579106e-06
all O 0 4.014586920675356e-07
family O 0 1.0478606782271527e-06
members O 0 1.5250915907927265e-07
demonstrated O 0 1.1048401802327135e-06
that O 0 3.9506424798219086e-08
the O 0 1.4247908097786421e-07
missense O 0 4.2332307202741504e-05
mutation O 0 1.999075266212458e-06
co O 0 1.6072644939413294e-05
- O 0 6.422479054890573e-05
segregated O 0 1.4328483302961104e-05
with O 0 6.895648766658269e-06
patients O 0 0.00019681442063301802
with O 0 0.00020204851171001792
tumors B-Disease 1 0.999996542930603
or O 0 2.1461642973008566e-05
who O 0 2.2765534595237114e-06
, O 0 2.031046903994138e-07
as O 0 2.4510921292630883e-08
a O 0 6.383846340440869e-08
result O 0 6.422978060527385e-08
of O 0 2.0212496565363836e-08
linkage O 0 5.789020178781357e-06
analysis O 0 1.0119786111317808e-06
had O 0 1.2969408089702483e-06
been O 0 2.708304123189009e-07
predicted O 0 3.524269459376228e-06
to O 0 6.01734981842128e-08
carry O 0 8.955105386121431e-07
the O 0 8.039685894800641e-07
predisposing O 0 0.0001912471925606951
mutation O 0 1.769890877767466e-05
. O 0 8.315158083860297e-06

These O 0 1.7389022559655132e-06
observations O 0 2.30243563237309e-06
point O 0 1.1934337180719012e-06
to O 0 1.3912692509165936e-07
another O 0 1.8579672200758068e-07
region O 0 2.8271267638046993e-07
of O 0 2.6931177288247454e-08
the O 0 1.6401682501054893e-07
RB1 O 0 0.00184059573803097
gene O 0 9.543657597532729e-07
where O 0 3.469554030743893e-07
mutations O 0 2.808450290103792e-07
only O 0 2.19667128931178e-08
modify O 0 3.2594968502053234e-07
the O 0 1.7462854273730954e-08
function O 0 2.2961103240959346e-08
of O 0 6.689904630263754e-09
the O 0 1.2213381417325309e-08
gene O 0 7.273997226775464e-08
and O 0 7.309197513905019e-08
raise O 0 1.7700045873425552e-07
important O 0 3.932681735818733e-08
questions O 0 9.341546558516711e-08
for O 0 5.812359304968595e-08
genetic O 0 5.562072601605905e-06
counseling O 0 9.90615262708161e-06
in O 0 7.295553814401501e-07
families O 0 8.734890570849529e-07
with O 0 1.3605695414753427e-07
these O 0 1.4565854655756993e-07
distinctive O 0 6.46705120743718e-06
phenotypes O 0 2.5843808543868363e-05
. O 0 9.030988508129667e-07
. O 0 5.197032351134112e-06

Maternal B-Disease 0 0.010934903286397457
disomy I-Disease 0 0.338169664144516
and O 0 0.023757997900247574
Prader B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999985694885254
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999876022338867
consistent O 0 4.23377932747826e-05
with O 0 1.4281933999882312e-06
gamete O 0 0.0002797659544739872
complementation O 1 0.5305027961730957
in O 0 7.253367471093952e-07
a O 0 7.954512284413795e-07
case O 0 1.893206786007795e-06
of O 0 2.8887265557386854e-07
familial O 0 0.001711835153400898
translocation O 0 0.0006867736228741705
( O 0 4.1701886743794603e-07
3 O 0 6.307968192231783e-07
; O 0 1.731718697328688e-07
15 O 0 1.9294724040719302e-07
) O 0 5.0103569293469263e-08
( O 0 5.17070475325454e-08
p25 O 0 1.7467573343310505e-06
; O 0 9.185902882791197e-08
q11 O 0 3.035864438061253e-06
. O 0 9.238439702130563e-08
2 O 0 5.510939899977529e-07
) O 0 3.475873029401555e-07
. O 0 1.5517401834586053e-06

Maternal B-Disease 0 0.3829585313796997
uniparental I-Disease 1 0.9858172535896301
disomy I-Disease 1 0.9792242646217346
( I-Disease 0 0.0001360899186693132
UPD I-Disease 1 0.9991461038589478
) I-Disease 0 8.802962270237913e-07
for I-Disease 0 1.2779953806330013e-07
chromosome I-Disease 0 7.970375918375794e-06
15 I-Disease 0 4.7288952487178904e-07
is O 0 5.702167271692815e-08
responsible O 0 1.241556617515016e-07
for O 0 1.1324394755263256e-08
an O 0 1.1764058172047953e-08
estimated O 0 2.0992756333271245e-07
30 O 0 7.060588558260861e-08
% O 0 1.452994258244189e-08
of O 0 2.14221547167881e-08
cases O 0 1.6874365655894508e-06
of O 0 0.00024682775256223977
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999964237213135
( O 0 0.0002457365917507559
PWS B-Disease 1 0.9998993873596191
) O 0 8.402350431424566e-06
. O 0 1.5302683095796965e-05

We O 0 1.7341597413178533e-05
report O 0 2.7466280698718037e-06
on O 0 4.260572552539088e-07
an O 0 5.506769440444259e-08
unusual O 0 5.243052783043822e-07
case O 0 6.143162636362831e-07
of O 0 1.1584018722032852e-07
maternal B-Disease 0 2.7850699552800506e-05
disomy I-Disease 0 0.021689916029572487
15 I-Disease 0 5.959604550298536e-06
in O 0 3.4807137581083225e-06
PWS B-Disease 1 0.999806821346283
that O 0 1.4860422936635587e-07
is O 0 4.1820801044423206e-08
most O 0 1.8324458395113652e-08
consistent O 0 2.7056785256718285e-07
with O 0 1.0008702133745828e-07
adjacent O 0 2.9752040973107796e-06
- O 0 3.863877282128669e-05
1 O 0 3.4208363786092377e-07
segregation O 0 5.79357617880305e-07
of O 0 3.619820176936628e-08
a O 0 1.5231976249197032e-06
paternal O 0 0.0002728987601585686
t O 0 0.021695666015148163
( O 0 1.1276839728679988e-07
3 O 0 4.24872467874593e-07
; O 0 8.215616276174842e-08
15 O 0 8.626346215123704e-08
) O 0 1.6348234765928282e-08
( O 0 1.817020844896433e-08
p25 O 0 2.2374872514774324e-06
; O 0 9.790548460841819e-08
q11 O 0 7.413683761114953e-06
. O 0 3.511033952463549e-08
2 O 0 1.1675352595830191e-07
) O 0 1.088591172759834e-08
with O 0 1.5183166723886643e-08
simultaneous O 0 4.865707978751743e-07
maternal O 0 1.3235211554274429e-05
meiotic O 0 0.006933219265192747
nondisjunction O 0 0.0041720131412148476
for O 0 1.8743238570095855e-06
chromosome O 0 0.00010105531691806391
15 O 0 8.073399840213824e-06
. O 0 9.82600795396138e-06

The O 0 2.2281852579908445e-05
patient O 0 0.00038286412018351257
( O 0 1.0773491112558986e-06
J O 0 0.010257283225655556
. O 0 1.735577512818054e-07
B O 0 1.173563396150712e-05
. O 0 1.3080671656950926e-08
) O 0 9.98833105114727e-09
, O 0 1.2466365717500594e-08
a O 0 2.1535223382329605e-08
17 O 0 3.533284598233877e-07
- O 0 8.506478479830548e-06
year O 0 9.617307341613923e-07
- O 0 0.0007193146157078445
old O 0 7.463598012691364e-05
white O 0 2.971927278849762e-05
male O 0 1.0379902732893243e-06
with O 0 1.7352311942886445e-06
PWS B-Disease 1 0.9999308586120605
, O 0 2.7287123884889297e-06
was O 0 1.2011535091005499e-06
found O 0 1.948799308593152e-07
to O 0 3.432875317344042e-08
have O 0 3.118183400374619e-08
47 O 0 7.921989890746772e-07
chromosomes O 0 4.96708196351392e-07
with O 0 1.1814680078714446e-07
a O 0 4.3878179667444783e-07
supernumerary O 0 0.0003072130784858018
, O 0 4.067789177497616e-06
paternal O 0 0.00015835494559723884
der O 0 0.005533062387257814
( O 0 1.2836447638164827e-07
15 O 0 6.158507659392853e-08
) O 0 8.387724292902021e-09
consisting O 0 1.8750567321035305e-08
of O 0 7.811898683485197e-09
the O 0 3.9583433419920766e-08
short O 0 1.4660413398814853e-06
arm O 0 2.9263053875183687e-05
and O 0 1.2064914756138023e-07
the O 0 1.2070900368144066e-07
proximal O 0 0.0006012242520228028
long O 0 4.6648099669255316e-05
arm O 0 3.865244070766494e-05
of O 0 9.678736745399874e-08
chromosome O 0 8.82508720678743e-06
15 O 0 9.210655775859777e-07
, O 0 4.381060989544494e-07
and O 0 1.6658460708640632e-06
distal O 0 0.02319539710879326
chromosome O 0 0.0022222870029509068
arm O 0 0.06680362671613693
3p O 0 0.24117358028888702
. O 0 4.5678927563130856e-05

The O 0 2.1053570890217088e-05
t O 0 0.017420776188373566
( O 0 2.999755110977276e-07
3 O 0 4.222907534767728e-07
; O 0 6.609647584809863e-08
15 O 0 6.420737008738797e-08
) O 0 1.3587095892830803e-08
was O 0 4.2782513531847144e-08
present O 0 2.228460971309687e-08
in O 0 1.9392951244867618e-08
the O 0 1.1212567763152492e-08
balanced O 0 4.0517420529795345e-07
state O 0 3.764541389728038e-08
in O 0 4.280373389065062e-08
the O 0 4.640464794647414e-07
patients O 0 1.1031587746401783e-05
father O 0 6.1533687585324515e-06
and O 0 7.412845661747269e-07
a O 0 1.766216882970184e-06
sister O 0 0.0003933688858523965
. O 0 1.2767404768965207e-05

Fluorescent O 0 0.00013151874009054154
in O 0 1.4059145314604393e-06
situ O 0 1.285918551729992e-05
hybridization O 0 4.2045048758154735e-06
analysis O 0 1.5038933725008974e-06
demonstrated O 0 1.974045062524965e-06
that O 0 1.124688537856855e-07
the O 0 7.080162163219939e-07
PWS B-Disease 1 0.9987717270851135
critical O 0 9.612184840079863e-06
region O 0 3.820249276031973e-06
resided O 0 2.6723182600107975e-06
on O 0 1.2811938177037518e-07
the O 0 5.953760506827166e-08
derivative O 0 3.973771526943892e-06
chromosome O 0 1.9174276530975476e-06
3 O 0 3.9593331280229904e-07
and O 0 6.663190532663066e-08
that O 0 2.9234685783308123e-08
there O 0 7.110348576588876e-08
was O 0 4.15148690535716e-07
no O 0 9.70772617847615e-08
deletion O 0 3.770973933114874e-07
of O 0 7.893770970213154e-08
the O 0 2.5562285372870974e-06
PWS B-Disease 1 0.9999223947525024
region O 0 3.5249618122179527e-06
on O 0 1.8498909071240632e-07
the O 0 4.738122072467377e-08
normal O 0 2.2731207138804166e-07
pair O 0 5.588603357864486e-07
of O 0 8.46669720999671e-08
15s O 0 7.739075954305008e-06
present O 0 5.055855467617221e-07
in O 0 1.5315498558265972e-06
J O 0 0.010490556247532368
. O 0 9.178543223242741e-06

B O 0 0.015019247308373451
. O 0 0.0002459567040205002

Methylation O 0 0.00016403837071266025
analysis O 0 1.1354173693689518e-05
at O 0 1.8721855212788796e-06
exon O 0 4.562862159218639e-06
alpha O 0 1.1035281204385683e-06
of O 0 4.3788968895341895e-08
the O 0 3.9817187769131124e-08
small O 0 3.09798963371577e-07
nuclear O 0 9.380822302773595e-05
ribonucleoprotein O 0 0.00010682866559363902
- O 0 7.919656127342023e-06
associated O 0 3.4656684988476627e-07
polypeptide O 0 5.794300250272499e-06
N O 0 2.2871052351547405e-05
( O 0 5.397890134872796e-08
SNRPN O 0 1.988832991628442e-05
) O 0 2.7315865125387973e-08
gene O 0 1.0217305401738486e-07
showed O 0 4.3006113514820754e-07
a O 0 6.99167941320411e-08
pattern O 0 1.632356429581705e-06
characteristic O 0 1.5972612743553327e-07
of O 0 1.9797822048417402e-08
only O 0 2.890406669564527e-08
the O 0 1.2624452949694387e-07
maternal O 0 6.191123702592449e-06
chromosome O 0 7.996124622877687e-06
15 O 0 2.3751488242851337e-06
in O 0 3.0910239274817286e-06
J O 0 0.07752327620983124
. O 0 1.1757756510633044e-05

B O 0 0.01577007584273815
. O 0 0.0003790771006606519

Maternal B-Disease 0 0.0047350674867630005
disomy I-Disease 0 0.03418881446123123
was O 0 2.60384040302597e-05
confirmed O 0 3.296002205388504e-06
by O 0 4.767652796999755e-07
polymerase O 0 2.346903238503728e-05
chain O 0 6.316375220194459e-06
reaction O 0 1.7770169336017716e-07
analysis O 0 5.281363257836347e-08
of O 0 3.35250192051717e-08
microsatellite O 0 1.2922017049277201e-05
repeats O 0 8.592811582275317e-07
at O 0 1.7837065513504058e-07
the O 0 3.749171284539443e-08
gamma O 0 7.514767617067264e-07
- O 0 6.553136699949391e-06
aminobutyric O 0 1.4118456419964787e-05
acid O 0 7.406366080431326e-07
receptor O 0 6.010111519572092e-07
beta3 O 0 2.7866715299751377e-06
subunit O 0 1.4135172250462347e-06
( O 0 2.600966411137051e-07
GABRB3 O 0 2.3776263333274983e-05
) O 0 2.8695231435449386e-07
locus O 0 8.696524673723616e-06
. O 0 6.967915851419093e-06

A O 0 0.0002119109994964674
niece O 0 0.1204124465584755
( O 0 4.436976723809494e-06
B O 0 0.00010505153477424756
. O 0 2.77487600897075e-07
B O 0 1.826894367695786e-05
. O 0 2.4687054178684775e-08
) O 0 1.1037701419525092e-08
with O 0 1.55290020842358e-08
45 O 0 7.600754514669461e-08
chromosomes O 0 1.711581205654511e-07
and O 0 3.0425308494841374e-08
the O 0 1.4099136080858443e-08
derivative O 0 1.094201252271887e-06
3 O 0 1.562002580612898e-07
but O 0 5.0676000284965994e-08
without O 0 3.795275915763341e-08
the O 0 7.523157563582572e-08
der O 0 0.0003115262952633202
( O 0 4.9930324763636236e-08
15 O 0 1.149029884572883e-07
) O 0 3.023682637603997e-08
demonstrated O 0 3.280280793660495e-07
a O 0 1.835759206869625e-07
phenotype O 0 8.135555617627688e-06
consistent O 0 1.1555171113286633e-06
with O 0 1.4760057354124e-07
that O 0 1.0234722935820173e-07
reported O 0 9.703151135909138e-07
for O 0 1.3336685356080125e-07
haploinsufficiency O 0 0.00010895809100475162
of O 0 5.164840217730671e-07
distal O 0 0.003601999254897237
3 O 0 0.00012296513887122273
p O 0 0.003991684876382351
. O 0 7.976330380188301e-06

Uniparental B-Disease 1 0.9997723698616028
disomy I-Disease 1 0.9996057152748108
associated O 0 0.0005012645269744098
with O 0 4.403778802952729e-06
unbalanced O 0 0.00021883654699195176
segregation O 0 3.032605854969006e-05
of O 0 3.552906093773345e-07
non O 0 1.4173889212543145e-05
- O 0 0.005955872125923634
Robertsonian O 0 0.0007807791698724031
translocations O 0 8.19529959699139e-05
has O 0 6.18405010754941e-07
been O 0 4.246893468007329e-07
reported O 0 7.511602689191932e-06
previously O 0 1.7335078155156225e-06
but O 0 2.851871840903186e-07
has O 0 8.45819059236419e-08
not O 0 2.5809313797253708e-08
, O 0 1.6833277882710718e-08
to O 0 1.073637356796553e-08
our O 0 1.4985397811528856e-08
knowledge O 0 4.3788968895341895e-08
, O 0 5.865560126494529e-08
been O 0 3.8831814208606374e-08
observed O 0 2.4508730689376534e-07
in O 0 8.013844876586518e-08
a O 0 7.048141696941457e-07
case O 0 7.5390244091977365e-06
of O 0 1.3919562661612872e-05
PWS B-Disease 1 0.9998303651809692
. O 0 2.939820842584595e-05

Furthermore O 0 0.00012733618495985866
, O 0 3.4909126043203287e-06
our O 0 4.4584760416910285e-07
findings O 0 4.825586756851408e-07
are O 0 2.9801340062363124e-08
best O 0 1.3213603722306289e-07
interpreted O 0 1.3814789667776495e-07
as O 0 5.220132592853588e-08
true O 0 7.650700126760057e-07
gamete O 0 2.776054316200316e-05
complementation O 0 0.020367801189422607
resulting O 0 1.2731293281831313e-05
in O 0 7.677483154111542e-06
maternal B-Disease 0 0.00754741532728076
UPD I-Disease 1 0.9997157454490662
15 I-Disease 0 6.421437137760222e-05
and O 0 0.00019639151287265122
PWS B-Disease 1 0.9990635514259338

Schwartz B-Disease 1 0.5457406044006348
- I-Disease 1 0.997474730014801
Jampel I-Disease 1 0.9995959401130676
syndrome I-Disease 1 0.9982036352157593
type I-Disease 0 3.4126496757380664e-05
2 I-Disease 0 4.685834937845357e-06
and O 0 1.6398491425206885e-05
Stuve B-Disease 1 0.9954614043235779
- I-Disease 1 0.9999837875366211
Wiedemann I-Disease 1 0.9999946355819702
syndrome I-Disease 1 0.9996259212493896
: O 0 8.917318154999521e-07
a O 0 6.84754752455774e-07
case O 0 2.611960553622339e-06
for O 0 2.663205123099033e-07
" O 0 5.677332865161588e-06
lumping O 0 0.0002750737185124308
" O 0 9.191594472213183e-06
. O 0 7.87453700468177e-06

Recent O 0 6.202571239555255e-05
studies O 0 6.948777354409685e-06
demonstrated O 0 5.149463959241984e-06
the O 0 1.768037520832877e-07
existence O 0 3.401207777642412e-07
of O 0 1.0787489657104743e-07
a O 0 1.6737507166908472e-06
genetically O 0 6.4754440245451406e-06
distinct O 0 1.8252744382607489e-07
, O 0 1.7193750068145164e-07
usually O 0 6.621635151304872e-08
lethal O 0 1.669929332592801e-07
form O 0 9.515166432549904e-09
of O 0 1.3903549422877859e-08
the O 0 3.4712951446636e-07
Schwartz B-Disease 0 0.006437234114855528
- I-Disease 1 0.9949901700019836
Jampel I-Disease 1 0.9999346733093262
syndrome I-Disease 1 0.9937712550163269
( O 0 1.6670459217493772e-06
SJS B-Disease 0 0.22841903567314148
) O 0 7.684514002903597e-08
of O 0 3.491288111945323e-07
myotonia B-Disease 1 0.9299667477607727
and O 0 0.00016078632324934006
skeletal B-Disease 1 0.9975817203521729
dysplasia I-Disease 1 0.9999823570251465
, O 0 5.128629709361121e-06
which O 0 3.868618705382687e-07
we O 0 5.009702590541565e-07
called O 0 1.0051696335722227e-05
SJS B-Disease 1 0.5155146718025208
type I-Disease 0 1.2178219549241476e-05
2 I-Disease 0 5.523902018467197e-06
. O 0 6.118686087575043e-06

This O 0 9.81221382971853e-05
disorder O 1 0.6855899095535278
is O 0 1.5279201761586592e-06
reminiscent O 0 3.002488119818736e-05
of O 0 4.448359334219276e-07
another O 0 1.3515313185052946e-05
rare O 0 0.00013193349877838045
condition O 0 0.00020173646043986082
, O 0 8.692940127730253e-07
the O 0 2.405537998129148e-06
Stuve B-Disease 1 0.9962486624717712
- I-Disease 1 0.999990701675415
Wiedemann I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999243021011353
( O 0 1.7425312535124249e-06
SWS B-Disease 0 0.022596897557377815
) O 0 1.5183636037363613e-07
, O 0 4.9092509613046786e-08
which O 0 2.5918435397898065e-08
comprises O 0 3.007526458986831e-07
campomelia B-Disease 0 0.0009657953632995486
at O 0 5.81672338739736e-06
birth O 0 1.719277133815922e-05
with O 0 1.7779568224796094e-05
skeletal B-Disease 1 0.9888010025024414
dysplasia I-Disease 1 0.9999744892120361
, O 0 4.071573130204342e-05
contractures B-Disease 1 0.6409509181976318
, O 0 1.4113956012806739e-06
and O 0 4.5309286633710144e-07
early B-Disease 0 3.102080654571182e-06
death I-Disease 0 9.168342330667656e-06
. O 0 2.9749685381830204e-06

To O 0 4.994279152015224e-06
test O 0 2.4891417069738964e-06
for O 0 1.9351519142674078e-07
possible O 0 3.0309579415188637e-06
nosologic O 0 0.009721817448735237
identity O 0 4.1862808757286984e-06
between O 0 1.7230945559276734e-06
these O 0 5.579354819928994e-06
disorders O 0 0.14364247024059296
, O 0 7.143788707253407e-07
we O 0 1.0080584900151734e-07
reviewed O 0 4.129879016545601e-07
the O 0 1.9570530085388782e-08
literature O 0 4.7379955958604114e-08
and O 0 4.6753353188933033e-08
obtained O 0 5.380139000976669e-08
a O 0 4.396521546823351e-08
follow O 0 9.74752438764881e-08
- O 0 7.285046649485594e-06
up O 0 5.6989819086084026e-08
of O 0 5.417319481892946e-09
the O 0 7.766407961184996e-09
only O 0 1.081930012247767e-08
two O 0 4.508454765073111e-08
surviving O 0 3.610913336160593e-05
patients O 0 4.236200311424909e-06
, O 0 7.434744730971943e-08
one O 0 4.4758614592410595e-08
with O 0 6.893656063766684e-07
SJS B-Disease 0 0.1175239160656929
type I-Disease 0 2.7342141493136296e-06
2 I-Disease 0 3.141342972412531e-07
at O 0 2.454304421917186e-07
age O 0 7.929414636009824e-08
10 O 0 6.070642655231495e-08
years O 0 7.820131031621713e-08
and O 0 7.416672076487885e-08
another O 0 1.124306763244931e-07
with O 0 2.5415292270736245e-07
SWS B-Disease 0 0.0025050756521523
at O 0 1.150036723629455e-06
age O 0 7.159188726291177e-07
7 O 0 2.075182010230492e-06
years O 0 2.254040737170726e-06
. O 0 3.7739887375209946e-06

Patients O 0 0.18691113591194153
reported O 0 7.36032088752836e-05
as O 0 7.540618867096782e-07
having O 0 1.2191374025860569e-06
either O 0 4.727646228275262e-06
neonatal O 1 0.998595654964447
SJS B-Disease 1 0.9998294115066528
or O 0 2.079433215840254e-05
SWS B-Disease 0 0.05209626257419586
presented O 0 4.016580533061642e-06
a O 0 6.182752940731007e-07
combination O 0 1.3774022136203712e-06
of O 0 1.8949394586798007e-07
a O 0 7.445084975188365e-06
severe O 0 0.0005304698133841157
, O 0 1.1923622878384776e-05
prenatal O 1 0.8587564826011658
- O 1 0.9999545812606812
onset O 1 0.9999953508377075
neuromuscular B-Disease 1 0.9999991655349731
disorder I-Disease 1 0.999832272529602
( O 0 5.1608098146971315e-05
with O 0 0.001277073402889073
congenital B-Disease 1 0.9999953508377075
joint I-Disease 1 0.9803614616394043
contractures I-Disease 1 0.999991774559021
, O 0 0.2031606286764145
respiratory O 1 0.929418683052063
and O 0 8.408409485127777e-06
feeding O 0 0.0001045908429659903
difficulties O 0 0.00013034912990406156
, O 0 8.551388646083069e-07
tendency O 0 1.4987048189141206e-06
to O 0 9.486028034189076e-07
hyperthermia B-Disease 1 0.7963875532150269
, O 0 7.301066489162622e-07
and O 0 3.9589630773662066e-07
frequent O 0 5.620712727250066e-06
death O 0 3.3794326554925647e-06
in O 0 3.278523195149319e-07
infancy O 0 0.00013356689305510372
) O 0 8.872937229398303e-08
with O 0 5.5131273768438405e-08
a O 0 3.188457355918217e-07
distinct O 0 2.5188526251440635e-06
campomelic B-Disease 0 0.12221544981002808
- I-Disease 0 0.36629676818847656
metaphyseal I-Disease 1 0.9363030791282654
skeletal I-Disease 1 0.90598064661026
dysplasia I-Disease 1 0.9992530941963196
. O 0 0.00011630264634732157

The O 0 4.415339390106965e-06
similarity O 0 4.811305643670494e-06
of O 0 2.9978534143992874e-07
the O 0 3.3305715874121233e-07
clinical O 0 1.8362426999374293e-05
and O 0 1.9186863937648013e-06
radiographic O 0 0.1982463151216507
findings O 0 3.2052888855105266e-05
is O 0 3.4239695878568455e-07
so O 0 1.4417865656923823e-07
extensive O 0 1.6854099840202252e-06
that O 0 2.829252139235905e-07
these O 0 3.591203267205856e-06
disorders O 0 0.24718333780765533
appear O 0 8.728977718419628e-07
to O 0 7.587833295019664e-08
be O 0 9.108404697144579e-08
a O 0 4.734747847123799e-07
single O 0 6.840486548753688e-06
entity O 0 2.729000880208332e-05
. O 0 6.559601388289593e-06

The O 0 4.051845280628186e-06
follow O 0 2.0380468868097523e-06
- O 0 3.261039455537684e-05
up O 0 3.2609051459076e-07
observation O 0 4.514495230978355e-07
of O 0 3.753127941763523e-08
an O 0 4.6207777160134356e-08
identical O 0 3.6996559629187686e-06
and O 0 1.512526353053545e-07
unique O 0 9.811709844598226e-08
pattern O 0 1.6524883221791242e-06
of O 0 8.214040008169832e-07
progressive O 1 0.772373378276825
bone B-Disease 1 0.9994361996650696
dysplasia I-Disease 1 0.9999001026153564
in O 0 7.801774586368992e-07
the O 0 3.7624818105541635e-07
two O 0 2.3611487449670676e-06
patients O 0 3.191554424120113e-05
( O 0 4.248764540193406e-08
one O 0 4.4186059255935106e-08
with O 0 7.727998649897927e-07
SJS B-Disease 1 0.5222471952438354
type I-Disease 0 1.1056516996177379e-05
2 I-Disease 0 8.746794151193171e-07
, O 0 1.1636279850790743e-07
one O 0 5.6881006571529724e-08
with O 0 4.742331043416925e-07
SWS B-Disease 0 0.01209768746048212
) O 0 1.718414495144316e-07
surviving O 0 1.8248686046717921e-06
beyond O 0 2.6743682610685937e-06
infancy O 0 2.3756023438181728e-05
adds O 0 5.330710450834886e-07
to O 0 3.096662837265285e-08
the O 0 3.600031561745709e-08
evidence O 0 2.607816327326873e-07
in O 0 5.217295750981066e-08
favor O 0 4.669698796533339e-07
of O 0 3.964433972214465e-07
identity O 0 8.763895493757445e-06
. O 0 7.485550668206997e-06

The O 0 8.579409950471018e-06
hypothesis O 0 1.960963345482014e-05
that O 0 1.4526223139910144e-06
SWS B-Disease 0 0.005512676667422056
and O 0 9.385009434481617e-06
SJS B-Disease 1 0.779690682888031
type I-Disease 0 1.3834627679898404e-05
2 I-Disease 0 1.2372464652798953e-06
are O 0 5.228363164633265e-08
the O 0 2.1136793293408118e-07
same O 0 1.5516852727159858e-05
disorder O 0 0.013172153383493423
should O 0 1.830889999610008e-07
be O 0 3.3945379840361056e-08
testable O 0 1.2663064126172685e-06
by O 0 7.242378075034139e-08
molecular O 0 1.1769667480621138e-06
methods O 0 7.080277555360226e-07
. O 0 6.386793529600254e-07
. O 0 4.462152901396621e-06

A O 0 8.931024058256298e-05
mouse O 0 8.068992610787973e-05
model O 0 1.713528217806015e-05
of O 0 9.125706856139004e-05
severe O 1 0.999945878982544
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 0.999998927116394
: O 0 0.015953805297613144
defects O 1 0.9982472658157349
in O 0 4.5762113586533815e-05
hemostasis O 1 0.998965859413147
and O 0 0.002802364295348525
thrombosis B-Disease 1 0.9995489716529846
. O 0 0.0001874830632004887

von B-Disease 1 0.9979561567306519
Willebrand I-Disease 1 0.9974337220191956
factor I-Disease 0 0.00033425851142965257
( I-Disease 0 4.13529051002115e-05
vWf I-Disease 1 0.5649341940879822
) I-Disease 0 0.004962071310728788
deficiency I-Disease 1 0.9997627139091492
causes O 1 0.8130265474319458
severe O 1 0.9999529123306274
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999915361404419
in O 0 2.7721865990315564e-05
humans O 0 2.5519646442262456e-05
. O 0 2.4072814994724467e-05

We O 0 7.815991921233945e-06
generated O 0 4.32586102760979e-06
a O 0 1.0376102181908209e-06
mouse O 0 1.0409948117739987e-05
model O 0 1.7801968397179735e-06
for O 0 2.846288111868489e-07
this O 0 9.383491033077007e-07
disease O 0 1.4493382877844851e-05
by O 0 8.581725552403441e-08
using O 0 2.501014648714772e-07
gene O 0 1.3170682677809964e-06
targeting O 0 3.7382112623163266e-06
. O 0 4.482376880332595e-06

vWf B-Disease 0 0.33548080921173096
- I-Disease 1 0.8296418190002441
deficient I-Disease 0 0.20319895446300507
mice O 0 4.2499639675952494e-05
appeared O 0 1.3944654710940085e-06
normal O 0 7.30691112948989e-07
at O 0 1.4583856682293117e-06
birth O 0 4.677855940826703e-06
; O 0 1.594038252505925e-07
they O 0 3.2144111372645057e-08
were O 0 1.6332081997916248e-07
viable O 0 1.7515815216029296e-06
and O 0 8.579840482525469e-07
fertile O 0 0.00010002336784964427
. O 0 7.905077836767305e-06

Neither O 0 0.0006917896680533886
vWf O 0 0.0034402969758957624
nor O 0 0.0001576739305164665
vWf O 0 0.002113594440743327
propolypeptide O 0 0.0795316994190216
( O 0 6.761042459402233e-05
von B-Disease 1 0.9948930740356445
Willebrand I-Disease 1 0.9966403245925903
antigen O 0 0.046403247863054276
II O 0 0.02749078907072544
) O 0 4.1679302853481204e-07
were O 0 1.2936003201957647e-07
detectable O 0 9.641827318773721e-07
in O 0 2.4108279816914546e-08
plasma O 0 1.7891488823806867e-05
, O 0 2.7595092433330137e-07
platelets O 0 0.00012742448598146439
, O 0 2.2633518881320924e-07
or O 0 2.9349115493459976e-07
endothelial O 0 2.2805215849075466e-05
cells O 0 3.359832589922007e-07
of O 0 3.6068428244107054e-08
the O 0 5.355597636480525e-07
homozygous O 0 1.8616969100548886e-05
mutant O 0 5.625374978990294e-05
mice O 0 5.462880289996974e-05
. O 0 9.632943147153128e-06

The O 0 1.9271810742793605e-05
mutant O 0 0.0004972336464561522
mice O 0 0.003547327360138297
exhibited O 0 0.002601534128189087
defects O 1 0.9691811800003052
in O 0 6.922255124663934e-06
hemostasis O 1 0.8102584481239319
with O 0 2.352910314584733e-06
a O 0 3.942884632124333e-06
highly O 0 3.8425390812335536e-05
prolonged O 0 0.1902138590812683
bleeding O 0 0.13288457691669464
time O 0 6.50933429824363e-07
and O 0 9.549547712595086e-07
spontaneous O 0 1.1705923498084303e-05
bleeding O 0 0.0004858338215854019
events O 0 1.0472957256979498e-07
in O 0 4.455971946981663e-08
approximately O 0 1.4524060532039584e-07
10 O 0 1.4290147021256416e-07
% O 0 1.6918552603328862e-07
of O 0 2.997630303980259e-07
neonates O 0 0.0007821092149242759
. O 0 1.112170320993755e-05

As O 0 5.815558324684389e-06
in O 0 6.152778269097325e-07
the O 0 2.781407033580763e-07
human O 0 1.3205130017013289e-05
disease O 0 0.00017615761316847056
, O 0 7.260593548608085e-08
the O 0 3.377758517331131e-08
factor O 0 5.007505023968406e-07
VIII O 0 0.0005136915715411305
level O 0 5.899832444811182e-07
in O 0 3.194498532366197e-08
these O 0 3.36058789685012e-08
mice O 0 2.899025730584981e-06
was O 0 6.994893624323595e-07
reduced O 0 5.981179356240318e-07
strongly O 0 4.479816197999753e-07
as O 0 4.167841893831792e-08
a O 0 5.145400550077284e-08
result O 0 4.958732802151644e-08
of O 0 2.4992353075958817e-08
the O 0 7.567830095922545e-08
lack O 0 2.919446444593632e-07
of O 0 8.857550426455418e-08
protection O 0 4.1087419049290475e-06
provided O 0 8.617791991127888e-07
by O 0 2.856226046787924e-06
vWf O 0 0.0007291098590940237
. O 0 1.1958925824728794e-05

Defective O 1 0.9933028221130371
thrombosis B-Disease 1 0.998741090297699
in O 0 3.169120100210421e-05
mutant O 0 0.00038001546636223793
mice O 0 0.00019526561663951725
was O 0 3.945103799196659e-06
also O 0 1.377174783101509e-07
evident O 0 8.049843245316879e-07
in O 0 3.758902167305678e-08
an O 0 1.701296881151393e-08
in O 0 9.11866067099254e-08
vivo O 0 2.9820226700394414e-05
model O 0 5.1507013267837465e-06
of O 0 2.3373035219265148e-05
vascular B-Disease 1 0.9998723268508911
injury I-Disease 0 0.06621275842189789
. O 0 5.847900683875196e-05

In O 0 4.121669007872697e-06
this O 0 2.534874852244684e-07
model O 0 1.3697889471586677e-06
, O 0 1.6776840539023397e-07
the O 0 1.5232528483011265e-07
exteriorized O 0 0.00018007881590165198
mesentery O 0 0.00031207501888275146
was O 0 4.8519082156417426e-06
superfused O 0 0.0005187324713915586
with O 0 1.668066943238955e-06
ferric O 0 0.06580186635255814
chloride O 0 1.1226305105083156e-05
and O 0 1.3543619559186482e-07
the O 0 2.9547774005322935e-08
accumulation O 0 5.872225870007242e-07
of O 0 1.597828145349922e-07
fluorescently O 0 0.017405005171895027
labeled O 0 0.00014401138469111174
platelets O 0 0.0003414522507227957
was O 0 7.291596375580411e-07
observed O 0 5.389181296777679e-07
by O 0 3.72812820614854e-07
intravital O 0 0.0001192768249893561
microscopy O 0 5.070241604698822e-05
. O 0 9.141783266386483e-06

We O 0 6.708276487188414e-06
conclude O 0 8.789072126091924e-06
that O 0 1.8642626287146413e-07
these O 0 1.7446085109895648e-07
mice O 0 4.197882390144514e-06
very O 0 5.805318323837128e-07
closely O 0 7.674687367398292e-06
mimic O 0 0.019431300461292267
severe O 1 0.650974452495575
human O 0 0.19708819687366486
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999067783355713
and O 0 4.788276328326901e-06
will O 0 7.15655346539279e-07
be O 0 5.004626402183021e-08
very O 0 6.280200892661014e-08
useful O 0 7.318614336782048e-08
for O 0 3.008794280390248e-08
investigating O 0 1.468268806092965e-06
the O 0 2.5490921373716446e-08
role O 0 8.288426300850915e-08
of O 0 8.982084409581148e-08
vWf O 0 4.300982254790142e-05
in O 0 8.693539399473593e-08
normal O 0 8.506847848366306e-07
physiology O 0 5.8687664932222106e-06
and O 0 2.035779743891908e-06
in O 0 1.2719448932330124e-05
disease O 0 0.00017066419241018593
models O 0 4.315839760238305e-06
. O 0 1.1393505019441363e-06
. O 0 4.488763806875795e-06

Oral O 0 0.0011564504820853472
contraceptives O 0 0.0035295358393341303
and O 0 3.7913364394626115e-06
the O 0 1.7248733001906658e-06
risk O 0 0.00015661036013625562
of O 0 0.0009135653963312507
hereditary B-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999957084655762
. O 0 0.0006176785100251436

Hereditary B-Disease 1 0.9999740123748779
Ovarian I-Disease 1 0.9999964237213135
Cancer I-Disease 1 0.9996923208236694
Clinical O 0 0.008623207919299603
Study O 0 2.7647045499179512e-05
Group O 0 4.197534144623205e-05
. O 0 1.4249949344957713e-05

BACKGROUND O 0 0.0004420563636813313
Women O 0 6.225439392437693e-06
with O 0 1.463228159082064e-06
mutations O 0 2.8095373636460863e-06
in O 0 1.1859280846238107e-07
either O 0 1.2573914887070714e-07
the O 0 1.668547611188842e-07
BRCA1 O 0 2.8701066185021773e-05
or O 0 1.5405824171921267e-07
the O 0 1.4466002085100627e-07
BRCA2 O 0 1.0010083315137308e-05
gene O 0 4.40574325466514e-07
have O 0 4.3016200379497604e-08
a O 0 2.9920494171165046e-07
high O 0 3.382623617653735e-05
lifetime O 0 4.1516806959407404e-05
risk O 0 0.00011571943468879908
of O 0 0.019772769883275032
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999719858169556
. O 0 8.595630060881376e-05

Oral O 0 0.0027241904754191637
contraceptives O 0 0.1027427390217781
protect O 0 0.005906302016228437
against O 1 0.893927812576294
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999910593032837
in O 0 2.8242398002475966e-06
general O 0 9.804198271012865e-06
, O 0 9.447117577110475e-07
but O 0 8.23111321324177e-08
it O 0 2.6086963700322485e-08
is O 0 3.5944946574772985e-08
not O 0 3.251154367944764e-08
known O 0 9.424101676813734e-08
whether O 0 8.81665940255516e-08
they O 0 6.268639651807462e-08
also O 0 7.553207836963338e-08
protect O 0 2.1974146875436418e-06
against O 0 5.388598310673842e-06
hereditary B-Disease 0 0.0022740988060832024
forms I-Disease 0 2.227564800705295e-05
of I-Disease 0 0.17098811268806458
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999724626541138
. O 0 0.00010525999823585153

METHODS O 0 4.711789370048791e-05
We O 0 2.258115955555695e-06
enrolled O 0 2.5947526864911197e-06
207 O 0 1.0284196832799353e-05
women O 0 2.8730876238114433e-06
with O 0 0.0004264472227077931
hereditary B-Disease 1 0.9999974966049194
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
and O 0 9.927791325026192e-06
161 O 0 1.9130706277792342e-05
of O 0 2.712796742798673e-07
their O 0 2.52448927540172e-07
sisters O 0 3.603416189434938e-06
as O 0 4.553028176701446e-08
controls O 0 6.215901748873875e-07
in O 0 8.839221976586487e-08
a O 0 7.782008424328524e-07
case O 0 6.10200231676572e-06
- O 0 0.0001592904154676944
control O 0 3.9104625102481805e-06
study O 0 2.2269200599112082e-06
. O 0 6.3146590036922134e-06

All O 0 6.8465169533737935e-06
the O 0 2.4705955183890183e-06
patients O 0 3.3726897527230904e-05
carried O 0 1.4758003317183466e-06
a O 0 5.524621542463137e-07
pathogenic O 0 1.2326803471296444e-06
mutation O 0 4.80337405406317e-07
in O 0 1.3989220803978242e-07
either O 0 9.149931088359153e-07
BRCA1 O 0 7.81313719926402e-05
( O 0 1.9927205130443326e-07
179 O 0 5.87911836191779e-06
women O 0 2.985943581279571e-07
) O 0 1.4729064901075617e-07
or O 0 9.452415952182491e-07
BRCA2 O 0 5.34412611159496e-05
( O 0 2.3154176176376495e-07
28 O 0 3.3447117857576814e-06
women O 0 6.994026193751779e-07
) O 0 7.566428621430532e-07
. O 0 3.4610452530614566e-06

The O 0 1.2739770681946538e-05
control O 0 1.654650259297341e-05
women O 0 9.418977811037621e-07
were O 0 3.4331577580815065e-07
enrolled O 0 5.212829705669719e-07
regardless O 0 3.864687698751368e-07
of O 0 6.205732461239677e-08
whether O 0 7.95613573245646e-07
or O 0 4.574341403440485e-07
not O 0 1.4880504295433639e-07
they O 0 1.0979040609981894e-07
had O 0 7.803441235409991e-07
either O 0 1.2141678098487318e-06
mutation O 0 5.779757884738501e-06
. O 0 3.6264866594137857e-06

Lifetime O 0 0.0001669267803663388
histories O 0 2.451264845149126e-05
of O 0 1.2011386161248083e-06
oral O 0 3.896947600878775e-05
- O 0 0.013304983265697956
contraceptive O 0 0.0005289382534101605
use O 0 1.7623358417040436e-07
were O 0 8.929336559049261e-08
obtained O 0 1.268040392687908e-07
by O 0 2.088010688794384e-07
interview O 0 7.113737865438452e-06
or O 0 3.485113779788662e-07
by O 0 7.577189364837977e-08
written O 0 9.683316193331848e-08
questionnaire O 0 8.80969764693873e-07
and O 0 1.207336310926621e-07
were O 0 2.2641505381670868e-07
compared O 0 3.3683515994198387e-06
between O 0 9.567231700202683e-07
patients O 0 6.0371903600753285e-06
and O 0 6.663355520686309e-07
control O 0 7.297152023966191e-06
women O 0 2.835821817370743e-07
, O 0 1.1880914030371059e-07
after O 0 1.4815792326317023e-07
adjustment O 0 4.829445288123679e-07
for O 0 4.039117840193285e-08
year O 0 1.438613708160119e-07
of O 0 9.095523267887984e-08
birth O 0 5.747723662352655e-06
and O 0 1.0455457868374651e-06
parity O 0 1.8408678442938253e-05
. O 0 6.260733243834693e-06

RESULTS O 0 6.14835080341436e-05
The O 0 1.7786051103030331e-06
adjusted O 0 3.466693306108937e-05
odds O 0 0.00018738013750407845
ratio O 0 4.050787538290024e-05
for O 0 0.03459743410348892
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999964237213135
associated O 0 4.928211637889035e-05
with O 0 2.6932315222438774e-07
any O 0 1.0966483188212806e-07
past O 0 1.1532103627587276e-07
use O 0 6.353902648470466e-08
of O 0 9.376391574278387e-08
oral O 0 2.3136628442443907e-05
contraceptives O 0 0.0009461012086831033
was O 0 1.353943571302807e-05
0 O 0 1.783649349818006e-05
. O 0 6.661158295173664e-06

5 O 0 1.627910569368396e-05
( O 0 6.965736361053132e-07
95 O 0 1.2253652812432847e-06
percent O 0 1.1919335065613268e-06
confidence O 0 3.161487995839707e-07
interval O 0 3.153201362238178e-07
, O 0 3.859552677454303e-08
0 O 0 5.555604687401683e-08
. O 0 6.138404451405677e-09
3 O 0 1.7269879748482708e-08
to O 0 6.700503707435246e-09
0 O 0 9.219780139346767e-08
. O 0 2.768074480741234e-08
8 O 0 5.000695182388881e-07
) O 0 2.2194772952843778e-07
. O 0 1.0224513289358583e-06

The O 0 1.4244108569982927e-05
risk O 0 0.00013088482955936342
decreased O 0 1.5305951819755137e-05
with O 0 1.2066928434251167e-07
increasing O 0 2.3594915887770185e-07
duration O 0 1.0107449952556635e-06
of O 0 4.984088519677243e-08
use O 0 2.46240915657836e-07
( O 0 1.5151408661040477e-07
P O 0 5.942291682003997e-05
for O 0 5.1460286698556956e-08
trend O 0 1.1638082924037008e-06
, O 0 1.0587297794018014e-07
< O 0 2.6867235646932386e-05
0 O 0 2.2857200576709147e-07
. O 0 2.401832155385364e-08
001 O 0 7.47640171994135e-07
) O 0 6.9893837384427115e-09
; O 0 3.204835063996825e-09
use O 0 6.845704447755452e-09
for O 0 9.3274596935089e-09
six O 0 4.0883357144139154e-08
or O 0 2.833322909623348e-08
more O 0 1.3230218698367935e-08
years O 0 2.508694763037056e-07
was O 0 9.563474350215984e-07
associated O 0 2.0353864726985194e-07
with O 0 2.9332150930372336e-08
a O 0 8.990379996021147e-08
60 O 0 6.11177085829695e-07
percent O 0 6.1772761910106055e-06
reduction O 0 5.4830952649354e-06
in O 0 9.164165248876088e-07
risk O 0 2.1839101464138366e-05
. O 0 5.060292096459307e-06

Oral O 0 0.0008114652591757476
- O 0 0.0028707105666399
contraceptive O 0 0.002253534272313118
use O 0 6.559232133440673e-06
protected O 0 0.0016232272610068321
against O 1 0.7345195412635803
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999724626541138
both O 0 6.109609103077673e-07
for O 0 2.1657692172993848e-07
carriers O 0 1.0279362641085754e-06
of O 0 4.906180706143459e-08
the O 0 4.047401205298229e-07
BRCA1 O 0 0.00023719748423900455
mutation O 0 7.508377279918932e-07
( O 0 6.801248275678518e-08
odds O 0 8.05033414508216e-06
ratio O 0 1.9219098135181412e-07
, O 0 2.0744616691104056e-08
0 O 0 4.370877704218401e-08
. O 0 4.4036698731986235e-09
5 O 0 2.4096786788163627e-08
; O 0 1.0322430021858509e-08
95 O 0 1.6331725305462896e-07
percent O 0 3.855800798646669e-07
confidence O 0 2.0005427359137684e-07
interval O 0 2.0187113136671542e-07
, O 0 3.157738959203016e-08
0 O 0 8.415563002017734e-08
. O 0 4.760766891820367e-09
3 O 0 1.3912355711909186e-08
to O 0 7.281490077559738e-09
0 O 0 8.872159895645382e-08
. O 0 7.3788677390496105e-09
9 O 0 7.349963482283783e-08
) O 0 6.508066086041708e-09
and O 0 7.860323947284087e-09
for O 0 1.6095025756612813e-08
carriers O 0 1.3925583175478096e-07
of O 0 1.739975274972494e-08
the O 0 1.7558836873377004e-07
BRCA2 O 0 8.775318565312773e-05
mutation O 0 8.632499657323933e-07
( O 0 8.221259406582249e-08
odds O 0 5.8487521528149955e-06
ratio O 0 1.7849964706329047e-07
, O 0 2.227033313317861e-08
0 O 0 4.646389939466644e-08
. O 0 5.240920586402353e-09
4 O 0 3.457661890138297e-08
; O 0 1.186474030134832e-08
95 O 0 7.857044437287186e-08
percent O 0 2.8760871373378905e-07
confidence O 0 1.1284423351298756e-07
interval O 0 1.0617814183433438e-07
, O 0 1.1586512194128318e-08
0 O 0 3.872715481634259e-08
. O 0 4.692396693428691e-09
2 O 0 1.5430975608410336e-08
to O 0 9.030695302669756e-09
1 O 0 8.614278357299554e-08
. O 0 2.02501588830728e-08
1 O 0 2.05159281563283e-07
) O 0 1.7513731620510953e-07
. O 0 6.98076576099993e-07

CONCLUSIONS O 0 0.00025121888029389083
Oral O 0 0.00029526546131819487
- O 0 0.008152160793542862
contraceptive O 0 0.00045429987949319184
use O 0 5.773918019258417e-07
may O 0 5.385784902500745e-07
reduce O 0 6.522222406601941e-07
the O 0 2.436926536120154e-07
risk O 0 3.210685827070847e-05
of O 0 0.0031075351871550083
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999958276748657
in O 0 3.849275344691705e-06
women O 0 6.887735253258143e-07
with O 0 4.0158082015295804e-07
pathogenic O 0 3.3488515782664763e-06
mutations O 0 3.808771964486368e-07
in O 0 4.8711118694200195e-08
the O 0 5.606518129752658e-07
BRCA1 O 0 0.0003889301442541182
or O 0 1.87012610695092e-05
BRCA2 O 0 0.001538318581879139
gene O 0 0.00021521846065297723

A O 0 3.7221048842184246e-05
Japanese O 0 7.571932655991986e-05
family O 0 4.9769412726163864e-05
with O 0 3.281031968072057e-05
adrenoleukodystrophy B-Disease 1 0.9999892711639404
with O 0 9.775430953595787e-07
a O 0 5.334855472938216e-07
codon O 0 2.055569893855136e-06
291 O 0 5.272293037705822e-06
deletion O 0 1.8711376696955995e-06
: O 0 1.168268113360682e-07
a O 0 1.7461347567859775e-07
clinical O 0 7.538593308709096e-06
, O 0 4.970038958163059e-07
biochemical O 0 7.94445259089116e-06
, O 0 1.323468154623697e-06
pathological O 0 0.00016880173643585294
, O 0 1.6119562360472628e-06
and O 0 6.551411843247479e-06
genetic O 0 5.82913780817762e-05
report O 0 9.312509064329788e-06
. O 0 9.003555533126928e-06

We O 0 1.1956120943068527e-05
report O 0 2.3836514628783334e-06
a O 0 8.454946964775445e-07
Japanese O 0 6.067487447580788e-06
family O 0 3.469226794550195e-05
with O 0 0.0010734780225902796
adrenoleukodystrophy B-Disease 1 0.9999995231628418
( O 0 0.004628294613212347
ALD B-Disease 1 0.9999978542327881
) O 0 1.954384288183064e-06
with O 0 2.476660085903859e-07
a O 0 2.9546711743932974e-07
three O 0 1.6192950624827063e-07
base O 0 3.0462290396826575e-06
pair O 0 2.0781365037692012e-06
deletion O 0 2.287373717990704e-06
( O 0 1.1086740414611995e-07
delGAG O 0 4.780250492331106e-06
291 O 0 1.4286265468399506e-06
) O 0 5.562167615380531e-08
in O 0 1.3361523087951355e-07
the O 0 2.657055574672995e-06
ALD B-Disease 1 0.999916672706604
gene O 0 2.4379576643696055e-05
. O 0 1.1463322152849287e-05

A O 0 2.0301911717979237e-05
variety O 0 1.822291324060643e-06
of O 0 3.135090480554936e-07
phenotypes O 0 8.4878320194548e-06
were O 0 3.128746470792976e-07
observed O 0 8.300669946947892e-07
within O 0 1.906111606331251e-07
this O 0 1.8860079364912963e-07
family O 0 7.78746743890224e-06
. O 0 1.1031977010134142e-05

While O 0 9.89548243524041e-06
the O 0 9.561448450767784e-07
proband O 0 0.0011677726870402694
( O 0 6.080012440179416e-07
patient O 0 8.23175287223421e-06
1 O 0 4.88445380142366e-07
) O 0 7.348407393692469e-08
was O 0 9.221448635798879e-07
classified O 0 3.973134880652651e-06
as O 0 4.735122871579733e-08
having O 0 1.5479091075576434e-07
a O 0 2.0283680157717754e-07
rare O 0 1.359837028758193e-06
intermediate O 0 1.569021378600155e-06
type O 0 7.949128075779299e-07
of O 0 4.402857456398124e-08
adult O 0 8.928227543947287e-06
cerebral O 0 0.004167214035987854
and O 0 5.126365522301057e-06
cerebello O 0 0.28272491693496704
- O 1 0.6156641840934753
brain O 0 0.0022806667257100344
stem O 0 9.130038051807787e-06
forms O 0 2.490466215476772e-07
, O 0 2.8478467584136524e-07
his O 0 4.6496879235746746e-07
younger O 0 1.5049498870212119e-05
brother O 0 7.713963714195415e-05
( O 0 2.53997114896265e-07
patient O 0 4.244425326760393e-06
2 O 0 7.074121981531789e-07
) O 0 6.382993689157956e-08
and O 0 8.027213880268391e-07
nephew O 0 0.010877277702093124
( O 0 6.391607598743576e-07
patient O 0 1.0852722880372312e-05
3 O 0 2.0028080598422093e-06
) O 0 2.9918268751316646e-07
had O 0 1.2342777608864708e-06
a O 0 1.1469139280961826e-05
childhood O 0 0.2098761945962906
ALD B-Disease 1 0.9999881982803345
type O 0 0.0034138786140829325
. O 0 3.622001167968847e-05

Another O 0 0.00014425753033719957
nephew O 0 0.018052732571959496
( O 0 5.7642077990749385e-06
patient O 0 3.0235265512601472e-05
4 O 0 1.3059602679277305e-06
) O 0 3.1248813314732615e-08
of O 0 5.8247003664746444e-08
patient O 0 1.1340386663505342e-05
1 O 0 1.2685206911555724e-06
was O 0 3.468506292847451e-06
classified O 0 6.505674718937371e-06
as O 0 6.389377205096025e-08
having O 0 1.5206286718694173e-07
an O 0 7.568508664235196e-08
adolescent O 0 0.00022142122907098383
form O 0 3.153239504172234e-06
. O 0 6.919891802681377e-06

The O 0 5.700857400370296e-06
tau O 0 2.431227039778605e-05
level O 0 1.78346283519204e-06
in O 0 1.9789864325048256e-07
the O 0 3.610615237903403e-07
cerebrospinal O 0 0.0019114627502858639
fluid O 0 0.00011215567792532966
( O 0 1.4813376765232533e-06
CSF O 0 0.0591614730656147
) O 0 1.6695598503702058e-07
in O 0 1.240046714201526e-07
patient O 0 5.778280865342822e-06
1 O 0 9.6225278412021e-07
was O 0 1.6924825558817247e-06
as O 0 6.25447569291282e-08
high O 0 1.1824627108580898e-06
as O 0 1.0468260036589072e-08
that O 0 1.1180725678627823e-08
of O 0 2.889831876018434e-07
patients O 0 5.928730752202682e-05
with O 0 0.00029935393831692636
Alzheimers B-Disease 1 0.9999982118606567
disease I-Disease 0 0.029444092884659767
( O 0 5.672325187333627e-07
AD B-Disease 0 3.438430940150283e-05
) O 0 1.0753085462056333e-06
. O 0 3.0309813610074343e-06

His O 0 4.1099479858530685e-05
brain O 0 0.0004854046565014869
magnetic O 0 3.8633315853076056e-05
resonance O 0 5.7223543990403414e-05
image O 0 6.319465319393203e-05
( O 0 7.243330628625699e-07
MRI O 0 0.0005106671596877277
) O 0 1.4413482176678372e-06
showed O 0 0.00014672115503344685
abnormalities B-Disease 0 0.018678562715649605
in I-Disease 0 1.257953954336699e-07
the I-Disease 0 2.583468585726223e-07
bilateral I-Disease 0 6.922539614606649e-05
cerebellar I-Disease 0 0.30557379126548767
hemispheres I-Disease 0 0.000114568552817218
and O 0 2.1636586097883992e-05
brain O 0 0.012523125857114792
stem O 0 0.00010703309817472473
, O 0 3.745305150459899e-07
but O 0 5.34692183862262e-08
not O 0 2.601962911796818e-08
in O 0 5.9306390909341644e-08
the O 0 5.900569703953806e-07
cerebral O 0 0.08178848773241043
white O 0 7.94939769548364e-05
matter O 0 4.065373957473639e-07
, O 0 1.0431092789531249e-07
where O 0 5.957804205536377e-08
marked O 0 5.413417056843173e-07
reductions O 0 9.866505479294574e-07
of O 0 4.869783509775516e-08
the O 0 4.957622081747104e-07
cerebral O 0 0.005622091703116894
blood O 0 7.2257203100889456e-06
flow O 0 6.521662498926162e-07
and O 0 1.682538908198694e-07
oxygen O 0 6.591814099010662e-07
metabolism O 0 7.1104022936197e-07
were O 0 9.148624968702279e-08
clearly O 0 2.7324810503159824e-07
demonstrated O 0 1.399773594812359e-07
by O 0 4.828386224176029e-08
positron O 0 5.948844318481861e-06
emission O 0 2.786084223771468e-06
tomography O 0 7.21353399057989e-06
( O 0 3.901292586760974e-07
PET O 0 7.168649972300045e-06
) O 0 6.387683129105426e-07
. O 0 3.855528575513745e-06

In O 0 2.0116469386266544e-05
patients O 0 4.557398278848268e-05
2 O 0 1.8819271190295694e-06
and O 0 2.1086741242015705e-07
3 O 0 6.064630611035682e-07
, O 0 8.365264392296012e-08
the O 0 6.035234179080362e-08
autopsy O 0 0.0002162801247322932
findings O 0 7.949681275931653e-06
showed O 0 9.47212174651213e-05
massive O 0 0.015439287759363651
demyelination B-Disease 1 0.9997779726982117
of I-Disease 0 1.6759966001700377e-06
the I-Disease 0 1.227628490596544e-05
cerebral I-Disease 1 0.6019207835197449
white I-Disease 0 3.2815576560096815e-05
matter I-Disease 0 2.453263050483656e-07
with O 0 3.637545376022899e-08
sparing O 0 3.181802128437994e-07
of O 0 2.9739220863689297e-08
the O 0 2.391748239460867e-07
U O 0 0.1262446790933609
- O 0 0.031151071190834045
fibers O 0 0.00021755561465397477
, O 0 2.1977446351684193e-07
compatible O 0 1.4790213072046754e-06
with O 0 7.493455456142328e-08
the O 0 1.4349143384606577e-07
findings O 0 1.5755559843455558e-06
of O 0 4.7538460421492346e-06
childhood O 0 0.2943269610404968
ALD B-Disease 1 0.9999738931655884
. O 0 0.00012408412294462323

Oleic O 0 0.0038838123437017202
and O 0 1.9203271222067997e-05
erucic O 0 0.006058265920728445
acids O 0 1.405792545483564e-06
( O 0 2.011101827292805e-07
Lorenzos O 0 3.394549594304408e-06
Oil O 0 3.7046802958684566e-07
) O 0 9.986083071567009e-09
were O 0 1.0973844055683912e-08
administered O 0 2.293121070806592e-08
to O 0 2.5550065174684278e-08
patients O 0 4.6692932187397673e-07
1 O 0 1.2116225889258203e-07
and O 0 8.188395383967872e-08
4 O 0 6.304937301138125e-07
, O 0 5.7409632603366845e-08
but O 0 3.3845303448742925e-08
sufficient O 0 2.3962115847098175e-07
effectiveness O 0 6.161163241813483e-07
was O 0 2.9646801635863085e-07
not O 0 1.1535666999407113e-07
obtained O 0 1.6867141994225676e-06
. O 0 4.907631137029966e-06

The O 0 2.9273912787175504e-06
findings O 0 2.844629307219293e-06
in O 0 2.0459931704408518e-07
this O 0 9.225444586036247e-08
family O 0 6.878938734189433e-07
suggest O 0 5.028393843531376e-07
that O 0 7.606337959487064e-08
delGAG291 O 0 4.1714760300237685e-05
is O 0 6.998110535505475e-08
part O 0 1.0149324225494638e-07
of O 0 6.857678158667113e-08
the O 0 2.0272076994842791e-07
cause O 0 1.1105890962426201e-06
of O 0 2.956402056497609e-07
Japanese O 0 0.0003586563980206847
ALD B-Disease 1 0.999980092048645
with O 0 2.011187689276994e-06
phenotypic O 0 3.25043365592137e-05
variations O 0 3.65970772691071e-05
. O 0 1.3296696124598384e-05

Moreover O 0 0.0003006639308296144
, O 0 4.178303697699448e-06
although O 0 4.522959216046729e-07
the O 0 6.405141306231599e-08
scale O 0 4.277046173228882e-06
of O 0 3.572894868852927e-08
the O 0 3.567889450550865e-08
study O 0 1.193573240243495e-07
is O 0 7.827920711633851e-08
limited O 0 4.802063813258428e-07
, O 0 2.0465043348849576e-07
there O 0 5.006764780546291e-08
is O 0 2.7283373782438503e-08
a O 0 5.706574057739999e-08
possibility O 0 3.766229781376751e-07
that O 0 4.474035364410156e-08
PET O 0 1.9626098946901038e-05
can O 0 1.3313277236193244e-07
detect O 0 3.0114206310827285e-05
an O 0 1.4954481741824566e-07
insidious B-Disease 0 0.0034070052206516266
lesion I-Disease 0 0.1446121782064438
which O 0 2.415555684365245e-07
is O 0 1.3994130654282344e-07
undetectable O 0 2.6046152470371453e-06
by O 0 5.454772633584071e-08
computed O 0 8.828823752082826e-07
tomogram O 0 5.154184691491537e-05
( O 0 1.0250391113686419e-07
CT O 0 0.00018482260929886252
) O 0 2.522183173425674e-08
or O 0 3.418213623263e-08
MRI O 0 3.036611360585084e-06
analysis O 0 1.5526224217410345e-07
, O 0 6.944604535874532e-08
and O 0 4.765802685824383e-08
that O 0 6.602614011086416e-09
the O 0 1.5470051906163462e-08
higher O 0 7.474941554619363e-08
level O 0 2.2053402659594212e-08
of O 0 1.0498973246342302e-08
tau O 0 3.912269050942996e-07
reflects O 0 4.149249477336525e-08
the O 0 9.042519621971223e-09
process O 0 6.813999675614468e-08
of O 0 2.351458476823609e-07
neuronal B-Disease 0 0.000979757634922862
degeneration I-Disease 1 0.9792079329490662
in O 0 0.0005314056179486215
ALD B-Disease 1 0.999983549118042
. O 0 0.00017274935089517385

Lorenzos O 0 0.001624707947485149
Oil O 0 4.037890175823122e-05
should O 0 6.470527864621545e-07
be O 0 5.047804663149691e-08
given O 0 2.7948496850171978e-08
in O 0 1.9102309067875467e-08
the O 0 2.1756763501912246e-08
early O 0 4.2727552340693364e-07
stage O 0 8.270711987279356e-06
. O 0 6.341795142361661e-07
. O 0 2.8519525585579686e-06

Nonsense O 0 0.0010692465584725142
mutation O 0 3.9860649849288166e-05
in O 0 1.2863853271483094e-06
exon O 0 1.8201017155661248e-05
4 O 0 9.627439112591674e-07
of O 0 6.369955940499494e-08
human O 0 3.123344640698633e-07
complement O 0 1.2620579354916117e-06
C9 O 0 0.0006599670159630477
gene O 0 7.66106779792608e-07
is O 0 4.9727503892427194e-08
the O 0 4.4948027522195844e-08
major O 0 2.704231064853957e-06
cause O 0 1.8837838524632389e-06
of O 0 5.959827262813633e-07
Japanese O 0 0.0001414978178218007
complement B-Disease 0 0.002022352535277605
C9 I-Disease 1 0.9995908141136169
deficiency I-Disease 1 0.9499175548553467
. O 0 2.9969101888127625e-05

Deficiency B-Disease 1 0.9940032362937927
of I-Disease 0 2.8559481961565325e-06
the I-Disease 0 4.856867121816322e-07
ninth I-Disease 0 6.4564028434688225e-06
component I-Disease 0 1.379168907078565e-06
of I-Disease 0 5.7635972439129546e-08
human I-Disease 0 2.031899413168503e-07
complement I-Disease 0 8.365549888367241e-07
( O 0 3.1430599278792215e-07
C9 O 0 0.0007550917798653245
) O 0 8.182197319683837e-08
is O 0 2.567311874202005e-08
the O 0 2.5973960759984038e-08
most O 0 1.5581879608816962e-07
common O 0 9.11917959456332e-06
complement B-Disease 1 0.993545413017273
deficiency I-Disease 1 0.9999126195907593
in O 0 3.1683848078500887e-07
Japan O 0 3.212063120372477e-06
but O 0 3.9170961940726556e-07
is O 0 1.0781091930311959e-07
rare O 0 4.430662272625341e-07
in O 0 5.8274785885714664e-08
other O 0 3.5219802185793014e-08
countries O 0 1.72136026321823e-07
. O 0 2.7369169401936233e-06

We O 0 6.044801011739764e-06
studied O 0 1.6108589306895738e-06
the O 0 1.240030087501509e-07
molecular O 0 1.4582910807803273e-06
basis O 0 6.83037512771989e-07
of O 0 9.836048775468953e-06
C9 B-Disease 1 0.999953031539917
deficiency I-Disease 1 0.9639885425567627
in O 0 5.036197308072587e-07
four O 0 6.397315814865578e-07
Japanese O 0 8.531344974471722e-06
C9 B-Disease 1 0.6540494561195374
- I-Disease 1 0.966518223285675
deficient I-Disease 1 0.9410299062728882
patients O 0 0.0002713586436584592
who O 0 7.090418421284994e-06
had O 0 8.796355541562662e-05
suffered O 1 0.6416283249855042
from O 0 0.0002568352210801095
meningococcal B-Disease 1 0.999983549118042
meningitis I-Disease 1 0.999760091304779
. O 0 7.785677735228091e-05

Direct O 0 1.1543997970875353e-05
sequencing O 0 6.2320568758877926e-06
of O 0 5.595707079919521e-07
amplified O 0 8.186510058294516e-06
C9 O 0 0.0001028342594509013
cDNA O 0 8.70143594511319e-06
and O 0 1.6331863434970728e-06
DNA O 0 1.1594509487622418e-05
revealed O 0 5.355032953957561e-06
a O 0 2.859445373815106e-07
nonsense O 0 2.665580950633739e-06
substitution O 0 4.6780382945144083e-07
( O 0 1.6176404926682153e-07
CGA O 0 4.093200004717801e-06
- O 0 0.0001119328080676496
- O 0 0.00027070980286225677
> O 0 1.0214406756858807e-05
TGA O 0 3.294586349511519e-05
) O 0 2.0572661796336433e-08
at O 0 1.1394463150793399e-08
codon O 0 5.339176567531467e-08
95 O 0 4.008923681908527e-08
in O 0 8.720123290117954e-09
exon O 0 5.545714998334006e-07
4 O 0 1.1129411348065332e-07
in O 0 1.3088283346007756e-08
the O 0 2.4275221832681382e-08
four O 0 4.7652301304879074e-07
C9 B-Disease 0 0.3741190433502197
- I-Disease 0 0.19203130900859833
deficient I-Disease 0 0.002008728915825486
individuals O 0 1.0690620229070191e-06
. O 0 3.0407379654207034e-06

An O 0 4.000497483502841e-06
allele O 0 2.0273158952477388e-05
- O 0 2.0034738554386422e-05
specific O 0 4.893517484561016e-07
polymerase O 0 1.4262729564507026e-05
chain O 0 7.630234904354438e-06
reaction O 0 1.8362739240274095e-07
system O 0 1.53292191384935e-07
designed O 0 8.533669415555778e-07
to O 0 3.3899183904395613e-08
detect O 0 3.731023980435566e-06
exclusively O 0 3.532482040213836e-08
only O 0 6.345119984985104e-09
one O 0 7.312722427599283e-09
of O 0 6.589278456203829e-09
the O 0 2.211490190973109e-08
normal O 0 1.8754293762413e-07
and O 0 7.195151141559109e-08
mutant O 0 8.79334606906923e-07
alleles O 0 2.691844827040768e-07
indicated O 0 5.79886091145454e-07
that O 0 8.849576182967667e-09
all O 0 7.429311832396479e-09
the O 0 3.594686504015954e-08
four O 0 9.979495416700956e-07
patients O 0 2.561253040767042e-06
were O 0 1.4807541504069377e-07
homozygous O 0 2.1393250904111483e-07
for O 0 2.611653648898482e-08
the O 0 2.5633191569340852e-08
mutation O 0 8.47547028115514e-08
in O 0 2.2623067863491997e-08
exon O 0 1.8924268943010247e-06
4 O 0 6.780317107768496e-07
and O 0 9.903764208729626e-08
that O 0 1.2031486029684402e-08
the O 0 3.211004084846536e-08
parents O 0 1.2456946762995358e-07
of O 0 1.2044647235143202e-07
patient O 0 9.01226758287521e-06
2 O 0 1.4016920886206208e-06
were O 0 1.7120053144026315e-06
heterozygous O 0 1.4405304682441056e-05
. O 0 5.657680503645679e-06

The O 0 1.1488821655802894e-05
common O 0 3.7318743579817237e-06
mutation O 0 1.579898253112333e-06
at O 0 1.610317070799283e-07
codon O 0 2.0551372870158957e-07
95 O 0 1.9597432299178763e-07
in O 0 4.8661068063893254e-08
exon O 0 2.1587345599982655e-06
4 O 0 5.071265150036197e-07
might O 0 8.911234061770301e-08
be O 0 9.249985666315297e-09
responsible O 0 1.694050979494932e-07
for O 0 7.913021704553103e-08
most O 0 4.546571972241509e-07
Japanese O 0 0.0003922582254745066
C9 B-Disease 1 0.9999146461486816
deficiency I-Disease 1 0.8168613910675049
. O 0 1.3674343790626153e-06
. O 0 5.397310360422125e-06

BRCA1 O 0 0.0011697910958901048
required O 0 3.6533538150251843e-06
for O 0 5.892067633794795e-07
transcription O 0 6.856212621642044e-06
- O 0 0.0002794554166030139
coupled O 0 3.834097515209578e-05
repair O 0 0.0006203149678185582
of O 0 1.7654741668593488e-06
oxidative O 0 0.012281354516744614
DNA O 0 0.010836143977940083
damage O 0 0.010441488586366177
. O 0 2.642793879203964e-05

The O 0 0.00012493431859184057
breast B-Disease 1 0.9992477893829346
and I-Disease 1 0.9965831637382507
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
susceptibility O 0 0.1251189410686493
gene O 0 7.641874253749847e-05
BRCA1 O 0 0.00011571966024348512
encodes O 0 3.2742850635258947e-06
a O 0 4.334070581535343e-06
zinc O 0 0.0007187623414210975
finger O 0 2.9705784982070327e-05
protein O 0 6.786314088458312e-07
of O 0 2.63414165146969e-07
unknown O 0 2.0460061023186427e-06
function O 0 1.142963583333767e-06
. O 0 2.384565505053615e-06

Association O 0 4.1163970308844e-05
of O 0 7.80335199124238e-07
the O 0 3.723473867012217e-07
BRCA1 O 0 3.8404577935580164e-05
protein O 0 5.063078560851864e-07
with O 0 8.858851430204595e-08
the O 0 6.68337705178601e-08
DNA O 0 6.755648882972309e-06
repair O 0 0.0005386223783716559
protein O 0 1.945161557159736e-06
Rad51 O 0 0.00012779219832737
and O 0 1.0109698678206769e-07
changes O 0 4.397318420501506e-08
in O 0 8.619583269364739e-09
the O 0 8.708986420913334e-09
phosphorylation O 0 8.21284302787717e-08
and O 0 6.80773837302695e-08
cellular O 0 1.9212056940887123e-06
localization O 0 3.048592986942822e-07
of O 0 1.1854945469735867e-08
the O 0 2.1476813216736446e-08
protein O 0 7.076200603250982e-08
after O 0 2.0889527263534546e-07
exposure O 0 5.193031711314688e-07
to O 0 3.203981080446283e-08
DNA O 0 9.632906767365057e-06
- O 0 0.0005100205889903009
damaging O 0 5.064790457254276e-05
agents O 0 4.459415947621892e-07
are O 0 3.086255517814607e-08
consistent O 0 1.7113201522533927e-07
with O 0 3.958086480793099e-08
a O 0 1.0230663605170776e-07
role O 0 9.902121433924549e-08
for O 0 1.2402182392179384e-07
BRCA1 O 0 1.994748345168773e-05
in O 0 6.237189609237248e-07
DNA O 0 0.00017082472913898528
repair O 0 0.10900646448135376
. O 0 4.642788917408325e-05

Here O 0 2.0625073375413194e-05
, O 0 7.381925115623744e-07
it O 0 7.435396298660635e-08
is O 0 3.8812117963971104e-08
shown O 0 7.442348959330047e-08
that O 0 3.863249986579831e-08
mouse O 0 8.395669283345342e-06
embryonic O 0 3.671284866868518e-05
stem O 0 0.0001628579484531656
cells O 0 4.598101077135652e-05
deficient B-Disease 0 0.0006759066018275917
in I-Disease 0 2.574528252807795e-07
BRCA1 I-Disease 0 4.636293670046143e-05
are O 0 1.5710081413544685e-07
defective O 0 9.422493167221546e-05
in O 0 9.454636540340289e-08
the O 0 6.000696117780535e-08
ability O 0 1.2857532283305773e-07
to O 0 1.672756333448433e-08
carry O 0 7.609080654447098e-08
out O 0 4.964410749153103e-08
transcription O 0 3.1916883358462655e-07
- O 0 1.878428338386584e-05
coupled O 0 6.073322765587363e-06
repair O 0 0.00028931640554219484
of O 0 1.4793936031765043e-07
oxidative O 0 0.00010092087904922664
DNA O 0 0.0005166478804312646
damage O 0 0.006404710002243519
, O 0 3.198266824711027e-07
and O 0 1.0802230576700822e-07
are O 0 5.2813732054346474e-08
hypersensitive O 0 7.8706128988415e-05
to O 0 3.5995927305521036e-07
ionizing O 0 0.00012450083158910275
radiation O 0 2.3859029170125723e-05
and O 0 3.185135710737086e-07
hydrogen O 0 1.0715080861700699e-05
peroxide O 0 0.00034690601751208305
. O 0 4.1506773413857445e-06

These O 0 4.5437473090714775e-06
results O 0 4.618320417648647e-06
suggest O 0 1.518462113381247e-06
that O 0 1.4599454800645617e-07
BRCA1 O 0 1.25977039715508e-05
participates O 0 6.794162459300424e-07
, O 0 2.2794073117893277e-07
directly O 0 8.003198104233888e-08
or O 0 1.0295811136984412e-07
indirectly O 0 2.4257963104901137e-07
, O 0 1.9918116933581587e-08
in O 0 1.5237070272178244e-08
transcription O 0 6.509756644845766e-07
- O 0 0.00011570663627935573
coupled O 0 1.4943839232728351e-05
repair O 0 0.0004055614408571273
of O 0 4.945632099406794e-07
oxidative O 0 0.0011080006370320916
DNA O 0 0.0007801804458722472
damage O 0 0.0030655465088784695
. O 0 3.142519062748761e-06
. O 0 1.5629992049071006e-05

Truncation O 0 0.0009274387848563492
mutations O 0 0.00016520651115570217
in O 0 1.63412107667682e-06
the O 0 8.125422255034209e-07
transactivation O 0 0.00013905118976254016
region O 0 3.690712219395209e-06
of O 0 4.4850656877315487e-07
PAX6 O 0 0.010063146241009235
result O 0 1.6039304000514676e-06
in O 0 4.2149770251853624e-07
dominant O 0 1.5999328752513975e-05
- O 0 0.0002152001834474504
negative O 0 9.313255759479944e-06
mutants O 0 6.126367952674627e-05
. O 0 1.0752618436526973e-05

PAX6 O 0 0.07865512371063232
is O 0 6.630660209339112e-06
a O 0 1.2180786370663554e-06
transcription O 0 1.7463308950027567e-06
factor O 0 6.677070132354856e-07
with O 0 1.2584291653183755e-07
two O 0 1.4786319013637694e-07
DNA O 0 2.2048743630875833e-05
- O 0 0.00014560145791620016
binding O 0 2.412775302218506e-06
domains O 0 9.785653674043715e-07
( O 0 1.1186063630930221e-07
paired O 0 1.0497091125216684e-06
box O 0 7.792266842443496e-06
and O 0 4.082601492427784e-07
homeobox O 0 8.626511771581136e-06
) O 0 2.2070949512453808e-08
and O 0 1.1579288639040897e-08
a O 0 4.746769732832945e-08
proline O 0 2.6986017473973334e-06
- O 0 7.235456905618776e-06
serine O 0 5.866450010216795e-06
- O 0 1.621435694687534e-05
threonine O 0 1.1422333045629784e-05
( O 0 1.6701045524314395e-07
PST O 0 3.388626282685436e-05
) O 0 1.5534088504409738e-07
- O 0 6.144050985312788e-06
rich O 0 1.4805552837060532e-06
transactivation O 0 2.0070079699507914e-05
domain O 0 2.6492928100196877e-06
. O 0 2.2636979792878265e-06

PAX6 O 0 0.012569823302328587
regulates O 0 0.00039655345608480275
eye O 0 0.00041876116301864386
development O 0 4.775320576300146e-06
in O 0 7.667397312616231e-07
animals O 0 5.531538818104309e-07
ranging O 0 4.603027264238335e-06
from O 0 1.7368078886192961e-07
jellyfish O 0 1.2299806257942691e-06
to O 0 4.2054850268868904e-08
Drosophila O 0 5.961384772490419e-07
to O 0 3.1301314606935193e-07
humans O 0 1.061195803231385e-06
. O 0 2.3156019324233057e-06

Heterozygous O 0 0.0006072213873267174
mutations O 0 0.0001063992312992923
in O 0 6.86532018789876e-07
the O 0 2.344955021271744e-07
human O 0 8.982527219814074e-07
PAX6 O 0 0.0014316883170977235
gene O 0 1.8545359807831119e-06
result O 0 3.896202542819083e-07
in O 0 5.5641837803932503e-08
various O 0 9.540575263145001e-08
phenotypes O 0 1.0035529157903511e-05
, O 0 2.7859039164468413e-07
including O 0 5.473821602208773e-06
aniridia B-Disease 1 0.9999771118164062
, O 0 0.004252100363373756
Peters B-Disease 1 0.9999063014984131
anomaly I-Disease 1 0.9998260140419006
, O 0 0.0002772149455267936
autosomal B-Disease 0 0.003904176177456975
dominant I-Disease 0 0.0006412932416424155
keratitis I-Disease 1 0.892265260219574
, O 0 3.3629039535298944e-05
and O 0 0.00018019233539234847
familial B-Disease 1 0.9944921731948853
foveal I-Disease 1 0.9997512698173523
dysplasia I-Disease 1 0.9999150037765503
. O 0 0.00038427431718446314

It O 0 6.804934400861384e-06
is O 0 1.095485572477628e-06
believed O 0 7.413340199491358e-07
that O 0 2.789970920957785e-08
the O 0 5.0497018122541704e-08
mutated O 0 5.242172846919857e-07
allele O 0 2.4441507662231743e-07
of O 0 7.555916425872056e-08
PAX6 O 0 0.00043890453525818884
produces O 0 6.042358791091829e-07
an O 0 3.491127387178494e-08
inactive O 0 4.2376609599159565e-07
protein O 0 1.706489456410054e-07
and O 0 4.105551454358647e-07
aniridia B-Disease 1 0.9950724244117737
is O 0 6.640086667175638e-07
caused O 0 4.6141208258632105e-06
due O 0 1.1241003221584833e-06
to O 0 1.0304470379196573e-06
genetic O 0 3.9963411836652085e-05
haploinsufficiency O 0 0.0021636392921209335
. O 0 2.026596848736517e-05

However O 0 1.685072129475884e-05
, O 0 1.0671958534658188e-06
several O 0 1.2440408170277806e-07
truncation O 0 2.441019387333654e-05
mutations O 0 7.3221567618020345e-06
have O 0 1.9652830474115035e-07
been O 0 7.784237254782056e-08
found O 0 1.5453572643764346e-07
to O 0 3.719980767868947e-08
occur O 0 5.353942711394666e-08
in O 0 1.8997520001562407e-08
the O 0 7.513707345196963e-08
C O 0 0.0002060564875137061
- O 0 8.236290886998177e-05
terminal O 0 6.506195859401487e-06
half O 0 5.0805102347339925e-08
of O 0 4.3493056267607244e-08
PAX6 O 0 0.00018518265278544277
in O 0 1.2545124263851903e-06
patients O 0 7.852810995245818e-06
with O 0 5.972094072603795e-07
Aniridia B-Disease 1 0.9949163198471069
resulting O 0 2.193018417528947e-06
in O 0 3.780587576329708e-08
mutant O 0 5.458810505842848e-07
proteins O 0 1.6003680158860334e-08
that O 0 7.4004180561360045e-09
retain O 0 8.277398677591918e-08
the O 0 1.711076080823659e-08
DNA O 0 4.622003871190827e-06
- O 0 1.0806083082570694e-05
binding O 0 3.355989690589922e-07
domains O 0 1.6784825618287869e-07
but O 0 7.23003878988493e-08
have O 0 5.4203503907501727e-08
lost O 0 5.438690209302877e-07
most O 0 7.150875447337057e-09
of O 0 2.647453456461335e-08
the O 0 2.1092573376790824e-07
transactivation O 0 8.884661656338722e-05
domain O 0 3.764322627830552e-06
. O 0 3.2019579521147534e-06

It O 0 8.276267180917785e-06
is O 0 1.2177952157799155e-06
not O 0 1.2928282444590877e-07
clear O 0 3.704185473907273e-07
whether O 0 1.3166156520583172e-07
such O 0 1.0352641766075976e-07
mutants O 0 1.4041462236491498e-05
really O 0 3.948385710828006e-06
behave O 0 1.0928215488092974e-06
as O 0 3.845371310262635e-08
loss O 0 4.7664389057899825e-06
- O 0 8.499690920871217e-06
of O 0 8.844990162515387e-08
- O 0 5.0409096729708835e-05
function O 0 1.6290069027036225e-07
mutants O 0 1.0090566320286598e-06
as O 0 4.892220317742613e-08
predicted O 0 2.5434258077439154e-06
by O 0 4.517333707099169e-07
haploinsufficiency O 0 0.00033549690851941705
. O 0 6.100292011979036e-06

Contrary O 0 5.299991607898846e-05
to O 0 6.003598400639021e-07
this O 0 1.0003816441894742e-07
theory O 0 1.616070761656374e-07
, O 0 7.750576713760893e-08
our O 0 3.3861830672776705e-08
data O 0 4.3917947323279805e-07
showed O 0 1.1920335509785218e-06
that O 0 8.751281477259454e-09
these O 0 1.2487808120908994e-08
mutants O 0 1.0989962220264715e-06
are O 0 4.449585588872651e-08
dominant O 0 9.475087381360936e-07
- O 0 9.537329788145144e-06
negative O 0 1.797305202444477e-07
in O 0 2.675821697550873e-08
transient O 0 1.4842423752270406e-06
transfection O 0 4.9884030886460096e-05
assays O 0 2.418378016955103e-06
when O 0 8.168989751311528e-08
they O 0 1.8162825909939784e-08
are O 0 1.2368856161515396e-08
coexpressed O 0 9.829982445808128e-06
with O 0 1.5272048869974242e-07
wild O 0 1.3264376320876181e-05
- O 0 0.0015410350169986486
type O 0 0.00021245135576464236
PAX6 O 0 0.00215867068618536
. O 0 1.6300822608172894e-05

We O 0 1.3511343240679707e-05
found O 0 1.3009456552026677e-06
that O 0 4.679180420907869e-08
the O 0 7.868262485999367e-08
dominant O 0 1.1354389926054864e-06
- O 0 3.428293712204322e-05
negative O 0 9.58117539084924e-07
effects O 0 9.493856509834586e-07
result O 0 9.816501744808193e-08
from O 0 1.7992597634020058e-08
the O 0 1.817936023940092e-08
enhanced O 0 9.421556228517147e-07
DNA O 0 2.5448816813877784e-06
binding O 0 3.9478220514865825e-07
ability O 0 1.0722605026103338e-07
of O 0 6.347398340267318e-08
these O 0 2.2161481183502474e-07
mutants O 0 2.154007052013185e-05
. O 0 6.1235491557454225e-06

Kinetic O 0 8.115755917970091e-05
studies O 0 5.448322099255165e-06
of O 0 4.928531325276708e-07
binding O 0 3.364819804119179e-06
and O 0 7.377202564384788e-07
dissociation O 0 1.527136737422552e-05
revealed O 0 3.0024534680705983e-06
that O 0 1.3401500353893425e-08
various O 0 1.74503362870837e-08
truncation O 0 2.3092791252565803e-06
mutants O 0 4.740332769870292e-06
have O 0 4.96671219707423e-08
3 O 0 1.817496126932383e-07
- O 0 5.197245627641678e-06
5 O 0 1.4752359334124776e-07
- O 0 4.154178441240219e-06
fold O 0 2.965867622606311e-07
higher O 0 2.8711209409948424e-08
affinity O 0 2.072428806343396e-08
to O 0 2.357487760562549e-09
various O 0 4.373093442922027e-09
DNA O 0 3.6393919344845926e-07
- O 0 1.4647445141235949e-06
binding O 0 8.675599616481122e-08
sites O 0 1.0515330473026552e-07
when O 0 2.702549650734909e-08
compared O 0 2.2717358660884202e-07
with O 0 2.531233889158102e-08
the O 0 7.52288471517204e-08
wild O 0 4.40174244431546e-06
- O 0 0.0005904340068809688
type O 0 0.00011706415534717962
PAX6 O 0 0.0012905881740152836
. O 0 8.922218512452673e-06

These O 0 3.6430972158996155e-06
results O 0 2.785061496979324e-06
provide O 0 4.852792585552379e-07
a O 0 2.2047437653327506e-07
new O 0 1.5691769306158676e-07
insight O 0 3.5766319683716574e-07
into O 0 3.948668592101967e-08
the O 0 1.8414185731785437e-08
role O 0 4.852667245813791e-08
of O 0 1.1841029845527373e-07
mutant O 0 1.0287874829373322e-05
PAX6 O 0 0.0010395314311608672
in O 0 1.1059406688218587e-06
causing O 0 7.505091343773529e-05
aniridia B-Disease 1 0.9922555685043335
. O 0 3.941651357308729e-06
. O 0 7.607876796100754e-06

Reversal O 0 0.010130096226930618
of O 0 0.0011739246547222137
severe O 1 0.999941349029541
hypertrophic B-Disease 1 0.9999860525131226
cardiomyopathy I-Disease 1 0.999995231628418
and O 0 3.706194183905609e-05
excellent O 0 8.368646376766264e-05
neuropsychologic O 0 0.011944395489990711
outcome O 0 3.64401530532632e-05
in O 0 4.94032860842708e-07
very B-Disease 0 1.3641493978866492e-06
- I-Disease 0 0.00040545471711084247
long I-Disease 0 1.792544026102405e-05
- I-Disease 0 0.00032102185650728643
chain I-Disease 0 3.719872984220274e-05
acyl I-Disease 0 7.153113529057009e-06
- I-Disease 0 4.48643731942866e-05
coenzyme I-Disease 0 2.392321221122984e-05
A I-Disease 0 4.470392013899982e-05
dehydrogenase I-Disease 0 0.1516895741224289
deficiency I-Disease 0 0.05663846805691719
. O 0 1.0630864380800631e-05

Very B-Disease 0 6.701640813844278e-05
- I-Disease 0 0.0008558524423278868
long I-Disease 0 5.770137067884207e-05
- I-Disease 0 0.0005039596580900252
chain I-Disease 0 3.882925375364721e-05
acyl I-Disease 0 4.161847300565569e-06
- I-Disease 0 1.6382111425627954e-05
coenzyme I-Disease 0 1.8947022226711852e-06
A I-Disease 0 3.826648651283904e-07
dehydrogenase I-Disease 0 1.1928082130907569e-05
( I-Disease 0 7.979859901752206e-07
VLCAD I-Disease 0 0.38951125741004944
) I-Disease 0 3.178190308972262e-05
deficiency I-Disease 0 0.06280028820037842
is O 0 3.5827289934786677e-07
a O 0 4.223171345074661e-06
disorder O 0 0.0006028575589880347
of O 0 2.635528630889894e-07
fatty O 0 2.6104537028004415e-05
acid O 0 7.693516863582772e-07
beta O 0 1.520593855275365e-07
oxidation O 0 6.379877959261648e-08
that O 0 1.0262262151172763e-08
reportedly O 0 2.9192068495831336e-07
has O 0 2.249214325900084e-08
high O 0 5.328596444087452e-07
rates O 0 3.3830269785539713e-07
of O 0 1.4673237558326946e-07
morbidity O 0 0.0022474387660622597
and O 0 1.0998540346918162e-05
mortality O 0 0.0004006083763670176
. O 0 2.0127523384871893e-05

We O 0 1.2477836207835935e-05
describe O 0 5.712128313462017e-06
the O 0 1.998113674517299e-07
outcome O 0 7.812988087607664e-07
of O 0 6.469133495556889e-08
a O 0 1.7170400212762615e-07
5 O 0 9.315175475421711e-07
- O 0 2.6840038117370568e-05
year O 0 1.281233380723279e-06
- O 0 0.0007313016103580594
old O 0 0.0001262122968910262
girl O 0 0.001157012302428484
with O 0 0.00042703893268480897
VLCAD B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999973773956299
who O 0 3.7984916616551345e-06
was O 0 3.1554938573208346e-07
first O 0 1.0274251138753243e-07
seen O 0 4.6643884843433625e-07
at O 0 8.344818525074515e-08
5 O 0 4.536627429274631e-08
months O 0 8.3580872001221e-08
of O 0 4.271272047162711e-08
age O 0 5.542698545468738e-06
with O 0 6.880879664095119e-05
severe O 1 0.9992889165878296
hypertrophic B-Disease 1 0.9999793767929077
cardiomyopathy I-Disease 1 0.9999988079071045
, O 0 0.0728134885430336
hepatomegaly B-Disease 1 0.9999995231628418
, O 0 0.15789078176021576
encephalopathy B-Disease 1 0.8801381587982178
, O 0 3.49857486980909e-06
and O 0 1.849532600317616e-05
hypotonia B-Disease 1 0.6328326463699341
. O 0 3.495235068839975e-05

Biochemical O 0 0.0012436966644600034
studies O 0 0.0002846118004526943
indicated O 1 0.9900964498519897
VLCAD B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999995231628418
caused O 0 0.0019134077010676265
by O 0 1.553645802232495e-06
a O 0 2.5360143354191678e-06
stable O 0 6.69142318656668e-05
yet O 0 5.759718987974338e-06
inactive O 0 1.4908850062056445e-05
enzyme O 0 4.899297437077621e-06
. O 0 2.134714122803416e-06

Molecular O 0 0.00029507550061680377
genetic O 0 4.134130722377449e-05
analysis O 0 1.7422222526874975e-06
of O 0 5.491397701007372e-07
her O 0 5.693467755918391e-06
VLCAD O 0 0.009462382644414902
gene O 0 2.952574277514941e-06
revealed O 0 5.561340913118329e-06
a O 0 7.966355610733444e-07
T1372C O 0 0.00011629376967903227
( O 0 3.9988285038816684e-07
F458L O 0 2.6286197680747136e-05
) O 0 1.8836962567547744e-07
missense O 0 1.5307003195630386e-05
mutation O 0 9.941320513462415e-07
and O 0 2.889399013383809e-07
a O 0 2.1898124487051973e-06
1668 O 0 0.002142503159120679
ACAG O 0 0.025267815217375755
1669 O 0 0.00047504689428023994
splice O 0 0.0001400279434164986
site O 0 4.585472561302595e-05
mutation O 0 1.4981537788116839e-05
. O 0 6.957955065445276e-06

After O 0 2.699758260860108e-05
initial O 0 5.840644735144451e-05
treatment O 0 4.753880784846842e-05
with O 0 8.491730909554462e-07
intravenous O 0 1.4461477803706657e-05
glucose O 0 0.00017285184003412724
and O 0 1.805671900001471e-06
carnitine O 0 0.0008405435946770012
, O 0 2.4860619873834366e-07
the O 0 1.7162984988772223e-07
patient O 0 6.503528311441187e-06
has O 0 7.97005128561068e-08
thrived O 0 1.7085345689338283e-06
on O 0 9.873172501784211e-08
a O 0 1.5894266880422947e-07
low O 0 1.2563139534904622e-05
- O 0 3.721292523550801e-05
fat O 0 1.6794414250398404e-06
diet O 0 3.8818492953396344e-07
supplemented O 0 1.2140839089624933e-07
with O 0 4.8258815610324746e-08
medium O 0 2.769178763628588e-06
- O 0 1.042271287587937e-05
chain O 0 1.6238429907389218e-06
triglyceride O 0 9.688189948064974e-07
oil O 0 5.065986101726594e-07
and O 0 1.0101102532189543e-07
carnitine O 0 1.4075824765313882e-05
and O 0 1.7445584887809673e-07
avoidance O 0 5.006286755815381e-06
of O 0 5.105037530483969e-07
fasting O 0 2.6596755560603924e-05
. O 0 5.9685230553441215e-06

Her O 0 0.0005308648105710745
ventricular O 1 0.7774986028671265
hypertrophy O 0 0.2253989428281784
resolved O 0 0.00031410896917805076
significantly O 0 6.25318580205203e-06
over O 0 5.520892614185868e-07
1 O 0 4.460862044197711e-07
year O 0 3.8644077449134784e-07
, O 0 1.625338370558893e-07
and O 0 4.807709501619684e-07
cognitively O 0 0.0007463588262908161
, O 0 3.733622122581437e-07
she O 0 1.201287176400001e-07
is O 0 2.334026483197249e-08
in O 0 1.6752018439092353e-08
the O 0 3.2071724831439496e-08
superior O 0 9.063655852514785e-06
range O 0 1.4362425417857594e-06
for O 0 2.5696641614558757e-07
age O 0 5.285764927975833e-06
. O 0 5.904796580580296e-06

Clinical O 0 0.0008939148392528296
recognition O 0 6.872779340483248e-05
of O 0 0.0026409307029098272
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999994039535522
is O 0 5.796433924842859e-06
important O 0 1.1367716297172592e-06
because O 0 4.951436949340859e-07
it O 0 3.0880865864446605e-08
is O 0 1.2738650134735963e-08
one O 0 3.945173521202605e-09
of O 0 8.073723023471757e-09
the O 0 6.053899426206044e-08
few O 0 7.372342452072189e-07
directly O 0 1.1478834494482726e-05
treatable O 1 0.9475653171539307
causes O 0 1.667948890826665e-05
of O 0 4.930862269247882e-05
cardiomyopathy B-Disease 1 0.9999891519546509
in O 0 5.375274213292869e-06
children O 0 4.241621354594827e-06
. O 0 1.1751205875043524e-06
. O 0 7.470111995644402e-06

Cloning O 0 8.016180800041184e-05
of O 0 1.0403707619843772e-06
a O 0 1.2177453072581557e-06
novel O 0 9.001839771372033e-07
member O 0 9.582776527850001e-08
of O 0 1.5379438167428816e-08
the O 0 4.550631871325095e-08
low O 0 1.0726858818088658e-05
- O 0 4.2740211938507855e-05
density O 0 2.114339076797478e-05
lipoprotein O 0 0.1514824777841568
receptor O 0 2.6710224119597115e-05
family O 0 5.702543148800032e-06
. O 0 4.961238573741866e-06

A O 0 2.5592198653612286e-05
gene O 0 1.3076391041977331e-05
encoding O 0 3.5323314477864187e-06
a O 0 1.0659294957804377e-06
novel O 0 2.494041154932347e-06
transmembrane O 0 2.3147134925238788e-05
protein O 0 7.665364591957768e-07
was O 0 9.277841286348121e-07
identified O 0 3.512223543111759e-07
by O 0 3.955859995130595e-08
DNA O 0 2.7559298132473486e-07
sequence O 0 4.89752309817959e-08
analysis O 0 3.888443700361677e-08
within O 0 1.3253708353033744e-08
the O 0 2.3250468217383968e-08
insulin B-Disease 0 4.044013621751219e-05
- I-Disease 1 0.7358415126800537
dependent I-Disease 1 0.9490334391593933
diabetes I-Disease 1 0.9999997615814209
mellitus I-Disease 1 0.9999988079071045
( O 0 2.3669817892368883e-05
IDDM B-Disease 0 0.03440817818045616
) O 0 1.015150814964727e-06
locus O 0 1.5867983165662736e-05
IDDM4 O 0 0.0004048703412991017
on O 0 3.250331701565301e-06
chromosome O 0 0.00013936484174337238
11q13 O 0 0.0005819374928250909
. O 0 1.1010356502083596e-05

Based O 0 3.427264164201915e-05
on O 0 2.152099341401481e-06
its O 0 5.719158480133046e-07
chromosomal O 0 0.0023579762782901525
position O 0 1.2460682228265796e-06
, O 0 5.963636340311496e-08
this O 0 1.2389421932823552e-08
gene O 0 1.1137566247043651e-07
is O 0 2.5034623263309186e-08
a O 0 4.5729063202770703e-08
candidate O 0 7.209189902823709e-07
for O 0 1.9393291950109415e-07
conferring O 0 3.487480353214778e-05
susceptibility O 0 0.0031038031447678804
to O 0 6.148256943561137e-05
diabetes B-Disease 1 0.9965165853500366
. O 0 4.9268674047198147e-05

The O 0 4.5363776735030115e-06
gene O 0 6.4868231675063726e-06
, O 0 8.791032541921595e-07
termed O 0 7.1866043072077446e-06
low O 0 1.2524955309345387e-05
- O 0 1.4516816918330733e-05
density O 0 3.353492047608597e-06
lipoprotein O 0 0.0037152643781155348
receptor O 0 1.1616970141403726e-06
related O 0 3.5221489724790445e-07
protein O 0 1.4533995340570982e-07
5 O 0 1.4193051356414799e-07
( O 0 3.563258132999181e-08
LRP5 O 0 3.233377356082201e-05
) O 0 1.534474591835533e-08
, O 0 5.449019457870463e-09
encodes O 0 1.1755601825313988e-08
a O 0 1.1989770065667926e-08
protein O 0 2.473022320259588e-08
of O 0 1.2861452347578961e-08
1615 O 0 1.9087688087893184e-06
amino O 0 1.4154534433430399e-08
acids O 0 5.12713693723299e-09
that O 0 9.159161762362089e-10
contains O 0 3.6757072940929447e-09
conserved O 0 2.0352926455302622e-08
modules O 0 1.1165982982674905e-07
which O 0 1.7446474487314845e-08
are O 0 3.431014361510165e-09
characteristic O 0 1.909385893839044e-08
of O 0 3.738108933504236e-09
the O 0 1.524916370954088e-08
low O 0 2.252835201943526e-06
- O 0 2.4297596610267647e-05
density O 0 1.4808651940256823e-05
lipoprotein O 0 0.03123142383992672
( O 0 9.602241561879055e-07
LDL O 0 7.574886694783345e-05
) O 0 2.204318860776766e-07
receptor O 0 2.7671460429701256e-06
family O 0 1.930541429828736e-06
. O 0 3.1226347800838994e-06

These O 0 4.806599918083521e-06
modules O 0 1.569302003190387e-05
include O 0 1.3751396181760356e-06
a O 0 5.804797638120363e-07
putative O 0 5.408037850429537e-06
signal O 0 5.254706252344477e-07
peptide O 0 1.3608874382953218e-07
for O 0 1.023487516960131e-08
protein O 0 3.062290687694258e-08
export O 0 6.390693130242653e-08
, O 0 1.1464266869154471e-08
four O 0 3.068336340561473e-08
epidermal O 0 6.21663502897718e-06
growth O 0 1.5259572592185577e-06
factor O 0 1.094625076802913e-06
( O 0 2.0220294061346067e-07
EGF O 0 1.2742978469759692e-05
) O 0 8.43809715433963e-08
repeats O 0 3.8419773318310035e-07
with O 0 7.545057201241434e-08
associated O 0 2.792431246234628e-07
spacer O 0 8.205653102777433e-06
domains O 0 6.999164270382607e-07
, O 0 5.779041600817436e-08
three O 0 9.589084726258079e-08
LDL O 0 0.00013021670747548342
- O 0 3.0842318665236235e-05
receptor O 0 1.1578291605474078e-06
( O 0 6.942273955701239e-08
LDLR O 0 2.969326487800572e-05
) O 0 2.1779476000460818e-08
repeats O 0 1.1803597743664795e-07
, O 0 2.6322572566073177e-08
a O 0 3.3907589624959655e-08
single O 0 1.3174634716506262e-07
transmembrane O 0 1.0995319144058158e-06
spanning O 0 4.935238280268095e-07
domain O 0 1.5952943499542016e-07
, O 0 6.03175891455976e-08
and O 0 5.877184605651564e-08
a O 0 3.865513349410321e-07
cytoplasmic O 0 1.3391963875619695e-05
domain O 0 4.584553153108573e-06
. O 0 3.4039633192151086e-06

The O 0 1.9789213183685206e-06
encoded O 0 1.650495960348053e-06
protein O 0 7.105575718924229e-07
has O 0 4.731800373747319e-08
a O 0 2.270377308377647e-08
unique O 0 3.2611968237006295e-08
organization O 0 6.035303101725731e-08
of O 0 4.916541485044945e-08
EGF O 0 2.945557025668677e-05
and O 0 4.1101586134573154e-07
LDLR O 0 0.0013520288048312068
repeats O 0 1.0049750471807783e-06
; O 0 1.342932023362664e-07
therefore O 0 1.3585935221271939e-07
, O 0 1.8654151290320442e-07
LRP5 O 0 0.003869467880576849
likely O 0 1.48017272749712e-06
represents O 0 2.0071128403742478e-07
a O 0 6.17482101006317e-08
new O 0 1.1059031379545559e-07
category O 0 7.868642910580093e-07
of O 0 6.096251325971025e-08
the O 0 5.698969971490442e-07
LDLR O 0 0.00685249175876379
family O 0 7.968757017806638e-06
. O 0 6.8685822043335065e-06

Both O 0 1.1238216757192276e-05
human O 0 2.3243123905558605e-06
and O 0 1.2784736327375867e-06
mouse O 0 4.7340301534859464e-05
LRP5 O 0 0.004067174158990383
cDNAs O 0 0.0001944492250913754
have O 0 1.2748571975862433e-07
been O 0 1.446038737640265e-07
isolated O 0 1.4466720585915027e-06
and O 0 2.6867555291687495e-08
the O 0 9.258987354598958e-09
encoded O 0 3.3600624504970256e-08
mature O 0 3.7976292333041783e-08
proteins O 0 6.937399987805293e-09
are O 0 2.727508663369349e-09
95 O 0 1.1061900551112558e-07
% O 0 5.127863289544621e-08
identical O 0 5.118131412018556e-07
, O 0 1.1385343157144234e-07
indicating O 0 7.580368333037768e-07
a O 0 1.1747335548761839e-07
high O 0 1.4673394161945907e-06
degree O 0 2.231111153605525e-07
of O 0 5.960736615406859e-08
evolutionary O 0 1.0833259693754371e-06
conservation O 0 2.9713023650401738e-06
. O 0 6.755146273462742e-07
. O 0 4.231178081681719e-06

The O 0 2.139012940460816e-05
APC B-Disease 0 0.00012947381765116006
variants O 0 9.244101420335937e-06
I1307K O 0 4.9482441681902856e-05
and O 0 7.061732389956887e-07
E1317Q O 0 2.9997177989571355e-05
are O 0 1.8906072796198714e-07
associated O 0 1.3167393262847327e-05
with O 0 0.4093123972415924
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0002826564304996282
but O 0 3.2361999728891533e-06
not O 0 3.704807056692516e-07
always O 0 3.904840184532077e-07
with O 0 8.023909003895824e-08
a O 0 6.211712388903834e-07
family O 0 5.288724878482753e-06
history O 0 6.786969152017264e-06
. O 0 1.4487911357718986e-05

Classical O 0 0.04387202113866806
familial B-Disease 1 0.9999606609344482
adenomatous I-Disease 1 0.9999698400497437
polyposis I-Disease 1 0.9999954700469971
( O 0 0.0010333970421925187
FAP B-Disease 0 0.011055506765842438
) O 0 3.598072908062022e-06
is O 0 5.741334803133213e-07
a O 0 1.6588421658525476e-06
high O 0 0.0015581997577100992
- O 1 0.9866960048675537
penetrance O 1 0.9890968799591064
autosomal B-Disease 0 0.46975579857826233
dominant I-Disease 0 0.4427662193775177
disease I-Disease 0 0.0049490961246192455
that O 0 1.8144203295378247e-07
predisposes O 0 2.9810134947183542e-05
to O 0 1.3062575021649536e-07
hundreds O 0 5.36097388703638e-07
or O 0 2.63916291487476e-07
thousands O 0 3.5185571505280677e-06
of O 0 0.0013625515857711434
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9875427484512329
carcinoma I-Disease 1 1.0
and O 0 2.2466549125965685e-05
that O 0 2.774148413209332e-07
results O 0 1.7174770619021729e-06
from O 0 2.8128516760261846e-07
truncating O 0 4.713623275165446e-05
mutations O 0 1.0412740039100754e-06
in O 0 7.64033316613677e-08
the O 0 5.39629866125324e-07
APC B-Disease 0 5.217792568146251e-05
gene O 0 7.966378689161502e-06
. O 0 5.777272690465907e-06

A O 0 7.912219007266685e-05
variant O 0 6.109449896030128e-05
of O 0 3.500046659610234e-06
FAP B-Disease 0 0.0029448813293129206
is O 0 5.5054453696357086e-05
attenuated B-Disease 1 0.8475130796432495
adenomatous I-Disease 1 0.9999899864196777
polyposis I-Disease 1 0.9999804496765137
coli I-Disease 1 0.9994524121284485
, O 0 3.42863631885848e-06
which O 0 1.8985409155902744e-07
results O 0 6.251720492400636e-07
from O 0 1.894417209769017e-07
germ O 0 0.002975211013108492
- O 0 0.0005259824683889747
line O 0 6.523766842292389e-06
mutations O 0 1.9789976590800507e-07
in O 0 9.394844902033128e-09
the O 0 1.4741313059118966e-08
5 O 0 8.779439752970575e-08
and O 0 2.9315481597791404e-08
3 O 0 1.7226263082648074e-07
regions O 0 6.056451695712894e-08
of O 0 2.1426691532155928e-08
the O 0 1.5109375794963853e-07
APC B-Disease 0 2.3858983695390634e-05
gene O 0 3.844253569695866e-06
. O 0 5.323503501131199e-06

Attenuated B-Disease 1 0.9969736337661743
adenomatous I-Disease 1 0.9999779462814331
polyposis I-Disease 1 0.999995231628418
coli I-Disease 1 0.9999878406524658
patients O 1 0.8371276259422302
have O 0 4.202933723718161e-06
" O 0 9.995240361604374e-06
multiple O 0 0.00013939847121946514
" O 1 0.9384797811508179
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999988079071045
( O 0 5.589794000115944e-06
typically O 0 1.2828545550291892e-06
fewer O 0 2.488628467745002e-07
than O 0 4.080654392168981e-08
100 O 0 1.0266730043895222e-07
) O 0 3.273536464121207e-08
without O 0 3.837912032622626e-08
the O 0 7.271028579225458e-08
florid O 0 6.37188131804578e-05
phenotype O 0 3.984754130215151e-06
of O 0 2.8021258913213387e-07
classical O 0 7.557943717984017e-06
FAP B-Disease 0 0.0004668917099479586
. O 0 8.743326361582149e-06

Another O 0 2.1524916519410908e-05
group O 0 1.9395785784581676e-05
of O 0 1.8759924387268256e-06
patients O 0 9.349833999294788e-05
with O 0 2.389984047113103e-06
multiple O 0 0.0002164342295145616
adenomas B-Disease 1 0.9925727844238281
has O 0 6.842704806331312e-06
no O 0 7.484327966267301e-07
mutations O 0 7.977744189702207e-07
in O 0 3.956629868184791e-08
the O 0 1.276273167150066e-07
APC B-Disease 0 8.660984349262435e-06
gene O 0 2.7771289978772984e-07
, O 0 5.088287480248255e-08
and O 0 6.5198094034713e-08
their O 0 6.309038980134574e-08
phenotype O 0 3.322676548123127e-06
probably O 0 5.205268962527043e-07
results O 0 1.4809518233960262e-07
from O 0 3.1717675597064954e-08
variation O 0 6.051025707165536e-07
at O 0 4.993661377739045e-07
a O 0 1.8850782623758278e-07
locus O 0 1.5784673905727686e-06
, O 0 1.2018028883176157e-07
or O 0 8.802410889074963e-08
loci O 0 2.1598246746634686e-07
, O 0 7.108992861049046e-08
elsewhere O 0 1.5804120323537063e-07
in O 0 3.438117346377112e-08
the O 0 1.9506475723574113e-07
genome O 0 1.154862366092857e-05
. O 0 5.960104772384511e-06

Recently O 0 0.0003977316082455218
, O 0 5.049460014561191e-06
however O 0 1.2843381682614563e-06
, O 0 4.4551310907081643e-07
a O 0 6.404885652955272e-07
missense O 0 6.02213476668112e-05
variant O 0 3.6123342397331726e-06
of O 0 5.286186137709592e-07
APC B-Disease 0 4.5737546315649524e-05
( O 0 1.3794897313346155e-07
I1307K O 0 2.3130958652473055e-05
) O 0 8.015955188511725e-08
was O 0 4.150287509219197e-07
described O 0 5.177435582481849e-07
that O 0 2.7640911781645627e-08
confers O 0 1.7110995997882128e-07
an O 0 2.8615861680236776e-08
increased O 0 5.0145722525485326e-06
risk O 0 0.0005618422874249518
of O 0 0.29683342576026917
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.5454897948075086e-05
including O 0 5.507537935045548e-06
multiple O 0 6.987936649238691e-05
adenomas B-Disease 1 0.919727087020874
, O 0 2.7177009087608894e-06
in O 0 3.1759252578922315e-06
Ashkenazim O 0 0.0014536794042214751
. O 0 2.3305681679630652e-05

We O 0 8.94708136911504e-06
have O 0 3.146352867133828e-07
studied O 0 1.1796744558978389e-07
a O 0 2.5200096231969837e-08
set O 0 3.7611538772353015e-08
of O 0 6.905876404061928e-08
164 O 0 0.0002952424401883036
patients O 0 4.402091144584119e-05
with O 0 1.3288864465721417e-05
multiple O 1 0.978501558303833
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
and I-Disease 0 0.025438474491238594
/ I-Disease 1 0.9818006753921509
or I-Disease 0 0.13286034762859344
carcinoma I-Disease 1 0.9999992847442627
and O 0 6.568590379174566e-06
analyzed O 0 6.879266948089935e-06
codons O 0 3.1856689020060003e-06
1263 O 0 0.00011484659626148641
- O 0 0.00012897058331873268
1377 O 0 0.00026284108753316104
( O 0 3.5245076901446737e-07
exon O 0 6.070589279261185e-06
15G O 0 1.2705846529570408e-05
) O 0 2.3673390359135738e-08
of O 0 8.640190785058621e-09
the O 0 3.0501542624961075e-08
APC B-Disease 0 3.1842532735026907e-06
gene O 0 3.574334073164209e-07
for O 0 3.6278453308113967e-07
germ O 0 0.0009336135699413717
- O 0 0.00015525022172369063
line O 0 1.8893915694206953e-05
variants O 0 7.606868166476488e-06
. O 0 4.2854244384216145e-06

Three O 0 6.845811003586277e-05
patients O 0 0.00016762061568442732
with O 0 5.793808668386191e-07
the O 0 4.524559642504755e-07
I1307K O 0 4.8184821935137734e-05
allele O 0 9.989685167965945e-07
were O 0 1.485350935581664e-07
detected O 0 2.2775959678256186e-06
, O 0 4.986008761420635e-08
each O 0 2.3875726284927623e-08
of O 0 4.252177916441724e-07
Ashkenazi O 0 0.00018089608056470752
descent O 0 0.0002060474653262645
. O 0 1.6242773199337535e-05

Four O 0 0.0001559593074489385
patients O 0 0.0009025403414852917
had O 0 3.744426749108243e-06
a O 0 2.6415932552481536e-06
germ O 0 0.03817317634820938
- O 0 0.0018268452258780599
line O 0 4.975015326635912e-05
E1317Q O 0 6.947292422410101e-05
missense O 0 1.6218084056163207e-05
variant O 0 6.530637506330095e-07
of O 0 1.0307010711585463e-07
APC O 0 1.0953039236483164e-05
that O 0 6.069380731332785e-08
was O 0 3.9320519817920285e-07
not O 0 1.6182138296017e-08
present O 0 2.5571759820763873e-08
in O 0 2.897118456246517e-08
controls O 0 3.0198843887774274e-06
; O 0 1.2348304778697639e-07
one O 0 1.465605770079037e-08
of O 0 1.688018613776876e-08
these O 0 2.4628969086393226e-08
individuals O 0 5.006211267755134e-08
had O 0 1.5279915999144578e-07
an O 0 1.5094434147044922e-08
unusually O 0 6.226543973752996e-06
large O 0 1.734019150489985e-07
number O 0 3.762876232826784e-08
of O 0 1.6046158179960912e-07
metaplastic B-Disease 0 0.006071530282497406
polyps I-Disease 0 7.26581274648197e-05
of I-Disease 0 1.3472445914430864e-07
the I-Disease 0 1.445683210477e-06
colorectum I-Disease 0 0.0011303859064355493
. O 0 1.1015166819561273e-05

There O 0 8.014570084924344e-06
is O 0 6.237475531634118e-07
increasing O 0 7.833475592633476e-07
evidence O 0 5.770223765466653e-07
that O 0 1.0680230388970813e-07
there O 0 1.8310838356683234e-07
exist O 0 6.954293212402263e-07
germ O 0 0.001456033089198172
- O 0 0.00023206844343803823
line O 0 3.590572987377527e-06
variants O 0 1.2473613253405347e-07
of O 0 1.5711632883608218e-08
the O 0 9.948254842129245e-08
APC B-Disease 0 4.3498221202753484e-06
gene O 0 1.2166790952505835e-07
that O 0 1.914761504906437e-08
predispose O 0 2.495515900591272e-07
to O 0 2.0285220614368882e-08
the O 0 1.6604985830781516e-08
development O 0 3.0351586133292585e-07
of O 0 3.0366172723006457e-06
multiple O 1 0.9678720235824585
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
and I-Disease 1 0.9936231970787048
carcinoma I-Disease 1 1.0
, O 0 5.792907177237794e-05
but O 0 1.1098870800196892e-06
without O 0 2.1724800092215446e-07
the O 0 1.5658402219287382e-07
florid O 0 0.00040405834442935884
phenotype O 0 6.965417924220674e-06
of O 0 7.115625777487367e-08
classical O 0 1.0166922947973944e-06
FAP B-Disease 0 8.179997530533001e-05
, O 0 3.917873243608483e-07
and O 0 1.5073884185312636e-07
possibly O 0 3.4894441114374786e-07
with O 0 1.1805511945794933e-07
importance O 0 7.306712632271228e-06
for O 1 0.7151907086372375
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
risk O 0 0.0057359603233635426
in O 0 3.546538493992557e-07
the O 0 2.044649107801888e-07
general O 0 2.499441279724124e-06
population O 0 3.232166818634141e-07
. O 0 5.089233923172287e-07
. O 0 4.221174549456919e-06

Genomic O 0 0.00010764313628897071
structure O 0 1.0175430361414328e-05
of O 0 1.1403266171328141e-06
the O 0 1.0410424692963716e-05
human O 0 0.42043188214302063
congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.9999947547912598
diarrhea I-Disease 1 0.9999997615814209
( O 0 0.00023194699315354228
CLD B-Disease 1 0.9458420872688293
) O 0 2.2394726784114027e-06
gene O 0 3.838099019048968e-06
. O 0 5.704963768948801e-06

Congenital B-Disease 1 0.9999992847442627
chloride I-Disease 1 0.9999774694442749
diarrhea I-Disease 1 0.9999991655349731
( O 0 0.0014354753075167537
CLD B-Disease 1 0.9973692893981934
) O 0 3.4494892133807298e-06
is O 0 7.198383400464081e-07
caused O 0 2.373335064476123e-06
by O 0 2.552695832491736e-07
mutations O 0 8.218106586355134e-07
in O 0 2.948567789928802e-08
a O 0 1.5878373460509465e-07
gene O 0 3.3649246233835584e-07
which O 0 1.0294043306657841e-07
encodes O 0 1.0227166740151006e-06
an O 0 1.5894614762146375e-06
intestinal O 1 0.7313688397407532
anion O 0 0.001766312401741743
transporter O 0 0.0030434420332312584
. O 0 1.6204572602873668e-05

We O 0 1.6135794794536196e-05
report O 0 2.777303507173201e-06
here O 0 2.45673277277092e-07
the O 0 4.192670388647457e-08
complete O 0 5.673017540175351e-07
genomic O 0 2.646166876729694e-06
organization O 0 2.3050448305639293e-07
of O 0 2.5585713103737362e-08
the O 0 5.875940800592616e-08
human O 0 7.94987101926381e-07
CLD B-Disease 0 0.004825410433113575
gene O 0 4.07478268016348e-07
which O 0 4.71950620806183e-08
spans O 0 9.67297523857269e-07
approximately O 0 3.129874812657363e-07
39kb O 0 4.491591244004667e-05
, O 0 2.396570266682829e-07
and O 0 1.312343442805286e-07
comprises O 0 7.521392149101302e-07
21 O 0 1.965603360076784e-06
exons O 0 3.0356379284057766e-05
. O 0 5.719797627534717e-06

All O 0 1.2328847333265003e-05
exon O 0 0.00034838743158616126
/ O 0 0.000173860156792216
intron O 0 0.0002691894769668579
boundaries O 0 2.749474333541002e-06
conform O 0 1.7458846741646994e-06
to O 0 1.2275414462692424e-07
the O 0 7.137700777093414e-07
GT O 0 0.007667448837310076
/ O 0 0.10494977980852127
AG O 1 0.9745396375656128
rule O 0 2.541487083362881e-05
. O 0 1.4484595340036321e-05

An O 0 1.7013737760862568e-06
analysis O 0 1.8896244000643492e-06
of O 0 3.3475572536190157e-07
the O 0 3.7153014886825986e-07
putative O 0 2.834830775100272e-05
promoter O 0 0.00010574663610896096
region O 0 5.43830083188368e-07
sequence O 0 1.3418002708931454e-07
shows O 0 2.4207398041653505e-07
a O 0 2.8515671601780923e-07
putative O 0 4.000344779342413e-05
TATA O 0 0.018824689090251923
box O 0 2.499717811588198e-05
and O 0 4.1249941773457977e-07
predicts O 0 1.2198933291074354e-05
multiple O 0 4.40204729557081e-07
transcription O 0 1.219647856487427e-06
factor O 0 5.739002517657354e-07
binding O 0 1.8714107454798068e-06
sites O 0 3.4083486752933823e-06
. O 0 3.132603069389006e-06

The O 0 7.724580427748151e-06
genomic O 0 2.3344920919043943e-05
structure O 0 5.735529157391284e-06
was O 0 1.2583658417497645e-06
determined O 0 1.0981643754348624e-06
using O 0 1.5234955696996622e-07
DNA O 0 1.2628826198124443e-06
from O 0 1.6739690522626915e-08
several O 0 1.0503921288318452e-08
sources O 0 4.0023532932309536e-08
including O 0 4.96074790135026e-08
multiple O 0 2.184036276275947e-07
large O 0 1.191399292110873e-06
- O 0 7.474508311133832e-05
insert O 0 5.948872512817616e-06
libaries O 0 4.6528766688425094e-05
and O 0 1.9903161785350676e-07
genomic O 0 3.6466358324105386e-06
DNA O 0 5.722503829019843e-06
from O 0 9.331482146990311e-07
Finnish O 0 0.0021515029948204756
CLD B-Disease 1 0.9915281534194946
patients O 0 0.00012714786862488836
and O 0 1.7677588175502024e-06
controls O 0 4.053183147334494e-05
. O 0 1.9511924620019272e-05

Exon O 0 0.0010198336094617844
- O 0 0.00017720562755130231
specific O 0 1.7790410993256955e-06
primers O 0 1.3738072993874084e-05
developed O 0 1.4994610637586447e-06
in O 0 2.4225776940056676e-08
this O 0 1.1663384924531783e-08
study O 0 2.842134527725193e-08
will O 0 2.379221619719374e-08
facilitate O 0 2.395391334175656e-07
mutation O 0 1.9577520049551822e-07
screening O 0 4.784181442119007e-07
studies O 0 7.06344422951588e-08
of O 0 5.320572995515249e-07
patients O 0 5.439819869934581e-05
with O 0 2.3442760266334517e-06
the O 0 5.263851926429197e-05
disease O 0 0.013239903375506401
. O 0 1.3222155757830478e-05

Genomic O 0 0.00010690152703318745
sequencing O 0 2.428223888273351e-05
of O 0 2.334234977752203e-06
a O 0 3.22172672895249e-06
BAC O 0 0.00023295119171962142
clone O 0 0.06931447982788086
H O 1 0.9998793601989746
_ O 0 1.2228400919411797e-05
RG364P16 O 0 4.448058098205365e-05
revealed O 0 8.103360187305952e-07
the O 0 1.8940896850949684e-08
presence O 0 3.714634644325088e-08
of O 0 1.4231090084138032e-08
another O 0 1.3694659628527006e-07
, O 0 7.5820757672318e-08
highly O 0 8.219880243132138e-08
homologous O 0 3.279658358223969e-07
gene O 0 2.2211119699022674e-07
3 O 0 1.1433938595928339e-07
of O 0 4.6495550520830875e-08
the O 0 1.9337829826326924e-07
CLD B-Disease 0 0.0014096817467361689
gene O 0 8.867792189448664e-07
, O 0 1.979620662950765e-07
with O 0 5.198591068733549e-08
a O 0 8.452546040871312e-08
similar O 0 2.2907742902589234e-07
genomic O 0 1.3282071904541226e-06
structure O 0 1.5517446172452765e-06
, O 0 3.1452998427994316e-07
recently O 0 2.4311470951943193e-06
identified O 0 9.560181979395566e-07
as O 0 1.2863162623943936e-07
the O 0 4.434817674336955e-05
Pendred B-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999982118606567
gene O 0 2.4812234187265858e-05
( O 0 1.3684349369214033e-06
PDS B-Disease 0 0.00014544576697517186
) O 0 2.183846561365499e-07
. O 0 3.1911190490063746e-07
. O 0 3.3239189178857487e-06

The O 0 1.3490523997461423e-05
APCI1307K O 0 0.002332036616280675
allele O 0 6.611882417928427e-05
and O 0 0.00010114903125213459
cancer B-Disease 1 0.7065271139144897
risk O 0 3.9100326830521226e-05
in O 0 1.478380937669499e-07
a O 0 3.7186228496466356e-07
community O 0 2.4536140585951216e-07
- O 0 4.831863407162018e-05
based O 0 3.7498870142371743e-07
study O 0 2.3930189740895e-07
of O 0 6.23397909293999e-07
Ashkenazi O 0 0.0006782250129617751
Jews O 0 1.3918554031988606e-05
. O 0 7.495637873944361e-06

Mutations O 0 0.0008440847741439939
in O 0 7.5004572863690555e-06
APC O 0 0.0002344633248867467
are O 0 1.651004367886344e-06
classically O 0 0.0030772765167057514
associated O 0 0.00012614228762686253
with O 0 0.0013645450817421079
familial B-Disease 1 0.9999957084655762
adenomatous I-Disease 1 0.9999953508377075
polyposis I-Disease 1 0.9999991655349731
( O 0 0.0003643225063569844
FAP B-Disease 0 0.006923513952642679
) O 0 6.68288009819662e-07
, O 0 5.281524977363006e-07
a O 0 3.7370846257545054e-06
highly O 0 0.0005122410366311669
penetrant O 1 0.998555600643158
autosomal B-Disease 1 0.9999805688858032
dominant I-Disease 1 0.9998279809951782
disorder I-Disease 1 0.9999973773956299
characterized O 0 0.18149049580097198
by O 0 0.00019004674686584622
multiple O 0 0.14343395829200745
intestinal O 1 0.9999524354934692
polyps B-Disease 1 0.9726215600967407
and O 0 1.915944267238956e-05
, O 0 1.0953372111544013e-06
without O 0 4.1221625224352465e-07
surgical O 0 0.0005451363394968212
intervention O 0 1.878620651041274e-06
, O 0 8.673978868500853e-08
the O 0 3.9996670864184125e-08
development O 0 6.7795358518196736e-06
of O 1 0.5684942007064819
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
( O 0 0.00012175775191280991
CRC B-Disease 0 0.005817940458655357
) O 0 3.1992810818337603e-06
. O 0 5.8559858189255465e-06

APC B-Disease 0 0.0018939458532258868
is O 0 1.0729293535405304e-05
a O 0 1.9656292352010496e-05
tumour O 1 0.999383807182312
- O 0 0.0006689241272397339
suppressor O 0 6.987330561969429e-05
gene O 0 9.977707122743595e-07
, O 0 1.7084484227325447e-07
and O 0 2.0565803993122245e-07
somatic O 0 7.575839845230803e-05
loss O 0 0.001683747861534357
occurs O 0 5.707222044293303e-06
in O 0 1.2309226804063655e-05
tumours B-Disease 1 0.9998644590377808
. O 0 4.858592728851363e-05

The O 0 2.46883173531387e-05
germline O 0 0.0245351679623127
T O 1 0.5000020265579224
- O 0 9.826727182371542e-05
to O 0 3.999194575499132e-07
- O 0 4.9534093705005944e-05
A O 0 8.238076816269313e-07
transversion O 0 9.759554814081639e-05
responsible O 0 4.7398307856383326e-07
for O 0 3.1815527989920156e-08
the O 0 6.931066565130095e-08
APC O 0 8.20325112727005e-06
I1307K O 0 3.0318628887471277e-06
allele O 0 1.9966354614098236e-07
converts O 0 7.035234972363469e-08
the O 0 2.1168540698113247e-08
wild O 0 4.499194403706497e-07
- O 0 5.819963462272426e-06
type O 0 1.4682839832858008e-07
sequence O 0 2.3902016366150747e-08
to O 0 1.3290414102584691e-08
a O 0 3.2731560395404813e-07
homopolymer O 0 0.4470174312591553
tract O 0 0.22607359290122986
( O 0 1.2584295063788886e-06
A8 O 0 0.14180925488471985
) O 0 1.477118161119506e-07
that O 0 3.2197988275584066e-08
is O 0 1.511923528596526e-07
genetically O 0 6.5529616222193e-06
unstable O 0 0.0032125618308782578
and O 0 3.188203436366166e-06
prone O 0 0.00032726809149608016
to O 0 5.722426976717543e-07
somatic O 0 8.903438720153645e-05
mutation O 0 1.9302307919133455e-05
. O 0 6.8272956923465244e-06

The O 0 1.5278417777153663e-05
I1307K O 0 0.0002686784719116986
allele O 0 3.22959604091011e-05
was O 0 3.604790890676668e-06
found O 0 5.733958801101835e-07
in O 0 3.3310988101220573e-07
6 O 0 8.286912816402037e-06
. O 0 5.528524070541607e-06

1 O 0 3.754546196432784e-05
% O 0 2.4845880943757948e-06
of O 0 5.44758734122297e-07
unselected O 0 0.0010907879332080483
Ashkenazi O 0 0.00040916958823800087
Jews O 0 3.5323519114172086e-06
and O 0 4.4807393351220526e-07
higher O 0 1.1891607982761343e-06
proportions O 0 2.0183313154120697e-06
of O 0 1.3484952887665713e-07
Ashkenazim O 0 0.00029679122962988913
with O 0 1.6450351267849328e-06
family O 0 3.162928351230221e-06
or O 0 9.55517748479906e-07
personal O 0 9.774156751518603e-06
histories O 0 1.5245667782437522e-05
of O 0 5.161278295418015e-06
CRC B-Disease 0 0.06922730803489685
( O 0 2.373262759647332e-06
ref O 0 0.0026072580367326736
. O 0 3.9738441159897775e-07
2 O 0 1.9753067590499995e-06
) O 0 5.079318725620396e-07
. O 0 2.67254267782846e-06

To O 0 4.57227088190848e-06
evaluate O 0 1.183428776130313e-05
the O 0 2.6064887492793787e-07
role O 0 1.9652530625080544e-07
of O 0 9.365078312839614e-08
I1307K O 0 0.00018585218640509993
in O 0 2.1722410110669443e-06
cancer B-Disease 0 0.0021016362588852644
, O 0 2.3039372365474264e-07
we O 0 2.1467765520810644e-07
genotyped O 0 6.849441706435755e-05
5 O 0 9.155237989943998e-07
, O 0 5.038133394918987e-07
081 O 0 0.0003348606696818024
Ashkenazi O 0 2.0960535039193928e-05
volunteers O 0 5.797323296974355e-07
in O 0 6.73070985612867e-08
a O 0 2.9374876930887694e-07
community O 0 1.1545740790097625e-06
survey O 0 1.21882349048974e-05
. O 0 1.0268358892062679e-05

Risk O 0 0.0004626752343028784
of O 0 6.759090410923818e-06
developing O 0 0.0065100654028356075
colorectal B-Disease 1 0.9999995231628418
, I-Disease 0 0.03703395277261734
breast I-Disease 1 0.983223021030426
and I-Disease 0 2.3705757485004142e-05
other I-Disease 0 5.7547390497347806e-06
cancers I-Disease 0 0.24585795402526855
were O 0 1.3045847708781366e-06
compared O 0 3.893690518452786e-06
between O 0 3.9297353282563563e-07
genotyped O 0 0.00042937809485010803
I1307K O 0 6.525042408611625e-05
carriers O 0 8.265391784334497e-07
and O 0 9.522576505105462e-08
non O 0 1.126635311266e-06
- O 0 6.257877248572186e-05
carriers O 0 1.1997957471976406e-06
and O 0 2.7885025843943367e-08
their O 0 8.277980079185454e-09
first O 0 9.274544510162741e-08
- O 0 5.7329281844431534e-05
degree O 0 5.082379175291862e-06
relatives O 0 9.373927241540514e-06
. O 0 5.0515936891315505e-06

Sperm O 0 0.00032198094413615763
DNA O 0 5.6803266488714144e-05
analysis O 0 6.834266059740912e-06
in O 0 1.502607574366266e-06
a O 0 1.4730719158251304e-05
Friedreich B-Disease 1 0.9902179837226868
ataxia I-Disease 1 0.998451828956604
premutation O 1 0.6903761625289917
carrier O 0 0.0024267996195703745
suggests O 0 3.074328333241283e-06
both O 0 2.890280939027434e-07
meiotic O 0 0.00019238189270254225
and O 0 6.248484396564891e-07
mitotic O 0 0.00010676297824829817
expansion O 0 6.129181201686151e-06
in O 0 4.654457370634191e-07
the O 0 1.882246692730405e-06
FRDA B-Disease 0 0.0021162480115890503
gene O 0 1.267783864022931e-05
. O 0 9.397369467478711e-06

Friedreich B-Disease 1 0.9994087219238281
ataxia I-Disease 1 0.9996508359909058
is O 0 0.00011559084668988362
usually O 0 1.7066446162061766e-05
caused O 0 5.269256689643953e-06
by O 0 1.1849750336523357e-07
an O 0 2.1674672723293043e-08
expansion O 0 6.361542546073906e-07
of O 0 1.4086575106375676e-07
a O 0 2.2704869024892105e-06
GAA O 0 4.6970344556029886e-05
trinucleotide O 0 0.00019736691319849342
repeat O 0 2.814088020386407e-06
in O 0 1.4256879410368128e-07
intron O 0 7.291716610779986e-05
1 O 0 2.202690296826404e-07
of O 0 4.2293599733511655e-08
the O 0 2.9908852638982353e-07
FRDA B-Disease 0 0.0007965496042743325
gene O 0 6.850200861663325e-06
. O 0 5.009084816265386e-06

Occasionally O 0 9.814582153921947e-05
, O 0 1.6543773426747066e-06
a O 0 4.0386640876022284e-07
fully O 0 2.9427675940496556e-07
expanded O 0 2.1501411140434357e-07
allele O 0 7.823359169378818e-07
has O 0 1.0054220922484092e-07
been O 0 5.875727637771888e-08
found O 0 1.0755459101119413e-07
to O 0 5.1959741398377446e-08
arise O 0 4.6653494223392045e-07
from O 0 3.3135140853346456e-08
a O 0 1.3751589733601577e-07
premutation O 0 2.060423321381677e-05
of O 0 4.322230040543218e-08
100 O 0 1.560631375241428e-07
or O 0 1.3002347998281039e-07
less O 0 3.924102998098533e-07
triplet O 0 8.367290865862742e-05
repeats O 0 2.1406674932222813e-05
. O 0 7.268426088558044e-06

We O 0 1.0315568943042308e-05
have O 0 4.522208314483578e-07
examined O 0 3.2612083487038035e-06
the O 0 1.0537959127532304e-07
sperm O 0 2.8387378279148834e-06
DNA O 0 2.5658218874013983e-06
of O 0 2.3533296200639597e-07
a O 0 3.854297119687544e-06
premutation O 0 0.027025319635868073
carrier O 0 0.00083594536408782
. O 0 9.237836820830125e-06

This O 0 8.493499990436248e-06
mans O 0 0.00014281889889389277
leucocyte O 0 0.006698007229715586
DNA O 0 0.0001715298421913758
showed O 0 9.24977121030679e-06
one O 0 8.734842538160592e-08
normal O 0 2.3032782792142825e-07
allele O 0 3.1484117357649666e-07
and O 0 5.583702744615948e-08
one O 0 3.591027208926789e-08
allele O 0 2.2205018979093438e-07
of O 0 3.241377655172073e-08
approximately O 0 2.661976168383262e-07
100 O 0 4.512386340138619e-07
repeats O 0 5.498736754816491e-06
. O 0 3.0403666642087046e-06

His O 0 4.405626896186732e-05
sperm O 0 5.4332922445610166e-05
showed O 0 5.5710711421852466e-06
an O 0 5.9254379181084005e-08
expanded O 0 2.977697590722528e-07
allele O 0 3.9134184248723614e-07
in O 0 3.52818609883343e-08
a O 0 1.5345705151048605e-07
tight O 0 9.042313649842981e-06
range O 0 1.3869799886379042e-06
centering O 0 5.045528155278589e-07
on O 0 8.347476665448994e-08
a O 0 6.839338340114409e-08
size O 0 3.895838460721279e-07
of O 0 7.339918539628343e-08
approximately O 0 1.1129819768029847e-06
320 O 0 1.8363896742812358e-05
trinucleotide O 0 0.00034819787833839655
repeats O 0 3.7346988392528147e-05
. O 0 1.1165295290993527e-05

His O 0 3.2790332625154406e-05
affected O 0 0.00015244631504174322
son O 0 0.0024625686928629875
has O 0 8.980488814813725e-07
repeat O 0 4.774387434736127e-06
sizes O 0 3.34126889356412e-06
of O 0 2.2590562309687812e-07
1040 O 0 5.0393286073813215e-05
and O 0 2.016465259657707e-06
540 O 0 2.503241012163926e-05
. O 0 5.82551092520589e-06

These O 0 3.1322206268669106e-06
data O 0 2.702209940252942e-06
suggest O 0 6.529204483740614e-07
that O 0 5.1310721005393134e-08
expansion O 0 7.843701723686536e-07
occurs O 0 1.1281281331321225e-07
in O 0 2.8060455292688857e-08
two O 0 3.204384313448827e-08
stages O 0 2.9618558983202092e-06
, O 0 1.0760609825410938e-07
the O 0 1.1618334738727754e-08
first O 0 3.830408701332999e-08
during O 0 1.7975862931507436e-07
meiosis O 0 1.3492315247276565e-06
followed O 0 1.769624873304565e-07
by O 0 3.573916984578318e-08
a O 0 7.0013676634062e-08
second O 0 4.2210430706290936e-07
mitotic O 0 0.0003450572257861495
expansion O 0 4.68406688014511e-05
. O 0 1.793240153347142e-05

We O 0 1.4392423508979846e-05
also O 0 1.0373747727498994e-06
show O 0 7.832698543097649e-07
that O 0 7.6913174495985e-08
in O 0 4.435053924112253e-08
all O 0 1.9955535890403553e-08
informative O 0 2.1559878859989112e-06
carrier O 0 5.99509512539953e-05
father O 0 1.329369297309313e-06
to O 0 5.745717501781655e-08
affected O 0 2.543980883729091e-07
child O 0 2.125955688825343e-06
transmissions O 0 4.602298758982215e-06
, O 0 1.053677323170632e-07
with O 0 2.5604363074194225e-08
the O 0 2.4563432177160394e-08
notable O 0 2.1544185813127115e-07
exception O 0 1.0194744248792631e-07
of O 0 2.107161911624189e-08
the O 0 1.1897014218220647e-07
premutation O 0 0.0006099946913309395
carrier O 0 2.1501939045265317e-05
, O 0 3.258013592244424e-08
the O 0 7.916445277089679e-09
expansion O 0 5.44516183254018e-07
size O 0 4.19856269218144e-06
decreases O 0 4.0391250877291895e-06
. O 0 3.547996527686337e-07
. O 0 2.622806277940981e-06

The O 0 1.0997648132615723e-05
R496H O 0 0.00014046646538190544
mutation O 0 4.670465386880096e-06
of O 0 5.784830818811315e-07
arylsulfatase O 0 0.0007031370769254863
A O 0 3.47774744113849e-06
does O 0 2.2288747913989937e-06
not O 0 2.736859414653736e-06
cause O 0 0.0015799625543877482
metachromatic B-Disease 1 0.9998577833175659
leukodystrophy I-Disease 1 0.9997740387916565
. O 0 9.890569344861433e-05

Deficiency B-Disease 1 0.9968798160552979
of I-Disease 0 8.422422069997992e-06
arylsulfatase I-Disease 0 0.023247728124260902
A I-Disease 0 2.542839865782298e-05
( O 0 4.8809147301653866e-06
ARSA O 0 0.027763864025473595
) O 0 7.462689382009557e-07
enzyme O 0 2.192725560234976e-06
activity O 0 7.058500159473624e-06
causes O 0 0.00016646520816721022
metachromatic B-Disease 1 0.9999127388000488
leukodystrophy I-Disease 1 0.9999657869338989
( O 0 0.00017149483028333634
MLD B-Disease 1 0.9992629885673523
) O 0 9.442574992135633e-06
. O 0 1.031553892971715e-05

A O 0 1.976516614377033e-05
number O 0 1.7552904409967596e-06
of O 0 1.6980718555714702e-06
ARSA O 1 0.5429732799530029
gene O 0 1.994291778828483e-05
mutations O 0 6.94876416673651e-06
responsible O 0 2.4446010229439707e-06
for O 0 3.897186616086401e-06
MLD B-Disease 1 0.9998997449874878
have O 0 3.7916581732133636e-06
been O 0 2.8963645490875933e-06
identified O 0 1.6663430869812146e-05
. O 0 7.109831130946986e-06

Recently O 0 0.00014270674728322774
, O 0 2.0162881355645368e-06
the O 0 4.0438746395921044e-07
R496H O 0 3.956283399020322e-05
mutation O 0 2.0887682694592513e-06
of O 0 2.888638448439451e-07
ARSA O 0 0.28108713030815125
was O 0 2.718374844334903e-06
proposed O 0 9.720415619085543e-07
to O 0 7.984109373637693e-08
be O 0 5.839294558995789e-08
a O 0 6.021953709023364e-07
cause O 0 2.2180074665811844e-06
of O 0 1.130693362938473e-06
MLD B-Disease 1 0.999956488609314
( O 0 3.6639225982071366e-06
Draghia O 0 0.0007350874948315322
et O 0 5.930279803578742e-05
al O 0 5.566780600929633e-05
. O 0 1.7535509755362e-07
, O 0 1.2420741768437438e-07
1997 O 0 1.3574607464761357e-06
) O 0 5.374948273129121e-07
. O 0 1.922525370900985e-06

We O 0 1.0319859029550571e-05
have O 0 7.761167353237397e-07
investigated O 0 3.0327507829497335e-06
the O 0 1.0302844088982965e-07
R496H O 0 2.8359501811792143e-05
mutation O 0 8.427897455476341e-07
and O 0 2.6727312274488213e-07
found O 0 1.5706156375472347e-07
this O 0 2.9032142023766028e-08
mutation O 0 1.5737012404315465e-07
at O 0 8.24962782530747e-08
a O 0 9.340779882904826e-08
relatively O 0 3.811359192695818e-07
high O 0 5.019884383727913e-07
frequency O 0 1.0940264161263258e-07
in O 0 1.3115972308241908e-08
an O 0 3.0248694660173214e-09
African O 0 1.0131855354700292e-08
American O 0 1.6599919661075546e-08
population O 0 2.2443032321461942e-08
( O 0 4.0239388710006097e-08
f O 0 1.0505430509510916e-05
= O 0 9.298063901042042e-07
0 O 0 5.471423847325241e-08
. O 0 6.805787933217289e-09
09 O 0 2.31416365181758e-07
, O 0 4.94325540500995e-08
n O 0 5.119057277624961e-06
= O 0 3.086696551690693e-06
61 O 0 5.241442977421684e-07
subjects O 0 6.605595217479276e-07
) O 0 4.138090901051328e-07
. O 0 2.128597088812967e-06

The O 0 1.899718881759327e-05
ARSA O 0 0.007909514009952545
enzyme O 0 9.119560672843363e-06
activity O 0 1.9661827082018135e-06
in O 0 9.661786037895581e-08
subjects O 0 3.3589418535484583e-07
with O 0 1.1678726963282315e-07
and O 0 2.3399779536248388e-07
without O 0 7.198472928848787e-08
the O 0 6.349964820628884e-08
R496H O 0 3.942626062780619e-05
mutation O 0 4.924495442537591e-07
was O 0 2.7692186677086283e-07
determined O 0 6.839715638307098e-07
and O 0 9.605358286535193e-08
found O 0 1.0770013858518723e-07
to O 0 4.0118226962704284e-08
be O 0 1.114304808425004e-07
normal O 0 1.8127959720004583e-06
. O 0 3.226948138035368e-06

It O 0 3.3855069432320306e-06
is O 0 5.631168278341647e-07
therefore O 0 1.7699439069929213e-07
concluded O 0 8.400550655096595e-07
that O 0 3.237571277736606e-08
the O 0 5.315663642591062e-08
R496H O 0 2.229992242064327e-05
mutation O 0 3.6175774198454747e-07
of O 0 1.1408810252078183e-07
ARSA O 0 0.13721373677253723
does O 0 3.2899302482292114e-07
not O 0 2.7142451841655202e-08
negatively O 0 1.00905687361319e-07
influence O 0 3.4555789341084164e-08
the O 0 8.265752526881442e-09
activity O 0 1.5910221407011704e-07
of O 0 1.4647218904428883e-07
ARSA O 0 0.29596659541130066
and O 0 4.6336018044712546e-07
is O 0 1.2195555143534875e-07
not O 0 9.787149934936679e-08
a O 0 1.0780408956634346e-06
cause O 0 2.5071738491533324e-05
of O 0 3.0558076105080545e-05
MLD B-Disease 1 0.9996436834335327

Down O 0 0.00046301583643071353
- O 0 7.73286956246011e-05
regulation O 0 3.647707217169227e-06
of O 0 5.800763460683811e-07
transmembrane O 0 4.988027285435237e-05
carbonic O 0 7.009260298218578e-05
anhydrases O 0 0.0031875204294919968
in O 0 0.00017660985758993775
renal B-Disease 1 0.9999988079071045
cell I-Disease 1 0.9999885559082031
carcinoma I-Disease 1 1.0
cell O 1 0.5540323853492737
lines O 0 4.916691977996379e-05
by O 0 8.187346907106985e-07
wild O 0 1.4601389011659194e-05
- O 0 0.004544704686850309
type O 0 0.00036278751213103533
von B-Disease 1 0.6904425024986267
Hippel I-Disease 1 0.5997806787490845
- I-Disease 0 0.02422282099723816
Lindau I-Disease 0 0.034455593675374985
transgenes O 0 0.0006761694676242769
. O 0 2.0233333998476155e-05

To O 0 8.511046871717554e-06
discover O 0 2.1788715457660146e-05
genes O 0 2.6062255074066343e-06
involved O 0 1.8231327203466208e-06
in O 0 2.9064444788673427e-06
von B-Disease 1 0.9875619411468506
Hippel I-Disease 1 0.9944250583648682
- I-Disease 1 0.8908089399337769
Lindau I-Disease 1 0.7525290250778198
( O 0 1.5824164165678667e-06
VHL B-Disease 0 0.00012043148308293894
) O 0 1.5148070531267877e-07
- O 0 2.725520789681468e-05
mediated O 0 4.688746412284672e-05
carcinogenesis O 0 0.014049616642296314
, O 0 1.1395504770916887e-06
we O 0 8.606335200056492e-07
used O 0 0.00010382330947322771
renal B-Disease 1 0.999997615814209
cell I-Disease 1 0.999955415725708
carcinoma I-Disease 1 0.9999998807907104
cell O 1 0.5349410176277161
lines O 0 0.0007387103978544474
stably O 0 0.0012672841548919678
transfected O 0 0.00024938135175034404
with O 0 1.3080243661534041e-06
wild O 0 2.227190816483926e-05
- O 0 0.003371833823621273
type O 0 0.0003211363509763032
VHL O 0 0.001007347833365202
- O 0 0.00015638773038517684
expressing O 0 1.9334180251462385e-05
transgenes O 0 0.000402648322051391
. O 0 1.4925465620763134e-05

Large O 0 6.01455285504926e-05
- O 0 7.211542833829299e-05
scale O 0 1.1338343028910458e-05
RNA O 0 6.595341233150975e-07
differential O 0 9.077114668798458e-07
display O 0 4.3554533135647944e-07
technology O 0 3.9965982523426646e-07
applied O 0 4.559911204182754e-08
to O 0 1.657609516314551e-08
these O 0 1.983342734490634e-08
cell O 0 1.1173945495102089e-05
lines O 0 1.9563108253350947e-06
identified O 0 2.6863824587053386e-07
several O 0 2.2514848652122055e-08
differentially O 0 9.737802884046687e-07
expressed O 0 6.870390478752597e-08
genes O 0 1.077469846677559e-07
, O 0 5.489727783469789e-08
including O 0 5.885250331516545e-08
an O 0 4.0955864477609794e-08
alpha O 0 1.4407379467229475e-06
carbonic O 0 4.843568149226485e-06
anhydrase O 0 8.188289939425886e-06
gene O 0 6.0086790654168e-07
, O 0 6.808061812080268e-07
termed O 0 3.4969489206559956e-05
CA12 O 0 0.0021487344056367874
. O 0 1.6229703760473058e-05

The O 0 3.5749922062677797e-06
deduced O 0 7.093535714375321e-06
protein O 0 1.2233849702170119e-06
sequence O 0 5.129321039021306e-07
was O 0 5.601046382253116e-07
classified O 0 1.16598687327496e-06
as O 0 3.676087700910102e-08
a O 0 1.6539893010758533e-07
one O 0 1.490700753947749e-07
- O 0 0.00034305607550777495
pass O 0 4.040465682919603e-06
transmembrane O 0 1.5789546523592435e-05
CA O 0 5.31397745362483e-06
possessing O 0 8.861063065523922e-07
an O 0 3.794298564230303e-08
apparently O 0 4.686897909778054e-07
intact O 0 3.722060739619337e-07
catalytic O 0 2.830293794886529e-07
domain O 0 1.4135763137801405e-07
in O 0 3.405718729254659e-08
the O 0 9.191055028168194e-08
extracellular O 0 1.715127109491732e-05
CA O 0 6.337426020763814e-05
module O 0 0.00024200243933591992
. O 0 6.946703706489643e-06

Reintroduced O 0 0.000276825885521248
wild O 0 9.153055725619197e-05
- O 0 0.000903284118976444
type O 0 5.893949492019601e-05
VHL B-Disease 0 0.0002517696702852845
strongly O 0 1.3859196315024747e-06
inhibited O 0 7.093753993103746e-07
the O 0 3.463893349930913e-08
overexpression O 0 6.978202691243496e-07
of O 0 4.9289354819848086e-08
the O 0 1.5888507221006876e-07
CA12 O 0 0.00016555501497350633
gene O 0 2.618002952203824e-07
in O 0 9.184693539054933e-08
the O 0 1.3286683042679215e-06
parental O 0 0.30534523725509644
renal B-Disease 1 0.9999996423721313
cell I-Disease 1 0.9999949932098389
carcinoma I-Disease 1 0.9999998807907104
cell O 1 0.872412919998169
lines O 0 0.0006852901424281299
. O 0 4.4882555812364444e-05

Similar O 0 2.6406651159049943e-05
results O 0 9.66992593021132e-06
were O 0 4.858622446590743e-07
obtained O 0 1.0030428256868618e-06
with O 0 1.073610633284261e-06
CA9 O 0 0.16891779005527496
, O 0 3.6509402434603544e-07
encoding O 0 6.264444891712628e-07
another O 0 1.3082639043204836e-06
transmembrane O 0 6.378040416166186e-05
CA O 0 2.0095340005354956e-05
with O 0 8.050230348999321e-08
an O 0 7.542899282952931e-08
intact O 0 3.6426456517801853e-06
catalytic O 0 3.245905190851772e-06
domain O 0 4.403253569762455e-06
. O 0 2.5219171675416874e-06

Although O 0 9.027476153278258e-06
both O 0 6.158901442177012e-07
domains O 0 1.1530798929015873e-06
of O 0 1.1051693604713364e-07
the O 0 2.3495442746934714e-07
VHL B-Disease 0 3.173226650687866e-05
protein O 0 1.478541662436328e-07
contribute O 0 5.9117333250924275e-08
to O 0 2.082644456891103e-08
regulation O 0 1.0302883168833432e-07
of O 0 7.918154665276234e-08
CA12 O 0 0.00040558382170274854
expression O 0 1.811747125657348e-07
, O 0 5.241982847792315e-08
the O 0 2.6199655778214037e-08
elongin O 0 3.1570179999107495e-05
binding O 0 7.053830586301046e-07
domain O 0 3.377108725999278e-07
alone O 0 2.583049649729219e-07
could O 0 2.175170834561868e-07
effectively O 0 1.6444109860458411e-06
regulate O 0 1.2564001735881902e-05
CA9 O 0 0.00980744045227766
expression O 0 4.492177140491549e-06
. O 0 4.5608258005813695e-06

We O 0 2.236397995147854e-05
mapped O 0 0.00021601408661808819
CA12 O 0 0.0125603461638093
and O 0 1.287885879719397e-05
CA9 O 0 0.0361500084400177
loci O 0 1.2269262697373051e-05
to O 0 7.527211209890083e-07
chromosome O 0 4.7547062422381714e-05
bands O 0 1.954772051249165e-05
15q22 O 0 0.00011853959586005658
and O 0 4.1567855078028515e-06
17q21 O 0 0.00024364018463529646
. O 0 1.5669544154661708e-05

2 O 0 4.060564606334083e-05
respectively O 0 2.1242258299025707e-05
, O 0 1.137995241151657e-06
regions O 0 1.7665217910689535e-06
prone O 0 3.989007382187992e-05
to O 0 6.09927539585442e-08
amplification O 0 3.5969578675576486e-06
in O 0 1.0697804952997103e-07
some O 0 1.6468561625515576e-07
human O 0 1.0367979484726675e-05
cancers B-Disease 0 0.01904783770442009
. O 0 8.937138773035258e-06

Additional O 0 1.4384190762939397e-05
experiments O 0 1.2352749763522297e-05
are O 0 1.8010628366482706e-07
needed O 0 1.6166657701432996e-07
to O 0 3.6228868793841684e-08
define O 0 3.972086233261507e-07
the O 0 3.537579473800179e-08
role O 0 1.007097623073605e-07
of O 0 1.7405270114068117e-07
CA O 0 0.00030351229361258447
IX O 0 0.001365590374916792
and O 0 6.100059181335382e-06
CA O 0 0.0002598975843284279
XII O 0 0.0034709081519395113
enzymes O 0 6.474601832451299e-07
in O 0 1.9208519219660047e-08
the O 0 1.4833372752320884e-08
regulation O 0 1.1773197883258035e-07
of O 0 8.096719028571897e-08
pH O 0 5.8407782489666715e-05
in O 0 1.3106395080342281e-08
the O 0 1.6639988942301898e-08
extracellular O 0 4.6295556899167423e-07
microenvironment O 0 6.981217666179873e-06
and O 0 3.1474687745003394e-08
its O 0 2.1778353342938317e-08
potential O 0 2.687376650101214e-07
impact O 0 7.108557724677667e-07
on O 0 2.3496355424867943e-05
cancer B-Disease 0 0.09809117764234543
cell O 0 0.00026582067948766053
growth O 0 2.76819737337064e-05
. O 0 5.906159458390903e-06

A O 0 1.722693741612602e-05
gene O 0 7.699456546106376e-06
encoding O 0 1.923134277603822e-06
a O 0 9.067744599633443e-07
transmembrane O 0 2.2502525098389015e-05
protein O 0 6.598373829547199e-07
is O 0 1.5439373157732916e-07
mutated O 0 8.239247790697846e-07
in O 0 3.32844109607322e-07
patients O 0 0.00015154022548813373
with O 0 0.04897655174136162
diabetes B-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999996423721313
and O 1 0.9610484838485718
optic B-Disease 1 0.9999996423721313
atrophy I-Disease 1 0.9999861717224121
( O 1 0.99349045753479
Wolfram B-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999977350234985
) O 0 1.674128907325212e-05
. O 0 1.3767266864306293e-05

Wolfram B-Disease 1 0.9999915361404419
syndrome I-Disease 1 0.999998927116394
( O 0 0.0010526006808504462
WFS B-Disease 1 0.9920879006385803
; O 0 0.00046714648487977684
OMIM O 1 0.9456250071525574
222300 O 0 0.011593797244131565
) O 0 2.258410859212745e-06
is O 0 2.009492618526565e-06
an O 0 1.4846988051431254e-05
autosomal B-Disease 1 0.9992246627807617
recessive I-Disease 1 0.9999897480010986
neurodegenerative I-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9934166669845581
defined O 0 2.0899498849757947e-05
by O 0 1.8030099226962193e-06
young O 0 9.56990243139444e-06
- O 0 0.001991163706406951
onset O 0 0.0014203446917235851
non O 0 1.8301096133654937e-05
- O 0 0.023062249645590782
immune O 0 0.00015054040704853833
insulin B-Disease 0 6.511690298793837e-05
- I-Disease 0 0.49861666560173035
dependent I-Disease 0 0.4733542501926422
diabetes I-Disease 1 0.9999991655349731
mellitus I-Disease 1 0.9999973773956299
and O 0 0.0016973126912489533
progressive O 1 0.9524981379508972
optic B-Disease 1 0.9999790191650391
atrophy I-Disease 1 0.9596614241600037
. O 0 0.00014806094986852258

Linkage O 0 0.0005346339894458652
to O 0 5.081957624497591e-06
markers O 0 6.636182661168277e-05
on O 0 8.184309081116226e-06
chromosome O 0 0.0006574208964593709
4p O 1 0.9960098266601562
was O 0 1.4378896594280377e-05
confirmed O 0 2.1845517039764673e-06
in O 0 1.6968741078926541e-07
five O 0 6.235441674107278e-07
families O 0 1.7899242266139481e-06
. O 0 3.3903891107911477e-06

On O 0 5.26334042660892e-06
the O 0 3.034174653748778e-07
basis O 0 2.339096596415402e-07
of O 0 3.3750222883099923e-07
meiotic O 0 0.10970018059015274
recombinants O 1 0.8618051409721375
and O 0 0.00047546278801746666
disease O 0 0.10274398326873779
- O 0 0.030851343646645546
associated O 0 1.93743035197258e-05
haplotypes O 0 7.487279071938246e-05
, O 0 5.356037036108319e-07
the O 0 4.591557569710858e-07
WFS B-Disease 0 0.0008744159713387489
gene O 0 1.4564411685569212e-06
was O 0 5.209539608586056e-07
localized O 0 2.1811044916830724e-06
to O 0 7.722628225792505e-08
a O 0 5.32499939254194e-07
BAC O 0 1.230238558491692e-05
/ O 0 7.11367010808317e-06
P1 O 0 3.411667057662271e-05
contig O 0 1.0579214176686946e-05
of O 0 4.051648616609782e-08
less O 0 1.0148995954750717e-07
than O 0 1.4178102958339878e-07
250 O 0 1.5858154256420676e-06
kb O 0 0.0002864097186829895
. O 0 1.0317890883015934e-05

Mutations O 0 0.0003580954216886312
in O 0 1.4645461305917706e-06
a O 0 8.848447237141954e-07
novel O 0 1.754189270286588e-06
gene O 0 1.4755709116798243e-06
( O 0 3.773628804992768e-07
WFS1 O 0 0.00013237302482593805
) O 0 4.379155882361374e-08
encoding O 0 1.699971079460738e-07
a O 0 1.9885800384145114e-07
putative O 0 3.1627230328012956e-06
transmembrane O 0 2.219596581198857e-06
protein O 0 1.82613462129666e-07
were O 0 5.54027117516398e-08
found O 0 4.06579978573518e-08
in O 0 1.3647848184916711e-08
all O 0 1.3708164381398547e-08
affected O 0 5.063291155238403e-07
individuals O 0 5.890348475645624e-08
in O 0 8.520222394281518e-08
six O 0 2.424543708912097e-06
WFS B-Disease 0 0.04116593673825264
families O 0 9.086157319870836e-07
, O 0 2.2938917254577973e-07
and O 0 1.5189399960036098e-07
these O 0 5.941531000530631e-08
mutations O 0 6.151382194730104e-07
were O 0 3.506250152440771e-07
associated O 0 1.4280980167313828e-06
with O 0 1.4965937680244679e-06
the O 0 7.913901936262846e-05
disease O 0 0.07935363799333572
phenotype O 0 0.00036158450529910624
. O 0 1.676833926467225e-05

WFS1 O 0 0.12334737181663513
appears O 0 3.3024563890649006e-05
to O 0 6.804816052863316e-07
function O 0 3.7304116062841786e-07
in O 0 8.202761847542206e-08
survival O 0 4.5093934204487596e-06
of O 0 1.815995744891552e-07
islet O 0 0.08867404609918594
beta O 0 8.920056643546559e-06
- O 0 5.010514723835513e-05
cells O 0 8.140042382365209e-07
and O 0 8.951402463708291e-08
neurons O 0 1.237614583260438e-06
. O 0 2.2827595103080967e-07
. O 0 1.7279521671298426e-06

Stable O 0 0.00017379717610310763
interaction O 0 2.8661090709647397e-06
between O 0 4.1354439872520743e-07
the O 0 5.634090882722376e-08
products O 0 1.8899943654560047e-07
of O 0 1.923730152952885e-08
the O 0 1.0441065256827642e-07
BRCA1 O 0 7.481667853426188e-05
and O 0 3.2112791359395487e-06
BRCA2 O 0 0.0006776609807275236
tumor B-Disease 0 0.000842363340780139
suppressor O 0 2.404422775725834e-05
genes O 0 6.360741622302157e-07
in O 0 4.1733866851245693e-07
mitotic O 0 0.00040644986438564956
and O 0 1.5384095604531467e-05
meiotic O 0 0.36587002873420715
cells O 0 0.0002071800408884883
. O 0 1.5383451682282612e-05

BRCA1 O 0 0.016392743214964867
and O 0 4.050687130074948e-05
BRCA2 O 0 0.00020631916413549334
account O 0 1.55489101416606e-06
for O 0 2.2412494615764444e-07
most O 0 1.601480192903182e-07
cases O 0 2.6593676238917396e-07
of O 0 1.1886784534453909e-07
familial O 0 0.0027973290998488665
, O 0 1.4543329598382115e-06
early O 0 1.8749977243714966e-05
onset O 1 0.7383357882499695
breast B-Disease 1 0.7357292175292969
and I-Disease 0 0.0006447065388783813
/ I-Disease 1 0.9992318153381348
or I-Disease 1 0.9979586601257324
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999687671661377
and O 0 1.4804621741859592e-06
encode O 0 9.6394182946824e-07
products O 0 3.5301491152495146e-06
that O 0 3.987319985299109e-08
each O 0 2.6614880965780685e-08
interact O 0 2.1743329625678598e-07
with O 0 3.459800268501567e-07
hRAD51 O 0 0.00017262290930375457
. O 0 4.319463187130168e-06

Results O 0 6.615047459490597e-05
presented O 0 1.4482304322882555e-05
here O 0 1.3743215276917908e-06
show O 0 9.291397304878046e-07
that O 0 2.71719841293816e-07
BRCA1 O 0 7.188405288616195e-05
and O 0 4.5172359932621475e-06
BRCA2 O 0 0.0003783467400353402
coexist O 0 9.990475518861786e-06
in O 0 2.4818214683364204e-07
a O 0 3.532253742832836e-07
biochemical O 0 6.333040801109746e-06
complex O 0 5.462963144964306e-06
and O 0 4.163278219948552e-07
colocalize O 0 0.00021886135800741613
in O 0 2.1811491990320064e-07
subnuclear O 0 0.00012125110515626147
foci O 0 1.0394640412414446e-05
in O 0 9.070523532273e-08
somatic O 0 5.11415782966651e-06
cells O 0 1.5640492847524001e-06
and O 0 8.776861193382501e-08
on O 0 5.379040857178552e-08
the O 0 1.590417575414449e-08
axial O 0 2.6071847969433293e-07
elements O 0 6.594788004576912e-08
of O 0 1.4924717106623575e-07
developing O 0 1.570970198372379e-05
synaptonemal O 0 0.00885767675936222
complexes O 0 0.0002457637747284025
. O 0 1.490782688051695e-05

Like O 0 0.00014816445764154196
BRCA1 O 0 0.0011654188856482506
and O 0 9.860985301202163e-06
RAD51 O 0 0.012783283367753029
, O 0 3.16181217385747e-06
BRCA2 O 0 1.4781632671656553e-05
relocates O 0 5.693886123481207e-06
to O 0 3.2422002504972625e-07
PCNA O 0 0.0009326928993687034
+ O 0 7.059564268274698e-06
replication O 0 9.119101491705806e-07
sites O 0 3.6631467992265243e-07
following O 0 9.766041131342718e-08
exposure O 0 3.9826724673730496e-07
of O 0 6.716885536661721e-08
S O 0 0.0004875898302998394
phase O 0 1.9147186321788467e-05
cells O 0 1.52529798924661e-06
to O 0 1.1889029138956175e-07
hydroxyurea O 0 7.357954746112227e-05
or O 0 2.3548275294160703e-06
UV O 0 0.002305967267602682
irradiation O 0 8.242779585998505e-05
. O 0 6.851174475741573e-06

Thus O 0 2.3888285795692354e-05
, O 0 4.7458875087613706e-06
BRCA1 O 0 4.580490349326283e-05
and O 0 1.3132740832588752e-06
BRCA2 O 0 1.1292489944025874e-05
participate O 0 3.2494747870259744e-07
, O 0 1.9463550415821373e-07
together O 0 1.5676108944262523e-07
, O 0 6.879503899881456e-08
in O 0 2.6644643824624836e-08
a O 0 2.1905589164816774e-07
pathway O 0 1.170599603028677e-06
( O 0 2.5335674536108854e-07
s O 0 0.000932596973143518
) O 0 5.8329721497329956e-08
associated O 0 1.0415227791327197e-07
with O 0 1.1473016314766937e-08
the O 0 1.0541050698975596e-08
activation O 0 1.0634069269599422e-07
of O 0 2.8963230036538334e-08
double O 0 2.148405883417581e-06
- O 0 0.00010382311302237213
strand O 0 8.432138201897033e-06
break O 0 2.596034846646944e-06
repair O 0 0.000676649680826813
and O 0 7.519785754084296e-07
/ O 0 1.6421463442384265e-05
or O 0 3.349946098296641e-07
homologous O 0 7.182740318967262e-06
recombination O 0 4.944800821249373e-05
. O 0 1.156246435130015e-05

Dysfunction O 0 0.17649073898792267
of O 0 3.059429673157865e-06
this O 0 8.665278414810018e-07
pathway O 0 9.798636710911524e-06
may O 0 1.1230073369006277e-06
be O 0 2.4007604793041537e-08
a O 0 3.9346549129959385e-08
general O 0 3.9991184053178586e-07
phenomenon O 0 2.7347643936082022e-06
in O 0 4.454297908296212e-08
the O 0 2.0694585600722348e-08
majority O 0 1.3484708460964612e-07
of O 0 3.068195653099792e-08
cases O 0 7.894491886872856e-07
of O 0 1.734916963869182e-06
hereditary B-Disease 1 0.9946467280387878
breast I-Disease 1 0.9717760682106018
and I-Disease 0 0.002059291349723935
/ I-Disease 1 0.9987562894821167
or I-Disease 1 0.9968435764312744
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999772310256958
. O 0 8.276614607893862e-06
. O 0 1.87894438568037e-05

A O 0 4.6054123231442645e-05
novel O 0 2.4785227651591413e-05
Arg362Ser O 0 0.001285393605940044
mutation O 0 3.7508850709855324e-06
in O 0 1.606672270781928e-07
the O 0 1.2251508962890512e-07
sterol O 0 6.3451545429416e-05
27 O 0 1.1026970241800882e-05
- O 0 0.00025426404317840934
hydroxylase O 0 8.813610475044698e-05
gene O 0 9.029920988723461e-07
( O 0 9.143217027940409e-08
CYP27 O 0 4.1174022044287995e-05
) O 0 2.9081023811272644e-08
: O 0 1.1547373723885812e-08
its O 0 9.859243199628054e-09
effects O 0 9.263972344797367e-08
on O 0 1.1309849412555195e-07
pre O 0 1.2973877346666995e-05
- O 0 2.080204694721033e-06
mRNA O 0 7.172871363536615e-08
splicing O 0 1.1076890160666153e-07
and O 0 4.259507591086731e-08
enzyme O 0 4.2884965978373657e-07
activity O 0 1.1105212252005003e-06
. O 0 1.3769031284027733e-06

A O 0 2.9772374546155334e-05
novel O 0 1.2713627256744076e-05
C O 0 0.0001262972946278751
to O 0 2.3911528046483e-07
A O 0 3.9279893826460466e-07
mutation O 0 2.9778394150525855e-07
in O 0 1.979204711233251e-08
the O 0 5.28553556478073e-08
sterol O 0 2.306113856320735e-05
27 O 0 2.419415977783501e-06
- O 0 4.135803101235069e-05
hydroxylase O 0 3.490035669528879e-05
gene O 0 3.6572791373146174e-07
( O 0 7.159339077134064e-08
CYP27 O 0 2.8273900170461275e-05
) O 0 4.712453716138043e-08
was O 0 1.5737583680675016e-07
identified O 0 1.0969620944933922e-07
by O 0 1.015152850669665e-08
sequencing O 0 1.7493884740815702e-07
amplified O 0 4.136788902542321e-07
CYP27 O 0 1.103691101889126e-05
gene O 0 1.2307909003084205e-07
products O 0 1.995824447931227e-07
from O 0 3.6878933684647563e-08
a O 0 2.6585459522721067e-07
patient O 0 1.2625355338968802e-05
with O 0 9.559038517181762e-06
cerebrotendinous B-Disease 1 0.9999817609786987
xanthomatosis I-Disease 1 0.9999666213989258
( O 0 5.30820652784314e-05
CTX B-Disease 0 0.44295939803123474
) O 0 3.1745021260576323e-06
. O 0 4.157531293458305e-06

The O 0 1.201230497827055e-05
mutation O 0 2.2740256099496037e-05
changed O 0 2.14907208828663e-06
the O 0 2.2767437712900573e-07
adrenodoxin O 0 4.003783396910876e-05
cofactor O 0 3.58512897946639e-06
binding O 0 1.3855310498911422e-06
residue O 0 8.76112244441174e-06
362Arg O 0 1.865578451543115e-05
to O 0 3.2026312624111597e-07
362Ser O 0 3.549956818460487e-05
( O 0 3.1729538818581204e-07
CGT O 0 3.0453691579168662e-05
362Arg O 0 9.13611802388914e-06
to O 0 3.0582052090721845e-07
AGT O 0 0.0003867835912387818
362Ser O 0 5.803484600619413e-05
) O 0 1.192614007550219e-07
, O 0 7.900745657707375e-08
and O 0 1.1386494946918901e-07
was O 0 9.822661013458855e-07
responsible O 0 5.46074943486019e-06
for O 0 9.185618182527833e-06
deficiency O 0 0.04397330433130264
in O 0 3.871097931096301e-08
the O 0 6.627725213093072e-08
sterol O 0 2.836669773387257e-05
27 O 0 2.268335720145842e-06
- O 0 8.51336881169118e-06
hydroxylase O 0 5.976030024612555e-06
activity O 0 1.9040713539197895e-07
, O 0 3.268089798780238e-08
as O 0 1.0939111838581539e-08
confirmed O 0 7.82472682203661e-08
by O 0 1.5546248732789536e-08
expression O 0 1.7902122451118885e-08
of O 0 7.66515828587444e-09
mutant O 0 1.9234444437188358e-07
cDNA O 0 3.3618837846915994e-07
into O 0 1.321907490137164e-07
COS O 0 0.00013095897156745195
- O 0 1.880751551652793e-05
1 O 0 1.3108865459798835e-06
cells O 0 3.0388825962290866e-06
. O 0 1.5927024605844053e-06

Quantitative O 0 3.785714216064662e-05
analysis O 0 8.543134754290804e-06
showed O 0 1.2808453902835026e-05
that O 0 4.058934521822266e-08
the O 0 2.038074242705079e-08
expression O 0 4.77836366030715e-08
of O 0 4.431248967762258e-08
CYP27 O 0 4.8510330088902265e-05
gene O 0 1.328563996594312e-07
mRNA O 0 5.454585760844566e-08
in O 0 3.4254124869903535e-08
the O 0 8.530612660706538e-08
patient O 0 2.114995140800602e-06
represented O 0 1.3999687098475988e-06
52 O 0 1.5407911632792093e-05
. O 0 6.020074579282664e-06

5 O 0 4.451491258805618e-05
% O 0 1.6037865862017497e-06
of O 0 1.9385727512144513e-07
the O 0 4.0865978689907934e-07
normal O 0 2.8266999834158923e-06
level O 0 5.872024757991312e-06
. O 0 6.758046311006183e-06

As O 0 6.5809681473183446e-06
the O 0 7.888380650911131e-07
mutation O 0 3.001062168550561e-06
occurred O 0 1.480058358538372e-06
at O 0 1.3278940969030373e-07
the O 0 2.4281519017677056e-08
penultimate O 0 4.5705434104093e-07
nucleotide O 0 1.299704024404491e-07
of O 0 2.0793697430576685e-08
exon O 0 1.855360437730269e-06
6 O 0 7.242998663059552e-07
( O 0 2.7981355898987204e-08
- O 0 9.567989991410286e-07
2 O 0 5.169462014009696e-08
position O 0 9.528751121479218e-09
of O 0 8.362644798864949e-09
exon O 0 1.7678632957540685e-06
6 O 0 9.93549065242405e-07
- O 0 1.748240720189642e-05
intron O 0 5.738907202612609e-05
6 O 0 2.949120130324445e-07
splice O 0 1.5406970987896784e-06
site O 0 2.912541390287515e-07
) O 0 5.573495887034596e-09
of O 0 4.404198783447555e-09
the O 0 1.2388878367630696e-08
gene O 0 9.813992818408224e-08
, O 0 2.9534927392660393e-08
we O 0 2.818683242367115e-08
hypothesized O 0 2.2100823571236106e-07
that O 0 2.0495468433523456e-08
the O 0 4.684029164536696e-08
mutation O 0 4.702639841980272e-07
may O 0 1.9569118592244195e-07
partially O 0 2.7849421257997165e-07
affect O 0 6.803701069202361e-08
the O 0 7.77954323183394e-09
normal O 0 4.2603204519764404e-08
splicing O 0 1.462794188000771e-07
efficiency O 0 5.848780233463913e-07
in O 0 6.529665341759028e-08
exon O 0 3.6943392842658795e-06
6 O 0 1.3337159998627612e-06
and O 0 1.0513425507951979e-07
cause O 0 1.200432819814523e-07
alternative O 0 7.371247079390741e-08
splicing O 0 5.340990014701674e-07
elsewhere O 0 4.167167162449914e-07
, O 0 2.358100559263221e-08
which O 0 2.0291837543595648e-08
resulted O 0 3.1048517712406465e-07
in O 0 1.7263842266856955e-07
decreased O 0 4.8974852688843384e-06
transcript O 0 5.731482815463096e-06
in O 0 3.5524217878446507e-07
the O 0 1.0631690656737192e-06
patient O 0 6.643927190452814e-05
. O 0 7.935411304060835e-06

Transfection O 0 0.0021820911206305027
of O 0 5.36549214302795e-06
constructed O 0 8.650789095554501e-05
minigenes O 0 0.014151740819215775
, O 0 1.1529544963195804e-06
with O 0 1.8965231163292628e-07
or O 0 2.597684272132028e-07
without O 0 7.12370606947843e-08
the O 0 2.5712763473961786e-08
mutation O 0 1.4277397042405937e-07
, O 0 1.8224110220899092e-08
into O 0 3.437317275256646e-08
COS O 0 0.0002707467065192759
- O 0 2.8203234251122922e-05
1 O 0 5.671010967489565e-07
cells O 0 4.2145910583712975e-07
confirmed O 0 9.360898900467873e-08
that O 0 9.76086056425629e-09
the O 0 2.3922128278286436e-08
mutant O 0 1.4890797501720954e-06
minigene O 0 7.507640111725777e-05
was O 0 7.5760755180454e-07
responsible O 0 1.7849795597157936e-07
for O 0 2.4006871157666865e-08
a O 0 4.059755553953437e-08
mRNA O 0 9.210763352029971e-08
species O 0 1.6898354715522146e-08
alternatively O 0 1.0133173589110811e-07
spliced O 0 6.894011335134564e-07
at O 0 1.7184406431169919e-07
an O 0 2.1410063055782302e-08
activated O 0 1.371996972920897e-06
cryptic O 0 4.5915047053313174e-07
5 O 0 5.5450708913440394e-08
splice O 0 6.743662765984482e-07
site O 0 2.733283679390297e-07
88 O 0 1.7384699901867862e-07
bp O 0 4.830283160117688e-07
upstream O 0 6.57998739939103e-08
from O 0 1.051675102559102e-08
the O 0 7.919979339021666e-09
3 O 0 7.063578522092939e-08
end O 0 1.5267782771388738e-07
of O 0 8.084188607426768e-08
exon O 0 1.7057853256119415e-05
6 O 0 6.666757599305129e-06
. O 0 3.5151799693267094e-06

Our O 0 1.4752003153262194e-05
data O 0 5.387436885939678e-06
suggest O 0 1.4381079154190957e-06
that O 0 6.137552333029817e-08
the O 0 5.083088439050698e-08
C O 0 2.19511039176723e-05
to O 0 4.481431403746683e-08
A O 0 1.6490029963733832e-07
mutation O 0 1.919292316188148e-07
at O 0 6.415460518383043e-08
the O 0 1.353097633938205e-08
penultimate O 0 4.6938581022004655e-07
nucleotide O 0 9.744196916017245e-08
of O 0 1.5110190432210402e-08
exon O 0 9.009860946207482e-07
6 O 0 9.966868219635217e-08
of O 0 7.431962600890074e-09
the O 0 2.453767677934593e-08
CYP27 O 0 6.650036812061444e-05
gene O 0 1.90618251849628e-07
not O 0 1.4369048173534793e-08
only O 0 3.0139517548377626e-08
causes O 0 2.270893901368254e-06
the O 0 2.0950167254341068e-06
deficiency B-Disease 0 0.009688032791018486
in I-Disease 0 5.786100132354477e-08
the I-Disease 0 1.1226118346030489e-07
sterol I-Disease 0 4.245496529620141e-05
27 I-Disease 0 2.4856308300513774e-06
- I-Disease 0 1.2551331565191504e-05
hydroxylase I-Disease 0 4.741231805382995e-06
activity I-Disease 0 2.2102045704741613e-07
, O 0 4.4229064855016986e-08
but O 0 2.7122009527147384e-08
also O 0 3.376856838599451e-08
partially O 0 5.921399406361161e-07
leads O 0 7.234204701944691e-08
to O 0 6.933219331983764e-09
alternative O 0 5.381421530614716e-08
pre O 0 4.626660938811256e-06
- O 0 6.422623641810787e-07
mRNA O 0 4.612658699443273e-08
splicing O 0 7.482658759272454e-08
of O 0 1.9504273751635992e-08
the O 0 9.991936167352833e-08
gene O 0 1.6967799183476018e-06
. O 0 2.31633521252661e-06

To O 0 7.649702638445888e-06
our O 0 1.4610850485041738e-06
knowledge O 0 6.740390290360665e-07
, O 0 1.1555860623957415e-07
this O 0 1.019711248773092e-08
is O 0 2.7496623644651663e-08
the O 0 1.1447878200954165e-08
first O 0 7.486498532216501e-08
report O 0 9.979841308904724e-08
regarding O 0 1.814929220245176e-07
effects O 0 5.837958383381192e-07
on O 0 2.4250653041235637e-07
pre O 0 2.8616424970095977e-05
- O 0 2.9127711513865506e-06
mRNA O 0 6.334433066967904e-08
splicing O 0 7.829294190742075e-08
of O 0 1.1457795601188536e-08
a O 0 5.7550405330175636e-08
mutation O 0 1.8995207540228876e-07
at O 0 5.234080191485191e-08
the O 0 2.0117651544637738e-08
- O 0 1.4084499525779393e-05
2 O 0 2.381996466738201e-07
position O 0 5.062189956106522e-08
of O 0 1.7322465239999474e-08
a O 0 1.7369453075843921e-07
5 O 0 6.102696943344199e-07
splice O 0 2.0117198801017366e-05
site O 0 4.815083229914308e-06
. O 0 3.6519954846880864e-06

ATM O 0 0.0037336833775043488
germline O 0 0.008535157889127731
mutations O 0 0.00015723388059996068
in O 0 8.40252687339671e-06
classical O 0 0.00036734953755512834
ataxia B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999897480010986
telangiectasia I-Disease 1 0.9999982118606567
patients O 0 0.007541246246546507
in O 0 5.659087491949322e-07
the O 0 5.293753133628343e-07
Dutch O 0 4.1050909203477204e-05
population O 0 9.453164580008888e-07
. O 0 3.772056516027078e-06

Germline O 0 0.08011922240257263
mutations O 0 0.00043435857514850795
in O 0 2.0651350496336818e-06
the O 0 4.4025637180311605e-07
ATM O 0 4.6955698053352535e-05
gene O 0 7.316701271520287e-07
are O 0 6.395961094085578e-08
responsible O 0 1.254002881978522e-06
for O 0 3.879476025758777e-06
the O 0 0.07838413864374161
autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999995231628418
( O 0 0.0004782965697813779
A B-Disease 1 0.9745543599128723
- I-Disease 1 0.999937891960144
T I-Disease 1 0.9999555349349976
) O 0 2.7018904802389443e-06
. O 0 3.2744439977250295e-06

In O 0 5.9723324739024974e-06
our O 0 7.375303425760649e-07
study O 0 2.932198128746677e-07
, O 0 1.4868192010908388e-07
we O 0 4.223749172638236e-08
have O 0 1.7617551861803804e-08
determined O 0 9.322625516006156e-08
the O 0 2.1359202406756594e-08
ATM O 0 9.985827091441024e-06
mutation O 0 1.330701877577667e-07
spectrum O 0 8.476001767121488e-07
in O 0 6.362670745829746e-08
19 O 0 3.4910152635347913e-07
classical O 0 8.02191777893313e-07
A B-Disease 0 0.32653728127479553
- I-Disease 1 0.9999667406082153
T I-Disease 1 0.9999995231628418
patients O 0 0.00016503396909683943
, O 0 2.2356351792041096e-07
including O 0 9.712430681929618e-08
some O 0 5.051368390240896e-08
immigrant O 0 4.167546649114229e-06
populations O 0 1.7570344823525375e-07
, O 0 5.072144659834521e-08
as O 0 1.418388517748781e-08
well O 0 1.8249188826757745e-08
as O 0 1.0373807590724482e-08
12 O 0 4.646602747016004e-08
of O 0 6.324062695739485e-08
Dutch O 0 2.97130804938206e-06
ethnic O 0 7.723688213445712e-07
origin O 0 1.6095627870527096e-06
. O 0 4.012820681964513e-06

Both O 0 4.342179181549e-06
the O 0 4.1432244302086474e-07
protein O 0 4.6001741793588735e-07
truncation O 0 5.506167326529976e-06
test O 0 1.599253437234438e-06
( O 0 7.783138045169835e-08
PTT O 0 1.145086798715056e-06
) O 0 2.546662436486713e-08
and O 0 1.5163427846687227e-08
the O 0 1.273901517606646e-08
restriction O 0 2.1435177188777743e-07
endonuclease O 0 2.229992242064327e-05
fingerprinting O 0 0.0001518096396466717
( O 0 3.160589585604612e-07
REF O 0 0.0001024371013045311
) O 0 1.2825344342104472e-08
method O 0 1.752598777216008e-08
were O 0 1.4310844953513424e-08
used O 0 2.9616611385563374e-08
and O 0 6.628180670986694e-08
compared O 0 2.292924961011522e-07
for O 0 1.1988444015287314e-08
their O 0 1.177366559801385e-08
detection O 0 4.906639787805034e-07
efficiency O 0 7.751750672468916e-07
, O 0 3.453068586622976e-08
identifying O 0 1.910457427811707e-07
76 O 0 1.1874949450429995e-06
% O 0 2.539619181618491e-08
and O 0 2.4148503641185926e-08
60 O 0 1.1244032549484473e-07
% O 0 1.8486364439240788e-08
of O 0 1.924361292537924e-08
the O 0 2.6474694436728896e-07
mutations O 0 4.344060016592266e-06
, O 0 5.688875148734951e-07
respectively O 0 6.746185135853011e-06
. O 0 5.2812706599070225e-06

Most O 0 9.507350478088483e-05
patients O 0 0.0005252307746559381
were O 0 1.2148801715738955e-06
found O 0 7.454906949533324e-07
to O 0 1.2322942666287418e-07
be O 0 3.491001905331359e-07
compound O 0 1.8369748431723565e-05
heterozygote O 0 0.00014276498404797167
. O 0 9.928188774210867e-06

Seventeen O 0 9.371238411404192e-05
mutations O 0 5.351286017685197e-05
were O 0 7.70841154462687e-07
distinct O 0 2.864382793177356e-07
, O 0 6.213478087602198e-08
of O 0 1.5087698201909916e-08
which O 0 9.215542462470694e-08
10 O 0 1.6726357898733113e-07
were O 0 1.489063947701652e-07
not O 0 1.779550586888945e-07
reported O 0 3.700686193042202e-06
previously O 0 3.535809582899674e-06
. O 0 5.265288564260118e-06

Mutations O 0 0.0002961100544780493
are O 0 1.4240330301618087e-06
small O 0 2.0713364392577205e-06
deletions O 0 3.0456392778432928e-05
or O 0 2.201003098889487e-06
point O 0 4.750256721308688e-06
mutations O 0 5.95888332100003e-06
frequently O 0 1.5654908338547102e-06
affecting O 0 2.260466317238752e-06
splice O 0 9.079892333829775e-05
sites O 0 2.5364701286889613e-05
. O 0 1.4957898201828357e-05

Moreover O 0 0.00015426245226990432
, O 0 3.819913672487019e-06
a O 0 1.992383431570488e-06
16 O 0 5.942578809481347e-06
. O 0 8.222690667025745e-06

7 O 0 0.00021189828112255782
- O 0 0.0002520689449738711
kb O 0 8.870608871802688e-05
genomic O 0 4.198715032543987e-06
deletion O 0 1.9854032871080562e-06
of O 0 6.771529115212616e-08
the O 0 4.442521372993724e-08
3 O 0 2.0105994735786226e-07
end O 0 9.09652939640182e-08
of O 0 9.844717041573858e-09
the O 0 1.943271854543127e-08
gene O 0 9.988144711314817e-08
, O 0 5.776980671612364e-08
most O 0 3.6054533580909265e-08
likely O 0 1.3990542413466756e-07
a O 0 3.54242750688627e-08
result O 0 3.3939489441081605e-08
of O 0 2.1045270415243067e-08
recombination O 0 2.337431396881584e-06
between O 0 2.8876468149974244e-07
two O 0 1.384839976026342e-07
LINE O 0 4.16035527450731e-06
elements O 0 3.066581371058419e-07
, O 0 4.645145281756413e-07
was O 0 2.5782260308915284e-06
identified O 0 8.861316928232554e-06
. O 0 5.005417733627837e-06

The O 0 4.132295543968212e-06
most O 0 7.991283155206474e-07
frequently O 0 2.0728698473249096e-06
found O 0 1.1073760788349318e-06
mutation O 0 1.4050621075512026e-06
, O 0 7.884319757067715e-07
identified O 0 1.930944563355297e-06
in O 0 8.528302686272582e-08
three O 0 1.4092621825056995e-07
unrelated O 0 6.663407930318499e-06
Turkish O 0 4.624076154868817e-06
A B-Disease 0 0.04198338836431503
- I-Disease 1 0.9990856647491455
T I-Disease 1 0.9999840259552002
individuals O 0 6.544253778884013e-07
, O 0 1.808260350344426e-07
was O 0 1.080924334928568e-06
previously O 0 8.35368666685099e-07
described O 0 1.9945014173572417e-06
to O 0 5.593829754957369e-08
be O 0 3.8487172560053295e-08
a O 0 2.424152114599565e-07
Turkish O 0 3.2405482670583297e-06
A B-Disease 0 0.022652506828308105
- I-Disease 1 0.9986832737922668
T I-Disease 1 0.99996018409729
founder O 0 0.0004418689350131899
mutation O 0 2.4851829948602244e-05
. O 0 6.625325113418512e-06

The O 0 5.036407856096048e-06
presence O 0 1.8338464542466681e-06
of O 0 2.7752176379181037e-07
a O 0 1.7926746522789472e-06
founder O 0 0.00012074194091837853
mutation O 0 2.8883296181447804e-06
among O 0 2.446685698487272e-07
relatively O 0 9.348335083814163e-07
small O 0 3.5519946095519117e-07
ethnic O 0 8.957840691437013e-08
population O 0 2.285819711289605e-08
groups O 0 1.5084332005699252e-08
in O 0 1.3131792542253606e-08
Western O 0 8.893676550769669e-08
Europe O 0 1.592121066096297e-07
could O 0 2.051739613762038e-07
indicate O 0 2.5330720632155135e-07
a O 0 1.3671809995230433e-07
high O 0 3.890535481332336e-06
carrier O 0 3.6561318665917497e-06
frequency O 0 1.8253544453727955e-07
in O 0 6.235227800743814e-08
such O 0 3.2501938562745636e-07
communities O 0 2.491920440661488e-06
. O 0 4.724612608697498e-06

In O 0 9.013545059133321e-05
patients O 0 0.0002324551169294864
of O 0 8.633833772364596e-07
Dutch O 0 3.4232234611408785e-05
ethnic O 0 1.021902562570176e-06
origin O 0 3.1630591479370196e-07
, O 0 2.843865161139547e-07
however O 0 1.778909251015648e-07
, O 0 1.9113758753519505e-07
no O 0 1.769295749909361e-07
significant O 0 9.310343784818542e-07
founder O 0 2.7573849365580827e-05
effect O 0 1.5246305338223465e-06
could O 0 5.465665822157462e-07
be O 0 2.2667302346235374e-07
identified O 0 4.314716079534264e-06
. O 0 2.667490662133787e-06

The O 0 1.4998850019765086e-05
observed O 0 2.345560642424971e-05
genetic O 0 1.4429419934458565e-05
heterogeneity O 0 2.296249476785306e-05
including O 0 7.308429985641851e-07
the O 0 2.6926099394586345e-07
relative O 0 1.2686801710515283e-05
high O 0 7.409371391986497e-06
percentage O 0 9.41375105867337e-07
of O 0 6.944286212728912e-08
splice O 0 9.207032417180017e-05
- O 0 0.0007863606442697346
site O 0 1.3683756151294801e-05
mutations O 0 8.630112802165968e-07
had O 0 1.054105496223201e-07
no O 0 5.2393239968751004e-08
reflection O 0 3.545699769347266e-07
on O 0 3.393425345166179e-07
the O 0 8.151026804625872e-07
phenotype O 0 8.199786680052057e-05
. O 0 7.083923719619634e-06

All O 0 3.9283873775275424e-05
patients O 0 0.0002934905933216214
manifested O 0 1.1882213584613055e-05
classical O 0 7.138781711546471e-06
A B-Disease 0 0.022450949996709824
- I-Disease 1 0.9845874309539795
T I-Disease 1 0.999594509601593
and O 0 7.587933623653953e-07
increased O 0 1.1296779121039435e-06
cellular O 0 1.4974251826060936e-05
radioresistant O 0 0.0001433067227480933
DNA O 0 1.0698396181396674e-05
synthesis O 0 6.665562523266999e-06
. O 0 5.07571439811727e-06

Determination O 0 5.208431321079843e-05
of O 0 9.809124321691343e-07
the O 0 3.6868948427581927e-07
genomic O 0 3.4909894566226285e-06
structure O 0 5.303824650582101e-07
of O 0 4.780715201491148e-08
the O 0 1.4713327800564002e-07
COL4A4 O 0 0.0002894341596402228
gene O 0 6.603145266126376e-07
and O 0 1.6516517575837497e-07
of O 0 4.5426625661093567e-07
novel O 0 0.00015714306209702045
mutations O 0 0.0037918861489742994
causing O 0 0.1809229701757431
autosomal B-Disease 1 0.9995673298835754
recessive I-Disease 1 0.9999830722808838
Alport I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.999968409538269
. O 0 0.0005496881785802543

Autosomal B-Disease 1 0.9999186992645264
recessive I-Disease 1 0.9999904632568359
Alport I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999939203262329
is O 0 9.084361954592168e-05
a O 0 0.00013614949421025813
progressive O 1 0.5945835113525391
hematuric B-Disease 1 0.999697208404541
glomerulonephritis I-Disease 1 0.9999923706054688
characterized O 0 0.12142916768789291
by O 0 0.00023042960674501956
glomerular B-Disease 1 0.9969049096107483
basement I-Disease 1 0.927520751953125
membrane I-Disease 0 0.11583693325519562
abnormalities I-Disease 1 0.9614895582199097
and O 0 1.2995051292818971e-05
associated O 0 1.1072176675952505e-05
with O 0 2.4293810838571517e-06
mutations O 0 3.5772088722296758e-06
in O 0 7.36708614113013e-08
either O 0 8.629785241964782e-08
the O 0 9.255636257421429e-08
COL4A3 O 0 0.0010680737905204296
or O 0 1.34368917770189e-07
the O 0 4.455589674989824e-08
COL4A4 O 0 6.80542943882756e-05
gene O 0 2.0762081476277672e-07
, O 0 2.0265073175096404e-08
which O 0 7.447443550745447e-09
encode O 0 4.5765101930328456e-08
the O 0 3.624566602411505e-08
alpha3 O 0 2.047817724815104e-05
and O 0 3.843846343443147e-07
alpha4 O 0 0.0009233811288140714
type O 0 0.0001863733632490039
IV O 1 0.674145519733429
collagen O 0 0.006407800130546093
chains O 0 0.00013128944556228817
, O 0 1.6107237570395228e-06
respectively O 0 1.0096831829287112e-05
. O 0 3.6038627513335086e-06

To O 0 6.3418951867788564e-06
date O 0 6.660879080300219e-06
, O 0 4.6394163177865266e-07
mutation O 0 5.187230840419943e-07
screening O 0 1.2387316701278905e-06
in O 0 2.525100128991653e-08
the O 0 2.2182028658335184e-08
two O 0 3.0243750614999954e-08
genes O 0 1.21434453603797e-07
has O 0 4.5498335765614684e-08
been O 0 9.906012365945571e-08
hampered O 0 5.699513712897897e-05
by O 0 1.1792672438559748e-07
the O 0 4.798035391218036e-08
lack O 0 1.6365650878924498e-07
of O 0 1.377258911361423e-07
genomic O 0 8.22116999188438e-06
structure O 0 5.673765826941235e-06
information O 0 4.941944553138455e-06
. O 0 5.7722945712157525e-06

We O 0 1.814351708162576e-05
report O 0 3.1456465876544826e-06
here O 0 3.857831245568377e-07
the O 0 4.1947661344465814e-08
complete O 0 4.838314566768531e-07
characterization O 0 6.198550181579776e-06
of O 0 7.553207836963338e-08
the O 0 4.908698514327625e-08
48 O 0 2.1083563694901386e-07
exons O 0 2.4826761091389926e-07
of O 0 1.7966124588042476e-08
the O 0 5.5940855503422426e-08
COL4A4 O 0 0.00021034045494161546
gene O 0 3.191983353190153e-07
, O 0 4.952664411916885e-08
a O 0 6.11364754377064e-08
comprehensive O 0 6.426299705708516e-07
gene O 0 2.684556363874435e-07
screen O 0 2.0982479327358305e-06
, O 0 1.2695190321210248e-07
and O 0 5.635294542116753e-08
the O 0 1.1087371021289982e-08
subsequent O 0 9.261498945534186e-08
detection O 0 5.926601716055302e-07
of O 0 2.4025744949085492e-08
10 O 0 2.0137792944296962e-07
novel O 0 3.4071973686877755e-07
mutations O 0 6.842573156973231e-07
in O 0 2.6774867478707165e-07
eight O 0 9.894550748867914e-05
patients O 0 0.4790048897266388
diagnosed O 1 0.9990978240966797
with O 0 0.12319941073656082
autosomal B-Disease 1 0.999915599822998
recessive I-Disease 1 0.99997878074646
Alport I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.9999656677246094
. O 0 0.0003332571650389582

Furthermore O 0 0.00016242246783804148
, O 0 3.1201877845887793e-06
we O 0 3.657945057966572e-07
identified O 0 2.29725870326547e-07
a O 0 5.0882974278465554e-08
glycine O 0 2.5906927021424053e-06
to O 0 3.024438299803478e-08
alanine O 0 8.184583748516161e-07
substitution O 0 1.1639522057294016e-07
in O 0 2.940609356016921e-08
the O 0 2.3556101069743818e-08
collagenous O 0 6.0257014411035925e-05
domain O 0 1.6653950751788216e-07
that O 0 2.4390832464860068e-08
is O 0 6.658057571939935e-08
apparently O 0 9.369210829390795e-07
silent O 0 1.7922335473485873e-06
in O 0 4.9635776377954244e-08
the O 0 9.058577177256666e-08
heterozygous O 0 8.53762571750849e-07
carriers O 0 1.3337133850654936e-06
, O 0 1.7875073865525337e-07
in O 0 1.6891144127839652e-07
11 O 0 3.901775471604196e-06
. O 0 4.3997442844556645e-06

5 O 0 2.7633073841570877e-05
% O 0 1.2196757097626687e-06
of O 0 1.2030699281240231e-07
all O 0 3.69932706689724e-08
control O 0 6.717730798300181e-07
individuals O 0 6.680828334992839e-08
, O 0 1.129335984728641e-07
and O 0 1.2144602123953518e-07
in O 0 5.883947906681897e-08
one O 0 4.5672489790149484e-08
control O 0 3.125960859051702e-07
individual O 0 4.1523847471580666e-08
homozygous O 0 3.40312197977255e-07
for O 0 3.1642141351539976e-08
this O 0 1.1917318687437728e-07
glycine O 0 3.0159011657815427e-05
substitution O 0 4.893297500530025e-06
. O 0 5.1343995437491685e-06

There O 0 1.1919189091713633e-05
has O 0 1.144798488894594e-06
been O 0 2.1758057755505433e-07
no O 0 1.215568090628949e-07
previous O 0 1.893010335152212e-07
finding O 0 3.3579391356397537e-07
of O 0 1.938204263751686e-08
a O 0 8.629029224493934e-08
glycine O 0 2.0431825760169886e-06
substitution O 0 4.427371536053215e-08
that O 0 1.7286422959728043e-08
is O 0 2.3311791608193744e-08
not O 0 1.972259511262564e-08
associated O 0 2.01454952275526e-07
with O 0 6.501095839439586e-08
any O 0 2.8625149184335896e-07
obvious O 0 5.4860192904016e-06
phenotype O 0 1.037545644066995e-05
in O 0 5.795466222480172e-07
homozygous O 0 1.5122987861104775e-05
individuals O 0 1.812946379686764e-06
. O 0 6.576701707672328e-06

Founder O 0 0.004797595553100109
BRCA1 O 0 0.0038100718520581722
and O 0 1.9798462744802237e-05
BRCA2 O 0 0.0005505649605765939
mutations O 0 7.134650331863668e-06
in O 0 4.690251103056653e-07
French O 0 1.1525418813107535e-05
Canadian O 0 0.0003180419735144824
breast B-Disease 1 0.9997856020927429
and I-Disease 1 0.9985998272895813
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999966621398926
families O 0 0.0004125608829781413
. O 0 6.604987720493227e-05

We O 0 2.3196811525849625e-05
have O 0 1.7238243117390084e-06
identified O 0 1.4728069572811364e-06
four O 0 1.7963319010050327e-07
mutations O 0 5.829295446346805e-07
in O 0 1.5805470710006375e-08
each O 0 7.167589188838974e-09
of O 0 5.146362624941503e-08
the O 0 8.795327630650718e-06
breast B-Disease 1 0.9989757537841797
cancer I-Disease 1 0.9315345287322998
- O 0 0.2021300345659256
susceptibility O 0 0.0004540760419331491
genes O 0 9.505117191110912e-07
, O 0 6.359140343192848e-07
BRCA1 O 0 2.534262603148818e-05
and O 0 1.0983078482240671e-06
BRCA2 O 0 2.232918268418871e-05
, O 0 1.230351927006268e-07
in O 0 7.845409299989115e-08
French O 0 9.826560926740058e-06
Canadian O 0 0.00020904427219647914
breast B-Disease 1 0.9981288313865662
cancer I-Disease 1 0.9637606143951416
and O 0 0.10097876191139221
breast B-Disease 1 0.9999966621398926
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
families O 0 4.661065759137273e-05
from O 0 4.975795036443742e-06
Quebec O 0 0.00018959282897412777
. O 0 1.623585012566764e-05

To O 0 1.09789125417592e-05
identify O 0 1.3960855540062767e-05
founder O 0 6.342698179651052e-05
effects O 0 1.2913368664158043e-05
, O 0 4.7036985506565543e-07
we O 0 1.579756485625694e-07
examined O 0 1.8575096873973962e-06
independently O 0 1.6691285509295994e-07
ascertained O 0 1.0861790542548988e-06
French O 0 4.049109975312604e-06
Canadian O 0 9.9464479717426e-05
cancer B-Disease 0 0.1155473068356514
families O 0 3.8568305171793327e-07
for O 0 4.612834914041741e-08
the O 0 5.142123526979958e-08
distribution O 0 2.501539597687952e-07
of O 0 5.0145061436523974e-08
these O 0 1.323563765254221e-07
eight O 0 1.489393525844207e-06
mutations O 0 1.3866989320376888e-05
. O 0 4.890199761575786e-06

Mutations O 0 0.0002210143575211987
were O 0 2.3512259303970495e-06
found O 0 3.907242671630229e-07
in O 0 7.081385433593823e-08
41 O 0 4.93225513764628e-07
of O 0 8.864074629855168e-08
97 O 0 1.2223807061673142e-05
families O 0 3.257062189732096e-06
. O 0 4.826599706575507e-06

Six O 0 5.592790785158286e-06
of O 0 6.71707766741747e-07
eight O 0 1.585807922310778e-06
mutations O 0 2.8231302167114336e-06
were O 0 2.7634754928840266e-07
observed O 0 1.092523575607629e-06
at O 0 6.195401738295914e-07
least O 0 3.8802650692559837e-07
twice O 0 2.704966163946665e-06
. O 0 5.27208158018766e-06

The O 0 2.831420897564385e-05
BRCA1 O 0 0.002019622130319476
C4446T O 0 0.0010431886184960604
mutation O 0 2.3807935576769523e-05
was O 0 2.0202262476232136e-06
the O 0 1.382679641892537e-07
most O 0 1.8346111119171837e-07
common O 0 7.339763783420494e-07
mutation O 0 1.979474518520874e-06
found O 0 9.448054356653302e-07
, O 0 1.0546645512476971e-07
followed O 0 3.1731354965813807e-07
by O 0 1.4174993623328191e-07
the O 0 6.507348189188633e-07
BRCA2 O 0 0.0002688960521481931
8765delAG O 0 0.00035928681609220803
mutation O 0 2.1125655621290207e-05
. O 0 8.94687673280714e-06

Together O 0 1.8918472051154822e-05
, O 0 1.1730402320608846e-06
these O 0 8.790129868430085e-08
mutations O 0 7.512402930842654e-07
were O 0 1.7971888155443594e-07
found O 0 1.1423377088704001e-07
in O 0 2.5832461503227933e-08
28 O 0 2.086657104882761e-07
of O 0 2.7404263747143887e-08
41 O 0 4.437759344000369e-06
families O 0 5.379271215133485e-07
identified O 0 4.915866043120332e-07
to O 0 6.501542060277643e-08
have O 0 1.6429954996510787e-07
a O 0 1.0067919902212452e-06
mutation O 0 1.0024471521319356e-05
. O 0 5.393399987951852e-06

The O 0 1.3211303667048924e-05
odds O 0 7.194192585302517e-05
of O 0 3.70719646980433e-07
detection O 0 3.5983541692985455e-06
of O 0 3.976254348003749e-08
any O 0 3.147504656908495e-08
of O 0 2.716176972228368e-08
the O 0 5.685139470301692e-08
four O 0 3.177144378696539e-07
BRCA1 O 0 9.777328523341566e-05
mutations O 0 2.548719066908234e-06
was O 0 1.8939579149446217e-06
18 O 0 3.017454673681641e-06
. O 0 4.381254711915972e-06

7x O 0 0.03111778199672699
greater O 0 2.078592478937935e-05
if O 0 1.2467219221434789e-06
one O 0 4.74727670507491e-08
or O 0 4.971451161850382e-08
more O 0 4.134894737717332e-08
cases O 0 1.2070237289663055e-06
of O 0 0.004576135892421007
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999792575836182
were O 0 3.275624749221606e-06
also O 0 2.446296036850981e-07
present O 0 2.76357013717643e-07
in O 0 2.380790533607069e-07
the O 0 7.348069743784436e-07
family O 0 1.25775950436946e-05
. O 0 1.0515293070056941e-05

The O 0 6.535710781463422e-06
odds O 0 5.150238939677365e-05
of O 0 2.784318269277719e-07
detection O 0 6.363026386679849e-06
of O 0 4.623563754080351e-08
any O 0 5.180813289484831e-08
of O 0 5.341010123061096e-08
the O 0 1.5415450604905345e-07
four O 0 1.1360824601069908e-06
BRCA2 O 0 9.953657718142495e-05
mutations O 0 1.9617305042629596e-06
was O 0 1.200979454551998e-06
5 O 0 2.663723307705368e-06
. O 0 6.093431238696212e-06

3x O 0 0.0015611121198162436
greater O 0 1.5593665011692792e-05
if O 0 2.2653262021776754e-06
there O 0 2.0118865506901784e-07
were O 0 1.0553809204338904e-07
at O 0 1.1491461293644534e-07
least O 0 3.872397869031374e-08
five O 0 8.053024913579065e-08
cases O 0 4.825513428841077e-07
of O 0 4.396129497763468e-06
breast B-Disease 1 0.9997119307518005
cancer I-Disease 1 0.6320741176605225
in O 0 6.388572728610598e-07
the O 0 9.725866902954294e-07
family O 0 2.2379470465239137e-05
. O 0 8.583167073084041e-06

Interestingly O 0 0.0003159157349728048
, O 0 2.3933096144901356e-06
the O 0 1.3171280954793474e-07
presence O 0 1.3436698509394773e-07
of O 0 6.920618034200743e-08
a O 0 4.2860046960413456e-05
breast B-Disease 1 0.9995997548103333
cancer I-Disease 1 0.6007481217384338
case O 0 1.3946137187303975e-05
< O 0 0.0008470385218970478
36 O 0 5.123425239617063e-07
years O 0 1.1731370364032045e-07
of O 0 4.4570686696943085e-08
age O 0 5.237375830802193e-07
was O 0 3.0102324899417e-07
strongly O 0 1.1987225434495485e-07
predictive O 0 1.4885088717164763e-07
of O 0 1.11371365463242e-08
the O 0 1.3321273861777172e-08
presence O 0 3.2274229511131125e-08
of O 0 5.1715098869919984e-09
any O 0 1.1999035542942238e-08
of O 0 1.6185287776693258e-08
the O 0 6.609748481878341e-08
eight O 0 2.6353982320870273e-06
mutations O 0 7.945876859594136e-06
screened O 0 1.9986935512861237e-05
. O 0 7.15003079676535e-06

Carriers O 0 0.00011256292782491073
of O 0 1.1601414371398278e-06
the O 0 3.711529927841184e-07
same O 0 5.062359491603274e-07
mutation O 0 8.264099164989602e-07
, O 0 1.0919438153678129e-07
from O 0 2.2189519555126935e-08
different O 0 1.2633950774443292e-08
families O 0 1.792030275282741e-07
, O 0 1.231760791142733e-07
shared O 0 1.032893450769734e-07
similar O 0 8.691149560036138e-07
haplotypes O 0 1.806916407076642e-05
, O 0 3.948917992602219e-07
indicating O 0 1.6695007616363e-06
that O 0 2.1715306885994323e-08
the O 0 3.268033665904113e-08
mutant O 0 4.754063525069796e-07
alleles O 0 1.0899940861008872e-07
were O 0 1.7529472984278982e-07
likely O 0 3.1124142196858884e-07
to O 0 2.3290635198236487e-08
be O 0 4.054021474075853e-08
identical O 0 4.779913069796748e-07
by O 0 4.2559186397284066e-08
descent O 0 1.7018379594446742e-06
for O 0 4.094625793982232e-08
a O 0 2.400481946551736e-07
mutation O 0 2.470107176577585e-07
in O 0 3.2651865211619224e-08
the O 0 1.4314740326426545e-07
founder O 0 3.2939264201559126e-05
population O 0 9.127654152507603e-07
. O 0 2.5424944851693e-06

The O 0 4.64316599391168e-06
identification O 0 3.967091743106721e-06
of O 0 8.919938068174815e-07
common O 0 1.111563960876083e-05
BRCA1 O 0 0.0008407423156313598
and O 0 8.734058610571083e-06
BRCA2 O 0 0.0002756355097517371
mutations O 0 2.912543550337432e-06
will O 0 1.6803147673272179e-07
facilitate O 0 1.0671531072148355e-06
carrier O 0 2.5667064619483426e-05
detection O 0 3.138625515930471e-06
in O 0 1.1175762892889907e-07
French O 0 3.215247261323384e-06
Canadian O 0 7.310195360332727e-05
breast B-Disease 1 0.9956949949264526
cancer I-Disease 1 0.9290611147880554
and O 0 0.024193398654460907
breast B-Disease 1 0.9999977350234985
/ I-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999960660934448
families O 0 0.0001255726965609938
. O 0 6.032969758962281e-05

Are O 0 1.3083950761938468e-05
Dp71 O 0 0.0010188886662945151
and O 0 1.0664812180039007e-05
Dp140 O 0 0.0014324834337458014
brain O 0 0.0004206612065900117
dystrophin O 0 7.476961764041334e-05
isoforms O 0 2.874164692912018e-06
related O 0 4.681801328842994e-06
to O 0 1.744995756780554e-06
cognitive B-Disease 0 0.0022141921799629927
impairment I-Disease 1 0.976601243019104
in O 0 0.0038840596098452806
Duchenne B-Disease 1 0.9999793767929077
muscular I-Disease 1 0.999896764755249
dystrophy I-Disease 1 0.9998260140419006
? O 0 0.008664858527481556

Molecular O 0 0.0002234798448625952
study O 0 6.65874540572986e-06
and O 0 9.582427082932554e-07
neuropsychological O 0 3.164372901665047e-05
analysis O 0 5.401566340879072e-07
were O 0 1.743936479670083e-07
performed O 0 1.1094884655449277e-07
concurrently O 0 1.2279349448363064e-07
on O 0 6.792471367589314e-07
49 O 0 8.61070875544101e-05
patients O 0 3.652396480902098e-05
with O 0 0.0002556951658334583
Duchenne B-Disease 1 0.9999911785125732
muscular I-Disease 1 0.9999741315841675
dystrophy I-Disease 1 0.9999539852142334
( O 0 0.0006944807828404009
DMD B-Disease 1 0.9999886751174927
) O 0 8.051225677263574e-07
in O 0 1.0602899180867098e-07
order O 0 6.578054723149762e-08
to O 0 2.8504407723062286e-08
find O 0 1.551583324044259e-07
a O 0 4.95216418983091e-08
molecular O 0 1.1818189022960723e-06
explanation O 0 1.39320647463137e-07
for O 0 6.193446466795649e-08
the O 0 3.394001453216333e-07
cognitive B-Disease 0 6.437157571781427e-05
impairment I-Disease 0 0.0071340156719088554
observed O 0 4.358778824098408e-06
in O 0 1.3047229003859684e-06
most O 0 3.7093981518410146e-05
DMD B-Disease 1 0.9999929666519165
patients O 0 0.0033752997405827045
. O 0 2.6610001441440545e-05

Complete O 0 1.6798381693661213e-05
analysis O 0 3.404599510758999e-06
of O 0 2.3444812313755392e-07
the O 0 2.018283993265868e-07
dystrophin O 0 6.682992534479126e-05
gene O 0 1.1990956636509509e-06
was O 0 6.445006874855608e-07
performed O 0 3.3697511980790296e-07
to O 0 4.4273882338075055e-08
define O 0 3.420705638745858e-07
the O 0 2.8132371099331976e-08
localization O 0 6.330175210678135e-07
of O 0 4.945584919369139e-08
deletions O 0 1.9702722511283355e-06
and O 0 2.0839087255808408e-07
duplications O 0 3.1827382827032125e-06
in O 0 1.0839071507007247e-07
relation O 0 8.491714424962993e-07
to O 0 1.0028728780753227e-07
the O 0 3.0773890102864243e-07
different O 0 3.517822278809035e-06
DMD B-Disease 1 0.998869001865387
promoters O 0 0.0009043157333508134
. O 0 2.351051807636395e-05

Qualitative O 0 5.3400963224703446e-05
analysis O 0 2.8169367851660354e-06
of O 0 2.9749611485385685e-07
the O 0 2.1672177297205053e-07
Dp71 O 0 5.779455023002811e-05
transcript O 0 3.5874786590284202e-06
and O 0 1.6718382767066942e-07
testing O 0 5.129692794980656e-07
for O 0 1.985848641083976e-08
the O 0 9.882777263214848e-09
specific O 0 1.1818394263229948e-08
first O 0 3.328538866753661e-08
exon O 0 1.3215889111961587e-06
of O 0 9.129624345405318e-08
Dp140 O 0 2.7674743250827305e-05
were O 0 1.5236727790579607e-07
also O 0 6.759193382777084e-08
carried O 0 4.980306584911887e-07
out O 0 5.106858793624269e-07
. O 0 2.5603201265766984e-06

Neuropsychological O 0 0.002099044620990753
analysis O 0 4.533682295004837e-05
assessed O 0 0.0001224136503878981
verbal O 0 6.0185575421201065e-05
and O 0 2.9063448891974986e-06
visuospatial O 0 0.0006725440616719425
intelligence O 0 1.647451426833868e-05
, O 0 5.058566330262693e-07
verbal O 0 1.317177611781517e-05
memory O 0 0.00013327797933015972
, O 0 1.510486669076272e-07
and O 0 2.310143827344291e-07
reading O 0 3.892832864949014e-06
skills O 0 5.6631538427609485e-06
. O 0 5.906964815949323e-06

Comparison O 0 8.884949056664482e-05
of O 0 2.7697069526766427e-06
molecular O 0 2.51038909482304e-05
and O 0 1.6802439404273173e-06
psychometric O 0 0.0008267757948487997
findings O 0 6.9439943217730615e-06
demonstrated O 0 2.890434643632034e-06
that O 0 8.910247828453066e-08
deletions O 0 5.041539679950802e-06
and O 0 3.113768229923153e-07
duplications O 0 3.705291419464629e-06
that O 0 6.446470024457085e-08
were O 0 1.24923872135696e-07
localized O 0 2.35152629102231e-06
in O 0 5.0307725985021534e-08
the O 0 3.768269962733939e-08
distal O 0 3.2552576158195734e-05
part O 0 1.9579348986553669e-07
of O 0 2.3308855290338215e-08
the O 0 3.099404821682583e-08
gene O 0 1.71993917774671e-07
seemed O 0 3.8528750678779033e-07
to O 0 2.901199458449355e-08
be O 0 4.0211077134699735e-08
preferentially O 0 1.4597562767448835e-06
associated O 0 6.283615334723436e-07
with O 0 1.348301452708256e-06
cognitive B-Disease 0 0.0005163925816304982
impairment I-Disease 0 0.1536949723958969
. O 0 2.078057332255412e-05

Two O 0 1.137639264925383e-05
altered O 0 1.63436598086264e-05
Dp71 O 0 0.0001802650367608294
transcripts O 0 7.915858986962121e-06
and O 0 1.5296535593734006e-07
two O 0 4.7933337299355117e-08
deleted O 0 8.631207606413227e-07
Dp140 O 0 4.704614184447564e-06
DNA O 0 6.263130671868566e-07
sequences O 0 1.4332894693325215e-07
were O 0 1.0178442266806087e-07
found O 0 1.0190738919391151e-07
in O 0 1.2645116953535762e-07
four O 0 3.4408708415867295e-06
patients O 0 0.00025118127814494073
with O 0 7.24515994079411e-05
severe O 1 0.9911612272262573
cerebral B-Disease 1 0.9996746778488159
dysfunction I-Disease 1 0.9864907264709473
. O 0 0.00018873895169235766

These O 0 5.8141276895185e-06
findings O 0 6.22115430815029e-06
suggest O 0 2.015926611420582e-06
that O 0 5.643996559001607e-08
some O 0 1.6277295955546833e-08
sequences O 0 9.9120036622935e-08
located O 0 3.136807436021627e-07
in O 0 2.2292347523489298e-08
the O 0 2.0722470850387253e-08
distal O 0 2.5581632144167088e-05
part O 0 1.804816491812744e-07
of O 0 1.9997106193159198e-08
the O 0 1.9892832270329563e-08
gene O 0 1.0800562932899993e-07
and O 0 1.6962835047706903e-07
, O 0 1.204524409104124e-07
in O 0 3.34308367655467e-08
particular O 0 6.534624219511898e-08
, O 0 7.42238910333981e-08
some O 0 4.7602064512375364e-08
DMD B-Disease 1 0.7367656826972961
isoforms O 0 1.4936580328139826e-07
expressed O 0 9.389707145146531e-08
in O 0 4.499477768149518e-08
the O 0 5.527836606233905e-07
brain O 0 0.0022330572828650475
may O 0 9.142760859504051e-07
be O 0 3.175193441506963e-08
related O 0 2.346592822277671e-07
to O 0 6.318541068139893e-08
the O 0 1.1600794778132695e-06
cognitive B-Disease 0 0.006708248984068632
impairment I-Disease 1 0.8348240256309509
associated O 0 9.074561239685863e-05
with O 0 5.867088111699559e-05
DMD B-Disease 1 0.9999760389328003
. O 0 9.00365921552293e-06
. O 0 1.752076241245959e-05

I1307K O 0 0.002278556115925312
APC O 0 0.0006170859560370445
and O 0 1.2946723472850863e-05
hMLH1 O 0 0.00033197193988598883
mutations O 0 3.938536337955156e-06
in O 0 1.1238523001111389e-07
a O 0 2.9768372655780695e-07
non O 0 3.763511585930246e-06
- O 0 0.00021651243150699884
Jewish O 0 2.0385250536492094e-06
family O 0 1.485574784965138e-06
with O 0 2.7218043214816134e-06
hereditary B-Disease 1 0.7754952907562256
non I-Disease 1 0.709743320941925
- I-Disease 1 0.9999969005584717
polyposis I-Disease 1 0.9999988079071045
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999943971633911
. O 0 0.0005395246553234756

We O 0 2.0219464204274118e-05
describe O 0 1.9389794033486396e-05
a O 0 1.6598753518337617e-06
French O 0 4.63579954157467e-06
Canadian O 0 1.8562328477855772e-05
hereditary B-Disease 1 0.7708263993263245
non I-Disease 1 0.7767524719238281
- I-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 0.01602225936949253
HNPCC B-Disease 1 0.9997277855873108
) O 0 5.233030151430285e-06
kindred O 0 4.277058906154707e-05
which O 0 1.4955408289551997e-07
carries O 0 1.0048793228634167e-06
a O 0 3.3472954896751617e-07
novel O 0 2.499164793334785e-06
truncating O 0 6.232631858438253e-05
mutation O 0 3.7786342090839753e-06
in O 0 1.310749098593078e-06
hMLH1 O 0 0.0006239081267267466
. O 0 1.2124888598918915e-05

Interestingly O 0 0.00015490627265535295
, O 0 3.2064162951428443e-06
the O 0 5.022671416554658e-07
I1307K O 0 5.580275319516659e-05
APC O 0 2.132141344191041e-05
polymorphism O 0 1.986702591239009e-05
, O 0 7.399729611279326e-07
associated O 0 3.1630227681489487e-07
with O 0 3.472903742363087e-08
an O 0 2.0200625172606124e-08
increased O 0 2.4582659534644336e-06
risk O 0 5.704232899006456e-05
of O 0 0.010167268104851246
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
, O 0 4.283169255359098e-05
is O 0 6.732648216711823e-07
also O 0 9.879709494953204e-08
present O 0 9.435271408619883e-08
in O 0 7.813063973571843e-08
this O 0 2.6580391931929626e-07
family O 0 1.1192737474630121e-05
. O 0 1.0803156328620389e-05

The O 0 6.268571723921923e-06
I1307K O 0 0.00023670837981626391
polymorphism O 0 7.50378894736059e-05
has O 0 1.1069885204051388e-06
previously O 0 7.446650442943792e-07
only O 0 2.7761430487771577e-08
been O 0 1.554090545141662e-07
identified O 0 9.143685133494728e-07
in O 0 3.186435293400791e-08
individuals O 0 3.0176330767517356e-08
of O 0 3.955377181341646e-08
self O 0 1.9614852135418914e-05
- O 0 0.02796965278685093
reported O 0 9.932742977980524e-05
Ashkenazi O 0 9.019407298183069e-05
Jewish O 0 1.6024014257709496e-06
origins O 0 4.427178737387294e-06
. O 0 3.648100118880393e-06

In O 0 2.430646190987318e-06
addition O 0 9.421942195331212e-07
, O 0 2.0620910845536855e-07
in O 0 4.4531766718591825e-08
this O 0 3.729756770098902e-08
family O 0 8.734107268537628e-07
, O 0 2.973344521706167e-07
there O 0 7.132243950991324e-08
appears O 0 3.0568816100640106e-07
to O 0 1.9949789376028093e-08
be O 0 6.410935071698987e-08
no O 0 5.5093746453849235e-08
relationship O 0 1.3676896060133004e-07
between O 0 6.878165237367284e-08
the O 0 5.4120963710602155e-08
I1307K O 0 1.56972419063095e-05
polymorphism O 0 3.988601292803651e-06
and O 0 7.32005176473649e-08
the O 0 2.8558174491877253e-08
presence O 0 1.263119600025675e-07
or O 0 1.64596286822416e-07
absence O 0 6.95125606853253e-07
of O 0 2.4936987301771296e-06
cancer B-Disease 0 0.04716802015900612
. O 0 1.4904208001098596e-06
. O 0 6.4585456129861996e-06

Identification O 0 4.180834730505012e-05
of O 0 2.8314836981735425e-06
a O 0 3.1779250093677547e-06
novel O 0 3.271700279583456e-06
mutation O 0 1.02292926840164e-06
of O 0 4.94464131861605e-08
the O 0 1.1282465806061737e-07
CPO O 0 7.821635517757386e-05
gene O 0 4.1008829043676087e-07
in O 0 8.766187420405913e-08
a O 0 4.335846313097136e-07
Japanese O 0 3.369696787558496e-05
hereditary B-Disease 0 0.11641585826873779
coproporphyria I-Disease 0 0.2965509295463562
family O 0 0.00011207250645384192
. O 0 2.3528866222477518e-05

Hereditary B-Disease 1 0.9980389475822449
coproporphyria I-Disease 1 0.9805124998092651
( O 0 0.00012808949395548552
HCP B-Disease 1 0.9318968057632446
) O 0 1.963224121936946e-06
is O 0 4.519156391324941e-07
an O 0 1.6556558648517239e-06
autosomal B-Disease 1 0.509381890296936
dominant I-Disease 1 0.8912013173103333
disease I-Disease 0 0.4316903352737427
characterized O 0 0.0017480453243479133
by O 0 4.230389095027931e-05
a O 0 0.013597593642771244
deficiency B-Disease 1 0.5761514902114868
of I-Disease 0 8.851536108522851e-07
coproporphyrinogen I-Disease 0 0.079456627368927
oxidase I-Disease 0 0.00016518919437658042
( O 0 2.7120569257022e-07
CPO O 0 4.3705556890927255e-05
) O 0 1.3146508592853934e-07
caused O 0 2.9796746048305067e-07
by O 0 2.9164123560576627e-08
a O 0 1.298611209676892e-07
mutation O 0 6.755854542461748e-07
in O 0 1.1259914600714183e-07
the O 0 2.7186499096387706e-07
CPO O 0 0.00024143088376149535
gene O 0 7.802461368555669e-06
. O 0 5.021137894800631e-06

Only O 0 6.892913461342687e-06
11 O 0 3.829652996500954e-06
mutations O 0 1.0422893410577672e-06
of O 0 5.858795404378725e-08
the O 0 1.1403491129158283e-07
gene O 0 7.612591730321583e-07
have O 0 2.0167678371763031e-07
been O 0 7.143952416299726e-07
reported O 0 1.8968132280861028e-05
in O 0 9.229347597283777e-06
HCP B-Disease 1 0.9991177916526794
patients O 0 0.0012241802178323269
. O 0 2.7131172828376293e-05

We O 0 2.304252120666206e-05
report O 0 3.3281442028965103e-06
another O 0 7.418050813612354e-07
mutation O 0 1.3439149597616051e-06
in O 0 1.5962638144628727e-07
a O 0 5.915590577387775e-07
Japanese O 0 9.836958270170726e-06
family O 0 1.1534346413100138e-05
. O 0 1.0011391168518458e-05

Polymerase O 0 0.0018185655353590846
chain O 0 0.0003991257690358907
reaction O 0 1.231127043865854e-05
- O 0 3.219325662939809e-05
single O 0 5.254104848972929e-07
strand O 0 3.0896003408997785e-06
conformational O 0 1.2378104656818323e-06
polymorphism O 0 4.994879418518394e-06
and O 0 6.84485854662853e-08
direct O 0 4.334399150707213e-08
sequence O 0 1.21143997944273e-07
analyses O 0 3.207325960374874e-07
demonstrated O 0 2.4843930646056833e-07
a O 0 1.0194705168942164e-07
C O 0 7.651373380213045e-06
to O 0 3.2046106213101666e-08
T O 0 5.558197244681651e-06
substitution O 0 8.545232077494802e-09
in O 0 5.154778826010897e-09
exon O 0 1.7423138842787012e-07
1 O 0 1.5721346002806058e-08
of O 0 3.568888518046265e-09
the O 0 1.1272458522171291e-08
CPO O 0 3.0615485684393207e-06
gene O 0 5.6127895220470236e-08
at O 0 1.8334876727976734e-08
nucleotide O 0 4.994175384354094e-08
position O 0 6.13682615835387e-08
85 O 0 2.2247201059144572e-07
, O 0 2.7834438753870927e-08
which O 0 2.0310425341563132e-08
lies O 0 5.040993187321874e-07
in O 0 2.235557694518775e-08
the O 0 4.920406482256112e-08
putative O 0 3.9460819607484154e-06
presequence O 0 8.749699190957472e-06
for O 0 5.5298407630743895e-08
targeting O 0 9.66539573710179e-07
to O 0 2.6586550916363194e-07
mitochondria O 0 1.8506654669181444e-05
. O 0 7.277963504748186e-06

This O 0 7.812906005710829e-06
mutation O 0 5.44473869013018e-06
changes O 0 3.654095905858412e-07
the O 0 6.794648754748778e-08
codon O 0 2.50383550337574e-07
for O 0 2.3162694873235523e-08
glutamine O 0 2.264103073912338e-07
to O 0 2.34611334803958e-08
a O 0 7.209561658783059e-08
termination O 0 1.165250978374388e-06
codon O 0 2.971785306726815e-07
at O 0 1.0789032245384078e-07
amino O 0 1.0102470326955881e-07
acid O 0 1.5260459917953995e-07
position O 0 1.569310086324549e-07
29 O 0 1.3909510698795202e-06
. O 0 1.824816422413278e-06

MaeI O 0 0.0010644281283020973
restriction O 0 2.30781442951411e-05
analysis O 0 3.321263420730247e-06
showed O 0 3.940403530577896e-06
two O 0 5.1715332460844365e-08
other O 0 6.525345241925606e-08
carriers O 0 8.561368076698272e-07
in O 0 7.479989960756939e-08
the O 0 3.3363892271154327e-07
family O 0 1.06697843875736e-05
. O 0 7.021754299785243e-06

The O 0 1.2548866834549699e-05
C O 0 0.005736449267715216
- O 0 0.094335176050663
T O 0 0.06382304430007935
mutation O 0 4.1801183670031605e-07
is O 0 2.945751376159933e-08
located O 0 1.3036267887400754e-07
within O 0 1.9644094351178865e-08
a O 0 7.163505699736561e-08
recently O 0 1.4221615174392355e-06
proposed O 0 7.946338769215799e-07
putative O 0 1.6329464642694802e-06
alternative O 0 1.1969815716383891e-07
translation O 0 8.266134443601914e-08
initiation O 0 1.1322713788786132e-07
codon O 0 2.7986379791400395e-07
( O 0 3.52286022575754e-08
TIC O 0 6.693699560855748e-06
- O 0 3.6104540868109325e-06
1 O 0 8.656393646333527e-08
) O 0 1.1585561843219239e-08
, O 0 8.340168555776017e-09
supporting O 0 5.13630133980314e-08
that O 0 3.2200567545714875e-08
TIC O 0 5.297283860272728e-05
- O 0 2.2584394173463807e-05
1 O 0 1.8237015808608703e-07
is O 0 1.8142918278840625e-08
the O 0 2.4829761358091673e-08
real O 0 1.3032703236603993e-06
TIC O 0 5.886652797926217e-05
rather O 0 1.5206474301976414e-07
than O 0 1.8268836754486983e-07
TIC O 0 9.784285794012249e-05
- O 0 4.258049375494011e-05
2 O 0 1.0327865993531304e-06
. O 0 2.3600135534707078e-07
. O 0 1.3066678548057098e-06

Human B-Disease 0 0.00012759592209476978
complement I-Disease 0 0.00020745696383528411
factor I-Disease 0 0.035594385117292404
H I-Disease 1 0.9999935626983643
deficiency I-Disease 1 0.9997742772102356
associated O 0 0.06279052793979645
with O 1 0.9887542724609375
hemolytic B-Disease 1 0.9999998807907104
uremic I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999878406524658
. O 0 0.0005168826319277287

This O 0 3.5544180718716234e-06
study O 0 1.5738648926344467e-06
reports O 0 8.069051773418323e-07
on O 0 2.680381214759109e-07
six O 0 1.676751139711996e-06
cases O 0 4.429121418070281e-06
of O 0 5.2141469495836645e-05
deficiency B-Disease 1 0.9613182544708252
in I-Disease 0 1.8322400308079523e-07
the I-Disease 0 4.759479921290222e-08
human I-Disease 0 9.228999431343254e-08
complement I-Disease 0 2.925410740317602e-07
regulatory I-Disease 0 2.403533699180116e-06
protein I-Disease 0 7.819816119081224e-07
Factor I-Disease 0 3.334491793793859e-06
H I-Disease 1 0.959860622882843
( O 0 4.547942467070243e-07
FH O 0 3.500241655274294e-05
) O 0 1.74041332456909e-08
in O 0 5.3639368502444995e-09
the O 0 9.349975016448298e-09
context O 0 9.62189758979548e-08
of O 0 5.828122766615706e-07
an O 0 0.0018964741611853242
acute B-Disease 1 0.9999967813491821
renal I-Disease 1 1.0
disease I-Disease 1 0.9999819993972778
. O 0 0.0003069899685215205

Five O 0 5.2237260206311475e-06
of O 0 5.046669002695126e-07
the O 0 2.016663955828335e-07
cases O 0 4.768803592014592e-07
were O 0 1.642096378873248e-07
observed O 0 1.047141381604888e-06
in O 0 1.7854732448085997e-07
children O 0 1.1379562465663184e-06
presenting O 0 0.0003840847930405289
with O 1 0.992914080619812
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
( O 0 0.07175954431295395
HUS B-Disease 1 0.9999430179595947
) O 0 2.4344544726773165e-05
. O 0 3.390423080418259e-05

Two O 0 3.6190169794281246e-06
of O 0 6.143607720332511e-07
the O 0 6.175369549055176e-07
children O 0 3.7771790175611386e-06
exhibited O 0 6.733234476996586e-05
a O 0 0.0002145022590411827
homozygous O 1 0.9426165819168091
deficiency O 1 0.9942060112953186
characterized O 0 0.00011481638648547232
by O 0 3.860996287130547e-07
the O 0 1.5957355969931086e-07
absence O 0 3.967497264056874e-07
of O 0 2.2511326136509524e-08
the O 0 5.086841881052351e-08
150 O 0 2.4932037945291086e-07
- O 0 1.1540916602825746e-05
kD O 0 1.552366120449733e-05
form O 0 2.7870671104324174e-08
of O 0 3.348201360608982e-08
Factor O 0 7.415299023705302e-07
H O 1 0.8315905928611755
and O 0 1.2169333274414385e-07
the O 0 1.5325031910151665e-08
presence O 0 5.060838503823106e-08
, O 0 1.7211215563861515e-08
upon O 0 2.2337461658139546e-08
immunoblotting O 0 8.867243195709307e-06
, O 0 2.0517800791708396e-08
of O 0 7.895273768099287e-09
the O 0 1.8547533287005535e-08
42 O 0 4.958695285495196e-07
- O 0 3.698354248626856e-06
kD O 0 3.42320381605532e-05
Factor O 0 5.509972993422707e-07
H O 0 0.052515171468257904
- O 0 2.447766746627167e-06
like O 0 4.1648458903864594e-08
protein O 0 2.4057063896520958e-08
1 O 0 3.3358734441435445e-08
( O 0 1.4403841674948126e-08
FHL O 0 3.5270602438686183e-06
- O 0 2.6933698791253846e-06
1 O 0 6.79365115274777e-08
) O 0 7.628767839662487e-09
and O 0 1.0217438450865757e-08
other O 0 1.6129106938933546e-08
FH O 0 0.00011062361591029912
- O 0 4.96230750286486e-05
related O 0 4.904084562440403e-06
protein O 0 5.072764679425745e-07
( O 0 1.689839592700082e-07
FHR O 0 6.79799632052891e-05
) O 0 1.2495627288444666e-07
bands O 0 1.5557083088424406e-06
. O 0 2.1428688796731876e-06

Southern O 0 9.401777788298205e-05
blot O 0 0.00016843756020534784
and O 0 8.902041486180678e-07
PCR O 0 2.286872131662676e-06
analysis O 0 1.4652317759100697e-07
of O 0 4.108347440023863e-08
DNA O 0 1.0479966476850677e-06
of O 0 1.0459941535145845e-07
one O 0 1.460434418731893e-06
patient O 0 0.00025273527717217803
with O 0 4.068216003361158e-05
homozygous O 1 0.6945116519927979
deficiency O 1 0.9574834108352661
ruled O 0 1.725584479572717e-05
out O 0 1.5551326271179278e-07
the O 0 2.9184713312702115e-08
presence O 0 4.2910492936698574e-08
of O 0 1.1861300386328821e-08
a O 0 9.861560101853684e-08
large O 0 2.830137475484662e-07
deletion O 0 2.939533771950664e-07
of O 0 2.846420343871614e-08
the O 0 1.0295850216834879e-07
FH O 0 0.00023899361258372664
gene O 0 2.9156180403333565e-07
as O 0 3.989548957861189e-08
the O 0 1.6695233284735878e-07
underlying O 0 0.0007663533324375749
defect O 0 0.005009647458791733
for O 0 4.02895284423721e-06
the O 0 0.0001178304009954445
deficiency O 1 0.9037895798683167
. O 0 1.2053294994984753e-05

The O 0 2.9937184535810957e-06
other O 0 2.9267084755701944e-07
four O 0 3.753436033093749e-07
children O 0 9.81580683401262e-07
presented O 0 6.532794486702187e-06
with O 0 2.8134951207903214e-05
heterozygous O 0 0.04090052470564842
deficiency O 1 0.9145792722702026
and O 0 1.12124382667389e-06
exhibited O 0 5.726762537960894e-06
a O 0 5.648718683914922e-07
normal O 0 1.8965316712638014e-06
immunoblotting O 0 9.418216359335929e-05
pattern O 0 7.221038345051056e-07
of O 0 3.013779448224341e-08
proteins O 0 4.0131165945922476e-08
of O 0 5.069591324513567e-08
the O 0 1.1974386779911583e-06
FH O 0 0.009918158873915672
family O 0 9.856660653895233e-06
. O 0 1.1448070836195257e-05

Factor B-Disease 1 0.8657159209251404
H I-Disease 1 0.9999953508377075
deficiency I-Disease 1 0.997795820236206
is O 0 1.791438990039751e-06
the O 0 6.622316277571372e-07
only O 0 3.916799869330134e-06
complement B-Disease 1 0.9981147050857544
deficiency I-Disease 1 0.9999864101409912
associated O 0 5.09531055286061e-05
with O 0 5.094766311231069e-05
HUS B-Disease 1 0.9997972846031189
. O 0 4.8702779167797416e-05

These O 0 4.9667492021399084e-06
observations O 0 1.1463616829132661e-05
suggest O 0 4.150265795033192e-06
a O 0 5.584096243183012e-07
role O 0 2.800375966671709e-07
for O 0 2.1304157371559995e-07
FH O 0 0.005677184090018272
and O 0 1.5421303487528348e-06
/ O 0 0.0001421493652742356
or O 0 1.2669249827013118e-06
FH O 0 0.0005201118183322251
receptors O 0 1.1806349675680394e-06
in O 0 8.60404796299008e-08
the O 0 2.5677411485958146e-07
pathogenesis O 0 0.000494144216645509
of O 0 0.00010928346455330029
idiopathic O 1 0.9999803304672241
HUS B-Disease 1 0.9999148845672607
. O 0 1.1433907275204547e-05
. O 0 2.089527333737351e-05

Further O 0 9.060112461156677e-06
evidence O 0 5.990317276882706e-06
for O 0 1.9806402917765809e-07
a O 0 4.910824600301567e-07
major O 0 3.930307684640866e-06
ancient O 0 1.1712691048160195e-05
mutation O 0 0.0006772529450245202
underlying O 1 0.9713530540466309
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999839067459106
from O 0 8.455756869807374e-06
linkage O 0 0.0006665733526460826
disequilibrium O 0 0.013668843545019627
studies O 0 2.0543000118777854e-06
in O 0 4.665585322527477e-07
the O 0 4.15657751773324e-07
Japanese O 0 3.4996594422409544e-06
population O 0 6.07273364039429e-07
. O 0 3.6114938666287344e-06

The O 0 0.005671115126460791
myotonic B-Disease 1 0.9999918937683105
dystrophy I-Disease 1 0.9999974966049194
( O 0 0.012320191599428654
DM B-Disease 1 0.9999972581863403
) O 0 1.090717614715686e-05
mutation O 0 6.195080914039863e-06
is O 0 1.9401356610160292e-07
an O 0 2.434338739476516e-07
unstable O 0 0.005646961275488138
( O 0 3.3722685088832804e-07
CTG O 0 0.00021098300931043923
) O 0 6.369032945485742e-08
n O 0 5.000951659894781e-06
repeat O 0 5.140790335644851e-07
, O 0 4.0874859053019463e-08
present O 0 3.283453864355579e-08
at O 0 7.857419603851667e-08
a O 0 2.0523044597098306e-08
copy O 0 8.759501923805146e-08
number O 0 6.7047993823621255e-09
of O 0 7.453198946905104e-09
5 O 0 2.4159749045793433e-07
- O 0 1.2195700037409551e-05
37 O 0 1.6854633599905355e-07
repeats O 0 8.225149628060535e-08
on O 0 3.777229196089138e-08
normal O 0 7.579501470900141e-08
chromosomes O 0 1.4545283022471267e-07
but O 0 2.4280637944684713e-08
amplified O 0 6.771258398430291e-08
to O 0 1.4834052208811954e-08
50 O 0 6.150489895162536e-08
- O 0 1.8311865233044955e-06
3000 O 0 5.093453978588514e-07
copies O 0 3.6379202583702863e-07
on O 0 3.2206514788413187e-06
DM B-Disease 1 0.999586284160614
chromosomes O 0 5.424977280199528e-05
. O 0 8.459741366095841e-06

Previous O 0 7.808802183717489e-05
findings O 0 2.3351780328084715e-05
in O 0 1.036227786244126e-06
Caucasian O 0 2.6801008061738685e-05
populations O 0 5.473448254633695e-07
of O 0 1.3506510754268675e-07
a O 0 1.4083841051615309e-05
DM B-Disease 1 0.9999984502792358
founder O 0 0.001772738411091268
chromosome O 0 3.2695967092877254e-05
raise O 0 1.3427941212285077e-06
a O 0 3.437298516928422e-07
question O 0 3.856734736018552e-07
about O 0 9.640763920515383e-08
the O 0 2.5881238485681024e-08
molecular O 0 4.438659573224868e-07
events O 0 1.0537858230463826e-07
involved O 0 1.8205770402346388e-07
in O 0 1.1220851803273035e-07
the O 0 2.1107847203438723e-07
expansion O 0 1.6947802578215487e-05
mutation O 0 1.615271503396798e-05
. O 0 8.169149623427074e-06

To O 0 1.0325548828404862e-05
investigate O 0 3.33403077092953e-05
whether O 0 1.8646234138941509e-06
a O 0 1.240452775164158e-06
founder O 0 3.390698111616075e-05
chromosome O 0 1.2645440619962756e-05
for O 0 3.721926020716637e-07
the O 0 5.033128218201455e-06
DM B-Disease 1 0.9999959468841553
mutation O 0 1.331599833065411e-05
exists O 0 5.164563958715007e-07
in O 0 6.125553397851036e-08
the O 0 3.091103906172066e-08
Japanese O 0 3.468406077899999e-07
population O 0 4.5036586016067304e-08
, O 0 6.256217943700904e-08
we O 0 8.260775530288811e-08
genotyped O 0 2.2428870579460636e-05
families O 0 9.238510045861403e-08
using O 0 8.452723676555252e-08
polymorphic O 0 5.046532805863535e-06
markers O 0 1.5213134247460403e-05
near O 0 6.454494268837152e-06
the O 0 7.580123906336667e-08
( O 0 1.5607012926466268e-07
CTG O 0 0.0001306308404309675
) O 0 1.7007315022965486e-07
n O 0 1.593478191352915e-05
repeat O 0 3.333210315759061e-06
region O 0 9.724291203383473e-07
and O 0 4.810764266949263e-07
constructed O 0 2.9251696105347946e-05
haplotypes O 0 3.563201244105585e-05
. O 0 5.998961569275707e-06

Six O 0 1.7753460269887e-05
different O 0 1.3791477613267489e-06
haplotypes O 0 2.4298755306517705e-05
were O 0 1.2097134458599612e-06
found O 0 3.2476268643222284e-06
and O 0 1.6459407561342232e-05
DM B-Disease 1 0.9999896287918091
alleles O 0 1.7809759810916148e-05
were O 0 2.471182142471662e-06
always O 0 4.336435722507304e-06
haplotype O 0 0.00010946056863758713
A O 0 9.18910518521443e-06
. O 0 1.2512370631156955e-05

To O 0 7.013369213382248e-06
find O 0 3.489747768981033e-06
an O 0 9.804133327406817e-08
origin O 0 1.1321871795644256e-07
of O 0 4.60002489433009e-08
the O 0 1.1868411320392624e-07
( O 0 1.4679059745503764e-07
CTG O 0 0.0001672515063546598
) O 0 2.4899580353121564e-07
n O 0 2.031951953540556e-05
repeat O 0 1.0478107697053929e-06
mutation O 0 1.0926271443167934e-07
and O 0 2.1705700348206847e-08
to O 0 1.429963081278629e-08
investigate O 0 3.5923599739362544e-07
the O 0 1.2780290603586764e-08
mechanism O 0 4.374789597250128e-08
of O 0 4.4857393355357544e-09
the O 0 1.613593703098104e-08
expansion O 0 5.092074388812762e-07
mutation O 0 9.772190168177985e-08
in O 0 1.0541894468474311e-08
the O 0 1.7816587316588084e-08
Japanese O 0 2.193738737332751e-07
population O 0 2.1566792796079426e-08
we O 0 2.014187749921348e-08
have O 0 7.161986559367506e-09
studied O 0 3.7791025420119695e-08
90 O 0 1.5372700090665603e-07
Japanese O 0 1.8121288576367078e-06
DM B-Disease 1 0.9998214840888977
families O 0 3.5012479315810197e-07
comprising O 0 1.99613666040932e-07
190 O 0 6.89538524056843e-07
affected O 0 2.577075690624042e-07
and O 0 1.4753611310425185e-07
130 O 0 1.136620994657278e-06
unaffected O 0 1.0904451301030349e-05
members O 0 1.1918573363800533e-06
. O 0 4.105146217625588e-06

The O 0 7.729547178314533e-06
results O 0 5.594129561359296e-06
suggest O 0 3.4134689030906884e-06
that O 0 1.320614586575175e-07
a O 0 5.400556233325915e-07
few O 0 3.6353955579215835e-07
common O 0 6.620674639634672e-07
ancestral O 0 1.2333598533587065e-05
mutations O 0 6.767978106836381e-07
in O 0 1.1809565592102444e-07
both O 0 5.927156365714836e-08
Caucasian O 0 3.61118372893543e-06
and O 0 3.5757523164647864e-07
Japanese O 0 2.917235860877554e-06
populations O 0 3.0632753578174743e-07
have O 0 2.1965957941461056e-08
originated O 0 2.2181055214787193e-08
by O 0 6.443431121994081e-09
expansion O 0 8.723720412717739e-08
of O 0 2.1882783585169818e-08
an O 0 2.6683499854129877e-08
ancestral O 0 3.2515501970920013e-06
n O 0 6.240369111765176e-05
= O 0 1.755452785801026e-06
5 O 0 6.670120455964934e-08
repeat O 0 2.142845403341198e-07
to O 0 2.2830963786191205e-08
n O 0 7.501129857701017e-06
= O 0 9.10397318421019e-07
19 O 0 1.9249382887664979e-07
- O 0 2.1747819118900225e-06
37 O 0 6.266440664148831e-07
copies O 0 9.11792767510633e-07
. O 0 1.5784584093125886e-06

These O 0 4.094113592145732e-06
data O 0 3.773193384404294e-06
support O 0 1.4371303223015275e-06
multistep O 0 1.279121897823643e-05
models O 0 1.7202818298756029e-06
of O 0 1.6650965051212552e-07
triplet O 0 0.00017271081742364913
repeat O 0 4.7109533625189215e-06
expansion O 0 1.6314397726091556e-06
that O 0 9.035368009335798e-08
have O 0 3.938258785751714e-08
been O 0 2.1524137139294908e-08
proposed O 0 8.30995503520171e-08
for O 0 7.567396664853732e-08
both O 0 2.034943236139952e-06
DM B-Disease 1 0.9999864101409912
and O 0 0.00013069636770524085
Friedreichs B-Disease 1 0.820473313331604
ataxia I-Disease 1 0.8138638734817505
. O 0 5.008808329876047e-06
. O 0 1.7083446437027305e-05

The O 0 6.120874786574859e-06
molecular O 0 1.699308631941676e-05
basis O 0 3.980621386290295e-06
of O 0 0.0002707085513975471
C6 B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999871253967285
in O 0 4.951691607857356e-07
the O 0 1.3667990117482987e-07
western O 0 4.682108851739031e-07
Cape O 0 1.3785816918243654e-05
, O 0 3.26158925645359e-07
South O 0 9.553374411552795e-07
Africa O 0 1.7129590332842781e-06
. O 0 2.9784062007820467e-06

Deficiency B-Disease 1 0.9905237555503845
of I-Disease 0 1.8294009578312398e-06
the I-Disease 0 5.783451229035563e-07
sixth I-Disease 0 8.134245945257135e-06
component I-Disease 0 2.3475647594750626e-06
of I-Disease 0 1.2369851276616828e-07
human I-Disease 0 2.341531626370852e-07
complement I-Disease 0 1.3326671250979416e-06
( O 0 3.8715862160643155e-07
C6 O 0 0.0011979058617725968
) O 0 8.417698182938693e-08
has O 0 6.29586409672811e-08
been O 0 5.4749730082903625e-08
reported O 0 3.311495788693719e-07
in O 0 1.4467167908094325e-08
a O 0 3.0866381450778135e-08
number O 0 1.739172184045401e-08
of O 0 1.916076719510329e-08
families O 0 9.912381671028925e-08
from O 0 1.916997938167242e-08
the O 0 3.252084823657242e-08
western O 0 3.5547463994589634e-07
Cape O 0 1.4234045920602512e-05
, O 0 2.749904410848103e-07
South O 0 9.206931963490206e-07
Africa O 0 1.3925225630373461e-06
. O 0 3.6903531963616842e-06

Meningococcal B-Disease 1 0.9998838901519775
disease I-Disease 1 0.9979175925254822
is O 0 3.7120804336154833e-05
endemic O 0 0.0006321278633549809
in O 0 5.027655447520374e-07
the O 0 4.6550741217288305e-07
Cape O 0 0.00015974443522281945
and O 0 4.034383493944915e-07
almost O 0 9.458803873485522e-08
all O 0 1.724736264918647e-08
pedigrees O 0 1.1186249366801349e-06
of O 0 2.5528831315568823e-07
total O 0 0.017425553873181343
C6 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999977350234985
( O 0 1.35070683882077e-06
C6Q0 O 0 0.012868768535554409
) O 0 1.5731986025002698e-07
have O 0 4.021115529440067e-08
been O 0 5.104774203346096e-08
ascertained O 0 1.5530325754298246e-06
because O 0 2.1748785172803764e-07
of O 0 4.3484037632879335e-06
recurrent O 1 0.9975231289863586
disease O 0 0.24499404430389404
. O 0 3.5414359444985166e-05

We O 0 1.3976948139315937e-05
have O 0 6.630721713918319e-07
sequenced O 0 1.4846725662209792e-06
the O 0 1.0136189132481377e-07
expressed O 0 1.2055841125402367e-07
exons O 0 7.818056246833294e-07
of O 0 5.1593161742857774e-08
the O 0 1.1993205362159642e-07
C6 O 0 0.00013934532762505114
gene O 0 5.394961135607446e-07
from O 0 6.115583772725586e-08
selected O 0 1.5954344689816935e-07
cases O 0 2.453440686167596e-07
and O 0 3.1993891980164335e-07
have O 0 1.1733854421436263e-07
found O 0 5.141947099218669e-07
three O 0 2.669641219199548e-07
molecular O 0 0.0010375367710366845
defects O 0 0.3033370077610016
leading O 0 2.1935454697086243e-06
to O 0 3.6166630934530986e-07
total O 0 7.549797737738118e-05
deficiency O 0 0.4795071482658386
879delG O 0 0.000423651683377102
, O 0 2.4400517872891214e-07
which O 0 4.9909566257611004e-08
is O 0 5.5348849059555505e-08
the O 0 1.0759665514115113e-07
common O 0 3.841405941784615e-06
defect O 0 0.00021805652067996562
in O 0 7.134693191801489e-08
the O 0 9.049389149140552e-08
Cape O 0 1.9699680706253275e-05
and O 0 2.40163586795461e-07
hitherto O 0 2.1351925170165487e-06
unreported O 0 2.0790939743164927e-06
, O 0 8.122984240799269e-08
and O 0 5.639595457296309e-08
1195delC O 0 2.313861477887258e-05
and O 0 3.701049706705817e-07
1936delG O 0 2.511797174520325e-05
, O 0 7.268130985949028e-08
which O 0 5.913763345688494e-08
have O 0 2.809290755578786e-08
been O 0 6.663571383569433e-08
previously O 0 6.164302135402977e-07
reported O 0 1.628517225071846e-06
in O 0 9.46311615734885e-08
African O 0 5.125448296894319e-07
- O 0 0.0004927419358864427
Americans O 0 7.755271326459479e-06
. O 0 6.7689661591430195e-06

We O 0 9.677732123236638e-06
also O 0 3.004914503890177e-07
show O 0 2.603373445708712e-07
that O 0 4.6368640482796764e-08
the O 0 6.554296305694152e-08
879delG O 0 6.739086529705673e-05
and O 0 1.2749226698360872e-05
1195delC O 1 0.7151248455047607
defects O 1 0.8467320799827576
are O 0 3.069858678372839e-07
associated O 0 2.0462871361814905e-06
with O 0 2.0189975202811183e-06
characteristic O 0 8.091676863841712e-05
C6 O 1 0.8794388771057129
/ O 0 0.007303058169782162
C7 O 0 0.0025678251404315233
region O 0 7.5567759267869405e-06
DNA O 0 2.537479122111108e-05
marker O 0 4.675774835050106e-05
haplotypes O 0 2.038755155808758e-05
, O 0 3.694328540859715e-07
although O 0 1.2697719853349554e-07
small O 0 2.3823599804018158e-07
variations O 0 9.243706813322206e-07
were O 0 5.033220986661036e-07
observed O 0 2.8245065095688915e-06
. O 0 2.6581024030747358e-06

The O 0 3.1659419619245455e-05
1936delG O 0 0.10198329389095306
defect O 0 0.012086649425327778
was O 0 5.893781235499773e-06
observed O 0 1.9732526652660454e-06
only O 0 8.6245201202928e-08
once O 0 2.99780737123001e-07
in O 0 5.222721810582698e-08
the O 0 9.351958141223804e-08
Cape O 0 3.1527575629297644e-05
, O 0 1.0486589729907791e-07
but O 0 4.3851823505747234e-08
its O 0 5.4352788936284924e-08
associated O 0 1.2895150121039478e-06
haplotype O 0 2.1061403458588757e-05
could O 0 5.760326757808798e-07
be O 0 1.7452524048167106e-07
deduced O 0 5.656978828483261e-06
. O 0 3.6148294384474866e-06

The O 0 4.863146841671551e-06
data O 0 1.6750666418374749e-06
from O 0 1.291416111826038e-07
the O 0 9.73897584799488e-08
haplotypes O 0 5.413899998529814e-06
indicate O 0 3.637108534348954e-07
that O 0 1.9480740576227618e-08
these O 0 2.1282138717992893e-08
three O 0 2.1183046783335158e-07
molecular O 0 0.002284051151946187
defects O 0 0.12898851931095123
account O 0 2.3222287381940987e-07
for O 0 2.69324686996697e-07
the O 0 3.721500206665951e-06
defects O 0 0.13831427693367004
in O 0 4.1018324736796785e-08
all O 0 7.170269267220419e-09
the O 0 3.4244589386389634e-08
38 O 0 1.3165871450837585e-06
unrelated O 0 5.41805820830632e-06
C6Q0 O 0 0.002222048118710518
individuals O 0 8.706681597914212e-08
we O 0 5.954669290986203e-08
have O 0 2.9038345061849213e-08
studied O 0 1.23193359513607e-07
from O 0 8.727864297952692e-08
the O 0 2.915184040830354e-07
Cape O 0 0.00012855263776145875
. O 0 9.644534657127224e-06

We O 0 1.9188773876521736e-05
have O 0 5.200485588829906e-07
also O 0 8.47013765792326e-08
observed O 0 4.3277822214804473e-07
the O 0 2.1840257602434576e-07
879delG O 0 0.0009523350745439529
defect O 0 0.00016954245802480727
in O 0 2.442838820115867e-07
two O 0 6.253163746805512e-07
Dutch O 0 0.004210534505546093
C6 B-Disease 1 0.9999604225158691
- I-Disease 1 0.9989975094795227
deficient I-Disease 1 0.9990335702896118
kindreds O 0 0.00017379916971549392
, O 0 2.582700062703225e-07
but O 0 6.00125673599905e-08
the O 0 6.160116328146614e-08
879delG O 0 0.0008966376772150397
defect O 0 5.064563447376713e-05
in O 0 6.049340584013407e-08
the O 0 1.1320813797510709e-07
Cape O 0 8.117187826428562e-05
probably O 0 1.7318520804110449e-06
did O 0 6.526042284349387e-08
not O 0 6.5900578327671155e-09
come O 0 1.645943115136106e-08
from O 0 1.1297642821261888e-08
The O 0 3.4673043103339296e-08
Netherlands O 0 2.601650976430392e-06
. O 0 2.9342427865231e-07
. O 0 2.086844915538677e-06

Complement B-Disease 1 0.9478603005409241
C7 I-Disease 1 0.9999959468841553
deficiency I-Disease 1 0.9999879598617554
: O 0 3.55373663296632e-06
seven O 0 1.0619328350003343e-06
further O 0 9.090915682463674e-07
molecular O 0 0.0036233856808394194
defects O 1 0.8663437366485596
and O 0 2.1168636976653943e-06
their O 0 5.458211944642244e-07
associated O 0 1.610254548722878e-05
marker O 0 0.0006156631279736757
haplotypes O 0 0.0003472992975730449
. O 0 1.886025165731553e-05

Seven O 0 1.514798805146711e-05
further O 0 1.930266989802476e-06
molecular O 0 1.4907428521837573e-05
bases O 0 1.433806392014958e-05
of O 0 0.0005349073908291757
C7 B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999954700469971
are O 0 4.1443568079557735e-06
described O 0 9.818558464758098e-05
. O 0 1.7073623894248158e-05

All O 0 1.78346283519204e-06
these O 0 3.0992100619187113e-07
new O 0 9.55824020820728e-07
molecular O 0 0.00020187000336591154
defects O 0 0.028171831741929054
involve O 0 1.8069760017169756e-06
single O 0 1.3949975254945457e-06
- O 0 3.109307726845145e-05
nucleotide O 0 4.69299862970729e-07
events O 0 5.313261297601457e-08
, O 0 5.053565388379866e-08
deletions O 0 3.8239309674281685e-07
and O 0 1.1053612070099916e-07
substitutions O 0 3.197269506927114e-07
, O 0 2.7320867346247724e-08
some O 0 2.854410929842288e-09
of O 0 6.033942678840276e-09
which O 0 2.4826730893323656e-08
alter O 0 1.0557871519267792e-06
splice O 0 4.51502637588419e-06
sites O 0 5.495499522112368e-07
, O 0 8.670720319514658e-08
and O 0 1.5042033396639454e-07
others O 0 4.4150684175292554e-07
codons O 0 1.3719297385250684e-05
. O 0 5.884199708816595e-06

They O 0 7.260935944941593e-06
are O 0 2.3542183669178485e-07
distributed O 0 1.9395048411752214e-07
along O 0 2.1642208025696164e-07
the O 0 7.71803385646308e-08
C7 O 0 8.041952969506383e-05
gene O 0 7.540654678450665e-07
, O 0 1.0322887789016022e-07
but O 0 2.8668964091593807e-08
predominantly O 0 1.76582588551355e-08
towards O 0 4.1796639038693684e-08
the O 0 6.325064560996907e-08
3 O 0 8.104566404654179e-07
end O 0 3.6144847399555147e-06
. O 0 3.601729304136825e-06

All O 0 2.1048297185188858e-06
were O 0 1.2172007473054691e-06
found O 0 5.107492029310379e-07
in O 0 1.567607768038215e-07
compound O 0 5.56136728846468e-06
heterozygous O 0 4.771060048369691e-06
individuals O 0 1.2604640460267547e-06
. O 0 6.1858359003963415e-06

The O 0 5.0819417083403096e-05
C6 O 1 0.5554788112640381
/ O 0 0.021208208054304123
C7 O 0 0.26767697930336
marker O 0 0.003431406570598483
haplotypes O 0 0.0009715677588246763
associated O 0 1.645494921831414e-05
with O 0 1.5492308875764138e-06
most O 0 1.5733692634967156e-05
C7 B-Disease 1 0.9994658827781677
defects I-Disease 1 0.9861252903938293
are O 0 1.6544562413400854e-06
tabulated O 0 7.989570440258831e-05
. O 0 1.869898028417083e-06
. O 0 8.24062772153411e-06

A O 0 3.323726195958443e-05
genome O 0 7.122354145394638e-05
- O 0 7.219152757897973e-05
wide O 0 4.246466232871171e-06
search O 0 1.3084386409900617e-06
for O 0 2.776800442916283e-07
chromosomal O 0 0.0009838087717071176
loci O 0 1.0160158126382157e-05
linked O 0 0.00011842852836707607
to O 0 4.0216859815700445e-06
mental O 0 0.3662278354167938
health O 0 0.0002223093033535406
wellness O 0 0.00027870771009474993
in O 0 7.42318150059873e-07
relatives O 0 7.900254786363803e-06
at O 0 1.8685235545490286e-06
high O 0 0.0002137065166607499
risk O 0 0.0001301903830608353
for O 0 9.54837232711725e-05
bipolar B-Disease 1 0.999996542930603
affective I-Disease 1 0.9999642372131348
disorder I-Disease 1 0.9877158999443054
among O 0 1.0617910675136955e-06
the O 0 4.846442607231438e-07
Old O 0 9.629242413211614e-06
Order O 0 2.6592231279209955e-06
Amish O 0 0.00012168347166152671
. O 0 1.4947059753467329e-05

Bipolar B-Disease 1 0.9999839067459106
affective I-Disease 1 0.9999431371688843
disorder I-Disease 1 0.9999021291732788
( O 0 0.0006665351684205234
BPAD B-Disease 1 0.9999490976333618
; O 0 0.005898948758840561
manic B-Disease 1 0.999958872795105
- I-Disease 1 0.9999942779541016
depressive I-Disease 1 0.9999986886978149
illness I-Disease 1 0.9882457256317139
) O 0 2.115370307365083e-06
is O 0 8.598631211498287e-07
characterized O 0 6.798097729188157e-06
by O 0 1.0496835045614716e-07
episodes O 0 8.226135719269223e-07
of O 0 1.1847596397274174e-06
mania B-Disease 1 0.6854606866836548
and O 0 2.2549273126060143e-05
/ O 0 0.00441744877025485
or O 0 8.678760423208587e-06
hypomania B-Disease 0 0.11211469024419785
interspersed O 0 1.7304822904407047e-05
with O 0 2.5876187237372505e-07
periods O 0 2.7748758384404937e-06
of O 0 2.888902372433222e-06
depression B-Disease 0 0.019689569249749184
. O 0 1.2697826605290174e-05

Compelling O 0 0.0001340121525572613
evidence O 0 3.487889625830576e-05
supports O 0 1.1250441275478806e-05
a O 0 1.2278569556656294e-06
significant O 0 2.8907654723298037e-06
genetic O 0 1.3268918337416835e-05
component O 0 1.1262399311817717e-05
in O 0 3.16804943167881e-07
the O 0 5.794294111183262e-07
susceptibility O 0 4.275040191714652e-05
to O 0 2.192861529692891e-06
develop O 0 0.00027202125056646764
BPAD B-Disease 1 0.9992713332176208
. O 0 4.684219311457127e-05

To O 0 8.374638127861544e-06
date O 0 9.171420060738456e-06
, O 0 5.27406598394009e-07
however O 0 1.551029953361649e-07
, O 0 6.57656187286193e-08
linkage O 0 1.6627066088403808e-06
studies O 0 1.1141474942633067e-07
have O 0 4.698202005215535e-08
attempted O 0 2.2080735107010696e-06
only O 0 3.375697588126059e-08
to O 0 5.6385520252888455e-08
identify O 0 1.8613221755003906e-06
chromosomal O 0 0.0001759053411660716
loci O 0 1.2672898037635605e-06
that O 0 1.7424152076728205e-07
cause O 0 2.6404673008073587e-06
or O 0 2.2592975312818453e-07
increase O 0 2.9486642461051815e-07
the O 0 2.9307440740922175e-07
risk O 0 1.0319730790797621e-05
of O 0 1.2266023077245336e-06
developing O 0 0.0002163643075618893
BPAD B-Disease 1 0.9990814924240112
. O 0 3.955573993152939e-05

To O 0 8.104898370220326e-06
determine O 0 7.2738002927508205e-06
whether O 0 1.2151049304520711e-06
there O 0 2.6106258133040683e-07
could O 0 3.111064188487944e-07
be O 0 1.0139998352087787e-07
protective O 0 4.820159574592253e-06
alleles O 0 1.4658047575721866e-07
that O 0 3.9504914894905596e-08
prevent O 0 1.4906339629305876e-06
or O 0 2.114977917244687e-07
reduce O 0 4.479064443785319e-07
the O 0 9.919038745920261e-08
risk O 0 7.64088554205955e-07
of O 0 5.179587958537013e-08
developing O 0 2.4113944164128043e-05
BPAD B-Disease 1 0.9999141693115234
, O 0 1.021316961669072e-06
similar O 0 1.82236632895183e-07
to O 0 5.388190160715567e-08
what O 0 9.750387874873923e-08
is O 0 5.588966445202459e-08
observed O 0 5.501802888829843e-07
in O 0 2.3851424657550524e-07
other O 0 1.11985236799228e-05
genetic B-Disease 1 0.9999667406082153
disorders I-Disease 1 0.9999948740005493
, O 0 6.172576377139194e-06
we O 0 2.172584572690539e-06
used O 0 3.824873056146316e-05
mental O 0 0.4858473241329193
health O 0 0.0006093003903515637
wellness O 0 0.0018326211720705032
( O 0 6.159847885101044e-07
absence O 0 2.4515068162145326e-06
of O 0 1.005566559797444e-06
any O 0 0.0014233468100428581
psychiatric B-Disease 1 0.9999810457229614
disorder I-Disease 1 0.9840866923332214
) O 0 6.7884303689425e-07
as O 0 1.0837479180736409e-07
the O 0 1.0496174951413195e-07
phenotype O 0 5.2640434660133906e-06
in O 0 1.3437198731480748e-07
our O 0 1.792478059314817e-07
genome O 0 1.7906207858686685e-06
- O 0 2.8644546546274796e-05
wide O 0 2.8868973913631635e-06
linkage O 0 3.661948767330614e-06
scan O 0 1.0901913810812403e-05
of O 0 3.987677033023829e-08
several O 0 6.9004514102744e-08
large O 0 1.2439024885679828e-06
multigeneration O 0 0.00012803616118617356
Old O 0 2.895268153224606e-06
Order O 0 1.5885719051311753e-07
Amish O 0 4.434615675563691e-06
pedigrees O 0 7.0776436587038916e-06
exhibiting O 0 2.1053876935184235e-06
an O 0 1.0042874265536739e-07
extremely O 0 2.3698798031546175e-05
high O 0 6.242327071959153e-05
incidence O 0 0.0004901077481918037
of O 0 7.3557093855924904e-06
BPAD B-Disease 1 0.9997859597206116
. O 0 7.183059642557055e-05

We O 0 2.1833020582562312e-05
have O 0 1.1623309319475084e-06
found O 0 5.95061521835305e-07
strong O 0 3.018399183929432e-07
evidence O 0 3.7193143498370773e-07
for O 0 5.0211287572210495e-08
a O 0 2.1513798742489598e-07
locus O 0 1.8856387669075048e-06
on O 0 1.1671284028125228e-06
chromosome O 0 7.958157948451117e-05
4p O 1 0.8534881472587585
at O 0 1.491896910010837e-06
D4S2949 O 0 1.0856078006327152e-05
( O 0 7.059282580712534e-08
maximum O 0 4.828892201658164e-07
GENEHUNTER O 0 8.638588769827038e-05
- O 0 7.836008990125265e-06
PLUS O 0 9.227078976437042e-07
nonparametric O 0 5.561165835388238e-06
linkage O 0 2.0614552340703085e-06
score O 0 2.167391244256578e-07
= O 0 5.638250399897515e-07
4 O 0 8.772777704280088e-08
. O 0 2.217970163087557e-08
05 O 0 8.695618589626974e-07
, O 0 5.240103817527597e-08
P O 0 3.336435474921018e-05
= O 0 2.7579253014664573e-07
5 O 0 3.005106208320285e-08
. O 0 6.323228163296335e-09
22 O 0 2.959695954984909e-08
x O 0 7.937764507914835e-07
10 O 0 2.078731498045272e-08
( O 0 1.4661817537842126e-08
- O 0 1.4016426348462119e-06
4 O 0 5.5746149030255765e-08
) O 0 7.238563526357211e-09
; O 0 1.8117189526378752e-08
SIBPAL O 0 1.5078979231475387e-05
Pempirical O 0 3.6577605442289496e-06
value O 0 6.73605242695885e-08
< O 0 1.8852791754397913e-06
3 O 0 9.251311894331593e-08
x O 0 2.9702994197577937e-06
10 O 0 4.6481805071607596e-08
( O 0 2.2974814939402677e-08
- O 0 3.6961716887162765e-06
5 O 0 1.1459559345894377e-07
) O 0 1.018857886947444e-08
) O 0 6.024742926769022e-09
and O 0 1.713025632454901e-08
suggestive O 0 9.019490221362503e-07
evidence O 0 8.58816093796122e-08
for O 0 2.9626441744312615e-08
a O 0 1.379465999207241e-07
locus O 0 2.9772020297968993e-06
on O 0 2.208865225838963e-06
chromosome O 0 0.00010657988605089486
4q O 0 0.06473654508590698
at O 0 2.7604144179349532e-06
D4S397 O 0 1.5120709576876834e-05
( O 0 4.890419447178829e-08
maximum O 0 3.427249453125114e-07
GENEHUNTER O 0 7.254583033500239e-05
- O 0 5.133772901899647e-06
PLUS O 0 6.485985863946553e-07
nonparametric O 0 2.7202524961467134e-06
linkage O 0 1.8949696141135064e-06
score O 0 3.234454766243289e-07
= O 0 3.5042708645960374e-07
3 O 0 5.498624489064241e-08
. O 0 7.182780148440315e-09
29 O 0 8.474548707226859e-08
, O 0 3.53535369868041e-08
P O 0 2.448739360261243e-05
= O 0 1.5588106805353164e-07
2 O 0 1.3753839844810045e-08
. O 0 2.9497306819337155e-09
57 O 0 9.30752364070031e-08
x O 0 1.8249592130814563e-06
10 O 0 4.214590987317024e-08
( O 0 2.2337546923267837e-08
- O 0 4.05207310905098e-06
3 O 0 7.467502882718691e-08
) O 0 7.54283835391334e-09
; O 0 1.327880827517447e-08
SIBPAL O 0 4.450147571333218e-06
Pempirical O 0 1.8636312688613543e-06
value O 0 5.163273542052593e-08
< O 0 2.1621176529151853e-06
1 O 0 7.802356805086674e-08
x O 0 2.1219573227426736e-06
10 O 0 2.626800643668048e-08
( O 0 1.5184731694262155e-08
- O 0 2.958702452815487e-06
3 O 0 7.475583174709755e-08
) O 0 6.920905626373042e-09
) O 0 3.141217730373569e-09
that O 0 2.187117154051066e-09
are O 0 2.0300975123177523e-08
linked O 0 7.239708793349564e-06
to O 0 2.7834310003527207e-06
mental O 0 0.1673927903175354
health O 0 0.0004893652512691915
wellness O 0 0.006312145385891199
. O 0 2.8305545129114762e-05

These O 0 7.758918400213588e-06
findings O 0 7.063173597998684e-06
are O 0 3.3894502848852426e-07
consistent O 0 6.451685408137564e-07
with O 0 1.313395188162758e-07
the O 0 9.420561752904177e-08
hypothesis O 0 1.032758973451564e-06
that O 0 2.2627425266819046e-08
certain O 0 4.665625041866406e-08
alleles O 0 2.0611749107501964e-07
could O 0 1.905200974761101e-07
prevent O 0 8.984532655631483e-07
or O 0 4.4269413024267124e-07
modify O 0 2.1986722913425183e-06
the O 0 1.6745030961828888e-07
clinical O 0 1.1996667126368266e-05
manifestations O 0 4.915387762594037e-06
of O 0 2.1949936126475222e-06
BPAD B-Disease 1 0.9999768733978271
and O 0 1.2894269275420811e-05
perhaps O 0 3.661788241515751e-06
other O 0 1.1335737326589879e-06
related O 0 0.03002629615366459
affective B-Disease 1 0.9996658563613892
disorders I-Disease 1 0.9989816546440125
. O 0 0.0001158981176558882

Segregation O 0 0.008261415176093578
distortion O 0 0.0600958876311779
in O 0 0.006340741645544767
myotonic B-Disease 1 0.9999860525131226
dystrophy I-Disease 1 0.9999693632125854
. O 0 0.0014862713869661093

Myotonic B-Disease 1 0.9999918937683105
dystrophy I-Disease 1 0.9999954700469971
( O 0 0.022595182061195374
DM B-Disease 1 0.9999983310699463
) O 0 3.793668656726368e-05
is O 0 3.492497853585519e-06
an O 0 2.661178996277158e-06
autosomal B-Disease 0 0.22314490377902985
dominant I-Disease 1 0.6091277003288269
disease I-Disease 0 0.03026195988059044
which O 0 7.720639132458018e-07
, O 0 3.5671382647706196e-07
in O 0 5.241043155024272e-08
the O 0 9.538082679227955e-08
typical O 0 5.710690402338514e-06
pedigree O 0 3.059997470700182e-05
, O 0 1.3677797028321947e-07
shows O 0 1.584684667932379e-07
a O 0 9.57837258397376e-08
three O 0 2.0954513502147165e-07
generation O 0 8.051662916841451e-06
anticipation O 0 1.3711658539250493e-05
cascade O 0 0.0003052391984965652
. O 0 1.2387963579385541e-05

This O 0 5.900000815017847e-06
results O 0 1.0244493751088157e-05
in O 0 1.2187792890472338e-05
infertility B-Disease 1 0.9994088411331177
and O 1 0.9983890056610107
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.0005605336627922952
CDM B-Disease 0 0.024755334481596947
) O 0 3.867563975745725e-07
with O 0 8.950240726335323e-08
the O 0 1.0282230533675829e-07
disappearance O 0 1.005466856440762e-05
of O 0 3.788047479247325e-06
DM B-Disease 1 0.9999974966049194
in O 0 3.701455625559902e-06
that O 0 1.5659508108001319e-06
pedigree O 0 0.00026598366093821824
. O 0 7.96288441051729e-06

The O 0 3.4000408959400374e-06
concept O 0 2.042446112682228e-06
of O 0 3.829971149116318e-07
segregation O 0 1.3631735782837495e-05
distortion O 0 0.00015529849042650312
, O 0 8.990386390905769e-07
where O 0 1.7829447074291238e-07
there O 0 2.7435747895765417e-08
is O 0 1.7438658517221484e-08
preferential O 0 3.34060473505815e-07
transmission O 0 1.3176411357562756e-06
of O 0 2.057752901407639e-08
the O 0 4.6245691720514515e-08
larger O 0 2.3194708376195194e-07
allele O 0 3.4126509262932814e-07
at O 0 1.477170314956311e-07
the O 0 3.531455377014936e-07
DM B-Disease 1 0.9999594688415527
locus O 0 2.7716207114281133e-05
, O 0 8.773611170909135e-07
has O 0 7.904679932835279e-08
been O 0 4.4673669208350475e-08
put O 0 6.918083528262287e-08
forward O 0 5.51917729296747e-08
to O 0 2.685889555209542e-08
explain O 0 4.393755546061584e-07
partially O 0 9.633224635763327e-07
the O 0 4.419499433083729e-08
maintenance O 0 1.7857939383247867e-05
of O 0 1.1871234164573252e-06
DM B-Disease 1 0.9999939203262329
in O 0 2.994110275267303e-07
the O 0 3.38849986292189e-07
population O 0 1.102873625313805e-06
. O 0 4.580934728437569e-06

In O 0 9.927999599312898e-06
a O 0 2.264540171381668e-06
survey O 0 4.424595772434259e-06
of O 0 8.404765594605124e-07
DM B-Disease 1 0.9999818801879883
in O 0 6.483622883024509e-07
Northern O 0 7.00831492395082e-07
Ireland O 0 5.068939117336413e-07
, O 0 2.6242199169246305e-07
59 O 0 5.1867332331312355e-06
pedigrees O 0 1.2143775165895931e-05
were O 0 1.6657508012940525e-06
ascertained O 0 2.5857762011582963e-05
. O 0 4.297194209357258e-06

Sibships O 0 0.007781817112118006
where O 0 6.661044608335942e-06
the O 0 2.509946455120371e-07
status O 0 2.648853296705056e-07
of O 0 3.2311309183796766e-08
all O 0 1.406845928642042e-08
the O 0 1.8318797145866483e-08
members O 0 3.9084010694523386e-08
had O 0 2.1671826289093588e-07
been O 0 6.870062918551412e-08
identified O 0 3.965296002661489e-07
were O 0 5.522968393734118e-08
examined O 0 1.286987867388234e-06
to O 0 2.6816460163558986e-08
determine O 0 2.638239493535366e-07
the O 0 2.5235401324152917e-08
transmission O 0 1.1723345778591465e-06
of O 0 3.8635743493387054e-08
the O 0 5.407029561865784e-07
DM B-Disease 1 0.9998940229415894
expansion O 0 3.162330813211156e-06
from O 0 2.5125999059127935e-07
affected O 0 6.006788453305489e-07
parents O 0 1.0349996415470741e-07
to O 0 6.03547576361052e-08
their O 0 2.8994162448725547e-07
offspring O 0 9.171167221211363e-06
. O 0 4.182162683719071e-06

Where O 0 1.3534143363358453e-05
the O 0 1.6739838883950142e-06
transmitting O 0 8.288401295430958e-05
parent O 0 2.118771408277098e-05
was O 0 2.166319973184727e-06
male O 0 1.170566065411549e-06
, O 0 8.9542686509958e-07
58 O 0 1.767782487149816e-05
. O 0 5.304802471073344e-06

3 O 0 1.4900491805747151e-05
% O 0 9.198103043672745e-07
of O 0 9.486610252906758e-08
the O 0 8.75465815397547e-08
offspring O 0 1.1887775599461747e-06
were O 0 1.8554688097083272e-07
affected O 0 3.1738315442453313e-07
, O 0 9.416303470288767e-08
and O 0 8.084820990461594e-08
in O 0 2.3609899812981894e-08
the O 0 6.193174328927853e-08
case O 0 6.906639100634493e-07
of O 0 2.8414786967800865e-08
a O 0 5.367382414078747e-07
female O 0 1.2551670351967914e-06
transmitting O 0 7.350500527536497e-05
parent O 0 5.174550551600987e-06
, O 0 5.324877747625578e-07
68 O 0 1.0336386367271189e-05
. O 0 4.509474820224568e-06

7 O 0 0.00014542636927217245
% O 0 1.6012671039788984e-05
were O 0 4.15534304920584e-06
affected O 0 1.3580519407696556e-05
. O 0 1.08743133750977e-05

Studies O 0 1.4745729458809365e-05
on O 0 3.52783058588102e-06
meiotic O 0 0.0015046598855406046
drive O 0 0.0003441756125539541
in O 0 2.2030457330401987e-05
DM B-Disease 1 0.9999916553497314
have O 0 6.887150334478065e-07
shown O 0 3.848603853384702e-07
increased O 0 2.6647396111911803e-07
transmission O 0 4.584250348216301e-07
of O 0 1.755355505395073e-08
the O 0 3.478963250813649e-08
larger O 0 2.609488092275569e-07
allele O 0 3.4285932315469836e-07
at O 0 1.8718091610026022e-07
the O 0 3.863213748900307e-07
DM B-Disease 1 0.9997360110282898
locus O 0 6.97262885296368e-06
in O 0 4.880574806520599e-07
non O 0 1.9858538507833146e-05
- O 0 0.1774987131357193
DM O 1 0.9999744892120361
heterozygotes O 0 0.0001692187797743827
for O 0 1.756102506078605e-06
CTGn O 0 0.0021495057735592127
. O 0 1.1722791896318085e-05

This O 0 1.9044775854126783e-06
study O 0 5.202708166507364e-07
provides O 0 2.0994438898469525e-07
further O 0 1.1270936539631293e-07
evidence O 0 7.427543664562108e-07
that O 0 4.744877912798984e-08
the O 0 3.6344317777547985e-07
DM B-Disease 1 0.9999562501907349
expansion O 0 1.6829008018248715e-05
tends O 0 3.0700948627782054e-06
to O 0 8.032117193579325e-08
be O 0 2.627036792546278e-07
transmitted O 0 2.4817557005007984e-06
preferentially O 0 5.634043645841302e-06
. O 0 2.742079459494562e-06

Diagnosis O 1 0.9723929166793823
of O 0 0.002787237288430333
hemochromatosis B-Disease 1 0.9998950958251953
. O 0 0.0006341366097331047

If O 0 0.0007324935868382454
untreated O 1 0.7224160432815552
, O 0 0.001251258421689272
hemochromatosis B-Disease 1 0.9999986886978149
can O 0 0.00031605700496584177
cause O 0 0.08928211033344269
serious O 1 0.8716157078742981
illness O 0 0.11628164350986481
and O 0 4.322570475778775e-06
early B-Disease 0 1.8255428585689515e-05
death I-Disease 0 3.122977796010673e-05
, O 0 7.046273822197691e-07
but O 0 3.7985427070452715e-07
the O 0 1.1751217243727297e-06
disease O 0 3.2833326258696616e-05
is O 0 8.127695849680094e-08
still O 0 7.051409056657576e-07
substantially O 0 9.126451914198697e-06
under O 0 2.081627280858811e-05
- O 1 0.9934079647064209
diagnosed O 1 0.6465170383453369
. O 0 1.2441430044418667e-05

The O 0 7.060109510348411e-06
cornerstone O 0 2.438897172396537e-05
of O 0 3.512334103561443e-07
screening O 0 1.3815588317811489e-05
and O 0 1.2512768989836331e-06
case O 0 4.88463047076948e-06
detection O 0 1.452360265830066e-05
is O 0 3.9759811443218496e-08
the O 0 1.2672926708034993e-08
measurement O 0 1.0366596825406305e-06
of O 0 1.373455091879805e-07
serum O 0 3.16667283186689e-05
transferrin O 0 2.5959607228287496e-05
saturation O 0 4.453586370800622e-06
and O 0 1.7493300674686907e-07
the O 0 1.731061587406657e-07
serum O 0 4.4626482122112066e-05
ferritin O 0 0.00015944737242534757
level O 0 3.1294648579205386e-06
. O 0 3.3861235806398327e-06

Once O 0 7.126593845896423e-05
the O 0 3.578021050998359e-06
diagnosis O 0 0.011524694040417671
is O 0 4.35699985246174e-06
suspected O 0 0.00019770443032030016
, O 0 6.432051122828852e-07
physicians O 0 6.613354344153777e-07
must O 0 8.760972036725434e-08
use O 0 1.6226930199536582e-07
serum O 0 4.340380837675184e-05
ferritin O 0 0.00015037627599667758
levels O 0 8.222511951316847e-07
and O 0 6.058861572455498e-07
hepatic O 0 0.042902711778879166
iron O 0 0.00012244272511452436
stores O 0 1.9078916011494584e-06
on O 0 4.021030235890066e-06
liver O 0 0.0015752885956317186
biopsy O 0 0.0013169791782274842
specimens O 0 2.829688583005918e-06
to O 0 2.5272063908232667e-07
assess O 0 0.00016333274834323674
patients O 0 5.286864052322926e-06
for O 0 5.000675784572195e-08
the O 0 1.0781235459944583e-07
presence O 0 6.503203735519492e-07
of O 0 2.454920377203962e-06
iron B-Disease 0 0.4080171585083008
overload I-Disease 0 0.01272859051823616
. O 0 1.8894957975135185e-05

Liver O 1 0.9978039860725403
biopsy O 1 0.9071424007415771
is O 0 2.4883820515242405e-06
also O 0 1.784982828212378e-07
used O 0 5.492754695524127e-08
to O 0 1.793004145156374e-08
establish O 0 7.58344995688276e-08
the O 0 1.58147592799196e-08
presence O 0 1.1324204507445756e-07
or O 0 6.965922949575543e-08
absence O 0 2.7138318614561285e-07
of O 0 9.885322924674256e-07
cirrhosis B-Disease 1 0.9761962890625
, O 0 6.768855200789403e-07
which O 0 2.775889811346133e-07
can O 0 7.901278422650648e-07
affect O 0 2.1525142074096948e-05
prognosis O 0 0.15958242118358612
and O 0 9.007953849504702e-06
management O 0 5.267743472359143e-05
. O 0 1.2347791198408231e-05

A O 0 6.488768849521875e-05
DNA O 0 0.00014880641538184136
- O 0 7.363415352301672e-05
based O 0 6.548585815835395e-07
test O 0 2.403292285180214e-07
for O 0 2.1469768185511384e-08
the O 0 5.715287798579993e-08
HFE O 0 9.103023330681026e-05
gene O 0 1.630778854178061e-07
is O 0 2.964893930368362e-08
commercially O 0 3.499485217162146e-07
available O 0 7.446807614996942e-08
, O 0 3.385059699212434e-08
but O 0 8.130684570062385e-09
its O 0 7.29818916411773e-09
place O 0 3.16180717163661e-08
in O 0 1.66708993276643e-08
the O 0 1.8357907549670927e-07
diagnosis O 0 0.00030884938314557076
of O 0 9.303170372731984e-06
hemochromatosis B-Disease 1 0.9999972581863403
is O 0 2.8213403311383445e-06
still O 0 4.163403446000302e-06
being O 0 2.483105163264554e-06
evaluated O 0 2.1400370314950123e-05
. O 0 6.0484335335786454e-06

Currently O 0 1.6050493286456913e-05
, O 0 1.304553620684601e-06
the O 0 5.8890456955396076e-08
most O 0 2.922035946539836e-08
useful O 0 7.173828464601684e-08
role O 0 4.107203110947921e-08
for O 0 1.1923496856525162e-08
this O 0 1.553353357053311e-08
test O 0 1.0094801154991728e-06
is O 0 5.291568072607333e-08
in O 0 1.701971896750365e-08
the O 0 2.1042460218723136e-08
detection O 0 2.7514781777426833e-06
of O 0 1.2312680155446287e-06
hemochromatosis B-Disease 1 0.9999909400939941
in O 0 8.040038323997578e-07
the O 0 2.3049788921980507e-07
family O 0 1.3112542092130752e-06
members O 0 7.012407365891704e-08
of O 0 9.956547728506848e-07
patients O 0 1.1590926987992134e-05
with O 0 1.1666682553368446e-07
a O 0 2.26302017836133e-06
proven O 0 0.00010910136188613251
case O 0 1.8637415450939443e-06
of O 0 4.6790731289547693e-07
the O 0 2.8673159249592572e-05
disease O 0 0.010210090316832066
. O 0 1.9725059246411547e-05

It O 0 4.16800367020187e-06
is O 0 8.633330708107678e-07
crucial O 0 4.191465905023506e-06
to O 0 2.255529398098588e-05
diagnose O 1 0.9999281167984009
hemochromatosis B-Disease 1 0.9999986886978149
before O 0 0.29176318645477295
hepatic B-Disease 1 0.9999860525131226
cirrhosis I-Disease 1 0.9999243021011353
develops O 0 0.005016321316361427
because O 0 7.248496785905445e-06
phlebotomy O 0 0.06767578423023224
therapy O 0 0.00021734682377427816
can O 0 6.482939625129802e-06
avert O 1 0.9373204112052917
serious O 1 0.9999673366546631
chronic O 1 0.9999995231628418
disease O 1 0.84969162940979
and O 0 8.606395567767322e-06
can O 0 1.5920162468319177e-06
even O 0 4.844870886699937e-07
lead O 0 5.57533724077075e-07
to O 0 9.330612726898835e-08
normal O 0 7.787383538016002e-07
life O 0 1.7857229295259458e-06
expectancy O 0 2.4627084712847136e-05
. O 0 5.116891657053202e-07
. O 0 6.56712518321001e-06

Prevalence O 0 0.0015365718863904476
of O 0 2.537436557759065e-06
the O 0 1.2447296739992453e-06
I1307K O 0 0.0001284587779082358
APC B-Disease 0 2.025802677962929e-05
gene O 0 1.1972833817708306e-06
variant O 0 1.793981141418044e-06
in O 0 1.268439575596858e-07
Israeli O 0 2.8108024707762524e-06
Jews O 0 3.354728619342495e-07
of O 0 5.4033289842436716e-08
differing O 0 2.091205004717267e-07
ethnic O 0 1.7491382209300355e-07
origin O 0 1.9526166283867497e-07
and O 0 3.370028707649908e-06
risk O 0 0.0008272344712167978
for O 0 0.09594796597957611
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999920129776001
. O 0 0.00015576535952277482

BACKGROUND O 0 0.0003049352380912751
& O 0 0.00018765708955470473
AIMS O 0 1.7796193787944503e-05
Israeli O 0 1.267200059373863e-05
Jews O 0 1.2212470892336569e-06
of O 0 1.180940714107237e-07
European O 0 6.908734349053702e-07
birth O 0 8.668850568938069e-06
, O 0 5.024530196351407e-07
i O 0 1.9257586245657876e-06
. O 0 7.226233833534934e-08
e O 0 1.1284504353170632e-06
. O 0 2.7253415524342017e-08
, O 0 1.0498676772385807e-07
Ashkenazim O 0 9.673579370428342e-06
, O 0 5.4196785725935115e-08
have O 0 3.6797565883261996e-08
the O 0 9.158818556898041e-07
highest O 1 0.9993601441383362
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
incidence O 0 0.4595493972301483
of O 0 2.835540442447382e-07
any O 0 6.225352535693673e-07
Israeli O 0 2.4277262127725407e-05
ethnic O 0 4.0493305277777836e-06
group O 0 1.533270005893428e-05
. O 0 6.844715244369581e-06

The O 0 1.3531664990296122e-05
I1307K O 0 0.0004331439849920571
APC B-Disease 0 9.7037831437774e-05
gene O 0 8.152433110808488e-06
variant O 0 1.3719689377467148e-05
was O 0 3.180835847160779e-06
found O 0 7.20029902367969e-07
in O 0 4.232087462696654e-07
6 O 0 1.0356980055803433e-05
. O 0 7.936712790979072e-06

1 O 0 2.0890531231998466e-05
% O 0 8.636880579615536e-07
of O 0 1.3677613708296121e-07
American O 0 2.0445263260171487e-07
Jews O 0 9.743813507157029e-07
, O 0 1.4526540326187387e-07
28 O 0 3.3750674788279866e-07
% O 0 4.234017225712705e-08
of O 0 8.637624659968424e-08
their O 0 2.0775183656951413e-05
familial O 1 0.9999984502792358
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cases O 0 0.0041441419161856174
, O 0 4.992612502974225e-06
but O 0 5.036346237830003e-07
not O 0 6.21881355300502e-08
in O 0 1.5083791993220075e-07
non O 0 4.428260126587702e-06
- O 0 0.0011322761420160532
Jews O 0 2.179729926865548e-05
. O 0 6.001737347105518e-06

We O 0 1.673011684033554e-05
assessed O 0 1.360487840429414e-05
the O 0 6.723447540935013e-07
I1307K O 0 0.0002023348060902208
prevalence O 0 0.00013486036914400756
in O 0 2.507338479063037e-07
Israeli O 0 6.528882749989862e-06
Jews O 0 5.204127546676318e-07
of O 0 7.859967610102103e-08
differing O 0 2.482749437149323e-07
ethnic O 0 1.8042811689156224e-07
origin O 0 2.5228695221812814e-07
and O 0 3.85693692805944e-06
risk O 0 0.002435030648484826
for O 0 0.1726696491241455
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999951124191284
. O 0 0.00037395296385511756

METHODS O 0 3.6858924431726336e-05
DNA O 0 1.8147429727832787e-05
samples O 0 6.542069286297192e-07
from O 0 7.144920033397284e-08
500 O 0 1.882184221813077e-07
unrelated O 0 6.680535307168611e-07
Jews O 0 1.4245802049117628e-07
of O 0 2.406757282358285e-08
European O 0 1.4793229752285697e-07
or O 0 3.3802339771682455e-07
non O 0 1.8454607015883084e-06
- O 0 2.965511885122396e-05
European O 0 1.196773808942453e-07
origin O 0 5.5876768101370544e-08
, O 0 1.1400369714920089e-07
with O 0 1.320121043590916e-07
or O 0 4.4954288114240626e-07
without O 0 1.025889915240441e-07
a O 0 2.9004809221078176e-07
personal O 0 1.2941056411364116e-05
and O 0 1.2559785318444483e-05
/ O 0 0.010045111179351807
or O 0 2.3338677692663623e-06
family O 0 9.305816774940467e-07
history O 0 2.893673354265047e-07
of O 0 8.826180533105799e-07
neoplasia B-Disease 1 0.6927279233932495
, O 0 1.0185721066591213e-06
were O 0 4.2970609115400293e-07
examined O 0 3.814962383330567e-06
for O 0 3.949971727479351e-08
the O 0 1.3834009848778805e-07
I1307K O 0 2.5972138246288523e-05
variant O 0 5.422086815087823e-07
by O 0 2.6857923884904267e-08
the O 0 2.0257807875623257e-08
allele O 0 3.821010921001289e-07
- O 0 1.9880144463968463e-06
specific O 0 1.0283348927941915e-07
oligonucleotide O 0 3.613734952523373e-05
( O 0 3.8862646078996477e-07
ASO O 0 0.00019806556520052254
) O 0 2.3822873629342212e-07
method O 0 9.615473572921474e-07
. O 0 2.8349745662126224e-06

RESULTS O 0 4.925749090034515e-05
In O 0 1.5486931488339906e-06
persons O 0 1.1814561275969027e-06
at O 0 1.080749143511639e-06
average O 0 2.1138330339454114e-05
risk O 0 0.0002626118657644838
for O 0 0.01165770273655653
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
, O 0 1.1958173672610428e-05
I1307K O 0 0.000811530277132988
was O 0 4.477485163079109e-06
found O 0 3.73971602130041e-07
in O 0 1.311925501568112e-07
5 O 0 1.427783445251407e-06
. O 0 2.224126774308388e-06

0 O 0 3.248382199672051e-05
% O 0 1.055807274497056e-06
of O 0 1.1662355348107667e-07
120 O 0 8.152084092216683e-07
European O 0 2.5320989038846164e-07
and O 0 3.7737225966338883e-07
1 O 0 3.0435230655712076e-06
. O 0 6.113885774539085e-06

6 O 0 3.675685002235696e-05
% O 0 6.988946097408189e-07
of O 0 9.11733835096129e-08
188 O 0 1.003817033051746e-06
non O 0 1.3859882983524585e-06
- O 0 2.2553014787263237e-05
European O 0 2.5393126179551473e-07
Jews O 0 9.54750817072636e-07
( O 0 1.8430091586196795e-07
P O 0 0.0009180773049592972
= O 0 1.80654865289398e-06
0 O 0 3.4568944329294027e-07
. O 0 4.4230581863757834e-08
08 O 0 5.712976758331934e-07
) O 0 1.2839949192766653e-07
. O 0 8.474256674162461e-07

It O 0 1.1509547221066896e-05
occurred O 0 1.2391981726977974e-05
in O 0 9.28471877159609e-07
15 O 0 4.1347084334120154e-06
. O 0 7.084274784574518e-06

4 O 0 2.011673859669827e-05
% O 0 6.409810566765373e-07
of O 0 3.0254022931330837e-07
52 O 0 4.081840870640008e-06
Ashkenazi O 0 3.862237645080313e-05
Israelis O 0 2.4451759600196965e-05
with O 0 1.3153925465303473e-05
familial O 1 0.9974201917648315
cancer B-Disease 1 0.9902382493019104
( O 0 5.464219157147454e-06
P O 0 0.336032897233963
= O 0 4.133785751037067e-06
0 O 0 2.1875612787880527e-07
. O 0 2.1226680857466818e-08
02 O 0 1.3256230886327103e-06
) O 0 6.6896879147293475e-09
and O 0 1.580308861548474e-08
was O 0 8.450176380847552e-08
not O 0 1.2741688593109757e-08
detected O 0 1.9790580552125903e-07
in O 0 9.071402296001452e-09
51 O 0 3.6833174021921877e-07
non O 0 2.9143615165594383e-07
- O 0 7.330289918172639e-06
European O 0 1.1753510165135594e-07
Jews O 0 6.340536629068083e-07
at O 0 1.8281905340700177e-06
increased O 0 4.901542706647888e-05
cancer B-Disease 0 0.2915002405643463
risk O 0 9.028073691297323e-05
. O 0 1.0465930245118216e-05

Colorectal B-Disease 1 0.9998664855957031
neoplasia I-Disease 1 0.9960689544677734
occurred O 0 0.001774450996890664
personally O 0 0.0004613168421201408
or O 0 1.4781343224967713e-06
in O 0 1.9625485947472043e-07
the O 0 5.776462685957995e-08
families O 0 1.313965185545385e-07
of O 0 4.9768495102853194e-08
13 O 0 5.387531700762338e-07
of O 0 9.900591635414457e-08
20 O 0 8.919495826376078e-07
Ashkenazi O 0 1.4462540093518328e-05
I1307K O 0 2.0299064999562688e-05
carriers O 0 1.0797149343488854e-06
, O 0 4.7494502553036e-08
8 O 0 1.1850247716438389e-07
of O 0 6.80553142728968e-08
whom O 0 3.4355655316176126e-06
also O 0 2.616470737848431e-07
had O 0 1.0039836979558459e-06
a O 0 8.388590231334092e-07
personal O 0 1.3479155313689262e-05
or O 0 1.3000094440940302e-06
family O 0 1.1367349088686751e-06
history O 0 1.273223347197927e-06
of O 0 7.510943760280497e-06
noncolonic O 1 0.510269820690155
neoplasia B-Disease 1 0.6452382206916809
. O 0 2.555383980507031e-05

CONCLUSIONS O 0 0.00014947123418096453
The O 0 6.8766171352763195e-06
I1307K O 0 0.000589669740293175
APC O 0 0.00031452463008463383
variant O 0 6.931721145519987e-05
may O 0 1.6621073655187502e-06
represent O 0 1.8890573016960843e-07
a O 0 3.814199089902104e-07
susceptibility O 0 2.2847620130050927e-05
gene O 0 2.4247194687632145e-06
for O 0 1.9452470951364376e-05
colorectal B-Disease 1 0.9999984502792358
, I-Disease 0 1.0543439202592708e-05
or I-Disease 0 9.637406037654728e-07
other I-Disease 0 1.2712247610124905e-07
, I-Disease 0 1.2380771295283921e-05
cancers I-Disease 0 0.09502828121185303
in O 0 6.929506639608007e-07
Ashkenazi O 0 6.262498209252954e-05
Jews O 0 1.0677333648345666e-06
, O 0 1.7768118709682312e-07
and O 0 9.071786877257182e-08
partially O 0 1.823988213800476e-06
explains O 0 2.8176575028737716e-07
the O 0 5.060066499140703e-08
higher O 0 4.047550191899063e-06
incidence O 0 0.005598652642220259
of O 0 0.04253488406538963
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999948740005493
in O 0 2.6711743430496426e-06
European O 0 3.376868335180916e-06
Israelis O 0 7.793685654178262e-05
. O 0 2.1426221792353317e-05

Systematic O 0 8.291081030620262e-05
analysis O 0 1.329998212895589e-05
of O 0 2.0287525330786593e-06
coproporphyrinogen O 0 0.002307857619598508
oxidase O 0 0.0005447602597996593
gene O 0 0.00015105490456335247
defects O 1 0.5273761749267578
in O 0 1.1745171832444612e-05
hereditary B-Disease 1 0.5481513738632202
coproporphyria I-Disease 0 0.24531038105487823
and O 0 1.8297278074896894e-05
mutation O 0 3.098929300904274e-05
update O 0 5.794001117465086e-05
. O 0 1.562984471092932e-05

Hereditary B-Disease 1 0.995936393737793
coproporphyria I-Disease 1 0.9152251482009888
( O 0 7.559696678072214e-05
HC B-Disease 1 0.9976600408554077
) O 0 6.285878953349311e-06
is O 0 3.228290097467834e-06
an O 0 3.646469485829584e-05
acute O 1 0.9998751878738403
hepatic B-Disease 1 0.9999943971633911
porphyria I-Disease 1 0.9999836683273315
with O 0 0.014755535870790482
autosomal O 1 0.9577239155769348
dominant O 0 0.3461771309375763
inheritance O 0 0.12112588435411453
caused O 0 0.00018140286556445062
by O 0 1.945851636264706e-06
deficient B-Disease 0 9.253188909497112e-05
activity I-Disease 0 3.748849906060059e-07
of I-Disease 0 2.3686018835178402e-07
coproporphyrinogen I-Disease 0 0.01902509480714798
III I-Disease 1 0.5341002345085144
oxidase I-Disease 0 0.0001743226166581735
( O 0 1.0565224783931626e-06
CPO O 0 0.00011213684774702415
) O 0 9.142211183643667e-07
. O 0 2.9848297344869934e-06

Clinical O 0 0.0069805169478058815
manifestations O 0 0.00011457708751549944
of O 0 2.7332755507814e-06
the O 0 4.6712822950212285e-05
disease O 0 0.07007803022861481
are O 0 7.978231337801844e-07
characterized O 0 0.0003597611503209919
by O 0 2.628149013617076e-05
acute O 0 0.30027705430984497
attacks O 0 0.0003489410737529397
of O 0 0.00555023830384016
neurological B-Disease 1 0.9999897480010986
dysfunction I-Disease 1 0.9880000948905945
often O 0 1.0163345905311871e-05
precipitated O 0 0.0006476897979155183
by O 0 2.2212736894289264e-06
drugs O 0 4.411454483488342e-06
, O 0 1.3329972148312663e-07
fasting O 0 1.6688386494934093e-06
, O 0 4.875304284723825e-07
cyclical O 0 0.001167205278761685
hormonal O 0 3.525121064740233e-05
changes O 0 8.128794206641032e-07
, O 0 5.813251846120693e-06
or O 0 0.0002089207264361903
infectious B-Disease 0 0.351691871881485
diseases I-Disease 0 0.007568647153675556
. O 0 1.5340116078732535e-05

Skin O 1 0.9984307885169983
photosensitivity O 1 0.998610258102417
may O 0 0.00028572953306138515
also O 0 1.8457388932802132e-06
be O 0 7.952820624268497e-07
present O 0 3.975863819505321e-06
. O 0 8.937819984566886e-06

The O 0 4.362733761809068e-06
seven O 0 1.802562906050298e-06
exons O 0 7.795700184942689e-06
, O 0 3.1552710311189003e-07
the O 0 1.3157948330899671e-07
exon O 0 8.975199307315052e-06
/ O 0 1.9757439076784067e-05
intron O 0 4.58854301541578e-05
boundaries O 0 2.777308907297993e-07
and O 0 5.687384430075326e-08
part O 0 4.711375467536527e-08
of O 0 2.4077859706039817e-08
3 O 0 2.2864918491904973e-07
noncoding O 0 8.383971362491138e-06
sequence O 0 6.662859419748202e-08
of O 0 1.5229979055675358e-08
the O 0 2.668828535945522e-08
CPO O 0 7.074876975821098e-06
gene O 0 1.5028024336061208e-07
were O 0 5.138486258715602e-08
systematically O 0 8.130538731165871e-07
analyzed O 0 2.2240031682940753e-07
by O 0 2.0499649977523404e-08
an O 0 2.002366983333559e-08
exon O 0 2.7841665541927796e-06
- O 0 1.833299575082492e-05
by O 0 3.6064062669538544e-07
- O 0 6.888757343403995e-05
exon O 0 4.694862582255155e-05
denaturing O 0 0.0004650922492146492
gradient O 0 0.0002162044693250209
gel O 0 0.0002908050373662263
electrophoresis O 0 0.0001719404972391203
( O 0 4.4866058601655823e-07
DGGE O 0 3.673603350762278e-05
) O 0 2.806441656844072e-08
strategy O 0 1.2095085821783869e-07
followed O 0 2.4190178748995095e-08
by O 0 5.082155141167277e-09
direct O 0 1.2139109273334725e-08
sequencing O 0 8.56112620795102e-08
in O 0 3.319966523918083e-08
seven O 0 3.020754775207024e-07
unrelated O 0 1.0729764653660823e-05
heterozygous O 0 1.681457069935277e-05
HC B-Disease 1 0.9996559619903564
patients O 0 8.9994166046381e-05
from O 0 2.6127179353352403e-07
France O 0 8.594355676905252e-06
, O 0 8.959162869359716e-07
Holland O 0 6.012156154611148e-05
, O 0 3.744140713024535e-07
and O 0 1.1132007102787611e-06
Czech O 0 5.117750333738513e-05
Republic O 0 5.24621145814308e-06
. O 0 4.88043951918371e-06

Seven O 0 4.7458910557907075e-05
novel O 0 1.898380469356198e-05
mutations O 0 6.705558462272165e-06
and O 0 3.228513207886863e-07
two O 0 6.425551646316308e-08
new O 0 7.544697382400045e-07
polymorphisms O 0 6.716317147947848e-05
were O 0 4.73097952635726e-06
detected O 0 4.253795850672759e-05
. O 0 3.917106369044632e-06

Among O 0 2.8985201424802653e-05
these O 0 9.440686881134752e-07
mutations O 0 2.7254875476501184e-06
two O 0 1.5739038872197852e-07
are O 0 2.3293929984902206e-07
missense O 0 2.741897878877353e-05
( O 0 2.6234914685119293e-07
G197W O 0 3.0085244361544028e-05
, O 0 3.7429947497003013e-07
W427R O 0 1.770542439771816e-05
) O 0 5.1847280246875016e-08
, O 0 2.222030914822426e-08
two O 0 2.625618478191427e-08
are O 0 3.9536875107160085e-08
nonsense O 0 5.716929535992676e-06
( O 0 1.0489109314448797e-07
Q306X O 0 1.1565266504476313e-05
, O 0 1.1396412702424641e-07
Q385X O 0 6.648313046753174e-06
) O 0 2.0188840821333542e-08
, O 0 2.117140773805204e-08
two O 0 1.3352308592118334e-08
are O 0 1.2117364889263627e-08
small O 0 1.3763187212134653e-07
deletions O 0 2.0677384782175068e-06
( O 0 1.064973886855114e-07
662de14bp O 0 6.756383754691342e-06
; O 0 1.3285665545481606e-07
1168del3bp O 0 1.8804626961355098e-05
removing O 0 5.443650934466859e-07
a O 0 5.653079071521461e-08
glycine O 0 3.4648496693989728e-06
at O 0 9.281446722297915e-08
position O 0 3.622334077135747e-08
390 O 0 2.089837352059476e-07
) O 0 1.4882457044507191e-08
, O 0 1.410639960397475e-08
and O 0 1.598458432283678e-08
one O 0 2.366381934848505e-08
is O 0 2.1341486799997256e-08
a O 0 6.314384393135697e-08
splicing O 0 8.539938676221936e-07
mutation O 0 5.299102667777333e-07
( O 0 1.2810058080958697e-07
IVS1 O 0 6.26081382506527e-05
- O 0 4.4693304516840726e-05
15c O 0 5.034395871916786e-05
- O 0 0.00010909917909884825
- O 0 0.0003417349071241915
> O 0 2.964391933346633e-05
g O 0 1.407558283972321e-05
) O 0 1.5126742525239933e-08
which O 0 1.47715981668739e-08
creates O 0 7.966007586901469e-08
a O 0 3.73845310264187e-08
new O 0 1.865178518301036e-07
acceptor O 0 3.980120254709618e-06
splice O 0 1.846957457019016e-05
site O 0 1.037201400322374e-05
. O 0 5.756396149081411e-06

The O 0 1.4036895663593896e-05
pathological O 0 0.0001971449819393456
significance O 0 4.212841758999275e-06
of O 0 2.8431384180294117e-07
the O 0 2.219070864839523e-07
point O 0 1.2779579492416815e-06
mutations O 0 9.019816502586764e-07
G197W O 0 1.1183550668647513e-05
, O 0 1.5181204560121841e-07
W427R O 0 1.0682287211238872e-05
, O 0 8.939493767456952e-08
and O 0 3.87952425739968e-08
the O 0 2.4716642954558665e-08
in O 0 1.2547955918762455e-07
- O 0 0.00018158182501792908
frame O 0 3.682111855596304e-05
deletion O 0 3.2623750030325027e-06
390delGly O 0 3.226886474294588e-05
were O 0 1.698366816071939e-07
assessed O 0 6.912536605341302e-07
by O 0 3.796101211150926e-08
their O 0 1.6092078780616248e-08
respective O 0 6.065769753149652e-08
expression O 0 3.752927213440671e-08
in O 0 1.3871684245714277e-08
a O 0 7.334600837793914e-08
prokaryotic O 0 5.808801120110729e-07
system O 0 1.6785642742433993e-07
using O 0 1.103334881236151e-07
site O 0 2.079550085909432e-06
- O 0 7.067304068186786e-06
directed O 0 2.718022415137966e-06
mutagenesis O 0 0.00011284115316811949
. O 0 4.646541128749959e-06

These O 0 1.092968614102574e-05
mutations O 0 3.215649485355243e-05
resulted O 0 8.201435775845312e-06
in O 0 3.3346651662213844e-07
the O 0 2.527158073917235e-07
absence O 0 2.3623290417162934e-06
or O 0 3.420200016535091e-07
a O 0 2.8548922159643553e-07
dramatic O 0 5.0518779062258545e-06
decrease O 0 4.060997980559478e-06
of O 0 3.519214146763261e-07
CPO O 0 0.00045530483475886285
activity O 0 8.942339263739996e-06
. O 0 4.825191354029812e-06

The O 0 4.788851583725773e-06
two O 0 9.850729156823945e-07
polymorphisms O 0 3.223620660719462e-05
were O 0 5.031761816098879e-07
localized O 0 4.177267783234129e-06
in O 0 8.7102698387298e-08
noncoding O 0 2.3760894691804424e-05
part O 0 5.540957914718092e-08
of O 0 1.320135645244136e-08
the O 0 1.5778812922917496e-08
gene O 0 6.998564572313626e-08
1 O 0 8.503937465320632e-08
) O 0 1.534255034130183e-08
a O 0 1.0093552305079356e-07
C O 0 0.0003013262466993183
/ O 0 2.6504187189857475e-05
G O 0 2.5082214051508345e-05
polymorphism O 0 1.6059232166298898e-06
in O 0 4.717166035561604e-08
the O 0 6.963438892171325e-08
promotor O 0 6.510921230074018e-05
region O 0 3.096409102454345e-07
, O 0 4.368577322111378e-08
142 O 0 2.339362055181482e-07
bp O 0 1.2345532240942703e-06
upstream O 0 1.3594177517006756e-07
from O 0 1.0115500437279934e-08
the O 0 7.918770528192454e-09
transcriptional O 0 1.44848598893077e-07
initiation O 0 1.3645691865349363e-07
site O 0 4.18587063677478e-07
( O 0 3.221174793566206e-08
- O 0 3.6718174669658765e-06
142C O 0 1.0578962246654555e-05
/ O 0 8.980772690847516e-06
G O 0 1.3832832337357104e-05
) O 0 1.9436351195167845e-08
, O 0 1.502053947888271e-08
and O 0 1.552065143073378e-08
2 O 0 9.334387129911192e-08
) O 0 8.989759159305777e-09
a O 0 2.2701998503293908e-08
6 O 0 2.0124603850035783e-07
bp O 0 2.8884974199172575e-06
deletion O 0 4.121997392303456e-07
polymorphism O 0 1.1715331993400468e-06
in O 0 3.856852259787047e-08
the O 0 2.5810152237681905e-08
3 O 0 4.034710343603365e-07
noncoding O 0 7.880840712459758e-06
part O 0 5.093395216704266e-08
of O 0 1.2784385994280001e-08
the O 0 2.935106557799827e-08
CPO O 0 6.836743068561191e-06
gene O 0 2.3394468939841317e-07
, O 0 4.180420987154321e-08
574 O 0 6.092102466936922e-07
bp O 0 1.340602238997235e-06
downstream O 0 1.3727506598115724e-07
of O 0 1.2994011200362365e-08
the O 0 2.468310000836027e-08
last O 0 1.0277427264782091e-07
base O 0 1.0282936813155175e-07
of O 0 6.044217126799367e-09
the O 0 1.8449448191404372e-08
normal O 0 2.5556090577083523e-07
termination O 0 1.5915212543404778e-06
codon O 0 6.826851404184708e-07
( O 0 1.4011264681812463e-07
+ O 0 5.5252507991099264e-06
574 O 0 7.984694093465805e-06
delATTCTT O 0 2.2637781512457877e-05
) O 0 8.42992335492454e-07
. O 0 1.776682552190323e-06

Five O 0 5.372700252337381e-05
intragenic O 0 0.002378293313086033
dimorphisms O 0 0.0013137983623892069
are O 0 7.558264769613743e-07
now O 0 5.645104579343752e-07
well O 0 2.1271877415074414e-07
characterized O 0 5.3765252232551575e-06
and O 0 3.761036282412533e-07
the O 0 1.5238427408803545e-07
high O 0 6.1301807363634e-06
degree O 0 3.362499398917862e-07
of O 0 1.9052792765705817e-07
allelic O 0 5.723631693399511e-05
heterogeneity O 0 0.00024823102285154164
in O 0 6.3747547756065615e-06
HC B-Disease 1 0.9993495345115662
is O 0 1.7865202153188875e-06
demonstrated O 0 2.043810127361212e-06
with O 0 6.494749982266512e-08
seven O 0 5.518945656035612e-08
new O 0 4.1101969827650464e-08
different O 0 1.4329034847548883e-08
mutations O 0 7.80293731850179e-08
making O 0 2.030453849499736e-08
a O 0 2.4062250858492007e-08
total O 0 3.3181940750637295e-08
of O 0 3.989077157484644e-08
nineteen O 0 3.0675428206450306e-06
CPO O 0 0.006264417432248592
gene B-Disease 0 5.703722490579821e-05
defects I-Disease 0 0.11253119260072708
reported O 0 1.0030333214672282e-05
so O 0 4.5354335043157334e-07
far O 0 8.382904184145445e-07
. O 0 5.147599608790188e-07
. O 0 3.6336423363536596e-06

Coincidence O 0 0.0001096470223274082
of O 0 3.1751501410326455e-06
two O 0 1.1893378086824669e-06
novel O 0 4.587116109178169e-06
arylsulfatase O 0 0.0004912163713015616
A O 0 2.0606494217645377e-06
alleles O 0 1.49800177950965e-06
and O 0 2.92676958224547e-07
mutation O 0 1.5847255099288304e-06
459 O 0 2.3167405743151903e-05
+ O 0 3.657384149846621e-05
1G O 0 0.0007199215469881892
> O 0 1.0172489965043496e-05
A O 0 2.4660468511683575e-07
within O 0 6.462659030148643e-08
a O 0 5.648993237628019e-07
family O 0 1.368387347611133e-05
with O 0 7.230651681311429e-05
metachromatic B-Disease 1 0.999991774559021
leukodystrophy I-Disease 1 0.9999465942382812
: O 0 8.483975761919282e-07
molecular O 0 1.9588458144426113e-06
basis O 0 2.4166087086996413e-07
of O 0 5.451319111671182e-07
phenotypic O 0 5.594336107606068e-05
heterogeneity O 0 0.0010223360732197762
. O 0 3.789929542108439e-05

In O 0 9.809109542402439e-06
a O 0 5.374305601435481e-06
family O 0 4.290888227842515e-06
with O 0 3.4914145885522885e-07
three O 0 7.076213819345867e-07
siblings O 0 2.861306711565703e-05
, O 0 1.9115854854589998e-07
one O 0 4.729292157890086e-08
developed O 0 2.871244646485138e-07
classical O 0 9.96667495201109e-07
late O 0 0.0003381179994903505
infantile O 1 0.9928568601608276
metachromatic B-Disease 1 0.9999967813491821
leukodystrophy I-Disease 1 0.9999942779541016
( O 0 2.4190136173274368e-05
MLD B-Disease 1 0.999537467956543
) O 0 1.5526771903751069e-06
, O 0 1.182585606329667e-06
fatal O 0 0.00013859938189852983
at O 0 1.5423582908624667e-06
age O 0 5.743196425100905e-07
5 O 0 3.892607480793231e-07
years O 0 5.029986596127856e-07
, O 0 2.434842656384717e-07
with O 0 1.37785684728442e-06
deficient O 0 0.006354064680635929
arylsulfatase O 0 0.001821195357479155
A O 0 2.77695676231815e-06
( O 0 3.511449904181063e-07
ARSA O 0 0.0008624433539807796
) O 0 5.137594527582223e-08
activity O 0 1.8144793045848928e-07
and O 0 1.3044139279827505e-07
increased O 0 1.685892357272678e-06
galactosylsulfatide O 0 0.001133626326918602
( O 0 1.4015063243277837e-06
GS O 1 0.6832475662231445
) O 0 9.432857268620864e-07
excretion O 0 1.039960807247553e-05
. O 0 3.6536048355628736e-06

The O 0 7.148114946176065e-06
two O 0 8.512747626809869e-07
other O 0 2.483100161043694e-07
siblings O 0 1.157402675744379e-05
, O 0 4.506984510044276e-07
apparently O 0 3.6944520616088994e-06
healthy O 0 8.320388928950706e-07
at O 0 3.738018676813226e-07
12 O 0 1.2977891117316176e-07
( O 0 1.487289402746228e-08
1 O 0 3.9226804915415414e-08
/ O 0 9.122850315179676e-07
2 O 0 4.893079008638779e-08
) O 0 5.422633009288802e-09
and O 0 1.05217274892766e-08
15 O 0 3.7477843051192394e-08
years O 0 2.4851555480154275e-08
, O 0 1.7917118455557102e-08
respectively O 0 1.530424071916059e-07
, O 0 5.2118650728516513e-08
and O 0 6.204264479947597e-08
their O 0 3.0672946849108484e-08
father O 0 3.9989377000893e-06
, O 0 3.665568613087089e-07
apparently O 0 1.0919933401964954e-06
healthy O 0 3.672013235700433e-07
as O 0 2.5246185586524916e-08
well O 0 4.5532715375884436e-08
, O 0 8.928502381877479e-08
presented O 0 1.53952191794815e-06
ARSA O 0 0.11885402351617813
and O 0 1.799152073544974e-06
GS O 1 0.7374745607376099
values O 0 2.506678526970063e-07
within O 0 5.147069259692216e-08
the O 0 4.197791625415448e-08
range O 0 1.9193780644854996e-06
of O 0 3.973597358708503e-06
MLD B-Disease 1 0.999951958656311
patients O 0 0.0010267397155985236
. O 0 2.8687600206467323e-05

Mutation O 0 0.00015334085037466139
screening O 0 2.7594312996370718e-05
and O 0 1.1940164768020622e-06
sequence O 0 3.982334533247922e-07
analysis O 0 8.217228355533734e-07
disclosed O 0 1.556392089696601e-05
the O 0 6.932997109743155e-08
involvement O 0 1.0298584811607725e-06
of O 0 6.314770217841215e-08
three O 0 1.0233181058083574e-07
different O 0 2.491748887223366e-07
ARSA O 0 0.2930353283882141
mutations O 0 1.1076400596721214e-06
being O 0 6.526627061020918e-08
the O 0 1.3849872360083282e-08
molecular O 0 3.752562918180047e-07
basis O 0 1.5955697563185822e-07
of O 0 5.834396006321185e-07
intrafamilial O 0 0.0017450184095650911
phenotypic O 0 9.399751434102654e-05
heterogeneity O 0 0.00039468021714128554
. O 0 2.0965933799743652e-05

The O 0 1.795322350517381e-05
late O 0 0.00033066238393075764
infantile O 1 0.9722884297370911
patient O 1 0.765394926071167
inherited O 1 0.6747705936431885
from O 0 4.198430815449683e-06
his O 0 8.83785560290562e-06
mother O 0 2.214882624684833e-05
the O 0 1.0836095043487148e-07
frequent O 0 2.0415911876625614e-06
0 O 0 2.3954924017743906e-06
- O 0 3.5772318369708955e-05
type O 0 3.7427953429869376e-06
mutation O 0 2.783062598155084e-07
459 O 0 4.0375189200858586e-06
+ O 0 6.325694812403526e-06
1G O 0 0.00013375835260376334
> O 0 4.0337858990824316e-06
A O 0 3.289249548288353e-07
, O 0 1.1496437934965797e-07
and O 0 5.927020652052306e-08
from O 0 4.607646886256589e-08
his O 0 3.0585144372707873e-07
father O 0 3.1707020298199495e-06
a O 0 1.6137146019445936e-07
novel O 0 3.082367356910254e-07
, O 0 8.22449024440175e-08
single O 0 1.5783349738285324e-07
basepair O 0 2.0106266674702056e-05
microdeletion O 0 6.835699878138257e-06
of O 0 3.697070027897098e-08
guanine O 0 4.559185526886722e-07
at O 0 3.4470868826019796e-08
nucleotide O 0 9.24402741020458e-08
7 O 0 6.22659968030348e-08
in O 0 2.0970421843458098e-08
exon O 0 1.921040848174016e-06
1 O 0 3.917820947663131e-07
( O 0 1.4175371632063616e-07
7delG O 0 1.4623613424191717e-05
) O 0 3.694613894822396e-07
. O 0 1.788286226656055e-06

The O 0 7.304009614017559e-06
two O 0 8.793096640147269e-06
clinically O 0 0.015893245115876198
unaffected O 0 0.0009131786646321416
siblings O 0 4.329690273152664e-05
carried O 0 1.8337765368414694e-06
the O 0 3.54695799842375e-07
maternal O 0 2.76710470643593e-05
mutation O 0 1.8938712855742779e-06
459 O 0 2.0017647329950705e-05
+ O 0 2.9190248824306764e-05
1G O 0 0.0006892409292049706
> O 0 1.8688335330807604e-05
A O 0 5.366732693801168e-07
and O 0 2.510097090180352e-07
, O 0 8.141938678818406e-08
on O 0 1.0090665369943963e-07
their O 0 4.284825294575967e-08
paternal O 0 1.4533984540321399e-06
allele O 0 4.314776163028e-07
, O 0 4.449373136594659e-08
a O 0 3.468574405474101e-08
novel O 0 1.6150754333921213e-07
cytosine O 0 4.30848501764558e-07
to O 0 2.1013102369238368e-08
thymidine O 0 1.7195387727042544e-06
transition O 0 6.733714599249652e-07
at O 0 1.4385877022959903e-07
nucleotide O 0 6.184899348227191e-07
2435 O 0 1.630797669349704e-05
in O 0 5.776319511596739e-08
exon O 0 2.52002041634114e-06
8 O 0 3.76484365460783e-07
, O 0 4.261588415488404e-08
resulting O 0 8.532630602076097e-08
in O 0 1.2310299446482986e-08
substitution O 0 5.290265647772685e-08
of O 0 1.0222529311931794e-07
alanine O 0 9.595855772204231e-06
464 O 0 5.280595814838307e-06
by O 0 2.997861656695022e-07
valine O 0 0.00012713343312498182
( O 0 1.0275736030962435e-06
A464V O 0 4.1305916965939105e-05
) O 0 8.66342759309191e-07
. O 0 2.6166253519477323e-06

The O 0 1.733766112010926e-05
fathers O 0 4.255946623743512e-05
genotype O 0 0.00020631974621210247
thus O 0 4.653960786527023e-06
was O 0 9.842232429946307e-06
7delG O 0 0.0006502516916953027
/ O 0 0.0003414326929487288
A464V O 0 0.0005541460122913122
. O 0 1.3025052794546355e-05

Mutation O 0 0.00039717770414426923
A464V O 0 0.0006026176852174103
was O 0 5.0260919124411885e-06
not O 0 1.6271467018214025e-07
found O 0 2.170396697920296e-07
in O 0 1.5211580262075586e-07
18 O 0 5.797788162453799e-06
unrelated O 0 0.0006193110602907836
MLD B-Disease 1 0.9999867677688599
patients O 0 0.00019492872525006533
and O 0 7.533761277045414e-07
50 O 0 1.6886230014279136e-06
controls O 0 1.4548693798133172e-05
. O 0 5.45242846783367e-06

A464V O 0 0.0037290495820343494
, O 0 1.3571314411819912e-05
although O 0 1.3166952612664318e-06
clearly O 0 1.7569551573615172e-06
modifying O 0 8.339370651810896e-06
ARSA O 0 0.24746984243392944
and O 0 2.0858162315562367e-05
GS O 1 0.9988202452659607
levels O 0 1.0685100278351456e-05
, O 0 6.108938919169304e-07
apparently O 0 2.0062832390976837e-06
bears O 0 7.179440899562906e-07
little O 0 1.653643977306274e-07
significance O 0 1.1248580733536073e-07
for O 0 1.5902939765055635e-07
clinical O 0 2.4769253286649473e-05
manifestation O 0 1.873290784715209e-05
of O 0 2.8347908482828643e-06
MLD B-Disease 1 0.9999080896377563
, O 0 4.668309884436894e-06
mimicking O 0 2.2547272237716243e-05
the O 0 1.1564188753254712e-06
frequent O 0 3.738803570740856e-05
ARSA O 0 0.3189309537410736
pseudodeficiency O 0 0.004361129365861416
allele O 0 6.524532363982871e-05
. O 0 6.284805749601219e-06

Our O 0 1.6162992324098013e-05
results O 0 1.061790590028977e-05
demonstrate O 0 2.754103434199351e-06
that O 0 1.317283846447026e-07
in O 0 2.0558684354909929e-07
certain O 0 4.799317139259074e-07
genetic O 0 4.715016621048562e-05
conditions O 0 0.0009036171832121909
MLD B-Disease 1 0.9999585151672363
- O 0 0.2506805658340454
like O 0 4.155847636866383e-05
ARSA O 0 0.37849751114845276
and O 0 7.855463081796188e-06
GS O 1 0.8344653248786926
values O 0 4.271606144357065e-07
need O 0 5.891764232046626e-08
not O 0 1.375530800373781e-08
be O 0 1.3313806945802753e-08
paralleled O 0 1.5065000980030163e-06
by O 0 2.114255039487034e-06
clinical O 0 0.06733577698469162
disease O 0 0.005118565633893013
, O 0 3.927165437289659e-07
a O 0 4.210923236769304e-07
finding O 0 2.4326220682269195e-06
with O 0 9.01991995760909e-07
serious O 0 0.0003016337868757546
diagnostic O 0 0.002613374497741461
and O 0 3.547435699147172e-05
prognostic O 0 0.2786535620689392
implications O 0 0.0002520857669878751
. O 0 1.8504517356632277e-05

Moreover O 0 0.00014217649004422128
, O 0 5.22076743436628e-06
further O 0 2.492329258529935e-06
ARSA O 0 0.03565842658281326
alleles O 0 7.837705197744071e-06
functionally O 0 1.6925449017435312e-05
similar O 0 8.876507422428404e-07
to O 0 2.496722970590781e-07
A464V O 0 0.00014954022481106222
might O 0 1.1222975899727317e-06
exist O 0 1.3690819855582959e-07
which O 0 2.983182412208407e-08
, O 0 2.6875142111748573e-08
together O 0 3.535582848712693e-08
with O 0 6.058184709445413e-08
0 O 0 4.51572395832045e-06
- O 0 0.002553967759013176
type O 0 3.744584319065325e-05
mutations O 0 1.736436502142169e-06
, O 0 4.54027627938558e-07
may O 0 2.2903382159711327e-06
cause O 0 5.3728244893136434e-06
pathological O 0 0.00013696111273020506
ARSA O 1 0.8665908575057983
and O 0 1.3806697097606957e-05
GS O 1 0.9993367791175842
levels O 0 4.8169981710088905e-06
, O 0 7.598492857141537e-08
but O 0 6.264002649913891e-08
not O 0 1.2656867909299763e-07
clinical O 0 1.9404853446758352e-05
outbreak O 0 1.3497769032255746e-05
of O 0 3.134962014428311e-07
the O 0 2.0693043552455492e-05
disease O 0 0.00968503300100565
. O 0 1.4660441820524284e-06
. O 0 1.6812839021440595e-05

Human O 0 0.041444867849349976
MLH1 O 1 0.9998006224632263
deficiency O 1 0.9996335506439209
predisposes O 0 0.050954170525074005
to O 0 0.00014551430649589747
hematological B-Disease 1 0.9994795918464661
malignancy I-Disease 1 0.9996870756149292
and O 0 0.005214270204305649
neurofibromatosis B-Disease 1 0.9997983574867249
type I-Disease 0 0.0003893849498126656
1 I-Disease 0 1.6577490896452218e-05
. O 0 1.0201692020928022e-05

Heterozygous O 0 0.000744778080843389
germ O 0 0.15976880490779877
- O 0 0.0026767724193632603
line O 0 2.551979196141474e-05
mutations O 0 1.5088179452504846e-06
in O 0 7.046919847653044e-08
the O 0 1.4705794626479474e-07
DNA O 0 4.8246529331663623e-05
mismatch O 0 0.13240283727645874
repair O 0 0.18252575397491455
genes O 0 4.017354513052851e-06
lead O 0 6.362953172356356e-06
to O 0 2.6546276785666123e-05
hereditary B-Disease 1 0.9998663663864136
nonpolyposis I-Disease 1 0.9999958276748657
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999946355819702
. O 0 0.0008724061772227287

The O 0 0.00014153830124996603
disease O 0 0.1418231576681137
susceptibility O 0 0.00026247749337926507
of O 0 9.843065527093131e-07
individuals O 0 7.158381777117029e-06
who O 0 7.379570433840854e-06
constitutionally O 0 1.912446714413818e-05
lack O 0 2.3432924081134843e-06
both O 0 2.2586425529880216e-07
wild O 0 2.3097958546713926e-05
- O 0 0.002336847363039851
type O 0 3.0169025194481947e-05
alleles O 0 1.4907193417457165e-06
is O 0 5.439390520223242e-07
unknown O 0 2.8230792850081343e-06
. O 0 3.4221127407363383e-06

We O 0 2.486320590833202e-05
have O 0 1.618888859411527e-06
identified O 0 9.991523484131903e-07
three O 0 1.7055278078714764e-07
offspring O 0 1.5487552218473866e-06
in O 0 4.741584973544377e-07
a O 0 5.885013524675742e-05
hereditary B-Disease 1 0.9998958110809326
nonpolyposis I-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 0.049455005675554276
who O 0 0.0001892868458526209
developed O 0 0.003917178604751825
hematological B-Disease 1 0.9995474219322205
malignancy I-Disease 1 0.980951189994812
at O 0 7.802543223078828e-06
a O 0 3.105197947661509e-07
very O 0 1.9196401979115763e-07
early O 0 5.135223659635813e-07
age O 0 3.888715127686737e-07
, O 0 4.8632301741236006e-08
and O 0 6.213572589786054e-08
at O 0 8.812220642084867e-08
least O 0 8.732706113789845e-09
two O 0 3.799757397615622e-09
of O 0 2.06868513430436e-08
them O 0 6.7493502342586e-08
displayed O 0 7.312473826459609e-07
signs O 0 1.2605013353095273e-06
of O 0 1.2212610727146966e-06
neurofibromatosis B-Disease 1 0.9882264733314514
type I-Disease 0 3.7552337744273245e-05
1 I-Disease 0 6.083449989091605e-06
( O 0 1.1730938922482892e-06
NF1 B-Disease 0 0.0008980762795545161
) O 0 1.1609261036937824e-06
. O 0 4.220063601678703e-06

DNA O 0 7.465276576112956e-05
sequence O 0 6.389154350472381e-06
analysis O 0 1.6590714722042321e-06
and O 0 1.8420058722767862e-07
allele O 0 2.1409814507933334e-06
- O 0 9.792405762709677e-06
specific O 0 1.1688633350104283e-07
amplification O 0 1.6776805296103703e-06
in O 0 7.612825214664554e-08
two O 0 1.512749889798215e-07
siblings O 0 7.306002316909144e-06
revealed O 0 5.6219350881292485e-06
a O 0 2.3404315925290575e-06
homozygous O 0 7.061623909976333e-05
MLH1 O 0 0.06333684921264648
mutation O 0 4.581148459692486e-06
( O 0 2.8512599214991496e-07
C676T O 0 2.5162542442558333e-05
- O 0 0.00032967087463475764
- O 0 0.0005020365351811051
> O 0 7.064978126436472e-05
Arg226Stop O 0 8.529148908564821e-05
) O 0 8.56818076044874e-07
. O 0 1.998103243749938e-06

Thus O 0 3.0423268981394358e-05
, O 0 2.685280833247816e-06
a O 0 1.4624163213738939e-06
homozygous O 0 2.1492651285370812e-05
germ O 0 0.001636433880776167
- O 0 0.0006251020822674036
line O 0 5.6958513596327975e-05
MLH1 O 0 0.006560108158737421
mutation O 0 4.870461452810559e-06
and O 0 2.4082487470877822e-06
consequent O 0 0.006045647896826267
mismatch O 1 0.9998078942298889
repair O 1 0.9999926090240479
deficiency O 1 0.9997627139091492
results O 0 2.3196524125523865e-05
in O 0 1.352916569885565e-06
a O 0 1.1151886610605288e-05
mutator O 1 0.9617577791213989
phenotype O 0 0.0015565359499305487
characterized O 0 0.000551029050257057
by O 0 9.433623199583963e-05
leukemia B-Disease 1 0.999846339225769
and O 0 7.8428907727357e-05
/ O 1 0.9591030478477478
or O 0 0.24666307866573334
lymphoma B-Disease 1 0.9999998807907104
associated O 0 0.0006776299560442567
with O 0 0.00010522969387238845
neurofibromatosis B-Disease 1 0.9996945858001709
type I-Disease 0 7.617943629156798e-05
1 I-Disease 0 3.6401104352989933e-06
. O 0 7.497873184547643e-07
. O 0 3.660451284304145e-06

Missense O 0 0.012793734669685364
mutations O 0 0.00017823306552600116
in O 0 1.1209251624677563e-06
the O 0 1.871473500614229e-07
most O 0 6.594675028281927e-08
ancient O 0 8.805836415604062e-08
residues O 0 2.0437504133496986e-07
of O 0 6.531396934406075e-08
the O 0 2.055286216773311e-07
PAX6 O 0 0.0006985011859796941
paired O 0 1.3177001392250531e-06
domain O 0 4.1173379372594354e-07
underlie O 0 2.730123242145055e-06
a O 0 3.080407395827933e-07
spectrum O 0 1.7884645785670727e-05
of O 0 1.2767210137099028e-05
human O 0 0.3031946122646332
congenital B-Disease 1 0.9999990463256836
eye I-Disease 1 0.9998461008071899
malformations I-Disease 1 0.999937891960144
. O 0 0.0008913317578844726

Mutations O 0 0.00017718164599500597
of O 0 1.5452468460352975e-06
the O 0 1.0712644780142e-06
human O 0 3.341813680890482e-06
PAX6 O 0 0.06025431677699089
gene O 0 0.00015311613969970495
underlie O 0 0.46560221910476685
aniridia B-Disease 1 0.9999979734420776
( O 0 0.0625569298863411
congenital B-Disease 1 0.9999909400939941
absence I-Disease 0 2.698378375498578e-05
of I-Disease 0 1.6366617501262226e-06
the I-Disease 0 1.295414494961733e-05
iris I-Disease 1 0.9761609435081482
) O 0 1.0091836202263949e-06
, O 0 3.1981505799194565e-07
a O 0 1.3658625448442763e-06
rare O 0 0.00019501328642945737
dominant O 0 0.024285731837153435
malformation B-Disease 1 0.9969713687896729
of I-Disease 0 1.2192524536658311e-06
the I-Disease 0 7.823270607332233e-06
eye I-Disease 0 0.003004400059580803
. O 0 3.3544802136020735e-05

The O 0 4.602122771757422e-06
spectrum O 0 1.4401375665329397e-05
of O 0 1.2361637118374347e-06
PAX6 O 0 0.011317274533212185
mutations O 0 2.0481635147007182e-05
in O 0 1.0909399861702695e-05
aniridia B-Disease 1 0.9999929666519165
patients O 0 0.0017552090575918555
is O 0 2.680158956991363e-07
highly O 0 4.3487585799084627e-07
biased O 0 3.7254490052873734e-06
, O 0 8.542107110542929e-08
with O 0 4.7383210244333895e-08
92 O 0 2.5784179342736024e-06
% O 0 5.2097082203772516e-08
of O 0 1.4262503178485986e-08
all O 0 6.345182868017218e-08
reported O 0 5.6474168559361715e-06
mutations O 0 1.2434992413545842e-06
leading O 0 3.9414908314938657e-07
to O 0 1.192670993077627e-07
premature O 0 1.1685711797326803e-05
truncation O 0 5.625238827633439e-06
of O 0 1.0639445235938183e-07
the O 0 7.952436220648451e-08
protein O 0 2.7567867277866753e-07
( O 0 3.497018852272049e-08
nonsense O 0 8.563180813325744e-07
, O 0 3.234275780528151e-08
splicing O 0 2.715374876061105e-07
, O 0 6.357794291034224e-08
insertions O 0 6.890152803862293e-07
and O 0 8.875764478943893e-08
deletions O 0 5.406508876149019e-07
) O 0 1.5979097156559874e-08
and O 0 2.7378144196177345e-08
just O 0 3.840928997078663e-08
2 O 0 1.518985044413057e-07
% O 0 2.128973264348133e-08
leading O 0 3.398645276320167e-08
to O 0 2.3838808704823578e-09
substitution O 0 1.689120132652988e-08
of O 0 7.735081020143753e-09
one O 0 1.3290768485774151e-08
amino O 0 4.3786716474869536e-08
acid O 0 7.049096950595413e-08
by O 0 2.0978022874373892e-08
another O 0 1.9277747753676522e-07
( O 0 1.8222132780465472e-07
missense O 0 9.70501423580572e-06
) O 0 5.968005893919326e-07
. O 0 1.914376525746775e-06

The O 0 4.510614871833241e-06
extraordinary O 0 5.4235638344835024e-06
conservation O 0 2.1421722067316296e-06
of O 0 7.446509897590659e-08
the O 0 2.9377343935266254e-07
PAX6 O 0 0.00025845252093859017
protein O 0 5.481775247062615e-07
at O 0 1.233071316164569e-07
the O 0 1.1971946101141384e-08
amino O 0 5.195795793611069e-08
acid O 0 1.260947044556815e-07
level O 0 6.119807238746944e-08
amongst O 0 7.125091627813163e-08
vertebrates O 0 4.958610020366905e-07
predicts O 0 2.895630314014852e-05
that O 0 1.8811685720265814e-07
pathological O 0 4.666233871830627e-05
missense O 0 0.00015067929052747786
mutations O 0 3.7331346902647056e-06
should O 0 1.7278502184581157e-07
in O 0 6.419965359327762e-08
fact O 0 4.0860521721697296e-07
be O 0 1.2439649310636014e-07
common O 0 3.0966927511144604e-07
even O 0 3.465083580067585e-07
though O 0 1.6849378425831674e-07
they O 0 5.256971746803174e-08
are O 0 4.436881440028628e-08
hardly O 0 3.5001326637029706e-07
ever O 0 3.615873538365122e-07
seen O 0 4.666587301471736e-06
in O 0 3.902489879692439e-06
aniridia B-Disease 1 0.9998181462287903
patients O 0 0.00019940924539696425
. O 0 9.078959010366816e-06

This O 0 4.7548073780490085e-06
indicates O 0 1.82617313839728e-05
that O 0 1.618450653495529e-07
there O 0 1.5359364624600857e-07
is O 0 7.67956152003535e-08
a O 0 2.2456141834936716e-07
heavy O 0 0.001282822689972818
ascertainment O 0 0.008923765271902084
bias O 0 2.9098533559590578e-05
in O 0 6.435978150420851e-08
the O 0 2.0355374275027316e-08
selection O 0 1.369569133657933e-07
of O 0 2.3456128417365107e-07
patients O 0 6.020867203915259e-06
for O 0 2.0238697118202253e-07
PAX6 O 0 0.0030301965307444334
mutation O 0 4.4768438556275214e-07
analysis O 0 2.2893065931839374e-07
and O 0 9.585335902784209e-08
that O 0 4.506838280349257e-08
the O 0 1.885587010974632e-07
missing O 0 1.8733622709987685e-05
PAX6 O 0 0.04252756014466286
missense O 0 0.0003989298711530864
mutations O 0 1.5433941371156834e-05
frequently O 0 2.1849853055755375e-06
may O 0 3.6944627481716452e-06
underlie O 0 0.00015148964303079993
phenotypes O 0 7.901354547357187e-05
distinct O 0 1.704210717434762e-06
from O 0 1.4533054581988836e-06
textbook O 0 0.0006686010747216642
aniridia B-Disease 1 0.9951253533363342
. O 0 7.301854930119589e-05

Here O 0 1.8953433027490973e-05
we O 0 9.173635362458299e-07
present O 0 6.424252774195338e-07
four O 0 4.7585541551598e-07
novel O 0 1.0225518053630367e-05
PAX6 O 0 0.032251838594675064
missense O 0 0.00037597690243273973
mutations O 0 1.1876310963998549e-05
, O 0 3.7104433658896596e-07
two O 0 9.131174749654747e-08
in O 0 2.3690357409122953e-07
association O 0 8.808470965959714e-07
with O 0 8.770683166403614e-07
atypical O 0 0.0002927394525613636
phenotypes O 0 0.0002536845568101853
ectopia B-Disease 0 0.16053259372711182
pupillae I-Disease 0 0.06695470958948135
( O 0 8.310333328154229e-07
displaced B-Disease 0 2.661303597051301e-06
pupils I-Disease 0 2.364587544434471e-06
) O 0 1.3868200312572299e-06
and O 0 0.0005021566757932305
congenital B-Disease 1 0.9999939203262329
nystagmus I-Disease 0 0.35249730944633484
( O 0 6.855389074189588e-07
searching B-Disease 0 8.235467248596251e-06
gaze I-Disease 0 5.46035926163313e-06
) O 0 7.430732296143105e-08
, O 0 4.9434159876682315e-08
and O 0 4.412020260247118e-08
two O 0 3.386209002087526e-08
in O 0 8.530921746796594e-08
association O 0 2.406448231795366e-07
with O 0 9.028425296264686e-08
more O 0 2.9891177177887585e-07
recognizable O 0 7.365740748355165e-05
aniridia B-Disease 1 0.9901158213615417
phenotypes O 0 0.00046971472329460084
. O 0 2.1145004211575724e-05

Strikingly O 0 0.0013893472496420145
, O 0 3.7676629744964885e-06
all O 0 1.5242802930970356e-07
four O 0 2.8689538567050477e-07
mutations O 0 1.3003428875890677e-06
are O 0 3.2720191001089916e-08
located O 0 3.925210592115036e-07
within O 0 6.097739913002442e-08
the O 0 5.6294503281151265e-08
PAX6 O 0 0.0001197989986394532
paired O 0 7.011109346422018e-07
domain O 0 9.390029731548566e-08
and O 0 3.7332441138460126e-08
affect O 0 9.758518615399225e-08
amino O 0 2.0658855959254652e-08
acids O 0 6.886550885099041e-09
which O 0 3.883431354267941e-09
are O 0 2.4757109695627832e-09
highly O 0 1.4082124799585927e-08
conserved O 0 3.279410876189104e-08
in O 0 1.148352435365041e-08
all O 0 1.589896037046401e-08
known O 0 9.158052449720344e-08
paired O 0 5.782513881058549e-07
domain O 0 7.609180556755746e-07
proteins O 0 7.880711336838431e-07
. O 0 2.4149783257598756e-06

Our O 0 1.4355633538798429e-05
results O 0 4.7593894123565406e-06
support O 0 1.0368802350058104e-06
the O 0 1.5737629155410104e-07
hypothesis O 0 1.2449040696083102e-06
that O 0 3.411517823792565e-08
the O 0 2.2808983146660466e-08
under O 0 1.2108844771319127e-07
- O 0 4.86252065456938e-06
representation O 0 2.2499656893160136e-07
of O 0 1.975298147272042e-07
missense O 0 0.0008157502743415534
mutations O 0 6.002750524203293e-06
is O 0 2.2696461599025497e-07
caused O 0 2.634237262100214e-06
by O 0 4.1689079921525263e-07
ascertainment O 0 0.02580823190510273
bias O 0 8.026178693398833e-05
and O 0 5.397837412601802e-07
suggest O 0 9.620407581678592e-07
that O 0 5.0503469850582405e-08
a O 0 2.0918932364111242e-07
substantial O 0 2.4594946808065288e-06
burden O 0 7.328053015953628e-06
of O 0 8.264319717454782e-07
PAX6 B-Disease 1 0.8425599932670593
- I-Disease 1 0.8286764621734619
related I-Disease 0 0.14214912056922913
disease I-Disease 0 0.013417234644293785
remains O 0 4.485759745875839e-06
to O 0 1.6432746008376853e-07
be O 0 3.328069624330965e-07
uncovered O 0 9.466749179409817e-05
. O 0 9.502779221293167e-07
. O 0 3.6599797113012755e-06

The O 0 2.0639201466110535e-05
chromosomal O 0 0.0009084732155315578
order O 0 1.1006607110175537e-06
of O 0 2.8248788908058486e-07
genes O 0 1.2387446304273908e-06
controlling O 0 1.039341077557765e-05
the O 0 3.2043848818830156e-07
major O 0 1.079648245649878e-05
histocompatibility O 0 0.12896858155727386
complex O 0 1.3695427696802653e-05
, O 0 3.009141664733761e-07
properdin O 0 3.62889222742524e-05
factor O 0 1.659715508139925e-06
B O 0 2.832744394254405e-05
, O 0 5.23060236901074e-07
and O 0 1.6266505554085597e-05
deficiency B-Disease 0 0.0021546685602515936
of I-Disease 0 2.9567788217832458e-08
the I-Disease 0 3.1829426205831624e-08
second I-Disease 0 2.1172179742734443e-07
component I-Disease 0 6.326825428004668e-07
of I-Disease 0 1.4636536604939465e-07
complement I-Disease 0 5.835503088746918e-06
. O 0 5.960258476989111e-06

The O 0 1.0316414773114957e-05
relationship O 0 7.430104233208112e-06
of O 0 1.798460829149917e-07
the O 0 1.2711932129150227e-07
genes O 0 4.088414584657585e-07
coding O 0 2.060374526990927e-06
for O 0 2.1849903930615255e-07
HLA O 0 0.00023908431467134506
to O 0 8.53049826332608e-08
those O 0 3.8677622882232754e-08
coding O 0 6.689498945888772e-07
for O 0 7.392225853664058e-08
properdin O 0 3.802948413067497e-05
Factor O 0 7.415030722768279e-07
B O 0 1.673241422395222e-05
allotypes O 0 9.877298725768924e-05
and O 0 1.2750156201946083e-06
for O 0 9.193137884722091e-06
deficiency B-Disease 0 0.008440572768449783
of I-Disease 0 2.120422237794628e-08
the I-Disease 0 2.02574987895332e-08
second I-Disease 0 1.6697572391422e-07
component I-Disease 0 4.08742835134035e-07
of I-Disease 0 3.5381393814759576e-08
complement I-Disease 0 4.253062115822104e-07
( O 0 5.812259828985589e-08
C2 O 0 8.813783097139094e-06
) O 0 2.141374011443986e-08
was O 0 3.979228679895641e-08
studied O 0 4.903411365830834e-08
in O 0 3.9007748142694254e-08
families O 0 1.316508928539406e-07
of O 0 1.0687765552575001e-06
patients O 0 0.00019288406474515796
with O 0 7.388497760985047e-05
connective O 1 0.9997164607048035
tissue O 1 0.9999196529388428
disorders O 1 0.9941791296005249
. O 0 4.911639916826971e-05

Patients O 0 0.00443707499653101
were O 0 3.8030152609280776e-06
selected O 0 9.90217472462973e-07
because O 0 4.612474526766164e-07
they O 0 7.772709409437084e-08
were O 0 1.5774833173054503e-07
heterozygous O 0 1.7424714542357833e-06
or O 0 2.059179905700148e-06
homozygous O 0 0.0002091607020702213
for O 0 0.006687046028673649
C2 B-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9999686479568481
. O 0 6.874726386740804e-05

12 O 0 4.9402948206989095e-05
families O 0 5.9436783885757904e-06
with O 0 6.615448455704609e-07
15 O 0 1.0696738854676369e-06
matings O 0 0.00010764611215563491
informative O 0 0.000276365433819592
for O 0 0.021165015175938606
C2 B-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.999988317489624
were O 0 1.306646936427569e-05
found O 0 9.96983999357326e-06
. O 0 8.053828423726372e-06

Of O 0 8.364166205865331e-06
57 O 0 1.6404497728217393e-05
informative O 0 7.134936367947375e-06
meioses O 0 0.0002617614809423685
, O 0 2.436131580907386e-07
two O 0 5.375943601393374e-08
crossovers O 0 1.035773266266915e-06
were O 0 2.075111495969395e-07
noted O 0 4.30885478408527e-07
between O 0 1.8229849274575827e-06
the O 0 0.0001305655896430835
C2 B-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.9998956918716431
gene O 0 7.915796800261887e-07
and O 0 1.925338466435278e-07
the O 0 1.7559892739882343e-07
HLA O 0 0.002005021320655942
- O 0 0.0005233946139924228
B O 0 2.2474947400041856e-05
gene O 0 1.2313402919517102e-07
, O 0 1.8185810191084784e-08
with O 0 1.2191479825673923e-08
a O 0 3.388935709836005e-08
recombinant O 0 4.2032920077872404e-07
fraction O 0 2.3120239234231121e-07
of O 0 1.3778172558431834e-07
0 O 0 3.3317769521090668e-06
. O 0 3.0340265766426455e-06

035 O 0 0.16280004382133484
. O 0 0.0012493196409195662

A O 0 3.1881565519142896e-05
lod O 0 0.0009388913167640567
score O 0 7.457253445863898e-07
of O 0 1.55780455202148e-07
13 O 0 3.7999120650056284e-07
was O 0 2.2460466198026552e-07
calculated O 0 2.1892097379350162e-07
for O 0 1.333327759311942e-07
linkage O 0 0.00013068578846286982
between O 0 0.0026478280778974295
C2 B-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.9999544620513916
and O 0 3.430304559515207e-06
HLA O 0 0.014667174778878689
- O 0 0.0025256825610995293
B O 0 4.410310066305101e-05
at O 0 1.6587488005370687e-07
a O 0 3.1232669783776146e-08
maximum O 0 1.824707140940518e-07
likelihood O 0 2.4170901724573923e-07
value O 0 1.9250881777566065e-08
of O 0 6.2182179405567695e-09
the O 0 1.4307515172617968e-08
recombinant O 0 4.688368449023983e-07
fraction O 0 3.7236904404380766e-07
of O 0 9.124907052182607e-08
0 O 0 5.196348411118379e-06
. O 0 3.9561391531606205e-06

04 O 0 0.01885053887963295
. O 0 0.000622167659457773

18 O 0 0.00011878116492880508
families O 0 6.64059598420863e-06
with O 0 5.314792019817105e-07
21 O 0 7.895093858678592e-07
informative O 0 1.0498912388356985e-06
matings O 0 2.8475869839894585e-05
for O 0 1.1371670893822738e-07
both O 0 8.197724810088403e-08
properdin O 0 3.1168128771241754e-05
Factor O 0 4.323871394262824e-07
B O 0 5.490803232532926e-06
allotype O 0 1.5497553249588236e-05
and O 0 3.120849498827738e-07
HLA O 0 0.002124861814081669
- O 0 0.0006145612569525838
B O 0 2.6703397452365607e-05
were O 0 3.5621343386083026e-07
found O 0 1.2135982387917466e-06
. O 0 2.8721808575937757e-06

Of O 0 5.083620635559782e-06
72 O 0 1.108100786950672e-05
informative O 0 6.5990684561256785e-06
meioses O 0 0.00035784015199169517
, O 0 3.8818083680780546e-07
three O 0 1.219081013914547e-07
recombinants O 0 0.0003939089074265212
were O 0 7.608861096741748e-07
found O 0 5.173367867428169e-07
, O 0 4.7463803554137485e-08
giving O 0 2.8046059696862358e-08
a O 0 3.2425461427010305e-08
recombinant O 0 4.333762717578793e-07
fraction O 0 4.3320190457052377e-07
of O 0 1.316167583809147e-07
0 O 0 4.0528034332965035e-06
. O 0 4.123249709664378e-06

042 O 0 0.026046402752399445
. O 0 0.0006234474130906165

A O 0 3.8735903217457235e-05
lod O 0 0.0007408600067719817
score O 0 1.4686105487271561e-06
of O 0 1.1683272305162973e-07
16 O 0 1.8297885162610328e-07
between O 0 2.636302838254778e-07
HLA O 0 0.0002321764623047784
- O 0 6.906543421791866e-05
B O 0 5.080848040961428e-06
and O 0 5.964807314740028e-08
Factor O 0 1.0719108445300662e-07
B O 0 1.461871079300181e-06
allotypes O 0 6.6490865719970316e-06
was O 0 8.976278564887252e-08
calculated O 0 6.912544847637037e-08
at O 0 2.5259431879476324e-08
a O 0 1.2805764448842183e-08
maximum O 0 1.0766440539100586e-07
likelihood O 0 1.94881039305983e-07
value O 0 1.2909699087515492e-08
of O 0 6.505211036511582e-09
the O 0 1.3059581860375147e-08
recombinant O 0 3.366220937550679e-07
fraction O 0 2.3956974359862215e-07
of O 0 9.618668173061451e-08
0 O 0 2.798151854221942e-06
. O 0 3.248816256018472e-06

04 O 0 0.01314422395080328
. O 0 0.0005907138111069798

A O 0 1.624263313715346e-05
crossover O 0 2.848051553883124e-05
was O 0 4.32337810707395e-06
shown O 0 4.655087764149357e-07
to O 0 9.029562164641902e-08
have O 0 4.937422914963463e-08
occurred O 0 1.6391128099257912e-07
between O 0 1.7339786495540466e-08
genes O 0 1.8863563155946395e-08
for O 0 8.761769976217693e-09
Factor O 0 1.0970458674819383e-07
B O 0 1.753470087351161e-06
and O 0 1.2251837233634433e-07
HLA O 0 0.002129990141838789
- O 0 0.020916152745485306
D O 0 0.02716490812599659
, O 0 9.374639375892002e-08
in O 0 3.063587783458388e-08
which O 0 1.2032798224481667e-07
HLA O 0 0.002784076379612088
- O 0 0.009864344261586666
D O 0 0.030840154737234116
segregared O 0 0.0001456372847314924
with O 0 6.371681706696108e-07
HLA O 0 0.0015882417792454362
- O 0 4.595567224896513e-05
A O 0 1.0015879752245382e-06
and O 0 2.508951183699537e-06
B O 0 0.0001714006793918088
. O 0 5.240026439423673e-06

These O 0 2.9295752028701827e-06
studies O 0 2.226062179033761e-06
suggest O 0 1.438195567970979e-06
that O 0 2.6634786820523004e-08
the O 0 1.239535407648873e-08
genes O 0 3.569666162661633e-08
for O 0 4.7096683886138635e-08
Factor O 0 1.9199985672457842e-06
B O 0 0.006307017523795366
and O 0 0.05009579658508301
C2 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9998698234558105
are O 0 1.2449048369944649e-07
located O 0 4.357227112450346e-07
outside O 0 1.151479480654416e-07
those O 0 2.0709235215576882e-08
for O 0 1.1886897510748895e-07
HLA O 0 0.010267816483974457
, O 0 2.386041160207242e-07
that O 0 1.1993247284181052e-08
the O 0 7.76760789023001e-09
order O 0 2.352108197101188e-08
of O 0 1.177869712876145e-08
genese O 0 5.916536247241311e-05
is O 0 2.462390398250136e-07
HLA O 0 0.00018111718236468732
- O 0 9.756498911883682e-06
A O 0 1.8883619645748695e-07
, O 0 6.618125070190217e-08
- O 0 1.6426460206275806e-05
B O 0 9.355485417472664e-06
, O 0 7.894404063790716e-08
- O 0 6.379823025781661e-05
D O 0 0.00011793337034760043
, O 0 4.3205819366676224e-08
Factor O 0 1.264950810764276e-07
B O 0 2.290748670930043e-05
allotype O 0 0.017074646428227425
, O 0 0.0038625707384198904
C2 B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9999610185623169
, O 0 4.0479571339346876e-07
that O 0 2.3411962146724363e-08
the O 0 3.909802970269993e-08
genes O 0 3.387947629107657e-07
coding O 0 1.8057105990010314e-05
for O 0 0.0001364963100058958
C2 B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9997921586036682
and O 0 4.801963200407044e-07
Factor O 0 9.198910220220569e-07
B O 0 9.350365871796384e-06
allotypes O 0 5.158675321581541e-06
are O 0 8.55273274424917e-09
approximately O 0 1.818123074315281e-08
3 O 0 9.209059470549619e-08
- O 0 7.153331353038084e-06
- O 0 6.012662652210565e-06
5 O 0 9.111219156920924e-08
centimorgans O 0 2.2997628548182547e-06
from O 0 1.5118088114718375e-08
the O 0 1.8407584789770226e-08
HLA O 0 5.7140983699355274e-05
- O 0 1.0107910384249408e-05
A O 0 1.385397325748272e-07
and O 0 2.2851882874874718e-07
HLA O 0 0.00043413692037574947
- O 0 9.364939614897594e-05
B O 0 7.6270412137091625e-06
loci O 0 2.483526202468056e-07
, O 0 3.6227831401447474e-08
and O 0 1.719920383891349e-08
that O 0 6.229448068495458e-09
the O 0 2.899694528935015e-08
apparent O 0 3.357389687153045e-06
lack O 0 1.0686976281704119e-07
of O 0 3.090219635737412e-08
recombinants O 0 3.264810948166996e-05
between O 0 5.571681072069623e-08
the O 0 2.0678722734146504e-08
Factor O 0 4.810570999325137e-07
B O 0 3.183747685397975e-05
gene O 0 2.6510113002586877e-06
and O 0 0.0012130383402109146
C2 B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999620914459229
gene O 0 1.4450533853960223e-06
suggests O 0 3.8190617601685517e-07
that O 0 1.3495355943859977e-08
these O 0 7.681638436451976e-09
two O 0 1.849817898857964e-08
genes O 0 1.6990196627375553e-07
lie O 0 6.66790219838731e-06
in O 0 5.007013115232439e-08
close O 0 5.241303142611287e-07
proximity O 0 6.493189630418783e-07
to O 0 5.289952653697583e-08
one O 0 8.431806719499946e-08
another O 0 1.057159352058079e-06
. O 0 3.3170472306665033e-06

Distribution O 0 3.728044612216763e-05
of O 0 3.5907819437852595e-06
emerin O 0 0.0010086442343890667
and O 0 4.344826720625861e-06
lamins O 0 0.00535180326551199
in O 0 6.62649881633115e-07
the O 0 5.874965154362144e-07
heart O 0 0.00010021162597695366
and O 0 1.143624331234605e-06
implications O 0 1.537231946713291e-05
for O 0 3.370652393641649e-06
Emery B-Disease 1 0.6475269198417664
- I-Disease 1 0.9992480874061584
Dreifuss I-Disease 1 0.9998151659965515
muscular I-Disease 1 0.9994995594024658
dystrophy I-Disease 1 0.9973921775817871
. O 0 0.00019723427249118686

Emerin O 0 0.008053666912019253
is O 0 2.7787286853708792e-06
a O 0 1.1875039263031795e-06
nuclear O 0 2.956532443931792e-05
membrane O 0 2.043837412202265e-06
protein O 0 2.2524733367390581e-07
which O 0 5.843773465130653e-08
is O 0 5.228941546420174e-08
missing O 0 4.852010420108854e-07
or O 0 1.3498539885858918e-07
defective O 0 3.697778083733283e-05
in O 0 1.0222348691968364e-06
Emery B-Disease 0 0.10925453156232834
- I-Disease 1 0.9997411370277405
Dreifuss I-Disease 1 0.9999260902404785
muscular I-Disease 1 0.9998335838317871
dystrophy I-Disease 1 0.9997791647911072
( O 0 0.0002302997891092673
EDMD B-Disease 1 0.9998960494995117
) O 0 7.314368303923402e-06
. O 0 1.3713882253796328e-05

It O 0 7.3517680903023575e-06
is O 0 4.145536820487905e-07
one O 0 9.152377344889828e-08
member O 0 1.1747492578706442e-07
of O 0 3.554244187853328e-08
a O 0 4.4920858499608585e-07
family O 0 6.312855020951247e-07
of O 0 5.049076321483881e-07
lamina O 1 0.9730365872383118
- O 0 0.0492989756166935
associated O 0 5.804747615911765e-07
proteins O 0 3.193864728245899e-08
which O 0 2.385915287561602e-08
includes O 0 1.811657313055548e-07
LAP1 O 0 8.345185779035091e-05
, O 0 2.9030354653514223e-07
LAP2 O 0 7.97478060121648e-05
and O 0 5.658321242663078e-07
lamin O 0 0.01722697913646698
B O 0 0.000680869328789413
receptor O 0 4.393376366351731e-05
( O 0 1.5678008367103757e-06
LBR O 0 0.0008207579376176
) O 0 1.231771875609411e-06
. O 0 4.870089924224885e-06

A O 0 1.8828315660357475e-05
panel O 0 8.404657819482964e-06
of O 0 3.000484696258354e-07
16 O 0 2.4691937596799107e-06
monoclonal O 0 5.986645555822179e-05
antibodies O 0 3.9867118175607175e-06
( O 0 1.416407400256503e-07
mAbs O 0 7.834933057893068e-06
) O 0 2.394595988164383e-08
has O 0 1.0470116329486245e-08
been O 0 1.1206943817398951e-08
mapped O 0 6.481421905846219e-07
to O 0 1.4924300018037684e-08
six O 0 2.1367879909917065e-08
specific O 0 1.1025013790799676e-08
sites O 0 7.872841223388605e-08
throughout O 0 1.4031906303557662e-08
the O 0 1.9235246284665664e-08
emerin O 0 5.730624707211973e-06
molecule O 0 2.447967233365489e-07
using O 0 8.610894042249129e-08
phage O 0 2.419646762064076e-06
- O 0 3.4135207442886895e-06
displayed O 0 2.735288830990612e-07
peptide O 0 1.7791400352962228e-07
libraries O 0 6.908800997962317e-08
and O 0 3.948194304825847e-08
has O 0 1.2548644789944774e-08
been O 0 8.569323917129168e-09
used O 0 7.048462702385905e-09
to O 0 1.0924037674442388e-08
localize O 0 5.392443654272938e-06
emerin O 0 0.00011198427091585472
in O 0 1.264106685994193e-07
human O 0 2.62341160350843e-07
and O 0 2.832318159562419e-06
rabbit O 0 0.0013346378691494465
heart O 0 0.0005836254567839205
. O 0 9.848635272646789e-06

Several O 0 4.0247730794362724e-05
mAbs O 0 0.0003415362152736634
against O 0 4.954269570589531e-06
different O 0 4.158092110628786e-07
emerin O 0 0.0009718759683892131
epitopes O 0 0.00037693369085900486
did O 0 4.440780685399659e-07
not O 0 7.552400660415515e-08
recognize O 0 2.481014576005691e-07
intercalated O 0 4.56659699921147e-06
discs O 0 5.018491356167942e-05
in O 0 2.4135616172316077e-07
the O 0 4.770804480358493e-07
heart O 0 0.00015922373859211802
, O 0 6.797953915338439e-07
though O 0 1.9540138396223483e-07
they O 0 4.388805407984364e-08
recognized O 0 9.611038365164859e-08
cardiomyocyte O 0 2.5067147362278774e-05
nuclei O 0 1.3047302900304203e-06
strongly O 0 2.2839182634015742e-07
, O 0 3.158992001317529e-08
both O 0 1.5932746677549403e-08
at O 0 9.307629511567939e-08
the O 0 3.60636107643586e-08
rim O 0 5.713081009162124e-06
and O 0 1.1147810141665104e-07
in O 0 1.2346139044439042e-07
intranuclear O 0 0.00016728657647036016
spots O 0 5.366546247387305e-06
or O 0 8.018766379791487e-07
channels O 0 3.308551868030918e-06
. O 0 3.361759809195064e-06

A O 0 0.00017444898549001664
polyclonal O 0 0.0016246074810624123
rabbit O 0 0.0004558044602163136
antiserum O 0 0.0009364326251670718
against O 0 2.1073135940241627e-05
emerin O 0 0.001567475264891982
did O 0 9.804915634958888e-07
recognize O 0 4.930712407258397e-07
both O 0 4.4841161894737525e-08
nuclear O 0 1.2217888979648706e-05
membrane O 0 6.566077104253054e-07
and O 0 7.798741563647127e-08
intercalated O 0 4.8533661356486846e-06
discs O 0 0.00010869326797546819
but O 0 3.73234058770322e-07
, O 0 5.6588934427281856e-08
after O 0 1.0280975715204477e-07
affinity O 0 2.515529899937974e-07
purification O 0 1.3759895409748424e-06
against O 0 1.620421272718886e-07
a O 0 7.798354317856138e-08
pure O 0 1.1881496675414382e-06
- O 0 6.047623173799366e-05
emerin O 0 8.256420551333576e-05
band O 0 2.9536852252931567e-07
on O 0 6.743611180581865e-08
a O 0 4.781280793508813e-08
western O 0 2.5290532335020544e-07
blot O 0 2.9766355510219e-05
, O 0 1.4180442065026e-07
it O 0 4.841323786308749e-08
stained O 0 6.242856761673465e-05
only O 0 2.7324722040589222e-08
the O 0 1.442395785034023e-07
nuclear O 0 0.00010086662950925529
membrane O 0 2.5379753424203955e-05
. O 0 5.947596037003677e-06

These O 0 2.9707809972023824e-06
results O 0 1.68634733199724e-06
would O 0 1.4836660966466297e-07
not O 0 2.5961679028796425e-08
be O 0 2.067493909407858e-08
expected O 0 5.553516757572652e-07
if O 0 1.79735494043598e-07
immunostaining O 0 0.00010641638073138893
at O 0 2.870185369374667e-07
intercalated O 0 2.8836118417530088e-06
discs O 0 2.300058440596331e-05
were O 0 2.3150840888774837e-07
due O 0 2.2365222207554325e-07
to O 0 2.561960421587628e-08
a O 0 9.657770050353065e-08
product O 0 2.0361399322155194e-07
of O 0 1.1669748722908935e-08
the O 0 3.273486370858336e-08
emerin O 0 7.173066842369735e-05
gene O 0 1.9183261201760615e-07
and O 0 8.8327844594005e-08
, O 0 9.48013436641304e-08
therefore O 0 6.292766840942932e-08
, O 0 5.648293921467484e-08
cast O 0 8.893049141533993e-08
some O 0 1.5654290308475538e-08
doubt O 0 1.197131069829993e-07
upon O 0 2.5204423437230616e-08
the O 0 3.9629135528684856e-08
hypothesis O 0 3.1006400149635738e-06
that O 0 2.3981347112567164e-06
cardiac B-Disease 1 0.946756899356842
defects I-Disease 1 0.9666896462440491
in O 0 1.5337174772867e-05
EDMD B-Disease 1 0.9999904632568359
are O 0 3.271126161052962e-06
caused O 0 9.549416063237004e-06
by O 0 1.7542751606924867e-07
absence O 0 6.865804493827454e-07
of O 0 4.594229210397316e-07
emerin O 0 0.0022652551997452974
from O 0 1.456887162021303e-06
intercalated O 0 0.00011322055797791108
discs O 0 0.00030217261519283056
. O 0 6.621023658226477e-06

Although O 0 5.652703475789167e-05
emerin O 0 0.00109551299829036
was O 0 3.5867535643774318e-06
abundant O 0 9.149529773821996e-07
in O 0 7.276717184367953e-08
the O 0 3.623764399662832e-08
membranes O 0 8.024504154491297e-07
of O 0 6.726115486799245e-08
cardiomyocyte O 0 0.00014859541261103004
nuclei O 0 3.169371666444931e-06
, O 0 9.388954680389361e-08
it O 0 2.7508583855251345e-08
was O 0 3.621284463406482e-07
absent O 0 2.3471210397474351e-07
from O 0 1.827029372236666e-08
many O 0 1.3752082139717459e-08
non O 0 5.870685981790302e-07
- O 0 0.000517786480486393
myocyte O 0 0.00532319163903594
cells O 0 1.409278524988622e-06
in O 0 1.3345005811515875e-07
the O 0 7.204736220955965e-07
heart O 0 0.00012125816283514723
. O 0 6.548776127601741e-06

This O 0 1.8335980485062464e-06
distribution O 0 1.5922469174256548e-06
of O 0 3.916662763003842e-07
emerin O 0 0.005698413122445345
was O 0 9.533187608212756e-07
similar O 0 1.0638268577167764e-07
to O 0 1.771337920786209e-08
that O 0 1.3770534934565148e-08
of O 0 7.372948118700151e-08
lamin O 0 0.030050693079829216
A O 0 2.314063067387906e-06
, O 0 1.4372891143921152e-07
a O 0 1.5096485128651693e-07
candidate O 0 1.890965563688951e-06
gene O 0 3.673260096093145e-07
for O 0 1.2735934262764204e-07
an O 0 4.2310867343076097e-07
autosomal O 0 5.695992513210513e-05
form O 0 1.0818432656378718e-06
of O 0 9.961297109839506e-06
EDMD B-Disease 1 0.9998470544815063
. O 0 3.422786176088266e-05

In O 0 1.258724387298571e-05
contrast O 0 2.4171755285351537e-05
, O 0 1.1504707799758762e-05
lamin O 1 0.9190542697906494
B1 O 1 0.9569873809814453
was O 0 1.2232063454575837e-05
absent O 0 3.7485854136320995e-06
from O 0 3.4571812079775555e-07
cardiomyocyte O 0 0.00010124911204911768
nuclei O 0 4.57916530649527e-06
, O 0 3.125030900719139e-07
showing O 0 2.2114536477602087e-06
that O 0 4.436116114447941e-07
lamin O 1 0.8783549070358276
B1 O 1 0.6558936238288879
is O 0 2.6936064045912644e-07
not O 0 1.7896592652277832e-08
essential O 0 1.3971764190046088e-08
for O 0 1.2930152060164346e-08
localization O 0 5.215514988776704e-07
of O 0 7.695396675444499e-08
emerin O 0 0.00015270759467966855
to O 0 1.9903161785350676e-07
the O 0 8.014087029550865e-07
nuclear O 0 0.0013546072877943516
lamina O 0 0.16685304045677185
. O 0 1.32895738715888e-05

Lamin O 1 0.9943918585777283
B1 O 1 0.9948941469192505
is O 0 2.0019977455376647e-05
also O 0 1.58774037117837e-06
almost O 0 6.725127832396538e-07
completely O 0 3.401925368962111e-06
absent O 0 5.841472557222005e-06
from O 0 1.0209703305008588e-06
skeletal O 0 0.0034083977807313204
muscle O 0 0.0001918630878208205
nuclei O 0 0.00020132986537646502
. O 0 1.3109042811265681e-05

In O 0 6.270212907111272e-05
EDMD B-Disease 1 0.9968879818916321
, O 0 1.0564427839199197e-06
the O 0 7.784414890465996e-08
additional O 0 1.1631509977405585e-07
absence O 0 4.236440815930109e-07
of O 0 5.198055532673607e-07
lamin O 1 0.9621281623840332
B1 O 1 0.9626238942146301
from O 0 3.8124023831187515e-06
heart O 0 0.00025962371728383005
and O 0 4.305619768274482e-06
skeletal O 0 0.00761675788089633
muscle O 0 1.6231406334554777e-05
nuclei O 0 3.0843366403132677e-06
which O 0 1.1990552195584314e-07
already O 0 5.669502343152999e-07
lack O 0 8.0807490121515e-07
emerin O 0 0.009469919838011265
may O 0 2.6253389933117433e-06
offer O 0 1.1751212980470882e-07
an O 0 1.0415660334217591e-08
alternative O 0 1.2083050648925564e-07
explanation O 0 1.0666896343991539e-07
of O 0 3.7777908801217563e-08
why O 0 5.401916496339254e-07
these O 0 2.5838080119910956e-08
tissues O 0 8.128050126288144e-07
are O 0 5.00424448546255e-08
particularly O 0 8.203893457903177e-07
affected O 0 1.2832534821427544e-06
. O 0 5.312045345817751e-07
. O 0 8.60324507812038e-06

Genetic O 0 0.00018764867854770273
mapping O 0 3.068867590627633e-05
of O 0 2.3458928808395285e-06
the O 0 2.463743840053212e-06
copper B-Disease 0 0.004983238875865936
toxicosis I-Disease 0 0.05512603372335434
locus O 0 1.827936648624018e-05
in O 0 1.3626125792143284e-06
Bedlington O 0 5.278414027998224e-05
terriers O 0 4.031095886602998e-05
to O 0 4.585286887959228e-07
dog O 0 6.225284596439451e-05
chromosome O 0 6.297735581028974e-06
10 O 0 3.874574474593828e-07
, O 0 1.1403306388046985e-07
in O 0 3.822788841034708e-08
a O 0 2.216313106373491e-07
region O 0 3.638385578597081e-06
syntenic O 0 8.793906454229727e-05
to O 0 1.5253679919169372e-07
human O 0 2.6742765157905524e-07
chromosome O 0 1.3669878171640448e-05
region O 0 7.0333690018742345e-06
2p13 O 0 0.00018813881615642458
- O 0 0.0001821325276978314
p16 O 0 6.269584991969168e-05
. O 0 4.934960543323541e-06

Abnormal O 1 0.990724503993988
hepatic B-Disease 1 0.9998006224632263
copper I-Disease 0 0.4301625192165375
accumulation I-Disease 0 0.0007556769996881485
is O 0 1.991745193663519e-06
recognized O 0 9.495712447460392e-07
as O 0 6.825289347034413e-07
an O 0 4.1878975025611e-05
inherited B-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9999892711639404
in O 0 6.471302185673267e-06
man O 0 0.0002079957048408687
, O 0 1.3938791880718782e-06
mouse O 0 4.20496980950702e-05
, O 0 1.2192710983072175e-06
rat O 0 0.00020039295486640185
and O 0 2.444999836370698e-06
dog O 0 0.000238396882195957
. O 0 1.369687743135728e-05

The O 0 6.867940101074055e-06
major O 0 2.261827467009425e-05
cause O 0 2.1504665710381232e-05
of O 0 4.213741704006679e-06
hepatic B-Disease 1 0.9995800852775574
copper I-Disease 1 0.6818697452545166
accumulation I-Disease 0 0.00014828177518211305
in O 0 8.578449524065945e-07
man O 0 1.8848348190658726e-05
is O 0 1.513521965534892e-07
a O 0 3.795906309278507e-07
dysfunctional O 0 4.09828862757422e-05
ATP7B O 0 0.004033831879496574
gene O 0 3.3736107525328407e-06
, O 0 2.2682404505758313e-06
causing O 0 0.0005011142930015922
Wilson B-Disease 0 0.2405063658952713
disease I-Disease 0 0.06153004989027977
( O 0 6.335716989269713e-06
WD B-Disease 0 0.445298433303833
) O 0 3.074504320466076e-06
. O 0 6.4077103161253035e-06

Mutations O 0 0.00021123986516613513
in O 0 2.6334837457397953e-06
the O 0 8.552016765861481e-07
ATP7B O 0 0.0008981575374491513
genes O 0 1.1360260714354808e-06
have O 0 1.1749195039101323e-07
also O 0 9.193071548452281e-08
been O 0 1.0809444717096994e-07
demonstrated O 0 9.366896733808971e-07
in O 0 1.3359739625684597e-07
mouse O 0 1.687377880443819e-05
and O 0 2.401574647592497e-06
rat O 0 0.0006289686425589025
. O 0 9.767745723365806e-06

The O 0 2.093795956170652e-05
ATP7B O 0 0.001717240666039288
gene O 0 1.2677452104981057e-05
has O 0 9.353631753583613e-07
been O 0 2.8194099854772503e-07
excluded O 0 8.692442747815221e-07
in O 0 4.717706048040782e-08
the O 0 4.794467400870417e-08
much O 0 6.791188980059815e-07
rarer O 0 0.00015562179032713175
human O 0 7.858205208322033e-06
copper B-Disease 1 0.9063397645950317
overload I-Disease 1 0.8491211533546448
disease O 0 0.0003323462442494929
non B-Disease 0 5.023599896958331e-06
- I-Disease 0 0.004851449280977249
Indian I-Disease 0 5.4921572882449254e-05
childhood I-Disease 0 0.072487972676754
cirrhosis I-Disease 1 0.9791433811187744
, O 0 4.514445208769757e-06
indicating O 0 0.00010089962597703561
genetic O 0 6.988696986809373e-05
heterogeneity O 0 0.0013712059007957578
. O 0 4.2423071135999635e-05

By O 0 3.948119774577208e-05
investigating O 0 0.00010850406397366896
the O 0 9.519264494883828e-06
common O 0 0.0002845900889951736
autosomal O 1 0.7934240698814392
recessive O 1 0.880534291267395
copper B-Disease 1 0.9951627254486084
toxicosis I-Disease 1 0.9948110580444336
( O 0 3.123328724541352e-06
CT B-Disease 0 0.04913775995373726
) O 0 1.4334780473745923e-07
in O 0 1.1946356437420036e-07
Bedlington O 0 1.5321284081437625e-05
terriers O 0 2.9973616619827226e-05
, O 0 3.49517932818344e-07
we O 0 1.493874464131295e-07
have O 0 4.384086693676181e-08
identified O 0 1.203895152457335e-07
a O 0 3.984256125022512e-08
new O 0 1.079932658853977e-07
locus O 0 1.1192139481863705e-06
involved O 0 1.4470060705207288e-06
in O 0 4.066742258146405e-05
progressive O 1 0.9997308850288391
liver B-Disease 1 0.9999995231628418
disease I-Disease 1 0.9996656179428101
. O 0 8.745344530325383e-05

We O 0 2.105353087245021e-05
examined O 0 2.9749839086434804e-05
whether O 0 1.2462203358154511e-06
the O 0 7.093212843756191e-07
WD B-Disease 0 0.00256174523383379
gene O 0 2.9483114758477313e-06
ATP7B O 0 0.0009887217311188579
was O 0 1.1861977782245958e-06
also O 0 1.262321234207775e-07
causative O 0 7.049499686218041e-07
for O 0 9.81388126319871e-08
CT B-Disease 0 0.004082007333636284
by O 0 2.597245725155517e-07
investigating O 0 7.1180534177983645e-06
the O 0 3.806081565471686e-07
chromosomal O 0 0.005340240430086851
co O 0 7.446137897204608e-05
- O 0 1.598953895154409e-05
localization O 0 7.69941891576309e-07
of O 0 7.417577307933243e-08
ATP7B O 0 0.0003158109320793301
and O 0 1.758732679491004e-07
C04107 O 0 4.809039182873676e-06
, O 0 1.3752632810337673e-08
using O 0 1.2953355721379012e-08
fluorescence O 0 4.0471232409799995e-07
in O 0 5.73262504133254e-08
situ O 0 5.092286755825626e-06
hybridization O 0 2.951735496026231e-06
( O 0 3.7278653053363087e-07
FISH O 0 1.0886597010539845e-06
) O 0 5.805412115478248e-07
. O 0 2.7664705157803837e-06

C04107 O 0 0.00897609256207943
is O 0 8.975078344519716e-06
an O 0 7.834095185899059e-07
anonymous O 0 2.4975686301331734e-06
microsatellite O 0 0.0003704321279656142
marker O 0 6.601391942240298e-05
closely O 0 4.952606559527339e-06
linked O 0 2.1840851331944577e-05
to O 0 3.364595158927841e-06
CT B-Disease 0 0.1985236257314682
. O 0 2.0069295715074986e-05

However O 0 3.7494653952308e-05
, O 0 8.219006303988863e-06
BAC O 0 3.920068047591485e-05
clones O 0 1.764760418154765e-05
containing O 0 2.3008158223092323e-06
ATP7B O 0 0.0003016222908627242
and O 0 7.26025348285475e-07
C04107 O 0 1.5106296814337838e-05
mapped O 0 6.853807917650556e-06
to O 0 1.7127013052231632e-07
the O 0 2.1915619186074764e-07
canine O 0 3.799606201937422e-05
chromosome O 0 1.1628349056991283e-05
regions O 0 1.39966027745686e-06
CFA22q11 O 0 8.879883534973487e-05
and O 0 6.31942043582967e-07
CFA10q26 O 0 0.000223076218389906
, O 0 1.6443657102627185e-07
respectively O 0 3.8824933312753274e-07
, O 0 1.0492512103610352e-07
demonstrating O 0 6.790346560592297e-07
that O 0 2.4080966909423296e-07
WD B-Disease 0 0.06672260165214539
cannot O 0 5.383838583838951e-07
be O 0 3.1401050648582896e-08
homologous O 0 1.2312821127125062e-06
to O 0 1.3371380873650196e-06
CT B-Disease 0 0.008787603117525578
. O 0 8.413960131292697e-06

The O 0 2.0918083464493975e-05
copper O 0 0.00014675348938908428
transport O 0 2.1900439605815336e-05
genes O 0 3.277021505709854e-06
CTR1 O 0 0.0002427058498142287
and O 0 1.207606260322791e-06
CTR2 O 0 0.0012553444830700755
were O 0 3.911683279511635e-07
also O 0 6.689933229608869e-08
excluded O 0 4.809874099009903e-07
as O 0 3.423139460778657e-08
candidate O 0 1.720032685170736e-07
genes O 0 2.7148717052227767e-08
for O 0 2.883182759205738e-08
CT B-Disease 0 0.03767549991607666
since O 0 2.2320475068227097e-07
they O 0 3.206316279147359e-08
both O 0 3.018807603893947e-08
mapped O 0 6.14133841736475e-06
to O 0 4.2303844338675844e-07
canine O 0 9.315391071140766e-05
chromosome O 0 3.153747093165293e-05
region O 0 2.1878247935092077e-05
CFA11q22 O 0 0.0012796290684491396
. O 0 1.325014000030933e-05

2 O 0 8.786454418441281e-05
- O 0 0.0003756301011890173
22 O 0 1.5277484635589644e-05
. O 0 5.636644800688373e-06

5 O 0 0.0009188464609906077
. O 0 0.00026011373847723007

A O 0 2.417210089333821e-05
transcribed O 0 1.7839711290434934e-05
sequence O 0 3.02776265925786e-06
identified O 0 2.0824179500777973e-06
from O 0 9.522214128310225e-08
the O 0 7.147632885562416e-08
C04107 O 0 4.4043626985512674e-05
- O 0 2.1498351998161525e-05
containing O 0 5.403771297096682e-07
BAC O 0 1.979568878596183e-06
was O 0 1.7955886733034276e-07
found O 0 3.169227369426153e-08
to O 0 7.180944727736005e-09
be O 0 7.387894296329023e-09
homologous O 0 8.69687326598978e-08
to O 0 1.4776500911750645e-08
a O 0 8.188536071429553e-08
gene O 0 2.1183812748404307e-07
expressed O 0 5.506464617610618e-08
from O 0 3.6691385929543685e-08
human O 0 8.563608844269766e-08
chromosome O 0 3.7716104088758584e-06
2p13 O 0 0.00014915985229890794
- O 0 0.000196506516658701
p16 O 0 7.377262136287754e-06
, O 0 9.460445227205128e-08
a O 0 7.561366288655336e-08
region O 0 1.7827456133545638e-07
devoid O 0 2.8768005222445936e-07
of O 0 2.68498325795008e-08
any O 0 5.018620541363816e-08
positional O 0 3.955509328079643e-06
candidate O 0 1.0414188182039652e-05
genes O 0 4.662610535888234e-06
. O 0 4.679913217842113e-06

Molecular O 0 4.513979365583509e-05
analysis O 0 2.469836772434064e-06
of O 0 1.9223240599330893e-07
the O 0 2.3244353997142753e-07
APC B-Disease 0 6.2220560721470974e-06
gene O 0 3.7881525827287987e-07
in O 0 6.033576482877834e-08
205 O 0 2.026845550062717e-06
families O 0 4.4667538645626337e-07
: O 0 1.0510959214116156e-07
extended O 0 7.543977744717267e-07
genotype O 0 9.514280827715993e-05
- O 0 0.0013332194648683071
phenotype O 0 2.8097489121137187e-05
correlations O 0 1.9644805433927104e-05
in O 0 3.926315343960596e-07
FAP B-Disease 0 3.1796305847819895e-05
and O 0 2.7153799919688026e-07
evidence O 0 2.272587380502955e-07
for O 0 2.181960034874919e-08
the O 0 3.63570009653813e-08
role O 0 8.554483343914399e-08
of O 0 7.158793380313e-08
APC B-Disease 0 1.2322476322879083e-05
amino O 0 3.8571835148104583e-07
acid O 0 8.361122922906361e-07
changes O 0 6.417701001737441e-07
in O 0 0.0007694472442381084
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
predisposition O 1 0.8810069561004639
. O 0 0.00017591239884495735

BACKGROUND O 0 0.00014882086543366313
/ O 0 0.00011090013140346855
AIMS O 0 4.428428837854881e-06
The O 0 1.2302534457830916e-07
development O 0 4.893656750937225e-06
of O 0 0.047198329120874405
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
and O 0 3.500814500512206e-06
a O 0 6.170459982968168e-07
variable O 0 2.9819445899192942e-06
range O 0 1.3700084764423082e-06
of O 0 3.0930479510971054e-07
extracolonic O 0 0.003684710944071412
manifestations O 0 9.02201427379623e-05
in O 0 0.00013792056415695697
familial B-Disease 1 0.9999934434890747
adenomatous I-Disease 1 0.9999903440475464
polyposis I-Disease 1 0.9999980926513672
( O 0 0.00010278994886903092
FAP B-Disease 0 0.004442580509930849
) O 0 5.090763579573832e-07
is O 0 7.738523066791458e-08
the O 0 3.1392549004749526e-08
result O 0 8.775304394248451e-08
of O 0 5.3224205487367726e-08
the O 0 5.67774293358525e-07
dominant O 0 1.9306504327687435e-05
inheritance O 0 0.00020941814000252634
of O 0 0.004758642986416817
adenomatous B-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999958276748657
coli I-Disease 1 0.9998327493667603
( O 0 1.53072669490939e-05
APC B-Disease 0 0.0001911238068714738
) O 0 1.0308460787200602e-06
gene O 0 7.436427495122189e-06
mutations O 0 1.3727541954722255e-05
. O 0 9.69303619058337e-06

In O 0 2.673710241651861e-06
this O 0 2.0431774316875817e-07
study O 0 1.953842456714483e-07
, O 0 6.337514690812895e-08
direct O 0 5.903057598288797e-08
mutation O 0 1.0924520665867021e-07
analysis O 0 4.2138434963590043e-08
of O 0 1.7411704078540424e-08
the O 0 7.904709775630181e-08
APC B-Disease 0 1.1929219908779487e-05
gene O 0 3.3186313430633163e-07
was O 0 3.074446794926189e-07
performed O 0 1.0774575542882303e-07
to O 0 2.873838411687757e-08
determine O 0 1.0158790928471717e-06
genotype O 0 7.42920019547455e-05
- O 0 0.0005281122867017984
phenotype O 0 8.835731023282278e-06
correlations O 0 3.7199426969891647e-06
for O 0 1.1816392486707628e-07
nine O 0 4.1962266550399363e-07
extracolonic O 0 0.00021833446226082742
manifestations O 0 1.9564170088415267e-06
and O 0 8.246276905765626e-08
to O 0 3.5092799777203254e-08
investigate O 0 1.0015708085120423e-06
the O 0 1.3379349184106104e-07
incidence O 0 4.4801006879424676e-05
of O 0 9.84246781854381e-08
APC B-Disease 0 2.4967970603029244e-05
mutations O 0 6.89716159740783e-07
in O 0 4.401787236929522e-07
non O 0 0.0001475525787100196
- O 1 0.9996397495269775
FAP O 1 0.9999247789382935
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999984622001648
. O 0 0.00013485101226251572

METHODS O 0 3.2559593819314614e-05
The O 0 1.1442964478192152e-06
APC B-Disease 0 1.4120462765276898e-05
gene O 0 1.6754117950767977e-06
was O 0 5.776946636615321e-07
analysed O 0 1.4631528983954922e-06
in O 0 1.4424549021896382e-07
190 O 0 1.4210335166353616e-06
unrelated O 0 5.8208629525324795e-06
FAP B-Disease 0 2.8664140700129792e-05
and O 0 3.779665576075786e-07
15 O 0 1.4778693184780423e-06
non O 0 8.570272621000186e-05
- O 1 0.9996024966239929
FAP O 1 0.9999810457229614
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
patients O 0 0.0003266247222200036
using O 0 3.942711828130996e-06
denaturing O 0 0.01945117861032486
gradient O 0 0.0014796757604926825
gel O 0 0.0011001202510669827
electrophoresis O 0 0.0001254601957043633
, O 0 1.3599131420960475e-07
the O 0 1.966561136157452e-08
protein O 0 1.0757901236502221e-07
truncation O 0 1.853121716521855e-06
test O 0 8.72455018452456e-07
, O 0 5.0371671278526264e-08
and O 0 2.7361856780316884e-08
direct O 0 1.891563101708016e-07
sequencing O 0 5.8622663345886394e-06
. O 0 4.7687581172795035e-06

RESULTS O 0 0.00023677200078964233
Chain O 0 7.477646431652829e-05
terminating O 0 9.839492122409865e-06
signals O 0 1.7502255786894239e-06
were O 0 2.2302134539131657e-07
only O 0 7.678272595512681e-08
identified O 0 2.2990589059190825e-06
in O 0 4.3713450281757105e-07
patients O 0 4.522537892626133e-06
belonging O 0 2.0661711914726766e-06
to O 0 5.6258009806242626e-08
the O 0 1.579288095854281e-07
FAP B-Disease 0 5.405601768870838e-05
group O 0 9.747967624207377e-07
( O 0 1.421974076265542e-07
105 O 0 1.309432445850689e-05
patients O 0 1.3697752365260385e-05
) O 0 5.122032575854973e-07
. O 0 1.6413870298492839e-06

Amino O 0 2.79956675512949e-05
acid O 0 6.028312782291323e-06
changes O 0 5.400613076744776e-07
were O 0 3.124375496099674e-07
identified O 0 8.771410762165033e-07
in O 0 1.0330411726044986e-07
four O 0 8.220536642511433e-07
patients O 0 4.84317070004181e-06
, O 0 1.0229571500985912e-07
three O 0 3.7846856315582045e-08
of O 0 2.402655354671879e-07
whom O 0 4.179180450591957e-06
belonged O 0 2.5973622541641816e-06
to O 0 3.2509252179124815e-08
the O 0 6.894767778931055e-08
non O 0 1.959856717803632e-06
- O 0 0.00017664404003880918
FAP O 0 7.70903643569909e-05
group O 0 1.5380092008854263e-05
of O 0 0.005401440430432558
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
patients O 0 0.04698045924305916
. O 0 4.235976666677743e-05

Genotype O 0 0.013226436451077461
- O 0 0.006576331797987223
phenotype O 0 0.0002683960774447769
correlations O 0 0.0002568778581917286
identified O 0 2.2359205104294233e-05
significant O 0 2.0019372186652618e-06
differences O 0 1.265802620764589e-05
in O 0 3.057732840261451e-07
the O 0 7.852310801581552e-08
nature O 0 2.0940530021107406e-07
of O 0 8.90713849344138e-08
certain O 0 6.040117455086147e-07
extracolonic O 0 0.0014667349169030786
manifestations O 0 2.8892503905808553e-05
in O 0 3.5810048757412005e-06
FAP B-Disease 0 0.011931177228689194
patients O 0 2.4256689357571304e-05
belonging O 0 2.233573013654677e-06
to O 0 1.3714813462684106e-07
three O 0 5.581578079727478e-07
mutation O 0 1.135439015342854e-05
subgroups O 0 3.56251148332376e-05
. O 0 9.527475413051434e-06

CONCLUSIONS O 0 8.052250632317737e-05
Extended O 0 2.9286502467584796e-05
genotype O 0 0.0008425459964200854
- O 0 0.0015033981762826443
phenotype O 0 1.708083800622262e-05
correlations O 0 1.5902280210866593e-05
made O 0 1.8867635276365036e-07
in O 0 5.977415185043355e-08
this O 0 2.8889351355587678e-08
study O 0 1.7933774643097422e-07
may O 0 5.930062343395548e-07
have O 0 2.463230508453762e-08
the O 0 1.5207685777340885e-08
potential O 0 1.119265817806081e-07
to O 0 1.7334924606871027e-08
determine O 0 8.076113289234854e-08
the O 0 1.5867906100197615e-08
most O 0 7.486138819956523e-09
appropriate O 0 4.009887177858218e-08
surveillance O 0 1.6851158761710394e-06
and O 0 2.967254033592326e-07
prophylactic O 0 0.0003898355062119663
treatment O 0 2.7015632440452464e-05
regimens O 0 1.7522266716696322e-05
for O 0 5.628209578389942e-07
those O 0 4.172131411905866e-06
patients O 0 1.7257605577469803e-05
with O 0 5.077440050627047e-07
mutations O 0 1.627913661650382e-05
associated O 0 3.516876176945516e-06
with O 0 1.1903022141268593e-06
life O 0 2.927343302872032e-05
threatening O 0 0.0015965536003932357
conditions O 0 0.0005264382343739271
. O 0 1.809734385460615e-05

This O 0 5.376709850679617e-06
study O 0 2.4212254174926784e-06
also O 0 4.1115814042314014e-07
provided O 0 1.9493457159569516e-07
evidence O 0 2.4997126502057654e-07
for O 0 4.693240285291722e-08
the O 0 2.3196655263291177e-07
pathological O 0 8.706552762305364e-05
nature O 0 4.015888919184363e-07
of O 0 6.18149087472375e-08
amino O 0 1.9844557641590654e-07
acid O 0 3.1223410701386456e-07
changes O 0 5.1010566437525995e-08
in O 0 1.1030339663875566e-07
APC O 0 2.2741949578630738e-05
associated O 0 8.447693176094617e-07
with O 0 9.116434540601404e-08
both O 0 1.447951376576384e-07
FAP B-Disease 0 1.926541699504014e-05
and O 0 9.511927601124626e-07
non O 0 0.00022426705982070416
- O 1 0.9998589754104614
FAP O 1 0.99997878074646
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
patients O 0 0.02365625463426113
. O 0 5.129999408381991e-06
. O 0 1.8862157958210446e-05

Inherited B-Disease 1 0.9999033212661743
colorectal I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.999987006187439
and O 1 0.914397120475769
cancer B-Disease 1 0.9998538494110107
risk O 0 0.0001738207065500319
of O 0 7.459273660970211e-07
the O 0 3.3842059110611444e-06
APC O 0 0.0013618356315419078
I1307K O 0 0.0007954748580232263
polymorphism O 0 0.00021944644686300308
. O 0 2.0202098312438466e-05

Germ O 0 0.05080673098564148
- O 0 0.0005708844983018935
line O 0 8.028063348319847e-06
and O 0 3.1640939823773806e-07
somatic O 0 5.841260644956492e-06
truncating O 0 3.0913906812202185e-05
mutations O 0 1.4868958260194631e-06
of O 0 1.255173742720217e-07
the O 0 3.2572935992902785e-07
APC B-Disease 0 6.5594199440965895e-06
gene O 0 2.130352640961064e-07
are O 0 1.9001070938884368e-08
thought O 0 5.572637817863324e-08
to O 0 1.7103150184993865e-07
initiate O 0 0.0029835421591997147
colorectal B-Disease 1 0.9999996423721313
tumor I-Disease 1 0.8098470568656921
formation O 0 0.0010992393363267183
in O 0 0.005594385322183371
familial B-Disease 1 0.9999984502792358
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999910593032837
and O 0 0.005013376008719206
sporadic O 1 0.995368480682373
colorectal O 1 0.9999994039535522
carcinogenesis O 1 0.9993084669113159
, O 0 0.00015980444732122123
respectively O 0 0.00013552376185543835
. O 0 3.121071858913638e-05

Recently O 0 0.00029145757434889674
, O 0 2.362867462579743e-06
an O 0 3.5341136594979616e-07
isoleucine O 0 0.00038481486262753606
- O 0 0.001618018141016364
- O 0 0.00023504503769800067
> O 0 5.429069460660685e-06
lysine O 0 7.954307079671707e-07
polymorphism O 0 7.648584414710058e-07
at O 0 1.522139001508549e-07
codon O 0 4.766520760313142e-07
1307 O 0 7.499999355786713e-06
( O 0 9.093424324646548e-08
I1307K O 0 1.4862393982184585e-06
) O 0 1.1569618152407202e-08
of O 0 3.6941076864138722e-09
the O 0 1.5684804566262756e-08
APC B-Disease 0 2.3511900053563295e-06
gene O 0 1.8502949217236164e-07
has O 0 4.945905729414335e-08
been O 0 3.964887085317059e-08
identified O 0 1.391883728274479e-07
in O 0 1.6214022124927396e-08
6 O 0 4.548861625153222e-07
% O 0 1.1176892655839765e-07
- O 0 2.654698801052291e-05
7 O 0 9.271075214201119e-07
% O 0 2.8446837774254163e-08
of O 0 1.5701507649623636e-08
the O 0 1.0457407739750124e-07
Ashkenazi O 0 1.8235452444059774e-05
Jewish O 0 1.3235111282483558e-06
population O 0 5.283076234263717e-07
. O 0 2.101668314935523e-06

To O 0 6.630704319832148e-06
assess O 0 4.0905615605879575e-05
the O 0 7.568160640403221e-07
risk O 0 2.4315504560945556e-06
of O 0 4.258906471932278e-08
this O 0 1.6936988345150894e-07
common O 0 1.1165295745740877e-06
APC B-Disease 0 4.63880569441244e-05
allelic O 0 7.19124436727725e-05
variant O 0 3.2056006602942944e-05
in O 0 2.291933196829632e-05
colorectal O 1 0.9999982118606567
carcinogenesis O 1 0.9894843697547913
, O 0 7.3758760663622525e-06
we O 0 3.1909303288557567e-07
have O 0 4.666479469506157e-08
analyzed O 0 3.383736952855543e-07
a O 0 5.626230148436662e-08
large O 0 3.101611127931392e-07
cohort O 0 1.3402826652963995e-06
of O 0 1.0423893570532528e-07
unselected O 0 0.00014381033543031663
Ashkenazi O 0 3.977308369940147e-05
Jewish O 0 2.04573279916076e-06
subjects O 0 1.929759037011536e-06
with O 0 3.653284466054174e-06
adenomatous B-Disease 1 0.9383256435394287
polyps I-Disease 0 0.12801511585712433
and O 0 5.893949946766952e-06
. O 0 1.6459753169328906e-05
or O 1 0.9337615966796875
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
, I-Disease 0 4.686147804022767e-06
for O 0 3.000187120960618e-07
the O 0 9.068843382920022e-07
APC O 0 0.00017573116929270327
I1307K O 0 0.00018721689411904663
polymorphism O 0 0.00010439474135637283
. O 0 1.490650356572587e-05

The O 0 2.0205105101922527e-05
APC O 0 0.00016325425531249493
I1307K O 0 0.0001026400932460092
allele O 0 1.0529603059694637e-05
was O 0 1.4043976079847198e-06
identified O 0 7.268587296493934e-07
in O 0 4.9636152965604197e-08
48 O 0 7.022545673862624e-07
( O 0 2.5786581758779903e-08
10 O 0 2.5678996706801627e-08
. O 0 1.336683297381569e-08
1 O 0 1.2532133553122549e-07
% O 0 3.498393397194377e-08
) O 0 1.0532168026600175e-08
of O 0 9.976871950811983e-08
476 O 0 0.000195213477127254
patients O 0 3.723951522260904e-05
. O 0 3.919632490578806e-06

Compared O 0 0.00011099979747086763
with O 0 9.084814109883155e-07
the O 0 8.809885088112424e-08
frequency O 0 3.4844026686187135e-07
in O 0 3.149786564904389e-08
two O 0 1.9555381314262377e-08
separate O 0 1.1372971897571915e-07
population O 0 3.8826929227298024e-08
control O 0 3.4535895565568353e-07
groups O 0 6.628408044662137e-08
, O 0 3.4707582585724595e-08
the O 0 5.126425861590178e-08
APC O 0 5.881922334083356e-06
I1307K O 0 8.318640539073385e-06
allele O 0 4.167389704434754e-07
is O 0 3.5929865305206476e-08
associated O 0 7.45371409038853e-08
with O 0 4.435824152437817e-08
an O 0 2.8421455411375973e-08
estimated O 0 2.6639975203579525e-06
relative O 0 1.4637706044595689e-05
risk O 0 1.4594626236430486e-06
of O 0 1.4255532221341127e-07
1 O 0 3.502210347505752e-06
. O 0 6.3545116972818505e-06

5 O 0 8.243872434832156e-05
- O 0 0.0003126623050775379
1 O 0 1.778580917743966e-05
. O 0 1.2496176168497186e-05

7 O 0 0.0004852015699725598
for O 0 0.0009703069808892906
colorectal B-Disease 1 0.9999986886978149
neoplasia I-Disease 1 0.9995531439781189
( O 0 7.732451194897294e-06
both O 0 3.1754225346958265e-06
P O 0 0.3815461993217468
= O 0 1.9870018149958923e-05
. O 0 2.5843533535407914e-07
01 O 0 1.4043765077076387e-05
) O 0 4.1337679590469634e-07
. O 0 1.8999278381670592e-06

Furthermore O 0 0.00015828611503820866
, O 0 5.582303401752142e-06
compared O 0 6.52677863399731e-06
with O 0 7.66020605169615e-07
noncarriers O 0 0.004280583467334509
, O 0 1.9180642993887886e-06
APC O 0 3.768622627831064e-05
I1307K O 0 4.6682627726113424e-05
carriers O 0 1.7425263649784029e-06
had O 0 1.1298120483616003e-07
increased O 0 5.413438586288066e-08
numbers O 0 3.900566625247848e-08
of O 0 1.1520912579499054e-07
adenomas B-Disease 1 0.645291805267334
and O 0 0.040887948125600815
colorectal B-Disease 1 0.9999998807907104
cancers I-Disease 1 0.9804336428642273
per O 0 3.8777670852141455e-05
patient O 0 0.0006313604535534978
( O 0 1.7862613503893954e-06
P O 0 0.22812266647815704
= O 0 5.8058271861227695e-06
. O 0 5.10567019773589e-08
03 O 0 1.0854894298972795e-06
) O 0 1.3525480291320946e-08
, O 0 8.781528393342342e-09
as O 0 5.0163690978877185e-09
well O 0 1.1241647612791894e-08
as O 0 7.458758943812427e-09
a O 0 8.142234264596482e-08
younger O 0 2.8395556910254527e-06
age O 0 1.2192130043331417e-06
at O 0 4.956055818183813e-06
diagnosis O 0 0.0007107687997631729
. O 0 1.108103879232658e-05

We O 0 1.4632374586653896e-05
conclude O 0 1.0192279660259373e-05
that O 0 4.188554214579199e-07
the O 0 4.0851563198884833e-07
APC O 0 2.0738561943289824e-05
I1307K O 0 2.4830842448864132e-05
variant O 0 2.6553684620012064e-06
leads O 0 7.159885058172222e-07
to O 0 3.754635713448806e-07
increased O 0 2.523232251405716e-05
adenoma B-Disease 1 0.999833345413208
formation O 0 9.893010428640991e-06
and O 0 1.1973845914781123e-07
directly O 0 4.1091542613003185e-08
contributes O 0 4.889897198268045e-08
to O 0 1.482121181339835e-08
3 O 0 1.8030013393399713e-07
% O 0 5.231275679307146e-08
- O 0 3.6312831070972607e-06
4 O 0 1.6549897452478035e-07
% O 0 1.993887188689314e-08
of O 0 1.5496336658316068e-08
all O 0 2.3006877825082483e-07
Ashkenazi O 0 0.014828563667833805
Jewish O 0 0.3119642734527588
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999781847000122
. O 0 0.0001742976892273873

The O 0 6.136919637356186e-06
estimated O 0 2.2402875401894562e-05
relative O 0 4.0456765418639407e-05
risk O 0 1.2629810953512788e-05
for O 0 6.575670568054193e-07
carriers O 0 7.73618376115337e-06
may O 0 5.278604362501937e-07
justify O 0 9.426723295291595e-07
specific O 0 1.148666228800721e-07
clinical O 0 2.8383481094351737e-06
screening O 0 1.5379400792880915e-06
for O 0 2.5763867483874492e-08
the O 0 2.1339451095059303e-08
360 O 0 2.82175022903175e-07
, O 0 2.901199458449355e-08
000 O 0 5.2695703800509364e-08
Americans O 0 4.651745655337436e-08
expected O 0 1.2696752094143449e-07
to O 0 3.7405929020906115e-08
harbor O 0 9.330396096629556e-06
this O 0 1.2347124211942173e-08
allele O 0 1.4504917089652736e-07
, O 0 3.0360499891912696e-08
and O 0 3.033549234032762e-08
genetic O 0 2.359781774430303e-07
testing O 0 2.3981456820365565e-07
in O 0 1.5939646047513634e-08
the O 0 1.7796415008319855e-08
setting O 0 1.276793000215548e-07
of O 0 4.135344511269068e-08
long O 0 4.190234903944656e-06
- O 0 7.63912103138864e-05
term O 0 3.13630380333052e-06
- O 0 1.5060296391311567e-05
outcome O 0 6.693225600429287e-07
studies O 0 8.775940329996956e-08
may O 0 1.440777595007603e-07
impact O 0 1.1593297131184954e-06
significantly O 0 7.915563037386164e-05
on O 1 0.8198157548904419
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
prevention O 0 0.000483596115373075
in O 0 5.645234182338754e-07
this O 0 3.124137037957553e-07
population O 0 1.1812037428171607e-06
. O 0 4.311799784773029e-06

Localization O 0 7.233755604829639e-05
of O 0 1.5090798797245952e-06
human O 0 2.3525826691184193e-06
BRCA1 O 0 0.00011117818212369457
and O 0 7.553926479886286e-07
its O 0 3.229381775327056e-07
loss O 0 3.9906397432787344e-05
in O 0 3.720811605489871e-07
high O 0 1.8699958673096262e-05
- O 0 0.0002986920007970184
grade O 0 3.194060627720319e-05
, O 0 2.9283526714607433e-07
non B-Disease 0 2.9808996259816922e-05
- I-Disease 1 0.9709075093269348
inherited I-Disease 1 0.9959832429885864
breast I-Disease 1 0.9994686245918274
carcinomas I-Disease 1 0.9999709129333496
. O 0 0.0001112213431042619

Although O 0 1.0807195394590963e-05
the O 0 9.321627203462413e-07
link O 0 4.872589215665357e-06
between O 0 6.778358283554553e-07
the O 0 9.244553211829043e-07
BRCA1 O 0 0.047835417091846466
tumour B-Disease 1 0.9998382329940796
- O 0 0.0016487137181684375
suppressor O 0 9.845495515037328e-05
gene O 0 2.2147460185806267e-06
and O 0 6.341326752590248e-06
hereditary B-Disease 1 0.9737274050712585
breast I-Disease 1 0.9998971223831177
and I-Disease 1 0.9998323917388916
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999977350234985
is O 0 2.2566669031220954e-06
established O 0 8.881655730874627e-07
, O 0 1.4633843647970934e-07
the O 0 2.6199357350265018e-08
role O 0 2.260396598785519e-07
, O 0 1.4095054723384237e-07
if O 0 2.9371339138606345e-08
any O 0 1.7053938705657856e-08
, O 0 2.4472615933746056e-08
of O 0 1.9712743437594327e-08
BRCA1 O 0 7.2110451583284885e-06
in O 0 2.5691153382467746e-07
non B-Disease 0 2.5178505893563852e-05
- I-Disease 1 0.9471284747123718
familial I-Disease 1 0.9979396462440491
cancers I-Disease 1 0.9616471529006958
is O 0 4.78397669212427e-06
unclear O 0 2.223595765826758e-05
. O 0 8.582283044233918e-06

BRCA1 O 0 0.022195987403392792
mutations O 0 0.000350257265381515
are O 0 2.175985173380468e-06
rare O 0 9.495563062955625e-06
in O 0 1.0990979717462324e-06
sporadic B-Disease 0 0.01920589804649353
cancers I-Disease 1 0.932371199131012
, O 0 3.087002824031515e-06
but O 0 4.7056190055627667e-07
loss O 0 1.4780434867134318e-05
of O 0 3.807272150879726e-07
BRCA1 O 0 0.0002392300229985267
resulting O 0 3.2069945063994965e-06
from O 0 3.417184188947431e-07
reduced O 0 5.94713185364526e-07
expression O 0 2.3032738738493208e-07
or O 0 1.5431984934366483e-07
incorrect O 0 4.116175773560826e-07
subcellular O 0 3.2091054436023114e-06
localization O 0 1.378679712615849e-06
is O 0 4.33560636281527e-08
postulated O 0 3.1383456189360004e-07
to O 0 1.853027953302444e-08
be O 0 1.5286234500422324e-08
important O 0 3.384988644938858e-08
in O 0 6.4351922901551e-08
non B-Disease 0 5.142435838934034e-06
- I-Disease 0 0.45786410570144653
familial I-Disease 1 0.9930383563041687
breast I-Disease 1 0.9999402761459351
and I-Disease 1 0.9988034963607788
ovarian I-Disease 1 0.9999998807907104
cancers I-Disease 1 0.9999879598617554
. O 0 0.00021506828488782048

Epigenetic O 0 0.010581770911812782
loss O 0 0.010941615328192711
, O 0 1.2640823115361854e-05
however O 0 1.1538983244463452e-06
, O 0 6.758077120139205e-07
has O 0 2.014860740473523e-07
not O 0 3.4594236808516143e-08
received O 0 8.050967181816304e-08
general O 0 2.709290924940433e-07
acceptance O 0 3.832203219644725e-06
due O 0 1.0907672276516678e-06
to O 0 9.220202201731809e-08
controversy O 0 7.256467142724432e-07
regarding O 0 1.947602754626132e-07
the O 0 6.540509644992198e-08
subcellular O 0 6.122392733232118e-06
localization O 0 1.3550858284361311e-06
of O 0 1.1709764180523052e-07
BRCA1 O 0 7.317835752473911e-06
proteins O 0 7.28228499724537e-08
, O 0 4.9967287196750476e-08
reports O 0 6.342533254155569e-08
of O 0 1.5915949447276034e-08
which O 0 5.3101711472436364e-08
have O 0 4.8738904467882094e-08
ranged O 0 2.1217367702774936e-06
from O 0 1.6129259705621735e-08
exclusively O 0 8.671166540352715e-08
nuclear O 0 7.883019861765206e-06
, O 0 2.057729275861675e-08
to O 0 1.2409310912175897e-08
conditionally O 0 4.42871578343329e-06
nuclear O 0 1.1702898518706206e-05
, O 0 1.6007465575285096e-08
to O 0 7.82566367263371e-09
the O 0 3.9365918524936205e-08
ER O 0 6.065735942684114e-05
/ O 0 1.1574368727451656e-05
golgi O 0 2.1924282918917015e-05
, O 0 7.626719877862342e-08
to O 0 2.8022586917586523e-08
cytoplasmic O 0 5.169092673895648e-07
invaginations O 0 5.697705091733951e-06
into O 0 8.529896433628892e-08
the O 0 1.5004967224285792e-07
nucleus O 0 3.125012199234334e-06
. O 0 2.3576656076329527e-06

In O 0 5.135692390467739e-06
an O 0 3.6228945532457146e-07
attempt O 0 2.181166792070144e-06
to O 0 1.963128823945226e-07
resolve O 0 5.5535078899993096e-06
this O 0 6.477010572325526e-08
issue O 0 1.0178340517086326e-06
, O 0 1.2836153473472223e-07
we O 0 3.2217155165881195e-08
have O 0 2.8679462360514663e-08
comprehensively O 0 1.1187337804585695e-05
characterized O 0 5.178826086194022e-06
19 O 0 2.0363197563710855e-06
anti O 0 7.894862937973812e-05
- O 0 0.004015948157757521
BRCA1 O 0 0.0004100649675820023
antibodies O 0 1.4769515473744832e-05
. O 0 5.787109785160283e-06

These O 0 7.379570433840854e-06
reagents O 0 2.6872154194279574e-05
detect O 0 2.103057522617746e-05
a O 0 4.3872068999917246e-07
220 O 0 1.3374467471294338e-06
- O 0 2.3637945560039952e-05
kD O 0 3.153975558234379e-05
protein O 0 2.032554533570874e-07
localized O 0 6.48554589588457e-07
in O 0 1.8698639081549118e-08
discrete O 0 1.008458298201731e-06
nuclear O 0 2.400825724180322e-05
foci O 0 3.3442559015384177e-06
in O 0 4.2967332802845704e-08
all O 0 7.215050601416806e-08
epithelial O 0 0.0009397066896781325
cell O 0 0.00018519588047638535
lines O 0 7.775741323712282e-06
, O 0 2.246470955924451e-07
including O 0 9.356667618476422e-08
those O 0 8.728746792030506e-08
derived O 0 2.5600436970307783e-07
from O 0 1.964212970051449e-06
breast B-Disease 0 0.4055285155773163
malignancies I-Disease 0 0.08328032493591309
. O 0 2.675519499462098e-05

Immunohistochemical O 0 0.004831917583942413
staining O 0 0.0004607356386259198
of O 0 4.984866791346576e-06
human O 0 5.4771677241660655e-05
breast O 1 0.7985429763793945
specimens O 0 0.0002035789075307548
also O 0 2.11779251912958e-06
revealed O 0 4.38252609455958e-05
BRCA1 O 0 0.00030079123098403215
nuclear O 0 0.0010913268197327852
foci O 0 0.00031033167033456266
in O 0 6.843266419309657e-06
benign O 1 0.8989207744598389
breast O 1 0.863311231136322
, O 0 4.599837484420277e-05
invasive B-Disease 1 0.5409775376319885
lobular I-Disease 1 0.9999774694442749
cancers I-Disease 1 0.9807408452033997
and O 0 1.863839315774385e-05
low B-Disease 0 0.015226620249450207
- I-Disease 1 0.843595564365387
grade I-Disease 1 0.8457043170928955
ductal I-Disease 1 0.9999146461486816
carcinomas I-Disease 1 0.9999762773513794
. O 0 0.00012277581845410168

Conversely O 0 0.0006168931140564382
, O 0 1.0575330634310376e-05
BRCA1 O 0 9.355817746836692e-05
expression O 0 2.6419004370836774e-06
was O 0 2.3392019556922605e-06
reduced O 0 2.1279638531268574e-06
or O 0 9.139352528109157e-07
undetectable O 0 1.6809439330245368e-05
in O 0 4.404394360335573e-08
the O 0 2.2979415703616723e-08
majority O 0 6.189902990172413e-08
of O 0 2.261870868380811e-08
high O 0 8.83099710335955e-06
- O 0 0.0014850801089778543
grade O 0 0.000193050189409405
, O 0 1.200955557578709e-05
ductal B-Disease 1 0.9999085664749146
carcinomas I-Disease 1 0.9999979734420776
, O 0 6.787415713915834e-06
suggesting O 0 3.383734792805626e-06
that O 0 7.576871041692357e-08
absence O 0 3.196242062131205e-07
of O 0 3.0351296231856395e-07
BRCA1 O 0 0.0001936207409016788
may O 0 1.0132108627658454e-06
contribute O 0 1.1072708616666205e-07
to O 0 2.9520622391032703e-08
the O 0 1.3364824269501696e-07
pathogenesis O 0 2.304511326656211e-05
of O 0 3.874776766110699e-08
a O 0 1.8362739240274095e-07
significant O 0 2.394436648955889e-07
percentage O 0 1.4890769080011523e-06
of O 0 5.142516101841466e-07
sporadic B-Disease 0 0.06231916695833206
breast I-Disease 1 0.9989827275276184
cancers I-Disease 1 0.749532163143158
. O 0 2.8772994937753538e-06
. O 0 9.246719855582342e-06

